{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/mangalm96/agreement_reddit_ap/blob/main/LogReg.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "uq0J5fpzaN5p"
      },
      "source": [
        "L2-regularized logistic regression for binary or multiclass classification; trains a model (on `train.txt`), optimizes L2 regularization strength on `dev.txt`, and evaluates performance on `test.txt`.  Reports test accuracy with 95% confidence intervals and prints out the strongest coefficients for each class."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 16,
      "metadata": {
        "id": "TQTT9x-6d2JI",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "f199695f-0862-4824-8832-a688bd89c37c"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[nltk_data] Downloading package stopwords to /root/nltk_data...\n",
            "[nltk_data]   Package stopwords is already up-to-date!\n"
          ]
        }
      ],
      "source": [
        "from scipy import sparse\n",
        "from sklearn import linear_model\n",
        "from collections import Counter\n",
        "import numpy as np\n",
        "import operator\n",
        "import nltk\n",
        "import math\n",
        "from scipy.stats import norm\n",
        "import nltk\n",
        "nltk.download('stopwords')\n",
        "from nltk.corpus import stopwords\n",
        "from nltk.tokenize import word_tokenize\n",
        "from nltk.util import ngrams\n",
        "from sklearn.metrics import confusion_matrix, ConfusionMatrixDisplay\n",
        "from sklearn.metrics import plot_confusion_matrix\n",
        "import matplotlib.pyplot as plt"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 17,
      "metadata": {
        "id": "e4KuVSCSqlUX",
        "scrolled": true,
        "outputId": "e7f276ec-ad78-44a4-e4dd-130dc67d527b",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "/usr/lib/python3.7/runpy.py:125: RuntimeWarning: 'nltk.downloader' found in sys.modules after import of package 'nltk', but prior to execution of 'nltk.downloader'; this may result in unpredictable behaviour\n",
            "  warn(RuntimeWarning(msg))\n",
            "[nltk_data] Downloading package punkt to /root/nltk_data...\n",
            "[nltk_data]   Package punkt is already up-to-date!\n"
          ]
        }
      ],
      "source": [
        "!python -m nltk.downloader punkt"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# If you have your folder of data on your Google drive account, you can connect that here\n",
        "from google.colab import drive\n",
        "drive.mount('/content/drive')"
      ],
      "metadata": {
        "id": "e9LBAOqSar4U",
        "outputId": "e46a5ed2-b691-43da-9422-eab6c5e6243a",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "execution_count": 18,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount(\"/content/drive\", force_remount=True).\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Change this to the directory with your data\n",
        "directory=\"/content/drive/MyDrive/Agreement_Reddit_AP/data/\""
      ],
      "metadata": {
        "id": "phhy5RpAasZY"
      },
      "execution_count": 19,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": 20,
      "metadata": {
        "id": "-esP6NmXaN5u"
      },
      "outputs": [],
      "source": [
        "def load_data(filename):\n",
        "    X = []\n",
        "    Y = []\n",
        "    with open(filename, encoding=\"utf-8\") as file:\n",
        "        for line in file:\n",
        "            cols = line.split(\"\\t\")\n",
        "            idd = cols[0]\n",
        "            label = cols[1].lstrip().rstrip()\n",
        "            text = cols[2]\n",
        "\n",
        "            X.append(text)\n",
        "            Y.append(label)\n",
        "\n",
        "    return X, Y\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 21,
      "metadata": {
        "id": "CGiM8qQiJOBU"
      },
      "outputs": [],
      "source": [
        "class Classifier:\n",
        "\n",
        "    def __init__(self, feature_method, trainX, trainY, devX, devY, testX, testY):\n",
        "        self.feature_vocab = {}\n",
        "        self.feature_method = feature_method\n",
        "        self.min_feature_count=2\n",
        "        self.log_reg = None\n",
        "\n",
        "        self.trainY=trainY\n",
        "        self.devY=devY\n",
        "        self.testY=testY\n",
        "        \n",
        "        self.trainX = self.process(trainX, training=True)\n",
        "        self.devX = self.process(devX, training=False)\n",
        "        self.testX = self.process(testX, training=False)\n",
        "\n",
        "\n",
        "\n",
        "    # Featurize entire dataset\n",
        "    def featurize(self, data):\n",
        "        featurized_data = []\n",
        "        for text in data:\n",
        "            feats = self.feature_method(text)\n",
        "            featurized_data.append(feats)\n",
        "        return featurized_data\n",
        "\n",
        "    # Read dataset and returned featurized representation as sparse matrix + label array\n",
        "    def process(self, X_data, training = False):\n",
        "          \n",
        "        data = self.featurize(X_data)\n",
        "\n",
        "        if training:\n",
        "            fid = 0\n",
        "            feature_doc_count = Counter()\n",
        "            for feats in data:\n",
        "                for feat in feats:\n",
        "                    feature_doc_count[feat]+= 1\n",
        "\n",
        "            for feat in feature_doc_count:\n",
        "                if feature_doc_count[feat] >= self.min_feature_count:\n",
        "                    self.feature_vocab[feat] = fid\n",
        "                    fid += 1\n",
        "\n",
        "        F = len(self.feature_vocab)\n",
        "        D = len(data)\n",
        "        X = sparse.dok_matrix((D, F))\n",
        "        for idx, feats in enumerate(data):\n",
        "            for feat in feats:\n",
        "                if feat in self.feature_vocab:\n",
        "                    X[idx, self.feature_vocab[feat]] = feats[feat]\n",
        "\n",
        "        return X\n",
        "\n",
        "    # Train model and evaluate on held-out data\n",
        "    def train(self):\n",
        "        (D,F) = self.trainX.shape\n",
        "        best_dev_accuracy=0\n",
        "        best_model=None\n",
        "        for C in [0.1, 1, 10, 100]:\n",
        "            self.log_reg = linear_model.LogisticRegression(C = C, max_iter=1000)\n",
        "            self.log_reg.fit(self.trainX, self.trainY)\n",
        "            training_accuracy = self.log_reg.score(self.trainX, self.trainY)\n",
        "            development_accuracy = self.log_reg.score(self.devX, self.devY)\n",
        "            if development_accuracy > best_dev_accuracy:\n",
        "                best_dev_accuracy=development_accuracy\n",
        "                best_model=self.log_reg\n",
        "\n",
        "#             print(\"C: %s, Train accuracy: %.3f, Dev accuracy: %.3f\" % (C, training_accuracy, development_accuracy))\n",
        "\n",
        "        self.log_reg=best_model\n",
        "        \n",
        "\n",
        "    def test(self):\n",
        "      return self.log_reg.score(self.testX, self.testY)\n",
        "\n",
        "    def dev(self):\n",
        "      return self.log_reg.score(self.devX, self.devY)\n",
        "        \n",
        "\n",
        "    def printWeights(self, n=10):\n",
        "\n",
        "        reverse_vocab=[None]*len(self.log_reg.coef_[0])\n",
        "        for k in self.feature_vocab:\n",
        "            reverse_vocab[self.feature_vocab[k]]=k\n",
        "\n",
        "        # binary\n",
        "        if len(self.log_reg.classes_) == 2:\n",
        "              weights=self.log_reg.coef_[0]\n",
        "\n",
        "              cat=self.log_reg.classes_[1]\n",
        "              for feature, weight in list(reversed(sorted(zip(reverse_vocab, weights), key = operator.itemgetter(1))))[:n]:\n",
        "                  print(\"%s\\t%.3f\\t%s\" % (cat, weight, feature))\n",
        "              print()\n",
        "\n",
        "              cat=self.log_reg.classes_[0]\n",
        "              for feature, weight in list(sorted(zip(reverse_vocab, weights), key = operator.itemgetter(1)))[:n]:\n",
        "                  print(\"%s\\t%.3f\\t%s\" % (cat, weight, feature))\n",
        "              print()\n",
        "\n",
        "        # multiclass\n",
        "        else:\n",
        "          for i, cat in enumerate(self.log_reg.classes_):\n",
        "\n",
        "              weights=self.log_reg.coef_[i]\n",
        "\n",
        "              for feature, weight in list(reversed(sorted(zip(reverse_vocab, weights), key = operator.itemgetter(1))))[:n]:\n",
        "                  print(\"%s\\t%.3f\\t%s\" % (cat, weight, feature))\n",
        "              print()\n",
        "\n",
        "            "
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 22,
      "metadata": {
        "id": "Exd1Bwb2aN5w"
      },
      "outputs": [],
      "source": [
        "def binary_bow_featurize(text):\n",
        "    feats = {}\n",
        "    words = nltk.word_tokenize(text)\n",
        "\n",
        "    for word in words:\n",
        "        word=word.lower()\n",
        "        feats[word]=1\n",
        "            \n",
        "    return feats"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 23,
      "metadata": {
        "id": "43B4Pd1daN5w"
      },
      "outputs": [],
      "source": [
        "def confidence_intervals(accuracy, n, significance_level):\n",
        "    critical_value=(1-significance_level)/2\n",
        "    z_alpha=-1*norm.ppf(critical_value)\n",
        "    se=math.sqrt((accuracy*(1-accuracy))/n)\n",
        "    return accuracy-(se*z_alpha), accuracy+(se*z_alpha)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def remove_stop_df(data):\n",
        "  # remove stopwords\n",
        "  filt_combined = []\n",
        "  for word in nltk.word_tokenize(data):\n",
        "\n",
        "    if word.lower() not in stopwords.words('english'):\n",
        "      filt_combined.append(word)\n",
        "\n",
        "  filtered_ip= \" \".join(filt_combined)\n",
        "  return filtered_ip"
      ],
      "metadata": {
        "id": "1e8AmRMktA2r"
      },
      "execution_count": 24,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def print_confusion(classifier):\n",
        "    fig, ax = plt.subplots(figsize=(10,10))\n",
        "    plot_confusion_matrix(classifier.log_reg, classifier.devX, classifier.devY, ax=ax, xticks_rotation=\"vertical\", values_format=\"d\")\n",
        "    plt.show()\n",
        "\n",
        "\n",
        "def print_confusion_test(classifier):\n",
        "    fig, ax = plt.subplots(figsize=(10,10))\n",
        "    plot_confusion_matrix(classifier.log_reg, classifier.testX, classifier.testY, ax=ax, xticks_rotation=\"vertical\", values_format=\"d\")\n",
        "    plt.show()"
      ],
      "metadata": {
        "id": "ZazoIU077WIP"
      },
      "execution_count": 25,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": 26,
      "metadata": {
        "id": "TkTQ7u0kaN5x"
      },
      "outputs": [],
      "source": [
        "def run(trainingFile, devFile, testFile):\n",
        "    trainX, trainY=load_data(trainingFile)\n",
        "    devX, devY=load_data(devFile)\n",
        "    testX, testY=load_data(testFile)\n",
        "\n",
        "    # trainX = list(map(remove_stop_df, trainX))\n",
        "    # devX = list(map(remove_stop_df, devX))\n",
        "    # testX = list(map(remove_stop_df, testX))\n",
        "\n",
        "    simple_classifier = Classifier(binary_bow_featurize, trainX, trainY, devX, devY, testX, testY)\n",
        "    simple_classifier.train()\n",
        "    accuracy_test=simple_classifier.test()\n",
        "    accuracy_dev=simple_classifier.dev()\n",
        "\n",
        "    \n",
        "    lower, upper=confidence_intervals(accuracy_dev, len(devY), .95)\n",
        "    print(\"Dev accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy_dev, lower, upper))\n",
        "    print(\"Test accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy_test, lower, upper))\n",
        "\n",
        "\n",
        "    print_confusion(simple_classifier)\n",
        "    print_confusion_test(simple_classifier)\n",
        "\n",
        "    simple_classifier.printWeights()\n",
        "    \n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 27,
      "metadata": {
        "id": "AU4ZHrkuaN5x",
        "outputId": "f1a81fc4-9eeb-4c8e-edcc-3250e6ea204a",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        }
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dev accuracy for best dev model: 0.750, 95% CIs: [0.690 0.810]\n",
            "\n",
            "Test accuracy for best dev model: 0.755, 95% CIs: [0.690 0.810]\n",
            "\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Agreement\t0.218\tother\n",
            "Agreement\t0.217\tthat\n",
            "Agreement\t0.198\tif\n",
            "Agreement\t0.197\t&\n",
            "Agreement\t0.196\t%\n",
            "Agreement\t0.175\tleast\n",
            "Agreement\t0.164\tget\n",
            "Agreement\t0.164\tbefore\n",
            "Agreement\t0.159\t'd\n",
            "Agreement\t0.158\t3\n",
            "\n",
            "Disagreement\t0.321\tn't\n",
            "Disagreement\t0.288\ti\n",
            "Disagreement\t0.284\t?\n",
            "Disagreement\t0.266\tactually\n",
            "Disagreement\t0.233\tthis\n",
            "Disagreement\t0.217\tgraph\n",
            "Disagreement\t0.206\tsay\n",
            "Disagreement\t0.187\tsure\n",
            "Disagreement\t0.184\tsimply\n",
            "Disagreement\t0.182\tme\n",
            "\n",
            "Neutral\t0.389\tand\n",
            "Neutral\t0.293\tabstract\n",
            "Neutral\t0.252\twe\n",
            "Neutral\t0.221\tcovid-19\n",
            "Neutral\t0.216\tour\n",
            "Neutral\t0.200\tby\n",
            "Neutral\t0.178\t(\n",
            "Neutral\t0.175\t)\n",
            "Neutral\t0.166\t.\n",
            "Neutral\t0.162\thas\n",
            "\n"
          ]
        }
      ],
      "source": [
        "trainingFile = directory + \"train.txt\" \n",
        "devFile = directory + \"dev.txt\" \n",
        "testFile = directory + \"test.txt\"\n",
        "    \n",
        "run(trainingFile, devFile, testFile)\n"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "###after stopword removal"
      ],
      "metadata": {
        "id": "a2Ti-IxUww_m"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def run(trainingFile, devFile, testFile):\n",
        "    trainX, trainY=load_data(trainingFile)\n",
        "    devX, devY=load_data(devFile)\n",
        "    testX, testY=load_data(testFile)\n",
        "\n",
        "    trainX = list(map(remove_stop_df, trainX))\n",
        "    devX = list(map(remove_stop_df, devX))\n",
        "    testX = list(map(remove_stop_df, testX))\n",
        "\n",
        "    simple_classifier = Classifier(binary_bow_featurize, trainX, trainY, devX, devY, testX, testY)\n",
        "    simple_classifier.train()\n",
        "    accuracy_test=simple_classifier.test()\n",
        "    accuracy_dev=simple_classifier.dev()\n",
        "\n",
        "    lower, upper=confidence_intervals(accuracy_dev, len(devY), .95)\n",
        "    print(\"Dev accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy_dev, lower, upper))\n",
        "    lower, upper=confidence_intervals(accuracy_dev, len(testY), .95)\n",
        "    print(\"Test accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy_test, lower, upper))\n",
        "\n",
        "    simple_classifier.printWeights()"
      ],
      "metadata": {
        "id": "IDWoepgyXJGb"
      },
      "execution_count": 28,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "run(trainingFile, devFile, testFile)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "rHqLp7tVuPAp",
        "outputId": "18363c73-9036-451d-81a5-1105da786d8f"
      },
      "execution_count": 29,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dev accuracy for best dev model: 0.740, 95% CIs: [0.679 0.801]\n",
            "\n",
            "Test accuracy for best dev model: 0.765, 95% CIs: [0.679 0.801]\n",
            "\n",
            "Agreement\t0.218\t&\n",
            "Agreement\t0.188\t%\n",
            "Agreement\t0.179\tleast\n",
            "Agreement\t0.175\tget\n",
            "Agreement\t0.175\t?\n",
            "Agreement\t0.175\tinfections\n",
            "Agreement\t0.154\tsimilar\n",
            "Agreement\t0.152\tshowed\n",
            "Agreement\t0.151\t3\n",
            "Agreement\t0.151\tsymptoms\n",
            "\n",
            "Disagreement\t0.331\tn't\n",
            "Disagreement\t0.310\t?\n",
            "Disagreement\t0.292\tactually\n",
            "Disagreement\t0.241\tgoing\n",
            "Disagreement\t0.227\tsay\n",
            "Disagreement\t0.223\tsure\n",
            "Disagreement\t0.218\tgraph\n",
            "Disagreement\t0.191\tsimply\n",
            "Disagreement\t0.184\tspikes\n",
            "Disagreement\t0.184\tcertain\n",
            "\n",
            "Neutral\t0.342\tabstract\n",
            "Neutral\t0.264\tcovid-19\n",
            "Neutral\t0.197\t(\n",
            "Neutral\t0.193\t)\n",
            "Neutral\t0.192\tpandemic\n",
            "Neutral\t0.186\t.\n",
            "Neutral\t0.186\tvaccine\n",
            "Neutral\t0.174\tsars-cov-2\n",
            "Neutral\t0.159\tb\n",
            "Neutral\t0.146\tmaturation\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### confusion matrix"
      ],
      "metadata": {
        "id": "VoMG8nAhrEk8"
      }
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "MLrG-qcow4EL"
      },
      "execution_count": 29,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def print_confusion(classifier):\n",
        "    fig, ax = plt.subplots(figsize=(10,10))\n",
        "    plot_confusion_matrix(classifier.log_reg, classifier.devX, classifier.devY, ax=ax, xticks_rotation=\"vertical\", values_format=\"d\")\n",
        "    plt.show()"
      ],
      "metadata": {
        "id": "jTZ-umck0ZKs"
      },
      "execution_count": 30,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def print_confusion_test(classifier):\n",
        "    fig, ax = plt.subplots(figsize=(10,10))\n",
        "    plot_confusion_matrix(classifier.log_reg, classifier.testX, classifier.testY, ax=ax, xticks_rotation=\"vertical\", values_format=\"d\")\n",
        "    plt.show()"
      ],
      "metadata": {
        "id": "6FCOqcVpOQWV"
      },
      "execution_count": 31,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def run(trainingFile, devFile, testFile):\n",
        "    trainX, trainY=load_data(trainingFile)\n",
        "    devX, devY=load_data(devFile)\n",
        "    testX, testY=load_data(testFile)\n",
        "\n",
        "    trainX = list(map(remove_stop_df, trainX))\n",
        "    devX = list(map(remove_stop_df, devX))\n",
        "    testX = list(map(remove_stop_df, testX))\n",
        "\n",
        "    simple_classifier = Classifier(binary_bow_featurize, trainX, trainY, devX, devY, testX, testY)\n",
        "    simple_classifier.train()\n",
        "    accuracy_test=simple_classifier.test()\n",
        "    accuracy_dev=simple_classifier.dev()\n",
        "\n",
        "    \n",
        "    lower, upper=confidence_intervals(accuracy_dev, len(devY), .95)\n",
        "    print(\"Dev accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy_dev, lower, upper))\n",
        "    lower, upper=confidence_intervals(accuracy_dev, len(testY), .95)\n",
        "    print(\"Test accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy_test, lower, upper))\n",
        "\n",
        "\n",
        "    print_confusion(simple_classifier)\n",
        "    print_confusion_test(simple_classifier)\n",
        "\n",
        "    simple_classifier.printWeights()"
      ],
      "metadata": {
        "id": "sDbmdDLR1hze"
      },
      "execution_count": 32,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "run(trainingFile, devFile, testFile)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "HjgPZbsH1sbe",
        "outputId": "48948c7e-9ad3-4e55-a9d1-481a067ec1d8"
      },
      "execution_count": 33,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dev accuracy for best dev model: 0.740, 95% CIs: [0.679 0.801]\n",
            "\n",
            "Test accuracy for best dev model: 0.765, 95% CIs: [0.679 0.801]\n",
            "\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "iVBORw0KGgoAAAANSUhEUgAAAnkAAAJYCAYAAAAe+fAyAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAADh0RVh0U29mdHdhcmUAbWF0cGxvdGxpYiB2ZXJzaW9uMy4yLjIsIGh0dHA6Ly9tYXRwbG90bGliLm9yZy+WH4yJAAAgAElEQVR4nO3dd7xkdX3/8dd7l6UufQGRIkUEsSGigiQExSgaI2qwhcSGQSOxERMlIT+NLSbGqBjUYImYoAKigo0igiiRsiBSpUjHRVh6h937+f0xZ/Gybrl7996ZOXNez8fjPGbO95wz5zP3MehnP99yUlVIkiRptMwYdACSJEmaeiZ5kiRJI8gkT5IkaQSZ5EmSJI0gkzxJkqQRtMqgA5AkSeqHFz53rbr1toV9ude5Fzx4YlXt3ZebLYVJniRJ6oRbb1vI2Sdu2Zd7zdz0ijl9udEy2F0rSZI0gqzkSZKkTihgjLFBh9E3VvIkSZJGkJU8SZLUEcXCspInSZKkFrOSJ0mSOqE3Jq8GHUbfWMmTJEkaQVbyJElSZzi7VpIkSa1mJU+SJHVCUSwsx+RJkiSpxUzyJEmSRpDdtZIkqTNcQkWSJEmtZiVPkiR1QgELreRJkiSpzazkSZKkznBMniRJklrNSp4kSeqEAhdDliRJUrtZyZMkSZ0xNugA+shKniRJUp8l+XKSm5NctIRjf5ukksxp9pPk0CRXJrkgyc4TuYdJniRJ6oSiWNinbQK+Auy9eGOSLYAXANeNa34RsF2zHQB8biI3MMmTJEnqs6o6HbhtCYc+Cfw9PCpT3Af4avWcCayXZNPl3cMxeZIkqRsKFvZvcu2cJHPH7R9eVYcv64Ik+wA3VtUvk4w/tBlw/bj9G5q2ecv6PJM8SZKkqTe/qnaZ6MlJ1gT+gV5X7ZQwyZMkSZ1QDPXs2m2BrYFFVbzNgfOSPAu4Edhi3LmbN23L5Jg8SZKkAauqC6tq46raqqq2otclu3NV3QQcD7yumWW7K3BnVS2zqxZM8iRJkvouydeBnwPbJ7khyf7LOP0HwFXAlcAXgLdN5B5210qSpI4IC8nyT+uDqnrtco5vNe59AQeu6D2s5EmSJI0gK3mSJKkTChjr3xIqA2clT5IkaQRZyZMkSZ0xLGPy+sFKniRJ0giykidJkjqhsJInSZKklrOSJ0mSOmOsrORJkiSpxazkSZKkTnBMniRJklrPSp4kSeqEIizsUH2rO99UkiSpQ6zkSZKkznB2rSRJklrNJE+SJGkE2V0rSZI6oWtLqJjkDZE5G8ysrbaYNegwNEKuuHCtQYegEVNVgw5BI+QB7uWherA7WVefmeQNka22mMXZJ24x6DA0Ql60za6DDkEjZuzBBwcdgkbIWWM/6vMdw8Lqzki17nxTSZKkDrGSJ0mSOqGAsQ7Vt7rzTSVJkjrESp4kSeqMLs2utZInSZI0gqzkSZKkTqhydq0kSZJazkqeJEnqjDHH5EmSJKnNrORJkqRO6D27tjv1re58U0mSpA6xkidJkjrC2bWSJElqOZM8SZKkEWR3rSRJ6oQCxjpU3+rON5UkSeoQK3mSJKkzFpaLIUuSJKnFrORJkqROKOJiyJIkSWo3K3mSJKkzxlwMWZIkSW1mJU+SJHVCgWPyJEmS1G5W8iRJUicUcZ08SZIktZuVPEmS1Bk+u1aSJEmtZiVPkiR1QhUsdJ08SZIktZmVPEmS1BFhDGfXSpIkqcVM8iRJkkaQ3bWSJKkTCideSJIkqeWs5EmSpM5Y2KH6Vne+qSRJUodYyZMkSZ1QhLFyCRVJkiS1mJU8SZLUGY7JkyRJUqtZyZMkSZ1QwJjr5EmSJKnNrORJkqSOCAtxdq0kSZJazEqeJEnqBMfkSZIkaVol+XKSm5NcNK7t40l+leSCJN9Ost64YwcnuTLJZUleOJF7mORJkqTOWNiMy5vubQK+Auy9WNvJwJOr6qnA5cDBAEl2BF4DPKm55rNJZi7vBiZ5kiRJfVZVpwO3LdZ2UlUtaHbPBDZv3u8DfKOqHqyqq4ErgWct7x4meZIkSVNvTpK547YDVvD6NwE/bN5vBlw/7tgNTdsyOfFCkiR1QlX6OfFiflXtMpkLk/wjsAA4cmUCMMmTJEkaEkneALwE2Kuqqmm+Edhi3GmbN23LZJInSZI6Y+EQL6GSZG/g74E/qqr7xh06Hvhakv8AHgtsB5y9vM8zyZMkSeqzJF8H9qQ3du8G4P30ZtOuBpycBODMqnprVV2c5GjgEnrduAdW1cLl3cMkT5IkdUIBY0PyWLOqeu0Smr+0jPM/AnxkRe4xvDVLSZIkTZqVPEmS1BEZ6jF5U60731SSJKlDrORJkqROKGCshmNMXj9YyZMkSRpBVvIkSVJnLOxQfas731SSJKlDrORJkqROKOKYPEmSJLWblTxJktQZYx2qb3Xnm0qSJHWISZ4kSdIIsrtWkiR1QhUs7NDEC5M8DZ1PvHsLzvrROqw3ZwGHn3rZo4598/Mb8YUPbsbRF17Iuhsu5JjPbsSPv7UBAAsXwvVXrM5RF17EOusvHEToaqEZM4pDj7uI+b9dlQ+8eftBh6OWO+gT1/Hs59/FHfNX4S177TDocNRxQ9tdm+RlSSpJa/8rab7DjoOOo21e8Orb+MiRV/1e+803zuK8n6zNxps99EjbK992C5/70WV87keX8aaD5/GU3e4xwdMK2eeNN3Hdr9cYdBgaEScdvQH/uN82gw5DyzBW6cs2DIY2yQNeC/yseZ2wJDOnJ5xJeRlgkreCnrLrvay9hETtvz6wGfsf8huylP92Tv3O+uz5stunOTqNkjmPeZBnPfcOTjxqo0GHohFx0VmzufuOYfq/IXXZUCZ5SWYDfwDsD7ymaZuR5LNJfpXk5CQ/SLJvc+yaJP+a5DzglUlekOTnSc5LckzzeSR5RpKfJDk3yYlJNm3aT0vyySRzk1ya5JlJvpXkiiQfHhfXXyQ5O8n5Sf5rUUKZ5J4kH0nyyyRnJtkkyXOAlwIfb87ftp9/w1Hzfyesw5zHPMy2T3pgiccfuC/MPW1t/uDFd/Y5MrXZW/7pWr70sS0ZGxuOf3VLml69xZBn9GUbBsMRxe/bBzihqi4Hbk3yDOAVwFb0KmN/Cey22DW3VtXOwI+AQ4DnN/tzgYOSzAI+A+xbVc8Avgx8ZNz1D1XVLsDngeOAA4EnA29IsmGSJwKvBnavqp2AhcB+zbVrAWdW1dOA04G/qqr/A44H/q6qdqqqXy/piyY5oEku595yq92MS/LAfeEbn9mE1/3dvKWec+bJ6/KkXe61q1YT9qzn3c4dt87iyovWGnQokjQthnXixWuBTzfvv9HsrwIcU1VjwE1JTl3smqOa113pJYJnpNevtyrwc2B7eknbyU37TGB81nB883ohcHFVzQNIchWwBb3K4jOAc5rr1wBubq55CPhe8/5c4I8n+kWr6nDgcIBdnrZ6TfS6Lpl37WrcdN2q/PXze8Mzb5k3iwNfuD2H/uByNth4AQA/OW49u2q1QnZ8xt3sutftPHPPO5i1WrHm7IX83X9cyccPevygQ5M0jRbSncr90CV5STYAngc8JUnRS8YK+PZyLr130UcAJ1fVo8byJXkKveRt8QrgIg82r2Pj3i/aX6X53COq6uAlXPtwVS1K0BYyhH/XNtv6iQ9w9IUXP7L/umftyGd+eBnrbtir2t171wwuOHM27/3P6wYVolroKx/fkq98fEsAnvLsu/izv5pngidppAxjd+2+wP9U1eOqaquq2gK4GrgN+LNmbN4mwJ5Luf5MYPckjwdIslaSJwCXARsl2a1pn5XkSSsQ1ynAvkk2bq7fIMnjlnPN3cDaK3APAf/y14/j3X+6HTf8enX2e8aOnPC1DZZ5/hk/XI9n7HE3q6851qcIJWnJ3nfYNXzy+CvYfNsH+N+5F/PC19w66JA0TtGt2bXDWHF6LfCvi7UdCzwRuAG4BLgeOA/4vVH2VXVLkjcAX0+yWtN8SFVd3kzUODTJuvS++6eAixf/jCWpqkuSHAKclGQG8DC9cXvXLuOybwBfSPIOemMBlzguT4928OeW9SeFr559yaP2X/Dq23jBq2+bzpA04i48ax0uPGudQYehEfCxA7cadAjSI4Yuyauq5y6h7VDozbqtqnuSbAicTW/8HFW11WLn/xh45hI+53xgjyW07znu/WnAaUs5dhS/G/s3/vrZ495/E/hm8/4MXEJFkqQhkaGZ+doPQ5fkLcf3kqxHbzLFh6rqpkEHJEmSNIxaleSNr6pJkiStqLEOza7tTs1SkiSpQ1pVyZMkSZqsKlg4JDNf+8FKniRJ0ggyyZMkSRpBdtdKkqTO6NISKt35ppIkSR1iJU+SJHVCMTyPHOsHK3mSJEkjyEqeJEnqDBdDliRJUqtZyZMkSZ1Q4Jg8SZIktZuVPEmS1BmukydJkqRWs5InSZK6oVwnT5IkSS1nJU+SJHVC4Tp5kiRJajkreZIkqTMckydJkqRWM8mTJEkaQXbXSpKkTvCxZpIkSWo9K3mSJKkzrORJkiSp1azkSZKkTih8rJkkSZJazkqeJEnqDB9rJkmSpFazkidJkrqhnF0rSZKklrOSJ0mSOsEnXkiSJKn1rORJkqTOsJInSZKkVrOSJ0mSOsEnXkiSJKn1TPIkSZJGkN21kiSpM8ruWkmSJLWZSZ4kSeqMMdKXbXmSfDnJzUkuGte2QZKTk1zRvK7ftCfJoUmuTHJBkp0n8l1N8iRJkvrvK8Dei7W9DzilqrYDTmn2AV4EbNdsBwCfm8gNTPIkSVInVPUWQ+7HtvxY6nTgtsWa9wGOaN4fAbxsXPtXq+dMYL0kmy7vHiZ5kiRJU29OkrnjtgMmcM0mVTWveX8TsEnzfjPg+nHn3dC0LZOzayVJUmf0cXbt/KraZbIXV1UlqZUJwEqeJEnScPjtom7Y5vXmpv1GYItx523etC2TSZ4kSeqI/ozHW4lHpx0PvL55/3rguHHtr2tm2e4K3DmuW3ep7K6VJEnqsyRfB/akN3bvBuD9wMeAo5PsD1wLvKo5/QfAi4ErgfuAN07kHiZ5kiSpM4bliRdV9dqlHNprCecWcOCK3sPuWkmSpBFkJU+SJHVCwcqMl2sdK3mSJEkjyEqeJEnqhuo99aIrrORJkiSNIJM8SZKkEWR3rSRJ6owxnHghSZKkFrOSJ0mSOqEYnsWQ+8FKniRJ0giykidJkjoiLoYsSZKkdrOSJ0mSOsPFkCVJktRqVvIkSVJnOLtWkiRJrWYlT5IkdUJVtyp5JnlD5FfXzWGPvz5g0GFohKzxwNmDDkGSNCAmeZIkqTNcJ0+SJEmtZiVPkiR1huvkSZIkqdVM8iRJkkaQ3bWSJKkzurSEipU8SZKkEWQlT5IkdUIRK3mSJElqNyt5kiSpMzq0goqVPEmSpFFkJU+SJHVDObtWkiRJLWclT5IkdUeHBuVZyZMkSRpBVvIkSVJnOCZPkiRJrWYlT5IkdUY5Jk+SJEltZiVPkiR1QuGYPEmSJLWcSZ4kSdIIsrtWkiR1QwF210qSJKnNrORJkqTOcAkVSZIktZqVPEmS1B1W8iRJktRmVvIkSVJHxMWQJUmS1G5W8iRJUnc4Jk+SJEltZiVPkiR1Q+GYPEmSJLWblTxJktQdjsmTJElSm1nJkyRJHeKYPEmSJLWYlTxJktQdjsmTJElSm5nkSZIkjSC7ayVJUnfYXStJkqQ2s5InSZK6oQAfayZJkqQ2s5InSZI6oxyTJ0mSpDYzyZMkSd1RfdomIMm7k1yc5KIkX0+yepKtk5yV5MokRyVZdbJf1SRPkiSpz5JsBrwD2KWqngzMBF4D/Cvwyap6PHA7sP9k72GSJ0mSuqPSn21iVgHWSLIKsCYwD3ge8M3m+BHAyyb7VU3yJEmSpt6cJHPHbQeMP1hVNwL/DlxHL7m7EzgXuKOqFjSn3QBsNtkAnF0rSZI6I/2bXTu/qnZZahzJ+sA+wNbAHcAxwN5TGcBSk7wkn2EZQwer6h1TGYgkSVKHPB+4uqpuAUjyLWB3YL0kqzTVvM2BGyd7g2VV8uZO9kMlSZKGzgrMfO2D64Bdk6wJ3A/sRS/3OhXYF/gG8HrguMneYKlJXlUdMX4/yZpVdd9kbyRJkqSeqjoryTeB84AFwC+Aw4HvA99I8uGm7UuTvcdyx+Ql2a25wWxgyyRPA95SVW+b7E0lSZL6b4Vmvk67qno/8P7Fmq8CnjUVnz+R2bWfAl4I3NoE9Etgj6m4uSRJkqbHhJZQqarrF2taOA2xSJIkaYpMZAmV65M8B6gks4B3ApdOb1iSJEnTYHgmXky7iVTy3gocSG8xvt8AOzX7kiRJGlLLreRV1Xxgvz7EIkmSNL2s5P1Okm2SfDfJLUluTnJckm36EZwkSZImZyLdtV8DjgY2BR5L77EbX5/OoCRJkqZF9WkbAhNJ8tasqv+pqgXN9r/A6tMdmCRJkiZvWc+u3aB5+8Mk76P3eI0CXg38oA+xSZIkTZ1iqBZDnm7LmnhxLr0/x6K/xlvGHSvg4OkKSpIkSStnWc+u3bqfgUiSJE23DMl4uX6YyGLIJHkysCPjxuJV1VenKyhJkiStnOUmeUneD+xJL8n7AfAi4GeASZ4kSWqXDlXyJjK7dl9gL+Cmqnoj8DRg3WmNSpIkSStlIt2191fVWJIFSdYBbga2mOa4JABWXWUBn/nb7zFrlYXMnDHGab/Yhv/+3jOA4s0vnctzd76KsbEZfOenT+TYU5886HDVMrvseRdv/dBvmDmj+OHXN+Do/9xk0CGp5fxNaZhMJMmbm2Q94Av0ZtzeA/x8eRclWQhcCMwCFtDr3v1kkzDuAryuqt4x6chbIsmewENV9X+DjqWNHlowk3d96k+4/8FZzJwxxmHvOZ6zLt6cxz3mDjZe/x7+4p9fRVVYb+37Bx2qWmbGjOLAj97Iwa/ZhvnzZvGZH1zBmSeuy3VXuAyoJsfflIbNRJ5d+7bm7eeTnACsU1UXTOCz76+qnQCSbEzvyRnrAO+vqrnA3EnGvFxJVqmqBdP1+StoT3qJsUnepIT7H5wFwCozx1hl5hhV4WV7XMoHv/xcqlnv6I671xhkkGqh7Z9+H7+5ZlVuum41AE47bj12e+Gd/h+yJs3fVDs4uxZIsvOyjlXVeRO9SVXdnOQA4JwkHwD+CHhPVb0kyR8Bn150KrBH83ocsD69SuAhVXVcc+9/Av4CuAW4Hji3qv49yWnA+cAfAF9v9v8DmA3MB95QVfOSbAscBmwE3Af8VVX9KslXgPuBpwMbA28CXgfsBpxVVW9o7v8C4J+B1YBfA2+sqnuSXAMcAfxpE/MrgQeAtwILk/wF8Paq+ulE/27qmZExvnDwt9lso7v4zk925NJrNuaxc+7iec+4ij/c6RruuGd1Dj3qOdxwi0NFNXEbPuZhbvnNqo/sz583ix12vm+AEant/E1p2CyrkveJZRwr4HkrcqOquirJTHoJ1HjvAQ6sqjOSzKaXGAG8vKruSjIHODPJ8cAuwJ/Rm/wxCziPXhfyIqtW1S5JZgE/AfapqluSvBr4CL3E7XDgrVV1RZJnA58d913Wp5fUvRQ4HtgdeDO95HQn4AbgEOD5VXVvkvcCBwEfbK6fX1U7J3kbvST2zUk+D9xTVf++pL9Lk/weALDaGutN+O/ZJWM1g/0/+mfMXuNBPvyWk9n6sbcxa5WFPPTwTA742MvZY6eree/rfsLbP/HSQYcqSdLQWNZiyM/tUwxnAP+R5EjgW1V1Q5OkfTTJHsAYsBmwCb2k67iqegB4IMl3F/uso5rX7YEnAycnAZgJzGuSyOcAxzTt0KvILfLdqqokFwK/raoLAZJcDGwFbE5vKZkzmutX5dHjE7/VvJ4LvGIiX76qDqeXeDJ7/c07VERecffcvxq/uPyxPHvHG7jljrU4/fytADj9/K143+t+Mtjg1Dq33jSLjR770CP7czZ9mPnzZg0wIrWdv6mW6NBjzSayhMqUSLINsJDe7NxHVNXH6FXL1qCXPO0A7EevO/UZzbi+3zJuIeZluHfR7YCLq2qnZntKVb2A3ve9Y1z7TlX1xHHXP9i8jo17v2h/leZzTx537Y5Vtf8Srl/IBBea1rKtO/t+Zq/R+7OuOmsBuzzxBq69aV1+9sutePoT5gGw03bzuP63dtVqxVx2/ppstvVDbLLFg6wya4w997mDM0/yd6TJ8zelYdOXRCTJRsDngf9sKmXjj23bVMwuTPJMYAd66/DdXFUPJ3ku8Ljm9DOA/0ryL03sL6Gpgi3mMmCjJLtV1c+byuATquriJFcneWVVHZNeIE+tql9O8KucCRyW5PFVdWWStYDNquryZVxzN70JJ5qEDde9j394/U+YmSIzilPP3YafX/Q4Lvz1Y/inN57Kq/a6kPsenMW//e8egw5VLTO2MBz2j5vx0a9dxYyZcNI3NuDayx0gr8nzN9UCRacWQ57OJG+NJOfzuyVU/ofeRIjFvatJ5MaAi4EfAmsD3226TecCvwKoqnOasXkX0KvuXQjcufgHVtVDSfYFDk2yLr3v+anm8/cDPpfkkCa2bwATSvKa8X1voDexY1E37yHAspK87wLfTLIPTrxYYVfduCFv/ujv93zfc/9qvPezew8gIo2Sc368Duf82H+Daer4m9IwSdWyU9qm2rUfsE1VfTDJlsBjqursfgS4hHhmN7NZ1wROBw5YkZm+w2z2+pvXTnu+c9BhaISscdxA/jOVpAk5q07hrrqtb4PkVttii9rsoHf35V5XH/S351bVLn252VJMZEzeZ+nNOH1ts383vSVIBuXwpkJ4HnDsqCR4kiRJU2ki3bXPbpYF+QVAVd2eZNXlXTRdqurPB3VvSZLUbl1aDHkilbyHm/XtCh6ZRDE2rVFJkiRppUwkyTsU+DawcZKPAD8DPjqtUUmSJE2H6tM2BCby7Nojk5wL7EVvnbiXVdWl0x6ZJEmSJm25SV4zm/Y+ekuBPNJWVddNZ2CSJElTbkiqbP0wkYkX36f3Jwm9p05sTW+x4SdNY1ySJElaCRPprn3K+P0kOwNvm7aIJEmSpkHK2bXL1KxL9+xpiEWSJElTZCJj8g4atzsD2Bn4zbRFJEmSNF2qbw/YGLiJjMlbe9z7BfTG6B07PeFIkiRpKiwzyWsWQV67qt7Tp3gkSZI0BZaa5CVZpaoWJNm9nwFJkiRNmw5NvFhWJe9seuPvzk9yPHAMcO+ig1X1rWmOTZIkSZM0kTF5qwO3As/jd+vlFWCSJ0mSWqVLS6gsK8nbuJlZexG/S+4W6dCfSJIkqX2WleTNBGbz6ORuEZM8SZLUPh3KYJaV5M2rqg/2LRJJkiRNmWUled1ZLVCSJI0+H2v2iL36FoUkSZKm1FIreVV1Wz8DkSRJmnZW8iRJktRmE1knT5IkaTRYyZMkSVKbWcmTJEmd4exaSZIktZpJniRJ0ggyyZMkSRpBJnmSJEkjyIkXkiSpO5x4IUmSpDazkidJkrqhXEJFkiRJLWclT5IkdYeVPEmSJLWZlTxJktQdVvIkSZLUZlbyJElSJwRn10qSJKnlrORJkqTusJInSZKkNjPJkyRJ3dA88aIf20QkWS/JN5P8KsmlSXZLskGSk5Nc0byuP9mva5InSZI0GJ8GTqiqHYCnAZcC7wNOqartgFOa/UkxyZMkSd1RfdqWI8m6wB7AlwCq6qGqugPYBziiOe0I4GWT/aomeZIkSVNvTpK547YDFju+NXAL8N9JfpHki0nWAjapqnnNOTcBm0w2AGfXSpIkTb35VbXLMo6vAuwMvL2qzkryaRbrmq2qSia/sp+VPEmS1B1D0l0L3ADcUFVnNfvfpJf0/TbJpgDN682T/aomeZIkSX1WVTcB1yfZvmnaC7gEOB54fdP2euC4yd7D7lpJktQZQ/ZYs7cDRyZZFbgKeCO9AtzRSfYHrgVeNdkPN8mTJEkagKo6H1jSuL29puLzTfIkSVJ3DFclb1o5Jk+SJGkEWcmTJEndMPGZryPBSp4kSdIIspInSZI6Y8hm104rK3mSJEkjyEqeJEnqDit5kiRJajMreZIkqTMckydJkqRWs5InSZK6w0qeJEmS2swkT5IkaQTZXStJkrrBx5pJkiSp7azkSZKkTkizdYWVPEmSpBFkJU+SJHVHh8bkmeQNkZn3Pszac28YdBgaIQsGHYBGT7rU2aVp16GEaxBM8iRJUmf4WDNJkiS1mpU8SZLUHVbyJEmS1GZW8iRJUndYyZMkSVKbWcmTJEndUM6ulSRJUstZyZMkSd1hJU+SJEltZpInSZI0guyulSRJneHEC0mSJLWalTxJktQdVvIkSZLUZlbyJElSZzgmT5IkSa1mJU+SJHVD4Zg8SZIktZuVPEmS1B1W8iRJktRmVvIkSVInBGfXSpIkqeWs5EmSpO6wkidJkqQ2s5InSZI6I9WdUp6VPEmSpBFkkidJkjSC7K6VJEnd4GPNJEmS1HZW8iRJUme4GLIkSZJazUqeJEnqDit5kiRJajMreZIkqTMckydJkqRWs5InSZK6w0qeJEmS2sxKniRJ6oZyTJ4kSZJazkqeJEnqDit5kiRJajMreZIkqROCY/IkSZLUciZ5kiRJI8juWkmS1B3Vnf5aK3mSJEkDkmRmkl8k+V6zv3WSs5JcmeSoJKtO9rNN8iRJUmek+rOtgHcCl47b/1fgk1X1eOB2YP/JfleTPEmSpAFIsjnwJ8AXm/0AzwO+2ZxyBPCyyX6+Y/IkSVI3FP1cDHlOkrnj9g+vqsMXO+dTwN8Dazf7GwJ3VNWCZv8GYLPJBmCSJ0mSNPXmV9UuSzuY5CXAzVV1bpI9pyMAkzxJktQZGRt0BI/YHXhpkhcDqwPrAJ8G1kuySlPN2xy4cbI3cEyeJElSn1XVwVW1eVVtBbwG+HFV7QecCuzbnPZ64LjJ3sMkT5IkdUf1aZu89wIHJbmS3hi9L032g+yulSRJGqCqOg04rXl/FfCsqfhckzxJktQZK7iGXavZXStJkjSCrORJkqRuKHx2rSRJktrNSp4kSeoMx+RJkiSp1azkSZKk7rCSJ0mSpDYzyZMkSRpBdtdKkqROCE68kCRJUstZyZMkSd1Q5WLIkiRJajcreXN0URkAABWsSURBVJIkqTMckydJkqRWM8nTUHvnP13AkSeewmHf+OkjbX+w1zw+e9RP+e5ZP+TxT7xzgNGp7XbZ8y6++NNf8d9nXMqr/ua3gw5HI+CgT1zHUb+8iP865VeDDkVLU33ahsDIJ3lJKsknxu2/J8kHJvlZ6yV52ySvvSbJnMlc22U/+t7m/L937PKotmt/vTYf+func9EvNhhQVBoFM2YUB370Rg7Zb2v+as/tee4+d7Dldg8MOiy13ElHb8A/7rfNoMOQgA4kecCDwCumKMFaD1hikpfE8Y3T4OJfbMDdd816VNv118zmxmtnDygijYrtn34fv7lmVW66bjUWPDyD045bj91eaGVYK+eis2Zz9x0zBx2GliHVn20YdCHJWwAcDrx78QNJNkpybJJzmm33pv0DSd4z7ryLkmwFfAzYNsn5ST6eZM8kP01yPHBJc+53kpyb5OIkB/Th+0mahA0f8zC3/GbVR/bnz5vFnE0fHmBEkjS1ulJ9Ogy4IMm/Ldb+aeCTVfWzJFsCJwJPXMbnvA94clXtBJBkT2Dnpu3q5pw3VdVtSdYAzklybFXdurQPbBLBAwBWn7n2JL6aJEmakALGhqTM1gedSPKq6q4kXwXeAdw/7tDzgR2TLNpfJ8mK9gOePS7BA3hHkpc377cAtgOWmuRV1eH0Ko2su+om3fnlSQN2602z2OixDz2yP2fTh5k/b9YyrpCkdulCd+0inwL2B9Ya1zYD2LWqdmq2zarqHnpdvOP/Nqsv43PvXfSmqew9H9itqp4G/GI510oakMvOX5PNtn6ITbZ4kFVmjbHnPndw5knrDjosSdPN2bWjp6puA46ml+gtchLw9kU7SXZq3l5DrxuWJDsDWzftdwPL6lNdF7i9qu5LsgOw65QE32F//+Hz+cSXz2Tzx93LEd/7MS946fXstudNHPG9H/PEp9zOBz45lw8ees6gw1QLjS0Mh/3jZnz0a1fxhZ9cxunfXY9rL/ffZFo57zvsGj55/BVsvu0D/O/ci3nha5bakSNNu050147zCeBvxu2/AzgsyQX0/hanA28FjgVel+Ri4CzgcoCqujXJGUkuAn4IfH+xzz8BeGuSS4HLgDOn88t0wb8dstMS239+2mP6HIlG0Tk/XodzfrzOoMPQCPnYgVsNOgQtx7DMfO2HkU/yqmr2uPe/BdYctz8fePUSrrkfeMFSPu/PF2s6bdyxB4EXLeW6rVYgbEmSpJXSme5aSZKkLhn5Sp4kSdIjqjv9tVbyJEmSRpCVPEmS1BldmnhhJU+SJGkEWcmTJEndMEQLFfeDlTxJkqQRZCVPkiR1QoA4u1aSJEltZiVPkiR1x9igA+gfK3mSJEkjyEqeJEnqDMfkSZIkqdWs5EmSpG5wnTxJkiS1nZU8SZLUEQWOyZMkSVKbmeRJkiSNILtrJUlSZ6Q7vbVW8iRJkkaRlTxJktQdTryQJElSm1nJkyRJ3VCQsUEH0T9W8iRJkkaQlTxJktQdjsmTJElSm1nJkyRJ3dGdQp6VPEmSpFFkJU+SJHVGHJMnSZKkNrOSJ0mSusNKniRJktrMSp4kSeqGAnzihSRJktrMJE+SJGkE2V0rSZI6IZRLqEiSJKndrORJkqTusJInSZKkNrOSJ0mSusNKniRJkqZLki2SnJrkkiQXJ3ln075BkpOTXNG8rj/Ze5jkSZKkbli0GHI/tuVbAPxtVe0I7AocmGRH4H3AKVW1HXBKsz8pJnmSJEl9VlXzquq85v3dwKXAZsA+wBHNaUcAL5vsPRyTJ0mSOqOP6+TNSTJ33P7hVXX4kk5MshXwdOAsYJOqmtccugnYZLIBmORJkiRNvflVtcvyTkoyGzgWeFdV3ZXkkWNVVUkmnZWa5EmSpO4Yotm1SWbRS/COrKpvNc2/TbJpVc1Lsilw82Q/3zF5kiRJfZZeye5LwKVV9R/jDh0PvL55/3rguMnew0qeJEnqiBqmSt7uwF8CFyY5v2n7B+BjwNFJ9geuBV412RuY5EmSJPVZVf0MyFIO7zUV9zDJkyRJ3VAMUyVv2jkmT5IkaQSZ5EmSJI0gu2slSVJ3TOyRYyPBSp4kSdIIspInSZI6o4+PNRs4K3mSJEkjyEqeJEnqDit5kiRJajMreZIkqRsKGLOSJ0mSpBazkidJkjqiHJMnSZKkdrOSJ0mSusNKniRJktrMSp4kSeoOK3mSJElqMyt5kiSpG1wnT5IkSW1nJW+I3PXwzfNPuOHQawcdRwvMAeYPOgiNFH9TE9WdIsjK8jc1MY8bdACjzCRviFTVRoOOoQ2SzK2qXQYdh0aHvylNNX9Tw6qgxgYdRN/YXStJkjSCrORJkqTucAkVaagdPugANHL8TWmq+ZvSwFnJU+tUlf/jqSnlb0pTzd/UkHIJFUmSJLWdlTxJktQdjsmTJElSm1nJkyRJ3WElTxoeSbaeSJu0IpLsPpE2aXmSbLCsbdDxqbus5KkNjgV2Xqztm8AzBhCLRsdn+P3f1ZLapOU5l968zSzhWAHb9DccLV11qpJnkqehlWQH4EnAukleMe7QOsDqg4lKbZdkN+A5wEZJDhp3aB1g5mCiUptVlT0LGkomeRpm2wMvAdYD/nRc+93AXw0kIo2CVYHZ9P73b+1x7XcB+w4kIo2MJOsD2zHuH6JVdfrgItKjFDDWnWfXmuRpaFXVccBxSXarqp8POh6Nhqr6CfCTJF+pqmsHHY9GR5I3A+8ENgfOB3YFfg48b5BxqbtM8tQGVyb5B2Arxv1mq+pNA4tIo2C1JIfz+78r/w9Zk/VO4JnAmVX13GbIyUcHHJMW55g8aagcB/wU+BGwcMCxaHQcA3we+CL+rjQ1HqiqB5KQZLWq+lWS7QcdlLrLJE9tsGZVvXfQQWjkLKiqzw06CI2UG5KsB3wHODnJ7YBDAjQwJnlqg+8leXFV/WDQgWikfDfJ24BvAw8uaqyq2wYXktqsql7evP1AklOBdYETBhiSlsTuWmmovBP4hyQPAQ/RW4uqqmqdwYallnt98/p349pc00yTkmQmcHFV7QCPTPCRBsokT0OvqtZe/lnSinFtM02lqlqY5LIkW1bVdYOOR0tTMGYlTxoaSQLsB2xdVR9KsgWwaVWdPeDQ1GJJ1gQOArasqgOSbAdsX1XfG3Boaq/1gYuTnA3cu6ixql46uJDUZSZ5aoPPAmP01pr6EHAPcBi9pQqkyfpveo+jek6zfyO9GbcmeZqsfxp0AFqOgqruLIY8Y9ABSBPw7Ko6EHgAoKpup/fUAmllbFtV/wY8DFBV97HkZ49KE/XiqvrJ+A148aCDUneZ5KkNHm4GNRdAko3oVfaklfFQkjX43e9qW8bNspUm4Y+X0PaivkehZRur/mxDwO5atcGh9Ja52DjJR+g9X/SQwYakEfB+estbbJHkSGB34A0DjUitlOSvgbcB2ya5YNyhtYH/G0xUkkmeWqCqjkxyLrAXve60l1XVpQMOSy1XVScnOY/e80UDvLOq5g84LLXT14AfAv8CvG9c+92uuziEXCdPGjq/pfdos1WANZLsXFXnDTgmtd9mwEx6v6s9klBV3xpwTGqZqroTuDPJ4k/mmZ1ktkuqaFBM8jT0knyIXjfar2nGTzWvPkhek5bky8BTgYv53RjPAkzyNFnfp/cbCrA6sDVwGfCkQQalcapgrDtDuk3y1AavojcT8qFBB6KRsmtV7TjoIDQ6quop4/eT7ExvrJ40EM6uVRtcBKw36CA0cn6exCRP06YZUvLsQcehxVT1ZxsCVvLUBv8C/CLJRTz6QfKuIq+V8VV6id5N9H5Xi56J/NTBhqW2SnLQuN0ZwM7AbwYUjmSSp1Y4AvhX4EJcH09T50vAX+LvSlNn/HO2F9Abo3fsgGLRUpRj8qShcl9VHTroIDRybqmq4wcdhEZHVf0z9J6L3DxBRRookzy1wU+T/AtwPI/urnUJFa2MXyT5GvBdHv27cnatJiXJbvQqxLOBLZM8DXhLVTn5QgNhkqc2eHrzuuu4NpdQ0cpag15y94JxbS6hopXxKeCF9P5BSlX9Mskegw1JjzY8kyL6wSRPQ6+qnjvoGDR6quqNg45Bo6eqrk8yvmnhoGKRXEJFQy/JJkm+lOSHzf6OSfYfdFxqtyRPSHJKM2ubJE9N4jORtTKuT/IcoJLMSvIewEcwDpMCxqo/2xAwyVMbfAU4EXhss3858K6BRaNR8QXgYOBhgKq6AHjNQCNS270VOJDe4/JuBHZq9qWBsLtWbTCnqo5OcjBAVS1IYheIVtaaVXX2Yl1rCwYVjNqvquYD+w06Di1HuYSKNEzuTbIhzXNrk+wK3DnYkDQC5ifZlt/9rvYF5g02JLVRkv+3jMNVVR/qWzDSOCZ5aoOD6M1W2zbJGcBGwL6DDUkj4EDgcGCHJDcCVwN/MdiQ1FL3LqFtLWB/YEPAJG9IFFBDMl6uH0zyNPSq6rwkfwRsT+/RU5dV1cMDDkstV1VXAc9PshYwo6ruHnRMaqeq+sSi90nWBt4JvBH4BvCJpV0nTTcnXmjoJVkTeB/wrqq6CNgqyUsGHJZabtGsbeCbVXW3s7a1MpJskOTDwAX0Cig7V9V7q+rmAYem8ap6Y/L6sQ0Bkzy1wX8DDwG7Nfs3Ah8eXDgaEV/BWduaAkk+DpwD3A08pao+UFW3DzgsySRPrbBtVf0bv1vq4j563bbSyphTVUcDY9CbtY0L12py/pbePxYOAX6T5K5muzvJXQOOTYupserLNgxM8tQGDyVZg9/NgtyWcc8alSbJWduaElU1o6rWqKq1q2qdcdvaVbXOoOPT8Eqyd5LLklyZ5H1T/flOvFAbvB84AdgiyZHA7sAbBhqRRoGztqUuGpLxcklmAocBfwzcAJyT5PiqumSq7mGSp6GWZAawPvAKYFd63bTvbBYdlSal+R/XP2o2Z21LGoRnAVc2M/1J8g1gH2DKkrxUDUe/sbQ0SeZW1S6DjkOjJcnZVfWsQcchqX+SnADM6dPtVgceGLd/eFUdPi6WfYG9q+rNzf5fAs+uqr+ZqgCs5KkNftQ86Psoxi06WlW3DS4kjYAzkvwnv/+7Om9wIUmaTlW196Bj6CeTPLXBq5vX8Q/6LmCbAcSi0bFT8/rBcW0FPG8AsUjqnhuBLcbtb960TRm7ayVJkvosySr01ufci15ydw7w51V18VTdw0qehl6SVyyh+U7gQleT12QlOWgJzXcC51bV+f2OR1K3VNWCJH9Db1H2mcCXpzLBAyt5aoEk36f3tItTm6Y9gXOBrYEPVtX/DCg0tViSrwG7AN9tml5C75FUWwHHNAtwS1JrmeRp6CU5EXhdVf222d8E+CrwWuD0qnryIONTOyU5HXhxVd3T7M8Gvg/sTa+at+Mg45OkleUTL9QGWyxK8Bo3N2230TzqTJqEjXn0k1MeBjapqvvxiSqSRoBj8tQGpyX5HnBMs/9nTdtawB2DC0stdyRwVpLjmv0/Bb7W/K6mbDFSSRoUu2s19JKE3hMv/qBpup1exeXApV8lLV+SZwLPaXbPqKq5g4xHkqaSlTwNvaqqJFfRe6zZK4GrgWMHG5VGQVWdk+RaeivTk2TLqrpuwGFJ0pQwydPQSvIEepMrXgvMp/dkglTVcwcamEZCkpcCnwAeS2+c55bAr4AnDTIuSZoqTrzQMPsVvacPvKSq/qCqPgMsHHBMGh0folcdvryqtgaeD5w52JAkaeqY5GmYvQKYB5ya5AtJ9gIy4Jg0Oh6uqluBGUlmVNWp9NbNk6SRYHethlZVfQf4TjPbcR/gXcDGST4HfLuqThpogGq7O5q18U4HjkxyM3DvgGOSpCnj7Fq1SpL16U2+eHVV7TXoeNRezT8e7qfXo7EfsC5wZFPdk6TWM8mT1EmLkryqGmsm+ewA/LCqXGBb0kgwyZPUSUnOBf4QWB84AzgHeKiq9htoYJI0RZx4IamrUlX30Zvg89mqeiUunyJphJjkSeqqJNmN3ni87zdtMwcYjyRNKZM8SV31LuBgejO1L06yDXDqgGOSpCnjmDxJkqQR5Dp5kjolyaeq6l1Jvgv83r9yq+qlAwhLkqacSZ6krvmf5vXfBxqFJE0zu2sldVaSjQCq6pZBxyJJU82JF5I6J8kHkswHLgMuT3JLkv836LgkaSqZ5EnqlCQHAbsDz6yqDapqfeDZwO5J3j3Y6CRp6thdK6lTkvwC+OOqmr9Y+0bASVX19MFEJklTy0qepK6ZtXiCB4+My5s1gHgkaVqY5EnqmocmeUySWsXuWkmdkmQhcO+SDgGrV5XVPEkjwSRPkiRpBNldK0mSNIJM8iRJkkaQSZ6kvkuyMMn5SS5KckySNVfis76SZN/m/ReT7LiMc/dM8pxJ3OOaJHMm2r7YOfes4L0+kOQ9KxqjJC3OJE/SINxfVTtV1ZPpzWh96/iDSSb1XO2qenNVXbKMU/YEVjjJk6Q2MsmTNGg/BR7fVNl+muR44JIkM5N8PMk5SS5I8haA9PxnksuS/AjYeNEHJTktyS7N+72TnJfkl0lOSbIVvWTy3U0V8Q+TbJTk2OYe5yTZvbl2wyQnJbk4yRfpzbxdpiTfSXJuc80Bix37ZNN+yqLn5SbZNskJzTU/TbLDVPwxJWmRSf1rWZKmQlOxexFwQtO0M/Dkqrq6SZTurKpnJlkNOCPJScDTge2BHYFNgEuALy/2uRsBXwD2aD5rg6q6LcnngXuq6t+b874GfLKqfpZkS+BE4InA+4GfVdUHk/wJsP8Evs6bmnusAZyT5NiquhVYC5hbVe9uno/7fuBvgMOBt1bVFUmeDXwWeN4k/oyStEQmeZIGYY0k5zfvfwp8iV436tlVdXXT/gLgqYvG2wHrAtsBewBfr6qFwG+S/HgJn78rcPqiz6qq25YSx/OBHZNHCnXrJJnd3OMVzbXfT3L7BL7TO5K8vHm/RRPrrcAYcFTT/r/At5p7PAc4Zty9V5vAPSRpwkzyJA3C/VW10/iGJtkZv0hxgLdX1YmLnffiKYxjBrBrVT2whFgmLMme9BLG3arqviSnAasv5fRq7nvH4n8DSZpKjsmTNKxOBP46ySyAJE9IshZwOvDqZszepsBzl3DtmcAeSbZurt2gab8bWHvceScBb1+0k2RR0nU68OdN24uA9ZcT67rA7U2CtwO9SuIiM4BF1cg/p9cNfBdwdZJXNvdIkqct5x6StEJM8iQNqy/SG293XpKLgP+i1/vwbeCK5thXgZ8vfmFV3QIcQK9r9Jf8rrv0u8DLF028AN4B7NJM7LiE383y/Wd6SeLF9Lptr1tOrCcAqyS5FPgYvSRzkXuBZzXf4XnAB5v2/YD9m/guBvaZwN9EkibMx5pJkiSNICt5kiRJI8gkT5IkaQSZ5EmSJI0gkzxJkqQRZJInSZI0gkzyJEmSRpBJniRJ0gj6/8rOgu5mB1itAAAAAElFTkSuQmCC\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Agreement\t0.218\t&\n",
            "Agreement\t0.188\t%\n",
            "Agreement\t0.179\tleast\n",
            "Agreement\t0.175\tget\n",
            "Agreement\t0.175\t?\n",
            "Agreement\t0.175\tinfections\n",
            "Agreement\t0.154\tsimilar\n",
            "Agreement\t0.152\tshowed\n",
            "Agreement\t0.151\t3\n",
            "Agreement\t0.151\tsymptoms\n",
            "\n",
            "Disagreement\t0.331\tn't\n",
            "Disagreement\t0.310\t?\n",
            "Disagreement\t0.292\tactually\n",
            "Disagreement\t0.241\tgoing\n",
            "Disagreement\t0.227\tsay\n",
            "Disagreement\t0.223\tsure\n",
            "Disagreement\t0.218\tgraph\n",
            "Disagreement\t0.191\tsimply\n",
            "Disagreement\t0.184\tspikes\n",
            "Disagreement\t0.184\tcertain\n",
            "\n",
            "Neutral\t0.342\tabstract\n",
            "Neutral\t0.264\tcovid-19\n",
            "Neutral\t0.197\t(\n",
            "Neutral\t0.193\t)\n",
            "Neutral\t0.192\tpandemic\n",
            "Neutral\t0.186\t.\n",
            "Neutral\t0.186\tvaccine\n",
            "Neutral\t0.174\tsars-cov-2\n",
            "Neutral\t0.159\tb\n",
            "Neutral\t0.146\tmaturation\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### finding counts"
      ],
      "metadata": {
        "id": "w_4Rn1A-4I_L"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# importing Counter module\n",
        "from collections import Counter"
      ],
      "metadata": {
        "id": "WHEkOdtA2shN"
      },
      "execution_count": 34,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "trainX, trainY=load_data(trainingFile)\n",
        "\n",
        "devX, devY=load_data(devFile)\n",
        "testX, testY=load_data(testFile)\n",
        "print(\"On Train:\",Counter(trainY))\n",
        "print(\"On Dev:\",Counter(devY))\n",
        "print(\"On Test :\",Counter(testY))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "cN0pyrUE2_f0",
        "outputId": "7076ac4a-eb6d-46ee-f09b-5248493e8f94"
      },
      "execution_count": 35,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "On Train: Counter({'Agreement': 442, 'Disagreement': 109, 'Neutral': 49})\n",
            "On Dev: Counter({'Agreement': 152, 'Disagreement': 36, 'Neutral': 12})\n",
            "On Test : Counter({'Agreement': 151, 'Disagreement': 29, 'Neutral': 20})\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### unigram features"
      ],
      "metadata": {
        "id": "D3MLbXIv37nH"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "agreement_words = ['yes','yeah','absolutely']\n",
        "diagree_words = [\"no\",\"only\",\"garbage\",\"wrong\"]\n",
        "neutral_words = ['should','probably']"
      ],
      "metadata": {
        "id": "4gDTiWkeNkYL"
      },
      "execution_count": 36,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def unigram_featurize(text):\n",
        "    feats = {}\n",
        "    words = nltk.word_tokenize(text)\n",
        "\n",
        "    for word in words:\n",
        "        word=word.lower()\n",
        "\n",
        "        if word in agreement_words: \n",
        "            feats[\"contains_agreement_word\"] = 1\n",
        "        if word in diagree_words:\n",
        "            feats[\"contains_diagree_word\"] = 1\n",
        "        if word in neutral_words:\n",
        "            feats[\"contains_neutral_word\"] = 1\n",
        "        \n",
        "            \n",
        "    return feats"
      ],
      "metadata": {
        "id": "xmRM4TIk4gc-"
      },
      "execution_count": 37,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def run_feature1(trainingFile, devFile, testFile):\n",
        "    trainX, trainY=load_data(trainingFile)\n",
        "    devX, devY=load_data(devFile)\n",
        "    testX, testY=load_data(testFile)\n",
        "\n",
        "    trainX = list(map(remove_stop_df, trainX))\n",
        "    devX = list(map(remove_stop_df, devX))\n",
        "    testX = list(map(remove_stop_df, testX))\n",
        "\n",
        "    simple_classifier = Classifier(unigram_featurize, trainX, trainY, devX, devY, testX, testY)\n",
        "    simple_classifier.train()\n",
        "    accuracy=simple_classifier.test()\n",
        "\n",
        "    print_confusion(simple_classifier)\n",
        "\n",
        "    \n",
        "    lower, upper=confidence_intervals(accuracy, len(devY), .95)\n",
        "    print(\"Test accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy, lower, upper))\n",
        "\n",
        "    simple_classifier.printWeights()"
      ],
      "metadata": {
        "id": "Nzu46UK564HR"
      },
      "execution_count": 38,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "run_feature1(trainingFile, devFile, testFile)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "id": "el6G7oI_OfmJ",
        "outputId": "d67ea3d6-d42c-4d71-9b47-c90f548cd601"
      },
      "execution_count": 39,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "iVBORw0KGgoAAAANSUhEUgAAAnkAAAJYCAYAAAAe+fAyAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAADh0RVh0U29mdHdhcmUAbWF0cGxvdGxpYiB2ZXJzaW9uMy4yLjIsIGh0dHA6Ly9tYXRwbG90bGliLm9yZy+WH4yJAAAgAElEQVR4nO3dd7xkdX3/8dd7l6WXBRaQskoRQWwIqGBBFKNojKjBShQVJUSi2JKoIdGIGmPvmrWiPxALKmChWAAl9CJVEEERWIQF6WXL/fz+mLNwWXfvXu7evTNnzuv5eMzjzvnOnDmfmccRP/v5tlQVkiRJGi7T+h2AJEmSJp9JniRJ0hAyyZMkSRpCJnmSJElDyCRPkiRpCK3S7wAkSZKmwnOesVbddPOiKbnWORfce3xV7TUlF1sGkzxJktQJN928iDOPf+iUXGv6pr+bNSUXGoPdtZIkSUPISp4kSeqEAkYY6XcYU8ZKniRJ0hCykidJkjqiWFRW8iRJktRiVvIkSVIn9MbkVb/DmDJW8iRJkoaQlTxJktQZzq6VJElSq1nJkyRJnVAUi8oxeZIkSWoxkzxJkqQhZHetJEnqDJdQkSRJUqtZyZMkSZ1QwCIreZIkSWozK3mSJKkzHJMnSZKkVrOSJ0mSOqHAxZAlSZLUblbyJElSZ4z0O4ApZCVPkiRpCFnJkyRJnVCU6+RJkiSp3azkSZKkbihY1J1CnpU8SZKkYWQlT5IkdULh7FpJkiS1nEmeJEnSELK7VpIkdURYRPodxJSxkidJkjSErORJkqROKGDEJVQkSZLUZlbyJElSZzgmT5IkSa1mJU+SJHVCYSVPkiRJLWclT5IkdcZIWcmTJEnSSpLkq0luSHLRUl57e5JKMqs5TpJPJ7kiyQVJdhrPNUzyJElSJywekzcVj3H4OrDXko1JZgPPBq4e1fxcYNvmcQDwhfFcwCRPkiRpilXVKcDNS3npE8C/0stJF9sb+Eb1nA7MTLLp8q7hmDxJktQJRVg0dfWtWUnOHnU8p6rmjHVCkr2Ba6vqN8kDqoGbA38adXxN0zZ3rM8zyZMkSZp886pql/G+OcmawLvpddVOCpM8SZLUGQM8u3YbYCtgcRVvC+DcJE8ErgVmj3rvFk3bmByTJ0mS1GdVdWFVbVxVW1bVlvS6ZHeqquuBY4BXN7NsdwVuraoxu2rBJE+SJGnKJfkWcBqwXZJrkuw/xtt/AlwJXAF8CXjjeK5hd60kSeqEQdrWrKpesZzXtxz1vICDHuw1TPIGyKwNpteWs2f0OwwNkcsvWLPfIUjSMt3Dncyvewcj6xpCJnkDZMvZMzjz+NnLf6M0Ts/ZbMd+hyBJy3RG/XyKrxgWVXdGqnXnm0qSJHWIlTxJktQJBYx0qL7VnW8qSZLUIVbyJElSZwzK7NqpYCVPkiRpCFnJkyRJnVDl7FpJkiS1nJU8SZLUGSOOyZMkSVKbWcmTJEmd0Nu7tjv1re58U0mSpA6xkidJkjrC2bWSJElqOZM8SZKkIWR3rSRJ6oQCRjpU3+rON5UkSeoQK3mSJKkzFpWLIUuSJKnFrORJkqROKOJiyJIkSWo3K3mSJKkzRlwMWZIkSW1mJU+SJHVCgWPyJEmS1G5W8iRJUicUcZ08SZIktZuVPEmS1BnuXStJkqRWs5InSZI6oQoWuU6eJEmS2sxKniRJ6ogwgrNrJUmS1GImeZIkSUPI7lpJktQJhRMvJEmS1HJW8iRJUmcs6lB9qzvfVJIkqUOs5EmSpE4owki5hIokSZJazEqeJEnqDMfkSZIkqdWs5EmSpE4oYMR18iRJktRmVvIkSVJHhEU4u1aSJEktZiVPkiR1gmPyJEmS1HpW8iRJUmc4Jk+SJEmtZpInSZI0hOyulSRJnVAVJ15IkiSp3azkSZKkzlhkJU+SJEltZiVPkiR1QgEjLqEiSZKkNrOSJ0mSOiKOyZMkSVK7WcmTJEmdUMBIOSZPkiRJLWYlT5IkdcaiDtW3uvNNJUmSBkSSrya5IclFo9o+kuS3SS5I8oMkM0e99q4kVyS5LMlzxnMNkzxJktQJRRipqXmMw9eBvZZoOxF4dFU9FrgceBdAkh2AlwOPas75fJLpy7uASZ4kSdIUq6pTgJuXaDuhqhY2h6cDWzTP9waOrKp7q+oq4Argicu7hmPyJElSZ4xMXX1rVpKzRx3Pqao5D+L81wHfbp5vTi/pW+yapm1MJnmSJEmTb15V7TKRE5P8O7AQOHxFAjDJkyRJGhBJXgM8H9izqqppvhaYPeptWzRtYzLJkyRJnVAFiwZ4MeQkewH/Cjy9qu4a9dIxwBFJPg5sBmwLnLm8zzPJ08D52Ftnc8bP1mXmrIXM+eVlAHzzow/hp0dswHobLALgte+6jifueTvnnLw2X/3gZixcEFaZUbzhP65jx6fe0c/w1SK77HEbBx56HdOnFT/91gZ857Ob9DsktZz3lMYrybeAPeiN3bsGeA+92bSrAScmATi9qg6sqouTfAe4hF437kFVtWh51xjYJC/JC4EfAI+sqt/2O56JaL7D5VV1Sb9jaZNnv+xmXvDaeXzk4Ic+oP1Fb7iRl/zTjQ9oW2+DRbzvsCvZ8CEL+cNvV+fdr9yaI87159byTZtWHPTBa3nXy7dm3twZfOYnv+P049fj6t+t3u/Q1FLeU+0wKNuaVdUrltL8lTHe/wHgAw/mGoO8hMorgF83f8dtPOvGTKEXAjv0O4i2ecyud7LO+sv9BwoAD3/M3Wz4kN5s84dtdw/33jON+fcOxv+ANdi2e/xdXPeHVbn+6tVYuGAaJx09k92ec2u/w1KLeU9p0AxkkpdkbeCpwP70Fv8jybQkn29Wgj4xyU+S7NO89ock/5PkXOAlSZ6d5LQk5yb5bvN5JNk5yclJzklyfJJNm/aTknwiydlJLk3yhCTfT/K7JO8fFdc/JDkzyflJ/ndxQpnkjiQfSPKbJKcn2STJk4EXAB9p3r/NVP6Gw+jYr23EgXtux8feOpvbb/nrXP7XP16Phz/6blZdrZZytvRAGz5kATdet+p9x/PmzmDWpgv6GJHazntq8PUWQ542JY9BMBhR/LW9geOq6nLgpiQ7Ay8GtqRXGXsVsNsS59xUVTsBPwMOAZ7VHJ8NvC3JDOAzwD5VtTPwVR5Y9pzfTHX+InA0cBDwaOA1STZM8kjgZcBTqmpHYBGwb3PuWvT6zR8HnAK8oar+j95AyX+pqh2r6vdL+6JJDmiSy7NvvGl81asuev5+8/jaaZfw+RMvY4NNFjDnvzZ7wOt/uGx1vvKBzTj4w3/qU4SSJA2WQR2T9wrgU83zI5vjVYDvVtUIcH2SXy5xzuIFA3ellwie2gxaXBU4DdiOXtK2eDDjdGDuqPOPaf5eCFxcVXMBklxJb9ryU4GdgbOa89cAbmjOmQ/8qHl+DvA34/2izcKIcwB2edzqlqCWYf2NFt73/Ln73sx/vnqr+45vvG4G79t/S/7lU1ez2Zbz+xGeWuim62ew0Wb33y+zNl3AvLkz+hiR2s57qh0W0Z0hPQOX5CXZAHgm8JgkRS8ZK3qTMMZy5+KPAE5cckBjksfQS96WrAAudm/zd2TU88XHqzSfe1hVvWsp5y4YtZbNIgbwd227m/68Chtu0kv0/u+n67HldvcAcMet0/mPV2/N6949l0c98c6xPkJ6gMvOX5PNt5rPJrPv5abrZ7DH3rfwoYMe1u+w1GLeUxo0g5iM7AN8s6r+cXFDkpPp7e/290kOAzaiN+34iKWcfzrwuSQPr6orkqxFb+uPy4CNkuxWVac13bePqKqLxxnXz4Gjk3yiqm5oktF1quqPY5xzO7DOOD9fjf/+p4dxwWlrc+vNq7DvzjvwqrdfzwWnrc3vL16DBDbZYj5vbrplj/naLK67alUO//hDOPzjD+mdf+TvmTlr4ViXkBhZFD7375vzwSOuZNp0OOHIDfjj5c6C1MR5Tw2+YnBm106FQUzyXgH8zxJtRwGPpLdX2yXAn4Bzgb+atlRVNzarRX8ryWpN8yFVdXkzUePTSdaj990/CYwryauqS5IcApyQZBqwgN64vbGSvCOBLyV5M72xgEsdl6cHetcX/von3euVNy/lnfDKt/yZV77lzys7JA2ps36xLmf9Yt1+h6Eh4j2lQTJwSV5VPWMpbZ+G3qzbqrojyYb0Vnq+sHl9yyXe/wvgCUv5nPOB3ZfSvseo5ycBJy3jtW9z/9i/0eevPer594DvNc9PxSVUJEkaEBmYma9TYeCSvOX4UZKZ9CZTHFpV1/c7IEmSpEHUqiRvdFVNkiTpwRrp0Oza7tQsJUmSOqRVlTxJkqSJqoJFHZpdayVPkiRpCJnkSZIkDSG7ayVJUmd0aQmV7nxTSZKkDrGSJ0mSOqFIp7Y1s5InSZI0hKzkSZKkznAxZEmSJLWalTxJktQJBY7JkyRJUrtZyZMkSZ3hOnmSJElqNSt5kiSpG8p18iRJktRyVvIkSVInFK6TJ0mSpJazkidJkjrDMXmSJElqNZM8SZKkIWR3rSRJ6gS3NZMkSVLrWcmTJEmdYSVPkiRJrWYlT5IkdULhtmaSJElqOSt5kiSpM9zWTJIkSa1mJU+SJHVDObtWkiRJLWclT5IkdYI7XkiSJKn1rORJkqTOsJInSZKkVrOSJ0mSOsEdLyRJktR6JnmSJElDyO5aSZLUGWV3rSRJktrMSp4kSeqMEazkSZIkqcWs5EmSpE6ocjFkSZIktZyVPEmS1BnOrpUkSVKrWcmTJEkd4bZmkiRJajkreZIkqTMckydJkqRWs5InSZI6oXCdPEmSJLWcSZ4kSeqG6u16MRWP5Uny1SQ3JLloVNsGSU5M8rvm7/pNe5J8OskVSS5IstN4vq5JniRJ0tT7OrDXEm3vBH5eVdsCP2+OAZ4LbNs8DgC+MJ4LmORJkiRNsao6Bbh5iea9gcOa54cBLxzV/o3qOR2YmWTT5V3DiReSJKkzRpiyiRezkpw96nhOVc1ZzjmbVNXc5vn1wCbN882BP4163zVN21zGYJInSZI0+eZV1S4TPbmqKsk4Rvctm0meJEnqhGLgF0P+c5JNq2pu0x17Q9N+LTB71Pu2aNrG5Jg8SZKkwXAMsF/zfD/g6FHtr25m2e4K3DqqW3eZrORJkqSOyMAshpzkW8Ae9MbuXQO8B/gQ8J0k+wN/BF7avP0nwPOAK4C7gNeO5xomeZIkSVOsql6xjJf2XMp7CzjowV7DJE+SJHXGeBYqHhaOyZMkSRpCVvIkSVJnDPjs2kllJU+SJGkIWcmTJEmdUNWtSp5J3gC57I+zePoBB/Q7DA2R1Tmz3yFIkvrEJE+SJHXGoKyTNxUckydJkjSErORJkqTOcJ08SZIktZpJniRJ0hCyu1aSJHVGl5ZQsZInSZI0hKzkSZKkTihiJU+SJEntZiVPkiR1RodWULGSJ0mSNIys5EmSpG4oZ9dKkiSp5azkSZKk7ujQoDwreZIkSUPISp4kSeoMx+RJkiSp1azkSZKkzijH5EmSJKnNrORJkqROKByTJ0mSpJYzyZMkSRpCdtdKkqRuKMDuWkmSJLWZlTxJktQZLqEiSZKkVrOSJ0mSusNKniRJktrMSp4kSeqIuBiyJEmS2s1KniRJ6g7H5EmSJKnNrORJkqRuKByTJ0mSpHazkidJkrrDMXmSJElqMyt5kiSpQxyTJ0mSpBazkidJkrrDMXmSJElqM5M8SZKkIWR3rSRJ6g67ayVJktRmVvIkSVI3FOC2ZpIkSWozK3mSJKkzyjF5kiRJajMreZIkqTus5EmSJKnNrORJkqTucHatJEmS2sxKniRJ6ox0aEzeMpO8JJ9hjOGJVfXmlRKRJEmSVthYlbyzpywKSZKkla3o1OzaZSZ5VXXY6OMka1bVXSs/JEmSJK2o5U68SLJbkkuA3zbHj0vy+ZUemSRJ0qRKb3btVDwGwHhm134SeA5wE0BV/QbYfWUGJUmSpBUzriVUqupPSzQtWgmxSJIkdUaStya5OMlFSb6VZPUkWyU5I8kVSb6dZNWJfv54krw/JXkyUElmJHkHcOlELyhJktQ3NUWP5UiyOfBmYJeqejQwHXg58D/AJ6rq4cBfgP0n+lXHk+QdCBwEbA5cB+zYHEuSJGniVgHWSLIKsCYwF3gm8L3m9cOAF67Ih4+pquYB+070ApIkSQNj6pZQmZVk9HJ0c6pqzn1hVF2b5KPA1cDdwAnAOcAtVbWweds19IpsE7LcJC/J1sCngF3p/TSnAW+tqisnelFJkqQhN6+qdlnWi0nWB/YGtgJuAb4L7DWZAYynu/YI4DvApsBmTRDfmswgJEmSpsSAjMkDngVcVVU3VtUC4PvAU4CZTfctwBbAtRP9quNJ8tasqm9W1cLm8f+A1Sd6QUmSJHE1sGuSNZME2BO4BPglsE/znv2Aoyd6gbH2rt2gefrTJO8EjqSXm74M+MlELyhJktQXxcAsVFxVZyT5HnAusBA4D5gD/Bg4Msn7m7avTPQaY43JO4fez7H41/jH0bEB75roRSVJkrquqt4DvGeJ5iuBJ07G54+1d+1Wk3EBSZKkQZGpm13bd8udXQuQ5NHADowai1dV31hZQUmSJGnFjGcJlfcAe9BL8n4CPBf4NWCSJ0mS2qVDlbzxzK7dh96Mj+ur6rXA44D1VmpUkiRJWiHj6a69u6pGkixMsi5wAzB7JcclAbDqKgv59L/8iBmrLGL69BFOPmdrvnbszkDx+heezR47X8nIyDSOPvmRHPWLR/c7XLXMLnvcxoGHXsf0acVPv7UB3/nsJv0OSS3nPaVBMp4k7+wkM4Ev0Ztxewe9XS/GlGQRcCEwg97U4G/Q23B3JMkuwKur6s0TjrwlkuwBzK+q/+t3LG00f+F03vrxv+Xue2cwffoIn/3XYzjjoi142Ka3sPH6d/Cq/3wpVWHmOnf3O1S1zLRpxUEfvJZ3vXxr5s2dwWd+8jtOP349rv6dy4BqYrynNGjGs3ftG5unX0xyHLBuVV0wjs++u6p2BEiyMb2dM9YF3lNVZwNnj3Xyikiyyqh93/ptD3qJsUnehIS7750BwCrTR1hl+ghF2Pvpl3Lol59BNesd3XL7Gv0MUi203ePv4ro/rMr1V68GwElHz2S359zq/yFrwryn2sHZtUCSncZ6rarOHe9FquqGJAcAZyV5L/B04B1V9fwkT6e3Ny70hkPu3vw9GlifXiXwkKo6urn2fwD/ANwI/Ak4p6o+muQk4HzgqcC3muOPA2sD84DXVNXcJNsAnwM2Au4C3lBVv03ydXobBD8e2Bh4HfBqYDfgjKp6TXP9ZwP/BawG/B54bVXdkeQPwGHA3zUxvwS4BzgQWJTkH4A3VdWvxvu7qWdaRphzyA/YfKPb+OFJO3DpVRuz2Ua38YwnXMnTdvwDt96xOp868slce4NDRTV+Gz5kATdet+p9x/PmzmD7ne7qY0RqO+8pDZqxKnkfG+O1Ap75YC5UVVcmmU4vgRrtHcBBVXVqkrXpJUYAL6qq25LMAk5PcgywC/D39CZ/zKC3SvQ5oz5r1araJckM4GRg76q6McnLgA/QS9zmAAdW1e+SPAn4/Kjvsj69pO4FwDH09pB7Pb3kdEfgGuAQ4FlVdWeSfwPeBryvOX9eVe2U5I30ktjXJ/kicEdVfXRpv0uT/B4AsNoaM8f9e3bJSE3j9Yf+PWuvcS/vf+OJbLXZzcxYZRHzF0znHz/4Ip72+Kt4534n86aPvKDfoUqSNDDGWgz5GVMUw6nAx5McDny/qq5pkrQPJtkdGAE2Bzahl3QdXVX3APckOXaJz/p283c74NHAib3t4JgOzG2SyCcD323aoVeRW+zYqqokFwJ/rqoLAZJcDGxJb6PgHYBTm/NX5YHjE7/f/D0HePF4vnxVzaGXeLLOzC06VER+8O64ezXO++1mPPFR13DjLWtxyrlbAvCr87bkna85ub/BqXVuun4GG202/77jWZsuYN7cGX2MSG3nPdUSA7Kt2VQYzxIqkyLJ1sAierNz71NVH6JXLVuDXvK0PbAvve7UnZtxfX9m1ELMY7hz8eWAi6tqx+bxmKp6Nr3ve8uo9h2r6pGjzr+3+Tsy6vni41Wazz1x1Lk7VNX+Szl/EeNcaFpjW2/tu1l7jd7PuuqMheyywzVcff16/Pq8Ldlp+7kA7PiIuVzzZ7tq9eBcdv6abL7VfDaZfS+rzBhhj71v4fQTvI80cd5TGjRTkogk2Qj4IvDZplI2+rVtmorZhUmeAGxPbx2+G6pqQZJnAA9r3n4q8L9J/ruJ/fk0VbAlXAZslGS3qjqtqQw+oqouTnJVkpdU1XfTC+SxVfWbcX6V04HPJXl4VV2RZC1g86q6fIxzbqc34UQTsOF6d/Hu157MtGlFUpx09tacduHDuPCKh3DI63/JS551IXffM4MPf2P3foeqlhlZFD7375vzwSOuZNp0OOHIDfjj5Q6Q18R5T7VA0anFkFdmkrdGkvO5fwmVb9KbCLGktzSJ3AhwMfBTYB3g2Kbb9GzgtwBVdVYzNu8CetW9C4Fbl/zAqpqfZB/g00nWo/c9P9l8/r7AF5Ic0sR2JDCuJK8Z3/caehM7FnfzHgKMleQdC3wvyd448eJBu/LaDXn9+/+65/uOu1fjnZ/Zqw8RaZic9Yt1OesX/htMk8d7SoMkVWOntE21a19g66p6X5KHAg+pqjOnIsClxLN2M5t1TeAU4IAHM9N3kK0zc4vacfeD+x2GhsjqP+rL/0wlaVzOqJ9zW908ZYPkVps9uzZ/21un5FpXve3t51TVLlNysWUYz5i8z9ObcfqK5vh2ekuQ9MucpkJ4LnDUsCR4kiRJk2k83bVPapYFOQ+gqv6SZNXlnbSyVNUr+3VtSZLUbl1aDHk8lbwFzfp2BfdNohhZqVFJkiRphYwnyfs08ANg4yQfAH4NfHClRiVJkrQy1BQ9BsB49q49PMk5wJ701ol7YVVdutIjkyRJ0oQtN8lrZtPeRW8pkPvaqurqlRmYJEnSpBuQKttUGM/Eix/T+0lCb9eJregtNvyolRiXJEmSVsB4umsfM/o4yU7AG1daRJIkSStBytm1Y2rWpXvSSohFkiRJk2Q8Y/LeNupwGrATcN1Ki0iSJGllqSnbYKPvxjMmb51RzxfSG6N31MoJR5IkSZNhzCSvWQR5nap6xxTFI0mSpEmwzCQvySpVtTDJU6YyIEmSpJWmQxMvxqrknUlv/N35SY4BvgvcufjFqvr+So5NkiRJEzSeMXmrAzcBz+T+9fIKMMmTJEmt0qUlVMZK8jZuZtZexP3J3WId+okkSZLaZ6wkbzqwNg9M7hYzyZMkSe3ToQxmrCRvblW9b8oikSRJ0qQZK8nrzmqBkiRp+Lmt2X32nLIoJEmSNKmWWcmrqpunMhBJkqSVzkqeJEmS2mw86+RJkiQNByt5kiRJajMreZIkqTOcXStJkqRWM8mTJEkaQiZ5kiRJQ8gkT5IkaQg58UKSJHWHEy8kSZLUZlbyJElSN5RLqEiSJKnlrORJkqTusJInSZKkNrOSJ0mSusNKniRJktrMSp4kSeqE4OxaSZIktZyVPEmS1B1W8iRJktRmVvIkSVI3uOOFJEmS2s5KniRJ6g4reZIkSWozkzxJkqQhZHetJEnqDrtrJUmS1GYmeZIkqTNSU/MYVyzJzCTfS/LbJJcm2S3JBklOTPK75u/6E/2uJnmSJEn98SnguKraHngccCnwTuDnVbUt8PPmeEJM8iRJUnfUFD2WI8l6wO7AVwCqan5V3QLsDRzWvO0w4IUT/aomeZIkSZNvVpKzRz0OWOL1rYAbga8lOS/Jl5OsBWxSVXOb91wPbDLRAJxdK0mSumGcVbZJMq+qdhnj9VWAnYA3VdUZST7FEl2zVVXJxDdis5InSZI09a4BrqmqM5rj79FL+v6cZFOA5u8NE72ASZ4kSeqMQZldW1XXA39Ksl3TtCdwCXAMsF/Tth9w9ES/q921kiRJ/fEm4PAkqwJXAq+lV4D7TpL9gT8CL53oh5vkSZKk7higHS+q6nxgaeP29pyMz7e7VpIkaQhZyZMkSZ0x8bmq7WMlT5IkaQhZyZMkSd1hJU+SJEltZpInSZI0hOyulSRJ3TC125r1nZU8SZKkIWQlT5IkdUKaR1dYyZMkSRpCVvIkSVJ3dGhMnkneAJl21wLWPv/afoehIbKw3wFIkvrGJE+SJHWG25pJkiSp1azkSZKk7rCSJ0mSpDazkidJkrrDSp4kSZLazEqeJEnqhnJ2rSRJklrOSp4kSeoOK3mSJElqM5M8SZKkIWR3rSRJ6gwnXkiSJKnVrORJkqTusJInSZKkNrOSJ0mSOsMxeZIkSWo1K3mSJKkbCsfkSZIkqd2s5EmSpO6wkidJkqQ2s5InSZI6ITi7VpIkSS1nJU+SJHWHlTxJkiS1mZU8SZLUGanulPKs5EmSJA0hkzxJkqQhZHetJEnqBrc1kyRJUttZyZMkSZ3hYsiSJElqNSt5kiSpO6zkSZIkqc2s5EmSpM5wTJ4kSZJazUqeJEnqDit5kiRJajMreZIkqRvKMXmSJElqOSt5kiSpO6zkSZIkqc2s5EmSpE4IjsmTJElSy5nkSZIkDSG7ayVJUndUd/prreRJkiQNISt5kiSpM5x4IUmSpFazkidJkrqhcDFkSZIktZtJniRJ6oyMTM1j3PEk05Ocl+RHzfFWSc5IckWSbydZdaLf1SRPkiSpfw4GLh11/D/AJ6rq4cBfgP0n+sEmeZIkqTtqih7jkGQL4G+BLzfHAZ4JfK95y2HACyf6VU3yJEmSJt+sJGePehywlPd8EvhXYHEH74bALVW1sDm+Bth8ogE4u1aSJHXGFK6TN6+qdllmHMnzgRuq6pwke6yMAEzyJEmSpt5TgBckeR6wOrAu8ClgZpJVmmreFsC1E72A3bWSJKkbit7etVPxWF4oVe+qqi2qakvg5cAvqmpf4JfAPs3b9gOOnujXNcmTJEkaHP8GvC3JFfTG6H1loh9kd60kSeqMQdy7tqpOAk5qnl8JPHEyPtdKniRJ0hCykidJkrpjACt5K4uVPEmSpCFkkidJkjSE7K6VJEmdEAZz4sXKYiVPkiRpCFnJkyRJ3dunQh4AABXXSURBVDDOhYqHhZU8SZKkIWQlT5IkdYZj8iRJktRqVvI00A4+5AKe+NQbuOUvq3LQK3YH4HVvupQnPu0GFi6Yxtxr1+ST73ssd94xo8+Rqo122eM2Djz0OqZPK376rQ34zmc36XdIajnvqRawkjc8klSSj406fkeS907ws2YmeeMEz/1DklkTObfLfvbjLfjPg5/wgLbzzpzFG1/xNP5536dx3dVr8dLX/L5P0anNpk0rDvrgtRyy71a8YY/teMbet/DQbe/pd1hqMe8pDZqhT/KAe4EXT1KCNRNYapKXxKroSnDxeRtw+20PrNKdd8ZGjCzq3bq/vWgmG27sf0T14G33+Lu47g+rcv3Vq7FwwTROOnomuz3n1n6HpRbznmqH1NQ8BkEXkryFwBzgrUu+kGSjJEclOat5PKVpf2+Sd4x630VJtgQ+BGyT5PwkH0myR5JfJTkGuKR57w+TnJPk4iQHTMH367S/+btrOOf/Nup3GGqhDR+ygBuvW/W+43lzZzBr0wV9jEht5z2lQdOV6tPngAuSfHiJ9k8Bn6iqXyd5KHA88MgxPuedwKOrakeAJHsAOzVtVzXveV1V3ZxkDeCsJEdV1U3L+sAmETwAYPXp60zgq3XXy157BYsWhV8et1m/Q5EktUEBIwNSZpsCnUjyquq2JN8A3gzcPeqlZwE7JFl8vG6StR/kx585KsEDeHOSFzXPZwPbAstM8qpqDr1KI+utukl37rwV9Ky/vYYnPPUG/v2NT6K3UY304Nx0/Qw22mz+fcezNl3AvLlO4NHEeU9p0HShu3axTwL7A2uNapsG7FpVOzaPzavqDnpdvKN/m9XH+Nw7Fz9pKnvPAnarqscB5y3nXE3AzrveyN+/6kre9/aduffe6f0ORy112flrsvlW89lk9r2sMmOEPfa+hdNPWK/fYanFvKdaoqboMQA6UckDaLpQv0Mv0ftq03wC8CbgIwBJdqyq84E/AM9v2nYCtmrefzswVp/qesBfququJNsDu0729+iafz30PB6z882sO3M+hx37Cw7/0ra8ZL/fM2PVET7w2TOB3uSLz33oMX2OVG0zsih87t8354NHXMm06XDCkRvwx8v9N5kmzntKg6YzSV7jY8A/jzp+M/C5JBfQ+y1OAQ4EjgJeneRi4AzgcoCquinJqUkuAn4K/HiJzz8OODDJpcBlwOkr88t0wYf/4/F/1XbCMbP7EImG0Vm/WJezfrFuv8PQEPGeGnyDMvN1Kgx9kldVa496/mdgzVHH84CXLeWcu4FnL+PzXrlE00mjXrsXeO4yztvyQYQtSZK0Qro0Jk+SJKkzhr6SJ0mSdJ/qTn+tlTxJkqQhZCVPkiR1RpcmXljJkyRJGkJW8iRJUjcM0ELFU8FKniRJ0hCykidJkjohQJxdK0mSpDazkidJkrpjpN8BTB0reZIkSUPISp4kSeoMx+RJkiSp1azkSZKkbnCdPEmSJLWdlTxJktQRBY7JkyRJUpuZ5EmSJA0hu2slSVJnpDu9tVbyJEmShpGVPEmS1B1OvJAkSVKbWcmTJEndUJCRfgcxdazkSZIkDSEreZIkqTsckydJkqQ2s5InSZK6ozuFPCt5kiRJw8hKniRJ6ow4Jk+SJEltZiVPkiR1h5U8SZIktZmVPEmS1A0FuOOFJEmS2swkT5IkaQjZXStJkjohlEuoSJIkqd2s5EmSpO6wkidJkqQ2s5InSZK6w0qeJEmS2sxKniRJ6gYXQ5YkSdLKlGR2kl8muSTJxUkObto3SHJikt81f9ef6DVM8iRJUmekakoe47AQeHtV7QDsChyUZAfgncDPq2pb4OfN8YSY5EmSJE2xqppbVec2z28HLgU2B/YGDmvedhjwwolewzF5kiSpO6Zudu2sJGePOp5TVXOW9sYkWwKPB84ANqmquc1L1wObTDQAkzxJkqTJN6+qdlnem5KsDRwFvKWqbkty32tVVUkmnJWa5EmSpI6ogVonL8kMegne4VX1/ab5z0k2raq5STYFbpjo5zsmT5IkaYqlV7L7CnBpVX181EvHAPs1z/cDjp7oNazkSZKkbigGqZL3FOBVwIVJzm/a3g18CPhOkv2BPwIvnegFTPIkSZKmWFX9GsgyXt5zMq5hd60kSdIQspInSZK6w23NJEmS1GZW8iRJUmeMc8uxoWAlT5IkaQhZyZMkSd1hJU+SJEltZiVPkiR1QwEjVvIkSZLUYlbyJElSR5Rj8iRJktRuVvIkSVJ3WMmTJElSm1nJkyRJ3WElT5IkSW1mJU+SJHWD6+RJkiSp7azkDZDbFtww77g/feqP/Y6jBWYB8/odhIaK95Qmm/fU+Dys3wEMM5O8AVJVG/U7hjZIcnZV7dLvODQ8vKc02bynBlVBjfQ7iCljd60kSdIQspInSZK6wyVUpIE2p98BaOh4T2myeU+p76zkqXWqyv94alJ5T2myeU8NKJdQkSRJUttZyZMkSd3hmDxJkiS1mZU8SZLUHVbypMGRZKvxtEkPRpKnjKdNWp4kG4z16Hd86i4reWqDo4Cdlmj7HrBzH2LR8PgMf31fLa1NWp5z6M3bzFJeK2DrqQ1Hy1adquSZ5GlgJdkeeBSwXpIXj3ppXWD1/kSltkuyG/BkYKMkbxv10rrA9P5EpTarKnsWNJBM8jTItgOeD8wE/m5U++3AG/oSkYbBqsDa9P77t86o9tuAffoSkYZGkvWBbRn1D9GqOqV/EekBChjpzt61JnkaWFV1NHB0kt2q6rR+x6PhUFUnAycn+XpV/bHf8Wh4JHk9cDCwBXA+sCtwGvDMfsal7jLJUxtckeTdwJaMumer6nV9i0jDYLUkc/jr+8r/Q9ZEHQw8ATi9qp7RDDn5YJ9j0pIckycNlKOBXwE/Axb1ORYNj+8CXwS+jPeVJsc9VXVPEpKsVlW/TbJdv4NSd5nkqQ3WrKp/63cQGjoLq+oL/Q5CQ+WaJDOBHwInJvkL4JAA9Y1JntrgR0meV1U/6XcgGirHJnkj8APg3sWNVXVz/0JSm1XVi5qn703yS2A94Lg+hqSlsbtWGigHA+9OMh+YT28tqqqqdfsbllpuv+bvv4xqc00zTUiS6cDFVbU93DfBR+orkzwNvKpaZ/nvkh4c1zbTZKqqRUkuS/LQqrq63/FoWQpGrORJAyNJgH2Brarq0CSzgU2r6sw+h6YWS7Im8DbgoVV1QJJtge2q6kd9Dk3ttT5wcZIzgTsXN1bVC/oXkrrMJE9t8HlghN5aU4cCdwCfo7dUgTRRX6O3HdWTm+Nr6c24NcnTRP1HvwPQchRUdWcx5Gn9DkAahydV1UHAPQBV9Rd6uxZIK2KbqvowsACgqu5i6XuPSuP1vKo6efQDeF6/g1J3meSpDRY0g5oLIMlG9Cp70oqYn2QN7r+vtmHULFtpAv5mKW3PnfIoNLaRmprHALC7Vm3waXrLXGyc5AP09hc9pL8haQi8h97yFrOTHA48BXhNXyNSKyX5J+CNwDZJLhj10jrA//UnKskkTy1QVYcnOQfYk1532gur6tI+h6WWq6oTk5xLb3/RAAdX1bw+h6V2OgL4KfDfwDtHtd/uuosDyHXypIHzZ3pbm60CrJFkp6o6t88xqf02B6bTu692T0JVfb/PMallqupW4NYkS+7Ms3aStV1SRf1ikqeBl+RQet1ov6cZP9X8dSN5TViSrwKPBS7m/jGeBZjkaaJ+TO8eCrA6sBVwGfCofgalUapgpDtDuk3y1AYvpTcTcn6/A9FQ2bWqduh3EBoeVfWY0cdJdqI3Vk/qC2fXqg0uAmb2OwgNndOSmORppWmGlDyp33FoCVVT8xgAVvLUBv8NnJfkIh64kbyryGtFfINeonc9vftq8Z7Ij+1vWGqrJG8bdTgN2Am4rk/hSCZ5aoXDgP8BLsT18TR5vgK8Cu8rTZ7R+2wvpDdG76g+xaJlKMfkSQPlrqr6dL+D0NC5saqO6XcQGh5V9V/Q2xe52UFF6iuTPLXBr5L8N3AMD+yudQkVrYjzkhwBHMsD7ytn12pCkuxGr0K8NvDQJI8D/rGqnHyhvjDJUxs8vvm766g2l1DRilqDXnL37FFtLqGiFfFJ4Dn0/kFKVf0mye79DUkPNDiTIqaCSZ4GXlU9o98xaPhU1Wv7HYOGT1X9KcnopkX9ikVyCRUNvCSbJPlKkp82xzsk2b/fcandkjwiyc+bWdskeWwS90TWivhTkicDlWRGkncAbsE4SAoYqal5DACTPLXB14Hjgc2a48uBt/QtGg2LLwHvAhYAVNUFwMv7GpHa7kDgIHrb5V0L7NgcS31hd63aYFZVfSfJuwCqamESu0C0otasqjOX6Fpb2K9g1H5VNQ/Yt99xaDnKJVSkQXJnkg1p9q1Nsitwa39D0hCYl2Qb7r+v9gHm9jcktVGS/xzj5aqqQ6csGGkUkzy1wdvozVbbJsmpwEbAPv0NSUPgIGAOsH2Sa4GrgH/ob0hqqTuX0rYWsD+wIWCSNyAKqAEZLzcVTPI08Krq3CRPB7ajt/XUZVW1oM9hqeWq6krgWUnWAqZV1e39jkntVFUfW/w8yTrAwcBrgSOBjy3rPGllc+KFBl6SNYF3Am+pqouALZM8v89hqeUWz9oGvldVtztrWysiyQZJ3g9cQK+AslNV/VtV3dDn0DRaVW9M3lQ8BoBJntrga8B8YLfm+Frg/f0LR0Pi6zhrW5MgyUeAs4DbgcdU1Xur6i99DksyyVMrbFNVH+b+pS7uotdtK62IWVX1HWAEerO2ceFaTczb6f1j4RDguiS3NY/bk9zW59i0hBqpKXkMApM8tcH8JGtw/yzIbRi116g0Qc7a1qSoqmlVtUZVrVNV6456rFNV6/Y7Pg2uJHsluSzJFUneOdmf78QLtcF7gOOA2UkOB54CvKavEWkYOGtb6qIBGS+XZDrwOeBvgGuAs5IcU1WXTNY1TPI00JJMA9YHXgzsSq+b9uBm0VFpQpr/uD69eThrW1I/PBG4opnpT5Ijgb2BSUvyUjUY/cbSsiQ5u6p26XccGi5JzqyqJ/Y7DklTJ8lxwKwputzqwD2jjudU1ZxRsewD7FVVr2+OXwU8qar+ebICsJKnNvhZs9H3txm16GhV3dy/kDQETk3yWf76vjq3fyFJWpmqaq9+xzCVTPLUBi9r/o7e6LuArfsQi4bHjs3f941qK+CZfYhFUvdcC8wedbxF0zZp7K6VJEmaYklWobc+5570kruzgFdW1cWTdQ0reRp4SV68lOZbgQtdTV4TleRtS2m+FTinqs6f6ngkdUtVLUzyz/QWZZ8OfHUyEzywkqcWSPJjertd/LJp2gM4B9gKeF9VfbNPoanFkhwB7AIc2zQ9n96WVFsC320W4Jak1jLJ08BLcjzw6qr6c3O8CfAN4BXAKVX16H7Gp3ZKcgrwvKq6ozleG/gxsBe9at4O/YxPklaUO16oDWYvTvAaNzRtN9NsdSZNwMY8cOeUBcAmVXU37qgiaQg4Jk9tcFKSHwHfbY7/vmlbC7ilf2Gp5Q4HzkhydHP8d8ARzX01aYuRSlK/2F2rgZck9Ha8eGrT9Bd6FZeDln2WtHxJngA8uTk8tarO7mc8kjSZrORp4FVVJbmS3rZmLwGuAo7qb1QaBlV1VpI/0luZniQPraqr+xyWJE0KkzwNrCSPoDe54hXAPHo7E6SqntHXwDQUkrwA+BiwGb1xng8Ffgs8qp9xSdJkceKFBtlv6e0+8PyqempVfQZY1OeYNDwOpVcdvryqtgKeBZze35AkafKY5GmQvRiYC/wyyZeS7AmkzzFpeCyoqpuAaUmmVdUv6a2bJ0lDwe5aDayq+iHww2a2497AW4CNk3wB+EFVndDXANV2tzRr450CHJ7kBuDOPsckSZPG2bVqlSTr05t88bKq2rPf8ai9mn883E2vR2NfYD3g8Ka6J0mtZ5InqZMWJ3lVNdJM8tke+GlVucC2pKFgkiepk5KcAzwNWB84FTgLmF9V+/Y1MEmaJE68kNRVqaq76E3w+XxVvQSXT5E0REzyJHVVkuxGbzzej5u26X2MR5ImlUmepK56C/AuejO1L06yNfDLPsckSZPGMXmSJElDyHXyJHVKkk9W1VuSHAv81b9yq+oFfQhLkiadSZ6krvlm8/ejfY1CklYyu2sldVaSjQCq6sZ+xyJJk82JF5I6J8l7k8wDLgMuT3Jjkv/sd1ySNJlM8iR1SpK3AU8BnlBVG1TV+sCTgKckeWt/o5OkyWN3raROSXIe8DdVNW+J9o2AE6rq8f2JTJIml5U8SV0zY8kED+4blzejD/FI0kphkiepa+ZP8DVJahW7ayV1SpJFwJ1LewlYvaqs5kkaCiZ5kiRJQ8juWkmSpCFkkidJkjSETPIkTbkki5Kcn+SiJN9NsuYKfNbXk+zTPP9ykh3GeO8eSZ48gWv8Icms8bYv8Z47HuS13pvkHQ82RklakkmepH64u6p2rKpH05vReuDoF5NMaF/tqnp9VV0yxlv2AB50kidJbWSSJ6nffgU8vKmy/SrJMcAlSaYn+UiSs5JckOQfAdLz2SSXJfkZsPHiD0pyUpJdmud7JTk3yW+S/DzJlvSSybc2VcSnJdkoyVHNNc5K8pTm3A2TnJDk4iRfpjfzdkxJfpjknOacA5Z47RNN+88X75ebZJskxzXn/CrJ9pPxY0rSYhP617IkTYamYvdc4LimaSfg0VV1VZMo3VpVT0iyGnBqkhOAxwPbATsAmwCXAF9d4nM3Ar4E7N581gZVdXOSLwJ3VNVHm/cdAXyiqn6d5KHA8cAjgfcAv66q9yX5W2D/cXyd1zXXWAM4K8lRVXUTsBZwdlW9tdkf9z3APwNzgAOr6ndJngR8HnjmBH5GSVoqkzxJ/bBGkvOb578CvkKvG/XMqrqqaX828NjF4+2A9YBtgd2Bb1XVIuC6JL9YyufvCpyy+LOq6uZlxPEsYIfkvkLduknWbq7x4ubcHyf5yzi+05uTvKh5PruJ9SZgBPh20/7/gO8313gy8N1R115tHNeQpHEzyZPUD3dX1Y6jG5pkZ/QixQHeVFXHL/G+501iHNOAXavqnqXEMm5J9qCXMO5WVXclOQlYfRlvr+a6tyz5G0jSZHJMnqRBdTzwT0lmACR5RJK1gFOAlzVj9jYFnrGUc08Hdk+yVXPuBk377cA6o953AvCmxQdJFiddpwCvbNqeC6y/nFjXA/7SJHjb06skLjYNWFyNfCW9buDbgKuSvKS5RpI8bjnXkKQHxSRP0qD6Mr3xducmuQj4X3q9Dz8Afte89g3gtCVPrKobgQPodY3+hvu7S48FXrR44gXwZmCXZmLHJdw/y/e/6CWJF9Prtr16ObEeB6yS5FLgQ/SSzMXuBJ7YfIdnAu9r2vcF9m/iuxjYexy/iSSNm9uaSZIkDSEreZIkSUPIJE+SJGkImeRJkiQNIZM8SZKkIWSSJ0mSNIRM8iRJkoaQSZ4kSdIQ+v+uHJ0h+XZ0sQAAAABJRU5ErkJggg==\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Test accuracy for best dev model: 0.755, 95% CIs: [0.695 0.815]\n",
            "\n",
            "Agreement\t0.168\tcontains_agreement_word\n",
            "Agreement\t0.075\tcontains_neutral_word\n",
            "Agreement\t-0.032\tcontains_diagree_word\n",
            "\n",
            "Disagreement\t0.079\tcontains_diagree_word\n",
            "Disagreement\t-0.035\tcontains_neutral_word\n",
            "Disagreement\t-0.090\tcontains_agreement_word\n",
            "\n",
            "Neutral\t-0.040\tcontains_neutral_word\n",
            "Neutral\t-0.048\tcontains_diagree_word\n",
            "Neutral\t-0.078\tcontains_agreement_word\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "LdcvAgR-YCNS"
      },
      "execution_count": 39,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "###Bigram Features"
      ],
      "metadata": {
        "id": "mu_AzxfvX46Y"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "agreement_bigram = ['i agree','great point','good point','great comment']\n",
        "diagree_bigram = [\"so this\",\"is that\",\"i don't\", \"not exactly\"]\n",
        "# neutral_bigram = ['should','probably']\n"
      ],
      "metadata": {
        "id": "Cw8J_f4uYi25"
      },
      "execution_count": 40,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def bigram_featurize(text):\n",
        "    feats = {}\n",
        "    tokens = nltk.word_tokenize(text)\n",
        "\n",
        "    # lower each token\n",
        "    token_lower = [token.lower() for token in tokens]\n",
        "\n",
        "    bigram = list(ngrams(token_lower, 2))\n",
        "\n",
        "    # separate each bigram with space\n",
        "    for bi in bigram:\n",
        "      joined_w = \" \".join(bi)\n",
        "      if joined_w in agreement_bigram:\n",
        "        print(joined_w)\n",
        "        feats[\"contains_agreement_bigram\"] = 1\n",
        "      if joined_w in diagree_bigram:\n",
        "        print(joined_w)\n",
        "        feats[\"contains_diagree_bigram\"] = 1\n",
        "      # if joined_w in neutral_bigram:\n",
        "      #   feats[\"contains_neutral_bigram\"] = 1\n",
        "            \n",
        "    return feats"
      ],
      "metadata": {
        "id": "6-koT-xRYCq8"
      },
      "execution_count": 41,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def run_feature2(trainingFile, devFile, testFile):\n",
        "    trainX, trainY=load_data(trainingFile)\n",
        "    devX, devY=load_data(devFile)\n",
        "    testX, testY=load_data(testFile)\n",
        "\n",
        "    trainX = list(map(remove_stop_df, trainX))\n",
        "    devX = list(map(remove_stop_df, devX))\n",
        "    testX = list(map(remove_stop_df, testX))\n",
        "\n",
        "    simple_classifier = Classifier(bigram_featurize, trainX, trainY, devX, devY, testX, testY)\n",
        "    simple_classifier.train()\n",
        "    accuracy=simple_classifier.test()\n",
        "\n",
        "    print_confusion(simple_classifier)\n",
        "\n",
        "    \n",
        "    lower, upper=confidence_intervals(accuracy, len(devY), .95)\n",
        "    print(\"Test accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy, lower, upper))\n",
        "\n",
        "    simple_classifier.printWeights()"
      ],
      "metadata": {
        "id": "1Ggdfxs8YL7b"
      },
      "execution_count": 42,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "run_feature2(trainingFile, devFile, testFile)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "id": "rvaaGfCzeh4w",
        "outputId": "128d011a-daf4-4236-b526-1f226ad64560"
      },
      "execution_count": 43,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "good point\n",
            "great comment\n",
            "good point\n",
            "good point\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Test accuracy for best dev model: 0.755, 95% CIs: [0.695 0.815]\n",
            "\n",
            "Agreement\t0.050\tcontains_agreement_bigram\n",
            "\n",
            "Disagreement\t-0.034\tcontains_agreement_bigram\n",
            "\n",
            "Neutral\t-0.016\tcontains_agreement_bigram\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### combined features "
      ],
      "metadata": {
        "id": "o4TmpZlSOjx1"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def combiner_function(text):\n",
        "\n",
        "    # Here the `all_feats` dict should contain the features -- the key should be the feature name, \n",
        "    # and the value is the feature value.  See `simple_featurize` for an example.\n",
        "    \n",
        "  all_feats={}\n",
        "  for feature in [binary_bow_featurize, unigram_featurize]:\n",
        "    all_feats.update(feature(text))\n",
        "  return all_feats"
      ],
      "metadata": {
        "id": "IddcYktSXDRi"
      },
      "execution_count": 44,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def run_combined(trainingFile, devFile, testFile):\n",
        "    trainX, trainY=load_data(trainingFile)\n",
        "    devX, devY=load_data(devFile)\n",
        "    testX, testY=load_data(testFile)\n",
        "\n",
        "    trainX = list(map(remove_stop_df, trainX))\n",
        "    devX = list(map(remove_stop_df, devX))\n",
        "    testX = list(map(remove_stop_df, testX))\n",
        "\n",
        "    simple_classifier = Classifier(combiner_function, trainX, trainY, devX, devY, testX, testY)\n",
        "    simple_classifier.train()\n",
        "    accuracy_test=simple_classifier.test()\n",
        "    accuracy_dev=simple_classifier.dev()\n",
        "\n",
        "    \n",
        "    lower, upper=confidence_intervals(accuracy_dev, len(devY), .95)\n",
        "    print(\"Dev accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy_dev, lower, upper))\n",
        "    lower, upper=confidence_intervals(accuracy_dev, len(testY), .95)\n",
        "    print(\"Test accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy_test, lower, upper))\n",
        "\n",
        "    print_confusion(simple_classifier)\n",
        "    print_confusion_test(simple_classifier)\n",
        "\n",
        "    simple_classifier.printWeights()"
      ],
      "metadata": {
        "id": "ECUZed6kXth1"
      },
      "execution_count": 45,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "run_combined(trainingFile, devFile, testFile)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 0
        },
        "id": "OE5VanfHXxrG",
        "outputId": "f50a347f-5572-4b6c-9f26-41a248a84b8c"
      },
      "execution_count": 46,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dev accuracy for best dev model: 0.740, 95% CIs: [0.679 0.801]\n",
            "\n",
            "Test accuracy for best dev model: 0.765, 95% CIs: [0.679 0.801]\n",
            "\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Agreement\t0.218\t&\n",
            "Agreement\t0.189\t%\n",
            "Agreement\t0.179\tleast\n",
            "Agreement\t0.177\t?\n",
            "Agreement\t0.176\tinfections\n",
            "Agreement\t0.174\tget\n",
            "Agreement\t0.153\tsimilar\n",
            "Agreement\t0.153\tshowed\n",
            "Agreement\t0.152\t3\n",
            "Agreement\t0.150\tsymptoms\n",
            "\n",
            "Disagreement\t0.330\tn't\n",
            "Disagreement\t0.309\t?\n",
            "Disagreement\t0.292\tactually\n",
            "Disagreement\t0.243\tgoing\n",
            "Disagreement\t0.226\tsay\n",
            "Disagreement\t0.223\tsure\n",
            "Disagreement\t0.218\tgraph\n",
            "Disagreement\t0.191\tsimply\n",
            "Disagreement\t0.184\tspikes\n",
            "Disagreement\t0.184\tcertain\n",
            "\n",
            "Neutral\t0.342\tabstract\n",
            "Neutral\t0.264\tcovid-19\n",
            "Neutral\t0.197\t(\n",
            "Neutral\t0.192\t)\n",
            "Neutral\t0.191\tpandemic\n",
            "Neutral\t0.186\t.\n",
            "Neutral\t0.186\tvaccine\n",
            "Neutral\t0.174\tsars-cov-2\n",
            "Neutral\t0.159\tb\n",
            "Neutral\t0.146\tmaturation\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### with punctuation removal"
      ],
      "metadata": {
        "id": "D3FnpKyeXzbK"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import string\n",
        "import re"
      ],
      "metadata": {
        "id": "C5zI94Qs7cEp"
      },
      "execution_count": 47,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# list_punct = string.punctuation"
      ],
      "metadata": {
        "id": "3WqouvOe7crd"
      },
      "execution_count": 48,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def punct_removal(data):\n",
        "  # remove punctutation\n",
        "  filt_data = re.sub(r'[^\\w\\d\\s\\%\\&\\?]+', '', data)\n",
        "\n",
        "  return filt_data"
      ],
      "metadata": {
        "id": "xfQ4Jp0O5K2O"
      },
      "execution_count": 49,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def print_confusion_test(classifier):\n",
        "    fig, ax = plt.subplots(figsize=(10,10))\n",
        "    plot_confusion_matrix(classifier.log_reg, classifier.testX, classifier.testY, ax=ax, xticks_rotation=\"vertical\", values_format=\"d\")\n",
        "    plt.show()"
      ],
      "metadata": {
        "id": "bnGvbs_BOCl-"
      },
      "execution_count": 50,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def run_punct(trainingFile, devFile, testFile):\n",
        "    trainX, trainY=load_data(trainingFile)\n",
        "    devX, devY=load_data(devFile)\n",
        "    testX, testY=load_data(testFile)\n",
        "\n",
        "    # remove stopwords\n",
        "    trainX = list(map(remove_stop_df, trainX))\n",
        "    devX = list(map(remove_stop_df, devX))\n",
        "    testX = list(map(remove_stop_df, testX))\n",
        "\n",
        "    # remove punct\n",
        "    trainX = list(map(punct_removal, trainX))\n",
        "    print(trainX)\n",
        "    devX = list(map(punct_removal, devX))\n",
        "    testX = list(map(punct_removal, testX))\n",
        "\n",
        "    simple_classifier = Classifier(binary_bow_featurize, trainX, trainY, devX, devY, testX, testY)\n",
        "    simple_classifier.train()\n",
        "    accuracy_test=simple_classifier.test()\n",
        "    accuracy_dev=simple_classifier.dev()\n",
        "\n",
        "    \n",
        "    lower, upper=confidence_intervals(accuracy_dev, len(devY), .95)\n",
        "    print(\"Dev accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy_dev, lower, upper))\n",
        "    lower, upper=confidence_intervals(accuracy_dev, len(testY), .95)\n",
        "    print(\"Test accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy_test, lower, upper))\n",
        "\n",
        "    print_confusion(simple_classifier)\n",
        "    print_confusion_test(simple_classifier)\n",
        "    \n",
        "    simple_classifier.printWeights()"
      ],
      "metadata": {
        "id": "oOAxfVyP4ynU"
      },
      "execution_count": 81,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "run_punct(trainingFile, devFile, testFile)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "xNi-QDgAAMJg",
        "outputId": "5c5bbf40-517a-475b-cff6-45ca92d69f2c"
      },
      "execution_count": 82,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "['seems likely  s surely vaccine passes action assume purpose prevent health services becoming overwhelmed unvaccinated patients ', 'assume virus severity effects virus effects ?', '1  assume someone exposed spike proteins vaccine opposed actual viral infection ? 2  inflammation leads myocarditis result body s immune response antigen  almost certain likely see harsher immune response actual virus opposed vaccine ', '1 evolution nt  intentional   2 omicron evolve delta  unclear less severe per infection evolved  3 seen variants probably severe evolved form  ie  delta   4 selection pressure fairly complicated select severity  example  evolving higher replication viral load makes spread cause severe cases ?', 'sensitivity analysis using cutoff 4 months also found vaccinated within 4 months prior enrollment  n39  lower viral load unvaccinated  but vaccinated â4 months prior enrollment  n58    Supplemental Figure 2 ', 'Also press release   Antibody TCell Responses Heterologous Boosting Regimen Greater Homologous Regimen Omicron Variant  analysis 65 individuals received primary vaccination two doses mRNA COVID19 vaccine  BNT162b2   followed homologous booster shot BNT162b2  n24  heterologous booster Johnson & Johnson COVID19 vaccine  n41  least six months  found regimens increased humoral cellular responses Omicron   Antibody responses Omicron boosted Johnson & Johnson COVID19 vaccine BNT162b2 vaccine  Johnson & Johnson COVID19 vaccine increasing neutralizing antibody titers 41fold four weeks postboost  BNT162b2 vaccine found increase antibody titers higher level week two postboost  declining represent 17fold increase week four postboost   progressive increase antibodies weeks following vaccination Johnson & Johnson booster similar seen following first vaccine  rapid immune response followed waning antibody response BNT162b2 booster also similar seen following twodose priming regimen   The Johnson & Johnson COVID19 vaccine boosted median Omicronreactive CD8 Tcells 55fold  Omicronreactive CD4 Tcells 31fold  homologous  BNT162b2  regimen boosted Omicronreactive CD4 CD8 Tcells 14fold   believe early update earlier preprint  https  wwwmedrxivorgcontent1011012021120221267198v1 Kind interesting J & J boosted much better nAb  might expect better cell response  increase vs pfizer nAb quite marked  interesting see NIH lancet booster study get updated Omicron compares ', 'unvaccinated less likely tested ?', 'IÄôm sure IÄôm buying still  Even earlier human series  VoC specific boosters worse response wild type increased variantspecific responses  indicating werenÄôt dumping massive amounts imprinted antibodies  rather developing separate response  IÄôll hold Pfizer numbers come showing naive protocol ', 'point imo way compare severity look death rate unvaccinated people confirmed Omicron try account approximate rates prior infection  Everything else many variables reliably control ', 'nb  data 3rd dose even less certain  authors really clear text paper ', ' cell model used study carcinoma cell line  active DNA replication differs nondividing somatic cells  also shown Huh7 cells display significant different gene protein expression including upregulated proteins involved RNA metabolism  56   Huge caveat   Furthermore  recent study showed SARSCoV2 RNA reversetranscribed integrated genome human cells  given much junk DNA seems viral origin  know exceptional viruses probably ? Like  anyone tried looking human coronaviruses ? vaccines  like flu ?', '79 % 60 % impressive  Although  lot ÄúlongcovidÄù symptoms really diagnosed months line 6 weeks proper assessment  meaningless either  hopes would higher  Edit  Fixed based reply s feedback', 'One thing end pandemic way better knowledge immunity viruses  mostly sub  thanks everyone contributing ', 'get itÄôs probably worth immunizing Omicron ancestral strain  wonder itÄôs worth exposing immune system wider variety variants multivalent vaccines  Could lead body becoming likely produce universal  Äúcommon denominatorÄù antibodies ?', 'examples continue quite stark   Norway Omicron case study   https  wwwredditcomrCOVID19commentsrhsodboutbreak_caused_by_the_sarscov2_omicron_variant   99 % Omicron symptomatic  65 % uninfected also symptomatic   Swiss study long covid kids   https  wwwredditcomrCOVID19commentsobm0wylongterm_symptoms_after_sarscov2_infection_in   9 % covid symptoms 4 weeks  Among without covid  10 % symptoms 4 weeks ', 'mRNA vaccine costs 10x  World developed countries  Also  inactivated vaccines works great kids  Coronavac kids aged 5 11 year 76 % protection symptomatic cases 90 % hospitalization  Similar protection Pfizer  83 % symptomatic cases   Data Chile  Delta  coronavac maybe could worse numbers one  recombinant vaccine ', ' Results   Among 52238 employees  4718  9 %  previously infected  36922  71 %  vaccinated studyÄôs end  Cumulative incidence COVID19 substantially higher throughout previously uninfected remained unvaccinated groups  lower vaccinated unvaccinated  lower previously infected  Incidence COVID19 increased dramatically groups Omicron variant emerged  multivariable Cox proportional hazards regression  prior COVID19 vaccination independently associated significantly lower risk COVID19  Among previously infected subjects  lower risk COVID19 overall demonstrated  vaccination associated significantly lower risk symptomatic COVID19 preOmicron  HR 060  95 % CI 040Äì090  Omicron  HR 036  95 % CI 023Äì057  phases    Conclusions   previous infection vaccination provide substantial protection COVID19  Vaccination previously infected individuals provide additional protection COVID19 several months  provides significant protection least symptomatic COVID19  Seems like vaccine previous infection similarly protective  much better immunologically naive  Vaccination postinfection helps reduce risk infection ', 'Vaccinated people less restrictions vaccinated  nt think would possible control NPIs studies like ', 's says  fact  explicitly says even Pfizer  young men twice likely get myocarditis vaccination infected  Moderna spikes much higher ', 'saying agree  maybe necessary individually sufficient conditions myocarditis ', 'IÄôve got questionconcern  mRNA vaccines  big point concern introduction proteins spikes body  see potentially harmful  people often donÄôt seem concerned billions spikes attached live viruses infection  letÄôs put aside moment   big part rebuttal concern spikes lungs could potentially great idea  thatÄôs precisely injection arm muscle  keep far away lungs even bloodstream possible  inhaled  isnÄôt good chance least adenoviruses going wind lungs produce spikes ?', 'Well one shot max per year would nice  Nearcomplete protection serious disease  protection infection  really much ask ?', 'would say thatÄôs opposite conclusion would draw ', 'clear folks home  say  negative vaccine effectiveness  mean exactly ? mean vaccinated fair worse control group  unvaccinated  case ?', 'clarification needed first paragraph  author states  Patients sometimes develop GBS recent respiratory illness digestive tract infection  rare cases  receiving certain vaccines   statement misleading  author paraphrased section reference listed 1  Mayo Clinic  GuillainBarre syndrome  source   exact cause GuillainBarre syndrome nt known  GuillainBarre syndrome may occur infection COVID19 virus  s also rare reaction receive Johnson & Johnson COVID19 vaccine  implication stating GBS result  certain vaccines  unfounded contradicted source  Mayo Clinic specifies Causes section webpage J & J Covid19 vaccine implicated rare GBS disease presentation  rather  certain vaccines   distinction crucial since reader could infer author s statement vaccines cause GBS disease presentation  would incorrect assumptioninference ', 'late make much difference Canada  hope approval allow supply GAVI  Especially considering s fridge stable ', 'Looks like study covers Delta  Delta mentioned several times Omicron never  Feel like studies info abstract ', 'Moderate intensity jogging mile every 10 minutes  go jogging 9 miles vaccine shot ? ?', 'isnÄôt study  itÄôs news directly related pediatric vaccines Covid  thought would share see mods would allow ', 'continue course without expecting constant mutations immune evasion years  Best case scenario slowly turns effectively another cold flu years mutation immunity build  see less less people walking booster come  think Dr Michael Mina others outlined worthwhile plan keep manageable levels nt overrun hospitals  real goal   Rapid tests extremely cheap compared total cost covid could manufactured incredibly large quantities quickly  Encouraging free rapids taken work school  even adhered percentage population days week  would likely massive impact', 'rate dose even worth giving 11 year old ?', 'cite paper https  pubmedncbinlmnihgov33958444 showing SARS RNA possibly reversed DNA  use evidence could also possibly happen vaccine  seems like inappropriate assumption  would  however  raise question proven SARS cause DNA edits proven mRNA vaccines cause DNA changes  causes significant edits ? could similar situation heightened concern cardiac effects vaccine cardiac effects COVID fact much worse  Study showing cardiac effects COVID worse vaccine  https  pubmedncbinlmnihgov34907393', 'adjust age   calculated 1HR HR  hazard ratio  estimated Cox regression model adjusted age  sex geographical region  using calendar time underlying time scale ', 'getting second shot 3 weeks actually harm terms eliciting broader response variants  make difference third shot 68 months second one ?', 'still lot identical epitopes antibodies attach  way less original strain  getting huge boost antibodies would amplify also ones still work    protection severe disease still 70 % even 2 doses remember well  cell response ', ' Houston Methodist sequencing 100 % COVID patients  amazing data trove  d love know s central way find s used  brief google nt find  say  page Houston Methodist website lists research s used data ', 'Would efficacy greater larger interval doses eg eight weeks Australia Canada ?', 'd like see sort study extended effectiveness   boosters ', 'Abstract emerging SARSCoV2 variants concern  VOC  harbor mutations associated increasing transmission immune escape  hence undermine effectiveness current COVID19 vaccines  late November 2021  Omicron  B11529  variant identified South Africa rapidly spread across globe  shown exhibit significant resistance neutralization serum convalescent patients  also individuals recieving currently used COVID19 vaccines multiple booster shots  Therefore  urgent need develop next generation vaccines VOCs like Omicron  study  develop panel mRNALNPbased vaccines using receptor binding domain  RBD  Omicron Delta variants  dominant current wave COVID19  addition Omicron Deltaspecific vaccines  panel also includes Hybrid vaccine uses RBD containing 16 pointmutations shown Omicron Delta RBD  well bivalent vaccine composed Omicron Delta RBDLNP half dose  Interestingly  Omicronspecific Hybrid RBDLNP elicited extremely high titer neutralizing antibody Omicron  none neutralizing antibody SARSCoV2 variants  bivalent RBDLNP  hand  generated antibody broadly neutralizing activity wildtype virus variants  Surprisingly  similar crossprotection also shown Deltaspecifc RBDLNP  Taken together  data demonstrated Omicronspecific mRNA vaccine induce potent neutralizing antibody response Omicron  inclusion epitopes variants may required eliciting crossprotection  study would lay foundation rational development next generation vaccines SARSCoV2 VOCs ', 'abstract  Vaccine efficacy infection 30 %  95 % CI  9 % 55 %  11 %  95 % CI  43 % 43 %  BNT162b2 mRNA1273  respectively  Local systemic adverse reactions reported 80 % 40 %  respectively', 'study nt considering actually happens humans  Omicron slower go lung tissue compared bronchus still lower respiratory tract infection  study also Delta less prone replicate lung tissue original impair Delta s severity  counterfactual nt concerning ', 'P value nearly much function sample size effect magnitude  good supporting evidence people believe structured observations world lead credible perspectives  ie  science   pvalue 02 massive anything ', 'study literally says risk myocarditis doubled certain demographics when compared COVID infection  ', 'Tcells nothing protection infection  damage done first couple days infection Tcells begin nuking virus ', '70 % average across participants  s 606 % vs 791 % vaccinated vs unvaccinated   lower prevalence among vaccinated participants  606 %  compared unvaccinated participants  606 % vs 791 %  aRR 070  95 % CI 058084   ', 'incubation time measles 1012 days  omicron 3 days ', 'nt think   ÄúEither boost completely shut viral replication within two days  Äù think fundamental problem fast Omicron replicates  get breakthrough infections even appropriate antibodies  ca nt get immune system act faster  unless keep boosting every 4 months never let neutralising antibody titers wane  good idea  accept breakthrough infections going happen  memory B cells time stop infection becoming severe  second problem boosters tending amplify antibody clones present first Covid jab ever took  instead developing new antibodies specifically recognize Omicron s mutated epitopes  boosted Omicronspecific vaccine  memory B cells already generated recognise nonmutated epitopes dominate response  AKA original antigenic sin ', 'Water Reed vaccine severely overhyped  s cludging different spike proteins one vaccine  s evidence simply mixing spike proteins together  like tetravalent flu vaccines  would nt work well assembling mixed nanoparticles  s good chance new variant comes  would need incorporate new variant s spike protein vaccine  making slow hell  bit dodgy whether  single vaccine  refers concept  would nt need change  vs exact formulation  s concept  s faster  probably slower  redesigning mRNA vaccine  also nt addressed whether crossstrain effect would work someone already vaccinated approved vaccines  infected  thus already  original antigenic sin  problem ', 'chances get told pursue BLA route  like FDA recently recommended  Covaxin shot ?', 'Note authors state   predicting continued efficacy existing vaccines   efficacy refers preventing moderate severe symptoms asymptomatic infection  ABSTRACT time writing  December 2021  potential emergence vaccine escape variants severe acute respiratory syndrome coronavirus 2  SARSCoV2  grave global concern  interface receptorbinding domain  RBD  SARSCoV2 spike   protein host receptor  ACE2  overlaps binding site principal neutralizing antibodies  NAb   limiting repertoire viable mutations  Nonetheless  variants multiple RBD mutations risen dominance  Nonadditive  epistatic relationships among RBD mutations apparent  assessing impact epistasis mutational landscape  particularly risk vaccine escape  crucial  employed protein structure modeling using Rosetta compare effects single mutants RBDNAb RBDACE2 interfaces wild type Delta  Gamma  Omicron variants  Overall  epistasis RBD interface appears limited  effects multiple mutations additive  Epistasis Delta variant interface weakly stabilizes NAb interaction relative ACE2 interaction  whereas Gamma  epistasis substantially destabilizes NAb interaction  Despite bearing many RBD mutations  epistatic landscape Omicron closely resembles Gamma  Thus  although Omicron poses new risks observed Delta  structural constraints RBD appear hamper continued evolution toward complete vaccine escape  modest ensemble mutations relative wild type currently known reduce vaccine efficacy likely contain majority possible escape mutations future variants  predicting continued efficacy existing vaccines  IMPORTANCE Emergence vaccine escape variants SARSCoV2 arguably pressing problem COVID19 pandemic vaccines distributed worldwide  employed computational approach assess risk antibody escape resulting mutations receptorbinding domain spike protein wildtype SARSCoV2 virus well Delta  Gamma  Omicron variants  efficacy existing vaccines Omicron could substantially reduced relative wild type  potential vaccine escape grave concern  results suggest although Omicron poses new evolutionary risks observed Delta  structural constraints RBD make continued evolution toward complete vaccine escape either Delta Omicron unlikely  modest set escapeenhancing mutations already identified wild type likely include majority possible mutations effect ', ' next used logistic additive model test negative case control design estimate relative vaccine effectiveness becoming confirmed case Delta  2553 cases  andor Omicron  1001 cases  population 12 million people largest health board Scotland  NHS GG & C  6th 12th December 2021   ran two models  one time since vaccination included  estimate protection provided recent vaccination  one without  observe current protection todayÄôs mixed waned population ', 'Vaccines nt provide much protection infection brandnew 3rd dose   slight boost  claim accounting waning protection  also warn sample size small  margin error large mention real world data suggests larger effect ', 'immunologist would know far better  s two cents someone follows commercial side things  role nonneutralizing binding antibodies COVID multifaceted still explored  one hand  nonneutralizing binding antibodies may role viral clearance  fixing complement  triggering opsonization macrophages  etc   feel people speak  papers read  assume protective role nonneutralizing antibodies  hand  nonneutralizing binding antibodies might also play role increasing disease severity  especially accompanied sufficient titers neutralizing antibodies  example papers touching upon subject   https  wwwscienceorgdoi101126scitranslmedabm7853   https  wwwscienceorgdoi101126scitranslmedabm7853   https  linkspringercomarticle101007s41745021002688   https  linkspringercomarticle101007s41745021002688   https  wwwncbinlmnihgovpmcarticlesPMC8092137   https  wwwncbinlmnihgovpmcarticlesPMC8092137  line ideas expressed papers  early stages COVID vaccine development  vaccine associated enhanced respiratory disease  VAERD  viewed potential hurdle successfully creating COVID vaccine  Like manifestations ADE  VAERD thought caused binding antibodies insufficient neutralizing activity  invitro animal model experiments demonstrated VAERD theoretically possible coronavirus vaccines  fortunately  turned none approved COVID vaccines elicited VAERD ', 'Abstract emergence severe acute respiratory syndrome coronavirus 2  SARSCoV2  variants continues shape coronavirus disease 2019  Covid19  pandemic  detection rapid spread SARSCoV2 Omicron variant  lineage B11529  Botswana South Africa became global concern contained 15 mutations spike protein immunogenic receptor binding domain less neutralized sera derived vaccinees compared previously dominant Delta variant  investigate Omicron likely Delta cause infections vaccinated persons  analyzed 37877 nasal swab PCR tests conducted 1226 December 2021 calculated test positivity rates variant vaccination status  found positivity rate among unvaccinated persons higher Delta  52 %  Omicron  45 %   found similar results persons received single vaccine dose  Conversely  results show Omicron higher positivity rates Delta among received two doses within five months  Omicron  47 % vs Delta  26 %   two doses five months ago  42 % vs 29 %   three vaccine doses  22 % vs 09 %   estimates Omicron positivity rates persons receiving one two vaccine doses significantly lower unvaccinated persons 497 % lower three doses  comparison  reduction Delta positivity rates unvaccinated 2 vaccine doses 456496 % 3 vaccine doses 832 %  Despite higher positivity rates Omicron vaccinated persons  still found 912 % Omicron infections study occurred persons eligible 1 vaccine doses time PCR testing  conclusion  escape vaccineinduced immunity likely contributed rapid rise Omicron infections ', 'Could mildly effective vaccine still protected people prior 8 months  8 months less likely natural immunity  nt read yet  unless sure found immune naive controls  graph basically  pop level  vax  nativity become less effective months living pandemic level natural immunity   would bet broke groups  vax  natural would still better natural  vax  naive would still better naive  see differing ratios assume re equal  Simpson s paradox  ?  ', 'VAERS pretty bad way identify adverse events  IÄôd love see analysis incidence myocarditis booster doses young men', 'wouldnÄôt follow age deescalation protocol approval  skip age group go younger group ', 'Abstract  Infectionneutralizing antibody responses SARSCoV2 infection COVID19 vaccination essential component antiviral immunity  Antibodymediated protection challenged emergence SARSCoV2 variants concern  VoCs  immune escape properties  omicron  B11529  rapidly spreading worldwide   report neutralizing antibody dynamics longitudinal cohort COVID19 convalescent infectionnaive individuals vaccinated mRNA BNT162b2 quantifying antiSARSCoV2spike antibodies determining avidity neutralization capacity serum  Using livevirus neutralization assays  show superior infectionneutralizing capacity VoCs  including omicron  developed either two vaccinations convalescents third vaccination breakthrough infection twicevaccinated  naive individuals  three consecutive spike antigen exposures resulted increasing neutralization capacity per antispike antibody unit paralleled stepwise increases antibody avidity  conclude infectionplusvaccinationinduced hybrid immunity triple immunization induce highquality antibodies superior neutralization capacity VoCs  including omicron ', 'agree considered  study China would nt contact SARSCoV2  routine basis  ', 'good question  appear danish data  PCRtested less pr 100000 person   Report Breakthrough infections    Danish    https  filesssidkcovid19gennembrudsinfektionrapportgennembrudsinfektioncovid19uge492021ji88  Figure 10  shows roughly 30 & unvaccinated 1664 tested latest period  611412   roughly 40 % doublejabbed beenIf recent  less 12 weeks old  positive PCRtest  also advised get tested  think could possibly skew results  Edit  positive PCRtest advised test first 12 weeks  reason think could skew results  due higher prevalence infections unvaccinated group months leading period omicron ', 'd imagine something dosag  higher Moderna', 'Vaxart phase 2 trial oral vax nucleocapsid protein mutates slightly  addition spike  Oramed also oral vax spike  membrane  envelope proteins  Sadly  small companies less money giants like Pfizer  ll probably get approved  Another oral vax Migvax also nucleocapsid spike  re crowd funded moving even slower trials ', 'took something like 7 months create H1N1pdm vaccine 12 years ago  take much less mRNA vaccines ', ' Despite recent efforts demonstrating organization presentation vaccine components important composition dictating vaccine efficacy  antiviral vaccines long focused solely identification immunological target  Herein  describe study aimed exploring vaccine component presentation context spherical nucleic acids  SNAs  used elicit maximize antiviral response  Using COVID19 topical example infectious disease urgent need rapid vaccine development  designed antiviral SNA vaccine  encapsulating receptorbinding domain  RBD  subunit liposome decorating core dense shell CpG motif tolllike receptor 9 agonist oligonucleotides  vaccine induces memory B cell formation human cells  vivo administration mice generates robust binding neutralizing antibody titers  Moreover  SNA vaccine outperforms multiple simple mixtures incorporating clinically employed adjuvants  modular changes SNA structure  uncover key relationships proteomic insights adjuvant antigen ratios  concepts potentially translatable across vaccine platforms disease models  Importantly  humanized ACE2 transgenic mice challenged vivo lethal live virus  mice received SNA vaccine 100 % survival rate lungs clear virus plaque analysis  work underscores potential SNAs implemented easily adaptable generalizable platform fight infectious disease demonstrates importance structure presentation design nextgeneration antiviral vaccines ', 'evidence severity because hospitalisation data limited ', 'believe s 3 doses  2 ', 'rapid test could produced distributed  200 % profit   1 customers  near 99 % efficiency rate negative results  imo wont happen least another year ppl focused  companies want money  add insult injury s  information im stating provided nearly 1 year ago  still sold upwards  10 cheap end  maybe  57 gethave wholesale account  ppl companies trying maintain market gets dropped bottom themimo', 'Good point ', 'know press statement 3x AZ  Neutralising antibody levels Omicron following third dose boost Vaxzevria broadly similar levels achieved two doses Delta variant https  wwwastrazenecacommediacentrepressreleases2021vaxzevriasignificantlyboostedantibodylevelsagainstomicronhtml EDIT  Also https  oldredditcomrCOVID19search ? qvaxzevria & sortnew & restrict_sron', 'Safe EFFECTIVE', 'Yes  taken face value  study shows  people 91 days 2dose vaccination  ', 'understanding government provides supply canÄôt prescribe outside officially authorized circumstances ', 'Totally correct  Viral load measured PCR meaningless  Infectious Virus Titers key metric  People pumping bad science get published pandemic  s academic opportunist behaviour ', 'get ? Cause s lot breakthroughs lately ', ' Overall  COVID19 convalescents showed higher neutralization capacity 140 SARSCoV2 VoCs compared infectionnaive individuals  even three vaccinations 141 latter  Interesting  first time IÄôve seen stated ', 'In review analysis death reports VAERS following mRNA vaccination  found unusual patterns cause death among death reports received  COVID19 vaccine EUA regulations  healthcare providers required report deaths lifethreatening adverse health events COVID19 vaccinations VAERS regardless potential association vaccination  ', 'think study looked  Sub thread   redditcomrCOVID19commentsr9oijyprotection_and_waning_of_natural_and_hybrid   https  wwwredditcomrCOVID19commentsr9oijyprotection_and_waning_of_natural_and_hybrid ', 'think re right would note extreme care many scientists taken avoid even appearance discouraging vaccination  recollection Pfizer Moderna phase 13 trials excluded  intended exclude  patients prior history COVID infection  still question interest  study also notes   higher increased rate antibody titer worsened group nonworsened group suggests excessive immune response vaccination associated worsening sequelae ', 'brain nt working well today  know wo nt yield exact results  anyone take stab 2 doses vs Omicron data ? 3 doses 673 % efficacy compared unvaxxed  3 doses 663 % compared 2 doses  would make 2 doses nearly zero  right ?', 'Yes  Novavax included COVBOOST trial conducted UK fall 2021 http  wwwthelancetcomjournalslancetarticlePIIS01406736  21  027173fulltext', ' tcell vaccines  ? method vaccination virus somehow spur Bcell activity antibody production ? references pointers somewhere read ?', 'Source ? nt believe ve seen data severity omicron yet ', 'Friendly reminder VAERS data nt moderated verified  anyone allowed submit data ', 'let study run past dec 27th  well omicron spike  week could see change  counted previous infections dated 13 months ago  Definitely 2nd vaccine doses later  Perhaps 56 months later  fairer way compare immunity would include infections prior average 2nd dose timing  prior infection risk getting covid twice year ', 'Yes seen hypothesizing Twitter would little bit less immune escape  nice see theory translate real world data ', 'IÄôm expert read lot stuff pretty much answer  third vaccinationexposure antigen seems stimulate immune system able make ÄúbetterÄù antibodies equipped Äúdeal withÄù variants  illustrate point  immune system could ÄúthinkÄù ÄútalkÄù  itÄôs basically saying Äúlooks like weÄôre going see often  letÄôs brainstorm deal better futureÄù also stands reason even antibodies wane expected  B cells boosted immune systems would remain better equipped jump back action ÄúbetterÄù antibodies upon subsequent infection  Another interesting question Äúif 3 better 2  4 better 3  point diminishing returns begins set ? Äù', 'Yeah  itÄôs odd see shift quickly decently positive protection hugely negative  timespan months  Even assume true 91150 literally zero  takes decent sized behavioral adjustment get estimate 75 0  apply adjustment previous intervals  become much higher estimates weÄôve seen studies Omicron', ' nt think new research Omicron would time next mutation occurs  Current vaccines based wildtype strain work well Delta lineage  Omicron branch Beta lineage  vaccines nt work well Omicron  Basing new vaccinationbooster strategy base likely lineage next serious variant extremely prudent  current vaccines nt need match Delta work Delta  Omicronbased vaccines nt need match new variant variant descendant Omicron ', 'think could   https  wwwredditcomrCOVID19commentsse4fvacommenthumyxxm ? utm_sourceshare & utm_mediumweb2x & context3   https  wwwredditcomrCOVID19commentsse4fvacommenthumyxxm ? utm_sourceshare & utm_mediumweb2x & context3  calculations correct  incidence rates hospitalization & death 2dose vaxxed seem better really unvaxxed  case incidence rates seem way worse among 2dose vaxxed unvaxxed  think big question whether 2dose vaxxed actually prone infection somehow  eg  could happen something like ADE ?   case counts higher behavioral confounders  theyÄôre prone infection would least seem two doses still provides high degree protection severe disease death outcomes balance unvaxxed  thinking correctly ? say itÄôs making boosters look much worse youÄôd expect ?', ' AstraZeneca  Sputnik Sinopharm Argentina ', 'since studied immunology  really interesting new  phenomenon name point towards literature subject ? d like read ', 'Denmark may data make varied analysis ', 'suggesting effectiveness 2 doses nearly zero vs omicron ?', 'Apparently  striations figures 2   2    m reading right  make extremely skeptical overall validity model  reflection ', 'first sentence  data give p value  donÄôt see conclude vaccine covid statistically significant increase immunity clinically significant increase  94 % people vaccinated  number unvaccinated prior infection small likely small enough power use data definitively  Finally forget relative risk  absolute risk reduction shot post covid infection compare risk vaccine ? change age sex ? sample 84 % women average age 46  seem overgeneralize findings data support claim ', 'great article  anything offers glimpse advanced understanding social media used influence public opinion become  sure think  mixed feelings say least ', 'Africa much healthier ? nt close quarter Africa HIV ? well  study massive sample size  N227k  control group  s re comparing vaxxed Africans unvaxxed Americans ', 'Prior dominant variants may direct descendants one another  genetically much closer  nt think Omicron necessarily established new norm VoCs complete  breakaways  coming nowhere ', 'heart inflammation exists person walks doors hospital ? trying say guy ?', 'headline think significantly negative vaccine effectiveness estimates Omicron  2dose vaccination either Pfizer Moderna  91150 days 14 days second dose  authors offer following explanation   negative estimates final period arguably suggest different behaviour andor exposure patterns vaccinated unvaccinated cohorts causing underestimation  likely result Omicron spreading rapidly initially single  superspreading  events causing many infections among young  vaccinated individuals  explanation seems reasonable  though want suggest another possibility  mention excluded previously PCRpositive individuals  however  would wonder adequately controls prior infection  might reasonably expect higher proportion undocumented prior infection unvaccinated  less protected infection Delta wave   perhaps  less likely tested  Thoughts ?', 'Yes  exactly  tell room full people  exposed xx  many feeling symptoms ?  brains make hypersensitive anything resembling symptoms ', 'actually effectiveness infection roughly 0 % 8 months gotten vaccinated changes behavior  think could see graph like ', 'holds true s likely vaccines saved many lives giving Omicron advantage Delta  Omicron significantly less likely cause death recovery infection seem prevent reinfection Delta least near term  speed science able develop deploy vaccines C19 essential occur ', 'would concerned effect well  trying estimate using hypothetical recently  Imagine 3 groups people base line hospitalization rate 3 %  causes  hypothetical disease hospitalizes 10 % people get  also 2 vaccines  vaccine B 100 % effective hospitalization 0 % effective infection  vaccine C 100 % effective infection  extension hospitalization   give vaccine first group  group   vaccine B second group  group B   vaccine C third group  group C   study count  disease associated hospitalizations  patient hospitalized tests positive infection  nt require hospitalization _caused_ disease  Imagine group 1000 people  everyone infected study  effect scales  pick infection rate without effecting outcome much    Group  1  13 %    110 %   1000  127 hospitalizations  disease associated  everyone exposed   Group B 3 % 1000  30 hospitalizations  _marked_ disease associated  even though would happened anyway   Group C baseline rate 30 hospitalizations  infection prevention means none marked disease associated  0 per study  hypothetical study  vaccine C would show 100 % protection hospitalization  vaccine B would show 764 % effective hospitalization even though s reality perfect vaccine  effect gets worse group gets older baseline hospitalization rate increases  vaccine trial protocols PfizerModerna explicitly control effect counting  severe  cases instead hospitalizations explicit symptomatic criteria cases  fact observational studies nt seem always concerning ', 'Confidence interval incubation time  means statistics show 95 % chance true incubation period somewhere 287 days 36 days ', 'doesnÄôt make sense youÄôd comparison information means  Like doesnÄôt tell anything effect Covid vaccine ', 'Came say  Omicron qualitative change  need roll updated vaccine September latest', 'Omicron better replication upper respiratory tract lungs  spreads efficiently less severe disease   ÄúOmicron SARSCoV2 infects multiplies 70 times faster Delta variant original SARSCoV2 human bronchus  may explain Omicron may transmit faster humans previous variants  study also showed Omicron infection lung significantly lower original SARSCoV2  may indicator lower disease severityÄù   https  wwwmedhkuhkennewspress20211215omicronsarscov2infection ', 'think idea load  infection one presumably significant exposure spike s spread time whereas vaccination massive load created body short time period  Basically idea poison dose  exposure per unit time   m cellular biologist ca nt act expert one way another  playing devil s advocate think s important genuinely want understand opposition ', 'Yes  age sexweighted increase first second doses combined 152 cases per 100000 vaccinees  ie  1 65800  females   65 combined increase 462 cases per 100000 vaccinees  ie  1 21600  confidence intervals quite wide  See rightmost column Table 1 detail ', 'widely reported degree ? Sometimes papers say  X effective  actually mean  X barely effective  ', 'Seems  Though least itÄôs talking catching  badly effect ', 'Usually confounding factors  could genuine situations  read  case  negative  meaning s enhanced risk infection opposed reduced one  case s likely combination cryptic infections unvaccinated group  boosting aggregate immunity true zero  well better healthcare seeking behavior vaccinated group  boosting aggregate immunity equivalent unvaccinated group   protection vaccine close true zero  get artefactual negative VEs ', 'relevant numbers study follows   vaccine status omicron  delta  cov negative                    3 mrna  2441  679  18587   2 mrna  7245  4570  19456   0 mrna  3412  5044  8721  simplicity let s consider authors call  crude  oddsratio   crude odds ratio 2 mrna vs unvaccinated omicron would defined   2 mrna omicron positive   2 mrna cov negative     0 mrna omicron positive   0 mrna cov negative    724519456    34128721   095179210094 relative effectiveness taken  1  odds ratio  gives us 1  095179210094  004820789905  482 % relative effectiveness 2 mrna vs unvaccinated omicron', 'estimates protection natural immunity similar timeframes ?', 'research funded J & J  Janssen Vaccines  J & J   Barouch patent conflicts interest  Previous papers similar positive spin narrative  general tenor tension findings independent studies  n24  41 small numbers  canÄôt find information preprint demographic characteristics two study groups  vaguest allusion selected  split 65  24  41 JJ BNT appear randomized way  missing something ?', 'Abstract  paper presents effect COVID19 mRNA  PfizerBioNT  vaccine vitro glial cells brain studied means Raman spectroscopy imaging  results obtained human brain normal tumor glial cells astrocytes  astrocytoma  glioblastoma incubated Covid19 mRNA vaccine PfizerBioNT vaccine show alterations reductionoxidation pathways associated Cytochrome c found PfizerBioNT vaccine regulate concentration cytochrome c mitochondria upon incubation normal tumorous glial cells  Concentration oxidized form cytochrome c brain cells shown decrease upon incubation mRNA vaccine  Lower concentration oxidized cytochrome c results lower effectiveness oxidative phosphorylation  respiration   reduced apoptosis lessened ATP production  Alteration Amide concentration  may reflect decrease mRNA adenine nucleotide translocator  Moreover  mRNA vaccine leads alterations biochemical composition lipids suggest increasing role signaling  mRNA vaccine produce statistically significant changes cell nucleus due histone alterations  results obtained mitochondria  lipid droplets  cytoplasm may suggest COVID19 mRNA  PfizerBioNT  vaccine reprograms immune responses  observed alterations biochemical profiles upon incubation COVID19 mRNA specific organelles glial cells similar observe brain cancer vs grade aggressiveness ', ' Associations strongest males younger 40 years vaccine types additional 3  95 % CI 1  5  12  95 % CI 117  events per million estimated 128 days following first dose BNT162b2 mRNA1273  respectively  14  95 % CI 8  17   12  95 % CI 1  7  101  95 % CI 95  104  additional events following second dose ChAdOx1  BNT162b2 mRNA1273  respectively  13  95 % CI 7  15  additional events following third dose BNT162b2  compared 7  95 % CI 2  11  additional events following COVID19 infection   still supports mandated double vaccinations healthy young males already Covid19 ?  scientific rationale 1316 years age group ?', 'third explanation likelihood seek testing  wish investigated  study nt say anything specific testing protocol  given re using administrative data expect re looking share group positive test January October normal Swedish testing protocol time  could heavily influenced vaccinated people likely get tested various reasons  trust health system  conscientious  generally concerned COVID   match criteria used would nt control effect ', 'Abstract SARSCoV2 Omicron highly transmissible substantial resistance antibody neutralization following immunization ancestral spikematched vaccines  unclear whether boosting Omicronspecific vaccines would enhance immunity protection   nonhuman primates received mRNA1273 weeks 0 4 boosted week 41 mRNA1273 mRNAOmicron  Neutralizing antibody titers D614G 4760 270 reciprocal ID50 week 6  peak  week 41  preboost   respectively  320 110 Omicron  Two weeks boost  titers D614G Omicron increased 5360 2980  respectively  mRNA1273 2670 1930 mRNAOmicron  Following either boost  7080 % spikespecific B cells crossreactive WA1 Omicron  Significant equivalent control virus replication lower airways observed following either boost  Therefore  an Omicron boost may provide greater immunity protection compared boost current mRNA1273 vaccine  ', 'Also many asymptomatic went ED Urgent care get tested ?', ' Admission rates  545 % alpha  430 % delta  147 % omicron Median lengthofstay  days   51 alpha  54 delta  30 omicron  Although nt explicitly say  median stay length must admitted patients  else would 0 delta omicron  since less half admitted  ', 'spring wave seems par course seasonality virus  far  saying would likely happen since even Omicron  Anecdotally  people tend report increase common colds change season  nt found cold hard data support  Many people seems think seasonal pattern mean flulike pattern  course absolutely case  However  fall winter wave seems tend much higher intensity  may depend variants circulation level immunity built previous wave  Without models precise enough know uncertainty new variants  encourage booster doses vulnerable people case wait fall  perhaps adapted doses  think public health perspective second option may much favorable  avoid losing confidence many people ', 'paper states  took prescribed amphetaminedextroamphetamine school year attention deficit hyperactivity disorder currently receiving  Chronic stimulant use long known bad heart  nt think draw conclusions  nt see reason avoid vaccination history stimulant use ', 'think itÄôs safe point assume significant number unvaccinated things covid mitigation even acknowledging itÄôs existence  ergo would seek testing ', 'Sad literally address evidence  rapid decline   hyperelevated  antibodies vaccinated within study  mention absent titleabstract  generous  suppose could interpret  suggests potential need maintain high RBD antibody levels control infectious SARSCoV2 variants  hint ', ' think fundamental problem fast Omicron replicates  get breakthrough infections even appropriate antibodies  mean people might start get infected every 2 months possibly week period ?', 'Probably due dose lower booster Modena', 'course questions knowing someone ended emergency room following vaccine right ? Thank God reddit commenters ones designing studies confirm existing biases   Mostly ', ' advantage survival matter slight TEND reduce virulence enhance transmission   tend  heavy lifting  whole classes beneficial  virus  adaptions increase transmission virulence  things like higher replication rate  higher receptor affinity  etc  Delta pretty clear case study important ', 'time though could expect become generally linear ?  variants like Omicron  BA2  becoming dominant  time expect nondominant variants die  least fewer opportunities mutate  therefore less likely  ?', 'Yep ', 'Broader antibodies induced process somatic hypermutation affinity maturation within B cells germinal centres ', 'nt advised exercise two weeks vaccination order prevent myocarditis ?', 'Symptomatic infection â hospitalizeddead  WeÄôre back start means ', 'mean omicron end story Covid 19 fully adapted humans ?', 'thing thought interesting use prefusion spike  nice see ', 'difference study vaccine COVID variants predate omicron  might assume would effective unfortunately longer community  question regulators would whether approve similar original vaccines variants  repeat trials something geared towards current variants  Given taken years complete  repeating would likely take least another year  would bet approve plan boosters align age groups ', 'think headlines stop focusing Äúpreventing infectionÄù instead much help protect severe disease hospitalization long', 'anyone give good reason FDA nt approved Covaxin ? ve pediatric data months  appears safe effective  Approving traditional vaccine like seems like nobrainer  especially one well 100 mil already recieved ', 'Wait  anyone else find title absurdly misleading ?  Myocarditis Risk 17 Times Higher Unvaccinated Patients Ages 1230 Get COVID19 COVIDVaccinated Patients certain saying risk myocarditis COVID19 infection 17fold lower vaccinated patients   vaccine reduces odds COVIDinduced myocarditis 17 fold  looking contents data  ItÄôs literally another comparison postvaccine myocarditis versus postCOVID myocarditis  way theyÄôve worded highly confusing  ?', 'suggest explanation  negative estimates final period arguably suggest different behaviour andor exposure patterns vaccinated unvaccinated cohorts causing underestimation  likely result Omicron spreading rapidly initially single  superspreading  events causing many infections among young  vaccinated individuals', 'unless m missing something ', 'https  wwwosfhealthcareorgblogcovidneurologicalimpact hereÄôs example post effects  thatÄôs even counting harm infection like https  wwwhopkinsmedicineorghealthconditionsanddiseasescoronaviruswhatcoronavirusdoestothelungs', 'TBF  study nt designed detect anything consequence  unfortunately  small safety efficacy  less 50 % infection 0 % severe disease ', 'say booster dose within last 25 months  donÄôt see specify booster least 2 weeks ago  implied triple vaxxed ? missing somewhere ?', 'though ', ' think pandemic organism simply wanting survive   imagine organism primary reservoir survival fights back old school physiological responses millions years old also utilizes physical barriers transmission vaccines keep surviving   face challenges continued existence  ? Yes  realize engaging anthropomorphism  bottom line pretty much Omicron outcome  studied researched great deal years pandemic organisms  work   Frankly  tip spear epi academic one  nt care genomic details except need understand aspect population penetration sequelae  best research gets things concerned bird pandemic organisms followed coast coast analysis organisms changed course pandemic  generalizations  observations come see virulent  become less spread naive population  advantage survival matter slight TEND reduce virulence enhance transmission  happen surprisingly quickly  nt forget two main Coronaviruses live  population  primarily seasonal PITA present  m surprised reading anything happened SARS ? change efficient killing machine essentially disappearing extant threat ? MERS able make transition something like Covid ? Heck  happened syphilis turn sexually transmitted slow motion killer days ? ca nt find journal articles  remember one article m trying find bird virus started east somewhat virulent became less extremely quickly point almost benign got west coast  reason became much virulent ran physical barrier ocean reservoir burden became close 100 % animals susceptible certain characteristics died others live  point virus became virulent essentially disappearing distinct antagonistic organism certain bird populations  also look things like CCR5 see species reacted existential threats  Much research see levels genome someone develops desriptive epi associated organism  little seems done levels  example  surprised virus  tend  toward improved transmission characteristics depressed virulence  speed bit surprising  reminded study read one bird epidemic US less  yes  fully understanding distinctions humans birds different types viruses  blah blah  know analyzing bark tree detail  world goes time figure  could late  still wonder many Epis would acted John Snow would still waiting statistical significance better constructed study  still much learn different perspectives inform others   genomic understanding bird viruses better epidemiologic understanding human pandemic organisms could actually result better response overall  OH maybe bit Crisis Communications training whole lot public health including Fauci ', 'South Africa likely hybrid immunity among infected vaccinated people  nt many naive adults left South Africa  Three major waves  Delta unimpaired vaccination  unlike Northern Hemisphere  high population fatality ratio  excess deaths  young population ', 'vaccine would lot sensitive variants affect RBD  would guess efficacy omicron whatsoever  good news ', 'lucky  s pressure covid become less deadly since kills people infectious 2 weeks  symptoms presented infectious would merit argument ', ' put context  preOmicron era  UK ÄúSIRENÄù study COVID infection healthcare workers estimated prior infection afforded 85 % protection second COVID infection 6 months  Absolutely inexplicable use UK SIREN study  make mention multitude factors point 85 % huge underestimate   published paper   https  wwwthelancetcomjournalslancetarticlePIIS01406736  21  006759fulltext  caveat  1  two ÄúreinfectionsÄù classified ÄúpossibleÄù  remaining two ÄúprobableÄù  none ÄúconfirmedÄù  84 % estimate based using ÄúpossibleÄù reinfections  kind ridiculous  Using ÄúprobableÄù ÄúconfirmedÄù 99 %   2  one third ÄúreinfectionsÄù typical COVID symptoms 3  authors include baseline seronegative people converted seropositive COVID19 cases  would underestimate protection since youÄôre undercounting cases seronegative group  4  authors found pattern indicated seemed consistent RNA shedding  counting ÄúreinfectionsÄù authors note issues paper   Restricting reinfections probable reinfections  estimated June November 2020  participants positive cohort 99 % lower odds probable reinfection  adjusted  aOR  001  95 % CI 000003   Restricting reinfections symptomatic estimated participants positive cohort 95 % lower odds reinfection  aOR 008  95 % CI 005013   Using sensitive definition reinfections  including possible probable adjusted odds ratio 017  95 % CI 013024    prior history SARSCoV2 infection associated 83 % lower risk infection  median protective effect observed five months following primary infection  This minimum likely effect seroconversions included    There 864 seroconversions participants without positive PCR test  included primary infections interim analysis    We believe minimum probable effect curve positive cohort gradual throughout  indicating potential reinfections probably residual RNA detection low population prevalence rather true reinfections  canÄôt really understand using paper reference using 85 % number without giving thought caveats  540 fold higher risk reinfection would still point 95 % protection if number Äúprobable confirmedÄù reinfections used  example ', 'Please note traditional inactivated vaccine  uses Newcastle disease virus viral vector expresses second generation prefusion stabilized spike protein  different Sinopharm inactivated vaccines ', 'link Deltaspecific booster ? seen results Beta one  impression Deltaspecific booster trials yet released data ', 'Ok  s one possible situation  also could 20 infecting one new person  however like go Occam s razor guess multiple people work COVID positive people showed party already infected COVID ', 'much disagree line thinking believe harmful border propaganda  multiple goals  one central goal vaccines beyond  help harm   least  goal trying reduce spreading mathematically decreasing R value pandemics end  also vaccines historically understood PR standpoint look Youtube vaccines COVID reputable science channel  notice focus preventing spread rather keeping hospital  vaccine nt reduce spread protect individuals mean failure ?  see wave PR claiming  well actually nt supposed protect ways ve claimed primary purpose vaccines  something nt smell right   well Measles vaccine kept hospital ? people answer  nt know  hardly anyone gets Measles anymore thanks vaccines   real truth COVID different enough disease like Measles vaccines nt work well still work well enough medical miracles  Unfortunately  many medical communicators nt want try communicate complex message truthfully resorted lying never cared preventing infections spread ', 'whole thing weird  FDA basically said d approve without seeing data begged Pfizer submit Pfizer said nt effective  Pfizer tell FDA  Bizarre ', 'nt even get mRNA vax  HK13 whole virion vaccine  Sinovac like Sinovac ? Ca nt find generic name ', 'immune system prepared fight disease immediately  often wo nt even know got   infuse lab produced antibodies  eg  mentioned sotrovimab  already  virus could cause damage  Since submission myocarditis  damage could happen even asymptomatic ', 've told time  unvaccinated skews previously infected  reason apparent negative efficacy UK  instance   true seems like would confound results considerably ', 'Vaccine effectiveness studies conclusively demonstrated benefit COVID19 vaccines reducing individual symptomatic severe disease  resulting reduced hospitalisations intensive care unit admissions  However  impact vaccination transmissibility SARSCoV2 needs elucidated  prospective cohort study UK Anika Singanayagam colleaguesregarding community transmission SARSCoV2 among unvaccinated vaccinated individuals provides important information needs considered reassessing vaccination policies  study showed impact vaccination community transmission circulating variants SARSCoV2 appeared significantly different impact among unvaccinated people  scientific rationale mandatory vaccination USA relies premise vaccination prevents transmission others  resulting Äúpandemic unvaccinatedÄù  Yet  demonstration COVID19 breakthrough infections among fully vaccinated healthcare workers  HCW  Israel  turn may transmit infection patients  requires reassessment compulsory vaccination policies leading job dismissal unvaccinated HCW USA  Indeed  growing evidence peak viral titres upper airways lungs culturable virus similar vaccinated unvaccinated individuals  A recent investigation US Centers Disease Control Prevention outbreak COVID19 prison Texas showed equal presence infectious virus nasopharynx vaccinated unvaccinated individuals  Similarly  researchers California observed major differences vaccinated unvaccinated individuals terms SARSCoV2 viral loads nasopharynx  even proven asymptomatic infection  Thus  current evidence suggests current mandatory vaccination policies might need reconsidered  vaccination status replace mitigation practices mask wearing  physical distancing  contacttracing investigations  even within highly vaccinated populations ', 'thought recommendation J & J came adverse events and significantly lowered efficacy  Protection severe disease equalizer  J & J always held well comparatively  ? source ? looking hospitalization protection Omicron three vaccines doubt thereÄôs much data  mean  many people gotten single J & J dose booster ? Probably many ', 'Researchers said poor results likely due antigenic imprinting  OAS  even post people denying  lot evidence regarding imprinting since beginning Omicron  Please deny imprinting due itÄôs association antivaxxers  IÄôm sure sub everybody knows actual infection causes worse imprinting  Also vaccinated infected people use vaccines produces mucosal immunity  counter imprinting problem need solutions like Paxlovid  Omicron specific mAbs etcÄ soon possible  ÄúThe observation boosting either mRNA1273 mRNAOmicron resulted expansion similarly high frequency crossreactive B cells likely stems principle original antigenic sin  otherwise termed antigenic imprinting  whereby prior immune memory recalled related antigenic encounter  Davenport Hennessy  1957  Davenport et al1953   Äú', '  Conclusion  important recognize factors fueling vaccine hesitancy  anxieties around pace technological change feelings political disempowerment  within control medical community  example health media literacy initiatives schools suggests  addressing issues require longterm effort part multiple stakeholders working across several sectors society43  Like virus gave rise  seems probable myths conspiracy theories around COVID19 vaccines things need learn live manage time come  new landscape  best measure progress toward building vaccine confidence longer term perhaps number doses administered far  public trust institutions responsible delivering ', ' 437 % vaccine efficacy 375 % presume infection  nt  standard  50 % ? Granted years influenza vaccine nt reach 50 % efficacy curious anyone knows minimum regulators consider acceptable ', ' NEW YORK MAINZ  GERMANY  MARCH 15  2022 Äî Pfizer Inc  NYSE  PFE  BioNTech SE  Nasdaq  BNTX  today announced companies submitted application US Food Drug Administration  FDA  Emergency Use Authorization  EUA  additional booster dose adults 65 years age older received initial booster authorized approved COVID19 vaccines  submission based two realworld data sets Israel analyzed time Omicron variant widely circulating  data sets showed evidence additional mRNA booster increases immunogenicity lowers rates confirmed infections severe illness   analysis Israeli Ministry Health records conducted 11 million adults 60 years age older known history SARSCoV2 infection eligible additional  fourth dose  booster  data showed rates confirmed infections 2 times lower rates severe illness 4 times lower among individuals received additional booster dose PfizerBioNTech COVID19 Vaccine administered least four months initial booster  third  dose compared received one booster dose   Also included submission results ongoing  openlabel  nonrandomized clinical trial healthcare workers 18 years age older single study center Israel vaccinated three doses PfizerBioNTech COVID19 Vaccine  Among 154  700  participants received additional booster  fourth  dose PfizerBioNTech COVID19 Vaccine least four months following initial booster  neutralizing antibody titers increased approximately 7fold 8fold two three weeks additional booster  fourth  dose compared five months initial booster  third  dose  Additionally  8fold 10fold increase neutralizing antibody titers Omicron variant  B11529  one two weeks additional booster dose  respectively  compared five months initial booster  study also revealed new safety concerns individuals received additional booster dose vaccine   Emerging evidence  including data Kaiser Permanente Southern California  suggests effectiveness symptomatic COVID19 12345 severe disease15 caused Omicron wanes 3 6 months receipt initial booster  third  dose  Thus  additional booster doses may needed ensure individuals remain adequately protected  early studies indicate additional booster dose PfizerBioNTech COVID19 Vaccine administered least 4 months initial booster dose could restore antibody titers peak postthird dose titer levels6 improve protection infection severe disease individuals 60 years age older Israel7 similar safety profile previous doses6 data included EUA filing submission reviewed FDA ', 'Really interesting paper authors major roles advisory committees public health  important comprehensive dataset absolutely used inform public policy UK abroad  main take home   risk following COVID19 vaccination largely restricted younger males aged less 40 years  risks myocarditis following vaccination infection similar  However  notable exception younger males receiving second dose mRNA1273 vaccine  risk myocarditis higher following vaccination infection  additional 101 events estimated following second dose mRNA1273 vaccine compared 7 events following positive SARSCoV2 test  ie second dose  full strength  Moderna males 1340 gives spike myocarditis markedly higher risk myocarditis covid infection  nt enough cases myocarditis comprehensive dataset properly assess myocarditis children aged 1317  authors state  needs pursued pooling international datasets  expect already pursuing  interesting data  thanks posting  stated elsewhere  one piece public health puzzle  obviously number risks benefits feed recommendations made  else equal  data could certainly affect recommendations Moderna vs vaccine options males 40  Watching interest  thanks posting OP ', 'Thank  Sorry could done  enough coffee morning  internal bias American unvaccinated would free behavior probably different Sweden ', 'pre boost neutralization titres 6 months post primary  s unusual  adenoviral vaccines nt wane fast Pfizer vaccine ', 'Saw cited post saying around 800 people', 'ItÄôs plausible seems like best explanation itÄôs still somewhat shocking result  apply behavioral adjustment thatÄôs large enough offset 75 %  even assuming true zero  applying behavioral adjustment previous intervals would make high efficacy  higher weÄôve seen studies involving Omicron  seems like authorÄôs theory rapid spread happen vaccinated ago might explain though  behavioral adjustment wouldnÄôt constant across timescales ', 'Given data 6mo2year appears  adequate  review ? Pfizer asking hence FDA nt proactively ? maybe subset nt statistically valid d need data ?', 'know J & J vaccine came doctors pointing vaccine effective preventing serious disease  people taking mean point taking vaccine going get sick anyway  significantly less likely though people taken vaccine die COVID  nt forget people also die flu  sense  yes  COVID19 similar flu ', 'fighting risk myocarditis yes  Overall though many potential likely negative outcomes either group weighted potentially worse ', ' IÄôm sure sub everybody knows actual infection causes worse imprinting  Got references read ?', ' Omicron SARSCoV2 variant predominated US KidCOVE study younger age groups  secondary endpoint vaccine efficacy confirms statistically significant  lower efficacy COVID19 infection expected Omicron wave consistent adult observational data  Using Phase 3 COVE study COVID19 definition  vaccine efficacy children 6 months 2 years 437 % vaccine efficacy 375 % 2 6 years age group  case  statistically significant defined lower bound 95 % confidence interval greater 0  majority cases mild  severe COVID19 disease observed either age group  absence severe disease  hospitalization death study precludes assessment vaccine efficacy endpoints  &  x200B  best case scenario since know efficacy wane ', 'seem recall sources advising young males strenous exercise period either mRNA vaccine Covid19 infection chance develop heart inflammation either one  Given rare  nt sample size used study seems  1628 participants different stages  bit small determine exercise woulds exacerbate condition ?', 'advice given Germany days week depending feel  come back quickly exercise normally within two days  paper says 50mins time start kicking ', ' Findings like nt immediately grouped  good   bad      Um  headline says  without increase side effects   unfortunately right findings much grouped  good   bad   reluctance consider anything side effects valid potentially pretty dangerous case ', 'One largest complaints many COVID studies IÄôve seen coming  media pull headlines based extremely poor studies spread misinformation quickly  Feels like canÄôt figure true nowadays without reading study fully IÄôve come resort nowadays  maddening dense  quantitative analysis  please ', 'antigenic change vaccine evasion  assume layperson find hard time understand stuff simple manner ', 'get ball rolling review process data ? ItÄôs rolling submission review 3rd dose data comes  opposed waiting data reviewing would take longer', 'summary  NDV underperforming vaccine  title misguiding readers interpret inactivated vaccine far better Comirnaty  fact totally opposite  Ratio makes sense selling vaccine advantage based importance protein targeting  Comirnaty way higher antibody levels terms neutralizing non neutralizing ones  Based data provided vaccine totally outperformed mRNA vaccine  log scales used figure  Comirnaty general performs around 10 fold better terms binding neutralizing activity nearly tests  also used CoronaVac control compare difference performance platform ', 'account possibility vaccinated people test unvaccinated  vice versa ?', 'Vaers fine consider data source  ItÄôs large pool largely self reported illness injuries  ItÄôs intentionally inclusive ensure identify trends early  itÄôs actually found issue begin  filter lot BS without much difficulty ', 'would want also want check vaccinated group  places nt Europe acknowledgement convalescent immunity whatsoever  necessarily reason assume proportion previously infected even greater unvaccinated group ', 'mean Boy likely ADHD prescribed medication treat ? Amphetamine well documented side effects IÄôm sure see would impact   mean medical exemptions taking medication ADHD ?', 'intentional selection pressure vaccines would create infectious less severe variant  lucky ? donÄôt think paper says anything possible benefits selection pressure creating less sever variants  would imagine itÄôs still possible selection pressure general create infectious sever variants ', 'know  thatÄôs said wasnÄôt fault  Misleading title publishing ', 'Essentially yes  manifestation OAS', 'Abstract Importance  limited evidence effectiveness BNT162b2 vaccine children  particularly 511 years Omicron variant s emergence  Objective  estimate BNT162b2 vaccine effectiveness COVID cases hospitalizations among children 511 years 1217 years December  2021 January  2022  Design  Analyses cohorts constructed linked statewide immunization  laboratory testing  hospitalization databases  SettingParticipants  New York State children 517 years  Main outcomesmeasures  New laboratoryconfirmed COVID19 cases hospitalizations  Comparisons made using incidence rate ratio  IRR   comparing outcomes vaccination status  estimated vaccine effectiveness   1  1IRR    Results  December 13  2021 January 30  2022  among 852384 fullyvaccinated children 1217 years 365502 children 511 years  cases declined 66 %  95 % CI  64 %  67 %  51 %  95 % CI  48 %  54 %  1217 years 68 %  95 % CI  63 %  72 %  12 %  95 % CI  6 %  16 %  511 years  January 2430 week  children 11 years 11 %  95 % CI 3 %  23 %  age 12 67 %  95 % CI  62 %  71 %   hospitalization declined changed 85 %  95 % CI  63 %  95 %  73 %  95 % CI  53 %  87 %  children 1217 years  100 %  95 % CI  189 %  100 %  48 %  95 % CI  12 %  75 %  511 years  Among children newly fullyvaccinated December 13  2021 January 2  2022  cases within two weeks full vaccination children 1217 years 76 %  95 % CI  71 %  81 %  2834 days 56 %  95 % CI  43 %  63 %   children 511  cases declined 65 %  95 % CI  62 %  68 %  12 %  95 % CI  8 %  16 %  2834 days  Conclusions Relevance  Omicron era  effectiveness cases BNT162b2 declined rapidly children  particularly 511 years  However  vaccination children 511 years protective severe disease recommended  results highlight potential need study alternative vaccine dosing children continued importance layered protections  including mask wearing  prevent infection transmission ', 'window benefits ? Within hour ? Week ?', 'BC  Canada spaced  2 months due vaccine availability  protecting omicron far see ', 'two doses seems enough  real need third', 'One possible factor  unvaccinated cohort wouldÄôve surely likely recent prior infection vaccinated cohort  due protective effect vaccination previous months   Individuals study matched based documented prior infection status  course infections end confirmed  donÄôt think prior infection fully controlled  UK example  weekly random PCR sampling done ONS suggests around 50 % infections missed June 2021  Jan 2022  assume PCR positivity lasts 14 days average   US  CDC previously estimated 75 % infections missed Feb 2020  September 2021 ', 'anybody looked basic mechanical parameters exercise activity post vaccinations ? know Singapore recommends men 30 donÄôt engage vigorous activity two weeks mRNA shot  canÄôt find hard data hypothetically explains 95 % myocarditis cases sounds like easy solution ', 'symptom myocarditis ?', 's reasonable assume might confounding factors  sure completely explain away negative ? nt remain open possibility ?', 'IÄôm great math department  Could somebody calculate rough vaccine efficacy fully vaccinated boosted numbers ? enough info ? IÄôd much obliged  thanks ', 'delta adjusted vaccine nt commercialised existing MRNA vaccines satisfactory delta  boosters providing immunity symptomatic illness large majority cases ', ' Despite reports postvaccination MISC  vaccination clearly lowers overall MISC burden  probably preventing infection  studies also suggest low likelihood vaccination triggering development MISC  vaccination play role MISC pathogenesis  likely extremely rare event may involve underlying genetic predisposition contingent extraneous factors like recent SARSCoV2 community exposure  findings 2 cases MISC within 1 week dose BNT162b2 raise possibility vaccination may alter symptom profile MISC  ', 'assumes people  young healthy   headline excludes lot people    Gili RegevYochay  physician infectiousdiseases researcher Sheba Medical Center Ramat Gan  coauthored study  Äúpeople young healthy donÄôt risk factors probably benefit much fourth doseÄù faced Omicron  says     Still  others say fourth dose could beneficial people higher risk severe illness  Several countries  including Israel  Chile Sweden  offering fourth doses older adults groups ', 'problem Covid evolving linear fashion  Delta descendant Alpha  Omicron descendant Delta  nt confident next dominant variant necessarily descendant Omicron  contrast  update flu vaccines roll ahead time flu evolution linear predict next dominant variant current dominant variant  usually  ', ' analysis shows unvaccinated patients COVID19 infection nearly five times likely develop GBS COVIDvaccinated patients  rate 28 per million COVIDvaccinated patients  130 per million unvaccinated  COVIDpositive patients ', 'WouldnÄôt Omicron boost required 416 weeks post priming trigger bcells undergoing affinity maturation transform plasma bcells subsequently generate omicron specific antibodies ?', 'nt actually see information phase  Possibly look neutralising antibodies rather effectiveness  children s trial iirc ', 'Thanks lot haha  IÄôm bit confused though  read fourth dose mRNA vaccines likely recommended doses probably tailored dominant variant changes time  like flu suppose   DoesnÄôt contradict article somewhat ?', 'Abstract concerns SARSCoV2 Omicron variant evades immune responses due unusually high numbers mutations spike protein  report superspreading event Omicron infections amongst triplevaccinated healthcare workers  infecting 21 33 attending private gathering Faroe Islands  _____ Additional clarification PDF  _____ Faroe Islands  selfgoverning group islands located Iceland Norway  relatively successful containing COVID19 pandemic  78   On December 30  2020  first Faroese received BNT162b2 vaccine  Comirnaty  BioNTech  Mainz  Germany   vaccine used Faroe Islands  since high proportion population vaccinated  December 8  746 % population vaccinated two times  136 % three times  9   March 2020 September 2021  Faroe Islands registered 1001 cases COVID19  1867 per 100000  two deaths  373 per 100000   However  loosening restrictions introduction contagious Delta variant  large outbreak plagued islands  3300 cases 11 deaths registered last two half months  9   This paper reports superspreading event 21 33 healthcare workers infected Omicron variant attending social gathering early December 2021  even though infected participants vaccinated three times recent negative test  ', 'clear  say 85 % effective hospitalization  comparison ? s regular hospitalization rate unvaxxed person ?', 'VOCs theorised emerge chronic infections immunosuppressed patients  since emerged without clear predecessors   m sure much vaccination rates really impact emergence VOCs', 'Yes think theyÄôre agenda  wouldnÄôt first wonÄôt last ', 'think due multiple reasons   USA seems already enough  approved vaccine  may need another good enough   2 fully approved  Pfizer  Moderna  adults   younger age groups EUA  etc  1 EUA  J & J  2 coming way   Novavax  seems soon get EUA   Medicago  may far future   vaccine safe effective  Covaxin data s may less full  promising aspects  documents like one   Interim recommendations use Bharat Biotech BBV152 COVAXINÆ vaccine COVID19    https  wwwwhointpublicationsiitemWHO2019nCoVvaccinesSAGErecommendationbbv152covaxin   annexes   https  wwwwhointpublicationsiitemWHO2019nCoVvaccinesSAGErecommendationbbv152covaxinannexes  points  like   Safety  Adults  aged 18Äì59 years   Limitation study design  Impact  Serious  Efficacy  Older adults  aged â60 years    moderately confident 2 doses BBV152 vaccine efficacious preventing PCRconfirmed COVID19 older adults  â65 years      points like s    general 60 age groups  comorbidity  etc  data s moderate confident   CI values seem wide limits  etc   may also miss FDA important points  like  well   tested latinos  inuits  etc   May  existing  data  certifications manufacturing  etc  enough pass thru FDA process', 'Wait CI 43 43  nt efficacy 0 ? really means lot  s very big interval ', 'get opinion study ?', ' means variant indeed worse Delta ?', ' papers keep talking viral load ignore fact majority viral load dead  noninfectious virus  thatÄôs studies  review paper  whole point summarize people done  ItÄôs lot labor intensive try culture virus itÄôs better data none  viral load data isnÄôt perfect  useful warning sign delta infectious vaccinated people previous strains ', '  Also  thought VAERS reports worth paying attention  thus view change recently ?  ', 'Study conducted JanuaryAugust 2021  weÄôre talking alpha strain breakthrough infections  Likely higher delta omicron ', ' Interesting study 36000 genomic sequences patients analysis  90 % total patients   rest could nt get sequenced time analysis assumed Omicron Sgene target failure  Houston Methodist sequencing 100 % COVID patients  said  point chances SGTF Omicron slimtonone  nt imagine full sequencing really required yield good data ', 'm seeing attempted differentiation severity vaccinatedpreviously infected unvaccinatedpreviously uninfected  s biggest tell pandemic  endemic  waning  Many infections still happening  many fewer ever needing hospital  severity difference vaccinatedpre infected infections unvaccinatednever previously infected  basically like catching novel virus  concerning ', 'western world South Africa  spend countless hours threads debating technical details studies matters US POV much larger country far older  unhealthy population  studies mean next nothing  South Africa never going indicative US experience variant reckless naive way scientific community media latched idea  edit  mentioned  US 65 pop   55mm US 65 pop   80 % total Covid deaths  SA 65 pop  35mmÄ get picture ?', 've asked many people 18 died covid last year 12 ? ca nt find good statistics ', 'Noteworthy  appears little protection variant last vaxxed 6 month ago  big boost booster even recently vaxxed  Perhaps slight edge moderna booster ', 'think paper 2x az plus one mrna provides excelent results  titers ', 'someone could ELI5  could boosting vaccine would elicit broader responsecrossreactivity knowing original antigen presented immune system ? would expect dramatic  albeit temporary  increase titers would help  induce broader response ', 'sample sizes adequate ? Seem little small  m layman nt know  least could easily find volunteers  imagine ', 's autopsy paper written MDs  typical type publication ', ' Omicron displaces delta completely risk Delta infection removed  possibility boosting wuhan variant spike Omicron breakthrough counter productive d already producing Omicron specific antibodies ?  seems unlikely  time adaptive immune system sees similar antigen  time passed since last time saw  causes broaden repertoire memory B cells  produce antibodies cover wider range close variants   example  re finding people got booster antibodies effective omicron nt get booster  even though booster based Wuhan strain initial vaccination  presented antigen make adaptive system  narrow focus   seems fear  makes broaden  possible future variations ', 'wa nt suggested interval doses ?', 's definitely bad way  best  nt link  remember seeing one paper analysing VAERS reports finding questionable  large majority real  likely cases nt reported  generally assume s completely reliable  s right ballpark  Unfortunately many people think along lines VAERS many faults  ignored  s faulty thinking  thinking correlation implies causation faulty ', 'Abstract  Severe acute respiratory syndrome coronavirus 2  SARSCoV2  antibodies decay persist 6 months postvaccination  lower levels neutralizing titers persist Delta wildtype virus  227 vaccinated healthcare workers tested  2 experienced outpatient symptomatic breakthrough infections  despite 59227 exhibiting serologic evidence SARSCoV2 infection  defined presence nucleocapsid protein antibodies ', 'Per press release 100 % efficacy  75 % efficacy severe disease ', 'nt advice move one s arm frequently injected vaccine influenza COVID19 ? seems tested exercises least moved injected arm quite bit ?', '2x AZ 1y BNT  probably nt apply combination  AZ nt discussed papers anyways ', '? flair makes clear s preprint  Preprints posted routinely many report high quality research  although one unfortunately nt   conversely  peer review nt guarantee high quality ', 's also suggestions infected healthcare setting prone long covid', 'didnÄôt realize risk covid  saying could get covid vaccine ?', 'Beta Delta variants 2021  nature defeated Beta eventually Delta variant much quicker Pfizer BioNTech scientists  nt think new research Omicron would time next mutation occurs ', 'Wow  authors nt even take break consider non breakthrough infections  authors story seem inferring transmissibility vaccinated based breakthrough infections  authors completely ignored people vaccinated never test positive  IE majority  according vaccine efficacy trials  paper absolute antivax garbage  great lie considering breakthrough vaccinations vaccinated population reached maximum saturation ', ' Cohort  3  n205   VaccinenaØve participants receive three doses Omicronbased vaccine   going find people vaccinenaØve 2022 willing partake scientific research ?', 'vaccinated mean  selection pressure differ regular vaccination ?', 'Vaccinated almost half rate controls ? could see something like lower prevalence infectious diseases implicated GBS compared 2019  nt 48 also really high baseline ? thought much rarer ', 'inhibition numbers look phenomenal  much better adult 2 series  https  wwwmedrxivorgcontent1011012021122321267374v1fullpdfhtml   especially omicron  something better others omicron results maybe ', 'Worse case 105 myocarditis cases based million jabs  even bad incidence fungal infections  viruses parasites  s   minor ', 'point think enough empirical information treat future variants like flu ? Eg  development vaccines well advance flu season ', 'assuming prevented deathhospitalizations m pretty sure  case  ca nt even show 01 % protection  Additionally  risk infection much lower simply virus lull  know protection likely wane lot 6 months  re probably talking 20 % average protection minimum 6 months get booster summer  takes 200k shots children prevent 300 coldlike infections  seems unlikely get approval ', 'Thanks summary  Much appreciated ', 'Results Participants detectable SARSCoV2Äìspecific antibodies milk baseline  n  9 IgA n  3 IgG  previous positive polymerase chain reaction test  n  7  excluded analyses  thus  total 1650 human milk samples 124 lactating mothers included final analysis  Figure  shows percentage participants detectable IgA study period  Almost participants received mRNAbased vaccine showed detectable IgA milk  25 26  96 %  37 38  97 %  BNT162b2 MRNA1273 vaccines  respectively  participants received vectorbased vaccine  remarkably lower  13 33  39 %  10 21  48 %  showed detectable IgA AZD1222 Ad26COV2S vaccines  respectively  percentage participants detectable IgG study period depicted Figure  B  doses BNT162b2  MRNA1273  AZD1222 vaccines  participants showed detectable IgG  However  mRNAbased vaccines  day 23 day 32 first dose  AZD1222 vaccine  participants showed IgG day 94  vaccination Ad26COV2S  1 dose  6 23  28 %  participants detectable IgG milk  Discussion demonstrated SARSCoV2Äìspecific IgA human milk present frequently vaccination mRNAbased vaccine compared vectorbased vaccine  Additionally  IgG present participants receiving 2 vaccine doses  independent vaccine type  However  IgG detectable earlier vaccination either mRNA vaccines  explained timing second dose  limitation study measure neutralizing capacity human milk antibodies  abundant antibody human milk IgA  plays key role first line defense invading viruses5 Although  knowledge  studies shown indisputable evidence humanmilk IgA directly protects respiratory tract infections  likely antibody plays critical role  Based data  suggest mRNAbased vaccine optimal choice lactating women want transfer antibodies infants ', 'fair worse  likely test positive realtive unvaccinated  Outcomes', ' Abstract BACKGROUND duration effectiveness immunity infection vaccination severe acute respiratory syndrome coronavirus 2  SARSCoV2  relevant pandemic policy interventions  including timing vaccine boosters  METHODS investigated duration effectiveness immunity prospective cohort asymptomatic health care workers United Kingdom underwent routine polymerasechainreaction  PCR  testing  Vaccine effectiveness  â10 months first dose vaccine  infectionacquired immunity assessed comparing time PCRconfirmed infection vaccinated persons unvaccinated persons  stratified according previous infection status  used Cox regression model adjustment previous SARSCoV2 infection status  vaccine type dosing interval  demographic characteristics  workplace exposure SARSCoV2  RESULTS 35768 participants  27 %  9488  previous SARSCoV2 infection  Vaccine coverage high  97 % participants received two doses  78 % received BNT162b2 vaccine  PfizerÄìBioNTech  long interval doses  9 % BNT162b2 vaccine short interval doses  8 % ChAdOx1 nCoV19 vaccine  AstraZeneca    December 7  2020  September 21  2021  total 2747 primary infections 210 reinfections observed  Among previously uninfected participants received longinterval BNT162b2 vaccine  adjusted vaccine effectiveness decreased 85 %  95 % confidence interval  CI   72 92  14 73 days second dose 51 %  95 % CI  22 69  median 201 days  interquartile range  197 205  second dose  effectiveness differ significantly longinterval shortinterval BNT162b2 vaccine recipients  14 73 days second dose  adjusted vaccine effectiveness among ChAdOx1 nCoV19 vaccine recipients 58 %  95 % CI  23 77  Äî considerably lower among BNT162b2 vaccine recipients  Infectionacquired immunity waned 1 year unvaccinated participants remained consistently higher 90 % subsequently vaccinated  even persons infected 18 months previously  CONCLUSIONS Two doses BNT162b2 vaccine associated high shortterm protection SARSCoV2 infection  protection waned considerably 6 months  Infectionacquired immunity boosted vaccination remained high 1 year infection ', 'Thank  know applied full approval  ide typical timeline ?', 'Controls pandemic  completely eliminate COVID19 vaccines and virus factor   cohort includes patients aged 099 least one office visit encounter January 1  2019  June 30  2019  cohort inclusion date earliest office visit patient dates  patients documentation excluding condition documentation GuillainBarr prior inclusion date removed cohort seems likely lower rate vaccinated patients due NPIs  masking  distancing  etc   reducing exposure viruses might cause GBS  Despite association people mentally vaccines GBS  viral infections far common cause ', 'excecise suppose increase antibody two weeks 90 min lol ? Really ? Shouldnt study everyday excercise ', '020 % effectiveness 2 doses ? back beginning pandemic ?', 'say hospitalized ?', 'Science struggle  WasnÄôt ', 'Huh ? study says  Overall  30day incidence myocarditis following COVID19 diagnosis nearly 17 times higher incidence among patients receiving COVID19 vaccine   see nothing hospitalization ', 'could possibly explained ? also mean chances higher infected eg  get fourth fifth dose ?', 'guess s short interval   https  wwwresearchsquarecomarticlers1226339v1 paper got improvement neut  post 2nd dose infected  3rd dose good improvement ', 'much anosmia defining feature mild cases ', ' Remember SARSCoV2 migrates body affected organs one time another among various cases covid  one reason SARSCoV2 vaccines effective  high serum antibody levels help prevent kind wide dissemination  Vaccines general really good preventing kind dissemination  highly contagious respiratory viruses require dissemination lymphatic system cause disease  like measles varicella  respiratory route infection  virus disseminates cause rash transmission   respiratory diseases dont require dissemination disease progression  like RSV rhinovirus parainfluenza metapneumonia  durable immunity  vaccines otherwise  keep getting infected repeatedly viruses  SARSCoV2 follows similar paradigm prior infection vaccination not prevent infection long term  seems adequately prevent dissemination thus severe disease ', 'results  measurably better multivalent vaccine  WTbeta  211  vaccine 50 % higher neutralization Delta Gamma WT alone  50 % higher nt huge number  effect get doubling dose  s also worth noting Delta farther Beta wildtype  phase 1 trials supposed repeated WTBetaDelta  213  vaccine  seen results  Indeed  results named Q2 report since removed   knowledge  never published  even medical preprint  ', 'far  VOC specific boosters proven effective another shot original based Wildtype generating immune response  Moderna posted results  seek 3rd quarter earning report PDF interested   re considering maturation immune response time  additional exposure original vaccines  ____ ____   Superior immunity allows neutralization SARSCoV2 variants concern develops COVID19 convalescents naØve individuals three vaccinations    https  wwwresearchsquarecomarticlers1226339v1  ____ ____   Structural basis Omicron neutralization affinitymatured public antibodies    https  wwwbiorxivorgcontent10110120220103474825v1  ____ latter  _____  resolved structure CABA17 Fab complex Omicron spike overall resolution 26 Ö cryoelectron microscopy defined structural basis breadth  Thus  public SARSCoV2 neutralizing antibodies  without modified spike vaccines  mature crossneutralize exceptionally antigenically diverged SARSCoV2 variants  ', 'Incorrect  significantly second  barely  third doses Moderna  Myocarditis incidence rate infection 73 per million  Moderna third dose measured 104 believe  believe thereÄôs also language study suggesting severity myocarditis worse Covid patients need reread section carefully  top  statistically significant potential side effect rna vaccines thus far  Myocarditis potential severe side effect Covid infection  far  Measured whole  2dose vaccines would better young males take risk Covid infection  Although available may worth considering vaxs Moderna young males  EDIT  needed check carefully  73 number infection older males  7 number younger males  Moderna numbers second dose  points starting paragraph 2 still stand except fact definitely reconsider using Moderna younger males options  Pfizer  AZ  available ', 'Sorry  explanation itÄôs statistical noise hold  look right edge graph  even upper range confidence interval intersecting yaxis  0   Additionally  actually went zero  instead past zero  negative   would expect curve asymptotically approach zero  Instead  rate descent much steadier straighter ', 'also nt seem take account reduced severity & duration vaccinated individuals  leading reduced window infecting others ', 'makes lot sense  thanks thoughtful response ', 's comparison sputnik vaccine antibodies concentration Pfizers Modernas vaccine ?', 'ÄúConsidering small effect size association good prognosis patients SSNHL  potential influence condition public health appears relatively minorÄù from source article', 'boosters less bad doubly vaccinated', 'news 3rd shots ages 511 ? Wonder ll help bring back protection ', 'many studies ignore impact hybrid immunity ?', 'rather opposite making pronouncement  sentence literally translates  nt enough evidence make pronouncement yet  ', 'Wait two weeks booster find increased risk symptomatic cases ? boosters useful two weeks metric ', ' Beyond lower rates pneumonia CT  clinical course patients paralleled chest CT findings  vaccinated patients much less likely require supplemental oxygen  odds ratios  24  p005  lower rate intensive care unit admission  odds ratio  08  p02  unvaccinated patients  odds ratio 008 nt impressive ?', 'pick battles  canÄôt control virus  itÄôs becoming transmissible point catching becoming hard  Long covid huge issue something iÄôm concerned ? canÄôt force world stay indoors anymore  mask mandates dropped people starting live like itÄôs 2019  preventing infection seems impossible average person age omicron ', 'kinda agree  One caveat looked time period dominant AlphaDelta  Omicron  far prevalent variant  seemingly much less virulent  Hopefully likelyhood  long covid  Omicron infection turn significantly less groups  also nt  could nt  include anyone received 3 shots perhaps provides greater protection Long Covid primary course 2 shots win month ', 'links studies sinovac omicron ? ve tough time finding anything  m triple vaxxed Sinovac really freaked getting virus ', 'source ? TCell based ? data long booster seems work ?', 'answer  d need know severity vaccineassociated myocarditis  rate covid reinfection  rates severity myocarditis reinfection  rate severity sequelae following covid reinfection  Trying put whole picture together public health recommendations ', ' 3 days ago sub study published saying omicron infections fact much mild delta study linked looking viral replication rates  says nothing disease severity  re referring South African study showed Omicron 29 % lower hospitalisation rate ancestral strain  nt fully controlled immunity prior infection  specify  documented  infection  vast majority COVID cases go unreported  surveillance South Africa nt great    However  hospitalization rates Africa would fact suggest ommicron mild  Lower hospitalisation rates nt necessarily evidence Omicron variant less virulent  re evidence mild cases occuring current wave  also attributed higher levels immunity population  edit  Reading study re referring  actually outright states  ÄúThis lesser severity could  however  confounded high seroprevalence levels SARS CoV2 antibodies general South African population  especially following extensive Delta wave infectionsÄù', 'Every cold exists today variant virus existed year two year two forth ', 'Moderna mainly', 'boys preexisting heart anomalies  myocardial scarring  Boy  cardiomegaly  Boy B   Boy also history amphetamine use ', 'think equally plausible explanation occurring Omicron spike divergent able engage existing B cells particularly well  merely acts like  first dose  prime  second booster may work much better  Note mouse study vaccine  Omicronspecific one engage wildtype trained B cells would consistent ', 'effective treatment options available locally  eg  paxlovid  sotrovimab  forego vaccinebooster instead plan seek early treatment upon symptomatic infection ? especially knowing may one many infected turn asymptomatic UPDATE  donÄôt get downvoted  people taking issue last statement  systematic review concluded 35 % cases asymptomatic   https  wwwpnasorgcontent11834e2109229118   https  wwwpnasorgcontent11834e2109229118   also donÄôt think itÄôs controversial say first couple vaccine doses contemplating booster likely even asymptomatic case  Omicron declared milder conjecture ratio asymptomatic cases higher also  weÄôll still see data bears piece ', 'curve probably informed observations point  chance might given unintuitive results ', 'Bharat Biotech got approval Indian regulators phase 3 trial last month ', 'Curious  imagine something antibody affinity maturation ', 'seem two points   Along previous data showing superiority third dose second dose4 results suggest maximal immunogenicity mRNA vaccines achieved three doses antibody levels restored fourth dose   boosting results increase antibody levels  nt seem surprising imagine future studies observing similar results 5th  6th  Nth booster  Furthermore  observed low vaccine efficacy infections health care workers  well relatively high viral loads suggesting infected infectious  Thus  fourth vaccination healthy young health care workers may marginal benefits  important point  Despite increase antibodies  existing vaccines nt efficacious reducing viral loads  adds existing evidence suggesting omicronrelated strains better able evade immune detection  imagine due  least part  current 2022 strains diverged 2019 strain used make vaccines ', ' Also preprint  think given title abstract misleading going  Yes  think lot people interpret  omicron specific boosters wo nt induce strong responses VOC   study looks mice unexposed COVID rather people vaccinated WT  response someone already previously exposed WTDelta omicron booster wo nt ', 'Sweden much restrictions none  s study done  exclude correlation much possible ', 'vaccines really donÄôt prevent transmission well', 'anyone know timeline goes human trials ?', 'Interesting  memory serves correctly  Pfizer 70 % effective Omicron used booster  Perhaps better booster option know antibodies continue rise beyond timeframe mRNA vaccines begin fall ', 'doesnÄôt covaxin safe & effective pediatric data  USapproved vaccines yet ?', 'study covered first 6 months vaccination dose  yes accounted  future monitoring probably wise ', 's acute response s important  fearstress works probably nt much actual exercise much convincing body s attacked lion ', 'thought Tcell immunity always long lasting  whether resulted vaccination infection  havenÄôt seen papers published noted tcell immunity temporary ', 'think youÄôre reading bit much lines  really think paper opinionated ? Reads like theyÄôre simply reporting results  HavenÄôt read whole thing thoroughly though  missing something ?', 'paper ever claim  shot helps improve mental health  ?', 'one gave correct explanation  ItÄôs graph cubic spline fitted observed values  look table instead  9 months estimated 23 % effectiveness infection wide confidence interval  zero line actually data proper informed model  ItÄôs simple smoothing line', 'WhatÄôs next big treatment potentially horizon ?', 'read somewhere else significantly younger population overall  basically common observation  make virus ca nt translate west difference age ', 'think mixed  P02 MASSIVE risk reduction ', 'doesnÄôt  table shows drop 23 %  graph smoothing line  actually data ', ' data provide evidence fourth dose mRNA vaccine immunogenic  safe  somewhat efficacious  primarily symptomatic disease   comparison initial response fourth dose peak response third dose show substantial differences humoral response levels omicronspecific neutralizing antibodies  Along previous data showing superiority third dose second dose4 results suggest maximal immunogenicity mRNA vaccines achieved three doses antibody levels restored fourth dose  Furthermore  observed low vaccine efficacy infections health care workers  well relatively high viral loads suggesting infected infectious  Thus  fourth vaccination healthy young health care workers may marginal benefits  Older vulnerable populations assessed ', 'needs better education awareness longterm risks infection varios pathogens  People incorrectly assess risk vaccineinduced injury greater pathogens  people aware viruses cause autoimmune diseases  future researchers focused relationship viral infections various comorbidities ', 'possible selective pressure towards milder forms  IÄôve seen argued time die covid  virus gone  moved  die live irrelevant virus  die inflammation left behind  entirely separate second phase  Suggesting selective pressure  opinions ? valid argument ?', 'Beta major vaccine evader well ', 'recommending nonmRNA vaccines young male cohort ?', 'find odd neutralization titers Moderna lower Pfizer  yet efficacy Moderna consistently higher almost every study ', 'DoesnÄôt jnj study contradict consensus ? got mRNA booster jnj consensus CDC told itÄôs superior  Looking  thatÄôs clearly case ', 'nt South Africa seeing uptick deaths yet ?', 'WeÄôre also dealing contagious variants time passes  delta  omicron  ', 'clear imprinting issue  study date give sufficient time antibody maturation occur boost trigger plasma bcell conversion antibody generation  immune system problems tracking immune escape existing  hCoVs   https  journalsplosorgplospathogensarticle ? id101371journalppat1009453  would astounded SARSCoV2 different ', 'Moderate intensity activity jogging 10 minute mile average American  average American overweight obese  Americans probably could jog mile without take walking breaks  certainly would nt 6mph pace  Moderate intensity activity average American  obese  middle aged person  walking ', 'Old law needs rethought  protect 6months 2 years  arenÄôt ?', 'nAb data interesting  Pfizer s vaccine initially edges J & J s  bindingneutralizing titers start falling Pfizer almost immediately  consistent earlier literature demonstrating thing   Differential Kinetics Immune Responses Elicited Covid19 Vaccines  NEJM   https  wwwnejmorgdoifull101056NEJMc2115596    Very potent early humoral immunity  significant issues staying power  nt mind getting boosts routinely counteract  m sure sustainable public policy perspective  Still  imagine difference efficacy J & J Pfizer Omicron almost certainly related cell function  mRNAs induce remarkable antibody response  s useful broad majority antibodies ca nt bind Omicron RBD  Adenoviral platforms like J & J s  trade comparably low antibody titers stronger cell function  cells tend robust largescale changes sequence ', 'speed omicron  50 % US infected end january probably  means limited effectiveness  &  x200B  speed mutations thats happening incomprehensible total guess attempting vaccinate  BA2 whatever seems like next explode march northeast US  Would better could go  knows next variant South June 2022  Could BA22 could even newer one  winter 2022 ? ?   ', 'reading  testicular inoculation  correctly ? stabbed needle testicle injected SARSCoV2 straight testicles hamsters ? exactly injecting virus normally spreads respiratory aerosols testicles hamsters supposed demonstrate ? testicular inoculation respiratory viruses thing normally done ?', 'started suspicious variant doses first heard Deltaspecific booster nt better third shot original ? time  everyone framed  wow og booster good   effective Delta  still nt weird Deltaspecific one nt better Delta ?', 'm confused comment  nt asymptomatic COVID  COVID19like illness ?  nt positive test typically result diagnosis ?', 'Considering amount vaccine hesitancy antivaxxers  possible risk VAERS reports even coincidental accurate even greater prior pandemic  symptoms ignored  many psychosomatic variables well ', 'd really like looking population survey  state publishes reinfectionbreakthrough infection  etc  also published vaccination rate convalescent patients  could really start see consistent analysis  currently  breakthrough infection seems common reinfection based MN doh data ', 'reported cases', 'entirely false  Threedose vaccination defeated delta every country tried  nothing else except letting everyone catch delta waiting reinfections start succeeded  also know multivalent wtbetadelta vaccines used small trials significantly effective delta  though ve done research  certainly lot effective omicron  wtomicron  deltaomicronb1640  deltaomicronsarsmers spike would  nearcertainty  better every existing variant much better future variant  idea science solve vaccines nt really hold water  ve betadelta spikes  engineered polymutant spikes  sarsmers spikes available vaccine use nearly year  fear science stopped us even trying  even research tried shown us broad multivalent vaccine would dramatically effective ', 'Waste water detection increased starkly many places US  large spikes abroad  d say sooner better data supports efficacy safety ', 'youÄôve already covid  getting vaccinated results robust protectionÄî better infection alone better vaccination alone  Makes sense  wonder reverse folks vaccinated first subsequently breakthrough infection  assume better vaccination alone  wonder compares infection first ', 'Reducing hospitalizationdeath avoiding infection different success criteria ', 'would agree  mean failure ?   real truth COVID different enough   must consider short period time created vaccines  rushed get something public help slow deaths  Try imagine might took standard procedures developing vaccine ? long take create vaccines ?', 'WouldnÄôt safe say lot people heightened stress  fear  anxiety  etc  reassured taking shot protection ? placebo effect Äúthe shot helps improve mental healthÄù  ', 'clear  study estimate probability infected either Omicron Delta vaccination status  examines test positivity rate  given chosen get PCR test  percentage time PCR tests give positive result  vaccination status variant  People choose get PCR test likely biased sample  symptoms  compared broader population  actual probability random person population infected likely different  course  authors make claim  clarifying could misread way ', 's pretty much authors wrote  &  x200B   Omicron  similarity ORs 3 doses using unvaccinated referent group 2dose referent group consistent attenuation 2 doses vs unvaccinated time since second dose  which reflected significant association 6 months second dose products ', 'great response', 'Yeah low effort contribution isnÄôt even based paperÄôs results  Countless papers shown Äúvaccines workÄù  one  21 people working age hospitalized hardly evidence vaccines reducing severity hospitalization rate low single digits begin  perhaps well 1 % Omicron age group  even unvaccinated people  ', 'paper state whether vaccinated hamsters got sarscov2 injected testes ?', 'NIAID study showed starting J & J boosting mRNA big bump antibodies  erred already waning significantly week 2 week 4  way around  still increasing week 4 ', 'antigenic sin', ' even delta 20 weeks less 50 % effective  against infection  still provided 95 % protection hospitalization Delta hospitalization immunocompetent population ', 'anyone access full paper ? ratio pre post vaccination antibody titer could also higher levels antibodies much lower prevaccination individuals ', 'BA2 information best vague  anyone published results ? Interested new mutation impact US', 'part stuck   absence severe disease  hospitalization death study precludes assessment vaccine efficacy endpoints   think s good thing  serves reminder low risk Omicron young children  NOTE  edited clarity ', 'seems protection severe disease stable tcells severe disease previous infection  important  https  wwwbiorxivorgcontent10110120211212472315v1', 'Yes  even discussion developing vaccines back 2020 set antivaxxers  already gaining traction years prior Covid  back Wakefield days 1998  Pointing hypocrisy concern vaccines thereÄôs far less concern 350000 chemicals environment  several thousand MSDS  several known carcinogens  neurotoxins  endocrine disrupters VOCÄôs one way get discussion risk benefitharmrisk analysis broached  Another topic shortterm macro economic societal costs  Humans tend focused shortterm  immediate concerns  underestimate longterm costs risks  even consciously choose Äúkick roadÄù  enough education known unknown risks pathogens  chemicals drugstreatments  potential benefit outweighs risks  part donÄôt know donÄôt know  thereÄôs additional unknown yettobe discovered longterm sequelae macroeconomic costs every variable ', 'Yes  valid  Usually pressure become milder driven fact symptomatic people likely home bed  actively riding subway whatever  reducing symptoms virus access hosts ', 'layman terms  clue virology   Covid endemic stage ? Like time next year  would bear resemblance say common cold ? still long way go  finally reaches ?', ' summary leaves lot important dataassumptions  really  main finding breadth immune response N501Y better mRNA vaccinated individuals convalescents  rest points would perhaps explain difference overall titer decreasing titer time  breadth  majority abstract  ', 'Also  Novavax spike protein slightly different PfizerBioNTech Moderna   vaccine NVXCoV2373  PS   developed Novavax Ad26COV2S vaccine  nrVV  Janssen Pharmaceuticals  vaccines deploy glycoprotein mutated furin cleavage site K986PV987P proline substitutions  https  wwwfrontiersinorgarticles103389fimmu2021701501full', 'Seems like one possibility would variant specific boosting needs 2 doses  anyone else come away open question ?', 'ThatÄôs saw reported  FDA encouraged Pfizer submit data approval could review  review  looks like data needed', 'Sorry  couldnÄôt find  title article ?', 'graph drop zero 8 months ? seems odd ', 'idea mild forms viruses selected time isnÄôt really fact much true offers little predictive power itÄôs true long timescales   commonly stated idea often evolutionary tradeoff virulence transmissibility intrahost virus replication necessary facilitate interhost transmission may also lead disease  impossible natural selection optimize traits simultaneously  case MYXV  tradeoff thought lead ÄòintermediateÄô virulence grades selectively advantageous  higher virulence may mean rabbit host dies interhost transmission  whereas lower virulence selected increase virus transmission rates  similar tradeoff model proposed explain evolution HIV virulence40  However  many doubts raised general applicability tradeoff model35414243  virus fitness affected traits virulence transmissibility394144  contrary results observed experimental studies45 relatively little known evolutionary tradeoffs nature  example  case second virus released biocontrol European rabbits Australia Äî rabbit haemorrhagic disease virus  RHDV  Äî evidence virulence increased time  probably virus transmission often occurs blow flies feed animal carcasses  making host death selectively favourable46  Similarly  experimental studies plant RNA viruses shown high virulence necessarily impede host adaptation47  case malaria  higher virulence shown provide Plasmodium parasites competitive advantage within hosts48  https  wwwnaturecomarticless4157601800555 plenty evidence virulence selected Since beginning pandemic people predicting SARSCoV2 would mutate become milder  mentioned SARS MERS  epidemiologist  know neither passed asymptomatically much lower R0  SARS presented fever example  point Covid started mild could spread asymptomatically  much idea mild strain would selected ix true  requires strain transmit better mild  spread without symptoms  space fitness landscape much smaller   point virus became virulent essentially disappearing distinct antagonistic organism certain bird populations  also look things like CCR5 see species reacted existential threats  Dude  ccr5 adaptation either plague  consensus  smallpox  read paper argued smallpox likely provided selective pressure  either way  demonstrates changed pathogen  takes literally generations trait get fixed ', 'Conclusions crosssectional analysis baseline data collected patients enrolled phase 3 randomized trial early outpatient treatment SARSCoV2 infection  vaccinated individuals lower viral load lower prevalence systemic symptoms vaccinated  effect viral load longer present persons vaccinated 6 months prior  primary goal Äúfully vaccinatedÄù prevent serious disease  may still occur 6 months  Future research look viral load beyond 6 months understand whether term Äúfully vaccinatedÄù viral load transmission define vaccinated within previous 6 months  Vaccine boosterinduced reduction viral load may important component achieving reduced coronavirus spread ', 'thing found Betaspecific booster recall  seems fairly clear imprinting problem  guess nobody wants admit  way know sure would find sample group   unvaccinated  previously infected  willing participate vaccine trial probably pretty small group ', 'YouÄôre linking study mostly Delta cases months ago  omicron  thereÄôs qualitative difference viral load weÄôd see result household secondary attack rates  Whatever factor may  thereÄôs real world evidence itÄôs 10 fold ', 'would question underlying data  UK example myocarditis adverse events reported voluntary basis  Adverse events go unreported case  case C19 patients likely hospital setting monitored  whole report could simply interpreted patients likely diagnosed myocarditis  others ', 's curious post downvoted  Noone said disagreed  s really nothing controversial  idea secondary adaptive immune response stronger persistent primary basic immunology  idea covid infection  vaccine dose gives similar immune response infections two vaccine doses demonstrated number studies basis guidance countries single dose required previously infected  reviewed   https  wwwnaturecomarticlesd41586021016094   https  wwwnaturecomarticlesd41586021016094    NB prior 3rd dose recommendations previously vaccinated  Perhaps one downvoters would care give thoughts ?', 'mean link COVID vaccines could inferred ? associations  nonCOVID ones certainly exist  eg  influenza ', 'thought beginning  lowest acceptable efficacy going 50 % ? misremembering ?', 'Early Pfizer data Israel states boosterÄôs peak efficiency neighborhood 10 weeks  got Moderna booster August  full size  half size booster theyÄôre giving  tested positive first week January  Anecdotal  case mild  Primarily sore throat  congestion  fatigue  low grade feverchills ', 'IÄôm sure understand point  Using 99 % protection reinfection previous strains instead 85 % makes omicron look way worse ', 's definitely possibility  inability get consistent results across regions make impossible measure  may first time s seen boosters  2dose data place  Ontario long dosing interval 100 % measured omicron one point ', 'ThereÄôs early data study AVV gene therapy showed elevated troponin levels mild transient myocarditis postIP dose younger adult male subject physically active  need dig deeper relationship immune activationstress  testosterone levels  physical activity level  age  troponinmyocarditis  whether myocarditis mild transient  sequelae occur ', 'EDIT  edited response reading study well authors  previous one  pair studies used 16 peptides  23mer   10 peptides  Tcell epitope optimized  contain known Bcell epitopes  selected based computationally predicted Tcell epitopes filtered various criteria  including HLA binding  predicted immunogenicity  location   N protein  opposed proteins like ORF s  etc   etc  6 peptides  Bcell epitope optimized  based around three linear Bcell epitopes located functional  conserved surface regions Spike protein  Although peptides broad coverage HLAI alleles  coverage HLAII alleles generally poor  immunology review  peptide s ability bind range widelyexpressed HLA alleles major limiting factor viability good Tcell epitope   authors suggest vaccine designed stimulate Bcell CD4 Tcells would require use nonspatially overlapping sequences  studies  strong humoral response detected peptides  including Bcell epitope optimized peptides  Tcell epitope optimized peptides elicited strong Tcell responses  per second study  mice seem gain protection infection disease viral challenge  way background  general discovering peptides designed elicit Tcell responses relatively developed discovering linear epitopes designed elicit Bcell responses  authors note first study  attempts discover linear epitopes elicit protective Bcell responses failed  practice nt much use practical application using linear peptides either since would probably need scaffolded something anyways   immunology review  naturally occurring Bcell epitopes linear   Current development efforts peptide vaccines focused cancer  surprise    Tcells primary focus ', ' log scales used figure  Comirnaty general performs around 10 fold better terms binding neutralizing activity nearly tests  agree looks worse Comirnaty re overestimating difference neutralizing antibody titers  selected 3 µg dose trials  s one looking  Comparison using WT shows little difference  delta  difference approximately 4fold  approximately 1021 vs 1015   beta looks similar  ratio neutralizing nonneutralizing antibodies using RBDbased vaccine general interest  even nt say anything good particular vaccine ', 'Cutting risk hospitalization half still seems pretty good given rare serious side effects ', 'studies comparing NVX Omicron enough time set proper study compare ?', 'Please correct reading wrong  indicate vaccine preventing hospitalization kids 511 decreased 100 % 48 % ?', 'seems authors arguing ', 'Spell  saying immunity less specific word protection ? m sure s always case ', 'anyone know would two doses vaccine breakthrough infection long ago  12 months  offer significant protection ? Especially considering itÄôs long since covid infection ', 'Great comment  trade giving enough time enable least part dormancy maintaining neutralizing antibody levels circulation   differentiation  B cells recognize unseen mutations absolutely fascinating  One could wonder got evolutionary conserved ', 's proposed mechanism action vaccination reducing symptoms existing long COVID ?', 'person  AimingWineSnailz  said  incorrect  Moderna developed tested VOC specific boosters based Delta & Beta  Neither elicited robust response another shot original vaccine based wildtype  Moderna also tested two VOC boosters Omicron first discovered late last year  another shot original worked well  Omicron much mutated previous VOCs decent chance updated vaccines Pfizer & Moderna developingtesting good option time  potentially  next mutation  stems Omicron   Notwithstanding  lack variant specific boosters BetaDelta nothing w development time  nt prove significantly effective original well manufactureddistributed point  Moderna s info VOC boosters found 3rd Quarter earning report  PDF  last year ', 'Read last paragraph page 5  Please', 'Weirdly  people 3 vaccine doses infection  full seriesbooster  lower risk people 2 doses  ie  effect reversed  guess would strange confounding factor https  wwwmedrxivorgcontentmedrxivearly202202132022021022270744F4largejpg', 'personal level  nt seem evidence  unless ve missed something big  case d appreciate links  risk Omicron variants  spectacularly low risk  indeed  less risk flu normal winter  last time checked figures   re possibly  nt seen enough data recent second dose efficacy  somewhat higher risk contracting passing around  increased risk higher transmissibility   still nt something particularly concerned personal health outcomes perspective  Obviously  wider societal issues  secondary personal negative effects things like isolation  narrow personal health perspective  s pretty much wash ', 'Perhaps unvaccinated cohort likely higher neutralizing antibody levels recent infection point time vaccinated cohort  since latter less likely infected months ? Basically unvaccinated group slowly building immunity time infections  one neutralizing antibody levels dwindling hitting low point certain level synchronicity  live Canada  time late December government showing data risks infection  based positive PCR testing  unvaccinated 07x risks vaccinated  2 doses  Omicron  course could due unvaccinated less likely get tested  although 07x used 35x early December  numbers based previous 28 days data  got wondering unvaccinated less likely infected Omicron due much likely infected Delta months prior ', ' people notice vast bulk vaccinated mild side effects  beaten thing  vaccination accepted  less think optimistic  Conspiratorial  magical thinking moves goalposts time  beyond reason  could say  Äúwait years  vaxxed see effectsÄù  Likewise theyÄôll interpret deaths unvaxxed deliberate  even targeting HCP ', 'says re teens  theory adult Pfizer dose  believe start lowering size dose 12s', 'Exactly  critical question  unvaccinated previously infected question settled  Definitely get vaccine  crux ADDITIONAL benefit either boosting vaccination previously infected people offers regards severe diseasemyocarditis  additional benefit  available evidence would say  additional benefit worth context potential side effects  key demographic young teenager  30 yo man  Depends study  seem 110000 risk myocarditis vaccination  Much higher women older younger men ', 'Thanks helpful ', 'hmm ve loop studies mortality  got ta admit figures 2 dose  59 %  less might expected  albeit  s fing massive CIs  482 %  may play role  Still great 3 dose working wonderfully  though', 'Correct IÄôm wrong wonÄôt basically everyone get covid young men children get vaccine myocarditis chance plus covid myocarditis chance ', 'true Omicron variant nt attack lungs like original Covid19  thus fewer hospitalizations ?', 'Literally billion dollar question nobody seems know answer ', 'OPÄôs fault  title misleading theyÄôre talking booster  original vaccination ', 'China Russia happily violate patent problem fundamental reagents needed even make pills short supply  Actually s even reagents products needed make reagents products make products  Literally sodium shortfall  s insane  https  wwwscienceorgcontentblogpostmakingpaxlovid  DIBOC pretty much commodity  look closely supply chain  find many original suppliers might thought   fact  supply problems scale right making DIBOC needs  among things  another reagent called sodium tbutoxide  Well  s another commodity  ve used stuff every often since 1980s never gave moment s thought comes  make  need tbutanol sodium metal  turns  things  bottleneck sodium tbutoxide s quite enough sodium go around  Sodium metal produced bruteforce  energyintensive electrolysis process goes back 1924  electricity supply problems interfered plants making  ', 'ItÄôd interested see clinical outcomes matched cohorts vaccine types 1 month vs 36 months intervals first series ', ' Vaccine efficacy SARSCoV2 infection 30 %  95 % confidence interval  CI   àí9 55  BNT162b2 11 %  95 % CI  àí43 44  mRNA1273  Figure 1C   infected health care workers reported negligible symptoms  control group intervention groups  However  infected participants potentially infectious  relatively high viral loads  nucleocapsid gene cycle threshold  â25   Table S6   Vaccine efficacy estimated higher prevention symptomatic disease  43 % BNT162b2 31 % mRNA1273   Fig  S4   additional protection 30 % infection 43 % symptomatic infection bad 4th dose  diminishing returns expected  feel like using terms  marginal benefit  bit uncharitable ', 'thought marginally increased protection delta decreasing alpha  wild type  etcÄ deemed unnecessary perhaps detrimental net ', 'thing greater risk taking argument getting vaccinated  majority unvaccinated living way entire time', 'agree  mean one main authors Dr Ferguson  aka Dr Doom circles  recently predicted like 5000 deaths per day Uk measures put place  find number quite absurd honest  Even peak Delta etc nt numbers like ', 'Moderna tried back last fall believe  half wildtype  half Beta specific booster   results  Perhaps first exposure someone d effective  ca nt go back ', 'tcell response various vaccines different  personal observation  little scratching throat people 2 3 doses sinovac comparing people biontech  3 doses   &  x200B  known sinovac generates less antibodies significantly better cell response structural protein', 'Interested seemingly better vaccine neutralization BA2 BA1  would possibly seeing BA2 currently replacing BA1  implications ', 'guess theyÄôd likely tested due vaccineortest mandates lot workplaces  donÄôt buy behavioural difference  Vaccination natural immunity reduce symptoms thus likeliness suspecting covid  difference portion  albeit possibly high  unvaccinated effect ', 'Abstract Several variants SARSCoV2 emerged  mutations angiotensinconverting enzyme  ACE2  receptor binding domain  RBD  associated increased transmission severity  study  developed antibody quantification functional neutralization assays  Analyses COVID19 convalescent diagnostic cohorts strongly support use RBD antibody levels excellent surrogate biochemical neutralization activities  Data revealed samples mRNA vaccinated individuals median 17 times higher RBD antibody levels similar degree increased neutralization activities RBDACE2 binding natural infections  data showed N501Y RBD fivefold higher ACE2 binding original variant  antisera naturally infected subjects substantially reduced neutralization ability N501Y RBD  blood samples vaccinated individuals highly effective neutralizing  Thus  our data indicates mRNA vaccination may generate neutralizing RBD antibodies natural immunity  suggests potential need maintain high RBD antibody levels control infectious SARSCoV2 variants  ', 'study measures IgG titers  nt think ve seen study measures neutralizing IgA titers Omicron  Omicron rapidly reproduces nose throat  Maybe s case IgG antibodies nt capable preventing breakthrough infection seeing vaccines  IgA neutralizing responses Omicron pretty weak ?', 'read ? IÄôve googling past 15 minutes canÄôt find mention EUA withdrawn uultra003  googling  find FauciÄôs reasoning matter itÄôs worth  canÄôt copy link  IÄôll capture relevant section &  x200B   GET APPROVED UNITED STATES ? Fauci mistakenly said ÄúMorning AmericaÄù CovaxinÄôs manufacturer  Bharat  applied FDA approval  office followed later day statement  ÄúBharat Biotech  company developed Covaxin  applied FDA emergency use authorization  EUA  vaccine  FDA currently evaluating data decision madeÄù ÄúThe FDA looks data data order give good scientific rationale approve  FDA approve  Äù Fauci also said ÄúMorning AmericaÄù interview  ÄúThere interventions approved reasons theyÄôve either submitted approval data strong enough warrant approvalÄù asked FDA application  spokesperson Ocugen stated Phase 3 clinical trial Covaxin 934 effective preventing severe COVID cases  778 percent effective overall disease  also noted trial children got similar results  ÄúOcugen submitted pediatric Emergency Use Authorization  EUA  based data FDA Nov 5  2021  parents healthcare providers US safe effective vaccine option children effort end coronavirus pandemic  Äù Ocugen said statement NewsNation  Fauci said think United States needed another vaccine  Instead  said  needed get people vaccinated vaccines currently approved   ÄúItÄôs alternative  ItÄôs another vaccine  Äù Fauci said Covaxin appearance ÄúMorning AmericaÄù ÄúWe donÄôt need another vaccine', 'Moderna higher effective dose active ingredient  100ug Moderna vs 30ug Pfizer  booster doses 50ug 30ug  respectively ', 'nt poorly understood phenomenon called  viral interference  ? thought fairly uncommondifficult get competing infections time  infection ramps bodies immune system fairly broadgeneral fashion short period time  study explicitly states everyone booster arm booster less three months ago  Would nt deliberate infection competing coronavirus  anything really matter  also illicit  neutralizing immunity   least brief period time ? something ve curious since get go  especially quickly vaccines appeared wane  group persons given vaccine another group infected minor cold virus interval  would meaningfully different outcomes resisting covid19 variants intervals time ? study would plainly unethical likely lethal number succumb deliberate cold infection matter mild  ve wondering mattered dosed people time observed results vaccines sort results d capture stuck anything people induced general immune response ', 'Sweden part official guidelines unvaccinated extra careful avoid crowded places   https  wwwkrisinformationseenhazardsandrisksdisastersandincidents2020officialinformationonthenewcoronaviruscurrentrulesandrecommendations   https  wwwkrisinformationseenhazardsandrisksdisastersandincidents2020officialinformationonthenewcoronaviruscurrentrulesandrecommendations ', 'understand opposition  peddling arguments related duration exposure spike protein  Really  seen argument  s government conspiracy thing anything', ' one admitted hospital  Vaccines work', 'negative 91150 looks similar s happening England s infected per 100k among vaccinated unvaccinated age groups  Omicron related  like long ', 'nt understand  thought spike protein significantly different ?', ' assigned control  participants started sedentary period within 30 min vaccination  sedentary period consisted sitting watching videos 90 min  Adults randomized exercise performed 90 min exercise cycle ergometer 60Äì70 % estimated maximal heart rate  HR max   Looks like studying effects exercise immediately immunization  would interesting see effects exercise outside time window  think beyond scope paper ', 'Super interesting stuff  though think mice nt exposed WT  One thing sure  nt expect Delta well  Though  would loved tried instead making hybrid  try new spike add bivalent alongside omicron  Edit  still omicron plasma experiments attempting identify omicron serum escape mutations yet ?', 'Abstract  Vaccines thought best available solution controlling ongoing SARSCoV2 pandemic  However  emergence vaccineresistant strains may come rapidly current vaccine developments alleviate health  economic social consequences pandemic  quantify characterize risk scenario  created SIRderived model initial stochastic dynamics vaccineresistant strain study probability emergence establishment  Using parameters realistically resembling SARSCoV2 transmission  model wavelike pattern pandemic consider impact rate vaccination strength nonpharmaceutical intervention measures probability emergence resistant strain  expected  found fast rate vaccination decreases probability emergence resistant strain  Counterintuitively  when relaxation nonpharmaceutical interventions happened time individuals population already vaccinated probability emergence resistant strain greatly increased  Consequently  show period transmission reduction close end vaccination campaign substantially reduce probability resistant strain establishment  results suggest policymakers individuals consider maintaining nonpharmaceutical interventions transmissionreducing behaviours throughout entire vaccination period   emphasis added', 'Yes  s exactly comparison  would like know risk get covid vaccination  someone study ?', 'HereÄôs one many https  wwwnaturecomarticless4156902100662w Myocarditis never huge issue  Ever  ItÄôs really people understand statistics read headlines', 'EDIT   reflection  think better understanding poster trying convey  m modifying response result  ularge_pp_smol_brain  although initially understand getting worked  think understand  Basically  complaint seems journalism standards article reported paper  necessarily preprint paper  fairly insignificant speculative comment Discussion section original paper placed first paragraph article reporting  thereby amplifying people read article  agree point journalist editor responsible article chosen amplify comment matter  paper s main focus  confused thought commenting original paper  really focuses Omicron infection various populations  apologize assuming nt read paper ', 'actually expect next variant descendant Omicron ? Omicron descendant Delta  Delta descendant Alpha  seems odd dominant variant keeps failing produce successful next major mutation  going priors  good position bet favor Omicron based variants ', 'including incidental findings Covid unrelated visits ? omicron huge proportion patients coming reason Covid ', 'study clearly blinded placebo  real claim vaccine improves GAD7 PHQ9  see purpose paper counter concerns vaccine could worsen GAD MDD symptomatology   Though  believe major vaccine trials collected PHQ9 well addressed properly since blinded  adds picture  article title dumb though', 'would liked see use PMS20 Rockefeller group ', 'Wow  pretty compelling evidence vaccines held well meant  preventing symptomatic covid  even face delta ', 'GBS occur vaccines  meningitis vaccine  well known though extremely rare ', 'studies chronic infections vaccinated immunocompromised people ? case studies seen predate vaccines ', 'mean unvaccinated ? mean  vaccinated less likely  would make results better longer keep watching ', 'ItÄôs probably difficult many variables consider  vaccines  order matters  Hence studies posted usually stick vaccination schedules single variety  even structure immune response changes ordering  basic example mRNA vaccines  immune response natural infection followed full vaccination looks different generated breakthrough case full vaccination  latter case fascinating  immune response expands immune response  itÄôs still mostly dependent antispike antibodies  also breadth antibodies enlarged get stuff like Tcells latter case  immune system seems treat breakthrough infection almost another  powerful  vaccine  Basically  answer question probably comparing COVID naive vaccinees COVID recovered nonvacinees far easier deal empirical scientific study POV ', 'See graph page 12 PDF  compares test positivity rate Omicron & Delta vaccination status  Per  among unvaccinated people Delta higher positivity rate  take look graph image disagree please reply ', 'odds ratio thing tells much intervention better control  Intervention outcomes  Control outcomes 1 null hypothesis  1 intervention better control   1 control better intervention  92 % time people intervention group nt go ICU compared control group  P factor way show something statistically significant  P value tells likely result NULL hypothesis true  null hypothesis difference outcomes  small P value tells null hypothesis probably correct one correlation data  smaller P value nt mean anything s less likely happen null hypothesis true   fairly simplified though ', ' previous studies  note develop  treatment wait hour goes away sure would like see studies ', 'sounds promising  m curious decrease hospitalization  severity stands accounting age individuals study   Omicron patients significantly younger   ', 'https  wwwmedrxivorgcontent1011012021102521265304v1fullpdfhtml https  wwwmedrxivorgcontent1011012021101721265101v2fullpdfhtml https  wwwmedrxivorgcontent1011012021122821268436v1fullpdfhtml  Last omicron  around 65 % protection hospitalization  Boosting brings 85 % ', 'mean immediately  vaccine chance work ? risk would similar without taking vaccine  mean protected risk reduced  antibodies start neutralizing virus make hard replicate  likely closer none  Anyway  myocarditis rare   vaccine well covid  Edit  idea statements would polarizing  Looks like post brigaded ', 'would reduced severity anything transmissibility ?', 'Remember SARSCoV2 migrates body affected organs one time another among various cases covid  s inefficient vaccinate half  inject 1000 hamsters  via normal route  screen ones got migration testes  could  assess effect placebo vs vaccination  potentially individuals assessment provide enough data points defensible conclusion  example  hear positive finding cancer test animals exposed chemical needing assessment  often injected directly organs researcher knows look damage  Kidneys popular purpose  normal ingestion route eating similarly always useful research  particularly true causative agent expresses effect infrequently ', 'See figures brackets ? s 95 % confidence interval  authors conclude yet  nt conclude yet  genuine increase risk Pfizer AZ  Moderna result though clear  Stats really important part analysing sort data ', 'Note convalescents study COVID infection well least two doses vaccine  either 2 doses followed booster 6 months later  single dose followed booster 6 months later   everyone  headline covers  3 exposures  fact infection  vaccination produces higher titers really surprising  even   two doses vaccine   developed either two vaccinations convalescents third vaccination breakthrough infection twicevaccinated  naive individuals  68 convalescents gave written informed consent analyses COVID19 vaccination     naive 2568 convalescent individuals continuously followedup received two doses BNT162b2 mRNAvaccine  ComirnatyÑ  BiontechPfizer  immunization     Due change national guidelines March 2021  remaining 4368 convalescents first wave vaccinated BNT162b2 mid 2021 assuming prior infection substitutes one vaccination', 'Yes  TWIV analysis exactly', 'm immunologist  ca nt say People  research  much want  nt go school learn virology  immunology  whateverology  s like  would walk lawyer s office start telling strats win cases ? surgery room start critiquing surgical technique  m saying blindly listen Fauci whoever  people need stop acting like know exactly re talking  saying  means  s questions like internet strangers nt answering', 'keywords posts get frequently brigaded  Masks myocarditis two ', ' imagine due  least part  current 2022 strains diverged 2019 strain used make vaccines   s probably current strains reproduce fast upper respiratory tract result symptoms immune system chance kick higher gear  incubation period shorter time needed reactivate memory B cells  re relying circulating antibody levels reduce peak viral loads  Peak viral load typically occurs day symptoms appearing day  could 2 days postexposure ', 'gave total number suspected myocarditis cases subgroup  nt see total number subgroup  IE  number total immunized persons per age range sex  sure one extrapolate data elsewhere  including analysis would help comfortable interpretation  ll see much changed get past peer review  anyone else noted authors estimating myocarditis rate around 21000000 vaccinated group  small number  oppose COVID s mortality 2100  complication rate small   calculate state s public data  US   mortality 21000 2040 year old range ', 'Actually  Abbott reported much higher  Independent tests came 65 %  Taking two antigen tests contact surely better PCR done days beforehand  Unless s rapid PCR  s practical ', 'includes PCR testing  large amount testing Omicron done va rapidantigen tests ', 'vaccines help prevent humans potentially ?', 'Ha yeah suck math  IÄôm going ask math sub  Whatever itÄôs 0  ItÄôs basically saying 67 % 67 % higher x  canÄôt wrap mind around calculation  IÄôll report back', 'booster provide greater protection severe illness ? protection infection seems short lived', ' recall seeing speculation 2 doses vaccine  IIRC Pfizer testing ', 'important definition constitutes  interaction health system  C19 positive data  s data hospitals ca nt generalize population level ', 'Studies show reduced transmission vaccinated individual infected delta variant   s example published less 2 weeks ago   https  wwwnejmorgdoifull101056NEJMoa2116597   Risk transmission reduced half index case vaccinated BNT162b2  aka Comirnaty  Pfizer vaccine   lower reduction risk transmission alpha variant still significant  course s caveat risk reduction  like aspects vaccine effectiveness  decreased time ', ' canÄôt find hard data hypothetically explains 95 % myocarditis cases sounds like easy solution  mean thatÄôs totally speculative hypothetical  myocarditis numbers Singapore suggest experiencing ?', 'directly clickbaity title suggests  Also kind Äúwe studied common sense reached obvious outcome  Äù  sure actual relevance virus  ', 'undated Omicron specific vaccine turned offer near zero protection Delta  according early studies  ca nt really make bet right  next major surge variant based Omicron  fine  turns unrelated variant  Omicron vaccines may well fare worse original formula  Given Delta descendant Alpha  Omicron descendant Delta  would say odds great next dominant variant descendant Omicron ', 'unknowns think s quite clear mandates wrong ', 'ÄúAn epidemic uncertainty  rumors  conspiracy theories vaccine hesitancyÄù https  wwwnaturecomarticless4159102201728z Abstract COVID19 ÄòinfodemicÄô continues undermine trust vaccination efforts aiming bring end pandemic  However  challenge vaccine hesitancy problem information ecosystem often little vaccines  Perspective  argue epidemiological social crises brought COVID19 magnified widely held social anxieties trust issues  unique circumstances global pandemic  exacerbated skepticism toward vaccines  argue trust key overcoming vaccine hesitancy  especially context widespread social uncertainty brought pandemic  public sentiment volatile  Finally  draw implications argument strategies build vaccine confidence ', 'noted commenters  myocarditis mild  transient  resolved without intervention  occur infections  vaccinations stress active younger men ? part typical immune response never looking prior current times ? Could mild transient myocarditis one causes fatigue many postinfection andor postvaccination ?', 'reading figure 2 correctly ? seems say occurrence myocarditis higher prior vaccine  green bar  2019 rates  larger blue bar  post vaccination rates  1517 age group ', 'Exactly thought well  patients infected Omikron still less likely become hospitalized compared Delta age group ?', 'promising vaccine already use infrastructure place several countries influenza vaccine  Butanta institute Brazil produce 20 million vaccines monthly  without production expansion   Actually already vaccine stock  40 million recall  Another advantage price  cost  1  2 dollar  Normal storage ', 'Improving indoor air quality developing prophylactic treatments including nasal sprays  enhancement IgA immunity  fir respiratory pathogens  barriers prevent viral adhesion highest priority research currently  account respiratory pathogens  collectively cause high amount illness ranging mild fatal  potentially preventable  least able mitigate risk   cost healthcare systems economies globally billions lost productivity  days workschool  healthcare costs  etc ', 'Summary emerging SARSCoV2 variants concern  VOC  threaten effectiveness current COVID19 vaccines administered intramuscularly designed target spike protein  pressing need develop nextgeneration vaccine strategies broader longlasting protection  Using adenoviral vectors  Ad  human chimpanzee origin  evaluated Advectored trivalent COVID19 vaccines expressing Spike1  Nucleocapsid RdRp antigens murine models  show singledose intranasal immunization  particularly chimpanzee Advectored vaccine  superior intramuscular immunization induction tripartite protective immunity consisting local systemic antibody responses  mucosal tissueresident memory cells mucosal trained innate immunity  show intranasal immunization provides protection ancestral SARSCoV2 two VOC  B117 B1351  Our findings indicate respiratory mucosal delivery Advectored multivalent vaccine represents effective nextgeneration COVID19 vaccine strategy induce allaround mucosal immunity current future VOC  ', 'According article cited  SSNHL also observed vaccination OxfordAstraZeneca  well older vaccines  influenza  tetanus diphtheria  meningococcal polysaccharide  rabies   mechanism known  may immune autoimmunerelated   Sudden sensorineural hearing loss COVID19 vaccination   https  wwwsciencedirectcomsciencearticlepiiS1201971221008158 ', 'CI surrounds 0  s likely statistical noise bringing 0  also seems largely ChAdOx1 dragging data set   vaccine effectiveness BNT162b2 92 %  95 % CI 92 93  p  0001  15Äì30 days  47 %  39 55  p  0001  121Äì180 days  23 %  àí2 41  p007  day 211 onwards  Waning slightly slower mRNA1273  vaccine effectiveness 96 %  94 97  p  0001  15Äì30 days 59 %  18 79  p0012  day 181 onwards  Waning also slightly slower heterologous ChAdOx1 nCoV19 plus mRNA vaccine schedules  vaccine effectiveness 89 %  79 94  p  0001  15Äì30 days 66 %  41 80  p  0001  day 121 onwards  contrast  vaccine effectiveness homologous ChAdOx1 nCoV19 68 %  52 79  p  0001  15Äì30 days  detectable effectiveness day 121 onwards  àí19 %  95 % CI Äì98 28   p049  ', 'means elderly really need drop hesitancy get vaccine  big problem vaccine hesitancy among elderly  esp  80 age range   chart proportion vaccinated vs age opposite countries ', 'UK papers continue study 2x AZ w BNT M1273 boosters ', 'Absence evidence  evidence absence ', 'actually know viral load show infectious ? s RNA fragments  would necessarily correlate infectivity  Every study seen tried culture viral load reported significantly lower vaccinated  though range vary study study ', 'Seeing vaccines  J & J excepted  originally designed given prime  boost regimen  people vaccinated exposed spike protein twice  3x boosted   would expected stronger persistent response second exposure  single infection vaccine encountered sarscov2 antigens  Giving people vaccine would act bit like heterologous boost priming infection  would interesting see people infected twice better immunity caught  probably enough cases able appropriate comparative studies  TWiV Clinical Update recently  Dr Daniel Griffin commented patients infected four times  ', 'thought  could covid pass force  vaccinated would social occasions get infected ?', 'Exactly point going make  Luckily improved diet also help vaccine efficacy improve weight  cholesterol high blood pressure vaccination https  wwwncbinlmnihgovpmcarticlesPMC8487656', 'really  state three exposures like flu lineages time 10 years old  yearly sequence matched flu boost turbocharges little ', 'Yes  according study twice likely get vaccine first  second dose biontech  31215 per million  compared covid  7 per million   only cared myocarditis risk would make sense get vaccinated young male ', 'One statutory requirements granting EUA   adequate  approved  available alternative product diagnosing  preventing  treating disease condition  https  wwwlawcornelleduuscodetext21360bbb3 two FDAapproved vaccines COVID available adults  bar new EUA s getting higher spaces Pfizer & Moderna adequate & approved small shrinking ', ' CONCLUSIONS messenger RNA  mRNA  boosterswerehighly effective symptomaticdelta infection  but wereless effective againstsymptomatic omicron infection Ä Discussion BNT162b2 booster vaccinationwas associated an861 % reductionin incidenceofsymptomaticdeltavariant infectionand a494 % reductionin incidenceofsymptomaticomicron infection  themRNA1273booster  reduction incidence symptomatic infectionwiththeomicron variantwas similarat 473 %   ', 'nt feel right  Even Omicron replicates  vaccine targeted Omicron work effectively one basically nt target  replicates quickly overwhelms vaccine initially  would nt expect virus deadly since viral load higher ? Omicron  even unvaccinated people  significantly less deadly  however still deadly many ', 'Would nt imply locking vaccinated  least closing bars etc  would huge impact new case rate ?', 'Infection naØve population ? would said south south island New Zealand  omicron couple days weeks s already country  Also hard find vaccine naØve uninfected ', ' health authorities almost  experts  wanted touch study 10 foot pole  Eh ? 27 studies cited five months since published  highprofile journals  NEJM  Lancet  JAMA  etc   s compelling example avoidance  https  wwwnejmorgdoifull101056NEJMoa2114114  article_citing_articles', 'Ah perfect thank ', 'Longer USA recommended time ? longer schedules recommending 23 months first second doses ?', 'vaccines development target stable part virus rather spike protein ?', 'Thankyou broadening vs narrowing analogy  would nt say feared way  much curious interactions aging vaccine relatively mutated variant  imagine gets complicated OAS would nt really exist always case though ? assumed boosters effective brute forced sterilization sheer magnitude numbers even stronger immune response  antibodies generated individual level remained less effective ', 'quick correction  lower bound 95 % CI mRNA1273 Omicron 699  positive 699  wondering estimate could outside CI range  looks like typo ', 's defined s even study  s peer reviewed  even published journal  s published blog  Nothing confirmed even evaluated  Total garbage ', 'downvoted ? ? ve wondering thing', 'press release text  sans footer   US Food Drug Administration notified Pfizer new data recently emerged regarding emergency use authorization request use PfizerBioNTech COVID19 Vaccine children 6 months 4 years age  part rolling submission  company recently notified agency additional findings ongoing clinical trial  Based agencyÄôs preliminary assessment  allow time evaluate additional data  believe additional information regarding ongoing evaluation third dose considered part decisionmaking potential authorization    Therefore  FDA postponing Vaccines Related Biological Products Advisory Committee meeting originally scheduled Feb 15  give agency time consider additional data  allowing transparent public discussion part usual scientific regulatory processes COVID19 vaccines  provide update timing advisory committee meeting receive additional data third dose age group companyÄôs ongoing clinical trial opportunity complete updated evaluation    Since early days pandemic  always followed science everchanging situation  Given recent omicron surge notable increase hospitalizations youngest children highest levels pandemic far  felt responsibility public health agency act urgency consider available options  including requesting company provide us initial data two doses ongoing study  goal understand two doses would provide sufficient protection move forward authorizing use vaccine age group  approach always conduct regulatory review thatÄôs responsive urgent public health needs created pandemic  adhering rigorous standards safety effectiveness  able begin evaluating initial data useful review vaccines  time  believe additional information regarding ongoing evaluation third dose considered    agency ensure data support effectiveness safety authorizing COVID19 vaccine use youngest children  meantime  best way protect children  including school daycare  practice social distancing masking accordance public health recommendations  family members caregivers get vaccinated receive booster dose eligible ', ' https  wwwmedrxivorgcontent1011012022020222270302v1  Detectable Omicronneutralizing activity nearly absent two vaccinations elicited 89 % individuals booster immunization  Neutralizing titers Wu01  Delta  Omicron variants showed similar postboost declines 81 % individuals maintained detectable activity Omicron  Levels fall  sheer ability neutralize distant VoC retained probably recalled ', ' getting huge boost antibodies would amplify also ones still work s paper reporting  nt contradict said  do believe amplifying antibody levels means whatever antibodies already still neutralize omicron would present greater numbers  paper  among others  reporting greater breadth antibody coverage   antibodies variants  nt exist yet  means greater chance antibodies work better particular variant different original  See comment post  https  wwwredditcomrCOVID19commentss635r8mrnabased_covid19_vaccine_boosters_induceht1t2f7 ? context1', ' Previous papers similar positive spin narrative  general tenor tension findings independent studies  post independent studies ? interested J & J efficacy severe disease  without booster  long COVID', 'honest  think vastly overestimating much thought people give topic  people show  rest population adopts group consensus tribe runs ', 'Memory B cells cells rescue ', 'current increases Europe China  nt think rule spike starting April May ', 'appears improvement fomite transmission side things per Japanese study  https  wwwbiorxivorgcontent10110120220118476607v1   https  wwwbiorxivorgcontent10110120220118476607v1  aspect watching since beginning  thing evolves substantively improve form transmission  bets  CDC backgrounder formite transmission  https  wwwcdcgovcoronavirus2019ncovmorescienceandresearchsurfacetransmissionhtml   https  wwwcdcgovcoronavirus2019ncovmorescienceandresearchsurfacetransmissionhtml  m thinking though something else play survival times various surfaces ', 'simply lot antibodies general ?', 'WouldnÄôt control number viral infections group control ? basically comparing group viral infections group less  Also comparable groups would vaxCovid positive vaxCovid positive vaccine vaccine  really isolating either Covid infection vax status relationship GBS design ', 'well  make blanket approach CDC took recommending either mRNA vaccine J & J ages groups  28 year old male probably less 1 1 million chance developing blood clot  even lower chance dying  Even though myocarditis cases typically resolve  still shows Moderna likely high higher risk J & J demographic  Note  nt think Moderna restricted group  point show blanket approach CDC took nt make sense  Especially since  context Omicron  main advantage mRNA vaccines  efficacy infection  nt seem much factor anymore  Protection severe disease equalizer  J & J always held well comparatively ', 'like  really frustrating piece information going around getting spun certain way  says  monkeys  omicronspecific doses offered additional protection OG mRNA vaccines in immunenaive test subjects  getting reported said   omicron dose nt offer additional protection   already knew experimental realworld data 1 2 shots OG mRNA nt offer highest level protection omicron  well 3rd dose OG upped protection level efficacy OG covid  important data overall vaccine production implementation  big part purpose developing omicronspecific dose assessing whether omicron booster 3rd  4th  whatever  shot offers additional protection omicron beyond 3rd  etc  dose OG formula people already vaccinated  article does contain information  yet portrayed though though s clear evidence development omicronspecific booster wo nt successful ', 'cells store memory invading pathogen immune systems response  nt activate cells ai nt trickin shyt ', ' think anybody idea hospitalized covid patient less chance developing myocarditis somebody getting vaccinated  m sure lol', 'Wow didnÄôt realize far along  seems pretty promising  Would love see direct comparison NovaVax  seems like might push novavax right way really ', 'Given sample size spread  authors really reaching draw conclusion different response breakthrough infections 2 3 vaccine doses  personally would call indistinguishable warranting study ', '511 already', 'infection  relevant end points like long covid  hospitalization death  2 shots still show protection ', '? Norwegen case one infecting 80 party ', 'agree  however d like perspective following  problem right Canada COVID prevalent  hospitals dedicate lot resources isolating infected hospitalized people whose issues nothing COVID  even clear provincial governments know many people hospitalized COVID opposed COVID  data never made public  least Quebec Ontario  long COVID treated like dangerous disease  healthcare get overwhelmed every winter  Omicron extremely dominant  recent data Delta prevalence however  vast majority population vaccinated  significant percentage immunity infections  unclear dangerous disease nt seem  hospitals started treating COVID normally  hospitals would nt overwhelmed  think  take lot time hospital protocols change  large segments public still highly scared catching COVID  governments would make decision  hope changes next autumn ', 'get covid test positive covid ? Oh s hospitalized covid ? tiny fraction percent age range get covid ?', 'Abstract ____ Objective   assess shortterm change depressive anxiety symptoms relation COVID19 vaccination among Swedish adults  Design   prospective cohort study monthly data collections selfreported depressive anxiety symptoms December 2020 October 2021 COVID19 vaccination July October 2021  Setting   Omtanke2020 Study  Sweden  Participants   7925 participants Omtanke2020 study complete data depressive anxiety symptoms vaccination status  Intervention   Exposure     Receiving first second dose COVID19 vaccine  Main outcomes   Measure     Binary measures depression  PHQ9  cutoff â 10  anxiety  GAD7  cutoff â 10  one month first dose  one month first dose   applicable  one month second dose  individuals vaccinated chose report vaccination status  unvaccinated individuals   selected three monthly measures PHQ9 GAD7 2month intervals inbetween based data availability  Results  5079  641 %  individuals received two doses COVID19 vaccine  1977  249 %  received one dose  305  39 %  vaccinated  564  71 %  chose report vaccination status  lower prevalence depression anxiety among vaccinated  compared unvaccinated  individuals  especially second dose  Among individuals receiving two doses vaccine  prevalence depression anxiety lower first  aRR082  95 % CI 076088 depression  aRR081  95 % CI 073089 anxiety  second  aRR079  95 % CI 073085 depression  aRR073  95 % CI 066081 anxiety  dose  compared vaccination  Similar results observed among individuals receiving one dose  aRR076  95 % CI 068084 depression  aRR082  95 % CI 072094 anxiety  comparing first dose vaccination   results independent age  sex  recruitment type  body mass index  smoking  relationship status  history psychiatric disorder  number comorbidities  COVID19 infection status  seasonality  Conclusions   observed positive shortterm change depressive anxiety symptoms among adults receiving COVID19 vaccine current pandemic ', 'takes longer get lungs', ' disappointingly low ? risk already relatively small marginally improved unvaccinated makes question s even worth billions spent lockdowns forced', ' lockdown measures resulted practically benefit  fact  arguably detrimental overall   research subreddit  Would mind citing ? quick search finds sources entirely contrary  https  journalsplosorgplosonearticle ? id101371journalpone0236619 https  wwwsciencedirectcomsciencearticlepiiS0048969720339528', 'could mention results vaccine effectiveness much negative 91150 days vaccination moderna pfizer  765 Pfizer 91150 days  extreme result ', 'IÄôm aware two studies Omicron  sub threads    redditcomrCOVID19coronavirus_disease_2019_covid19_vaccine_boosting   https  wwwredditcomrCOVID19commentssslf1a   redditcomrCOVID19protection_against_the_omicron_variant_from   https  wwwredditcomrCOVID19commentssophs7   redditcomrCOVID19protection_afforded_by_prior_infection_against   https  wwwredditcomrCOVID19commentsrxni1d   studydataset second believe ', 'people seriously uneducated fools ca nt sway', 'Would love know info  5yo getting second shot later today ', 'Anyone happen link study information protective ?', ' Could lead body becoming likely produce universal  Äúcommon denominatorÄù antibodies ? exposure naive people  maybe  given numbers either infected vaccinated seems like already locked imprinted response form first exposure ', ' 1  especially interesting  vaccines offer lifetime sterilizing immunity others donÄôt ? even without vaccines  get measles coronaviruses return periodically  simply coronaviruses replicate fast get foothold cellular immunity respond ? IÄôll use measles example  slow one ? replicate sinuses enter system first ?', ' 6 weeks illness onset  lower prevalence among vaccinated participants  606 %  compared unvaccinated participants  606 % vs 791 %  aRR 070  95 % CI 0580  Also remember s conditional infection breakthrough health care workers severe slice breakthrough infections asymptomatic  mildly symptomatic  individuals probably nt included study ', 'Oof   1 especially   2  serious question  nt small sample size ? 41 samples 33 convalesced patients  28 samples vaccinated ', ' WouldnÄôt control number viral infections group control ? ? study looking relative rates GBS vaccinated vs infected unvaccinated  relative rates infection ', 'Yeah gets rolled itÄôs either going leave people vulnerable worst time  going holidaywinter season  necessitate fifth dose  think weÄôre really going start seeing big amount diminishing returns terms participation round shots need careful ', 'think anybody idea hospitalized covid patient less chance developing myocarditis somebody getting vaccinated  would interesting check risks involved vaccination person already immunized  3rd dose present better protection chance getting myocarditis ? vaccines improve defense prior infection kind risks posed vaccines ?', 'X 100 would extremely common  Let s hope s significantly better ', ' study showed impact vaccination community transmission circulating variants SARSCoV2 appeared significantly different impact among unvaccinated people  m rather surprised interpretation  quoted paper   https  wwwthelancetcomjournalslaninfarticlePIIS14733099  21  006484fulltext   text paper   Vaccination reduces risk delta variant infection accelerates viral clearance  Nonetheless  fully vaccinated individuals breakthrough infections peak viral load similar unvaccinated cases efficiently transmit infection household settings  including fully vaccinated contacts  HostÄìvirus interactions early infection may shape entire viral trajectory  quite clearly say asserting  Even examine perspective break infection earlier viral clearance would expect reduce overall transmission ', 'moderna  nt Pfizer ? Thanks', 'make phase 1 2  trial soon phase 3 eua ? omnicrap long term effects would really like get rid ', 'wonder s mechanism long haul symptoms induced vaccination individuals case  long haulers recover get symptoms back worsened post vaccination  needs research underlying cause long term effects ', 'links similar comparative studies  ways harm  us ?', 'Really would loved seen questions knowing someone died COVID  impacted vaccine hesitancy ', 'IÄôm going memory  forgive IÄôm wrong didnÄôt Pfizer 85 % 10 months post vaccination ?', 'mean vaccine effectiveness drop below 0 % ? ?', ' also know  though less confidence  time  memory B cells become dormant  challenge immune system similar antigen happens  leads recruiting naive B cells process  Would exposure virus also challenge immune system ? instance  someone infectionacquired andor boosted immunity exposed antigen  would considered challenge ?', 'saying ? Maybe misinterpreting nt know abstract support selection pressure vaccines directly creating environment Omicron  omicron escape vaccineinduced immunity right ?', 'also need Paxlovid patent free mass produced ', 'would look previous infection since Ab levels usually drop months ?', 'think need thinking terms long immunity lasts  itÄôs strong month two thatÄôs going us lot good ', 'Although encouraging think wait data independent researchers  assay sanofi used could biased ', 'says  exercise increase side effects covid19 vaccination  side effects referring ? general soreness getting vaccine something else ?', 'Vaccination protected testicular damage SARSCoV2 challenge  Hamsters immunized two doses intramuscular inactivated whole virion vaccine 14 days apart  14  intranasally challenged 103 PFU SARSCoV2 HK13 14 days second vaccination  Testes examined 4 28dpi  Figure 10A   Serum neutralizing antibodies detected vaccinated animals challenge 4dpi 28dpi  GMT 1604382 1202309  respectively  Testicles showed histopathological changes nine vaccinated hamsters  Figure 10B   One group hamsters  n7  challenged 103 PFU 3 days first vaccination showed testicular histopathological damage 4dpi  Figure 10B   indicating vaccination effectively protects testes SARSCoV2  mild cases may spared   detectable histopathological changes observed 4dpi challenge 10PFU 102 PFU  Figure S1   Edit  added ', 'Bharat Biotech currently working stage III trials nasal COVID19 vaccine used booster shot ', 'doesnÄôt matter randomize correctly  effect previous infections similar cohorts ', 'previous study  Smith et al  Genome Medicine  2021  13101 Landscape selection vaccine epitopes SARSCoV2  https  doiorg101186s13073021009101   https  doiorg101186s13073021009101  Abstract Background  Early pandemic  designed SARSCoV2 peptide vaccine containing epitope regions optimized concurrent B cell  CD4  cell  CD8  cell stimulation  rationale design drive humoral cellular immunity high specificity avoiding undesired effects antibodydependent enhancement  ADE   Methods  explored set computationally predicted SARSCoV2 HLAI HLAII ligands  examining protein source  concurrent humanmurine coverage  population coverage  Beyond MHC affinity  cell vaccine candidates refined predicted immunogenicity  sequence conservation  source protein abundance  coverage high frequency HLA alleles  B cell epitope regions chosen linear epitope mapping studies convalescent patient serum  followed filtering surface accessibility  sequence conservation  spatial localization near functional domains spike glycoprotein  avoidance glycosylation sites    major histocompatibility complex  human leucocyte antigen ', 'betacoronaviruses less likely diverge subtypes influenza ?', 'IÄôm sure understand trying say simpler language  sounds like boosters blunted immune response high immune function ? certain ', 'https  coronavirushealthnygovcovid19breakthroughdata scientific compared Houston study graphs showing consider vaccine efficacy infections hospitalization mobile friendly  data 2 week lag fully omicron cases yet', '3rd shot  booster  produced robust immune response 2nd terms neutralizing antibodies also ability neutralize Omicron  much mutated Variants Concern   fourth shot  however  seemed restore antibody levels 3rd shot  greater  also found fourth shot seemed shift focus immune system parts virus spike  helpful  conclusion repeated boosting keep immunity long term option  looked group healthcare workers received shots inactivated CoV2 vaccines  mRNA type  PfizerModerna   Unlike inactivated kind  mRNA vaccines produces spike  s unclear point immune response shift away spike seems study w inactivated vaccines  include parts virus  ', ' unlikely happen  Furthermore  immersed brain cells vaccine 96hrs  Odd  happens immerse brain cells tap water 96hrs ? anything started spike protein brain cells  compare time  read last night baffled  ', 'going find 205 people vaccinate already willing participate clinical trial ?', 'nt Omicron started running course ? need prepared future variants omicron wave seems mostly USA ', 'Hospitalizations falling South Africa  Hopefully thing happens US', 'stop showing incidence rate 2 doses ?', 'Oslo study  none subjects boosters  double vaccinated 54 66 infected  81 %   Faroe  study  boostered  21 33 infected  64 %   Oslo average age 35  Faroe  45 ', 'still think need look spacing 1st 2nd doses apart much currently  2nd shot  especially recommended schedule  may actually great deal compared booster shot months later ', 'say third dose mean booster dose regular dose ?', 'inclusion criteria  COVID19 diagnosis   people test positive Covid  think word  patient  confusing lot people  paper said nothing hospitalizations ', 'also talk preexisting hypertrophy one boys nt specifically rule HO Cm despite running testing genetic markers arrhythmias  Moreover pair potentially questionable case reports  dont see smoking gun ', 'Also relevant myocarditis negative health outcome COVID19  s pretty easy call compare  low risk myocarditis   low risk myocarditis   comparing outcomes important well ', 'ca nt know things like  actual people actual time study  two things ca nt hurry study  Studies nearly way really know know  even  need reviewed scientific peers study organizers  things take time know ', 'Thanks nt understood beginning', 'Yeah  actually saw happen Ontario last month  populationadjusted infection rates fully vaccinated individuals actually surpassed rates unvaccinated  compelling theory heard case vaccinated individuals could attend highcongregate settings like movie theatres  bars sports games  Omicron  ripped settings meant even controlling population  still vaxxed getting infected ', 'Hong Kong highest CFR world  IÄôm sure means vaccine ', 'way could see happening feel confident willing risk exposure feeling confidence  live places fewer restrictions higher vax rates fewer restrictions  increasing possible exposures ?', 'someone help understand whatÄôs going  clearly seeing vaccine effectiveness decreasing timeÄ itÄôs almost every study IÄôve read   2 doses Pfizer Moderna effectiveness dropped around 65 70 % around 10 % 25 weeks second dose  2 doses  omicron low 10 % Pfizer Moderna  0 % percent AstraZenecaÄ  current boosters arenÄôt even omicron specific  theyÄôre exact formula original vaccine developed wild COVIDÄ  expecting booster diminish wellÄ ? point 2doses basically irrelevant  even delta 20 weeks less 50 % effective begs question  original Pfizer 10 month trials still high ? ?', 'matched based age location  comorbidities   individual matched  11  Statistics Sweden  national agency statistics  one randomly sampled individual total population Sweden birth year  sex  municipality  attempted adjust comorbidities using Cox proportional hazards model analysis ', 'one ? AZ close useless Omicron protection even hospitalisation severe symptoms drops cliff quickly  also expressly recommended many places people 30  J & J pulled  s basically Novovax nt know one ', 'extend definition Äúfocusing protecting hospitalization even immunocompromised Long CovidÄù wonÄôt care infections either would board ', 'N2  Major finding ? CÄômon ', 'exactly comparing ? m mistaken vaccine myocarditis risk hospitalised covid19 patient myocarditis risk ?', 'Discussion actual report  &  x200B  growth rates estimated Omicron translate doubling times 25 days  even allowing potentially slowing growth 11 th December  estimates consistent even faster doubling times reported South Africa  13   Assuming exponentially distributed generation time 52 days R1 currently Delta  reproduction number  R  estimates Omicron 3 SGTF genotype analyses  25 even period 8th 10th December  Shorter assumed generation times give lower R estimates  distribution Omicron age  region ethnicity currently differs markedly Delta  indicating Omicron transmission yet uniformly distributed across population  However  note given immune evasion  age distribution Omicron infection coming weeks may continue differ Delta  London substantially ahead English regions Omicron frequency  find strong evidence immune evasion  natural infection  risk reinfection 541  95 % CI  487600  fold higher Omicron Delta  vaccineinduced protection  estimates largely agree UKHSAÄôs TNCC study  11  predictions predicting neutralising antibody titres  414   suggesting limited remaining protection symptomatic infection afforded two doses AZ  low protection afforded two doses Pfizer  moderate high  5580 %  protection people boosted mRNA vaccine  estimate hazard ratio reinfection relative Delta also supports previous analysis reinfection risk South Africa  15   Prior Omicron  SIREN cohort study UK healthcare workers estimated SARSCoV2 infection gave 85 % protection reinfection 6 months  16   relative risk infection 015 compared prior infection  hazard ratio estimate would suggest relative risk reinfection risen 081   95 % CI  073100   ie  remaining protection 19 %   95 % CI  027 %    Omicron  find evidence  risk hospitalisation attendance symptom status  Omicron different severity Delta  though data hospitalisations still limited  several limitations analysis  case numbers increasing quickly  still limits ability examine interactions variables considered  distribution Omicron differed markedly Delta across English population time analysis conducted  likely due population groups initially seeded  increases risks confounding analyses  SGTF imperfect proxy Omicron  though SGTF 60 % specificity Omicron date range analysed SGTF analysis  close 100 % 10th December   Intensified contact tracing around known Omicron cases may increased case ascertainment time  potentially introducing additional biases  analysis reinforces still emerging increasingly clear picture Omicron poses immediate substantial threat public health England widely ', 'may simply confounding factor study design  One remember groups random blinded  example  pure speculation  could personnel working close contact covid patients likely want second booster shot may overrepresented  2 booster shots group  time might markedly increased risk catching omicron  scenario second booster shot could theoretically even raise immunity due study design  confounders look would make likely get infected  Another similar imaginable confounders could persons children may willing get extra booster thinking want protect families  time children could make likely catch omicron children  m saying true s likely hypothesis second booster lowers immunity  important remember correlations seen unblinded nonrandom studies often causations ', 'Unfortunately theyÄôre probably going crossed long time  think general consensus well year talking December  perhaps significantly longer  thatÄôs assuming work well hoped  Unless someone comes along Äúwarp speedsÄù  weÄôve seen indication occurring juncture ', 'type basic statistical analysis missing many published studies  worries peer review nt catching foundational aspects probability ', 'results really strange  adeno vaccines really higher neutralization titres vs mRNA vaccines studies  find hard believe single JJ dose lead higher neutralization titres vs Pfizer vaccine 56 year olds  said  Sanofi little bit careful 2020 maybe one major vaccines 2021 would  pitty ', 'Seems like title little misleading  Mixed cocktail seems work great  specific omicron delta RBD vaccine protocols nt work much  Also preprint  think given title abstract misleading going ', 'Without even looking study pretty sure sampling vaccinated cohorts going within 2 months second dose boost  antibodies start wane  almost always case studies favor vaccination compared natural immunity  point looking mixture 2 months  3 months  6 months  12 months second dose boosters accurately represent population  tells us nothing new really  s different two months following someone recovering Covid ', 'Omicron Delta  numbers concerning last two dominant strains wonder  Wait next study guess ', ' Controlling vaccine status  age  sex  ethnicity  asymptomatic status  region specimen date  Omicron associated 540  95 % CI  438663  fold higher risk reinfection compared Delta  put context  preOmicron era  UK ÄúSIRENÄù study COVID infection healthcare workers estimated prior infection afforded 85 % protection second COVID infection 6 months  reinfection risk estimated current study suggests protection fallen 19 %  95 % CI  027 %  Omicron infection   study finds evidence Omicron lower severity Delta  judged either proportion people testing positive report symptoms  proportion cases seeking hospital care infection   researchers found significantly increased risk developing symptomatic Omicron case compared Delta two weeks past second vaccine dose  two weeks past booster dose  AstraZeneca Pfizer vaccines    Depending estimates used vaccine effectiveness symptomatic infection Delta variant  translates vaccine effectiveness estimates symptomatic Omicron infection 0 % 20 % two doses  55 % 80 % booster dose ', '0327 relative risk versus 0337 relative risk 0970 relative risk 3 % efficacy  Math nt magic trick  learn stuff ', 'Abstract SARSCoV2 Omicron variant concern comprises three sublineages designated BA1  BA2  BA3  BA2 steadily replacing globally dominant BA1  show large number BA1 BA2 spike mutations severely dampen plasma neutralizing activity elicited infection seven clinical vaccines  crossneutralization BA2 consistently potent BA1  independent vaccine platform number doses  Although mRNA vaccines induced greatest magnitude Omicron BA1 BA2 plasma neutralizing activity  administration booster based WuhanHu1 spike sequence markedly increased neutralizing antibody titers breadth BA1 BA2 across vaccines evaluated  data suggest although BA1 BA2 evade polyclonal neutralizing antibody responses  current vaccine boosting regimens may provide sufficient protection Omicroninduced disease ', ' study vaccinated BALBc mice peptides derived SARSCoV2 proteome designed either elicit Tcell responses Bcell responses linear epitopes   m bit confused part  design antigen either elicit B cells response ? Would nt immune system automatically generate ?', 'worst part whole Äúmyocarditis vaccineÄù analysis even worst myocarditis post vaccination pretty small  study notes worst possible statistic around developing myocarditis vaccine 86 100000 00086 % developing Keep mind  previous studies  note develop  treatment wait hour goes away  Keep mind  worst outcome vaccine ÄúmyocarditisÄù folks  never huge issue continuation know  Covid worse normal operations body  side effects minimal  frankly  society didnÄôt make pst high school statistics', 'agree statement  sample size rather small  Hospitalization rates nt high COVID19 seem indications omicron strain less likely lead hospitalization ', 'Vaccine boosters must timed expected coronavirus season  idea maximum amount people maximum amount antibodies blood stream time peak COVID 19 season ', 'tried make vaccine focusing variants  nt make much difference according study  s subreddit ', 's widely reported immunity conferred omicron infection backwards compatible  apt term could come   nt know robust findings  also nt heard opposing viewpoints  may well moot Omicron displaced Delta anyway ', 'data original vaccination ?', 'Looks like itÄôs animal models far ? like concept sounds promising ', ' seen much protection severe disease drops single doseJJ vaccine ? recall seeing studies fall showed people vaccinated early spring 2021 still strong protection hospitalization Delta  although recall exact title papers moment  Recently  shown one dose J & J offered basically zero protection symptomatic Omicron donÄôt recall seeing numbers hospitalization', 'burn nonimmune people first becoming endemic    take longer since previous infection andor vaccination completely protective circulating variants  one knows many variants emerge  either ', 'nt Omicron specific vaccines fairing fairly equally original vaccines far ?', 'wish broken risk myocarditis COVID19 infected individuals age groups figure 2 ', 'going say  fact delta positivity reduced 4550 % two doses seemed surprising  since remember seeing figures  boosters widely available  7075 % effectiveness delta  makes sense particular study biased towards people symptomsaccess testing', 've seen timelag effects hospitalization & death statistics many different cases wo nt comfortable characterization SA s data weeks testing peak  testing even scales ', 'find quote paper ', 'addition usual efficacy data  report contains 17 pages vaccination pregnancy  s good charts tables birthweight stillbirths ', 'data studies progress booster otherwise mixed vax flavors ? looked really promising  attractive many people  year ago  s shame s taken long ', 'Protection infection dropping zero around point  undetected infection unvaccinated group setting true  graphed  apparent  baseline slightly zero  likely  seen estimates centers around specific waves timing studies like  design looking SARS2 infection outcomes  control healthcare seeking behavior  test negative design  would nt see ', ' conclusion repeated boosting keep immunity long term option  going research boosting different variant vaccine whether ll restore  usefulness  ? understand boosting 4 shots exact thing probably useful ', 'know partial2dose vaccination  particularly separated month CDC insisted recently  prevent Omicron infection  smaller dose would also strong impact hitting specific extremely high cutoff needed originaltargeted antibodies reasonably prevent Omicron infection  short  news  Antigenpresenting cells still teach B cells fight Covid  begin affinity maturation scale Omicron futurevariant specific protection   guess  boost dose given  primeboost vaccination prime boost often small nt trigger enough response prevent infection boost dose given  across many  many diseases  One might question usefulness second dose  since theoretically contribute much affinity maturation ', 's important note  however  booster thing original vaccine composition dosage  s second dosage  identical first  true Pfizer booster well  Moderna composition  half dosage', 'article assumes public reaction vaccination played individual interactions facebook  incoming information real world  think year covid comparable flu  perhaps vaccination year vulnerable groups  restrictions  people notice vast bulk vaccinated mild side effects  beaten thing  vaccination accepted  less  year still lockdowns vaccinations every four months required government edict hard sell lots stories people say forced accept vaccination harmed  think question far real news filters slowly facebook far facebook opinions driven dynamics short term individual interactions important understand damaging facebook  nt think question answered well model impact interactions ', 'Also extremely interested whether would probably repeated mRNA boosting well  deliver spike whole inactivated virus  Obviously  4th  5th  6th mRNA boostings arenÄôt going bring antibodies beyond 3rd dose got  would active harm immunity ?', 'Shorter length hospitalization hospitalization ?']\n",
            "Dev accuracy for best dev model: 0.745, 95% CIs: [0.685 0.805]\n",
            "\n",
            "Test accuracy for best dev model: 0.750, 95% CIs: [0.685 0.805]\n",
            "\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Agreement\t0.223\t&\n",
            "Agreement\t0.186\t?\n",
            "Agreement\t0.184\t%\n",
            "Agreement\t0.183\tleast\n",
            "Agreement\t0.175\tinfections\n",
            "Agreement\t0.172\tget\n",
            "Agreement\t0.159\tsimilar\n",
            "Agreement\t0.158\tshowed\n",
            "Agreement\t0.157\thttps\n",
            "Agreement\t0.157\tsymptoms\n",
            "\n",
            "Disagreement\t0.354\tnt\n",
            "Disagreement\t0.340\t?\n",
            "Disagreement\t0.292\tactually\n",
            "Disagreement\t0.249\tgoing\n",
            "Disagreement\t0.225\tsay\n",
            "Disagreement\t0.218\tsure\n",
            "Disagreement\t0.218\tgraph\n",
            "Disagreement\t0.195\tsimply\n",
            "Disagreement\t0.189\tcertain\n",
            "Disagreement\t0.180\tspikes\n",
            "\n",
            "Neutral\t0.400\tabstract\n",
            "Neutral\t0.257\tcovid19\n",
            "Neutral\t0.186\tvaccine\n",
            "Neutral\t0.180\tpandemic\n",
            "Neutral\t0.174\tsarscov2\n",
            "Neutral\t0.160\tage\n",
            "Neutral\t0.159\tb\n",
            "Neutral\t0.156\tmaturation\n",
            "Neutral\t0.149\tantibodies\n",
            "Neutral\t0.140\troll\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### combined (BOW + unigram) with stopword and punct removal"
      ],
      "metadata": {
        "id": "zomJfLvrJhfc"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def run_combined_punct(trainingFile, devFile, testFile):\n",
        "    trainX, trainY=load_data(trainingFile)\n",
        "    devX, devY=load_data(devFile)\n",
        "    testX, testY=load_data(testFile)\n",
        "\n",
        "    trainX = list(map(remove_stop_df, trainX))\n",
        "    devX = list(map(remove_stop_df, devX))\n",
        "    testX = list(map(remove_stop_df, testX))\n",
        "\n",
        "    # remove punct\n",
        "    trainX = list(map(punct_removal, trainX))\n",
        "    devX = list(map(punct_removal, devX))\n",
        "    testX = list(map(punct_removal, testX))\n",
        "\n",
        "    simple_classifier = Classifier(combiner_function, trainX, trainY, devX, devY, testX, testY)\n",
        "    simple_classifier.train()\n",
        "    accuracy=simple_classifier.test()\n",
        "\n",
        "    print_confusion(simple_classifier)\n",
        "\n",
        "    \n",
        "    lower, upper=confidence_intervals(accuracy, len(devY), .95)\n",
        "    print(\"Test accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy, lower, upper))\n",
        "\n",
        "    simple_classifier.printWeights()"
      ],
      "metadata": {
        "id": "Zg00GPcwJnpi"
      },
      "execution_count": 53,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "run_combined_punct(trainingFile, devFile, testFile)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "razLF60vKBJx",
        "outputId": "19f23db6-a97c-4d2b-91c9-e7b3cd40e0a6"
      },
      "execution_count": 54,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Test accuracy for best dev model: 0.750, 95% CIs: [0.690 0.810]\n",
            "\n",
            "Agreement\t0.223\t&\n",
            "Agreement\t0.188\t?\n",
            "Agreement\t0.185\t%\n",
            "Agreement\t0.183\tleast\n",
            "Agreement\t0.175\tinfections\n",
            "Agreement\t0.171\tget\n",
            "Agreement\t0.159\tsimilar\n",
            "Agreement\t0.159\tshowed\n",
            "Agreement\t0.157\thttps\n",
            "Agreement\t0.156\tsymptoms\n",
            "\n",
            "Disagreement\t0.354\tnt\n",
            "Disagreement\t0.339\t?\n",
            "Disagreement\t0.292\tactually\n",
            "Disagreement\t0.250\tgoing\n",
            "Disagreement\t0.224\tsay\n",
            "Disagreement\t0.218\tsure\n",
            "Disagreement\t0.217\tgraph\n",
            "Disagreement\t0.195\tsimply\n",
            "Disagreement\t0.189\tcertain\n",
            "Disagreement\t0.180\tspikes\n",
            "\n",
            "Neutral\t0.400\tabstract\n",
            "Neutral\t0.257\tcovid19\n",
            "Neutral\t0.186\tvaccine\n",
            "Neutral\t0.180\tpandemic\n",
            "Neutral\t0.174\tsarscov2\n",
            "Neutral\t0.160\tage\n",
            "Neutral\t0.160\tb\n",
            "Neutral\t0.156\tmaturation\n",
            "Neutral\t0.148\tantibodies\n",
            "Neutral\t0.140\troll\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "jVl3hWQeKGT4"
      },
      "execution_count": 54,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### SMOTE"
      ],
      "metadata": {
        "id": "c9hSWaeXpjO1"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install imbalanced-learn\n",
        "from imblearn.over_sampling import SMOTE"
      ],
      "metadata": {
        "id": "EDwdQBNIpoiO",
        "outputId": "07e45483-52d9-41cc-b4f4-e84fec5ff783",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "execution_count": 63,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: imbalanced-learn in /usr/local/lib/python3.7/dist-packages (0.8.1)\n",
            "Requirement already satisfied: scikit-learn>=0.24 in /usr/local/lib/python3.7/dist-packages (from imbalanced-learn) (1.0.2)\n",
            "Requirement already satisfied: numpy>=1.13.3 in /usr/local/lib/python3.7/dist-packages (from imbalanced-learn) (1.21.5)\n",
            "Requirement already satisfied: scipy>=0.19.1 in /usr/local/lib/python3.7/dist-packages (from imbalanced-learn) (1.4.1)\n",
            "Requirement already satisfied: joblib>=0.11 in /usr/local/lib/python3.7/dist-packages (from imbalanced-learn) (1.1.0)\n",
            "Requirement already satisfied: threadpoolctl>=2.0.0 in /usr/local/lib/python3.7/dist-packages (from scikit-learn>=0.24->imbalanced-learn) (3.1.0)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "7L031yfxsfet"
      },
      "execution_count": 56,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "trainX, trainY=load_data(trainingFile)\n",
        "trainX_array =  np.array(trainX)\n",
        "\n",
        "trainY_array =  np.array(trainY)"
      ],
      "metadata": {
        "id": "KFm9nZX6wiwf"
      },
      "execution_count": 78,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "BG6rR6G30aw1"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "class Classifier_SMOTE:\n",
        "\n",
        "    def __init__(self, feature_method, trainX, trainY, devX, devY, testX, testY):\n",
        "        self.feature_vocab = {}\n",
        "        self.feature_method = feature_method\n",
        "        self.min_feature_count=2\n",
        "        self.log_reg = None\n",
        "\n",
        "        self.trainY=trainY\n",
        "        self.devY=devY\n",
        "        self.testY=testY\n",
        "\n",
        "        \n",
        "        \n",
        "        self.trainX = self.process(trainX, training=True)\n",
        "        self.devX = self.process(devX, training=False)\n",
        "        self.testX = self.process(testX, training=False)\n",
        "\n",
        "\n",
        "\n",
        "    # Featurize entire dataset\n",
        "    def featurize(self, data):\n",
        "        featurized_data = []\n",
        "        for text in data:\n",
        "            feats = self.feature_method(text)\n",
        "            featurized_data.append(feats)\n",
        "        return featurized_data\n",
        "\n",
        "    # Read dataset and returned featurized representation as sparse matrix + label array\n",
        "    def process(self, X_data, training = False):\n",
        "          \n",
        "        data = self.featurize(X_data)\n",
        "        # print(data)\n",
        "\n",
        "        if training:\n",
        "            fid = 0\n",
        "            feature_doc_count = Counter()\n",
        "            for feats in data:\n",
        "                for feat in feats:\n",
        "                    feature_doc_count[feat]+= 1\n",
        "\n",
        "            for feat in feature_doc_count:\n",
        "                if feature_doc_count[feat] >= self.min_feature_count:\n",
        "                    self.feature_vocab[feat] = fid\n",
        "                    fid += 1\n",
        "\n",
        "        F = len(self.feature_vocab)\n",
        "        D = len(data)\n",
        "        X = sparse.dok_matrix((D, F))\n",
        "        for idx, feats in enumerate(data):\n",
        "            for feat in feats:\n",
        "                if feat in self.feature_vocab:\n",
        "                    X[idx, self.feature_vocab[feat]] = feats[feat]\n",
        "\n",
        "        # print(X)\n",
        "\n",
        "\n",
        "        # \n",
        "        return X\n",
        "\n",
        "    # Train model and evaluate on held-out data\n",
        "    def train(self):\n",
        "        (D,F) = self.trainX.shape\n",
        "        best_dev_accuracy=0\n",
        "        best_model=None\n",
        "        for C in [0.1, 1, 10, 100]:\n",
        "            self.log_reg = linear_model.LogisticRegression(C = C, max_iter=1000)\n",
        "            self.log_reg.fit(self.trainX, self.trainY)\n",
        "            training_accuracy = self.log_reg.score(self.trainX, self.trainY)\n",
        "            development_accuracy = self.log_reg.score(self.devX, self.devY)\n",
        "            if development_accuracy > best_dev_accuracy:\n",
        "                best_dev_accuracy=development_accuracy\n",
        "                best_model=self.log_reg\n",
        "\n",
        "#             print(\"C: %s, Train accuracy: %.3f, Dev accuracy: %.3f\" % (C, training_accuracy, development_accuracy))\n",
        "\n",
        "        self.log_reg=best_model\n",
        "        \n",
        "\n",
        "    def test(self):\n",
        "      return self.log_reg.score(self.testX, self.testY)\n",
        "\n",
        "    def dev(self):\n",
        "      return self.log_reg.score(self.devX, self.devY)\n",
        "        \n",
        "\n",
        "    def printWeights(self, n=10):\n",
        "\n",
        "        reverse_vocab=[None]*len(self.log_reg.coef_[0])\n",
        "        for k in self.feature_vocab:\n",
        "            reverse_vocab[self.feature_vocab[k]]=k\n",
        "\n",
        "        # binary\n",
        "        if len(self.log_reg.classes_) == 2:\n",
        "              weights=self.log_reg.coef_[0]\n",
        "\n",
        "              cat=self.log_reg.classes_[1]\n",
        "              for feature, weight in list(reversed(sorted(zip(reverse_vocab, weights), key = operator.itemgetter(1))))[:n]:\n",
        "                  print(\"%s\\t%.3f\\t%s\" % (cat, weight, feature))\n",
        "              print()\n",
        "\n",
        "              cat=self.log_reg.classes_[0]\n",
        "              for feature, weight in list(sorted(zip(reverse_vocab, weights), key = operator.itemgetter(1)))[:n]:\n",
        "                  print(\"%s\\t%.3f\\t%s\" % (cat, weight, feature))\n",
        "              print()\n",
        "\n",
        "        # multiclass\n",
        "        else:\n",
        "          for i, cat in enumerate(self.log_reg.classes_):\n",
        "\n",
        "              weights=self.log_reg.coef_[i]\n",
        "\n",
        "              for feature, weight in list(reversed(sorted(zip(reverse_vocab, weights), key = operator.itemgetter(1))))[:n]:\n",
        "                  print(\"%s\\t%.3f\\t%s\" % (cat, weight, feature))\n",
        "              print()\n",
        "\n",
        "            "
      ],
      "metadata": {
        "id": "NKnp-YMY0ahi"
      },
      "execution_count": 83,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def run_punct(trainingFile, devFile, testFile):\n",
        "    trainX, trainY=load_data(trainingFile)\n",
        "    devX, devY=load_data(devFile)\n",
        "    testX, testY=load_data(testFile)\n",
        "\n",
        "    # remove stopwords\n",
        "    trainX = list(map(remove_stop_df, trainX))\n",
        "    devX = list(map(remove_stop_df, devX))\n",
        "    testX = list(map(remove_stop_df, testX))\n",
        "\n",
        "    # remove punct\n",
        "    trainX = list(map(punct_removal, trainX))\n",
        "    print(trainX)\n",
        "    devX = list(map(punct_removal, devX))\n",
        "    testX = list(map(punct_removal, testX))\n",
        "\n",
        "    simple_classifier = Classifier_SMOTE(binary_bow_featurize, trainX, trainY, devX, devY, testX, testY)\n",
        "    simple_classifier.train()\n",
        "    accuracy_test=simple_classifier.test()\n",
        "    accuracy_dev=simple_classifier.dev()\n",
        "\n",
        "    \n",
        "    lower, upper=confidence_intervals(accuracy_dev, len(devY), .95)\n",
        "    print(\"Dev accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy_dev, lower, upper))\n",
        "    lower, upper=confidence_intervals(accuracy_dev, len(testY), .95)\n",
        "    print(\"Test accuracy for best dev model: %.3f, 95%% CIs: [%.3f %.3f]\\n\" % (accuracy_test, lower, upper))\n",
        "\n",
        "    print_confusion(simple_classifier)\n",
        "    print_confusion_test(simple_classifier)\n",
        "    \n",
        "    simple_classifier.printWeights()"
      ],
      "metadata": {
        "id": "n7btv1zn1CZ0"
      },
      "execution_count": 84,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "run_punct(trainingFile, devFile, testFile)\n"
      ],
      "metadata": {
        "id": "-CnhHK9H1Gx2",
        "outputId": "4a98d859-8e01-4bd2-f119-1cddd52eedb5",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        }
      },
      "execution_count": 85,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "['seems likely  s surely vaccine passes action assume purpose prevent health services becoming overwhelmed unvaccinated patients ', 'assume virus severity effects virus effects ?', '1  assume someone exposed spike proteins vaccine opposed actual viral infection ? 2  inflammation leads myocarditis result body s immune response antigen  almost certain likely see harsher immune response actual virus opposed vaccine ', '1 evolution nt  intentional   2 omicron evolve delta  unclear less severe per infection evolved  3 seen variants probably severe evolved form  ie  delta   4 selection pressure fairly complicated select severity  example  evolving higher replication viral load makes spread cause severe cases ?', 'sensitivity analysis using cutoff 4 months also found vaccinated within 4 months prior enrollment  n39  lower viral load unvaccinated  but vaccinated â4 months prior enrollment  n58    Supplemental Figure 2 ', 'Also press release   Antibody TCell Responses Heterologous Boosting Regimen Greater Homologous Regimen Omicron Variant  analysis 65 individuals received primary vaccination two doses mRNA COVID19 vaccine  BNT162b2   followed homologous booster shot BNT162b2  n24  heterologous booster Johnson & Johnson COVID19 vaccine  n41  least six months  found regimens increased humoral cellular responses Omicron   Antibody responses Omicron boosted Johnson & Johnson COVID19 vaccine BNT162b2 vaccine  Johnson & Johnson COVID19 vaccine increasing neutralizing antibody titers 41fold four weeks postboost  BNT162b2 vaccine found increase antibody titers higher level week two postboost  declining represent 17fold increase week four postboost   progressive increase antibodies weeks following vaccination Johnson & Johnson booster similar seen following first vaccine  rapid immune response followed waning antibody response BNT162b2 booster also similar seen following twodose priming regimen   The Johnson & Johnson COVID19 vaccine boosted median Omicronreactive CD8 Tcells 55fold  Omicronreactive CD4 Tcells 31fold  homologous  BNT162b2  regimen boosted Omicronreactive CD4 CD8 Tcells 14fold   believe early update earlier preprint  https  wwwmedrxivorgcontent1011012021120221267198v1 Kind interesting J & J boosted much better nAb  might expect better cell response  increase vs pfizer nAb quite marked  interesting see NIH lancet booster study get updated Omicron compares ', 'unvaccinated less likely tested ?', 'IÄôm sure IÄôm buying still  Even earlier human series  VoC specific boosters worse response wild type increased variantspecific responses  indicating werenÄôt dumping massive amounts imprinted antibodies  rather developing separate response  IÄôll hold Pfizer numbers come showing naive protocol ', 'point imo way compare severity look death rate unvaccinated people confirmed Omicron try account approximate rates prior infection  Everything else many variables reliably control ', 'nb  data 3rd dose even less certain  authors really clear text paper ', ' cell model used study carcinoma cell line  active DNA replication differs nondividing somatic cells  also shown Huh7 cells display significant different gene protein expression including upregulated proteins involved RNA metabolism  56   Huge caveat   Furthermore  recent study showed SARSCoV2 RNA reversetranscribed integrated genome human cells  given much junk DNA seems viral origin  know exceptional viruses probably ? Like  anyone tried looking human coronaviruses ? vaccines  like flu ?', '79 % 60 % impressive  Although  lot ÄúlongcovidÄù symptoms really diagnosed months line 6 weeks proper assessment  meaningless either  hopes would higher  Edit  Fixed based reply s feedback', 'One thing end pandemic way better knowledge immunity viruses  mostly sub  thanks everyone contributing ', 'get itÄôs probably worth immunizing Omicron ancestral strain  wonder itÄôs worth exposing immune system wider variety variants multivalent vaccines  Could lead body becoming likely produce universal  Äúcommon denominatorÄù antibodies ?', 'examples continue quite stark   Norway Omicron case study   https  wwwredditcomrCOVID19commentsrhsodboutbreak_caused_by_the_sarscov2_omicron_variant   99 % Omicron symptomatic  65 % uninfected also symptomatic   Swiss study long covid kids   https  wwwredditcomrCOVID19commentsobm0wylongterm_symptoms_after_sarscov2_infection_in   9 % covid symptoms 4 weeks  Among without covid  10 % symptoms 4 weeks ', 'mRNA vaccine costs 10x  World developed countries  Also  inactivated vaccines works great kids  Coronavac kids aged 5 11 year 76 % protection symptomatic cases 90 % hospitalization  Similar protection Pfizer  83 % symptomatic cases   Data Chile  Delta  coronavac maybe could worse numbers one  recombinant vaccine ', ' Results   Among 52238 employees  4718  9 %  previously infected  36922  71 %  vaccinated studyÄôs end  Cumulative incidence COVID19 substantially higher throughout previously uninfected remained unvaccinated groups  lower vaccinated unvaccinated  lower previously infected  Incidence COVID19 increased dramatically groups Omicron variant emerged  multivariable Cox proportional hazards regression  prior COVID19 vaccination independently associated significantly lower risk COVID19  Among previously infected subjects  lower risk COVID19 overall demonstrated  vaccination associated significantly lower risk symptomatic COVID19 preOmicron  HR 060  95 % CI 040Äì090  Omicron  HR 036  95 % CI 023Äì057  phases    Conclusions   previous infection vaccination provide substantial protection COVID19  Vaccination previously infected individuals provide additional protection COVID19 several months  provides significant protection least symptomatic COVID19  Seems like vaccine previous infection similarly protective  much better immunologically naive  Vaccination postinfection helps reduce risk infection ', 'Vaccinated people less restrictions vaccinated  nt think would possible control NPIs studies like ', 's says  fact  explicitly says even Pfizer  young men twice likely get myocarditis vaccination infected  Moderna spikes much higher ', 'saying agree  maybe necessary individually sufficient conditions myocarditis ', 'IÄôve got questionconcern  mRNA vaccines  big point concern introduction proteins spikes body  see potentially harmful  people often donÄôt seem concerned billions spikes attached live viruses infection  letÄôs put aside moment   big part rebuttal concern spikes lungs could potentially great idea  thatÄôs precisely injection arm muscle  keep far away lungs even bloodstream possible  inhaled  isnÄôt good chance least adenoviruses going wind lungs produce spikes ?', 'Well one shot max per year would nice  Nearcomplete protection serious disease  protection infection  really much ask ?', 'would say thatÄôs opposite conclusion would draw ', 'clear folks home  say  negative vaccine effectiveness  mean exactly ? mean vaccinated fair worse control group  unvaccinated  case ?', 'clarification needed first paragraph  author states  Patients sometimes develop GBS recent respiratory illness digestive tract infection  rare cases  receiving certain vaccines   statement misleading  author paraphrased section reference listed 1  Mayo Clinic  GuillainBarre syndrome  source   exact cause GuillainBarre syndrome nt known  GuillainBarre syndrome may occur infection COVID19 virus  s also rare reaction receive Johnson & Johnson COVID19 vaccine  implication stating GBS result  certain vaccines  unfounded contradicted source  Mayo Clinic specifies Causes section webpage J & J Covid19 vaccine implicated rare GBS disease presentation  rather  certain vaccines   distinction crucial since reader could infer author s statement vaccines cause GBS disease presentation  would incorrect assumptioninference ', 'late make much difference Canada  hope approval allow supply GAVI  Especially considering s fridge stable ', 'Looks like study covers Delta  Delta mentioned several times Omicron never  Feel like studies info abstract ', 'Moderate intensity jogging mile every 10 minutes  go jogging 9 miles vaccine shot ? ?', 'isnÄôt study  itÄôs news directly related pediatric vaccines Covid  thought would share see mods would allow ', 'continue course without expecting constant mutations immune evasion years  Best case scenario slowly turns effectively another cold flu years mutation immunity build  see less less people walking booster come  think Dr Michael Mina others outlined worthwhile plan keep manageable levels nt overrun hospitals  real goal   Rapid tests extremely cheap compared total cost covid could manufactured incredibly large quantities quickly  Encouraging free rapids taken work school  even adhered percentage population days week  would likely massive impact', 'rate dose even worth giving 11 year old ?', 'cite paper https  pubmedncbinlmnihgov33958444 showing SARS RNA possibly reversed DNA  use evidence could also possibly happen vaccine  seems like inappropriate assumption  would  however  raise question proven SARS cause DNA edits proven mRNA vaccines cause DNA changes  causes significant edits ? could similar situation heightened concern cardiac effects vaccine cardiac effects COVID fact much worse  Study showing cardiac effects COVID worse vaccine  https  pubmedncbinlmnihgov34907393', 'adjust age   calculated 1HR HR  hazard ratio  estimated Cox regression model adjusted age  sex geographical region  using calendar time underlying time scale ', 'getting second shot 3 weeks actually harm terms eliciting broader response variants  make difference third shot 68 months second one ?', 'still lot identical epitopes antibodies attach  way less original strain  getting huge boost antibodies would amplify also ones still work    protection severe disease still 70 % even 2 doses remember well  cell response ', ' Houston Methodist sequencing 100 % COVID patients  amazing data trove  d love know s central way find s used  brief google nt find  say  page Houston Methodist website lists research s used data ', 'Would efficacy greater larger interval doses eg eight weeks Australia Canada ?', 'd like see sort study extended effectiveness   boosters ', 'Abstract emerging SARSCoV2 variants concern  VOC  harbor mutations associated increasing transmission immune escape  hence undermine effectiveness current COVID19 vaccines  late November 2021  Omicron  B11529  variant identified South Africa rapidly spread across globe  shown exhibit significant resistance neutralization serum convalescent patients  also individuals recieving currently used COVID19 vaccines multiple booster shots  Therefore  urgent need develop next generation vaccines VOCs like Omicron  study  develop panel mRNALNPbased vaccines using receptor binding domain  RBD  Omicron Delta variants  dominant current wave COVID19  addition Omicron Deltaspecific vaccines  panel also includes Hybrid vaccine uses RBD containing 16 pointmutations shown Omicron Delta RBD  well bivalent vaccine composed Omicron Delta RBDLNP half dose  Interestingly  Omicronspecific Hybrid RBDLNP elicited extremely high titer neutralizing antibody Omicron  none neutralizing antibody SARSCoV2 variants  bivalent RBDLNP  hand  generated antibody broadly neutralizing activity wildtype virus variants  Surprisingly  similar crossprotection also shown Deltaspecifc RBDLNP  Taken together  data demonstrated Omicronspecific mRNA vaccine induce potent neutralizing antibody response Omicron  inclusion epitopes variants may required eliciting crossprotection  study would lay foundation rational development next generation vaccines SARSCoV2 VOCs ', 'abstract  Vaccine efficacy infection 30 %  95 % CI  9 % 55 %  11 %  95 % CI  43 % 43 %  BNT162b2 mRNA1273  respectively  Local systemic adverse reactions reported 80 % 40 %  respectively', 'study nt considering actually happens humans  Omicron slower go lung tissue compared bronchus still lower respiratory tract infection  study also Delta less prone replicate lung tissue original impair Delta s severity  counterfactual nt concerning ', 'P value nearly much function sample size effect magnitude  good supporting evidence people believe structured observations world lead credible perspectives  ie  science   pvalue 02 massive anything ', 'study literally says risk myocarditis doubled certain demographics when compared COVID infection  ', 'Tcells nothing protection infection  damage done first couple days infection Tcells begin nuking virus ', '70 % average across participants  s 606 % vs 791 % vaccinated vs unvaccinated   lower prevalence among vaccinated participants  606 %  compared unvaccinated participants  606 % vs 791 %  aRR 070  95 % CI 058084   ', 'incubation time measles 1012 days  omicron 3 days ', 'nt think   ÄúEither boost completely shut viral replication within two days  Äù think fundamental problem fast Omicron replicates  get breakthrough infections even appropriate antibodies  ca nt get immune system act faster  unless keep boosting every 4 months never let neutralising antibody titers wane  good idea  accept breakthrough infections going happen  memory B cells time stop infection becoming severe  second problem boosters tending amplify antibody clones present first Covid jab ever took  instead developing new antibodies specifically recognize Omicron s mutated epitopes  boosted Omicronspecific vaccine  memory B cells already generated recognise nonmutated epitopes dominate response  AKA original antigenic sin ', 'Water Reed vaccine severely overhyped  s cludging different spike proteins one vaccine  s evidence simply mixing spike proteins together  like tetravalent flu vaccines  would nt work well assembling mixed nanoparticles  s good chance new variant comes  would need incorporate new variant s spike protein vaccine  making slow hell  bit dodgy whether  single vaccine  refers concept  would nt need change  vs exact formulation  s concept  s faster  probably slower  redesigning mRNA vaccine  also nt addressed whether crossstrain effect would work someone already vaccinated approved vaccines  infected  thus already  original antigenic sin  problem ', 'chances get told pursue BLA route  like FDA recently recommended  Covaxin shot ?', 'Note authors state   predicting continued efficacy existing vaccines   efficacy refers preventing moderate severe symptoms asymptomatic infection  ABSTRACT time writing  December 2021  potential emergence vaccine escape variants severe acute respiratory syndrome coronavirus 2  SARSCoV2  grave global concern  interface receptorbinding domain  RBD  SARSCoV2 spike   protein host receptor  ACE2  overlaps binding site principal neutralizing antibodies  NAb   limiting repertoire viable mutations  Nonetheless  variants multiple RBD mutations risen dominance  Nonadditive  epistatic relationships among RBD mutations apparent  assessing impact epistasis mutational landscape  particularly risk vaccine escape  crucial  employed protein structure modeling using Rosetta compare effects single mutants RBDNAb RBDACE2 interfaces wild type Delta  Gamma  Omicron variants  Overall  epistasis RBD interface appears limited  effects multiple mutations additive  Epistasis Delta variant interface weakly stabilizes NAb interaction relative ACE2 interaction  whereas Gamma  epistasis substantially destabilizes NAb interaction  Despite bearing many RBD mutations  epistatic landscape Omicron closely resembles Gamma  Thus  although Omicron poses new risks observed Delta  structural constraints RBD appear hamper continued evolution toward complete vaccine escape  modest ensemble mutations relative wild type currently known reduce vaccine efficacy likely contain majority possible escape mutations future variants  predicting continued efficacy existing vaccines  IMPORTANCE Emergence vaccine escape variants SARSCoV2 arguably pressing problem COVID19 pandemic vaccines distributed worldwide  employed computational approach assess risk antibody escape resulting mutations receptorbinding domain spike protein wildtype SARSCoV2 virus well Delta  Gamma  Omicron variants  efficacy existing vaccines Omicron could substantially reduced relative wild type  potential vaccine escape grave concern  results suggest although Omicron poses new evolutionary risks observed Delta  structural constraints RBD make continued evolution toward complete vaccine escape either Delta Omicron unlikely  modest set escapeenhancing mutations already identified wild type likely include majority possible mutations effect ', ' next used logistic additive model test negative case control design estimate relative vaccine effectiveness becoming confirmed case Delta  2553 cases  andor Omicron  1001 cases  population 12 million people largest health board Scotland  NHS GG & C  6th 12th December 2021   ran two models  one time since vaccination included  estimate protection provided recent vaccination  one without  observe current protection todayÄôs mixed waned population ', 'Vaccines nt provide much protection infection brandnew 3rd dose   slight boost  claim accounting waning protection  also warn sample size small  margin error large mention real world data suggests larger effect ', 'immunologist would know far better  s two cents someone follows commercial side things  role nonneutralizing binding antibodies COVID multifaceted still explored  one hand  nonneutralizing binding antibodies may role viral clearance  fixing complement  triggering opsonization macrophages  etc   feel people speak  papers read  assume protective role nonneutralizing antibodies  hand  nonneutralizing binding antibodies might also play role increasing disease severity  especially accompanied sufficient titers neutralizing antibodies  example papers touching upon subject   https  wwwscienceorgdoi101126scitranslmedabm7853   https  wwwscienceorgdoi101126scitranslmedabm7853   https  linkspringercomarticle101007s41745021002688   https  linkspringercomarticle101007s41745021002688   https  wwwncbinlmnihgovpmcarticlesPMC8092137   https  wwwncbinlmnihgovpmcarticlesPMC8092137  line ideas expressed papers  early stages COVID vaccine development  vaccine associated enhanced respiratory disease  VAERD  viewed potential hurdle successfully creating COVID vaccine  Like manifestations ADE  VAERD thought caused binding antibodies insufficient neutralizing activity  invitro animal model experiments demonstrated VAERD theoretically possible coronavirus vaccines  fortunately  turned none approved COVID vaccines elicited VAERD ', 'Abstract emergence severe acute respiratory syndrome coronavirus 2  SARSCoV2  variants continues shape coronavirus disease 2019  Covid19  pandemic  detection rapid spread SARSCoV2 Omicron variant  lineage B11529  Botswana South Africa became global concern contained 15 mutations spike protein immunogenic receptor binding domain less neutralized sera derived vaccinees compared previously dominant Delta variant  investigate Omicron likely Delta cause infections vaccinated persons  analyzed 37877 nasal swab PCR tests conducted 1226 December 2021 calculated test positivity rates variant vaccination status  found positivity rate among unvaccinated persons higher Delta  52 %  Omicron  45 %   found similar results persons received single vaccine dose  Conversely  results show Omicron higher positivity rates Delta among received two doses within five months  Omicron  47 % vs Delta  26 %   two doses five months ago  42 % vs 29 %   three vaccine doses  22 % vs 09 %   estimates Omicron positivity rates persons receiving one two vaccine doses significantly lower unvaccinated persons 497 % lower three doses  comparison  reduction Delta positivity rates unvaccinated 2 vaccine doses 456496 % 3 vaccine doses 832 %  Despite higher positivity rates Omicron vaccinated persons  still found 912 % Omicron infections study occurred persons eligible 1 vaccine doses time PCR testing  conclusion  escape vaccineinduced immunity likely contributed rapid rise Omicron infections ', 'Could mildly effective vaccine still protected people prior 8 months  8 months less likely natural immunity  nt read yet  unless sure found immune naive controls  graph basically  pop level  vax  nativity become less effective months living pandemic level natural immunity   would bet broke groups  vax  natural would still better natural  vax  naive would still better naive  see differing ratios assume re equal  Simpson s paradox  ?  ', 'VAERS pretty bad way identify adverse events  IÄôd love see analysis incidence myocarditis booster doses young men', 'wouldnÄôt follow age deescalation protocol approval  skip age group go younger group ', 'Abstract  Infectionneutralizing antibody responses SARSCoV2 infection COVID19 vaccination essential component antiviral immunity  Antibodymediated protection challenged emergence SARSCoV2 variants concern  VoCs  immune escape properties  omicron  B11529  rapidly spreading worldwide   report neutralizing antibody dynamics longitudinal cohort COVID19 convalescent infectionnaive individuals vaccinated mRNA BNT162b2 quantifying antiSARSCoV2spike antibodies determining avidity neutralization capacity serum  Using livevirus neutralization assays  show superior infectionneutralizing capacity VoCs  including omicron  developed either two vaccinations convalescents third vaccination breakthrough infection twicevaccinated  naive individuals  three consecutive spike antigen exposures resulted increasing neutralization capacity per antispike antibody unit paralleled stepwise increases antibody avidity  conclude infectionplusvaccinationinduced hybrid immunity triple immunization induce highquality antibodies superior neutralization capacity VoCs  including omicron ', 'agree considered  study China would nt contact SARSCoV2  routine basis  ', 'good question  appear danish data  PCRtested less pr 100000 person   Report Breakthrough infections    Danish    https  filesssidkcovid19gennembrudsinfektionrapportgennembrudsinfektioncovid19uge492021ji88  Figure 10  shows roughly 30 & unvaccinated 1664 tested latest period  611412   roughly 40 % doublejabbed beenIf recent  less 12 weeks old  positive PCRtest  also advised get tested  think could possibly skew results  Edit  positive PCRtest advised test first 12 weeks  reason think could skew results  due higher prevalence infections unvaccinated group months leading period omicron ', 'd imagine something dosag  higher Moderna', 'Vaxart phase 2 trial oral vax nucleocapsid protein mutates slightly  addition spike  Oramed also oral vax spike  membrane  envelope proteins  Sadly  small companies less money giants like Pfizer  ll probably get approved  Another oral vax Migvax also nucleocapsid spike  re crowd funded moving even slower trials ', 'took something like 7 months create H1N1pdm vaccine 12 years ago  take much less mRNA vaccines ', ' Despite recent efforts demonstrating organization presentation vaccine components important composition dictating vaccine efficacy  antiviral vaccines long focused solely identification immunological target  Herein  describe study aimed exploring vaccine component presentation context spherical nucleic acids  SNAs  used elicit maximize antiviral response  Using COVID19 topical example infectious disease urgent need rapid vaccine development  designed antiviral SNA vaccine  encapsulating receptorbinding domain  RBD  subunit liposome decorating core dense shell CpG motif tolllike receptor 9 agonist oligonucleotides  vaccine induces memory B cell formation human cells  vivo administration mice generates robust binding neutralizing antibody titers  Moreover  SNA vaccine outperforms multiple simple mixtures incorporating clinically employed adjuvants  modular changes SNA structure  uncover key relationships proteomic insights adjuvant antigen ratios  concepts potentially translatable across vaccine platforms disease models  Importantly  humanized ACE2 transgenic mice challenged vivo lethal live virus  mice received SNA vaccine 100 % survival rate lungs clear virus plaque analysis  work underscores potential SNAs implemented easily adaptable generalizable platform fight infectious disease demonstrates importance structure presentation design nextgeneration antiviral vaccines ', 'evidence severity because hospitalisation data limited ', 'believe s 3 doses  2 ', 'rapid test could produced distributed  200 % profit   1 customers  near 99 % efficiency rate negative results  imo wont happen least another year ppl focused  companies want money  add insult injury s  information im stating provided nearly 1 year ago  still sold upwards  10 cheap end  maybe  57 gethave wholesale account  ppl companies trying maintain market gets dropped bottom themimo', 'Good point ', 'know press statement 3x AZ  Neutralising antibody levels Omicron following third dose boost Vaxzevria broadly similar levels achieved two doses Delta variant https  wwwastrazenecacommediacentrepressreleases2021vaxzevriasignificantlyboostedantibodylevelsagainstomicronhtml EDIT  Also https  oldredditcomrCOVID19search ? qvaxzevria & sortnew & restrict_sron', 'Safe EFFECTIVE', 'Yes  taken face value  study shows  people 91 days 2dose vaccination  ', 'understanding government provides supply canÄôt prescribe outside officially authorized circumstances ', 'Totally correct  Viral load measured PCR meaningless  Infectious Virus Titers key metric  People pumping bad science get published pandemic  s academic opportunist behaviour ', 'get ? Cause s lot breakthroughs lately ', ' Overall  COVID19 convalescents showed higher neutralization capacity 140 SARSCoV2 VoCs compared infectionnaive individuals  even three vaccinations 141 latter  Interesting  first time IÄôve seen stated ', 'In review analysis death reports VAERS following mRNA vaccination  found unusual patterns cause death among death reports received  COVID19 vaccine EUA regulations  healthcare providers required report deaths lifethreatening adverse health events COVID19 vaccinations VAERS regardless potential association vaccination  ', 'think study looked  Sub thread   redditcomrCOVID19commentsr9oijyprotection_and_waning_of_natural_and_hybrid   https  wwwredditcomrCOVID19commentsr9oijyprotection_and_waning_of_natural_and_hybrid ', 'think re right would note extreme care many scientists taken avoid even appearance discouraging vaccination  recollection Pfizer Moderna phase 13 trials excluded  intended exclude  patients prior history COVID infection  still question interest  study also notes   higher increased rate antibody titer worsened group nonworsened group suggests excessive immune response vaccination associated worsening sequelae ', 'brain nt working well today  know wo nt yield exact results  anyone take stab 2 doses vs Omicron data ? 3 doses 673 % efficacy compared unvaxxed  3 doses 663 % compared 2 doses  would make 2 doses nearly zero  right ?', 'Yes  Novavax included COVBOOST trial conducted UK fall 2021 http  wwwthelancetcomjournalslancetarticlePIIS01406736  21  027173fulltext', ' tcell vaccines  ? method vaccination virus somehow spur Bcell activity antibody production ? references pointers somewhere read ?', 'Source ? nt believe ve seen data severity omicron yet ', 'Friendly reminder VAERS data nt moderated verified  anyone allowed submit data ', 'let study run past dec 27th  well omicron spike  week could see change  counted previous infections dated 13 months ago  Definitely 2nd vaccine doses later  Perhaps 56 months later  fairer way compare immunity would include infections prior average 2nd dose timing  prior infection risk getting covid twice year ', 'Yes seen hypothesizing Twitter would little bit less immune escape  nice see theory translate real world data ', 'IÄôm expert read lot stuff pretty much answer  third vaccinationexposure antigen seems stimulate immune system able make ÄúbetterÄù antibodies equipped Äúdeal withÄù variants  illustrate point  immune system could ÄúthinkÄù ÄútalkÄù  itÄôs basically saying Äúlooks like weÄôre going see often  letÄôs brainstorm deal better futureÄù also stands reason even antibodies wane expected  B cells boosted immune systems would remain better equipped jump back action ÄúbetterÄù antibodies upon subsequent infection  Another interesting question Äúif 3 better 2  4 better 3  point diminishing returns begins set ? Äù', 'Yeah  itÄôs odd see shift quickly decently positive protection hugely negative  timespan months  Even assume true 91150 literally zero  takes decent sized behavioral adjustment get estimate 75 0  apply adjustment previous intervals  become much higher estimates weÄôve seen studies Omicron', ' nt think new research Omicron would time next mutation occurs  Current vaccines based wildtype strain work well Delta lineage  Omicron branch Beta lineage  vaccines nt work well Omicron  Basing new vaccinationbooster strategy base likely lineage next serious variant extremely prudent  current vaccines nt need match Delta work Delta  Omicronbased vaccines nt need match new variant variant descendant Omicron ', 'think could   https  wwwredditcomrCOVID19commentsse4fvacommenthumyxxm ? utm_sourceshare & utm_mediumweb2x & context3   https  wwwredditcomrCOVID19commentsse4fvacommenthumyxxm ? utm_sourceshare & utm_mediumweb2x & context3  calculations correct  incidence rates hospitalization & death 2dose vaxxed seem better really unvaxxed  case incidence rates seem way worse among 2dose vaxxed unvaxxed  think big question whether 2dose vaxxed actually prone infection somehow  eg  could happen something like ADE ?   case counts higher behavioral confounders  theyÄôre prone infection would least seem two doses still provides high degree protection severe disease death outcomes balance unvaxxed  thinking correctly ? say itÄôs making boosters look much worse youÄôd expect ?', ' AstraZeneca  Sputnik Sinopharm Argentina ', 'since studied immunology  really interesting new  phenomenon name point towards literature subject ? d like read ', 'Denmark may data make varied analysis ', 'suggesting effectiveness 2 doses nearly zero vs omicron ?', 'Apparently  striations figures 2   2    m reading right  make extremely skeptical overall validity model  reflection ', 'first sentence  data give p value  donÄôt see conclude vaccine covid statistically significant increase immunity clinically significant increase  94 % people vaccinated  number unvaccinated prior infection small likely small enough power use data definitively  Finally forget relative risk  absolute risk reduction shot post covid infection compare risk vaccine ? change age sex ? sample 84 % women average age 46  seem overgeneralize findings data support claim ', 'great article  anything offers glimpse advanced understanding social media used influence public opinion become  sure think  mixed feelings say least ', 'Africa much healthier ? nt close quarter Africa HIV ? well  study massive sample size  N227k  control group  s re comparing vaxxed Africans unvaxxed Americans ', 'Prior dominant variants may direct descendants one another  genetically much closer  nt think Omicron necessarily established new norm VoCs complete  breakaways  coming nowhere ', 'heart inflammation exists person walks doors hospital ? trying say guy ?', 'headline think significantly negative vaccine effectiveness estimates Omicron  2dose vaccination either Pfizer Moderna  91150 days 14 days second dose  authors offer following explanation   negative estimates final period arguably suggest different behaviour andor exposure patterns vaccinated unvaccinated cohorts causing underestimation  likely result Omicron spreading rapidly initially single  superspreading  events causing many infections among young  vaccinated individuals  explanation seems reasonable  though want suggest another possibility  mention excluded previously PCRpositive individuals  however  would wonder adequately controls prior infection  might reasonably expect higher proportion undocumented prior infection unvaccinated  less protected infection Delta wave   perhaps  less likely tested  Thoughts ?', 'Yes  exactly  tell room full people  exposed xx  many feeling symptoms ?  brains make hypersensitive anything resembling symptoms ', 'actually effectiveness infection roughly 0 % 8 months gotten vaccinated changes behavior  think could see graph like ', 'holds true s likely vaccines saved many lives giving Omicron advantage Delta  Omicron significantly less likely cause death recovery infection seem prevent reinfection Delta least near term  speed science able develop deploy vaccines C19 essential occur ', 'would concerned effect well  trying estimate using hypothetical recently  Imagine 3 groups people base line hospitalization rate 3 %  causes  hypothetical disease hospitalizes 10 % people get  also 2 vaccines  vaccine B 100 % effective hospitalization 0 % effective infection  vaccine C 100 % effective infection  extension hospitalization   give vaccine first group  group   vaccine B second group  group B   vaccine C third group  group C   study count  disease associated hospitalizations  patient hospitalized tests positive infection  nt require hospitalization _caused_ disease  Imagine group 1000 people  everyone infected study  effect scales  pick infection rate without effecting outcome much    Group  1  13 %    110 %   1000  127 hospitalizations  disease associated  everyone exposed   Group B 3 % 1000  30 hospitalizations  _marked_ disease associated  even though would happened anyway   Group C baseline rate 30 hospitalizations  infection prevention means none marked disease associated  0 per study  hypothetical study  vaccine C would show 100 % protection hospitalization  vaccine B would show 764 % effective hospitalization even though s reality perfect vaccine  effect gets worse group gets older baseline hospitalization rate increases  vaccine trial protocols PfizerModerna explicitly control effect counting  severe  cases instead hospitalizations explicit symptomatic criteria cases  fact observational studies nt seem always concerning ', 'Confidence interval incubation time  means statistics show 95 % chance true incubation period somewhere 287 days 36 days ', 'doesnÄôt make sense youÄôd comparison information means  Like doesnÄôt tell anything effect Covid vaccine ', 'Came say  Omicron qualitative change  need roll updated vaccine September latest', 'Omicron better replication upper respiratory tract lungs  spreads efficiently less severe disease   ÄúOmicron SARSCoV2 infects multiplies 70 times faster Delta variant original SARSCoV2 human bronchus  may explain Omicron may transmit faster humans previous variants  study also showed Omicron infection lung significantly lower original SARSCoV2  may indicator lower disease severityÄù   https  wwwmedhkuhkennewspress20211215omicronsarscov2infection ', 'think idea load  infection one presumably significant exposure spike s spread time whereas vaccination massive load created body short time period  Basically idea poison dose  exposure per unit time   m cellular biologist ca nt act expert one way another  playing devil s advocate think s important genuinely want understand opposition ', 'Yes  age sexweighted increase first second doses combined 152 cases per 100000 vaccinees  ie  1 65800  females   65 combined increase 462 cases per 100000 vaccinees  ie  1 21600  confidence intervals quite wide  See rightmost column Table 1 detail ', 'widely reported degree ? Sometimes papers say  X effective  actually mean  X barely effective  ', 'Seems  Though least itÄôs talking catching  badly effect ', 'Usually confounding factors  could genuine situations  read  case  negative  meaning s enhanced risk infection opposed reduced one  case s likely combination cryptic infections unvaccinated group  boosting aggregate immunity true zero  well better healthcare seeking behavior vaccinated group  boosting aggregate immunity equivalent unvaccinated group   protection vaccine close true zero  get artefactual negative VEs ', 'relevant numbers study follows   vaccine status omicron  delta  cov negative                    3 mrna  2441  679  18587   2 mrna  7245  4570  19456   0 mrna  3412  5044  8721  simplicity let s consider authors call  crude  oddsratio   crude odds ratio 2 mrna vs unvaccinated omicron would defined   2 mrna omicron positive   2 mrna cov negative     0 mrna omicron positive   0 mrna cov negative    724519456    34128721   095179210094 relative effectiveness taken  1  odds ratio  gives us 1  095179210094  004820789905  482 % relative effectiveness 2 mrna vs unvaccinated omicron', 'estimates protection natural immunity similar timeframes ?', 'research funded J & J  Janssen Vaccines  J & J   Barouch patent conflicts interest  Previous papers similar positive spin narrative  general tenor tension findings independent studies  n24  41 small numbers  canÄôt find information preprint demographic characteristics two study groups  vaguest allusion selected  split 65  24  41 JJ BNT appear randomized way  missing something ?', 'Abstract  paper presents effect COVID19 mRNA  PfizerBioNT  vaccine vitro glial cells brain studied means Raman spectroscopy imaging  results obtained human brain normal tumor glial cells astrocytes  astrocytoma  glioblastoma incubated Covid19 mRNA vaccine PfizerBioNT vaccine show alterations reductionoxidation pathways associated Cytochrome c found PfizerBioNT vaccine regulate concentration cytochrome c mitochondria upon incubation normal tumorous glial cells  Concentration oxidized form cytochrome c brain cells shown decrease upon incubation mRNA vaccine  Lower concentration oxidized cytochrome c results lower effectiveness oxidative phosphorylation  respiration   reduced apoptosis lessened ATP production  Alteration Amide concentration  may reflect decrease mRNA adenine nucleotide translocator  Moreover  mRNA vaccine leads alterations biochemical composition lipids suggest increasing role signaling  mRNA vaccine produce statistically significant changes cell nucleus due histone alterations  results obtained mitochondria  lipid droplets  cytoplasm may suggest COVID19 mRNA  PfizerBioNT  vaccine reprograms immune responses  observed alterations biochemical profiles upon incubation COVID19 mRNA specific organelles glial cells similar observe brain cancer vs grade aggressiveness ', ' Associations strongest males younger 40 years vaccine types additional 3  95 % CI 1  5  12  95 % CI 117  events per million estimated 128 days following first dose BNT162b2 mRNA1273  respectively  14  95 % CI 8  17   12  95 % CI 1  7  101  95 % CI 95  104  additional events following second dose ChAdOx1  BNT162b2 mRNA1273  respectively  13  95 % CI 7  15  additional events following third dose BNT162b2  compared 7  95 % CI 2  11  additional events following COVID19 infection   still supports mandated double vaccinations healthy young males already Covid19 ?  scientific rationale 1316 years age group ?', 'third explanation likelihood seek testing  wish investigated  study nt say anything specific testing protocol  given re using administrative data expect re looking share group positive test January October normal Swedish testing protocol time  could heavily influenced vaccinated people likely get tested various reasons  trust health system  conscientious  generally concerned COVID   match criteria used would nt control effect ', 'Abstract SARSCoV2 Omicron highly transmissible substantial resistance antibody neutralization following immunization ancestral spikematched vaccines  unclear whether boosting Omicronspecific vaccines would enhance immunity protection   nonhuman primates received mRNA1273 weeks 0 4 boosted week 41 mRNA1273 mRNAOmicron  Neutralizing antibody titers D614G 4760 270 reciprocal ID50 week 6  peak  week 41  preboost   respectively  320 110 Omicron  Two weeks boost  titers D614G Omicron increased 5360 2980  respectively  mRNA1273 2670 1930 mRNAOmicron  Following either boost  7080 % spikespecific B cells crossreactive WA1 Omicron  Significant equivalent control virus replication lower airways observed following either boost  Therefore  an Omicron boost may provide greater immunity protection compared boost current mRNA1273 vaccine  ', 'Also many asymptomatic went ED Urgent care get tested ?', ' Admission rates  545 % alpha  430 % delta  147 % omicron Median lengthofstay  days   51 alpha  54 delta  30 omicron  Although nt explicitly say  median stay length must admitted patients  else would 0 delta omicron  since less half admitted  ', 'spring wave seems par course seasonality virus  far  saying would likely happen since even Omicron  Anecdotally  people tend report increase common colds change season  nt found cold hard data support  Many people seems think seasonal pattern mean flulike pattern  course absolutely case  However  fall winter wave seems tend much higher intensity  may depend variants circulation level immunity built previous wave  Without models precise enough know uncertainty new variants  encourage booster doses vulnerable people case wait fall  perhaps adapted doses  think public health perspective second option may much favorable  avoid losing confidence many people ', 'paper states  took prescribed amphetaminedextroamphetamine school year attention deficit hyperactivity disorder currently receiving  Chronic stimulant use long known bad heart  nt think draw conclusions  nt see reason avoid vaccination history stimulant use ', 'think itÄôs safe point assume significant number unvaccinated things covid mitigation even acknowledging itÄôs existence  ergo would seek testing ', 'Sad literally address evidence  rapid decline   hyperelevated  antibodies vaccinated within study  mention absent titleabstract  generous  suppose could interpret  suggests potential need maintain high RBD antibody levels control infectious SARSCoV2 variants  hint ', ' think fundamental problem fast Omicron replicates  get breakthrough infections even appropriate antibodies  mean people might start get infected every 2 months possibly week period ?', 'Probably due dose lower booster Modena', 'course questions knowing someone ended emergency room following vaccine right ? Thank God reddit commenters ones designing studies confirm existing biases   Mostly ', ' advantage survival matter slight TEND reduce virulence enhance transmission   tend  heavy lifting  whole classes beneficial  virus  adaptions increase transmission virulence  things like higher replication rate  higher receptor affinity  etc  Delta pretty clear case study important ', 'time though could expect become generally linear ?  variants like Omicron  BA2  becoming dominant  time expect nondominant variants die  least fewer opportunities mutate  therefore less likely  ?', 'Yep ', 'Broader antibodies induced process somatic hypermutation affinity maturation within B cells germinal centres ', 'nt advised exercise two weeks vaccination order prevent myocarditis ?', 'Symptomatic infection â hospitalizeddead  WeÄôre back start means ', 'mean omicron end story Covid 19 fully adapted humans ?', 'thing thought interesting use prefusion spike  nice see ', 'difference study vaccine COVID variants predate omicron  might assume would effective unfortunately longer community  question regulators would whether approve similar original vaccines variants  repeat trials something geared towards current variants  Given taken years complete  repeating would likely take least another year  would bet approve plan boosters align age groups ', 'think headlines stop focusing Äúpreventing infectionÄù instead much help protect severe disease hospitalization long', 'anyone give good reason FDA nt approved Covaxin ? ve pediatric data months  appears safe effective  Approving traditional vaccine like seems like nobrainer  especially one well 100 mil already recieved ', 'Wait  anyone else find title absurdly misleading ?  Myocarditis Risk 17 Times Higher Unvaccinated Patients Ages 1230 Get COVID19 COVIDVaccinated Patients certain saying risk myocarditis COVID19 infection 17fold lower vaccinated patients   vaccine reduces odds COVIDinduced myocarditis 17 fold  looking contents data  ItÄôs literally another comparison postvaccine myocarditis versus postCOVID myocarditis  way theyÄôve worded highly confusing  ?', 'suggest explanation  negative estimates final period arguably suggest different behaviour andor exposure patterns vaccinated unvaccinated cohorts causing underestimation  likely result Omicron spreading rapidly initially single  superspreading  events causing many infections among young  vaccinated individuals', 'unless m missing something ', 'https  wwwosfhealthcareorgblogcovidneurologicalimpact hereÄôs example post effects  thatÄôs even counting harm infection like https  wwwhopkinsmedicineorghealthconditionsanddiseasescoronaviruswhatcoronavirusdoestothelungs', 'TBF  study nt designed detect anything consequence  unfortunately  small safety efficacy  less 50 % infection 0 % severe disease ', 'say booster dose within last 25 months  donÄôt see specify booster least 2 weeks ago  implied triple vaxxed ? missing somewhere ?', 'though ', ' think pandemic organism simply wanting survive   imagine organism primary reservoir survival fights back old school physiological responses millions years old also utilizes physical barriers transmission vaccines keep surviving   face challenges continued existence  ? Yes  realize engaging anthropomorphism  bottom line pretty much Omicron outcome  studied researched great deal years pandemic organisms  work   Frankly  tip spear epi academic one  nt care genomic details except need understand aspect population penetration sequelae  best research gets things concerned bird pandemic organisms followed coast coast analysis organisms changed course pandemic  generalizations  observations come see virulent  become less spread naive population  advantage survival matter slight TEND reduce virulence enhance transmission  happen surprisingly quickly  nt forget two main Coronaviruses live  population  primarily seasonal PITA present  m surprised reading anything happened SARS ? change efficient killing machine essentially disappearing extant threat ? MERS able make transition something like Covid ? Heck  happened syphilis turn sexually transmitted slow motion killer days ? ca nt find journal articles  remember one article m trying find bird virus started east somewhat virulent became less extremely quickly point almost benign got west coast  reason became much virulent ran physical barrier ocean reservoir burden became close 100 % animals susceptible certain characteristics died others live  point virus became virulent essentially disappearing distinct antagonistic organism certain bird populations  also look things like CCR5 see species reacted existential threats  Much research see levels genome someone develops desriptive epi associated organism  little seems done levels  example  surprised virus  tend  toward improved transmission characteristics depressed virulence  speed bit surprising  reminded study read one bird epidemic US less  yes  fully understanding distinctions humans birds different types viruses  blah blah  know analyzing bark tree detail  world goes time figure  could late  still wonder many Epis would acted John Snow would still waiting statistical significance better constructed study  still much learn different perspectives inform others   genomic understanding bird viruses better epidemiologic understanding human pandemic organisms could actually result better response overall  OH maybe bit Crisis Communications training whole lot public health including Fauci ', 'South Africa likely hybrid immunity among infected vaccinated people  nt many naive adults left South Africa  Three major waves  Delta unimpaired vaccination  unlike Northern Hemisphere  high population fatality ratio  excess deaths  young population ', 'vaccine would lot sensitive variants affect RBD  would guess efficacy omicron whatsoever  good news ', 'lucky  s pressure covid become less deadly since kills people infectious 2 weeks  symptoms presented infectious would merit argument ', ' put context  preOmicron era  UK ÄúSIRENÄù study COVID infection healthcare workers estimated prior infection afforded 85 % protection second COVID infection 6 months  Absolutely inexplicable use UK SIREN study  make mention multitude factors point 85 % huge underestimate   published paper   https  wwwthelancetcomjournalslancetarticlePIIS01406736  21  006759fulltext  caveat  1  two ÄúreinfectionsÄù classified ÄúpossibleÄù  remaining two ÄúprobableÄù  none ÄúconfirmedÄù  84 % estimate based using ÄúpossibleÄù reinfections  kind ridiculous  Using ÄúprobableÄù ÄúconfirmedÄù 99 %   2  one third ÄúreinfectionsÄù typical COVID symptoms 3  authors include baseline seronegative people converted seropositive COVID19 cases  would underestimate protection since youÄôre undercounting cases seronegative group  4  authors found pattern indicated seemed consistent RNA shedding  counting ÄúreinfectionsÄù authors note issues paper   Restricting reinfections probable reinfections  estimated June November 2020  participants positive cohort 99 % lower odds probable reinfection  adjusted  aOR  001  95 % CI 000003   Restricting reinfections symptomatic estimated participants positive cohort 95 % lower odds reinfection  aOR 008  95 % CI 005013   Using sensitive definition reinfections  including possible probable adjusted odds ratio 017  95 % CI 013024    prior history SARSCoV2 infection associated 83 % lower risk infection  median protective effect observed five months following primary infection  This minimum likely effect seroconversions included    There 864 seroconversions participants without positive PCR test  included primary infections interim analysis    We believe minimum probable effect curve positive cohort gradual throughout  indicating potential reinfections probably residual RNA detection low population prevalence rather true reinfections  canÄôt really understand using paper reference using 85 % number without giving thought caveats  540 fold higher risk reinfection would still point 95 % protection if number Äúprobable confirmedÄù reinfections used  example ', 'Please note traditional inactivated vaccine  uses Newcastle disease virus viral vector expresses second generation prefusion stabilized spike protein  different Sinopharm inactivated vaccines ', 'link Deltaspecific booster ? seen results Beta one  impression Deltaspecific booster trials yet released data ', 'Ok  s one possible situation  also could 20 infecting one new person  however like go Occam s razor guess multiple people work COVID positive people showed party already infected COVID ', 'much disagree line thinking believe harmful border propaganda  multiple goals  one central goal vaccines beyond  help harm   least  goal trying reduce spreading mathematically decreasing R value pandemics end  also vaccines historically understood PR standpoint look Youtube vaccines COVID reputable science channel  notice focus preventing spread rather keeping hospital  vaccine nt reduce spread protect individuals mean failure ?  see wave PR claiming  well actually nt supposed protect ways ve claimed primary purpose vaccines  something nt smell right   well Measles vaccine kept hospital ? people answer  nt know  hardly anyone gets Measles anymore thanks vaccines   real truth COVID different enough disease like Measles vaccines nt work well still work well enough medical miracles  Unfortunately  many medical communicators nt want try communicate complex message truthfully resorted lying never cared preventing infections spread ', 'whole thing weird  FDA basically said d approve without seeing data begged Pfizer submit Pfizer said nt effective  Pfizer tell FDA  Bizarre ', 'nt even get mRNA vax  HK13 whole virion vaccine  Sinovac like Sinovac ? Ca nt find generic name ', 'immune system prepared fight disease immediately  often wo nt even know got   infuse lab produced antibodies  eg  mentioned sotrovimab  already  virus could cause damage  Since submission myocarditis  damage could happen even asymptomatic ', 've told time  unvaccinated skews previously infected  reason apparent negative efficacy UK  instance   true seems like would confound results considerably ', 'Vaccine effectiveness studies conclusively demonstrated benefit COVID19 vaccines reducing individual symptomatic severe disease  resulting reduced hospitalisations intensive care unit admissions  However  impact vaccination transmissibility SARSCoV2 needs elucidated  prospective cohort study UK Anika Singanayagam colleaguesregarding community transmission SARSCoV2 among unvaccinated vaccinated individuals provides important information needs considered reassessing vaccination policies  study showed impact vaccination community transmission circulating variants SARSCoV2 appeared significantly different impact among unvaccinated people  scientific rationale mandatory vaccination USA relies premise vaccination prevents transmission others  resulting Äúpandemic unvaccinatedÄù  Yet  demonstration COVID19 breakthrough infections among fully vaccinated healthcare workers  HCW  Israel  turn may transmit infection patients  requires reassessment compulsory vaccination policies leading job dismissal unvaccinated HCW USA  Indeed  growing evidence peak viral titres upper airways lungs culturable virus similar vaccinated unvaccinated individuals  A recent investigation US Centers Disease Control Prevention outbreak COVID19 prison Texas showed equal presence infectious virus nasopharynx vaccinated unvaccinated individuals  Similarly  researchers California observed major differences vaccinated unvaccinated individuals terms SARSCoV2 viral loads nasopharynx  even proven asymptomatic infection  Thus  current evidence suggests current mandatory vaccination policies might need reconsidered  vaccination status replace mitigation practices mask wearing  physical distancing  contacttracing investigations  even within highly vaccinated populations ', 'thought recommendation J & J came adverse events and significantly lowered efficacy  Protection severe disease equalizer  J & J always held well comparatively  ? source ? looking hospitalization protection Omicron three vaccines doubt thereÄôs much data  mean  many people gotten single J & J dose booster ? Probably many ', 'Researchers said poor results likely due antigenic imprinting  OAS  even post people denying  lot evidence regarding imprinting since beginning Omicron  Please deny imprinting due itÄôs association antivaxxers  IÄôm sure sub everybody knows actual infection causes worse imprinting  Also vaccinated infected people use vaccines produces mucosal immunity  counter imprinting problem need solutions like Paxlovid  Omicron specific mAbs etcÄ soon possible  ÄúThe observation boosting either mRNA1273 mRNAOmicron resulted expansion similarly high frequency crossreactive B cells likely stems principle original antigenic sin  otherwise termed antigenic imprinting  whereby prior immune memory recalled related antigenic encounter  Davenport Hennessy  1957  Davenport et al1953   Äú', '  Conclusion  important recognize factors fueling vaccine hesitancy  anxieties around pace technological change feelings political disempowerment  within control medical community  example health media literacy initiatives schools suggests  addressing issues require longterm effort part multiple stakeholders working across several sectors society43  Like virus gave rise  seems probable myths conspiracy theories around COVID19 vaccines things need learn live manage time come  new landscape  best measure progress toward building vaccine confidence longer term perhaps number doses administered far  public trust institutions responsible delivering ', ' 437 % vaccine efficacy 375 % presume infection  nt  standard  50 % ? Granted years influenza vaccine nt reach 50 % efficacy curious anyone knows minimum regulators consider acceptable ', ' NEW YORK MAINZ  GERMANY  MARCH 15  2022 Äî Pfizer Inc  NYSE  PFE  BioNTech SE  Nasdaq  BNTX  today announced companies submitted application US Food Drug Administration  FDA  Emergency Use Authorization  EUA  additional booster dose adults 65 years age older received initial booster authorized approved COVID19 vaccines  submission based two realworld data sets Israel analyzed time Omicron variant widely circulating  data sets showed evidence additional mRNA booster increases immunogenicity lowers rates confirmed infections severe illness   analysis Israeli Ministry Health records conducted 11 million adults 60 years age older known history SARSCoV2 infection eligible additional  fourth dose  booster  data showed rates confirmed infections 2 times lower rates severe illness 4 times lower among individuals received additional booster dose PfizerBioNTech COVID19 Vaccine administered least four months initial booster  third  dose compared received one booster dose   Also included submission results ongoing  openlabel  nonrandomized clinical trial healthcare workers 18 years age older single study center Israel vaccinated three doses PfizerBioNTech COVID19 Vaccine  Among 154  700  participants received additional booster  fourth  dose PfizerBioNTech COVID19 Vaccine least four months following initial booster  neutralizing antibody titers increased approximately 7fold 8fold two three weeks additional booster  fourth  dose compared five months initial booster  third  dose  Additionally  8fold 10fold increase neutralizing antibody titers Omicron variant  B11529  one two weeks additional booster dose  respectively  compared five months initial booster  study also revealed new safety concerns individuals received additional booster dose vaccine   Emerging evidence  including data Kaiser Permanente Southern California  suggests effectiveness symptomatic COVID19 12345 severe disease15 caused Omicron wanes 3 6 months receipt initial booster  third  dose  Thus  additional booster doses may needed ensure individuals remain adequately protected  early studies indicate additional booster dose PfizerBioNTech COVID19 Vaccine administered least 4 months initial booster dose could restore antibody titers peak postthird dose titer levels6 improve protection infection severe disease individuals 60 years age older Israel7 similar safety profile previous doses6 data included EUA filing submission reviewed FDA ', 'Really interesting paper authors major roles advisory committees public health  important comprehensive dataset absolutely used inform public policy UK abroad  main take home   risk following COVID19 vaccination largely restricted younger males aged less 40 years  risks myocarditis following vaccination infection similar  However  notable exception younger males receiving second dose mRNA1273 vaccine  risk myocarditis higher following vaccination infection  additional 101 events estimated following second dose mRNA1273 vaccine compared 7 events following positive SARSCoV2 test  ie second dose  full strength  Moderna males 1340 gives spike myocarditis markedly higher risk myocarditis covid infection  nt enough cases myocarditis comprehensive dataset properly assess myocarditis children aged 1317  authors state  needs pursued pooling international datasets  expect already pursuing  interesting data  thanks posting  stated elsewhere  one piece public health puzzle  obviously number risks benefits feed recommendations made  else equal  data could certainly affect recommendations Moderna vs vaccine options males 40  Watching interest  thanks posting OP ', 'Thank  Sorry could done  enough coffee morning  internal bias American unvaccinated would free behavior probably different Sweden ', 'pre boost neutralization titres 6 months post primary  s unusual  adenoviral vaccines nt wane fast Pfizer vaccine ', 'Saw cited post saying around 800 people', 'ItÄôs plausible seems like best explanation itÄôs still somewhat shocking result  apply behavioral adjustment thatÄôs large enough offset 75 %  even assuming true zero  applying behavioral adjustment previous intervals would make high efficacy  higher weÄôve seen studies involving Omicron  seems like authorÄôs theory rapid spread happen vaccinated ago might explain though  behavioral adjustment wouldnÄôt constant across timescales ', 'Given data 6mo2year appears  adequate  review ? Pfizer asking hence FDA nt proactively ? maybe subset nt statistically valid d need data ?', 'know J & J vaccine came doctors pointing vaccine effective preventing serious disease  people taking mean point taking vaccine going get sick anyway  significantly less likely though people taken vaccine die COVID  nt forget people also die flu  sense  yes  COVID19 similar flu ', 'fighting risk myocarditis yes  Overall though many potential likely negative outcomes either group weighted potentially worse ', ' IÄôm sure sub everybody knows actual infection causes worse imprinting  Got references read ?', ' Omicron SARSCoV2 variant predominated US KidCOVE study younger age groups  secondary endpoint vaccine efficacy confirms statistically significant  lower efficacy COVID19 infection expected Omicron wave consistent adult observational data  Using Phase 3 COVE study COVID19 definition  vaccine efficacy children 6 months 2 years 437 % vaccine efficacy 375 % 2 6 years age group  case  statistically significant defined lower bound 95 % confidence interval greater 0  majority cases mild  severe COVID19 disease observed either age group  absence severe disease  hospitalization death study precludes assessment vaccine efficacy endpoints  &  x200B  best case scenario since know efficacy wane ', 'seem recall sources advising young males strenous exercise period either mRNA vaccine Covid19 infection chance develop heart inflammation either one  Given rare  nt sample size used study seems  1628 participants different stages  bit small determine exercise woulds exacerbate condition ?', 'advice given Germany days week depending feel  come back quickly exercise normally within two days  paper says 50mins time start kicking ', ' Findings like nt immediately grouped  good   bad      Um  headline says  without increase side effects   unfortunately right findings much grouped  good   bad   reluctance consider anything side effects valid potentially pretty dangerous case ', 'One largest complaints many COVID studies IÄôve seen coming  media pull headlines based extremely poor studies spread misinformation quickly  Feels like canÄôt figure true nowadays without reading study fully IÄôve come resort nowadays  maddening dense  quantitative analysis  please ', 'antigenic change vaccine evasion  assume layperson find hard time understand stuff simple manner ', 'get ball rolling review process data ? ItÄôs rolling submission review 3rd dose data comes  opposed waiting data reviewing would take longer', 'summary  NDV underperforming vaccine  title misguiding readers interpret inactivated vaccine far better Comirnaty  fact totally opposite  Ratio makes sense selling vaccine advantage based importance protein targeting  Comirnaty way higher antibody levels terms neutralizing non neutralizing ones  Based data provided vaccine totally outperformed mRNA vaccine  log scales used figure  Comirnaty general performs around 10 fold better terms binding neutralizing activity nearly tests  also used CoronaVac control compare difference performance platform ', 'account possibility vaccinated people test unvaccinated  vice versa ?', 'Vaers fine consider data source  ItÄôs large pool largely self reported illness injuries  ItÄôs intentionally inclusive ensure identify trends early  itÄôs actually found issue begin  filter lot BS without much difficulty ', 'would want also want check vaccinated group  places nt Europe acknowledgement convalescent immunity whatsoever  necessarily reason assume proportion previously infected even greater unvaccinated group ', 'mean Boy likely ADHD prescribed medication treat ? Amphetamine well documented side effects IÄôm sure see would impact   mean medical exemptions taking medication ADHD ?', 'intentional selection pressure vaccines would create infectious less severe variant  lucky ? donÄôt think paper says anything possible benefits selection pressure creating less sever variants  would imagine itÄôs still possible selection pressure general create infectious sever variants ', 'know  thatÄôs said wasnÄôt fault  Misleading title publishing ', 'Essentially yes  manifestation OAS', 'Abstract Importance  limited evidence effectiveness BNT162b2 vaccine children  particularly 511 years Omicron variant s emergence  Objective  estimate BNT162b2 vaccine effectiveness COVID cases hospitalizations among children 511 years 1217 years December  2021 January  2022  Design  Analyses cohorts constructed linked statewide immunization  laboratory testing  hospitalization databases  SettingParticipants  New York State children 517 years  Main outcomesmeasures  New laboratoryconfirmed COVID19 cases hospitalizations  Comparisons made using incidence rate ratio  IRR   comparing outcomes vaccination status  estimated vaccine effectiveness   1  1IRR    Results  December 13  2021 January 30  2022  among 852384 fullyvaccinated children 1217 years 365502 children 511 years  cases declined 66 %  95 % CI  64 %  67 %  51 %  95 % CI  48 %  54 %  1217 years 68 %  95 % CI  63 %  72 %  12 %  95 % CI  6 %  16 %  511 years  January 2430 week  children 11 years 11 %  95 % CI 3 %  23 %  age 12 67 %  95 % CI  62 %  71 %   hospitalization declined changed 85 %  95 % CI  63 %  95 %  73 %  95 % CI  53 %  87 %  children 1217 years  100 %  95 % CI  189 %  100 %  48 %  95 % CI  12 %  75 %  511 years  Among children newly fullyvaccinated December 13  2021 January 2  2022  cases within two weeks full vaccination children 1217 years 76 %  95 % CI  71 %  81 %  2834 days 56 %  95 % CI  43 %  63 %   children 511  cases declined 65 %  95 % CI  62 %  68 %  12 %  95 % CI  8 %  16 %  2834 days  Conclusions Relevance  Omicron era  effectiveness cases BNT162b2 declined rapidly children  particularly 511 years  However  vaccination children 511 years protective severe disease recommended  results highlight potential need study alternative vaccine dosing children continued importance layered protections  including mask wearing  prevent infection transmission ', 'window benefits ? Within hour ? Week ?', 'BC  Canada spaced  2 months due vaccine availability  protecting omicron far see ', 'two doses seems enough  real need third', 'One possible factor  unvaccinated cohort wouldÄôve surely likely recent prior infection vaccinated cohort  due protective effect vaccination previous months   Individuals study matched based documented prior infection status  course infections end confirmed  donÄôt think prior infection fully controlled  UK example  weekly random PCR sampling done ONS suggests around 50 % infections missed June 2021  Jan 2022  assume PCR positivity lasts 14 days average   US  CDC previously estimated 75 % infections missed Feb 2020  September 2021 ', 'anybody looked basic mechanical parameters exercise activity post vaccinations ? know Singapore recommends men 30 donÄôt engage vigorous activity two weeks mRNA shot  canÄôt find hard data hypothetically explains 95 % myocarditis cases sounds like easy solution ', 'symptom myocarditis ?', 's reasonable assume might confounding factors  sure completely explain away negative ? nt remain open possibility ?', 'IÄôm great math department  Could somebody calculate rough vaccine efficacy fully vaccinated boosted numbers ? enough info ? IÄôd much obliged  thanks ', 'delta adjusted vaccine nt commercialised existing MRNA vaccines satisfactory delta  boosters providing immunity symptomatic illness large majority cases ', ' Despite reports postvaccination MISC  vaccination clearly lowers overall MISC burden  probably preventing infection  studies also suggest low likelihood vaccination triggering development MISC  vaccination play role MISC pathogenesis  likely extremely rare event may involve underlying genetic predisposition contingent extraneous factors like recent SARSCoV2 community exposure  findings 2 cases MISC within 1 week dose BNT162b2 raise possibility vaccination may alter symptom profile MISC  ', 'assumes people  young healthy   headline excludes lot people    Gili RegevYochay  physician infectiousdiseases researcher Sheba Medical Center Ramat Gan  coauthored study  Äúpeople young healthy donÄôt risk factors probably benefit much fourth doseÄù faced Omicron  says     Still  others say fourth dose could beneficial people higher risk severe illness  Several countries  including Israel  Chile Sweden  offering fourth doses older adults groups ', 'problem Covid evolving linear fashion  Delta descendant Alpha  Omicron descendant Delta  nt confident next dominant variant necessarily descendant Omicron  contrast  update flu vaccines roll ahead time flu evolution linear predict next dominant variant current dominant variant  usually  ', ' analysis shows unvaccinated patients COVID19 infection nearly five times likely develop GBS COVIDvaccinated patients  rate 28 per million COVIDvaccinated patients  130 per million unvaccinated  COVIDpositive patients ', 'WouldnÄôt Omicron boost required 416 weeks post priming trigger bcells undergoing affinity maturation transform plasma bcells subsequently generate omicron specific antibodies ?', 'nt actually see information phase  Possibly look neutralising antibodies rather effectiveness  children s trial iirc ', 'Thanks lot haha  IÄôm bit confused though  read fourth dose mRNA vaccines likely recommended doses probably tailored dominant variant changes time  like flu suppose   DoesnÄôt contradict article somewhat ?', 'Abstract concerns SARSCoV2 Omicron variant evades immune responses due unusually high numbers mutations spike protein  report superspreading event Omicron infections amongst triplevaccinated healthcare workers  infecting 21 33 attending private gathering Faroe Islands  _____ Additional clarification PDF  _____ Faroe Islands  selfgoverning group islands located Iceland Norway  relatively successful containing COVID19 pandemic  78   On December 30  2020  first Faroese received BNT162b2 vaccine  Comirnaty  BioNTech  Mainz  Germany   vaccine used Faroe Islands  since high proportion population vaccinated  December 8  746 % population vaccinated two times  136 % three times  9   March 2020 September 2021  Faroe Islands registered 1001 cases COVID19  1867 per 100000  two deaths  373 per 100000   However  loosening restrictions introduction contagious Delta variant  large outbreak plagued islands  3300 cases 11 deaths registered last two half months  9   This paper reports superspreading event 21 33 healthcare workers infected Omicron variant attending social gathering early December 2021  even though infected participants vaccinated three times recent negative test  ', 'clear  say 85 % effective hospitalization  comparison ? s regular hospitalization rate unvaxxed person ?', 'VOCs theorised emerge chronic infections immunosuppressed patients  since emerged without clear predecessors   m sure much vaccination rates really impact emergence VOCs', 'Yes think theyÄôre agenda  wouldnÄôt first wonÄôt last ', 'think due multiple reasons   USA seems already enough  approved vaccine  may need another good enough   2 fully approved  Pfizer  Moderna  adults   younger age groups EUA  etc  1 EUA  J & J  2 coming way   Novavax  seems soon get EUA   Medicago  may far future   vaccine safe effective  Covaxin data s may less full  promising aspects  documents like one   Interim recommendations use Bharat Biotech BBV152 COVAXINÆ vaccine COVID19    https  wwwwhointpublicationsiitemWHO2019nCoVvaccinesSAGErecommendationbbv152covaxin   annexes   https  wwwwhointpublicationsiitemWHO2019nCoVvaccinesSAGErecommendationbbv152covaxinannexes  points  like   Safety  Adults  aged 18Äì59 years   Limitation study design  Impact  Serious  Efficacy  Older adults  aged â60 years    moderately confident 2 doses BBV152 vaccine efficacious preventing PCRconfirmed COVID19 older adults  â65 years      points like s    general 60 age groups  comorbidity  etc  data s moderate confident   CI values seem wide limits  etc   may also miss FDA important points  like  well   tested latinos  inuits  etc   May  existing  data  certifications manufacturing  etc  enough pass thru FDA process', 'Wait CI 43 43  nt efficacy 0 ? really means lot  s very big interval ', 'get opinion study ?', ' means variant indeed worse Delta ?', ' papers keep talking viral load ignore fact majority viral load dead  noninfectious virus  thatÄôs studies  review paper  whole point summarize people done  ItÄôs lot labor intensive try culture virus itÄôs better data none  viral load data isnÄôt perfect  useful warning sign delta infectious vaccinated people previous strains ', '  Also  thought VAERS reports worth paying attention  thus view change recently ?  ', 'Study conducted JanuaryAugust 2021  weÄôre talking alpha strain breakthrough infections  Likely higher delta omicron ', ' Interesting study 36000 genomic sequences patients analysis  90 % total patients   rest could nt get sequenced time analysis assumed Omicron Sgene target failure  Houston Methodist sequencing 100 % COVID patients  said  point chances SGTF Omicron slimtonone  nt imagine full sequencing really required yield good data ', 'm seeing attempted differentiation severity vaccinatedpreviously infected unvaccinatedpreviously uninfected  s biggest tell pandemic  endemic  waning  Many infections still happening  many fewer ever needing hospital  severity difference vaccinatedpre infected infections unvaccinatednever previously infected  basically like catching novel virus  concerning ', 'western world South Africa  spend countless hours threads debating technical details studies matters US POV much larger country far older  unhealthy population  studies mean next nothing  South Africa never going indicative US experience variant reckless naive way scientific community media latched idea  edit  mentioned  US 65 pop   55mm US 65 pop   80 % total Covid deaths  SA 65 pop  35mmÄ get picture ?', 've asked many people 18 died covid last year 12 ? ca nt find good statistics ', 'Noteworthy  appears little protection variant last vaxxed 6 month ago  big boost booster even recently vaxxed  Perhaps slight edge moderna booster ', 'think paper 2x az plus one mrna provides excelent results  titers ', 'someone could ELI5  could boosting vaccine would elicit broader responsecrossreactivity knowing original antigen presented immune system ? would expect dramatic  albeit temporary  increase titers would help  induce broader response ', 'sample sizes adequate ? Seem little small  m layman nt know  least could easily find volunteers  imagine ', 's autopsy paper written MDs  typical type publication ', ' Omicron displaces delta completely risk Delta infection removed  possibility boosting wuhan variant spike Omicron breakthrough counter productive d already producing Omicron specific antibodies ?  seems unlikely  time adaptive immune system sees similar antigen  time passed since last time saw  causes broaden repertoire memory B cells  produce antibodies cover wider range close variants   example  re finding people got booster antibodies effective omicron nt get booster  even though booster based Wuhan strain initial vaccination  presented antigen make adaptive system  narrow focus   seems fear  makes broaden  possible future variations ', 'wa nt suggested interval doses ?', 's definitely bad way  best  nt link  remember seeing one paper analysing VAERS reports finding questionable  large majority real  likely cases nt reported  generally assume s completely reliable  s right ballpark  Unfortunately many people think along lines VAERS many faults  ignored  s faulty thinking  thinking correlation implies causation faulty ', 'Abstract  Severe acute respiratory syndrome coronavirus 2  SARSCoV2  antibodies decay persist 6 months postvaccination  lower levels neutralizing titers persist Delta wildtype virus  227 vaccinated healthcare workers tested  2 experienced outpatient symptomatic breakthrough infections  despite 59227 exhibiting serologic evidence SARSCoV2 infection  defined presence nucleocapsid protein antibodies ', 'Per press release 100 % efficacy  75 % efficacy severe disease ', 'nt advice move one s arm frequently injected vaccine influenza COVID19 ? seems tested exercises least moved injected arm quite bit ?', '2x AZ 1y BNT  probably nt apply combination  AZ nt discussed papers anyways ', '? flair makes clear s preprint  Preprints posted routinely many report high quality research  although one unfortunately nt   conversely  peer review nt guarantee high quality ', 's also suggestions infected healthcare setting prone long covid', 'didnÄôt realize risk covid  saying could get covid vaccine ?', 'Beta Delta variants 2021  nature defeated Beta eventually Delta variant much quicker Pfizer BioNTech scientists  nt think new research Omicron would time next mutation occurs ', 'Wow  authors nt even take break consider non breakthrough infections  authors story seem inferring transmissibility vaccinated based breakthrough infections  authors completely ignored people vaccinated never test positive  IE majority  according vaccine efficacy trials  paper absolute antivax garbage  great lie considering breakthrough vaccinations vaccinated population reached maximum saturation ', ' Cohort  3  n205   VaccinenaØve participants receive three doses Omicronbased vaccine   going find people vaccinenaØve 2022 willing partake scientific research ?', 'vaccinated mean  selection pressure differ regular vaccination ?', 'Vaccinated almost half rate controls ? could see something like lower prevalence infectious diseases implicated GBS compared 2019  nt 48 also really high baseline ? thought much rarer ', 'inhibition numbers look phenomenal  much better adult 2 series  https  wwwmedrxivorgcontent1011012021122321267374v1fullpdfhtml   especially omicron  something better others omicron results maybe ', 'Worse case 105 myocarditis cases based million jabs  even bad incidence fungal infections  viruses parasites  s   minor ', 'point think enough empirical information treat future variants like flu ? Eg  development vaccines well advance flu season ', 'assuming prevented deathhospitalizations m pretty sure  case  ca nt even show 01 % protection  Additionally  risk infection much lower simply virus lull  know protection likely wane lot 6 months  re probably talking 20 % average protection minimum 6 months get booster summer  takes 200k shots children prevent 300 coldlike infections  seems unlikely get approval ', 'Thanks summary  Much appreciated ', 'Results Participants detectable SARSCoV2Äìspecific antibodies milk baseline  n  9 IgA n  3 IgG  previous positive polymerase chain reaction test  n  7  excluded analyses  thus  total 1650 human milk samples 124 lactating mothers included final analysis  Figure  shows percentage participants detectable IgA study period  Almost participants received mRNAbased vaccine showed detectable IgA milk  25 26  96 %  37 38  97 %  BNT162b2 MRNA1273 vaccines  respectively  participants received vectorbased vaccine  remarkably lower  13 33  39 %  10 21  48 %  showed detectable IgA AZD1222 Ad26COV2S vaccines  respectively  percentage participants detectable IgG study period depicted Figure  B  doses BNT162b2  MRNA1273  AZD1222 vaccines  participants showed detectable IgG  However  mRNAbased vaccines  day 23 day 32 first dose  AZD1222 vaccine  participants showed IgG day 94  vaccination Ad26COV2S  1 dose  6 23  28 %  participants detectable IgG milk  Discussion demonstrated SARSCoV2Äìspecific IgA human milk present frequently vaccination mRNAbased vaccine compared vectorbased vaccine  Additionally  IgG present participants receiving 2 vaccine doses  independent vaccine type  However  IgG detectable earlier vaccination either mRNA vaccines  explained timing second dose  limitation study measure neutralizing capacity human milk antibodies  abundant antibody human milk IgA  plays key role first line defense invading viruses5 Although  knowledge  studies shown indisputable evidence humanmilk IgA directly protects respiratory tract infections  likely antibody plays critical role  Based data  suggest mRNAbased vaccine optimal choice lactating women want transfer antibodies infants ', 'fair worse  likely test positive realtive unvaccinated  Outcomes', ' Abstract BACKGROUND duration effectiveness immunity infection vaccination severe acute respiratory syndrome coronavirus 2  SARSCoV2  relevant pandemic policy interventions  including timing vaccine boosters  METHODS investigated duration effectiveness immunity prospective cohort asymptomatic health care workers United Kingdom underwent routine polymerasechainreaction  PCR  testing  Vaccine effectiveness  â10 months first dose vaccine  infectionacquired immunity assessed comparing time PCRconfirmed infection vaccinated persons unvaccinated persons  stratified according previous infection status  used Cox regression model adjustment previous SARSCoV2 infection status  vaccine type dosing interval  demographic characteristics  workplace exposure SARSCoV2  RESULTS 35768 participants  27 %  9488  previous SARSCoV2 infection  Vaccine coverage high  97 % participants received two doses  78 % received BNT162b2 vaccine  PfizerÄìBioNTech  long interval doses  9 % BNT162b2 vaccine short interval doses  8 % ChAdOx1 nCoV19 vaccine  AstraZeneca    December 7  2020  September 21  2021  total 2747 primary infections 210 reinfections observed  Among previously uninfected participants received longinterval BNT162b2 vaccine  adjusted vaccine effectiveness decreased 85 %  95 % confidence interval  CI   72 92  14 73 days second dose 51 %  95 % CI  22 69  median 201 days  interquartile range  197 205  second dose  effectiveness differ significantly longinterval shortinterval BNT162b2 vaccine recipients  14 73 days second dose  adjusted vaccine effectiveness among ChAdOx1 nCoV19 vaccine recipients 58 %  95 % CI  23 77  Äî considerably lower among BNT162b2 vaccine recipients  Infectionacquired immunity waned 1 year unvaccinated participants remained consistently higher 90 % subsequently vaccinated  even persons infected 18 months previously  CONCLUSIONS Two doses BNT162b2 vaccine associated high shortterm protection SARSCoV2 infection  protection waned considerably 6 months  Infectionacquired immunity boosted vaccination remained high 1 year infection ', 'Thank  know applied full approval  ide typical timeline ?', 'Controls pandemic  completely eliminate COVID19 vaccines and virus factor   cohort includes patients aged 099 least one office visit encounter January 1  2019  June 30  2019  cohort inclusion date earliest office visit patient dates  patients documentation excluding condition documentation GuillainBarr prior inclusion date removed cohort seems likely lower rate vaccinated patients due NPIs  masking  distancing  etc   reducing exposure viruses might cause GBS  Despite association people mentally vaccines GBS  viral infections far common cause ', 'excecise suppose increase antibody two weeks 90 min lol ? Really ? Shouldnt study everyday excercise ', '020 % effectiveness 2 doses ? back beginning pandemic ?', 'say hospitalized ?', 'Science struggle  WasnÄôt ', 'Huh ? study says  Overall  30day incidence myocarditis following COVID19 diagnosis nearly 17 times higher incidence among patients receiving COVID19 vaccine   see nothing hospitalization ', 'could possibly explained ? also mean chances higher infected eg  get fourth fifth dose ?', 'guess s short interval   https  wwwresearchsquarecomarticlers1226339v1 paper got improvement neut  post 2nd dose infected  3rd dose good improvement ', 'much anosmia defining feature mild cases ', ' Remember SARSCoV2 migrates body affected organs one time another among various cases covid  one reason SARSCoV2 vaccines effective  high serum antibody levels help prevent kind wide dissemination  Vaccines general really good preventing kind dissemination  highly contagious respiratory viruses require dissemination lymphatic system cause disease  like measles varicella  respiratory route infection  virus disseminates cause rash transmission   respiratory diseases dont require dissemination disease progression  like RSV rhinovirus parainfluenza metapneumonia  durable immunity  vaccines otherwise  keep getting infected repeatedly viruses  SARSCoV2 follows similar paradigm prior infection vaccination not prevent infection long term  seems adequately prevent dissemination thus severe disease ', 'results  measurably better multivalent vaccine  WTbeta  211  vaccine 50 % higher neutralization Delta Gamma WT alone  50 % higher nt huge number  effect get doubling dose  s also worth noting Delta farther Beta wildtype  phase 1 trials supposed repeated WTBetaDelta  213  vaccine  seen results  Indeed  results named Q2 report since removed   knowledge  never published  even medical preprint  ', 'far  VOC specific boosters proven effective another shot original based Wildtype generating immune response  Moderna posted results  seek 3rd quarter earning report PDF interested   re considering maturation immune response time  additional exposure original vaccines  ____ ____   Superior immunity allows neutralization SARSCoV2 variants concern develops COVID19 convalescents naØve individuals three vaccinations    https  wwwresearchsquarecomarticlers1226339v1  ____ ____   Structural basis Omicron neutralization affinitymatured public antibodies    https  wwwbiorxivorgcontent10110120220103474825v1  ____ latter  _____  resolved structure CABA17 Fab complex Omicron spike overall resolution 26 Ö cryoelectron microscopy defined structural basis breadth  Thus  public SARSCoV2 neutralizing antibodies  without modified spike vaccines  mature crossneutralize exceptionally antigenically diverged SARSCoV2 variants  ', 'Incorrect  significantly second  barely  third doses Moderna  Myocarditis incidence rate infection 73 per million  Moderna third dose measured 104 believe  believe thereÄôs also language study suggesting severity myocarditis worse Covid patients need reread section carefully  top  statistically significant potential side effect rna vaccines thus far  Myocarditis potential severe side effect Covid infection  far  Measured whole  2dose vaccines would better young males take risk Covid infection  Although available may worth considering vaxs Moderna young males  EDIT  needed check carefully  73 number infection older males  7 number younger males  Moderna numbers second dose  points starting paragraph 2 still stand except fact definitely reconsider using Moderna younger males options  Pfizer  AZ  available ', 'Sorry  explanation itÄôs statistical noise hold  look right edge graph  even upper range confidence interval intersecting yaxis  0   Additionally  actually went zero  instead past zero  negative   would expect curve asymptotically approach zero  Instead  rate descent much steadier straighter ', 'also nt seem take account reduced severity & duration vaccinated individuals  leading reduced window infecting others ', 'makes lot sense  thanks thoughtful response ', 's comparison sputnik vaccine antibodies concentration Pfizers Modernas vaccine ?', 'ÄúConsidering small effect size association good prognosis patients SSNHL  potential influence condition public health appears relatively minorÄù from source article', 'boosters less bad doubly vaccinated', 'news 3rd shots ages 511 ? Wonder ll help bring back protection ', 'many studies ignore impact hybrid immunity ?', 'rather opposite making pronouncement  sentence literally translates  nt enough evidence make pronouncement yet  ', 'Wait two weeks booster find increased risk symptomatic cases ? boosters useful two weeks metric ', ' Beyond lower rates pneumonia CT  clinical course patients paralleled chest CT findings  vaccinated patients much less likely require supplemental oxygen  odds ratios  24  p005  lower rate intensive care unit admission  odds ratio  08  p02  unvaccinated patients  odds ratio 008 nt impressive ?', 'pick battles  canÄôt control virus  itÄôs becoming transmissible point catching becoming hard  Long covid huge issue something iÄôm concerned ? canÄôt force world stay indoors anymore  mask mandates dropped people starting live like itÄôs 2019  preventing infection seems impossible average person age omicron ', 'kinda agree  One caveat looked time period dominant AlphaDelta  Omicron  far prevalent variant  seemingly much less virulent  Hopefully likelyhood  long covid  Omicron infection turn significantly less groups  also nt  could nt  include anyone received 3 shots perhaps provides greater protection Long Covid primary course 2 shots win month ', 'links studies sinovac omicron ? ve tough time finding anything  m triple vaxxed Sinovac really freaked getting virus ', 'source ? TCell based ? data long booster seems work ?', 'answer  d need know severity vaccineassociated myocarditis  rate covid reinfection  rates severity myocarditis reinfection  rate severity sequelae following covid reinfection  Trying put whole picture together public health recommendations ', ' 3 days ago sub study published saying omicron infections fact much mild delta study linked looking viral replication rates  says nothing disease severity  re referring South African study showed Omicron 29 % lower hospitalisation rate ancestral strain  nt fully controlled immunity prior infection  specify  documented  infection  vast majority COVID cases go unreported  surveillance South Africa nt great    However  hospitalization rates Africa would fact suggest ommicron mild  Lower hospitalisation rates nt necessarily evidence Omicron variant less virulent  re evidence mild cases occuring current wave  also attributed higher levels immunity population  edit  Reading study re referring  actually outright states  ÄúThis lesser severity could  however  confounded high seroprevalence levels SARS CoV2 antibodies general South African population  especially following extensive Delta wave infectionsÄù', 'Every cold exists today variant virus existed year two year two forth ', 'Moderna mainly', 'boys preexisting heart anomalies  myocardial scarring  Boy  cardiomegaly  Boy B   Boy also history amphetamine use ', 'think equally plausible explanation occurring Omicron spike divergent able engage existing B cells particularly well  merely acts like  first dose  prime  second booster may work much better  Note mouse study vaccine  Omicronspecific one engage wildtype trained B cells would consistent ', 'effective treatment options available locally  eg  paxlovid  sotrovimab  forego vaccinebooster instead plan seek early treatment upon symptomatic infection ? especially knowing may one many infected turn asymptomatic UPDATE  donÄôt get downvoted  people taking issue last statement  systematic review concluded 35 % cases asymptomatic   https  wwwpnasorgcontent11834e2109229118   https  wwwpnasorgcontent11834e2109229118   also donÄôt think itÄôs controversial say first couple vaccine doses contemplating booster likely even asymptomatic case  Omicron declared milder conjecture ratio asymptomatic cases higher also  weÄôll still see data bears piece ', 'curve probably informed observations point  chance might given unintuitive results ', 'Bharat Biotech got approval Indian regulators phase 3 trial last month ', 'Curious  imagine something antibody affinity maturation ', 'seem two points   Along previous data showing superiority third dose second dose4 results suggest maximal immunogenicity mRNA vaccines achieved three doses antibody levels restored fourth dose   boosting results increase antibody levels  nt seem surprising imagine future studies observing similar results 5th  6th  Nth booster  Furthermore  observed low vaccine efficacy infections health care workers  well relatively high viral loads suggesting infected infectious  Thus  fourth vaccination healthy young health care workers may marginal benefits  important point  Despite increase antibodies  existing vaccines nt efficacious reducing viral loads  adds existing evidence suggesting omicronrelated strains better able evade immune detection  imagine due  least part  current 2022 strains diverged 2019 strain used make vaccines ', ' Also preprint  think given title abstract misleading going  Yes  think lot people interpret  omicron specific boosters wo nt induce strong responses VOC   study looks mice unexposed COVID rather people vaccinated WT  response someone already previously exposed WTDelta omicron booster wo nt ', 'Sweden much restrictions none  s study done  exclude correlation much possible ', 'vaccines really donÄôt prevent transmission well', 'anyone know timeline goes human trials ?', 'Interesting  memory serves correctly  Pfizer 70 % effective Omicron used booster  Perhaps better booster option know antibodies continue rise beyond timeframe mRNA vaccines begin fall ', 'doesnÄôt covaxin safe & effective pediatric data  USapproved vaccines yet ?', 'study covered first 6 months vaccination dose  yes accounted  future monitoring probably wise ', 's acute response s important  fearstress works probably nt much actual exercise much convincing body s attacked lion ', 'thought Tcell immunity always long lasting  whether resulted vaccination infection  havenÄôt seen papers published noted tcell immunity temporary ', 'think youÄôre reading bit much lines  really think paper opinionated ? Reads like theyÄôre simply reporting results  HavenÄôt read whole thing thoroughly though  missing something ?', 'paper ever claim  shot helps improve mental health  ?', 'one gave correct explanation  ItÄôs graph cubic spline fitted observed values  look table instead  9 months estimated 23 % effectiveness infection wide confidence interval  zero line actually data proper informed model  ItÄôs simple smoothing line', 'WhatÄôs next big treatment potentially horizon ?', 'read somewhere else significantly younger population overall  basically common observation  make virus ca nt translate west difference age ', 'think mixed  P02 MASSIVE risk reduction ', 'doesnÄôt  table shows drop 23 %  graph smoothing line  actually data ', ' data provide evidence fourth dose mRNA vaccine immunogenic  safe  somewhat efficacious  primarily symptomatic disease   comparison initial response fourth dose peak response third dose show substantial differences humoral response levels omicronspecific neutralizing antibodies  Along previous data showing superiority third dose second dose4 results suggest maximal immunogenicity mRNA vaccines achieved three doses antibody levels restored fourth dose  Furthermore  observed low vaccine efficacy infections health care workers  well relatively high viral loads suggesting infected infectious  Thus  fourth vaccination healthy young health care workers may marginal benefits  Older vulnerable populations assessed ', 'needs better education awareness longterm risks infection varios pathogens  People incorrectly assess risk vaccineinduced injury greater pathogens  people aware viruses cause autoimmune diseases  future researchers focused relationship viral infections various comorbidities ', 'possible selective pressure towards milder forms  IÄôve seen argued time die covid  virus gone  moved  die live irrelevant virus  die inflammation left behind  entirely separate second phase  Suggesting selective pressure  opinions ? valid argument ?', 'Beta major vaccine evader well ', 'recommending nonmRNA vaccines young male cohort ?', 'find odd neutralization titers Moderna lower Pfizer  yet efficacy Moderna consistently higher almost every study ', 'DoesnÄôt jnj study contradict consensus ? got mRNA booster jnj consensus CDC told itÄôs superior  Looking  thatÄôs clearly case ', 'nt South Africa seeing uptick deaths yet ?', 'WeÄôre also dealing contagious variants time passes  delta  omicron  ', 'clear imprinting issue  study date give sufficient time antibody maturation occur boost trigger plasma bcell conversion antibody generation  immune system problems tracking immune escape existing  hCoVs   https  journalsplosorgplospathogensarticle ? id101371journalppat1009453  would astounded SARSCoV2 different ', 'Moderate intensity activity jogging 10 minute mile average American  average American overweight obese  Americans probably could jog mile without take walking breaks  certainly would nt 6mph pace  Moderate intensity activity average American  obese  middle aged person  walking ', 'Old law needs rethought  protect 6months 2 years  arenÄôt ?', 'nAb data interesting  Pfizer s vaccine initially edges J & J s  bindingneutralizing titers start falling Pfizer almost immediately  consistent earlier literature demonstrating thing   Differential Kinetics Immune Responses Elicited Covid19 Vaccines  NEJM   https  wwwnejmorgdoifull101056NEJMc2115596    Very potent early humoral immunity  significant issues staying power  nt mind getting boosts routinely counteract  m sure sustainable public policy perspective  Still  imagine difference efficacy J & J Pfizer Omicron almost certainly related cell function  mRNAs induce remarkable antibody response  s useful broad majority antibodies ca nt bind Omicron RBD  Adenoviral platforms like J & J s  trade comparably low antibody titers stronger cell function  cells tend robust largescale changes sequence ', 'speed omicron  50 % US infected end january probably  means limited effectiveness  &  x200B  speed mutations thats happening incomprehensible total guess attempting vaccinate  BA2 whatever seems like next explode march northeast US  Would better could go  knows next variant South June 2022  Could BA22 could even newer one  winter 2022 ? ?   ', 'reading  testicular inoculation  correctly ? stabbed needle testicle injected SARSCoV2 straight testicles hamsters ? exactly injecting virus normally spreads respiratory aerosols testicles hamsters supposed demonstrate ? testicular inoculation respiratory viruses thing normally done ?', 'started suspicious variant doses first heard Deltaspecific booster nt better third shot original ? time  everyone framed  wow og booster good   effective Delta  still nt weird Deltaspecific one nt better Delta ?', 'm confused comment  nt asymptomatic COVID  COVID19like illness ?  nt positive test typically result diagnosis ?', 'Considering amount vaccine hesitancy antivaxxers  possible risk VAERS reports even coincidental accurate even greater prior pandemic  symptoms ignored  many psychosomatic variables well ', 'd really like looking population survey  state publishes reinfectionbreakthrough infection  etc  also published vaccination rate convalescent patients  could really start see consistent analysis  currently  breakthrough infection seems common reinfection based MN doh data ', 'reported cases', 'entirely false  Threedose vaccination defeated delta every country tried  nothing else except letting everyone catch delta waiting reinfections start succeeded  also know multivalent wtbetadelta vaccines used small trials significantly effective delta  though ve done research  certainly lot effective omicron  wtomicron  deltaomicronb1640  deltaomicronsarsmers spike would  nearcertainty  better every existing variant much better future variant  idea science solve vaccines nt really hold water  ve betadelta spikes  engineered polymutant spikes  sarsmers spikes available vaccine use nearly year  fear science stopped us even trying  even research tried shown us broad multivalent vaccine would dramatically effective ', 'Waste water detection increased starkly many places US  large spikes abroad  d say sooner better data supports efficacy safety ', 'youÄôve already covid  getting vaccinated results robust protectionÄî better infection alone better vaccination alone  Makes sense  wonder reverse folks vaccinated first subsequently breakthrough infection  assume better vaccination alone  wonder compares infection first ', 'Reducing hospitalizationdeath avoiding infection different success criteria ', 'would agree  mean failure ?   real truth COVID different enough   must consider short period time created vaccines  rushed get something public help slow deaths  Try imagine might took standard procedures developing vaccine ? long take create vaccines ?', 'WouldnÄôt safe say lot people heightened stress  fear  anxiety  etc  reassured taking shot protection ? placebo effect Äúthe shot helps improve mental healthÄù  ', 'clear  study estimate probability infected either Omicron Delta vaccination status  examines test positivity rate  given chosen get PCR test  percentage time PCR tests give positive result  vaccination status variant  People choose get PCR test likely biased sample  symptoms  compared broader population  actual probability random person population infected likely different  course  authors make claim  clarifying could misread way ', 's pretty much authors wrote  &  x200B   Omicron  similarity ORs 3 doses using unvaccinated referent group 2dose referent group consistent attenuation 2 doses vs unvaccinated time since second dose  which reflected significant association 6 months second dose products ', 'great response', 'Yeah low effort contribution isnÄôt even based paperÄôs results  Countless papers shown Äúvaccines workÄù  one  21 people working age hospitalized hardly evidence vaccines reducing severity hospitalization rate low single digits begin  perhaps well 1 % Omicron age group  even unvaccinated people  ', 'paper state whether vaccinated hamsters got sarscov2 injected testes ?', 'NIAID study showed starting J & J boosting mRNA big bump antibodies  erred already waning significantly week 2 week 4  way around  still increasing week 4 ', 'antigenic sin', ' even delta 20 weeks less 50 % effective  against infection  still provided 95 % protection hospitalization Delta hospitalization immunocompetent population ', 'anyone access full paper ? ratio pre post vaccination antibody titer could also higher levels antibodies much lower prevaccination individuals ', 'BA2 information best vague  anyone published results ? Interested new mutation impact US', 'part stuck   absence severe disease  hospitalization death study precludes assessment vaccine efficacy endpoints   think s good thing  serves reminder low risk Omicron young children  NOTE  edited clarity ', 'seems protection severe disease stable tcells severe disease previous infection  important  https  wwwbiorxivorgcontent10110120211212472315v1', 'Yes  even discussion developing vaccines back 2020 set antivaxxers  already gaining traction years prior Covid  back Wakefield days 1998  Pointing hypocrisy concern vaccines thereÄôs far less concern 350000 chemicals environment  several thousand MSDS  several known carcinogens  neurotoxins  endocrine disrupters VOCÄôs one way get discussion risk benefitharmrisk analysis broached  Another topic shortterm macro economic societal costs  Humans tend focused shortterm  immediate concerns  underestimate longterm costs risks  even consciously choose Äúkick roadÄù  enough education known unknown risks pathogens  chemicals drugstreatments  potential benefit outweighs risks  part donÄôt know donÄôt know  thereÄôs additional unknown yettobe discovered longterm sequelae macroeconomic costs every variable ', 'Yes  valid  Usually pressure become milder driven fact symptomatic people likely home bed  actively riding subway whatever  reducing symptoms virus access hosts ', 'layman terms  clue virology   Covid endemic stage ? Like time next year  would bear resemblance say common cold ? still long way go  finally reaches ?', ' summary leaves lot important dataassumptions  really  main finding breadth immune response N501Y better mRNA vaccinated individuals convalescents  rest points would perhaps explain difference overall titer decreasing titer time  breadth  majority abstract  ', 'Also  Novavax spike protein slightly different PfizerBioNTech Moderna   vaccine NVXCoV2373  PS   developed Novavax Ad26COV2S vaccine  nrVV  Janssen Pharmaceuticals  vaccines deploy glycoprotein mutated furin cleavage site K986PV987P proline substitutions  https  wwwfrontiersinorgarticles103389fimmu2021701501full', 'Seems like one possibility would variant specific boosting needs 2 doses  anyone else come away open question ?', 'ThatÄôs saw reported  FDA encouraged Pfizer submit data approval could review  review  looks like data needed', 'Sorry  couldnÄôt find  title article ?', 'graph drop zero 8 months ? seems odd ', 'idea mild forms viruses selected time isnÄôt really fact much true offers little predictive power itÄôs true long timescales   commonly stated idea often evolutionary tradeoff virulence transmissibility intrahost virus replication necessary facilitate interhost transmission may also lead disease  impossible natural selection optimize traits simultaneously  case MYXV  tradeoff thought lead ÄòintermediateÄô virulence grades selectively advantageous  higher virulence may mean rabbit host dies interhost transmission  whereas lower virulence selected increase virus transmission rates  similar tradeoff model proposed explain evolution HIV virulence40  However  many doubts raised general applicability tradeoff model35414243  virus fitness affected traits virulence transmissibility394144  contrary results observed experimental studies45 relatively little known evolutionary tradeoffs nature  example  case second virus released biocontrol European rabbits Australia Äî rabbit haemorrhagic disease virus  RHDV  Äî evidence virulence increased time  probably virus transmission often occurs blow flies feed animal carcasses  making host death selectively favourable46  Similarly  experimental studies plant RNA viruses shown high virulence necessarily impede host adaptation47  case malaria  higher virulence shown provide Plasmodium parasites competitive advantage within hosts48  https  wwwnaturecomarticless4157601800555 plenty evidence virulence selected Since beginning pandemic people predicting SARSCoV2 would mutate become milder  mentioned SARS MERS  epidemiologist  know neither passed asymptomatically much lower R0  SARS presented fever example  point Covid started mild could spread asymptomatically  much idea mild strain would selected ix true  requires strain transmit better mild  spread without symptoms  space fitness landscape much smaller   point virus became virulent essentially disappearing distinct antagonistic organism certain bird populations  also look things like CCR5 see species reacted existential threats  Dude  ccr5 adaptation either plague  consensus  smallpox  read paper argued smallpox likely provided selective pressure  either way  demonstrates changed pathogen  takes literally generations trait get fixed ', 'Conclusions crosssectional analysis baseline data collected patients enrolled phase 3 randomized trial early outpatient treatment SARSCoV2 infection  vaccinated individuals lower viral load lower prevalence systemic symptoms vaccinated  effect viral load longer present persons vaccinated 6 months prior  primary goal Äúfully vaccinatedÄù prevent serious disease  may still occur 6 months  Future research look viral load beyond 6 months understand whether term Äúfully vaccinatedÄù viral load transmission define vaccinated within previous 6 months  Vaccine boosterinduced reduction viral load may important component achieving reduced coronavirus spread ', 'thing found Betaspecific booster recall  seems fairly clear imprinting problem  guess nobody wants admit  way know sure would find sample group   unvaccinated  previously infected  willing participate vaccine trial probably pretty small group ', 'YouÄôre linking study mostly Delta cases months ago  omicron  thereÄôs qualitative difference viral load weÄôd see result household secondary attack rates  Whatever factor may  thereÄôs real world evidence itÄôs 10 fold ', 'would question underlying data  UK example myocarditis adverse events reported voluntary basis  Adverse events go unreported case  case C19 patients likely hospital setting monitored  whole report could simply interpreted patients likely diagnosed myocarditis  others ', 's curious post downvoted  Noone said disagreed  s really nothing controversial  idea secondary adaptive immune response stronger persistent primary basic immunology  idea covid infection  vaccine dose gives similar immune response infections two vaccine doses demonstrated number studies basis guidance countries single dose required previously infected  reviewed   https  wwwnaturecomarticlesd41586021016094   https  wwwnaturecomarticlesd41586021016094    NB prior 3rd dose recommendations previously vaccinated  Perhaps one downvoters would care give thoughts ?', 'mean link COVID vaccines could inferred ? associations  nonCOVID ones certainly exist  eg  influenza ', 'thought beginning  lowest acceptable efficacy going 50 % ? misremembering ?', 'Early Pfizer data Israel states boosterÄôs peak efficiency neighborhood 10 weeks  got Moderna booster August  full size  half size booster theyÄôre giving  tested positive first week January  Anecdotal  case mild  Primarily sore throat  congestion  fatigue  low grade feverchills ', 'IÄôm sure understand point  Using 99 % protection reinfection previous strains instead 85 % makes omicron look way worse ', 's definitely possibility  inability get consistent results across regions make impossible measure  may first time s seen boosters  2dose data place  Ontario long dosing interval 100 % measured omicron one point ', 'ThereÄôs early data study AVV gene therapy showed elevated troponin levels mild transient myocarditis postIP dose younger adult male subject physically active  need dig deeper relationship immune activationstress  testosterone levels  physical activity level  age  troponinmyocarditis  whether myocarditis mild transient  sequelae occur ', 'EDIT  edited response reading study well authors  previous one  pair studies used 16 peptides  23mer   10 peptides  Tcell epitope optimized  contain known Bcell epitopes  selected based computationally predicted Tcell epitopes filtered various criteria  including HLA binding  predicted immunogenicity  location   N protein  opposed proteins like ORF s  etc   etc  6 peptides  Bcell epitope optimized  based around three linear Bcell epitopes located functional  conserved surface regions Spike protein  Although peptides broad coverage HLAI alleles  coverage HLAII alleles generally poor  immunology review  peptide s ability bind range widelyexpressed HLA alleles major limiting factor viability good Tcell epitope   authors suggest vaccine designed stimulate Bcell CD4 Tcells would require use nonspatially overlapping sequences  studies  strong humoral response detected peptides  including Bcell epitope optimized peptides  Tcell epitope optimized peptides elicited strong Tcell responses  per second study  mice seem gain protection infection disease viral challenge  way background  general discovering peptides designed elicit Tcell responses relatively developed discovering linear epitopes designed elicit Bcell responses  authors note first study  attempts discover linear epitopes elicit protective Bcell responses failed  practice nt much use practical application using linear peptides either since would probably need scaffolded something anyways   immunology review  naturally occurring Bcell epitopes linear   Current development efforts peptide vaccines focused cancer  surprise    Tcells primary focus ', ' log scales used figure  Comirnaty general performs around 10 fold better terms binding neutralizing activity nearly tests  agree looks worse Comirnaty re overestimating difference neutralizing antibody titers  selected 3 µg dose trials  s one looking  Comparison using WT shows little difference  delta  difference approximately 4fold  approximately 1021 vs 1015   beta looks similar  ratio neutralizing nonneutralizing antibodies using RBDbased vaccine general interest  even nt say anything good particular vaccine ', 'Cutting risk hospitalization half still seems pretty good given rare serious side effects ', 'studies comparing NVX Omicron enough time set proper study compare ?', 'Please correct reading wrong  indicate vaccine preventing hospitalization kids 511 decreased 100 % 48 % ?', 'seems authors arguing ', 'Spell  saying immunity less specific word protection ? m sure s always case ', 'anyone know would two doses vaccine breakthrough infection long ago  12 months  offer significant protection ? Especially considering itÄôs long since covid infection ', 'Great comment  trade giving enough time enable least part dormancy maintaining neutralizing antibody levels circulation   differentiation  B cells recognize unseen mutations absolutely fascinating  One could wonder got evolutionary conserved ', 's proposed mechanism action vaccination reducing symptoms existing long COVID ?', 'person  AimingWineSnailz  said  incorrect  Moderna developed tested VOC specific boosters based Delta & Beta  Neither elicited robust response another shot original vaccine based wildtype  Moderna also tested two VOC boosters Omicron first discovered late last year  another shot original worked well  Omicron much mutated previous VOCs decent chance updated vaccines Pfizer & Moderna developingtesting good option time  potentially  next mutation  stems Omicron   Notwithstanding  lack variant specific boosters BetaDelta nothing w development time  nt prove significantly effective original well manufactureddistributed point  Moderna s info VOC boosters found 3rd Quarter earning report  PDF  last year ', 'Read last paragraph page 5  Please', 'Weirdly  people 3 vaccine doses infection  full seriesbooster  lower risk people 2 doses  ie  effect reversed  guess would strange confounding factor https  wwwmedrxivorgcontentmedrxivearly202202132022021022270744F4largejpg', 'personal level  nt seem evidence  unless ve missed something big  case d appreciate links  risk Omicron variants  spectacularly low risk  indeed  less risk flu normal winter  last time checked figures   re possibly  nt seen enough data recent second dose efficacy  somewhat higher risk contracting passing around  increased risk higher transmissibility   still nt something particularly concerned personal health outcomes perspective  Obviously  wider societal issues  secondary personal negative effects things like isolation  narrow personal health perspective  s pretty much wash ', 'Perhaps unvaccinated cohort likely higher neutralizing antibody levels recent infection point time vaccinated cohort  since latter less likely infected months ? Basically unvaccinated group slowly building immunity time infections  one neutralizing antibody levels dwindling hitting low point certain level synchronicity  live Canada  time late December government showing data risks infection  based positive PCR testing  unvaccinated 07x risks vaccinated  2 doses  Omicron  course could due unvaccinated less likely get tested  although 07x used 35x early December  numbers based previous 28 days data  got wondering unvaccinated less likely infected Omicron due much likely infected Delta months prior ', ' people notice vast bulk vaccinated mild side effects  beaten thing  vaccination accepted  less think optimistic  Conspiratorial  magical thinking moves goalposts time  beyond reason  could say  Äúwait years  vaxxed see effectsÄù  Likewise theyÄôll interpret deaths unvaxxed deliberate  even targeting HCP ', 'says re teens  theory adult Pfizer dose  believe start lowering size dose 12s', 'Exactly  critical question  unvaccinated previously infected question settled  Definitely get vaccine  crux ADDITIONAL benefit either boosting vaccination previously infected people offers regards severe diseasemyocarditis  additional benefit  available evidence would say  additional benefit worth context potential side effects  key demographic young teenager  30 yo man  Depends study  seem 110000 risk myocarditis vaccination  Much higher women older younger men ', 'Thanks helpful ', 'hmm ve loop studies mortality  got ta admit figures 2 dose  59 %  less might expected  albeit  s fing massive CIs  482 %  may play role  Still great 3 dose working wonderfully  though', 'Correct IÄôm wrong wonÄôt basically everyone get covid young men children get vaccine myocarditis chance plus covid myocarditis chance ', 'true Omicron variant nt attack lungs like original Covid19  thus fewer hospitalizations ?', 'Literally billion dollar question nobody seems know answer ', 'OPÄôs fault  title misleading theyÄôre talking booster  original vaccination ', 'China Russia happily violate patent problem fundamental reagents needed even make pills short supply  Actually s even reagents products needed make reagents products make products  Literally sodium shortfall  s insane  https  wwwscienceorgcontentblogpostmakingpaxlovid  DIBOC pretty much commodity  look closely supply chain  find many original suppliers might thought   fact  supply problems scale right making DIBOC needs  among things  another reagent called sodium tbutoxide  Well  s another commodity  ve used stuff every often since 1980s never gave moment s thought comes  make  need tbutanol sodium metal  turns  things  bottleneck sodium tbutoxide s quite enough sodium go around  Sodium metal produced bruteforce  energyintensive electrolysis process goes back 1924  electricity supply problems interfered plants making  ', 'ItÄôd interested see clinical outcomes matched cohorts vaccine types 1 month vs 36 months intervals first series ', ' Vaccine efficacy SARSCoV2 infection 30 %  95 % confidence interval  CI   àí9 55  BNT162b2 11 %  95 % CI  àí43 44  mRNA1273  Figure 1C   infected health care workers reported negligible symptoms  control group intervention groups  However  infected participants potentially infectious  relatively high viral loads  nucleocapsid gene cycle threshold  â25   Table S6   Vaccine efficacy estimated higher prevention symptomatic disease  43 % BNT162b2 31 % mRNA1273   Fig  S4   additional protection 30 % infection 43 % symptomatic infection bad 4th dose  diminishing returns expected  feel like using terms  marginal benefit  bit uncharitable ', 'thought marginally increased protection delta decreasing alpha  wild type  etcÄ deemed unnecessary perhaps detrimental net ', 'thing greater risk taking argument getting vaccinated  majority unvaccinated living way entire time', 'agree  mean one main authors Dr Ferguson  aka Dr Doom circles  recently predicted like 5000 deaths per day Uk measures put place  find number quite absurd honest  Even peak Delta etc nt numbers like ', 'Moderna tried back last fall believe  half wildtype  half Beta specific booster   results  Perhaps first exposure someone d effective  ca nt go back ', 'tcell response various vaccines different  personal observation  little scratching throat people 2 3 doses sinovac comparing people biontech  3 doses   &  x200B  known sinovac generates less antibodies significantly better cell response structural protein', 'Interested seemingly better vaccine neutralization BA2 BA1  would possibly seeing BA2 currently replacing BA1  implications ', 'guess theyÄôd likely tested due vaccineortest mandates lot workplaces  donÄôt buy behavioural difference  Vaccination natural immunity reduce symptoms thus likeliness suspecting covid  difference portion  albeit possibly high  unvaccinated effect ', 'Abstract Several variants SARSCoV2 emerged  mutations angiotensinconverting enzyme  ACE2  receptor binding domain  RBD  associated increased transmission severity  study  developed antibody quantification functional neutralization assays  Analyses COVID19 convalescent diagnostic cohorts strongly support use RBD antibody levels excellent surrogate biochemical neutralization activities  Data revealed samples mRNA vaccinated individuals median 17 times higher RBD antibody levels similar degree increased neutralization activities RBDACE2 binding natural infections  data showed N501Y RBD fivefold higher ACE2 binding original variant  antisera naturally infected subjects substantially reduced neutralization ability N501Y RBD  blood samples vaccinated individuals highly effective neutralizing  Thus  our data indicates mRNA vaccination may generate neutralizing RBD antibodies natural immunity  suggests potential need maintain high RBD antibody levels control infectious SARSCoV2 variants  ', 'study measures IgG titers  nt think ve seen study measures neutralizing IgA titers Omicron  Omicron rapidly reproduces nose throat  Maybe s case IgG antibodies nt capable preventing breakthrough infection seeing vaccines  IgA neutralizing responses Omicron pretty weak ?', 'read ? IÄôve googling past 15 minutes canÄôt find mention EUA withdrawn uultra003  googling  find FauciÄôs reasoning matter itÄôs worth  canÄôt copy link  IÄôll capture relevant section &  x200B   GET APPROVED UNITED STATES ? Fauci mistakenly said ÄúMorning AmericaÄù CovaxinÄôs manufacturer  Bharat  applied FDA approval  office followed later day statement  ÄúBharat Biotech  company developed Covaxin  applied FDA emergency use authorization  EUA  vaccine  FDA currently evaluating data decision madeÄù ÄúThe FDA looks data data order give good scientific rationale approve  FDA approve  Äù Fauci also said ÄúMorning AmericaÄù interview  ÄúThere interventions approved reasons theyÄôve either submitted approval data strong enough warrant approvalÄù asked FDA application  spokesperson Ocugen stated Phase 3 clinical trial Covaxin 934 effective preventing severe COVID cases  778 percent effective overall disease  also noted trial children got similar results  ÄúOcugen submitted pediatric Emergency Use Authorization  EUA  based data FDA Nov 5  2021  parents healthcare providers US safe effective vaccine option children effort end coronavirus pandemic  Äù Ocugen said statement NewsNation  Fauci said think United States needed another vaccine  Instead  said  needed get people vaccinated vaccines currently approved   ÄúItÄôs alternative  ItÄôs another vaccine  Äù Fauci said Covaxin appearance ÄúMorning AmericaÄù ÄúWe donÄôt need another vaccine', 'Moderna higher effective dose active ingredient  100ug Moderna vs 30ug Pfizer  booster doses 50ug 30ug  respectively ', 'nt poorly understood phenomenon called  viral interference  ? thought fairly uncommondifficult get competing infections time  infection ramps bodies immune system fairly broadgeneral fashion short period time  study explicitly states everyone booster arm booster less three months ago  Would nt deliberate infection competing coronavirus  anything really matter  also illicit  neutralizing immunity   least brief period time ? something ve curious since get go  especially quickly vaccines appeared wane  group persons given vaccine another group infected minor cold virus interval  would meaningfully different outcomes resisting covid19 variants intervals time ? study would plainly unethical likely lethal number succumb deliberate cold infection matter mild  ve wondering mattered dosed people time observed results vaccines sort results d capture stuck anything people induced general immune response ', 'Sweden part official guidelines unvaccinated extra careful avoid crowded places   https  wwwkrisinformationseenhazardsandrisksdisastersandincidents2020officialinformationonthenewcoronaviruscurrentrulesandrecommendations   https  wwwkrisinformationseenhazardsandrisksdisastersandincidents2020officialinformationonthenewcoronaviruscurrentrulesandrecommendations ', 'understand opposition  peddling arguments related duration exposure spike protein  Really  seen argument  s government conspiracy thing anything', ' one admitted hospital  Vaccines work', 'negative 91150 looks similar s happening England s infected per 100k among vaccinated unvaccinated age groups  Omicron related  like long ', 'nt understand  thought spike protein significantly different ?', ' assigned control  participants started sedentary period within 30 min vaccination  sedentary period consisted sitting watching videos 90 min  Adults randomized exercise performed 90 min exercise cycle ergometer 60Äì70 % estimated maximal heart rate  HR max   Looks like studying effects exercise immediately immunization  would interesting see effects exercise outside time window  think beyond scope paper ', 'Super interesting stuff  though think mice nt exposed WT  One thing sure  nt expect Delta well  Though  would loved tried instead making hybrid  try new spike add bivalent alongside omicron  Edit  still omicron plasma experiments attempting identify omicron serum escape mutations yet ?', 'Abstract  Vaccines thought best available solution controlling ongoing SARSCoV2 pandemic  However  emergence vaccineresistant strains may come rapidly current vaccine developments alleviate health  economic social consequences pandemic  quantify characterize risk scenario  created SIRderived model initial stochastic dynamics vaccineresistant strain study probability emergence establishment  Using parameters realistically resembling SARSCoV2 transmission  model wavelike pattern pandemic consider impact rate vaccination strength nonpharmaceutical intervention measures probability emergence resistant strain  expected  found fast rate vaccination decreases probability emergence resistant strain  Counterintuitively  when relaxation nonpharmaceutical interventions happened time individuals population already vaccinated probability emergence resistant strain greatly increased  Consequently  show period transmission reduction close end vaccination campaign substantially reduce probability resistant strain establishment  results suggest policymakers individuals consider maintaining nonpharmaceutical interventions transmissionreducing behaviours throughout entire vaccination period   emphasis added', 'Yes  s exactly comparison  would like know risk get covid vaccination  someone study ?', 'HereÄôs one many https  wwwnaturecomarticless4156902100662w Myocarditis never huge issue  Ever  ItÄôs really people understand statistics read headlines', 'EDIT   reflection  think better understanding poster trying convey  m modifying response result  ularge_pp_smol_brain  although initially understand getting worked  think understand  Basically  complaint seems journalism standards article reported paper  necessarily preprint paper  fairly insignificant speculative comment Discussion section original paper placed first paragraph article reporting  thereby amplifying people read article  agree point journalist editor responsible article chosen amplify comment matter  paper s main focus  confused thought commenting original paper  really focuses Omicron infection various populations  apologize assuming nt read paper ', 'actually expect next variant descendant Omicron ? Omicron descendant Delta  Delta descendant Alpha  seems odd dominant variant keeps failing produce successful next major mutation  going priors  good position bet favor Omicron based variants ', 'including incidental findings Covid unrelated visits ? omicron huge proportion patients coming reason Covid ', 'study clearly blinded placebo  real claim vaccine improves GAD7 PHQ9  see purpose paper counter concerns vaccine could worsen GAD MDD symptomatology   Though  believe major vaccine trials collected PHQ9 well addressed properly since blinded  adds picture  article title dumb though', 'would liked see use PMS20 Rockefeller group ', 'Wow  pretty compelling evidence vaccines held well meant  preventing symptomatic covid  even face delta ', 'GBS occur vaccines  meningitis vaccine  well known though extremely rare ', 'studies chronic infections vaccinated immunocompromised people ? case studies seen predate vaccines ', 'mean unvaccinated ? mean  vaccinated less likely  would make results better longer keep watching ', 'ItÄôs probably difficult many variables consider  vaccines  order matters  Hence studies posted usually stick vaccination schedules single variety  even structure immune response changes ordering  basic example mRNA vaccines  immune response natural infection followed full vaccination looks different generated breakthrough case full vaccination  latter case fascinating  immune response expands immune response  itÄôs still mostly dependent antispike antibodies  also breadth antibodies enlarged get stuff like Tcells latter case  immune system seems treat breakthrough infection almost another  powerful  vaccine  Basically  answer question probably comparing COVID naive vaccinees COVID recovered nonvacinees far easier deal empirical scientific study POV ', 'See graph page 12 PDF  compares test positivity rate Omicron & Delta vaccination status  Per  among unvaccinated people Delta higher positivity rate  take look graph image disagree please reply ', 'odds ratio thing tells much intervention better control  Intervention outcomes  Control outcomes 1 null hypothesis  1 intervention better control   1 control better intervention  92 % time people intervention group nt go ICU compared control group  P factor way show something statistically significant  P value tells likely result NULL hypothesis true  null hypothesis difference outcomes  small P value tells null hypothesis probably correct one correlation data  smaller P value nt mean anything s less likely happen null hypothesis true   fairly simplified though ', ' previous studies  note develop  treatment wait hour goes away sure would like see studies ', 'sounds promising  m curious decrease hospitalization  severity stands accounting age individuals study   Omicron patients significantly younger   ', 'https  wwwmedrxivorgcontent1011012021102521265304v1fullpdfhtml https  wwwmedrxivorgcontent1011012021101721265101v2fullpdfhtml https  wwwmedrxivorgcontent1011012021122821268436v1fullpdfhtml  Last omicron  around 65 % protection hospitalization  Boosting brings 85 % ', 'mean immediately  vaccine chance work ? risk would similar without taking vaccine  mean protected risk reduced  antibodies start neutralizing virus make hard replicate  likely closer none  Anyway  myocarditis rare   vaccine well covid  Edit  idea statements would polarizing  Looks like post brigaded ', 'would reduced severity anything transmissibility ?', 'Remember SARSCoV2 migrates body affected organs one time another among various cases covid  s inefficient vaccinate half  inject 1000 hamsters  via normal route  screen ones got migration testes  could  assess effect placebo vs vaccination  potentially individuals assessment provide enough data points defensible conclusion  example  hear positive finding cancer test animals exposed chemical needing assessment  often injected directly organs researcher knows look damage  Kidneys popular purpose  normal ingestion route eating similarly always useful research  particularly true causative agent expresses effect infrequently ', 'See figures brackets ? s 95 % confidence interval  authors conclude yet  nt conclude yet  genuine increase risk Pfizer AZ  Moderna result though clear  Stats really important part analysing sort data ', 'Note convalescents study COVID infection well least two doses vaccine  either 2 doses followed booster 6 months later  single dose followed booster 6 months later   everyone  headline covers  3 exposures  fact infection  vaccination produces higher titers really surprising  even   two doses vaccine   developed either two vaccinations convalescents third vaccination breakthrough infection twicevaccinated  naive individuals  68 convalescents gave written informed consent analyses COVID19 vaccination     naive 2568 convalescent individuals continuously followedup received two doses BNT162b2 mRNAvaccine  ComirnatyÑ  BiontechPfizer  immunization     Due change national guidelines March 2021  remaining 4368 convalescents first wave vaccinated BNT162b2 mid 2021 assuming prior infection substitutes one vaccination', 'Yes  TWIV analysis exactly', 'm immunologist  ca nt say People  research  much want  nt go school learn virology  immunology  whateverology  s like  would walk lawyer s office start telling strats win cases ? surgery room start critiquing surgical technique  m saying blindly listen Fauci whoever  people need stop acting like know exactly re talking  saying  means  s questions like internet strangers nt answering', 'keywords posts get frequently brigaded  Masks myocarditis two ', ' imagine due  least part  current 2022 strains diverged 2019 strain used make vaccines   s probably current strains reproduce fast upper respiratory tract result symptoms immune system chance kick higher gear  incubation period shorter time needed reactivate memory B cells  re relying circulating antibody levels reduce peak viral loads  Peak viral load typically occurs day symptoms appearing day  could 2 days postexposure ', 'gave total number suspected myocarditis cases subgroup  nt see total number subgroup  IE  number total immunized persons per age range sex  sure one extrapolate data elsewhere  including analysis would help comfortable interpretation  ll see much changed get past peer review  anyone else noted authors estimating myocarditis rate around 21000000 vaccinated group  small number  oppose COVID s mortality 2100  complication rate small   calculate state s public data  US   mortality 21000 2040 year old range ', 'Actually  Abbott reported much higher  Independent tests came 65 %  Taking two antigen tests contact surely better PCR done days beforehand  Unless s rapid PCR  s practical ', 'includes PCR testing  large amount testing Omicron done va rapidantigen tests ', 'vaccines help prevent humans potentially ?', 'Ha yeah suck math  IÄôm going ask math sub  Whatever itÄôs 0  ItÄôs basically saying 67 % 67 % higher x  canÄôt wrap mind around calculation  IÄôll report back', 'booster provide greater protection severe illness ? protection infection seems short lived', ' recall seeing speculation 2 doses vaccine  IIRC Pfizer testing ', 'important definition constitutes  interaction health system  C19 positive data  s data hospitals ca nt generalize population level ', 'Studies show reduced transmission vaccinated individual infected delta variant   s example published less 2 weeks ago   https  wwwnejmorgdoifull101056NEJMoa2116597   Risk transmission reduced half index case vaccinated BNT162b2  aka Comirnaty  Pfizer vaccine   lower reduction risk transmission alpha variant still significant  course s caveat risk reduction  like aspects vaccine effectiveness  decreased time ', ' canÄôt find hard data hypothetically explains 95 % myocarditis cases sounds like easy solution  mean thatÄôs totally speculative hypothetical  myocarditis numbers Singapore suggest experiencing ?', 'directly clickbaity title suggests  Also kind Äúwe studied common sense reached obvious outcome  Äù  sure actual relevance virus  ', 'undated Omicron specific vaccine turned offer near zero protection Delta  according early studies  ca nt really make bet right  next major surge variant based Omicron  fine  turns unrelated variant  Omicron vaccines may well fare worse original formula  Given Delta descendant Alpha  Omicron descendant Delta  would say odds great next dominant variant descendant Omicron ', 'unknowns think s quite clear mandates wrong ', 'ÄúAn epidemic uncertainty  rumors  conspiracy theories vaccine hesitancyÄù https  wwwnaturecomarticless4159102201728z Abstract COVID19 ÄòinfodemicÄô continues undermine trust vaccination efforts aiming bring end pandemic  However  challenge vaccine hesitancy problem information ecosystem often little vaccines  Perspective  argue epidemiological social crises brought COVID19 magnified widely held social anxieties trust issues  unique circumstances global pandemic  exacerbated skepticism toward vaccines  argue trust key overcoming vaccine hesitancy  especially context widespread social uncertainty brought pandemic  public sentiment volatile  Finally  draw implications argument strategies build vaccine confidence ', 'noted commenters  myocarditis mild  transient  resolved without intervention  occur infections  vaccinations stress active younger men ? part typical immune response never looking prior current times ? Could mild transient myocarditis one causes fatigue many postinfection andor postvaccination ?', 'reading figure 2 correctly ? seems say occurrence myocarditis higher prior vaccine  green bar  2019 rates  larger blue bar  post vaccination rates  1517 age group ', 'Exactly thought well  patients infected Omikron still less likely become hospitalized compared Delta age group ?', 'promising vaccine already use infrastructure place several countries influenza vaccine  Butanta institute Brazil produce 20 million vaccines monthly  without production expansion   Actually already vaccine stock  40 million recall  Another advantage price  cost  1  2 dollar  Normal storage ', 'Improving indoor air quality developing prophylactic treatments including nasal sprays  enhancement IgA immunity  fir respiratory pathogens  barriers prevent viral adhesion highest priority research currently  account respiratory pathogens  collectively cause high amount illness ranging mild fatal  potentially preventable  least able mitigate risk   cost healthcare systems economies globally billions lost productivity  days workschool  healthcare costs  etc ', 'Summary emerging SARSCoV2 variants concern  VOC  threaten effectiveness current COVID19 vaccines administered intramuscularly designed target spike protein  pressing need develop nextgeneration vaccine strategies broader longlasting protection  Using adenoviral vectors  Ad  human chimpanzee origin  evaluated Advectored trivalent COVID19 vaccines expressing Spike1  Nucleocapsid RdRp antigens murine models  show singledose intranasal immunization  particularly chimpanzee Advectored vaccine  superior intramuscular immunization induction tripartite protective immunity consisting local systemic antibody responses  mucosal tissueresident memory cells mucosal trained innate immunity  show intranasal immunization provides protection ancestral SARSCoV2 two VOC  B117 B1351  Our findings indicate respiratory mucosal delivery Advectored multivalent vaccine represents effective nextgeneration COVID19 vaccine strategy induce allaround mucosal immunity current future VOC  ', 'According article cited  SSNHL also observed vaccination OxfordAstraZeneca  well older vaccines  influenza  tetanus diphtheria  meningococcal polysaccharide  rabies   mechanism known  may immune autoimmunerelated   Sudden sensorineural hearing loss COVID19 vaccination   https  wwwsciencedirectcomsciencearticlepiiS1201971221008158 ', 'CI surrounds 0  s likely statistical noise bringing 0  also seems largely ChAdOx1 dragging data set   vaccine effectiveness BNT162b2 92 %  95 % CI 92 93  p  0001  15Äì30 days  47 %  39 55  p  0001  121Äì180 days  23 %  àí2 41  p007  day 211 onwards  Waning slightly slower mRNA1273  vaccine effectiveness 96 %  94 97  p  0001  15Äì30 days 59 %  18 79  p0012  day 181 onwards  Waning also slightly slower heterologous ChAdOx1 nCoV19 plus mRNA vaccine schedules  vaccine effectiveness 89 %  79 94  p  0001  15Äì30 days 66 %  41 80  p  0001  day 121 onwards  contrast  vaccine effectiveness homologous ChAdOx1 nCoV19 68 %  52 79  p  0001  15Äì30 days  detectable effectiveness day 121 onwards  àí19 %  95 % CI Äì98 28   p049  ', 'means elderly really need drop hesitancy get vaccine  big problem vaccine hesitancy among elderly  esp  80 age range   chart proportion vaccinated vs age opposite countries ', 'UK papers continue study 2x AZ w BNT M1273 boosters ', 'Absence evidence  evidence absence ', 'actually know viral load show infectious ? s RNA fragments  would necessarily correlate infectivity  Every study seen tried culture viral load reported significantly lower vaccinated  though range vary study study ', 'Seeing vaccines  J & J excepted  originally designed given prime  boost regimen  people vaccinated exposed spike protein twice  3x boosted   would expected stronger persistent response second exposure  single infection vaccine encountered sarscov2 antigens  Giving people vaccine would act bit like heterologous boost priming infection  would interesting see people infected twice better immunity caught  probably enough cases able appropriate comparative studies  TWiV Clinical Update recently  Dr Daniel Griffin commented patients infected four times  ', 'thought  could covid pass force  vaccinated would social occasions get infected ?', 'Exactly point going make  Luckily improved diet also help vaccine efficacy improve weight  cholesterol high blood pressure vaccination https  wwwncbinlmnihgovpmcarticlesPMC8487656', 'really  state three exposures like flu lineages time 10 years old  yearly sequence matched flu boost turbocharges little ', 'Yes  according study twice likely get vaccine first  second dose biontech  31215 per million  compared covid  7 per million   only cared myocarditis risk would make sense get vaccinated young male ', 'One statutory requirements granting EUA   adequate  approved  available alternative product diagnosing  preventing  treating disease condition  https  wwwlawcornelleduuscodetext21360bbb3 two FDAapproved vaccines COVID available adults  bar new EUA s getting higher spaces Pfizer & Moderna adequate & approved small shrinking ', ' CONCLUSIONS messenger RNA  mRNA  boosterswerehighly effective symptomaticdelta infection  but wereless effective againstsymptomatic omicron infection Ä Discussion BNT162b2 booster vaccinationwas associated an861 % reductionin incidenceofsymptomaticdeltavariant infectionand a494 % reductionin incidenceofsymptomaticomicron infection  themRNA1273booster  reduction incidence symptomatic infectionwiththeomicron variantwas similarat 473 %   ', 'nt feel right  Even Omicron replicates  vaccine targeted Omicron work effectively one basically nt target  replicates quickly overwhelms vaccine initially  would nt expect virus deadly since viral load higher ? Omicron  even unvaccinated people  significantly less deadly  however still deadly many ', 'Would nt imply locking vaccinated  least closing bars etc  would huge impact new case rate ?', 'Infection naØve population ? would said south south island New Zealand  omicron couple days weeks s already country  Also hard find vaccine naØve uninfected ', ' health authorities almost  experts  wanted touch study 10 foot pole  Eh ? 27 studies cited five months since published  highprofile journals  NEJM  Lancet  JAMA  etc   s compelling example avoidance  https  wwwnejmorgdoifull101056NEJMoa2114114  article_citing_articles', 'Ah perfect thank ', 'Longer USA recommended time ? longer schedules recommending 23 months first second doses ?', 'vaccines development target stable part virus rather spike protein ?', 'Thankyou broadening vs narrowing analogy  would nt say feared way  much curious interactions aging vaccine relatively mutated variant  imagine gets complicated OAS would nt really exist always case though ? assumed boosters effective brute forced sterilization sheer magnitude numbers even stronger immune response  antibodies generated individual level remained less effective ', 'quick correction  lower bound 95 % CI mRNA1273 Omicron 699  positive 699  wondering estimate could outside CI range  looks like typo ', 's defined s even study  s peer reviewed  even published journal  s published blog  Nothing confirmed even evaluated  Total garbage ', 'downvoted ? ? ve wondering thing', 'press release text  sans footer   US Food Drug Administration notified Pfizer new data recently emerged regarding emergency use authorization request use PfizerBioNTech COVID19 Vaccine children 6 months 4 years age  part rolling submission  company recently notified agency additional findings ongoing clinical trial  Based agencyÄôs preliminary assessment  allow time evaluate additional data  believe additional information regarding ongoing evaluation third dose considered part decisionmaking potential authorization    Therefore  FDA postponing Vaccines Related Biological Products Advisory Committee meeting originally scheduled Feb 15  give agency time consider additional data  allowing transparent public discussion part usual scientific regulatory processes COVID19 vaccines  provide update timing advisory committee meeting receive additional data third dose age group companyÄôs ongoing clinical trial opportunity complete updated evaluation    Since early days pandemic  always followed science everchanging situation  Given recent omicron surge notable increase hospitalizations youngest children highest levels pandemic far  felt responsibility public health agency act urgency consider available options  including requesting company provide us initial data two doses ongoing study  goal understand two doses would provide sufficient protection move forward authorizing use vaccine age group  approach always conduct regulatory review thatÄôs responsive urgent public health needs created pandemic  adhering rigorous standards safety effectiveness  able begin evaluating initial data useful review vaccines  time  believe additional information regarding ongoing evaluation third dose considered    agency ensure data support effectiveness safety authorizing COVID19 vaccine use youngest children  meantime  best way protect children  including school daycare  practice social distancing masking accordance public health recommendations  family members caregivers get vaccinated receive booster dose eligible ', ' https  wwwmedrxivorgcontent1011012022020222270302v1  Detectable Omicronneutralizing activity nearly absent two vaccinations elicited 89 % individuals booster immunization  Neutralizing titers Wu01  Delta  Omicron variants showed similar postboost declines 81 % individuals maintained detectable activity Omicron  Levels fall  sheer ability neutralize distant VoC retained probably recalled ', ' getting huge boost antibodies would amplify also ones still work s paper reporting  nt contradict said  do believe amplifying antibody levels means whatever antibodies already still neutralize omicron would present greater numbers  paper  among others  reporting greater breadth antibody coverage   antibodies variants  nt exist yet  means greater chance antibodies work better particular variant different original  See comment post  https  wwwredditcomrCOVID19commentss635r8mrnabased_covid19_vaccine_boosters_induceht1t2f7 ? context1', ' Previous papers similar positive spin narrative  general tenor tension findings independent studies  post independent studies ? interested J & J efficacy severe disease  without booster  long COVID', 'honest  think vastly overestimating much thought people give topic  people show  rest population adopts group consensus tribe runs ', 'Memory B cells cells rescue ', 'current increases Europe China  nt think rule spike starting April May ', 'appears improvement fomite transmission side things per Japanese study  https  wwwbiorxivorgcontent10110120220118476607v1   https  wwwbiorxivorgcontent10110120220118476607v1  aspect watching since beginning  thing evolves substantively improve form transmission  bets  CDC backgrounder formite transmission  https  wwwcdcgovcoronavirus2019ncovmorescienceandresearchsurfacetransmissionhtml   https  wwwcdcgovcoronavirus2019ncovmorescienceandresearchsurfacetransmissionhtml  m thinking though something else play survival times various surfaces ', 'simply lot antibodies general ?', 'WouldnÄôt control number viral infections group control ? basically comparing group viral infections group less  Also comparable groups would vaxCovid positive vaxCovid positive vaccine vaccine  really isolating either Covid infection vax status relationship GBS design ', 'well  make blanket approach CDC took recommending either mRNA vaccine J & J ages groups  28 year old male probably less 1 1 million chance developing blood clot  even lower chance dying  Even though myocarditis cases typically resolve  still shows Moderna likely high higher risk J & J demographic  Note  nt think Moderna restricted group  point show blanket approach CDC took nt make sense  Especially since  context Omicron  main advantage mRNA vaccines  efficacy infection  nt seem much factor anymore  Protection severe disease equalizer  J & J always held well comparatively ', 'like  really frustrating piece information going around getting spun certain way  says  monkeys  omicronspecific doses offered additional protection OG mRNA vaccines in immunenaive test subjects  getting reported said   omicron dose nt offer additional protection   already knew experimental realworld data 1 2 shots OG mRNA nt offer highest level protection omicron  well 3rd dose OG upped protection level efficacy OG covid  important data overall vaccine production implementation  big part purpose developing omicronspecific dose assessing whether omicron booster 3rd  4th  whatever  shot offers additional protection omicron beyond 3rd  etc  dose OG formula people already vaccinated  article does contain information  yet portrayed though though s clear evidence development omicronspecific booster wo nt successful ', 'cells store memory invading pathogen immune systems response  nt activate cells ai nt trickin shyt ', ' think anybody idea hospitalized covid patient less chance developing myocarditis somebody getting vaccinated  m sure lol', 'Wow didnÄôt realize far along  seems pretty promising  Would love see direct comparison NovaVax  seems like might push novavax right way really ', 'Given sample size spread  authors really reaching draw conclusion different response breakthrough infections 2 3 vaccine doses  personally would call indistinguishable warranting study ', '511 already', 'infection  relevant end points like long covid  hospitalization death  2 shots still show protection ', '? Norwegen case one infecting 80 party ', 'agree  however d like perspective following  problem right Canada COVID prevalent  hospitals dedicate lot resources isolating infected hospitalized people whose issues nothing COVID  even clear provincial governments know many people hospitalized COVID opposed COVID  data never made public  least Quebec Ontario  long COVID treated like dangerous disease  healthcare get overwhelmed every winter  Omicron extremely dominant  recent data Delta prevalence however  vast majority population vaccinated  significant percentage immunity infections  unclear dangerous disease nt seem  hospitals started treating COVID normally  hospitals would nt overwhelmed  think  take lot time hospital protocols change  large segments public still highly scared catching COVID  governments would make decision  hope changes next autumn ', 'get covid test positive covid ? Oh s hospitalized covid ? tiny fraction percent age range get covid ?', 'Abstract ____ Objective   assess shortterm change depressive anxiety symptoms relation COVID19 vaccination among Swedish adults  Design   prospective cohort study monthly data collections selfreported depressive anxiety symptoms December 2020 October 2021 COVID19 vaccination July October 2021  Setting   Omtanke2020 Study  Sweden  Participants   7925 participants Omtanke2020 study complete data depressive anxiety symptoms vaccination status  Intervention   Exposure     Receiving first second dose COVID19 vaccine  Main outcomes   Measure     Binary measures depression  PHQ9  cutoff â 10  anxiety  GAD7  cutoff â 10  one month first dose  one month first dose   applicable  one month second dose  individuals vaccinated chose report vaccination status  unvaccinated individuals   selected three monthly measures PHQ9 GAD7 2month intervals inbetween based data availability  Results  5079  641 %  individuals received two doses COVID19 vaccine  1977  249 %  received one dose  305  39 %  vaccinated  564  71 %  chose report vaccination status  lower prevalence depression anxiety among vaccinated  compared unvaccinated  individuals  especially second dose  Among individuals receiving two doses vaccine  prevalence depression anxiety lower first  aRR082  95 % CI 076088 depression  aRR081  95 % CI 073089 anxiety  second  aRR079  95 % CI 073085 depression  aRR073  95 % CI 066081 anxiety  dose  compared vaccination  Similar results observed among individuals receiving one dose  aRR076  95 % CI 068084 depression  aRR082  95 % CI 072094 anxiety  comparing first dose vaccination   results independent age  sex  recruitment type  body mass index  smoking  relationship status  history psychiatric disorder  number comorbidities  COVID19 infection status  seasonality  Conclusions   observed positive shortterm change depressive anxiety symptoms among adults receiving COVID19 vaccine current pandemic ', 'takes longer get lungs', ' disappointingly low ? risk already relatively small marginally improved unvaccinated makes question s even worth billions spent lockdowns forced', ' lockdown measures resulted practically benefit  fact  arguably detrimental overall   research subreddit  Would mind citing ? quick search finds sources entirely contrary  https  journalsplosorgplosonearticle ? id101371journalpone0236619 https  wwwsciencedirectcomsciencearticlepiiS0048969720339528', 'could mention results vaccine effectiveness much negative 91150 days vaccination moderna pfizer  765 Pfizer 91150 days  extreme result ', 'IÄôm aware two studies Omicron  sub threads    redditcomrCOVID19coronavirus_disease_2019_covid19_vaccine_boosting   https  wwwredditcomrCOVID19commentssslf1a   redditcomrCOVID19protection_against_the_omicron_variant_from   https  wwwredditcomrCOVID19commentssophs7   redditcomrCOVID19protection_afforded_by_prior_infection_against   https  wwwredditcomrCOVID19commentsrxni1d   studydataset second believe ', 'people seriously uneducated fools ca nt sway', 'Would love know info  5yo getting second shot later today ', 'Anyone happen link study information protective ?', ' Could lead body becoming likely produce universal  Äúcommon denominatorÄù antibodies ? exposure naive people  maybe  given numbers either infected vaccinated seems like already locked imprinted response form first exposure ', ' 1  especially interesting  vaccines offer lifetime sterilizing immunity others donÄôt ? even without vaccines  get measles coronaviruses return periodically  simply coronaviruses replicate fast get foothold cellular immunity respond ? IÄôll use measles example  slow one ? replicate sinuses enter system first ?', ' 6 weeks illness onset  lower prevalence among vaccinated participants  606 %  compared unvaccinated participants  606 % vs 791 %  aRR 070  95 % CI 0580  Also remember s conditional infection breakthrough health care workers severe slice breakthrough infections asymptomatic  mildly symptomatic  individuals probably nt included study ', 'Oof   1 especially   2  serious question  nt small sample size ? 41 samples 33 convalesced patients  28 samples vaccinated ', ' WouldnÄôt control number viral infections group control ? ? study looking relative rates GBS vaccinated vs infected unvaccinated  relative rates infection ', 'Yeah gets rolled itÄôs either going leave people vulnerable worst time  going holidaywinter season  necessitate fifth dose  think weÄôre really going start seeing big amount diminishing returns terms participation round shots need careful ', 'think anybody idea hospitalized covid patient less chance developing myocarditis somebody getting vaccinated  would interesting check risks involved vaccination person already immunized  3rd dose present better protection chance getting myocarditis ? vaccines improve defense prior infection kind risks posed vaccines ?', 'X 100 would extremely common  Let s hope s significantly better ', ' study showed impact vaccination community transmission circulating variants SARSCoV2 appeared significantly different impact among unvaccinated people  m rather surprised interpretation  quoted paper   https  wwwthelancetcomjournalslaninfarticlePIIS14733099  21  006484fulltext   text paper   Vaccination reduces risk delta variant infection accelerates viral clearance  Nonetheless  fully vaccinated individuals breakthrough infections peak viral load similar unvaccinated cases efficiently transmit infection household settings  including fully vaccinated contacts  HostÄìvirus interactions early infection may shape entire viral trajectory  quite clearly say asserting  Even examine perspective break infection earlier viral clearance would expect reduce overall transmission ', 'moderna  nt Pfizer ? Thanks', 'make phase 1 2  trial soon phase 3 eua ? omnicrap long term effects would really like get rid ', 'wonder s mechanism long haul symptoms induced vaccination individuals case  long haulers recover get symptoms back worsened post vaccination  needs research underlying cause long term effects ', 'links similar comparative studies  ways harm  us ?', 'Really would loved seen questions knowing someone died COVID  impacted vaccine hesitancy ', 'IÄôm going memory  forgive IÄôm wrong didnÄôt Pfizer 85 % 10 months post vaccination ?', 'mean vaccine effectiveness drop below 0 % ? ?', ' also know  though less confidence  time  memory B cells become dormant  challenge immune system similar antigen happens  leads recruiting naive B cells process  Would exposure virus also challenge immune system ? instance  someone infectionacquired andor boosted immunity exposed antigen  would considered challenge ?', 'saying ? Maybe misinterpreting nt know abstract support selection pressure vaccines directly creating environment Omicron  omicron escape vaccineinduced immunity right ?', 'also need Paxlovid patent free mass produced ', 'would look previous infection since Ab levels usually drop months ?', 'think need thinking terms long immunity lasts  itÄôs strong month two thatÄôs going us lot good ', 'Although encouraging think wait data independent researchers  assay sanofi used could biased ', 'says  exercise increase side effects covid19 vaccination  side effects referring ? general soreness getting vaccine something else ?', 'Vaccination protected testicular damage SARSCoV2 challenge  Hamsters immunized two doses intramuscular inactivated whole virion vaccine 14 days apart  14  intranasally challenged 103 PFU SARSCoV2 HK13 14 days second vaccination  Testes examined 4 28dpi  Figure 10A   Serum neutralizing antibodies detected vaccinated animals challenge 4dpi 28dpi  GMT 1604382 1202309  respectively  Testicles showed histopathological changes nine vaccinated hamsters  Figure 10B   One group hamsters  n7  challenged 103 PFU 3 days first vaccination showed testicular histopathological damage 4dpi  Figure 10B   indicating vaccination effectively protects testes SARSCoV2  mild cases may spared   detectable histopathological changes observed 4dpi challenge 10PFU 102 PFU  Figure S1   Edit  added ', 'Bharat Biotech currently working stage III trials nasal COVID19 vaccine used booster shot ', 'doesnÄôt matter randomize correctly  effect previous infections similar cohorts ', 'previous study  Smith et al  Genome Medicine  2021  13101 Landscape selection vaccine epitopes SARSCoV2  https  doiorg101186s13073021009101   https  doiorg101186s13073021009101  Abstract Background  Early pandemic  designed SARSCoV2 peptide vaccine containing epitope regions optimized concurrent B cell  CD4  cell  CD8  cell stimulation  rationale design drive humoral cellular immunity high specificity avoiding undesired effects antibodydependent enhancement  ADE   Methods  explored set computationally predicted SARSCoV2 HLAI HLAII ligands  examining protein source  concurrent humanmurine coverage  population coverage  Beyond MHC affinity  cell vaccine candidates refined predicted immunogenicity  sequence conservation  source protein abundance  coverage high frequency HLA alleles  B cell epitope regions chosen linear epitope mapping studies convalescent patient serum  followed filtering surface accessibility  sequence conservation  spatial localization near functional domains spike glycoprotein  avoidance glycosylation sites    major histocompatibility complex  human leucocyte antigen ', 'betacoronaviruses less likely diverge subtypes influenza ?', 'IÄôm sure understand trying say simpler language  sounds like boosters blunted immune response high immune function ? certain ', 'https  coronavirushealthnygovcovid19breakthroughdata scientific compared Houston study graphs showing consider vaccine efficacy infections hospitalization mobile friendly  data 2 week lag fully omicron cases yet', '3rd shot  booster  produced robust immune response 2nd terms neutralizing antibodies also ability neutralize Omicron  much mutated Variants Concern   fourth shot  however  seemed restore antibody levels 3rd shot  greater  also found fourth shot seemed shift focus immune system parts virus spike  helpful  conclusion repeated boosting keep immunity long term option  looked group healthcare workers received shots inactivated CoV2 vaccines  mRNA type  PfizerModerna   Unlike inactivated kind  mRNA vaccines produces spike  s unclear point immune response shift away spike seems study w inactivated vaccines  include parts virus  ', ' unlikely happen  Furthermore  immersed brain cells vaccine 96hrs  Odd  happens immerse brain cells tap water 96hrs ? anything started spike protein brain cells  compare time  read last night baffled  ', 'going find 205 people vaccinate already willing participate clinical trial ?', 'nt Omicron started running course ? need prepared future variants omicron wave seems mostly USA ', 'Hospitalizations falling South Africa  Hopefully thing happens US', 'stop showing incidence rate 2 doses ?', 'Oslo study  none subjects boosters  double vaccinated 54 66 infected  81 %   Faroe  study  boostered  21 33 infected  64 %   Oslo average age 35  Faroe  45 ', 'still think need look spacing 1st 2nd doses apart much currently  2nd shot  especially recommended schedule  may actually great deal compared booster shot months later ', 'say third dose mean booster dose regular dose ?', 'inclusion criteria  COVID19 diagnosis   people test positive Covid  think word  patient  confusing lot people  paper said nothing hospitalizations ', 'also talk preexisting hypertrophy one boys nt specifically rule HO Cm despite running testing genetic markers arrhythmias  Moreover pair potentially questionable case reports  dont see smoking gun ', 'Also relevant myocarditis negative health outcome COVID19  s pretty easy call compare  low risk myocarditis   low risk myocarditis   comparing outcomes important well ', 'ca nt know things like  actual people actual time study  two things ca nt hurry study  Studies nearly way really know know  even  need reviewed scientific peers study organizers  things take time know ', 'Thanks nt understood beginning', 'Yeah  actually saw happen Ontario last month  populationadjusted infection rates fully vaccinated individuals actually surpassed rates unvaccinated  compelling theory heard case vaccinated individuals could attend highcongregate settings like movie theatres  bars sports games  Omicron  ripped settings meant even controlling population  still vaxxed getting infected ', 'Hong Kong highest CFR world  IÄôm sure means vaccine ', 'way could see happening feel confident willing risk exposure feeling confidence  live places fewer restrictions higher vax rates fewer restrictions  increasing possible exposures ?', 'someone help understand whatÄôs going  clearly seeing vaccine effectiveness decreasing timeÄ itÄôs almost every study IÄôve read   2 doses Pfizer Moderna effectiveness dropped around 65 70 % around 10 % 25 weeks second dose  2 doses  omicron low 10 % Pfizer Moderna  0 % percent AstraZenecaÄ  current boosters arenÄôt even omicron specific  theyÄôre exact formula original vaccine developed wild COVIDÄ  expecting booster diminish wellÄ ? point 2doses basically irrelevant  even delta 20 weeks less 50 % effective begs question  original Pfizer 10 month trials still high ? ?', 'matched based age location  comorbidities   individual matched  11  Statistics Sweden  national agency statistics  one randomly sampled individual total population Sweden birth year  sex  municipality  attempted adjust comorbidities using Cox proportional hazards model analysis ', 'one ? AZ close useless Omicron protection even hospitalisation severe symptoms drops cliff quickly  also expressly recommended many places people 30  J & J pulled  s basically Novovax nt know one ', 'extend definition Äúfocusing protecting hospitalization even immunocompromised Long CovidÄù wonÄôt care infections either would board ', 'N2  Major finding ? CÄômon ', 'exactly comparing ? m mistaken vaccine myocarditis risk hospitalised covid19 patient myocarditis risk ?', 'Discussion actual report  &  x200B  growth rates estimated Omicron translate doubling times 25 days  even allowing potentially slowing growth 11 th December  estimates consistent even faster doubling times reported South Africa  13   Assuming exponentially distributed generation time 52 days R1 currently Delta  reproduction number  R  estimates Omicron 3 SGTF genotype analyses  25 even period 8th 10th December  Shorter assumed generation times give lower R estimates  distribution Omicron age  region ethnicity currently differs markedly Delta  indicating Omicron transmission yet uniformly distributed across population  However  note given immune evasion  age distribution Omicron infection coming weeks may continue differ Delta  London substantially ahead English regions Omicron frequency  find strong evidence immune evasion  natural infection  risk reinfection 541  95 % CI  487600  fold higher Omicron Delta  vaccineinduced protection  estimates largely agree UKHSAÄôs TNCC study  11  predictions predicting neutralising antibody titres  414   suggesting limited remaining protection symptomatic infection afforded two doses AZ  low protection afforded two doses Pfizer  moderate high  5580 %  protection people boosted mRNA vaccine  estimate hazard ratio reinfection relative Delta also supports previous analysis reinfection risk South Africa  15   Prior Omicron  SIREN cohort study UK healthcare workers estimated SARSCoV2 infection gave 85 % protection reinfection 6 months  16   relative risk infection 015 compared prior infection  hazard ratio estimate would suggest relative risk reinfection risen 081   95 % CI  073100   ie  remaining protection 19 %   95 % CI  027 %    Omicron  find evidence  risk hospitalisation attendance symptom status  Omicron different severity Delta  though data hospitalisations still limited  several limitations analysis  case numbers increasing quickly  still limits ability examine interactions variables considered  distribution Omicron differed markedly Delta across English population time analysis conducted  likely due population groups initially seeded  increases risks confounding analyses  SGTF imperfect proxy Omicron  though SGTF 60 % specificity Omicron date range analysed SGTF analysis  close 100 % 10th December   Intensified contact tracing around known Omicron cases may increased case ascertainment time  potentially introducing additional biases  analysis reinforces still emerging increasingly clear picture Omicron poses immediate substantial threat public health England widely ', 'may simply confounding factor study design  One remember groups random blinded  example  pure speculation  could personnel working close contact covid patients likely want second booster shot may overrepresented  2 booster shots group  time might markedly increased risk catching omicron  scenario second booster shot could theoretically even raise immunity due study design  confounders look would make likely get infected  Another similar imaginable confounders could persons children may willing get extra booster thinking want protect families  time children could make likely catch omicron children  m saying true s likely hypothesis second booster lowers immunity  important remember correlations seen unblinded nonrandom studies often causations ', 'Unfortunately theyÄôre probably going crossed long time  think general consensus well year talking December  perhaps significantly longer  thatÄôs assuming work well hoped  Unless someone comes along Äúwarp speedsÄù  weÄôve seen indication occurring juncture ', 'type basic statistical analysis missing many published studies  worries peer review nt catching foundational aspects probability ', 'results really strange  adeno vaccines really higher neutralization titres vs mRNA vaccines studies  find hard believe single JJ dose lead higher neutralization titres vs Pfizer vaccine 56 year olds  said  Sanofi little bit careful 2020 maybe one major vaccines 2021 would  pitty ', 'Seems like title little misleading  Mixed cocktail seems work great  specific omicron delta RBD vaccine protocols nt work much  Also preprint  think given title abstract misleading going ', 'Without even looking study pretty sure sampling vaccinated cohorts going within 2 months second dose boost  antibodies start wane  almost always case studies favor vaccination compared natural immunity  point looking mixture 2 months  3 months  6 months  12 months second dose boosters accurately represent population  tells us nothing new really  s different two months following someone recovering Covid ', 'Omicron Delta  numbers concerning last two dominant strains wonder  Wait next study guess ', ' Controlling vaccine status  age  sex  ethnicity  asymptomatic status  region specimen date  Omicron associated 540  95 % CI  438663  fold higher risk reinfection compared Delta  put context  preOmicron era  UK ÄúSIRENÄù study COVID infection healthcare workers estimated prior infection afforded 85 % protection second COVID infection 6 months  reinfection risk estimated current study suggests protection fallen 19 %  95 % CI  027 %  Omicron infection   study finds evidence Omicron lower severity Delta  judged either proportion people testing positive report symptoms  proportion cases seeking hospital care infection   researchers found significantly increased risk developing symptomatic Omicron case compared Delta two weeks past second vaccine dose  two weeks past booster dose  AstraZeneca Pfizer vaccines    Depending estimates used vaccine effectiveness symptomatic infection Delta variant  translates vaccine effectiveness estimates symptomatic Omicron infection 0 % 20 % two doses  55 % 80 % booster dose ', '0327 relative risk versus 0337 relative risk 0970 relative risk 3 % efficacy  Math nt magic trick  learn stuff ', 'Abstract SARSCoV2 Omicron variant concern comprises three sublineages designated BA1  BA2  BA3  BA2 steadily replacing globally dominant BA1  show large number BA1 BA2 spike mutations severely dampen plasma neutralizing activity elicited infection seven clinical vaccines  crossneutralization BA2 consistently potent BA1  independent vaccine platform number doses  Although mRNA vaccines induced greatest magnitude Omicron BA1 BA2 plasma neutralizing activity  administration booster based WuhanHu1 spike sequence markedly increased neutralizing antibody titers breadth BA1 BA2 across vaccines evaluated  data suggest although BA1 BA2 evade polyclonal neutralizing antibody responses  current vaccine boosting regimens may provide sufficient protection Omicroninduced disease ', ' study vaccinated BALBc mice peptides derived SARSCoV2 proteome designed either elicit Tcell responses Bcell responses linear epitopes   m bit confused part  design antigen either elicit B cells response ? Would nt immune system automatically generate ?', 'worst part whole Äúmyocarditis vaccineÄù analysis even worst myocarditis post vaccination pretty small  study notes worst possible statistic around developing myocarditis vaccine 86 100000 00086 % developing Keep mind  previous studies  note develop  treatment wait hour goes away  Keep mind  worst outcome vaccine ÄúmyocarditisÄù folks  never huge issue continuation know  Covid worse normal operations body  side effects minimal  frankly  society didnÄôt make pst high school statistics', 'agree statement  sample size rather small  Hospitalization rates nt high COVID19 seem indications omicron strain less likely lead hospitalization ', 'Vaccine boosters must timed expected coronavirus season  idea maximum amount people maximum amount antibodies blood stream time peak COVID 19 season ', 'tried make vaccine focusing variants  nt make much difference according study  s subreddit ', 's widely reported immunity conferred omicron infection backwards compatible  apt term could come   nt know robust findings  also nt heard opposing viewpoints  may well moot Omicron displaced Delta anyway ', 'data original vaccination ?', 'Looks like itÄôs animal models far ? like concept sounds promising ', ' seen much protection severe disease drops single doseJJ vaccine ? recall seeing studies fall showed people vaccinated early spring 2021 still strong protection hospitalization Delta  although recall exact title papers moment  Recently  shown one dose J & J offered basically zero protection symptomatic Omicron donÄôt recall seeing numbers hospitalization', 'burn nonimmune people first becoming endemic    take longer since previous infection andor vaccination completely protective circulating variants  one knows many variants emerge  either ', 'nt Omicron specific vaccines fairing fairly equally original vaccines far ?', 'wish broken risk myocarditis COVID19 infected individuals age groups figure 2 ', 'going say  fact delta positivity reduced 4550 % two doses seemed surprising  since remember seeing figures  boosters widely available  7075 % effectiveness delta  makes sense particular study biased towards people symptomsaccess testing', 've seen timelag effects hospitalization & death statistics many different cases wo nt comfortable characterization SA s data weeks testing peak  testing even scales ', 'find quote paper ', 'addition usual efficacy data  report contains 17 pages vaccination pregnancy  s good charts tables birthweight stillbirths ', 'data studies progress booster otherwise mixed vax flavors ? looked really promising  attractive many people  year ago  s shame s taken long ', 'Protection infection dropping zero around point  undetected infection unvaccinated group setting true  graphed  apparent  baseline slightly zero  likely  seen estimates centers around specific waves timing studies like  design looking SARS2 infection outcomes  control healthcare seeking behavior  test negative design  would nt see ', ' conclusion repeated boosting keep immunity long term option  going research boosting different variant vaccine whether ll restore  usefulness  ? understand boosting 4 shots exact thing probably useful ', 'know partial2dose vaccination  particularly separated month CDC insisted recently  prevent Omicron infection  smaller dose would also strong impact hitting specific extremely high cutoff needed originaltargeted antibodies reasonably prevent Omicron infection  short  news  Antigenpresenting cells still teach B cells fight Covid  begin affinity maturation scale Omicron futurevariant specific protection   guess  boost dose given  primeboost vaccination prime boost often small nt trigger enough response prevent infection boost dose given  across many  many diseases  One might question usefulness second dose  since theoretically contribute much affinity maturation ', 's important note  however  booster thing original vaccine composition dosage  s second dosage  identical first  true Pfizer booster well  Moderna composition  half dosage', 'article assumes public reaction vaccination played individual interactions facebook  incoming information real world  think year covid comparable flu  perhaps vaccination year vulnerable groups  restrictions  people notice vast bulk vaccinated mild side effects  beaten thing  vaccination accepted  less  year still lockdowns vaccinations every four months required government edict hard sell lots stories people say forced accept vaccination harmed  think question far real news filters slowly facebook far facebook opinions driven dynamics short term individual interactions important understand damaging facebook  nt think question answered well model impact interactions ', 'Also extremely interested whether would probably repeated mRNA boosting well  deliver spike whole inactivated virus  Obviously  4th  5th  6th mRNA boostings arenÄôt going bring antibodies beyond 3rd dose got  would active harm immunity ?', 'Shorter length hospitalization hospitalization ?']\n",
            "[{'seems': 1, 'likely': 1, 's': 1, 'surely': 1, 'vaccine': 1, 'passes': 1, 'action': 1, 'assume': 1, 'purpose': 1, 'prevent': 1, 'health': 1, 'services': 1, 'becoming': 1, 'overwhelmed': 1, 'unvaccinated': 1, 'patients': 1}, {'assume': 1, 'virus': 1, 'severity': 1, 'effects': 1, '?': 1}, {'1': 1, 'assume': 1, 'someone': 1, 'exposed': 1, 'spike': 1, 'proteins': 1, 'vaccine': 1, 'opposed': 1, 'actual': 1, 'viral': 1, 'infection': 1, '?': 1, '2': 1, 'inflammation': 1, 'leads': 1, 'myocarditis': 1, 'result': 1, 'body': 1, 's': 1, 'immune': 1, 'response': 1, 'antigen': 1, 'almost': 1, 'certain': 1, 'likely': 1, 'see': 1, 'harsher': 1, 'virus': 1}, {'1': 1, 'evolution': 1, 'nt': 1, 'intentional': 1, '2': 1, 'omicron': 1, 'evolve': 1, 'delta': 1, 'unclear': 1, 'less': 1, 'severe': 1, 'per': 1, 'infection': 1, 'evolved': 1, '3': 1, 'seen': 1, 'variants': 1, 'probably': 1, 'form': 1, 'ie': 1, '4': 1, 'selection': 1, 'pressure': 1, 'fairly': 1, 'complicated': 1, 'select': 1, 'severity': 1, 'example': 1, 'evolving': 1, 'higher': 1, 'replication': 1, 'viral': 1, 'load': 1, 'makes': 1, 'spread': 1, 'cause': 1, 'cases': 1, '?': 1}, {'sensitivity': 1, 'analysis': 1, 'using': 1, 'cutoff': 1, '4': 1, 'months': 1, 'also': 1, 'found': 1, 'vaccinated': 1, 'within': 1, 'prior': 1, 'enrollment': 1, 'n39': 1, 'lower': 1, 'viral': 1, 'load': 1, 'unvaccinated': 1, 'but': 1, 'â4': 1, 'n58': 1, 'supplemental': 1, 'figure': 1, '2': 1}, {'also': 1, 'press': 1, 'release': 1, 'antibody': 1, 'tcell': 1, 'responses': 1, 'heterologous': 1, 'boosting': 1, 'regimen': 1, 'greater': 1, 'homologous': 1, 'omicron': 1, 'variant': 1, 'analysis': 1, '65': 1, 'individuals': 1, 'received': 1, 'primary': 1, 'vaccination': 1, 'two': 1, 'doses': 1, 'mrna': 1, 'covid19': 1, 'vaccine': 1, 'bnt162b2': 1, 'followed': 1, 'booster': 1, 'shot': 1, 'n24': 1, 'johnson': 1, '&': 1, 'n41': 1, 'least': 1, 'six': 1, 'months': 1, 'found': 1, 'regimens': 1, 'increased': 1, 'humoral': 1, 'cellular': 1, 'boosted': 1, 'increasing': 1, 'neutralizing': 1, 'titers': 1, '41fold': 1, 'four': 1, 'weeks': 1, 'postboost': 1, 'increase': 1, 'higher': 1, 'level': 1, 'week': 1, 'declining': 1, 'represent': 1, '17fold': 1, 'progressive': 1, 'antibodies': 1, 'following': 1, 'similar': 1, 'seen': 1, 'first': 1, 'rapid': 1, 'immune': 1, 'response': 1, 'waning': 1, 'twodose': 1, 'priming': 1, 'the': 1, 'median': 1, 'omicronreactive': 1, 'cd8': 1, 'tcells': 1, '55fold': 1, 'cd4': 1, '31fold': 1, '14fold': 1, 'believe': 1, 'early': 1, 'update': 1, 'earlier': 1, 'preprint': 1, 'https': 1, 'wwwmedrxivorgcontent1011012021120221267198v1': 1, 'kind': 1, 'interesting': 1, 'j': 1, 'much': 1, 'better': 1, 'nab': 1, 'might': 1, 'expect': 1, 'cell': 1, 'vs': 1, 'pfizer': 1, 'quite': 1, 'marked': 1, 'see': 1, 'nih': 1, 'lancet': 1, 'study': 1, 'get': 1, 'updated': 1, 'compares': 1}, {'unvaccinated': 1, 'less': 1, 'likely': 1, 'tested': 1, '?': 1}, {'iäôm': 1, 'sure': 1, 'buying': 1, 'still': 1, 'even': 1, 'earlier': 1, 'human': 1, 'series': 1, 'voc': 1, 'specific': 1, 'boosters': 1, 'worse': 1, 'response': 1, 'wild': 1, 'type': 1, 'increased': 1, 'variantspecific': 1, 'responses': 1, 'indicating': 1, 'werenäôt': 1, 'dumping': 1, 'massive': 1, 'amounts': 1, 'imprinted': 1, 'antibodies': 1, 'rather': 1, 'developing': 1, 'separate': 1, 'iäôll': 1, 'hold': 1, 'pfizer': 1, 'numbers': 1, 'come': 1, 'showing': 1, 'naive': 1, 'protocol': 1}, {'point': 1, 'imo': 1, 'way': 1, 'compare': 1, 'severity': 1, 'look': 1, 'death': 1, 'rate': 1, 'unvaccinated': 1, 'people': 1, 'confirmed': 1, 'omicron': 1, 'try': 1, 'account': 1, 'approximate': 1, 'rates': 1, 'prior': 1, 'infection': 1, 'everything': 1, 'else': 1, 'many': 1, 'variables': 1, 'reliably': 1, 'control': 1}, {'nb': 1, 'data': 1, '3rd': 1, 'dose': 1, 'even': 1, 'less': 1, 'certain': 1, 'authors': 1, 'really': 1, 'clear': 1, 'text': 1, 'paper': 1}, {'cell': 1, 'model': 1, 'used': 1, 'study': 1, 'carcinoma': 1, 'line': 1, 'active': 1, 'dna': 1, 'replication': 1, 'differs': 1, 'nondividing': 1, 'somatic': 1, 'cells': 1, 'also': 1, 'shown': 1, 'huh7': 1, 'display': 1, 'significant': 1, 'different': 1, 'gene': 1, 'protein': 1, 'expression': 1, 'including': 1, 'upregulated': 1, 'proteins': 1, 'involved': 1, 'rna': 1, 'metabolism': 1, '56': 1, 'huge': 1, 'caveat': 1, 'furthermore': 1, 'recent': 1, 'showed': 1, 'sarscov2': 1, 'reversetranscribed': 1, 'integrated': 1, 'genome': 1, 'human': 1, 'given': 1, 'much': 1, 'junk': 1, 'seems': 1, 'viral': 1, 'origin': 1, 'know': 1, 'exceptional': 1, 'viruses': 1, 'probably': 1, '?': 1, 'like': 1, 'anyone': 1, 'tried': 1, 'looking': 1, 'coronaviruses': 1, 'vaccines': 1, 'flu': 1}, {'79': 1, '%': 1, '60': 1, 'impressive': 1, 'although': 1, 'lot': 1, 'äúlongcovidäù': 1, 'symptoms': 1, 'really': 1, 'diagnosed': 1, 'months': 1, 'line': 1, '6': 1, 'weeks': 1, 'proper': 1, 'assessment': 1, 'meaningless': 1, 'either': 1, 'hopes': 1, 'would': 1, 'higher': 1, 'edit': 1, 'fixed': 1, 'based': 1, 'reply': 1, 's': 1, 'feedback': 1}, {'one': 1, 'thing': 1, 'end': 1, 'pandemic': 1, 'way': 1, 'better': 1, 'knowledge': 1, 'immunity': 1, 'viruses': 1, 'mostly': 1, 'sub': 1, 'thanks': 1, 'everyone': 1, 'contributing': 1}, {'get': 1, 'itäôs': 1, 'probably': 1, 'worth': 1, 'immunizing': 1, 'omicron': 1, 'ancestral': 1, 'strain': 1, 'wonder': 1, 'exposing': 1, 'immune': 1, 'system': 1, 'wider': 1, 'variety': 1, 'variants': 1, 'multivalent': 1, 'vaccines': 1, 'could': 1, 'lead': 1, 'body': 1, 'becoming': 1, 'likely': 1, 'produce': 1, 'universal': 1, 'äúcommon': 1, 'denominatoräù': 1, 'antibodies': 1, '?': 1}, {'examples': 1, 'continue': 1, 'quite': 1, 'stark': 1, 'norway': 1, 'omicron': 1, 'case': 1, 'study': 1, 'https': 1, 'wwwredditcomrcovid19commentsrhsodboutbreak_caused_by_the_sarscov2_omicron_variant': 1, '99': 1, '%': 1, 'symptomatic': 1, '65': 1, 'uninfected': 1, 'also': 1, 'swiss': 1, 'long': 1, 'covid': 1, 'kids': 1, 'wwwredditcomrcovid19commentsobm0wylongterm_symptoms_after_sarscov2_infection_in': 1, '9': 1, 'symptoms': 1, '4': 1, 'weeks': 1, 'among': 1, 'without': 1, '10': 1}, {'mrna': 1, 'vaccine': 1, 'costs': 1, '10x': 1, 'world': 1, 'developed': 1, 'countries': 1, 'also': 1, 'inactivated': 1, 'vaccines': 1, 'works': 1, 'great': 1, 'kids': 1, 'coronavac': 1, 'aged': 1, '5': 1, '11': 1, 'year': 1, '76': 1, '%': 1, 'protection': 1, 'symptomatic': 1, 'cases': 1, '90': 1, 'hospitalization': 1, 'similar': 1, 'pfizer': 1, '83': 1, 'data': 1, 'chile': 1, 'delta': 1, 'maybe': 1, 'could': 1, 'worse': 1, 'numbers': 1, 'one': 1, 'recombinant': 1}, {'results': 1, 'among': 1, '52238': 1, 'employees': 1, '4718': 1, '9': 1, '%': 1, 'previously': 1, 'infected': 1, '36922': 1, '71': 1, 'vaccinated': 1, 'studyäôs': 1, 'end': 1, 'cumulative': 1, 'incidence': 1, 'covid19': 1, 'substantially': 1, 'higher': 1, 'throughout': 1, 'uninfected': 1, 'remained': 1, 'unvaccinated': 1, 'groups': 1, 'lower': 1, 'increased': 1, 'dramatically': 1, 'omicron': 1, 'variant': 1, 'emerged': 1, 'multivariable': 1, 'cox': 1, 'proportional': 1, 'hazards': 1, 'regression': 1, 'prior': 1, 'vaccination': 1, 'independently': 1, 'associated': 1, 'significantly': 1, 'risk': 1, 'subjects': 1, 'overall': 1, 'demonstrated': 1, 'symptomatic': 1, 'preomicron': 1, 'hr': 1, '060': 1, '95': 1, 'ci': 1, '040äì090': 1, '036': 1, '023äì057': 1, 'phases': 1, 'conclusions': 1, 'previous': 1, 'infection': 1, 'provide': 1, 'substantial': 1, 'protection': 1, 'individuals': 1, 'additional': 1, 'several': 1, 'months': 1, 'provides': 1, 'significant': 1, 'least': 1, 'seems': 1, 'like': 1, 'vaccine': 1, 'similarly': 1, 'protective': 1, 'much': 1, 'better': 1, 'immunologically': 1, 'naive': 1, 'postinfection': 1, 'helps': 1, 'reduce': 1}, {'vaccinated': 1, 'people': 1, 'less': 1, 'restrictions': 1, 'nt': 1, 'think': 1, 'would': 1, 'possible': 1, 'control': 1, 'npis': 1, 'studies': 1, 'like': 1}, {'s': 1, 'says': 1, 'fact': 1, 'explicitly': 1, 'even': 1, 'pfizer': 1, 'young': 1, 'men': 1, 'twice': 1, 'likely': 1, 'get': 1, 'myocarditis': 1, 'vaccination': 1, 'infected': 1, 'moderna': 1, 'spikes': 1, 'much': 1, 'higher': 1}, {'saying': 1, 'agree': 1, 'maybe': 1, 'necessary': 1, 'individually': 1, 'sufficient': 1, 'conditions': 1, 'myocarditis': 1}, {'iäôve': 1, 'got': 1, 'questionconcern': 1, 'mrna': 1, 'vaccines': 1, 'big': 1, 'point': 1, 'concern': 1, 'introduction': 1, 'proteins': 1, 'spikes': 1, 'body': 1, 'see': 1, 'potentially': 1, 'harmful': 1, 'people': 1, 'often': 1, 'donäôt': 1, 'seem': 1, 'concerned': 1, 'billions': 1, 'attached': 1, 'live': 1, 'viruses': 1, 'infection': 1, 'letäôs': 1, 'put': 1, 'aside': 1, 'moment': 1, 'part': 1, 'rebuttal': 1, 'lungs': 1, 'could': 1, 'great': 1, 'idea': 1, 'thatäôs': 1, 'precisely': 1, 'injection': 1, 'arm': 1, 'muscle': 1, 'keep': 1, 'far': 1, 'away': 1, 'even': 1, 'bloodstream': 1, 'possible': 1, 'inhaled': 1, 'isnäôt': 1, 'good': 1, 'chance': 1, 'least': 1, 'adenoviruses': 1, 'going': 1, 'wind': 1, 'produce': 1, '?': 1}, {'well': 1, 'one': 1, 'shot': 1, 'max': 1, 'per': 1, 'year': 1, 'would': 1, 'nice': 1, 'nearcomplete': 1, 'protection': 1, 'serious': 1, 'disease': 1, 'infection': 1, 'really': 1, 'much': 1, 'ask': 1, '?': 1}, {'would': 1, 'say': 1, 'thatäôs': 1, 'opposite': 1, 'conclusion': 1, 'draw': 1}, {'clear': 1, 'folks': 1, 'home': 1, 'say': 1, 'negative': 1, 'vaccine': 1, 'effectiveness': 1, 'mean': 1, 'exactly': 1, '?': 1, 'vaccinated': 1, 'fair': 1, 'worse': 1, 'control': 1, 'group': 1, 'unvaccinated': 1, 'case': 1}, {'clarification': 1, 'needed': 1, 'first': 1, 'paragraph': 1, 'author': 1, 'states': 1, 'patients': 1, 'sometimes': 1, 'develop': 1, 'gbs': 1, 'recent': 1, 'respiratory': 1, 'illness': 1, 'digestive': 1, 'tract': 1, 'infection': 1, 'rare': 1, 'cases': 1, 'receiving': 1, 'certain': 1, 'vaccines': 1, 'statement': 1, 'misleading': 1, 'paraphrased': 1, 'section': 1, 'reference': 1, 'listed': 1, '1': 1, 'mayo': 1, 'clinic': 1, 'guillainbarre': 1, 'syndrome': 1, 'source': 1, 'exact': 1, 'cause': 1, 'nt': 1, 'known': 1, 'may': 1, 'occur': 1, 'covid19': 1, 'virus': 1, 's': 1, 'also': 1, 'reaction': 1, 'receive': 1, 'johnson': 1, '&': 1, 'vaccine': 1, 'implication': 1, 'stating': 1, 'result': 1, 'unfounded': 1, 'contradicted': 1, 'specifies': 1, 'causes': 1, 'webpage': 1, 'j': 1, 'implicated': 1, 'disease': 1, 'presentation': 1, 'rather': 1, 'distinction': 1, 'crucial': 1, 'since': 1, 'reader': 1, 'could': 1, 'infer': 1, 'would': 1, 'incorrect': 1, 'assumptioninference': 1}, {'late': 1, 'make': 1, 'much': 1, 'difference': 1, 'canada': 1, 'hope': 1, 'approval': 1, 'allow': 1, 'supply': 1, 'gavi': 1, 'especially': 1, 'considering': 1, 's': 1, 'fridge': 1, 'stable': 1}, {'looks': 1, 'like': 1, 'study': 1, 'covers': 1, 'delta': 1, 'mentioned': 1, 'several': 1, 'times': 1, 'omicron': 1, 'never': 1, 'feel': 1, 'studies': 1, 'info': 1, 'abstract': 1}, {'moderate': 1, 'intensity': 1, 'jogging': 1, 'mile': 1, 'every': 1, '10': 1, 'minutes': 1, 'go': 1, '9': 1, 'miles': 1, 'vaccine': 1, 'shot': 1, '?': 1}, {'isnäôt': 1, 'study': 1, 'itäôs': 1, 'news': 1, 'directly': 1, 'related': 1, 'pediatric': 1, 'vaccines': 1, 'covid': 1, 'thought': 1, 'would': 1, 'share': 1, 'see': 1, 'mods': 1, 'allow': 1}, {'continue': 1, 'course': 1, 'without': 1, 'expecting': 1, 'constant': 1, 'mutations': 1, 'immune': 1, 'evasion': 1, 'years': 1, 'best': 1, 'case': 1, 'scenario': 1, 'slowly': 1, 'turns': 1, 'effectively': 1, 'another': 1, 'cold': 1, 'flu': 1, 'mutation': 1, 'immunity': 1, 'build': 1, 'see': 1, 'less': 1, 'people': 1, 'walking': 1, 'booster': 1, 'come': 1, 'think': 1, 'dr': 1, 'michael': 1, 'mina': 1, 'others': 1, 'outlined': 1, 'worthwhile': 1, 'plan': 1, 'keep': 1, 'manageable': 1, 'levels': 1, 'nt': 1, 'overrun': 1, 'hospitals': 1, 'real': 1, 'goal': 1, 'rapid': 1, 'tests': 1, 'extremely': 1, 'cheap': 1, 'compared': 1, 'total': 1, 'cost': 1, 'covid': 1, 'could': 1, 'manufactured': 1, 'incredibly': 1, 'large': 1, 'quantities': 1, 'quickly': 1, 'encouraging': 1, 'free': 1, 'rapids': 1, 'taken': 1, 'work': 1, 'school': 1, 'even': 1, 'adhered': 1, 'percentage': 1, 'population': 1, 'days': 1, 'week': 1, 'would': 1, 'likely': 1, 'massive': 1, 'impact': 1}, {'rate': 1, 'dose': 1, 'even': 1, 'worth': 1, 'giving': 1, '11': 1, 'year': 1, 'old': 1, '?': 1}, {'cite': 1, 'paper': 1, 'https': 1, 'pubmedncbinlmnihgov33958444': 1, 'showing': 1, 'sars': 1, 'rna': 1, 'possibly': 1, 'reversed': 1, 'dna': 1, 'use': 1, 'evidence': 1, 'could': 1, 'also': 1, 'happen': 1, 'vaccine': 1, 'seems': 1, 'like': 1, 'inappropriate': 1, 'assumption': 1, 'would': 1, 'however': 1, 'raise': 1, 'question': 1, 'proven': 1, 'cause': 1, 'edits': 1, 'mrna': 1, 'vaccines': 1, 'changes': 1, 'causes': 1, 'significant': 1, '?': 1, 'similar': 1, 'situation': 1, 'heightened': 1, 'concern': 1, 'cardiac': 1, 'effects': 1, 'covid': 1, 'fact': 1, 'much': 1, 'worse': 1, 'study': 1, 'pubmedncbinlmnihgov34907393': 1}, {'adjust': 1, 'age': 1, 'calculated': 1, '1hr': 1, 'hr': 1, 'hazard': 1, 'ratio': 1, 'estimated': 1, 'cox': 1, 'regression': 1, 'model': 1, 'adjusted': 1, 'sex': 1, 'geographical': 1, 'region': 1, 'using': 1, 'calendar': 1, 'time': 1, 'underlying': 1, 'scale': 1}, {'getting': 1, 'second': 1, 'shot': 1, '3': 1, 'weeks': 1, 'actually': 1, 'harm': 1, 'terms': 1, 'eliciting': 1, 'broader': 1, 'response': 1, 'variants': 1, 'make': 1, 'difference': 1, 'third': 1, '68': 1, 'months': 1, 'one': 1, '?': 1}, {'still': 1, 'lot': 1, 'identical': 1, 'epitopes': 1, 'antibodies': 1, 'attach': 1, 'way': 1, 'less': 1, 'original': 1, 'strain': 1, 'getting': 1, 'huge': 1, 'boost': 1, 'would': 1, 'amplify': 1, 'also': 1, 'ones': 1, 'work': 1, 'protection': 1, 'severe': 1, 'disease': 1, '70': 1, '%': 1, 'even': 1, '2': 1, 'doses': 1, 'remember': 1, 'well': 1, 'cell': 1, 'response': 1}, {'houston': 1, 'methodist': 1, 'sequencing': 1, '100': 1, '%': 1, 'covid': 1, 'patients': 1, 'amazing': 1, 'data': 1, 'trove': 1, 'd': 1, 'love': 1, 'know': 1, 's': 1, 'central': 1, 'way': 1, 'find': 1, 'used': 1, 'brief': 1, 'google': 1, 'nt': 1, 'say': 1, 'page': 1, 'website': 1, 'lists': 1, 'research': 1}, {'would': 1, 'efficacy': 1, 'greater': 1, 'larger': 1, 'interval': 1, 'doses': 1, 'eg': 1, 'eight': 1, 'weeks': 1, 'australia': 1, 'canada': 1, '?': 1}, {'d': 1, 'like': 1, 'see': 1, 'sort': 1, 'study': 1, 'extended': 1, 'effectiveness': 1, 'boosters': 1}, {'abstract': 1, 'emerging': 1, 'sarscov2': 1, 'variants': 1, 'concern': 1, 'voc': 1, 'harbor': 1, 'mutations': 1, 'associated': 1, 'increasing': 1, 'transmission': 1, 'immune': 1, 'escape': 1, 'hence': 1, 'undermine': 1, 'effectiveness': 1, 'current': 1, 'covid19': 1, 'vaccines': 1, 'late': 1, 'november': 1, '2021': 1, 'omicron': 1, 'b11529': 1, 'variant': 1, 'identified': 1, 'south': 1, 'africa': 1, 'rapidly': 1, 'spread': 1, 'across': 1, 'globe': 1, 'shown': 1, 'exhibit': 1, 'significant': 1, 'resistance': 1, 'neutralization': 1, 'serum': 1, 'convalescent': 1, 'patients': 1, 'also': 1, 'individuals': 1, 'recieving': 1, 'currently': 1, 'used': 1, 'multiple': 1, 'booster': 1, 'shots': 1, 'therefore': 1, 'urgent': 1, 'need': 1, 'develop': 1, 'next': 1, 'generation': 1, 'vocs': 1, 'like': 1, 'study': 1, 'panel': 1, 'mrnalnpbased': 1, 'using': 1, 'receptor': 1, 'binding': 1, 'domain': 1, 'rbd': 1, 'delta': 1, 'dominant': 1, 'wave': 1, 'addition': 1, 'deltaspecific': 1, 'includes': 1, 'hybrid': 1, 'vaccine': 1, 'uses': 1, 'containing': 1, '16': 1, 'pointmutations': 1, 'well': 1, 'bivalent': 1, 'composed': 1, 'rbdlnp': 1, 'half': 1, 'dose': 1, 'interestingly': 1, 'omicronspecific': 1, 'elicited': 1, 'extremely': 1, 'high': 1, 'titer': 1, 'neutralizing': 1, 'antibody': 1, 'none': 1, 'hand': 1, 'generated': 1, 'broadly': 1, 'activity': 1, 'wildtype': 1, 'virus': 1, 'surprisingly': 1, 'similar': 1, 'crossprotection': 1, 'deltaspecifc': 1, 'taken': 1, 'together': 1, 'data': 1, 'demonstrated': 1, 'mrna': 1, 'induce': 1, 'potent': 1, 'response': 1, 'inclusion': 1, 'epitopes': 1, 'may': 1, 'required': 1, 'eliciting': 1, 'would': 1, 'lay': 1, 'foundation': 1, 'rational': 1, 'development': 1}, {'abstract': 1, 'vaccine': 1, 'efficacy': 1, 'infection': 1, '30': 1, '%': 1, '95': 1, 'ci': 1, '9': 1, '55': 1, '11': 1, '43': 1, 'bnt162b2': 1, 'mrna1273': 1, 'respectively': 1, 'local': 1, 'systemic': 1, 'adverse': 1, 'reactions': 1, 'reported': 1, '80': 1, '40': 1}, {'study': 1, 'nt': 1, 'considering': 1, 'actually': 1, 'happens': 1, 'humans': 1, 'omicron': 1, 'slower': 1, 'go': 1, 'lung': 1, 'tissue': 1, 'compared': 1, 'bronchus': 1, 'still': 1, 'lower': 1, 'respiratory': 1, 'tract': 1, 'infection': 1, 'also': 1, 'delta': 1, 'less': 1, 'prone': 1, 'replicate': 1, 'original': 1, 'impair': 1, 's': 1, 'severity': 1, 'counterfactual': 1, 'concerning': 1}, {'p': 1, 'value': 1, 'nearly': 1, 'much': 1, 'function': 1, 'sample': 1, 'size': 1, 'effect': 1, 'magnitude': 1, 'good': 1, 'supporting': 1, 'evidence': 1, 'people': 1, 'believe': 1, 'structured': 1, 'observations': 1, 'world': 1, 'lead': 1, 'credible': 1, 'perspectives': 1, 'ie': 1, 'science': 1, 'pvalue': 1, '02': 1, 'massive': 1, 'anything': 1}, {'study': 1, 'literally': 1, 'says': 1, 'risk': 1, 'myocarditis': 1, 'doubled': 1, 'certain': 1, 'demographics': 1, 'when': 1, 'compared': 1, 'covid': 1, 'infection': 1}, {'tcells': 1, 'nothing': 1, 'protection': 1, 'infection': 1, 'damage': 1, 'done': 1, 'first': 1, 'couple': 1, 'days': 1, 'begin': 1, 'nuking': 1, 'virus': 1}, {'70': 1, '%': 1, 'average': 1, 'across': 1, 'participants': 1, 's': 1, '606': 1, 'vs': 1, '791': 1, 'vaccinated': 1, 'unvaccinated': 1, 'lower': 1, 'prevalence': 1, 'among': 1, 'compared': 1, 'arr': 1, '070': 1, '95': 1, 'ci': 1, '058084': 1}, {'incubation': 1, 'time': 1, 'measles': 1, '1012': 1, 'days': 1, 'omicron': 1, '3': 1}, {'nt': 1, 'think': 1, 'äúeither': 1, 'boost': 1, 'completely': 1, 'shut': 1, 'viral': 1, 'replication': 1, 'within': 1, 'two': 1, 'days': 1, 'äù': 1, 'fundamental': 1, 'problem': 1, 'fast': 1, 'omicron': 1, 'replicates': 1, 'get': 1, 'breakthrough': 1, 'infections': 1, 'even': 1, 'appropriate': 1, 'antibodies': 1, 'ca': 1, 'immune': 1, 'system': 1, 'act': 1, 'faster': 1, 'unless': 1, 'keep': 1, 'boosting': 1, 'every': 1, '4': 1, 'months': 1, 'never': 1, 'let': 1, 'neutralising': 1, 'antibody': 1, 'titers': 1, 'wane': 1, 'good': 1, 'idea': 1, 'accept': 1, 'going': 1, 'happen': 1, 'memory': 1, 'b': 1, 'cells': 1, 'time': 1, 'stop': 1, 'infection': 1, 'becoming': 1, 'severe': 1, 'second': 1, 'boosters': 1, 'tending': 1, 'amplify': 1, 'clones': 1, 'present': 1, 'first': 1, 'covid': 1, 'jab': 1, 'ever': 1, 'took': 1, 'instead': 1, 'developing': 1, 'new': 1, 'specifically': 1, 'recognize': 1, 's': 1, 'mutated': 1, 'epitopes': 1, 'boosted': 1, 'omicronspecific': 1, 'vaccine': 1, 'already': 1, 'generated': 1, 'recognise': 1, 'nonmutated': 1, 'dominate': 1, 'response': 1, 'aka': 1, 'original': 1, 'antigenic': 1, 'sin': 1}, {'water': 1, 'reed': 1, 'vaccine': 1, 'severely': 1, 'overhyped': 1, 's': 1, 'cludging': 1, 'different': 1, 'spike': 1, 'proteins': 1, 'one': 1, 'evidence': 1, 'simply': 1, 'mixing': 1, 'together': 1, 'like': 1, 'tetravalent': 1, 'flu': 1, 'vaccines': 1, 'would': 1, 'nt': 1, 'work': 1, 'well': 1, 'assembling': 1, 'mixed': 1, 'nanoparticles': 1, 'good': 1, 'chance': 1, 'new': 1, 'variant': 1, 'comes': 1, 'need': 1, 'incorporate': 1, 'protein': 1, 'making': 1, 'slow': 1, 'hell': 1, 'bit': 1, 'dodgy': 1, 'whether': 1, 'single': 1, 'refers': 1, 'concept': 1, 'change': 1, 'vs': 1, 'exact': 1, 'formulation': 1, 'faster': 1, 'probably': 1, 'slower': 1, 'redesigning': 1, 'mrna': 1, 'also': 1, 'addressed': 1, 'crossstrain': 1, 'effect': 1, 'someone': 1, 'already': 1, 'vaccinated': 1, 'approved': 1, 'infected': 1, 'thus': 1, 'original': 1, 'antigenic': 1, 'sin': 1, 'problem': 1}, {'chances': 1, 'get': 1, 'told': 1, 'pursue': 1, 'bla': 1, 'route': 1, 'like': 1, 'fda': 1, 'recently': 1, 'recommended': 1, 'covaxin': 1, 'shot': 1, '?': 1}, {'note': 1, 'authors': 1, 'state': 1, 'predicting': 1, 'continued': 1, 'efficacy': 1, 'existing': 1, 'vaccines': 1, 'refers': 1, 'preventing': 1, 'moderate': 1, 'severe': 1, 'symptoms': 1, 'asymptomatic': 1, 'infection': 1, 'abstract': 1, 'time': 1, 'writing': 1, 'december': 1, '2021': 1, 'potential': 1, 'emergence': 1, 'vaccine': 1, 'escape': 1, 'variants': 1, 'acute': 1, 'respiratory': 1, 'syndrome': 1, 'coronavirus': 1, '2': 1, 'sarscov2': 1, 'grave': 1, 'global': 1, 'concern': 1, 'interface': 1, 'receptorbinding': 1, 'domain': 1, 'rbd': 1, 'spike': 1, 'protein': 1, 'host': 1, 'receptor': 1, 'ace2': 1, 'overlaps': 1, 'binding': 1, 'site': 1, 'principal': 1, 'neutralizing': 1, 'antibodies': 1, 'nab': 1, 'limiting': 1, 'repertoire': 1, 'viable': 1, 'mutations': 1, 'nonetheless': 1, 'multiple': 1, 'risen': 1, 'dominance': 1, 'nonadditive': 1, 'epistatic': 1, 'relationships': 1, 'among': 1, 'apparent': 1, 'assessing': 1, 'impact': 1, 'epistasis': 1, 'mutational': 1, 'landscape': 1, 'particularly': 1, 'risk': 1, 'crucial': 1, 'employed': 1, 'structure': 1, 'modeling': 1, 'using': 1, 'rosetta': 1, 'compare': 1, 'effects': 1, 'single': 1, 'mutants': 1, 'rbdnab': 1, 'rbdace2': 1, 'interfaces': 1, 'wild': 1, 'type': 1, 'delta': 1, 'gamma': 1, 'omicron': 1, 'overall': 1, 'appears': 1, 'limited': 1, 'additive': 1, 'variant': 1, 'weakly': 1, 'stabilizes': 1, 'interaction': 1, 'relative': 1, 'whereas': 1, 'substantially': 1, 'destabilizes': 1, 'despite': 1, 'bearing': 1, 'many': 1, 'closely': 1, 'resembles': 1, 'thus': 1, 'although': 1, 'poses': 1, 'new': 1, 'risks': 1, 'observed': 1, 'structural': 1, 'constraints': 1, 'appear': 1, 'hamper': 1, 'evolution': 1, 'toward': 1, 'complete': 1, 'modest': 1, 'ensemble': 1, 'currently': 1, 'known': 1, 'reduce': 1, 'likely': 1, 'contain': 1, 'majority': 1, 'possible': 1, 'future': 1, 'importance': 1, 'arguably': 1, 'pressing': 1, 'problem': 1, 'covid19': 1, 'pandemic': 1, 'distributed': 1, 'worldwide': 1, 'computational': 1, 'approach': 1, 'assess': 1, 'antibody': 1, 'resulting': 1, 'wildtype': 1, 'virus': 1, 'well': 1, 'could': 1, 'reduced': 1, 'results': 1, 'suggest': 1, 'evolutionary': 1, 'make': 1, 'either': 1, 'unlikely': 1, 'set': 1, 'escapeenhancing': 1, 'already': 1, 'identified': 1, 'include': 1, 'effect': 1}, {'next': 1, 'used': 1, 'logistic': 1, 'additive': 1, 'model': 1, 'test': 1, 'negative': 1, 'case': 1, 'control': 1, 'design': 1, 'estimate': 1, 'relative': 1, 'vaccine': 1, 'effectiveness': 1, 'becoming': 1, 'confirmed': 1, 'delta': 1, '2553': 1, 'cases': 1, 'andor': 1, 'omicron': 1, '1001': 1, 'population': 1, '12': 1, 'million': 1, 'people': 1, 'largest': 1, 'health': 1, 'board': 1, 'scotland': 1, 'nhs': 1, 'gg': 1, '&': 1, 'c': 1, '6th': 1, '12th': 1, 'december': 1, '2021': 1, 'ran': 1, 'two': 1, 'models': 1, 'one': 1, 'time': 1, 'since': 1, 'vaccination': 1, 'included': 1, 'protection': 1, 'provided': 1, 'recent': 1, 'without': 1, 'observe': 1, 'current': 1, 'todayäôs': 1, 'mixed': 1, 'waned': 1}, {'vaccines': 1, 'nt': 1, 'provide': 1, 'much': 1, 'protection': 1, 'infection': 1, 'brandnew': 1, '3rd': 1, 'dose': 1, 'slight': 1, 'boost': 1, 'claim': 1, 'accounting': 1, 'waning': 1, 'also': 1, 'warn': 1, 'sample': 1, 'size': 1, 'small': 1, 'margin': 1, 'error': 1, 'large': 1, 'mention': 1, 'real': 1, 'world': 1, 'data': 1, 'suggests': 1, 'larger': 1, 'effect': 1}, {'immunologist': 1, 'would': 1, 'know': 1, 'far': 1, 'better': 1, 's': 1, 'two': 1, 'cents': 1, 'someone': 1, 'follows': 1, 'commercial': 1, 'side': 1, 'things': 1, 'role': 1, 'nonneutralizing': 1, 'binding': 1, 'antibodies': 1, 'covid': 1, 'multifaceted': 1, 'still': 1, 'explored': 1, 'one': 1, 'hand': 1, 'may': 1, 'viral': 1, 'clearance': 1, 'fixing': 1, 'complement': 1, 'triggering': 1, 'opsonization': 1, 'macrophages': 1, 'etc': 1, 'feel': 1, 'people': 1, 'speak': 1, 'papers': 1, 'read': 1, 'assume': 1, 'protective': 1, 'might': 1, 'also': 1, 'play': 1, 'increasing': 1, 'disease': 1, 'severity': 1, 'especially': 1, 'accompanied': 1, 'sufficient': 1, 'titers': 1, 'neutralizing': 1, 'example': 1, 'touching': 1, 'upon': 1, 'subject': 1, 'https': 1, 'wwwscienceorgdoi101126scitranslmedabm7853': 1, 'linkspringercomarticle101007s41745021002688': 1, 'wwwncbinlmnihgovpmcarticlespmc8092137': 1, 'line': 1, 'ideas': 1, 'expressed': 1, 'early': 1, 'stages': 1, 'vaccine': 1, 'development': 1, 'associated': 1, 'enhanced': 1, 'respiratory': 1, 'vaerd': 1, 'viewed': 1, 'potential': 1, 'hurdle': 1, 'successfully': 1, 'creating': 1, 'like': 1, 'manifestations': 1, 'ade': 1, 'thought': 1, 'caused': 1, 'insufficient': 1, 'activity': 1, 'invitro': 1, 'animal': 1, 'model': 1, 'experiments': 1, 'demonstrated': 1, 'theoretically': 1, 'possible': 1, 'coronavirus': 1, 'vaccines': 1, 'fortunately': 1, 'turned': 1, 'none': 1, 'approved': 1, 'elicited': 1}, {'abstract': 1, 'emergence': 1, 'severe': 1, 'acute': 1, 'respiratory': 1, 'syndrome': 1, 'coronavirus': 1, '2': 1, 'sarscov2': 1, 'variants': 1, 'continues': 1, 'shape': 1, 'disease': 1, '2019': 1, 'covid19': 1, 'pandemic': 1, 'detection': 1, 'rapid': 1, 'spread': 1, 'omicron': 1, 'variant': 1, 'lineage': 1, 'b11529': 1, 'botswana': 1, 'south': 1, 'africa': 1, 'became': 1, 'global': 1, 'concern': 1, 'contained': 1, '15': 1, 'mutations': 1, 'spike': 1, 'protein': 1, 'immunogenic': 1, 'receptor': 1, 'binding': 1, 'domain': 1, 'less': 1, 'neutralized': 1, 'sera': 1, 'derived': 1, 'vaccinees': 1, 'compared': 1, 'previously': 1, 'dominant': 1, 'delta': 1, 'investigate': 1, 'likely': 1, 'cause': 1, 'infections': 1, 'vaccinated': 1, 'persons': 1, 'analyzed': 1, '37877': 1, 'nasal': 1, 'swab': 1, 'pcr': 1, 'tests': 1, 'conducted': 1, '1226': 1, 'december': 1, '2021': 1, 'calculated': 1, 'test': 1, 'positivity': 1, 'rates': 1, 'vaccination': 1, 'status': 1, 'found': 1, 'rate': 1, 'among': 1, 'unvaccinated': 1, 'higher': 1, '52': 1, '%': 1, '45': 1, 'similar': 1, 'results': 1, 'received': 1, 'single': 1, 'vaccine': 1, 'dose': 1, 'conversely': 1, 'show': 1, 'two': 1, 'doses': 1, 'within': 1, 'five': 1, 'months': 1, '47': 1, 'vs': 1, '26': 1, 'ago': 1, '42': 1, '29': 1, 'three': 1, '22': 1, '09': 1, 'estimates': 1, 'receiving': 1, 'one': 1, 'significantly': 1, 'lower': 1, '497': 1, 'comparison': 1, 'reduction': 1, '456496': 1, '3': 1, '832': 1, 'despite': 1, 'still': 1, '912': 1, 'study': 1, 'occurred': 1, 'eligible': 1, '1': 1, 'time': 1, 'testing': 1, 'conclusion': 1, 'escape': 1, 'vaccineinduced': 1, 'immunity': 1, 'contributed': 1, 'rise': 1}, {'could': 1, 'mildly': 1, 'effective': 1, 'vaccine': 1, 'still': 1, 'protected': 1, 'people': 1, 'prior': 1, '8': 1, 'months': 1, 'less': 1, 'likely': 1, 'natural': 1, 'immunity': 1, 'nt': 1, 'read': 1, 'yet': 1, 'unless': 1, 'sure': 1, 'found': 1, 'immune': 1, 'naive': 1, 'controls': 1, 'graph': 1, 'basically': 1, 'pop': 1, 'level': 1, 'vax': 1, 'nativity': 1, 'become': 1, 'living': 1, 'pandemic': 1, 'would': 1, 'bet': 1, 'broke': 1, 'groups': 1, 'better': 1, 'see': 1, 'differing': 1, 'ratios': 1, 'assume': 1, 're': 1, 'equal': 1, 'simpson': 1, 's': 1, 'paradox': 1, '?': 1}, {'vaers': 1, 'pretty': 1, 'bad': 1, 'way': 1, 'identify': 1, 'adverse': 1, 'events': 1, 'iäôd': 1, 'love': 1, 'see': 1, 'analysis': 1, 'incidence': 1, 'myocarditis': 1, 'booster': 1, 'doses': 1, 'young': 1, 'men': 1}, {'wouldnäôt': 1, 'follow': 1, 'age': 1, 'deescalation': 1, 'protocol': 1, 'approval': 1, 'skip': 1, 'group': 1, 'go': 1, 'younger': 1}, {'abstract': 1, 'infectionneutralizing': 1, 'antibody': 1, 'responses': 1, 'sarscov2': 1, 'infection': 1, 'covid19': 1, 'vaccination': 1, 'essential': 1, 'component': 1, 'antiviral': 1, 'immunity': 1, 'antibodymediated': 1, 'protection': 1, 'challenged': 1, 'emergence': 1, 'variants': 1, 'concern': 1, 'vocs': 1, 'immune': 1, 'escape': 1, 'properties': 1, 'omicron': 1, 'b11529': 1, 'rapidly': 1, 'spreading': 1, 'worldwide': 1, 'report': 1, 'neutralizing': 1, 'dynamics': 1, 'longitudinal': 1, 'cohort': 1, 'convalescent': 1, 'infectionnaive': 1, 'individuals': 1, 'vaccinated': 1, 'mrna': 1, 'bnt162b2': 1, 'quantifying': 1, 'antisarscov2spike': 1, 'antibodies': 1, 'determining': 1, 'avidity': 1, 'neutralization': 1, 'capacity': 1, 'serum': 1, 'using': 1, 'livevirus': 1, 'assays': 1, 'show': 1, 'superior': 1, 'including': 1, 'developed': 1, 'either': 1, 'two': 1, 'vaccinations': 1, 'convalescents': 1, 'third': 1, 'breakthrough': 1, 'twicevaccinated': 1, 'naive': 1, 'three': 1, 'consecutive': 1, 'spike': 1, 'antigen': 1, 'exposures': 1, 'resulted': 1, 'increasing': 1, 'per': 1, 'antispike': 1, 'unit': 1, 'paralleled': 1, 'stepwise': 1, 'increases': 1, 'conclude': 1, 'infectionplusvaccinationinduced': 1, 'hybrid': 1, 'triple': 1, 'immunization': 1, 'induce': 1, 'highquality': 1}, {'agree': 1, 'considered': 1, 'study': 1, 'china': 1, 'would': 1, 'nt': 1, 'contact': 1, 'sarscov2': 1, 'routine': 1, 'basis': 1}, {'good': 1, 'question': 1, 'appear': 1, 'danish': 1, 'data': 1, 'pcrtested': 1, 'less': 1, 'pr': 1, '100000': 1, 'person': 1, 'report': 1, 'breakthrough': 1, 'infections': 1, 'https': 1, 'filesssidkcovid19gennembrudsinfektionrapportgennembrudsinfektioncovid19uge492021ji88': 1, 'figure': 1, '10': 1, 'shows': 1, 'roughly': 1, '30': 1, '&': 1, 'unvaccinated': 1, '1664': 1, 'tested': 1, 'latest': 1, 'period': 1, '611412': 1, '40': 1, '%': 1, 'doublejabbed': 1, 'beenif': 1, 'recent': 1, '12': 1, 'weeks': 1, 'old': 1, 'positive': 1, 'pcrtest': 1, 'also': 1, 'advised': 1, 'get': 1, 'think': 1, 'could': 1, 'possibly': 1, 'skew': 1, 'results': 1, 'edit': 1, 'test': 1, 'first': 1, 'reason': 1, 'due': 1, 'higher': 1, 'prevalence': 1, 'group': 1, 'months': 1, 'leading': 1, 'omicron': 1}, {'d': 1, 'imagine': 1, 'something': 1, 'dosag': 1, 'higher': 1, 'moderna': 1}, {'vaxart': 1, 'phase': 1, '2': 1, 'trial': 1, 'oral': 1, 'vax': 1, 'nucleocapsid': 1, 'protein': 1, 'mutates': 1, 'slightly': 1, 'addition': 1, 'spike': 1, 'oramed': 1, 'also': 1, 'membrane': 1, 'envelope': 1, 'proteins': 1, 'sadly': 1, 'small': 1, 'companies': 1, 'less': 1, 'money': 1, 'giants': 1, 'like': 1, 'pfizer': 1, 'll': 1, 'probably': 1, 'get': 1, 'approved': 1, 'another': 1, 'migvax': 1, 're': 1, 'crowd': 1, 'funded': 1, 'moving': 1, 'even': 1, 'slower': 1, 'trials': 1}, {'took': 1, 'something': 1, 'like': 1, '7': 1, 'months': 1, 'create': 1, 'h1n1pdm': 1, 'vaccine': 1, '12': 1, 'years': 1, 'ago': 1, 'take': 1, 'much': 1, 'less': 1, 'mrna': 1, 'vaccines': 1}, {'despite': 1, 'recent': 1, 'efforts': 1, 'demonstrating': 1, 'organization': 1, 'presentation': 1, 'vaccine': 1, 'components': 1, 'important': 1, 'composition': 1, 'dictating': 1, 'efficacy': 1, 'antiviral': 1, 'vaccines': 1, 'long': 1, 'focused': 1, 'solely': 1, 'identification': 1, 'immunological': 1, 'target': 1, 'herein': 1, 'describe': 1, 'study': 1, 'aimed': 1, 'exploring': 1, 'component': 1, 'context': 1, 'spherical': 1, 'nucleic': 1, 'acids': 1, 'snas': 1, 'used': 1, 'elicit': 1, 'maximize': 1, 'response': 1, 'using': 1, 'covid19': 1, 'topical': 1, 'example': 1, 'infectious': 1, 'disease': 1, 'urgent': 1, 'need': 1, 'rapid': 1, 'development': 1, 'designed': 1, 'sna': 1, 'encapsulating': 1, 'receptorbinding': 1, 'domain': 1, 'rbd': 1, 'subunit': 1, 'liposome': 1, 'decorating': 1, 'core': 1, 'dense': 1, 'shell': 1, 'cpg': 1, 'motif': 1, 'tolllike': 1, 'receptor': 1, '9': 1, 'agonist': 1, 'oligonucleotides': 1, 'induces': 1, 'memory': 1, 'b': 1, 'cell': 1, 'formation': 1, 'human': 1, 'cells': 1, 'vivo': 1, 'administration': 1, 'mice': 1, 'generates': 1, 'robust': 1, 'binding': 1, 'neutralizing': 1, 'antibody': 1, 'titers': 1, 'moreover': 1, 'outperforms': 1, 'multiple': 1, 'simple': 1, 'mixtures': 1, 'incorporating': 1, 'clinically': 1, 'employed': 1, 'adjuvants': 1, 'modular': 1, 'changes': 1, 'structure': 1, 'uncover': 1, 'key': 1, 'relationships': 1, 'proteomic': 1, 'insights': 1, 'adjuvant': 1, 'antigen': 1, 'ratios': 1, 'concepts': 1, 'potentially': 1, 'translatable': 1, 'across': 1, 'platforms': 1, 'models': 1, 'importantly': 1, 'humanized': 1, 'ace2': 1, 'transgenic': 1, 'challenged': 1, 'lethal': 1, 'live': 1, 'virus': 1, 'received': 1, '100': 1, '%': 1, 'survival': 1, 'rate': 1, 'lungs': 1, 'clear': 1, 'plaque': 1, 'analysis': 1, 'work': 1, 'underscores': 1, 'potential': 1, 'implemented': 1, 'easily': 1, 'adaptable': 1, 'generalizable': 1, 'platform': 1, 'fight': 1, 'demonstrates': 1, 'importance': 1, 'design': 1, 'nextgeneration': 1}, {'evidence': 1, 'severity': 1, 'because': 1, 'hospitalisation': 1, 'data': 1, 'limited': 1}, {'believe': 1, 's': 1, '3': 1, 'doses': 1, '2': 1}, {'rapid': 1, 'test': 1, 'could': 1, 'produced': 1, 'distributed': 1, '200': 1, '%': 1, 'profit': 1, '1': 1, 'customers': 1, 'near': 1, '99': 1, 'efficiency': 1, 'rate': 1, 'negative': 1, 'results': 1, 'imo': 1, 'wont': 1, 'happen': 1, 'least': 1, 'another': 1, 'year': 1, 'ppl': 1, 'focused': 1, 'companies': 1, 'want': 1, 'money': 1, 'add': 1, 'insult': 1, 'injury': 1, 's': 1, 'information': 1, 'im': 1, 'stating': 1, 'provided': 1, 'nearly': 1, 'ago': 1, 'still': 1, 'sold': 1, 'upwards': 1, '10': 1, 'cheap': 1, 'end': 1, 'maybe': 1, '57': 1, 'gethave': 1, 'wholesale': 1, 'account': 1, 'trying': 1, 'maintain': 1, 'market': 1, 'gets': 1, 'dropped': 1, 'bottom': 1, 'themimo': 1}, {'good': 1, 'point': 1}, {'know': 1, 'press': 1, 'statement': 1, '3x': 1, 'az': 1, 'neutralising': 1, 'antibody': 1, 'levels': 1, 'omicron': 1, 'following': 1, 'third': 1, 'dose': 1, 'boost': 1, 'vaxzevria': 1, 'broadly': 1, 'similar': 1, 'achieved': 1, 'two': 1, 'doses': 1, 'delta': 1, 'variant': 1, 'https': 1, 'wwwastrazenecacommediacentrepressreleases2021vaxzevriasignificantlyboostedantibodylevelsagainstomicronhtml': 1, 'edit': 1, 'also': 1, 'oldredditcomrcovid19search': 1, '?': 1, 'qvaxzevria': 1, '&': 1, 'sortnew': 1, 'restrict_sron': 1}, {'safe': 1, 'effective': 1}, {'yes': 1, 'taken': 1, 'face': 1, 'value': 1, 'study': 1, 'shows': 1, 'people': 1, '91': 1, 'days': 1, '2dose': 1, 'vaccination': 1}, {'understanding': 1, 'government': 1, 'provides': 1, 'supply': 1, 'canäôt': 1, 'prescribe': 1, 'outside': 1, 'officially': 1, 'authorized': 1, 'circumstances': 1}, {'totally': 1, 'correct': 1, 'viral': 1, 'load': 1, 'measured': 1, 'pcr': 1, 'meaningless': 1, 'infectious': 1, 'virus': 1, 'titers': 1, 'key': 1, 'metric': 1, 'people': 1, 'pumping': 1, 'bad': 1, 'science': 1, 'get': 1, 'published': 1, 'pandemic': 1, 's': 1, 'academic': 1, 'opportunist': 1, 'behaviour': 1}, {'get': 1, '?': 1, 'cause': 1, 's': 1, 'lot': 1, 'breakthroughs': 1, 'lately': 1}, {'overall': 1, 'covid19': 1, 'convalescents': 1, 'showed': 1, 'higher': 1, 'neutralization': 1, 'capacity': 1, '140': 1, 'sarscov2': 1, 'vocs': 1, 'compared': 1, 'infectionnaive': 1, 'individuals': 1, 'even': 1, 'three': 1, 'vaccinations': 1, '141': 1, 'latter': 1, 'interesting': 1, 'first': 1, 'time': 1, 'iäôve': 1, 'seen': 1, 'stated': 1}, {'in': 1, 'review': 1, 'analysis': 1, 'death': 1, 'reports': 1, 'vaers': 1, 'following': 1, 'mrna': 1, 'vaccination': 1, 'found': 1, 'unusual': 1, 'patterns': 1, 'cause': 1, 'among': 1, 'received': 1, 'covid19': 1, 'vaccine': 1, 'eua': 1, 'regulations': 1, 'healthcare': 1, 'providers': 1, 'required': 1, 'report': 1, 'deaths': 1, 'lifethreatening': 1, 'adverse': 1, 'health': 1, 'events': 1, 'vaccinations': 1, 'regardless': 1, 'potential': 1, 'association': 1}, {'think': 1, 'study': 1, 'looked': 1, 'sub': 1, 'thread': 1, 'redditcomrcovid19commentsr9oijyprotection_and_waning_of_natural_and_hybrid': 1, 'https': 1, 'wwwredditcomrcovid19commentsr9oijyprotection_and_waning_of_natural_and_hybrid': 1}, {'think': 1, 're': 1, 'right': 1, 'would': 1, 'note': 1, 'extreme': 1, 'care': 1, 'many': 1, 'scientists': 1, 'taken': 1, 'avoid': 1, 'even': 1, 'appearance': 1, 'discouraging': 1, 'vaccination': 1, 'recollection': 1, 'pfizer': 1, 'moderna': 1, 'phase': 1, '13': 1, 'trials': 1, 'excluded': 1, 'intended': 1, 'exclude': 1, 'patients': 1, 'prior': 1, 'history': 1, 'covid': 1, 'infection': 1, 'still': 1, 'question': 1, 'interest': 1, 'study': 1, 'also': 1, 'notes': 1, 'higher': 1, 'increased': 1, 'rate': 1, 'antibody': 1, 'titer': 1, 'worsened': 1, 'group': 1, 'nonworsened': 1, 'suggests': 1, 'excessive': 1, 'immune': 1, 'response': 1, 'associated': 1, 'worsening': 1, 'sequelae': 1}, {'brain': 1, 'nt': 1, 'working': 1, 'well': 1, 'today': 1, 'know': 1, 'wo': 1, 'yield': 1, 'exact': 1, 'results': 1, 'anyone': 1, 'take': 1, 'stab': 1, '2': 1, 'doses': 1, 'vs': 1, 'omicron': 1, 'data': 1, '?': 1, '3': 1, '673': 1, '%': 1, 'efficacy': 1, 'compared': 1, 'unvaxxed': 1, '663': 1, 'would': 1, 'make': 1, 'nearly': 1, 'zero': 1, 'right': 1}, {'yes': 1, 'novavax': 1, 'included': 1, 'covboost': 1, 'trial': 1, 'conducted': 1, 'uk': 1, 'fall': 1, '2021': 1, 'http': 1, 'wwwthelancetcomjournalslancetarticlepiis01406736': 1, '21': 1, '027173fulltext': 1}, {'tcell': 1, 'vaccines': 1, '?': 1, 'method': 1, 'vaccination': 1, 'virus': 1, 'somehow': 1, 'spur': 1, 'bcell': 1, 'activity': 1, 'antibody': 1, 'production': 1, 'references': 1, 'pointers': 1, 'somewhere': 1, 'read': 1}, {'source': 1, '?': 1, 'nt': 1, 'believe': 1, 've': 1, 'seen': 1, 'data': 1, 'severity': 1, 'omicron': 1, 'yet': 1}, {'friendly': 1, 'reminder': 1, 'vaers': 1, 'data': 1, 'nt': 1, 'moderated': 1, 'verified': 1, 'anyone': 1, 'allowed': 1, 'submit': 1}, {'let': 1, 'study': 1, 'run': 1, 'past': 1, 'dec': 1, '27th': 1, 'well': 1, 'omicron': 1, 'spike': 1, 'week': 1, 'could': 1, 'see': 1, 'change': 1, 'counted': 1, 'previous': 1, 'infections': 1, 'dated': 1, '13': 1, 'months': 1, 'ago': 1, 'definitely': 1, '2nd': 1, 'vaccine': 1, 'doses': 1, 'later': 1, 'perhaps': 1, '56': 1, 'fairer': 1, 'way': 1, 'compare': 1, 'immunity': 1, 'would': 1, 'include': 1, 'prior': 1, 'average': 1, 'dose': 1, 'timing': 1, 'infection': 1, 'risk': 1, 'getting': 1, 'covid': 1, 'twice': 1, 'year': 1}, {'yes': 1, 'seen': 1, 'hypothesizing': 1, 'twitter': 1, 'would': 1, 'little': 1, 'bit': 1, 'less': 1, 'immune': 1, 'escape': 1, 'nice': 1, 'see': 1, 'theory': 1, 'translate': 1, 'real': 1, 'world': 1, 'data': 1}, {'iäôm': 1, 'expert': 1, 'read': 1, 'lot': 1, 'stuff': 1, 'pretty': 1, 'much': 1, 'answer': 1, 'third': 1, 'vaccinationexposure': 1, 'antigen': 1, 'seems': 1, 'stimulate': 1, 'immune': 1, 'system': 1, 'able': 1, 'make': 1, 'äúbetteräù': 1, 'antibodies': 1, 'equipped': 1, 'äúdeal': 1, 'withäù': 1, 'variants': 1, 'illustrate': 1, 'point': 1, 'could': 1, 'äúthinkäù': 1, 'äútalkäù': 1, 'itäôs': 1, 'basically': 1, 'saying': 1, 'äúlooks': 1, 'like': 1, 'weäôre': 1, 'going': 1, 'see': 1, 'often': 1, 'letäôs': 1, 'brainstorm': 1, 'deal': 1, 'better': 1, 'futureäù': 1, 'also': 1, 'stands': 1, 'reason': 1, 'even': 1, 'wane': 1, 'expected': 1, 'b': 1, 'cells': 1, 'boosted': 1, 'systems': 1, 'would': 1, 'remain': 1, 'jump': 1, 'back': 1, 'action': 1, 'upon': 1, 'subsequent': 1, 'infection': 1, 'another': 1, 'interesting': 1, 'question': 1, 'äúif': 1, '3': 1, '2': 1, '4': 1, 'diminishing': 1, 'returns': 1, 'begins': 1, 'set': 1, '?': 1, 'äù': 1}, {'yeah': 1, 'itäôs': 1, 'odd': 1, 'see': 1, 'shift': 1, 'quickly': 1, 'decently': 1, 'positive': 1, 'protection': 1, 'hugely': 1, 'negative': 1, 'timespan': 1, 'months': 1, 'even': 1, 'assume': 1, 'true': 1, '91150': 1, 'literally': 1, 'zero': 1, 'takes': 1, 'decent': 1, 'sized': 1, 'behavioral': 1, 'adjustment': 1, 'get': 1, 'estimate': 1, '75': 1, '0': 1, 'apply': 1, 'previous': 1, 'intervals': 1, 'become': 1, 'much': 1, 'higher': 1, 'estimates': 1, 'weäôve': 1, 'seen': 1, 'studies': 1, 'omicron': 1}, {'nt': 1, 'think': 1, 'new': 1, 'research': 1, 'omicron': 1, 'would': 1, 'time': 1, 'next': 1, 'mutation': 1, 'occurs': 1, 'current': 1, 'vaccines': 1, 'based': 1, 'wildtype': 1, 'strain': 1, 'work': 1, 'well': 1, 'delta': 1, 'lineage': 1, 'branch': 1, 'beta': 1, 'basing': 1, 'vaccinationbooster': 1, 'strategy': 1, 'base': 1, 'likely': 1, 'serious': 1, 'variant': 1, 'extremely': 1, 'prudent': 1, 'need': 1, 'match': 1, 'omicronbased': 1, 'descendant': 1}, {'think': 1, 'could': 1, 'https': 1, 'wwwredditcomrcovid19commentsse4fvacommenthumyxxm': 1, '?': 1, 'utm_sourceshare': 1, '&': 1, 'utm_mediumweb2x': 1, 'context3': 1, 'calculations': 1, 'correct': 1, 'incidence': 1, 'rates': 1, 'hospitalization': 1, 'death': 1, '2dose': 1, 'vaxxed': 1, 'seem': 1, 'better': 1, 'really': 1, 'unvaxxed': 1, 'case': 1, 'way': 1, 'worse': 1, 'among': 1, 'big': 1, 'question': 1, 'whether': 1, 'actually': 1, 'prone': 1, 'infection': 1, 'somehow': 1, 'eg': 1, 'happen': 1, 'something': 1, 'like': 1, 'ade': 1, 'counts': 1, 'higher': 1, 'behavioral': 1, 'confounders': 1, 'theyäôre': 1, 'would': 1, 'least': 1, 'two': 1, 'doses': 1, 'still': 1, 'provides': 1, 'high': 1, 'degree': 1, 'protection': 1, 'severe': 1, 'disease': 1, 'outcomes': 1, 'balance': 1, 'thinking': 1, 'correctly': 1, 'say': 1, 'itäôs': 1, 'making': 1, 'boosters': 1, 'look': 1, 'much': 1, 'youäôd': 1, 'expect': 1}, {'astrazeneca': 1, 'sputnik': 1, 'sinopharm': 1, 'argentina': 1}, {'since': 1, 'studied': 1, 'immunology': 1, 'really': 1, 'interesting': 1, 'new': 1, 'phenomenon': 1, 'name': 1, 'point': 1, 'towards': 1, 'literature': 1, 'subject': 1, '?': 1, 'd': 1, 'like': 1, 'read': 1}, {'denmark': 1, 'may': 1, 'data': 1, 'make': 1, 'varied': 1, 'analysis': 1}, {'suggesting': 1, 'effectiveness': 1, '2': 1, 'doses': 1, 'nearly': 1, 'zero': 1, 'vs': 1, 'omicron': 1, '?': 1}, {'apparently': 1, 'striations': 1, 'figures': 1, '2': 1, 'm': 1, 'reading': 1, 'right': 1, 'make': 1, 'extremely': 1, 'skeptical': 1, 'overall': 1, 'validity': 1, 'model': 1, 'reflection': 1}, {'first': 1, 'sentence': 1, 'data': 1, 'give': 1, 'p': 1, 'value': 1, 'donäôt': 1, 'see': 1, 'conclude': 1, 'vaccine': 1, 'covid': 1, 'statistically': 1, 'significant': 1, 'increase': 1, 'immunity': 1, 'clinically': 1, '94': 1, '%': 1, 'people': 1, 'vaccinated': 1, 'number': 1, 'unvaccinated': 1, 'prior': 1, 'infection': 1, 'small': 1, 'likely': 1, 'enough': 1, 'power': 1, 'use': 1, 'definitively': 1, 'finally': 1, 'forget': 1, 'relative': 1, 'risk': 1, 'absolute': 1, 'reduction': 1, 'shot': 1, 'post': 1, 'compare': 1, '?': 1, 'change': 1, 'age': 1, 'sex': 1, 'sample': 1, '84': 1, 'women': 1, 'average': 1, '46': 1, 'seem': 1, 'overgeneralize': 1, 'findings': 1, 'support': 1, 'claim': 1}, {'great': 1, 'article': 1, 'anything': 1, 'offers': 1, 'glimpse': 1, 'advanced': 1, 'understanding': 1, 'social': 1, 'media': 1, 'used': 1, 'influence': 1, 'public': 1, 'opinion': 1, 'become': 1, 'sure': 1, 'think': 1, 'mixed': 1, 'feelings': 1, 'say': 1, 'least': 1}, {'africa': 1, 'much': 1, 'healthier': 1, '?': 1, 'nt': 1, 'close': 1, 'quarter': 1, 'hiv': 1, 'well': 1, 'study': 1, 'massive': 1, 'sample': 1, 'size': 1, 'n227k': 1, 'control': 1, 'group': 1, 's': 1, 're': 1, 'comparing': 1, 'vaxxed': 1, 'africans': 1, 'unvaxxed': 1, 'americans': 1}, {'prior': 1, 'dominant': 1, 'variants': 1, 'may': 1, 'direct': 1, 'descendants': 1, 'one': 1, 'another': 1, 'genetically': 1, 'much': 1, 'closer': 1, 'nt': 1, 'think': 1, 'omicron': 1, 'necessarily': 1, 'established': 1, 'new': 1, 'norm': 1, 'vocs': 1, 'complete': 1, 'breakaways': 1, 'coming': 1, 'nowhere': 1}, {'heart': 1, 'inflammation': 1, 'exists': 1, 'person': 1, 'walks': 1, 'doors': 1, 'hospital': 1, '?': 1, 'trying': 1, 'say': 1, 'guy': 1}, {'headline': 1, 'think': 1, 'significantly': 1, 'negative': 1, 'vaccine': 1, 'effectiveness': 1, 'estimates': 1, 'omicron': 1, '2dose': 1, 'vaccination': 1, 'either': 1, 'pfizer': 1, 'moderna': 1, '91150': 1, 'days': 1, '14': 1, 'second': 1, 'dose': 1, 'authors': 1, 'offer': 1, 'following': 1, 'explanation': 1, 'final': 1, 'period': 1, 'arguably': 1, 'suggest': 1, 'different': 1, 'behaviour': 1, 'andor': 1, 'exposure': 1, 'patterns': 1, 'vaccinated': 1, 'unvaccinated': 1, 'cohorts': 1, 'causing': 1, 'underestimation': 1, 'likely': 1, 'result': 1, 'spreading': 1, 'rapidly': 1, 'initially': 1, 'single': 1, 'superspreading': 1, 'events': 1, 'many': 1, 'infections': 1, 'among': 1, 'young': 1, 'individuals': 1, 'seems': 1, 'reasonable': 1, 'though': 1, 'want': 1, 'another': 1, 'possibility': 1, 'mention': 1, 'excluded': 1, 'previously': 1, 'pcrpositive': 1, 'however': 1, 'would': 1, 'wonder': 1, 'adequately': 1, 'controls': 1, 'prior': 1, 'infection': 1, 'might': 1, 'reasonably': 1, 'expect': 1, 'higher': 1, 'proportion': 1, 'undocumented': 1, 'less': 1, 'protected': 1, 'delta': 1, 'wave': 1, 'perhaps': 1, 'tested': 1, 'thoughts': 1, '?': 1}, {'yes': 1, 'exactly': 1, 'tell': 1, 'room': 1, 'full': 1, 'people': 1, 'exposed': 1, 'xx': 1, 'many': 1, 'feeling': 1, 'symptoms': 1, '?': 1, 'brains': 1, 'make': 1, 'hypersensitive': 1, 'anything': 1, 'resembling': 1}, {'actually': 1, 'effectiveness': 1, 'infection': 1, 'roughly': 1, '0': 1, '%': 1, '8': 1, 'months': 1, 'gotten': 1, 'vaccinated': 1, 'changes': 1, 'behavior': 1, 'think': 1, 'could': 1, 'see': 1, 'graph': 1, 'like': 1}, {'holds': 1, 'true': 1, 's': 1, 'likely': 1, 'vaccines': 1, 'saved': 1, 'many': 1, 'lives': 1, 'giving': 1, 'omicron': 1, 'advantage': 1, 'delta': 1, 'significantly': 1, 'less': 1, 'cause': 1, 'death': 1, 'recovery': 1, 'infection': 1, 'seem': 1, 'prevent': 1, 'reinfection': 1, 'least': 1, 'near': 1, 'term': 1, 'speed': 1, 'science': 1, 'able': 1, 'develop': 1, 'deploy': 1, 'c19': 1, 'essential': 1, 'occur': 1}, {'would': 1, 'concerned': 1, 'effect': 1, 'well': 1, 'trying': 1, 'estimate': 1, 'using': 1, 'hypothetical': 1, 'recently': 1, 'imagine': 1, '3': 1, 'groups': 1, 'people': 1, 'base': 1, 'line': 1, 'hospitalization': 1, 'rate': 1, '%': 1, 'causes': 1, 'disease': 1, 'hospitalizes': 1, '10': 1, 'get': 1, 'also': 1, '2': 1, 'vaccines': 1, 'vaccine': 1, 'b': 1, '100': 1, 'effective': 1, '0': 1, 'infection': 1, 'c': 1, 'extension': 1, 'give': 1, 'first': 1, 'group': 1, 'second': 1, 'third': 1, 'study': 1, 'count': 1, 'associated': 1, 'hospitalizations': 1, 'patient': 1, 'hospitalized': 1, 'tests': 1, 'positive': 1, 'nt': 1, 'require': 1, '_caused_': 1, '1000': 1, 'everyone': 1, 'infected': 1, 'scales': 1, 'pick': 1, 'without': 1, 'effecting': 1, 'outcome': 1, 'much': 1, '1': 1, '13': 1, '110': 1, '127': 1, 'exposed': 1, '30': 1, '_marked_': 1, 'even': 1, 'though': 1, 'happened': 1, 'anyway': 1, 'baseline': 1, 'prevention': 1, 'means': 1, 'none': 1, 'marked': 1, 'per': 1, 'show': 1, 'protection': 1, '764': 1, 's': 1, 'reality': 1, 'perfect': 1, 'gets': 1, 'worse': 1, 'older': 1, 'increases': 1, 'trial': 1, 'protocols': 1, 'pfizermoderna': 1, 'explicitly': 1, 'control': 1, 'counting': 1, 'severe': 1, 'cases': 1, 'instead': 1, 'explicit': 1, 'symptomatic': 1, 'criteria': 1, 'fact': 1, 'observational': 1, 'studies': 1, 'seem': 1, 'always': 1, 'concerning': 1}, {'confidence': 1, 'interval': 1, 'incubation': 1, 'time': 1, 'means': 1, 'statistics': 1, 'show': 1, '95': 1, '%': 1, 'chance': 1, 'true': 1, 'period': 1, 'somewhere': 1, '287': 1, 'days': 1, '36': 1}, {'doesnäôt': 1, 'make': 1, 'sense': 1, 'youäôd': 1, 'comparison': 1, 'information': 1, 'means': 1, 'like': 1, 'tell': 1, 'anything': 1, 'effect': 1, 'covid': 1, 'vaccine': 1}, {'came': 1, 'say': 1, 'omicron': 1, 'qualitative': 1, 'change': 1, 'need': 1, 'roll': 1, 'updated': 1, 'vaccine': 1, 'september': 1, 'latest': 1}, {'omicron': 1, 'better': 1, 'replication': 1, 'upper': 1, 'respiratory': 1, 'tract': 1, 'lungs': 1, 'spreads': 1, 'efficiently': 1, 'less': 1, 'severe': 1, 'disease': 1, 'äúomicron': 1, 'sarscov2': 1, 'infects': 1, 'multiplies': 1, '70': 1, 'times': 1, 'faster': 1, 'delta': 1, 'variant': 1, 'original': 1, 'human': 1, 'bronchus': 1, 'may': 1, 'explain': 1, 'transmit': 1, 'humans': 1, 'previous': 1, 'variants': 1, 'study': 1, 'also': 1, 'showed': 1, 'infection': 1, 'lung': 1, 'significantly': 1, 'lower': 1, 'indicator': 1, 'severityäù': 1, 'https': 1, 'wwwmedhkuhkennewspress20211215omicronsarscov2infection': 1}, {'think': 1, 'idea': 1, 'load': 1, 'infection': 1, 'one': 1, 'presumably': 1, 'significant': 1, 'exposure': 1, 'spike': 1, 's': 1, 'spread': 1, 'time': 1, 'whereas': 1, 'vaccination': 1, 'massive': 1, 'created': 1, 'body': 1, 'short': 1, 'period': 1, 'basically': 1, 'poison': 1, 'dose': 1, 'per': 1, 'unit': 1, 'm': 1, 'cellular': 1, 'biologist': 1, 'ca': 1, 'nt': 1, 'act': 1, 'expert': 1, 'way': 1, 'another': 1, 'playing': 1, 'devil': 1, 'advocate': 1, 'important': 1, 'genuinely': 1, 'want': 1, 'understand': 1, 'opposition': 1}, {'yes': 1, 'age': 1, 'sexweighted': 1, 'increase': 1, 'first': 1, 'second': 1, 'doses': 1, 'combined': 1, '152': 1, 'cases': 1, 'per': 1, '100000': 1, 'vaccinees': 1, 'ie': 1, '1': 1, '65800': 1, 'females': 1, '65': 1, '462': 1, '21600': 1, 'confidence': 1, 'intervals': 1, 'quite': 1, 'wide': 1, 'see': 1, 'rightmost': 1, 'column': 1, 'table': 1, 'detail': 1}, {'widely': 1, 'reported': 1, 'degree': 1, '?': 1, 'sometimes': 1, 'papers': 1, 'say': 1, 'x': 1, 'effective': 1, 'actually': 1, 'mean': 1, 'barely': 1}, {'seems': 1, 'though': 1, 'least': 1, 'itäôs': 1, 'talking': 1, 'catching': 1, 'badly': 1, 'effect': 1}, {'usually': 1, 'confounding': 1, 'factors': 1, 'could': 1, 'genuine': 1, 'situations': 1, 'read': 1, 'case': 1, 'negative': 1, 'meaning': 1, 's': 1, 'enhanced': 1, 'risk': 1, 'infection': 1, 'opposed': 1, 'reduced': 1, 'one': 1, 'likely': 1, 'combination': 1, 'cryptic': 1, 'infections': 1, 'unvaccinated': 1, 'group': 1, 'boosting': 1, 'aggregate': 1, 'immunity': 1, 'true': 1, 'zero': 1, 'well': 1, 'better': 1, 'healthcare': 1, 'seeking': 1, 'behavior': 1, 'vaccinated': 1, 'equivalent': 1, 'protection': 1, 'vaccine': 1, 'close': 1, 'get': 1, 'artefactual': 1, 'ves': 1}, {'relevant': 1, 'numbers': 1, 'study': 1, 'follows': 1, 'vaccine': 1, 'status': 1, 'omicron': 1, 'delta': 1, 'cov': 1, 'negative': 1, '3': 1, 'mrna': 1, '2441': 1, '679': 1, '18587': 1, '2': 1, '7245': 1, '4570': 1, '19456': 1, '0': 1, '3412': 1, '5044': 1, '8721': 1, 'simplicity': 1, 'let': 1, 's': 1, 'consider': 1, 'authors': 1, 'call': 1, 'crude': 1, 'oddsratio': 1, 'odds': 1, 'ratio': 1, 'vs': 1, 'unvaccinated': 1, 'would': 1, 'defined': 1, 'positive': 1, '724519456': 1, '34128721': 1, '095179210094': 1, 'relative': 1, 'effectiveness': 1, 'taken': 1, '1': 1, 'gives': 1, 'us': 1, '004820789905': 1, '482': 1, '%': 1}, {'estimates': 1, 'protection': 1, 'natural': 1, 'immunity': 1, 'similar': 1, 'timeframes': 1, '?': 1}, {'research': 1, 'funded': 1, 'j': 1, '&': 1, 'janssen': 1, 'vaccines': 1, 'barouch': 1, 'patent': 1, 'conflicts': 1, 'interest': 1, 'previous': 1, 'papers': 1, 'similar': 1, 'positive': 1, 'spin': 1, 'narrative': 1, 'general': 1, 'tenor': 1, 'tension': 1, 'findings': 1, 'independent': 1, 'studies': 1, 'n24': 1, '41': 1, 'small': 1, 'numbers': 1, 'canäôt': 1, 'find': 1, 'information': 1, 'preprint': 1, 'demographic': 1, 'characteristics': 1, 'two': 1, 'study': 1, 'groups': 1, 'vaguest': 1, 'allusion': 1, 'selected': 1, 'split': 1, '65': 1, '24': 1, 'jj': 1, 'bnt': 1, 'appear': 1, 'randomized': 1, 'way': 1, 'missing': 1, 'something': 1, '?': 1}, {'abstract': 1, 'paper': 1, 'presents': 1, 'effect': 1, 'covid19': 1, 'mrna': 1, 'pfizerbiont': 1, 'vaccine': 1, 'vitro': 1, 'glial': 1, 'cells': 1, 'brain': 1, 'studied': 1, 'means': 1, 'raman': 1, 'spectroscopy': 1, 'imaging': 1, 'results': 1, 'obtained': 1, 'human': 1, 'normal': 1, 'tumor': 1, 'astrocytes': 1, 'astrocytoma': 1, 'glioblastoma': 1, 'incubated': 1, 'show': 1, 'alterations': 1, 'reductionoxidation': 1, 'pathways': 1, 'associated': 1, 'cytochrome': 1, 'c': 1, 'found': 1, 'regulate': 1, 'concentration': 1, 'mitochondria': 1, 'upon': 1, 'incubation': 1, 'tumorous': 1, 'oxidized': 1, 'form': 1, 'shown': 1, 'decrease': 1, 'lower': 1, 'effectiveness': 1, 'oxidative': 1, 'phosphorylation': 1, 'respiration': 1, 'reduced': 1, 'apoptosis': 1, 'lessened': 1, 'atp': 1, 'production': 1, 'alteration': 1, 'amide': 1, 'may': 1, 'reflect': 1, 'adenine': 1, 'nucleotide': 1, 'translocator': 1, 'moreover': 1, 'leads': 1, 'biochemical': 1, 'composition': 1, 'lipids': 1, 'suggest': 1, 'increasing': 1, 'role': 1, 'signaling': 1, 'produce': 1, 'statistically': 1, 'significant': 1, 'changes': 1, 'cell': 1, 'nucleus': 1, 'due': 1, 'histone': 1, 'lipid': 1, 'droplets': 1, 'cytoplasm': 1, 'reprograms': 1, 'immune': 1, 'responses': 1, 'observed': 1, 'profiles': 1, 'specific': 1, 'organelles': 1, 'similar': 1, 'observe': 1, 'cancer': 1, 'vs': 1, 'grade': 1, 'aggressiveness': 1}, {'associations': 1, 'strongest': 1, 'males': 1, 'younger': 1, '40': 1, 'years': 1, 'vaccine': 1, 'types': 1, 'additional': 1, '3': 1, '95': 1, '%': 1, 'ci': 1, '1': 1, '5': 1, '12': 1, '117': 1, 'events': 1, 'per': 1, 'million': 1, 'estimated': 1, '128': 1, 'days': 1, 'following': 1, 'first': 1, 'dose': 1, 'bnt162b2': 1, 'mrna1273': 1, 'respectively': 1, '14': 1, '8': 1, '17': 1, '7': 1, '101': 1, '104': 1, 'second': 1, 'chadox1': 1, '13': 1, '15': 1, 'third': 1, 'compared': 1, '2': 1, '11': 1, 'covid19': 1, 'infection': 1, 'still': 1, 'supports': 1, 'mandated': 1, 'double': 1, 'vaccinations': 1, 'healthy': 1, 'young': 1, 'already': 1, '?': 1, 'scientific': 1, 'rationale': 1, '1316': 1, 'age': 1, 'group': 1}, {'third': 1, 'explanation': 1, 'likelihood': 1, 'seek': 1, 'testing': 1, 'wish': 1, 'investigated': 1, 'study': 1, 'nt': 1, 'say': 1, 'anything': 1, 'specific': 1, 'protocol': 1, 'given': 1, 're': 1, 'using': 1, 'administrative': 1, 'data': 1, 'expect': 1, 'looking': 1, 'share': 1, 'group': 1, 'positive': 1, 'test': 1, 'january': 1, 'october': 1, 'normal': 1, 'swedish': 1, 'time': 1, 'could': 1, 'heavily': 1, 'influenced': 1, 'vaccinated': 1, 'people': 1, 'likely': 1, 'get': 1, 'tested': 1, 'various': 1, 'reasons': 1, 'trust': 1, 'health': 1, 'system': 1, 'conscientious': 1, 'generally': 1, 'concerned': 1, 'covid': 1, 'match': 1, 'criteria': 1, 'used': 1, 'would': 1, 'control': 1, 'effect': 1}, {'abstract': 1, 'sarscov2': 1, 'omicron': 1, 'highly': 1, 'transmissible': 1, 'substantial': 1, 'resistance': 1, 'antibody': 1, 'neutralization': 1, 'following': 1, 'immunization': 1, 'ancestral': 1, 'spikematched': 1, 'vaccines': 1, 'unclear': 1, 'whether': 1, 'boosting': 1, 'omicronspecific': 1, 'would': 1, 'enhance': 1, 'immunity': 1, 'protection': 1, 'nonhuman': 1, 'primates': 1, 'received': 1, 'mrna1273': 1, 'weeks': 1, '0': 1, '4': 1, 'boosted': 1, 'week': 1, '41': 1, 'mrnaomicron': 1, 'neutralizing': 1, 'titers': 1, 'd614g': 1, '4760': 1, '270': 1, 'reciprocal': 1, 'id50': 1, '6': 1, 'peak': 1, 'preboost': 1, 'respectively': 1, '320': 1, '110': 1, 'two': 1, 'boost': 1, 'increased': 1, '5360': 1, '2980': 1, '2670': 1, '1930': 1, 'either': 1, '7080': 1, '%': 1, 'spikespecific': 1, 'b': 1, 'cells': 1, 'crossreactive': 1, 'wa1': 1, 'significant': 1, 'equivalent': 1, 'control': 1, 'virus': 1, 'replication': 1, 'lower': 1, 'airways': 1, 'observed': 1, 'therefore': 1, 'an': 1, 'may': 1, 'provide': 1, 'greater': 1, 'compared': 1, 'current': 1, 'vaccine': 1}, {'also': 1, 'many': 1, 'asymptomatic': 1, 'went': 1, 'ed': 1, 'urgent': 1, 'care': 1, 'get': 1, 'tested': 1, '?': 1}, {'admission': 1, 'rates': 1, '545': 1, '%': 1, 'alpha': 1, '430': 1, 'delta': 1, '147': 1, 'omicron': 1, 'median': 1, 'lengthofstay': 1, 'days': 1, '51': 1, '54': 1, '30': 1, 'although': 1, 'nt': 1, 'explicitly': 1, 'say': 1, 'stay': 1, 'length': 1, 'must': 1, 'admitted': 1, 'patients': 1, 'else': 1, 'would': 1, '0': 1, 'since': 1, 'less': 1, 'half': 1}, {'spring': 1, 'wave': 1, 'seems': 1, 'par': 1, 'course': 1, 'seasonality': 1, 'virus': 1, 'far': 1, 'saying': 1, 'would': 1, 'likely': 1, 'happen': 1, 'since': 1, 'even': 1, 'omicron': 1, 'anecdotally': 1, 'people': 1, 'tend': 1, 'report': 1, 'increase': 1, 'common': 1, 'colds': 1, 'change': 1, 'season': 1, 'nt': 1, 'found': 1, 'cold': 1, 'hard': 1, 'data': 1, 'support': 1, 'many': 1, 'think': 1, 'seasonal': 1, 'pattern': 1, 'mean': 1, 'flulike': 1, 'absolutely': 1, 'case': 1, 'however': 1, 'fall': 1, 'winter': 1, 'much': 1, 'higher': 1, 'intensity': 1, 'may': 1, 'depend': 1, 'variants': 1, 'circulation': 1, 'level': 1, 'immunity': 1, 'built': 1, 'previous': 1, 'without': 1, 'models': 1, 'precise': 1, 'enough': 1, 'know': 1, 'uncertainty': 1, 'new': 1, 'encourage': 1, 'booster': 1, 'doses': 1, 'vulnerable': 1, 'wait': 1, 'perhaps': 1, 'adapted': 1, 'public': 1, 'health': 1, 'perspective': 1, 'second': 1, 'option': 1, 'favorable': 1, 'avoid': 1, 'losing': 1, 'confidence': 1}, {'paper': 1, 'states': 1, 'took': 1, 'prescribed': 1, 'amphetaminedextroamphetamine': 1, 'school': 1, 'year': 1, 'attention': 1, 'deficit': 1, 'hyperactivity': 1, 'disorder': 1, 'currently': 1, 'receiving': 1, 'chronic': 1, 'stimulant': 1, 'use': 1, 'long': 1, 'known': 1, 'bad': 1, 'heart': 1, 'nt': 1, 'think': 1, 'draw': 1, 'conclusions': 1, 'see': 1, 'reason': 1, 'avoid': 1, 'vaccination': 1, 'history': 1}, {'think': 1, 'itäôs': 1, 'safe': 1, 'point': 1, 'assume': 1, 'significant': 1, 'number': 1, 'unvaccinated': 1, 'things': 1, 'covid': 1, 'mitigation': 1, 'even': 1, 'acknowledging': 1, 'existence': 1, 'ergo': 1, 'would': 1, 'seek': 1, 'testing': 1}, {'sad': 1, 'literally': 1, 'address': 1, 'evidence': 1, 'rapid': 1, 'decline': 1, 'hyperelevated': 1, 'antibodies': 1, 'vaccinated': 1, 'within': 1, 'study': 1, 'mention': 1, 'absent': 1, 'titleabstract': 1, 'generous': 1, 'suppose': 1, 'could': 1, 'interpret': 1, 'suggests': 1, 'potential': 1, 'need': 1, 'maintain': 1, 'high': 1, 'rbd': 1, 'antibody': 1, 'levels': 1, 'control': 1, 'infectious': 1, 'sarscov2': 1, 'variants': 1, 'hint': 1}, {'think': 1, 'fundamental': 1, 'problem': 1, 'fast': 1, 'omicron': 1, 'replicates': 1, 'get': 1, 'breakthrough': 1, 'infections': 1, 'even': 1, 'appropriate': 1, 'antibodies': 1, 'mean': 1, 'people': 1, 'might': 1, 'start': 1, 'infected': 1, 'every': 1, '2': 1, 'months': 1, 'possibly': 1, 'week': 1, 'period': 1, '?': 1}, {'probably': 1, 'due': 1, 'dose': 1, 'lower': 1, 'booster': 1, 'modena': 1}, {'course': 1, 'questions': 1, 'knowing': 1, 'someone': 1, 'ended': 1, 'emergency': 1, 'room': 1, 'following': 1, 'vaccine': 1, 'right': 1, '?': 1, 'thank': 1, 'god': 1, 'reddit': 1, 'commenters': 1, 'ones': 1, 'designing': 1, 'studies': 1, 'confirm': 1, 'existing': 1, 'biases': 1, 'mostly': 1}, {'advantage': 1, 'survival': 1, 'matter': 1, 'slight': 1, 'tend': 1, 'reduce': 1, 'virulence': 1, 'enhance': 1, 'transmission': 1, 'heavy': 1, 'lifting': 1, 'whole': 1, 'classes': 1, 'beneficial': 1, 'virus': 1, 'adaptions': 1, 'increase': 1, 'things': 1, 'like': 1, 'higher': 1, 'replication': 1, 'rate': 1, 'receptor': 1, 'affinity': 1, 'etc': 1, 'delta': 1, 'pretty': 1, 'clear': 1, 'case': 1, 'study': 1, 'important': 1}, {'time': 1, 'though': 1, 'could': 1, 'expect': 1, 'become': 1, 'generally': 1, 'linear': 1, '?': 1, 'variants': 1, 'like': 1, 'omicron': 1, 'ba2': 1, 'becoming': 1, 'dominant': 1, 'nondominant': 1, 'die': 1, 'least': 1, 'fewer': 1, 'opportunities': 1, 'mutate': 1, 'therefore': 1, 'less': 1, 'likely': 1}, {'yep': 1}, {'broader': 1, 'antibodies': 1, 'induced': 1, 'process': 1, 'somatic': 1, 'hypermutation': 1, 'affinity': 1, 'maturation': 1, 'within': 1, 'b': 1, 'cells': 1, 'germinal': 1, 'centres': 1}, {'nt': 1, 'advised': 1, 'exercise': 1, 'two': 1, 'weeks': 1, 'vaccination': 1, 'order': 1, 'prevent': 1, 'myocarditis': 1, '?': 1}, {'symptomatic': 1, 'infection': 1, 'â': 1, 'hospitalizeddead': 1, 'weäôre': 1, 'back': 1, 'start': 1, 'means': 1}, {'mean': 1, 'omicron': 1, 'end': 1, 'story': 1, 'covid': 1, '19': 1, 'fully': 1, 'adapted': 1, 'humans': 1, '?': 1}, {'thing': 1, 'thought': 1, 'interesting': 1, 'use': 1, 'prefusion': 1, 'spike': 1, 'nice': 1, 'see': 1}, {'difference': 1, 'study': 1, 'vaccine': 1, 'covid': 1, 'variants': 1, 'predate': 1, 'omicron': 1, 'might': 1, 'assume': 1, 'would': 1, 'effective': 1, 'unfortunately': 1, 'longer': 1, 'community': 1, 'question': 1, 'regulators': 1, 'whether': 1, 'approve': 1, 'similar': 1, 'original': 1, 'vaccines': 1, 'repeat': 1, 'trials': 1, 'something': 1, 'geared': 1, 'towards': 1, 'current': 1, 'given': 1, 'taken': 1, 'years': 1, 'complete': 1, 'repeating': 1, 'likely': 1, 'take': 1, 'least': 1, 'another': 1, 'year': 1, 'bet': 1, 'plan': 1, 'boosters': 1, 'align': 1, 'age': 1, 'groups': 1}, {'think': 1, 'headlines': 1, 'stop': 1, 'focusing': 1, 'äúpreventing': 1, 'infectionäù': 1, 'instead': 1, 'much': 1, 'help': 1, 'protect': 1, 'severe': 1, 'disease': 1, 'hospitalization': 1, 'long': 1}, {'anyone': 1, 'give': 1, 'good': 1, 'reason': 1, 'fda': 1, 'nt': 1, 'approved': 1, 'covaxin': 1, '?': 1, 've': 1, 'pediatric': 1, 'data': 1, 'months': 1, 'appears': 1, 'safe': 1, 'effective': 1, 'approving': 1, 'traditional': 1, 'vaccine': 1, 'like': 1, 'seems': 1, 'nobrainer': 1, 'especially': 1, 'one': 1, 'well': 1, '100': 1, 'mil': 1, 'already': 1, 'recieved': 1}, {'wait': 1, 'anyone': 1, 'else': 1, 'find': 1, 'title': 1, 'absurdly': 1, 'misleading': 1, '?': 1, 'myocarditis': 1, 'risk': 1, '17': 1, 'times': 1, 'higher': 1, 'unvaccinated': 1, 'patients': 1, 'ages': 1, '1230': 1, 'get': 1, 'covid19': 1, 'covidvaccinated': 1, 'certain': 1, 'saying': 1, 'infection': 1, '17fold': 1, 'lower': 1, 'vaccinated': 1, 'vaccine': 1, 'reduces': 1, 'odds': 1, 'covidinduced': 1, 'fold': 1, 'looking': 1, 'contents': 1, 'data': 1, 'itäôs': 1, 'literally': 1, 'another': 1, 'comparison': 1, 'postvaccine': 1, 'versus': 1, 'postcovid': 1, 'way': 1, 'theyäôve': 1, 'worded': 1, 'highly': 1, 'confusing': 1}, {'suggest': 1, 'explanation': 1, 'negative': 1, 'estimates': 1, 'final': 1, 'period': 1, 'arguably': 1, 'different': 1, 'behaviour': 1, 'andor': 1, 'exposure': 1, 'patterns': 1, 'vaccinated': 1, 'unvaccinated': 1, 'cohorts': 1, 'causing': 1, 'underestimation': 1, 'likely': 1, 'result': 1, 'omicron': 1, 'spreading': 1, 'rapidly': 1, 'initially': 1, 'single': 1, 'superspreading': 1, 'events': 1, 'many': 1, 'infections': 1, 'among': 1, 'young': 1, 'individuals': 1}, {'unless': 1, 'm': 1, 'missing': 1, 'something': 1}, {'https': 1, 'wwwosfhealthcareorgblogcovidneurologicalimpact': 1, 'hereäôs': 1, 'example': 1, 'post': 1, 'effects': 1, 'thatäôs': 1, 'even': 1, 'counting': 1, 'harm': 1, 'infection': 1, 'like': 1, 'wwwhopkinsmedicineorghealthconditionsanddiseasescoronaviruswhatcoronavirusdoestothelungs': 1}, {'tbf': 1, 'study': 1, 'nt': 1, 'designed': 1, 'detect': 1, 'anything': 1, 'consequence': 1, 'unfortunately': 1, 'small': 1, 'safety': 1, 'efficacy': 1, 'less': 1, '50': 1, '%': 1, 'infection': 1, '0': 1, 'severe': 1, 'disease': 1}, {'say': 1, 'booster': 1, 'dose': 1, 'within': 1, 'last': 1, '25': 1, 'months': 1, 'donäôt': 1, 'see': 1, 'specify': 1, 'least': 1, '2': 1, 'weeks': 1, 'ago': 1, 'implied': 1, 'triple': 1, 'vaxxed': 1, '?': 1, 'missing': 1, 'somewhere': 1}, {'though': 1}, {'think': 1, 'pandemic': 1, 'organism': 1, 'simply': 1, 'wanting': 1, 'survive': 1, 'imagine': 1, 'primary': 1, 'reservoir': 1, 'survival': 1, 'fights': 1, 'back': 1, 'old': 1, 'school': 1, 'physiological': 1, 'responses': 1, 'millions': 1, 'years': 1, 'also': 1, 'utilizes': 1, 'physical': 1, 'barriers': 1, 'transmission': 1, 'vaccines': 1, 'keep': 1, 'surviving': 1, 'face': 1, 'challenges': 1, 'continued': 1, 'existence': 1, '?': 1, 'yes': 1, 'realize': 1, 'engaging': 1, 'anthropomorphism': 1, 'bottom': 1, 'line': 1, 'pretty': 1, 'much': 1, 'omicron': 1, 'outcome': 1, 'studied': 1, 'researched': 1, 'great': 1, 'deal': 1, 'organisms': 1, 'work': 1, 'frankly': 1, 'tip': 1, 'spear': 1, 'epi': 1, 'academic': 1, 'one': 1, 'nt': 1, 'care': 1, 'genomic': 1, 'details': 1, 'except': 1, 'need': 1, 'understand': 1, 'aspect': 1, 'population': 1, 'penetration': 1, 'sequelae': 1, 'best': 1, 'research': 1, 'gets': 1, 'things': 1, 'concerned': 1, 'bird': 1, 'followed': 1, 'coast': 1, 'analysis': 1, 'changed': 1, 'course': 1, 'generalizations': 1, 'observations': 1, 'come': 1, 'see': 1, 'virulent': 1, 'become': 1, 'less': 1, 'spread': 1, 'naive': 1, 'advantage': 1, 'matter': 1, 'slight': 1, 'tend': 1, 'reduce': 1, 'virulence': 1, 'enhance': 1, 'happen': 1, 'surprisingly': 1, 'quickly': 1, 'forget': 1, 'two': 1, 'main': 1, 'coronaviruses': 1, 'live': 1, 'primarily': 1, 'seasonal': 1, 'pita': 1, 'present': 1, 'm': 1, 'surprised': 1, 'reading': 1, 'anything': 1, 'happened': 1, 'sars': 1, 'change': 1, 'efficient': 1, 'killing': 1, 'machine': 1, 'essentially': 1, 'disappearing': 1, 'extant': 1, 'threat': 1, 'mers': 1, 'able': 1, 'make': 1, 'transition': 1, 'something': 1, 'like': 1, 'covid': 1, 'heck': 1, 'syphilis': 1, 'turn': 1, 'sexually': 1, 'transmitted': 1, 'slow': 1, 'motion': 1, 'killer': 1, 'days': 1, 'ca': 1, 'find': 1, 'journal': 1, 'articles': 1, 'remember': 1, 'article': 1, 'trying': 1, 'virus': 1, 'started': 1, 'east': 1, 'somewhat': 1, 'became': 1, 'extremely': 1, 'point': 1, 'almost': 1, 'benign': 1, 'got': 1, 'west': 1, 'reason': 1, 'ran': 1, 'barrier': 1, 'ocean': 1, 'burden': 1, 'close': 1, '100': 1, '%': 1, 'animals': 1, 'susceptible': 1, 'certain': 1, 'characteristics': 1, 'died': 1, 'others': 1, 'distinct': 1, 'antagonistic': 1, 'populations': 1, 'look': 1, 'ccr5': 1, 'species': 1, 'reacted': 1, 'existential': 1, 'threats': 1, 'levels': 1, 'genome': 1, 'someone': 1, 'develops': 1, 'desriptive': 1, 'associated': 1, 'little': 1, 'seems': 1, 'done': 1, 'example': 1, 'toward': 1, 'improved': 1, 'depressed': 1, 'speed': 1, 'bit': 1, 'surprising': 1, 'reminded': 1, 'study': 1, 'read': 1, 'epidemic': 1, 'us': 1, 'fully': 1, 'understanding': 1, 'distinctions': 1, 'humans': 1, 'birds': 1, 'different': 1, 'types': 1, 'viruses': 1, 'blah': 1, 'know': 1, 'analyzing': 1, 'bark': 1, 'tree': 1, 'detail': 1, 'world': 1, 'goes': 1, 'time': 1, 'figure': 1, 'could': 1, 'late': 1, 'still': 1, 'wonder': 1, 'many': 1, 'epis': 1, 'would': 1, 'acted': 1, 'john': 1, 'snow': 1, 'waiting': 1, 'statistical': 1, 'significance': 1, 'better': 1, 'constructed': 1, 'learn': 1, 'perspectives': 1, 'inform': 1, 'epidemiologic': 1, 'human': 1, 'actually': 1, 'result': 1, 'response': 1, 'overall': 1, 'oh': 1, 'maybe': 1, 'crisis': 1, 'communications': 1, 'training': 1, 'whole': 1, 'lot': 1, 'public': 1, 'health': 1, 'including': 1, 'fauci': 1}, {'south': 1, 'africa': 1, 'likely': 1, 'hybrid': 1, 'immunity': 1, 'among': 1, 'infected': 1, 'vaccinated': 1, 'people': 1, 'nt': 1, 'many': 1, 'naive': 1, 'adults': 1, 'left': 1, 'three': 1, 'major': 1, 'waves': 1, 'delta': 1, 'unimpaired': 1, 'vaccination': 1, 'unlike': 1, 'northern': 1, 'hemisphere': 1, 'high': 1, 'population': 1, 'fatality': 1, 'ratio': 1, 'excess': 1, 'deaths': 1, 'young': 1}, {'vaccine': 1, 'would': 1, 'lot': 1, 'sensitive': 1, 'variants': 1, 'affect': 1, 'rbd': 1, 'guess': 1, 'efficacy': 1, 'omicron': 1, 'whatsoever': 1, 'good': 1, 'news': 1}, {'lucky': 1, 's': 1, 'pressure': 1, 'covid': 1, 'become': 1, 'less': 1, 'deadly': 1, 'since': 1, 'kills': 1, 'people': 1, 'infectious': 1, '2': 1, 'weeks': 1, 'symptoms': 1, 'presented': 1, 'would': 1, 'merit': 1, 'argument': 1}, {'put': 1, 'context': 1, 'preomicron': 1, 'era': 1, 'uk': 1, 'äúsirenäù': 1, 'study': 1, 'covid': 1, 'infection': 1, 'healthcare': 1, 'workers': 1, 'estimated': 1, 'prior': 1, 'afforded': 1, '85': 1, '%': 1, 'protection': 1, 'second': 1, '6': 1, 'months': 1, 'absolutely': 1, 'inexplicable': 1, 'use': 1, 'siren': 1, 'make': 1, 'mention': 1, 'multitude': 1, 'factors': 1, 'point': 1, 'huge': 1, 'underestimate': 1, 'published': 1, 'paper': 1, 'https': 1, 'wwwthelancetcomjournalslancetarticlepiis01406736': 1, '21': 1, '006759fulltext': 1, 'caveat': 1, '1': 1, 'two': 1, 'äúreinfectionsäù': 1, 'classified': 1, 'äúpossibleäù': 1, 'remaining': 1, 'äúprobableäù': 1, 'none': 1, 'äúconfirmedäù': 1, '84': 1, 'estimate': 1, 'based': 1, 'using': 1, 'reinfections': 1, 'kind': 1, 'ridiculous': 1, '99': 1, '2': 1, 'one': 1, 'third': 1, 'typical': 1, 'symptoms': 1, '3': 1, 'authors': 1, 'include': 1, 'baseline': 1, 'seronegative': 1, 'people': 1, 'converted': 1, 'seropositive': 1, 'covid19': 1, 'cases': 1, 'would': 1, 'since': 1, 'youäôre': 1, 'undercounting': 1, 'group': 1, '4': 1, 'found': 1, 'pattern': 1, 'indicated': 1, 'seemed': 1, 'consistent': 1, 'rna': 1, 'shedding': 1, 'counting': 1, 'note': 1, 'issues': 1, 'restricting': 1, 'probable': 1, 'june': 1, 'november': 1, '2020': 1, 'participants': 1, 'positive': 1, 'cohort': 1, 'lower': 1, 'odds': 1, 'reinfection': 1, 'adjusted': 1, 'aor': 1, '001': 1, '95': 1, 'ci': 1, '000003': 1, 'symptomatic': 1, '008': 1, '005013': 1, 'sensitive': 1, 'definition': 1, 'including': 1, 'possible': 1, 'ratio': 1, '017': 1, '013024': 1, 'history': 1, 'sarscov2': 1, 'associated': 1, '83': 1, 'risk': 1, 'median': 1, 'protective': 1, 'effect': 1, 'observed': 1, 'five': 1, 'following': 1, 'primary': 1, 'this': 1, 'minimum': 1, 'likely': 1, 'seroconversions': 1, 'included': 1, 'there': 1, '864': 1, 'without': 1, 'pcr': 1, 'test': 1, 'infections': 1, 'interim': 1, 'analysis': 1, 'we': 1, 'believe': 1, 'curve': 1, 'gradual': 1, 'throughout': 1, 'indicating': 1, 'potential': 1, 'probably': 1, 'residual': 1, 'detection': 1, 'low': 1, 'population': 1, 'prevalence': 1, 'rather': 1, 'true': 1, 'canäôt': 1, 'really': 1, 'understand': 1, 'reference': 1, 'number': 1, 'giving': 1, 'thought': 1, 'caveats': 1, '540': 1, 'fold': 1, 'higher': 1, 'still': 1, 'if': 1, 'äúprobable': 1, 'confirmedäù': 1, 'used': 1, 'example': 1}, {'please': 1, 'note': 1, 'traditional': 1, 'inactivated': 1, 'vaccine': 1, 'uses': 1, 'newcastle': 1, 'disease': 1, 'virus': 1, 'viral': 1, 'vector': 1, 'expresses': 1, 'second': 1, 'generation': 1, 'prefusion': 1, 'stabilized': 1, 'spike': 1, 'protein': 1, 'different': 1, 'sinopharm': 1, 'vaccines': 1}, {'link': 1, 'deltaspecific': 1, 'booster': 1, '?': 1, 'seen': 1, 'results': 1, 'beta': 1, 'one': 1, 'impression': 1, 'trials': 1, 'yet': 1, 'released': 1, 'data': 1}, {'ok': 1, 's': 1, 'one': 1, 'possible': 1, 'situation': 1, 'also': 1, 'could': 1, '20': 1, 'infecting': 1, 'new': 1, 'person': 1, 'however': 1, 'like': 1, 'go': 1, 'occam': 1, 'razor': 1, 'guess': 1, 'multiple': 1, 'people': 1, 'work': 1, 'covid': 1, 'positive': 1, 'showed': 1, 'party': 1, 'already': 1, 'infected': 1}, {'much': 1, 'disagree': 1, 'line': 1, 'thinking': 1, 'believe': 1, 'harmful': 1, 'border': 1, 'propaganda': 1, 'multiple': 1, 'goals': 1, 'one': 1, 'central': 1, 'goal': 1, 'vaccines': 1, 'beyond': 1, 'help': 1, 'harm': 1, 'least': 1, 'trying': 1, 'reduce': 1, 'spreading': 1, 'mathematically': 1, 'decreasing': 1, 'r': 1, 'value': 1, 'pandemics': 1, 'end': 1, 'also': 1, 'historically': 1, 'understood': 1, 'pr': 1, 'standpoint': 1, 'look': 1, 'youtube': 1, 'covid': 1, 'reputable': 1, 'science': 1, 'channel': 1, 'notice': 1, 'focus': 1, 'preventing': 1, 'spread': 1, 'rather': 1, 'keeping': 1, 'hospital': 1, 'vaccine': 1, 'nt': 1, 'protect': 1, 'individuals': 1, 'mean': 1, 'failure': 1, '?': 1, 'see': 1, 'wave': 1, 'claiming': 1, 'well': 1, 'actually': 1, 'supposed': 1, 'ways': 1, 've': 1, 'claimed': 1, 'primary': 1, 'purpose': 1, 'something': 1, 'smell': 1, 'right': 1, 'measles': 1, 'kept': 1, 'people': 1, 'answer': 1, 'know': 1, 'hardly': 1, 'anyone': 1, 'gets': 1, 'anymore': 1, 'thanks': 1, 'real': 1, 'truth': 1, 'different': 1, 'enough': 1, 'disease': 1, 'like': 1, 'work': 1, 'still': 1, 'medical': 1, 'miracles': 1, 'unfortunately': 1, 'many': 1, 'communicators': 1, 'want': 1, 'try': 1, 'communicate': 1, 'complex': 1, 'message': 1, 'truthfully': 1, 'resorted': 1, 'lying': 1, 'never': 1, 'cared': 1, 'infections': 1}, {'whole': 1, 'thing': 1, 'weird': 1, 'fda': 1, 'basically': 1, 'said': 1, 'd': 1, 'approve': 1, 'without': 1, 'seeing': 1, 'data': 1, 'begged': 1, 'pfizer': 1, 'submit': 1, 'nt': 1, 'effective': 1, 'tell': 1, 'bizarre': 1}, {'nt': 1, 'even': 1, 'get': 1, 'mrna': 1, 'vax': 1, 'hk13': 1, 'whole': 1, 'virion': 1, 'vaccine': 1, 'sinovac': 1, 'like': 1, '?': 1, 'ca': 1, 'find': 1, 'generic': 1, 'name': 1}, {'immune': 1, 'system': 1, 'prepared': 1, 'fight': 1, 'disease': 1, 'immediately': 1, 'often': 1, 'wo': 1, 'nt': 1, 'even': 1, 'know': 1, 'got': 1, 'infuse': 1, 'lab': 1, 'produced': 1, 'antibodies': 1, 'eg': 1, 'mentioned': 1, 'sotrovimab': 1, 'already': 1, 'virus': 1, 'could': 1, 'cause': 1, 'damage': 1, 'since': 1, 'submission': 1, 'myocarditis': 1, 'happen': 1, 'asymptomatic': 1}, {'ve': 1, 'told': 1, 'time': 1, 'unvaccinated': 1, 'skews': 1, 'previously': 1, 'infected': 1, 'reason': 1, 'apparent': 1, 'negative': 1, 'efficacy': 1, 'uk': 1, 'instance': 1, 'true': 1, 'seems': 1, 'like': 1, 'would': 1, 'confound': 1, 'results': 1, 'considerably': 1}, {'vaccine': 1, 'effectiveness': 1, 'studies': 1, 'conclusively': 1, 'demonstrated': 1, 'benefit': 1, 'covid19': 1, 'vaccines': 1, 'reducing': 1, 'individual': 1, 'symptomatic': 1, 'severe': 1, 'disease': 1, 'resulting': 1, 'reduced': 1, 'hospitalisations': 1, 'intensive': 1, 'care': 1, 'unit': 1, 'admissions': 1, 'however': 1, 'impact': 1, 'vaccination': 1, 'transmissibility': 1, 'sarscov2': 1, 'needs': 1, 'elucidated': 1, 'prospective': 1, 'cohort': 1, 'study': 1, 'uk': 1, 'anika': 1, 'singanayagam': 1, 'colleaguesregarding': 1, 'community': 1, 'transmission': 1, 'among': 1, 'unvaccinated': 1, 'vaccinated': 1, 'individuals': 1, 'provides': 1, 'important': 1, 'information': 1, 'considered': 1, 'reassessing': 1, 'policies': 1, 'showed': 1, 'circulating': 1, 'variants': 1, 'appeared': 1, 'significantly': 1, 'different': 1, 'people': 1, 'scientific': 1, 'rationale': 1, 'mandatory': 1, 'usa': 1, 'relies': 1, 'premise': 1, 'prevents': 1, 'others': 1, 'äúpandemic': 1, 'unvaccinatedäù': 1, 'yet': 1, 'demonstration': 1, 'breakthrough': 1, 'infections': 1, 'fully': 1, 'healthcare': 1, 'workers': 1, 'hcw': 1, 'israel': 1, 'turn': 1, 'may': 1, 'transmit': 1, 'infection': 1, 'patients': 1, 'requires': 1, 'reassessment': 1, 'compulsory': 1, 'leading': 1, 'job': 1, 'dismissal': 1, 'indeed': 1, 'growing': 1, 'evidence': 1, 'peak': 1, 'viral': 1, 'titres': 1, 'upper': 1, 'airways': 1, 'lungs': 1, 'culturable': 1, 'virus': 1, 'similar': 1, 'a': 1, 'recent': 1, 'investigation': 1, 'us': 1, 'centers': 1, 'control': 1, 'prevention': 1, 'outbreak': 1, 'prison': 1, 'texas': 1, 'equal': 1, 'presence': 1, 'infectious': 1, 'nasopharynx': 1, 'similarly': 1, 'researchers': 1, 'california': 1, 'observed': 1, 'major': 1, 'differences': 1, 'terms': 1, 'loads': 1, 'even': 1, 'proven': 1, 'asymptomatic': 1, 'thus': 1, 'current': 1, 'suggests': 1, 'might': 1, 'need': 1, 'reconsidered': 1, 'status': 1, 'replace': 1, 'mitigation': 1, 'practices': 1, 'mask': 1, 'wearing': 1, 'physical': 1, 'distancing': 1, 'contacttracing': 1, 'investigations': 1, 'within': 1, 'highly': 1, 'populations': 1}, {'thought': 1, 'recommendation': 1, 'j': 1, '&': 1, 'came': 1, 'adverse': 1, 'events': 1, 'and': 1, 'significantly': 1, 'lowered': 1, 'efficacy': 1, 'protection': 1, 'severe': 1, 'disease': 1, 'equalizer': 1, 'always': 1, 'held': 1, 'well': 1, 'comparatively': 1, '?': 1, 'source': 1, 'looking': 1, 'hospitalization': 1, 'omicron': 1, 'three': 1, 'vaccines': 1, 'doubt': 1, 'thereäôs': 1, 'much': 1, 'data': 1, 'mean': 1, 'many': 1, 'people': 1, 'gotten': 1, 'single': 1, 'dose': 1, 'booster': 1, 'probably': 1}, {'researchers': 1, 'said': 1, 'poor': 1, 'results': 1, 'likely': 1, 'due': 1, 'antigenic': 1, 'imprinting': 1, 'oas': 1, 'even': 1, 'post': 1, 'people': 1, 'denying': 1, 'lot': 1, 'evidence': 1, 'regarding': 1, 'since': 1, 'beginning': 1, 'omicron': 1, 'please': 1, 'deny': 1, 'itäôs': 1, 'association': 1, 'antivaxxers': 1, 'iäôm': 1, 'sure': 1, 'sub': 1, 'everybody': 1, 'knows': 1, 'actual': 1, 'infection': 1, 'causes': 1, 'worse': 1, 'also': 1, 'vaccinated': 1, 'infected': 1, 'use': 1, 'vaccines': 1, 'produces': 1, 'mucosal': 1, 'immunity': 1, 'counter': 1, 'problem': 1, 'need': 1, 'solutions': 1, 'like': 1, 'paxlovid': 1, 'specific': 1, 'mabs': 1, 'etcä': 1, 'soon': 1, 'possible': 1, 'äúthe': 1, 'observation': 1, 'boosting': 1, 'either': 1, 'mrna1273': 1, 'mrnaomicron': 1, 'resulted': 1, 'expansion': 1, 'similarly': 1, 'high': 1, 'frequency': 1, 'crossreactive': 1, 'b': 1, 'cells': 1, 'stems': 1, 'principle': 1, 'original': 1, 'sin': 1, 'otherwise': 1, 'termed': 1, 'whereby': 1, 'prior': 1, 'immune': 1, 'memory': 1, 'recalled': 1, 'related': 1, 'encounter': 1, 'davenport': 1, 'hennessy': 1, '1957': 1, 'et': 1, 'al1953': 1, 'äú': 1}, {'conclusion': 1, 'important': 1, 'recognize': 1, 'factors': 1, 'fueling': 1, 'vaccine': 1, 'hesitancy': 1, 'anxieties': 1, 'around': 1, 'pace': 1, 'technological': 1, 'change': 1, 'feelings': 1, 'political': 1, 'disempowerment': 1, 'within': 1, 'control': 1, 'medical': 1, 'community': 1, 'example': 1, 'health': 1, 'media': 1, 'literacy': 1, 'initiatives': 1, 'schools': 1, 'suggests': 1, 'addressing': 1, 'issues': 1, 'require': 1, 'longterm': 1, 'effort': 1, 'part': 1, 'multiple': 1, 'stakeholders': 1, 'working': 1, 'across': 1, 'several': 1, 'sectors': 1, 'society43': 1, 'like': 1, 'virus': 1, 'gave': 1, 'rise': 1, 'seems': 1, 'probable': 1, 'myths': 1, 'conspiracy': 1, 'theories': 1, 'covid19': 1, 'vaccines': 1, 'things': 1, 'need': 1, 'learn': 1, 'live': 1, 'manage': 1, 'time': 1, 'come': 1, 'new': 1, 'landscape': 1, 'best': 1, 'measure': 1, 'progress': 1, 'toward': 1, 'building': 1, 'confidence': 1, 'longer': 1, 'term': 1, 'perhaps': 1, 'number': 1, 'doses': 1, 'administered': 1, 'far': 1, 'public': 1, 'trust': 1, 'institutions': 1, 'responsible': 1, 'delivering': 1}, {'437': 1, '%': 1, 'vaccine': 1, 'efficacy': 1, '375': 1, 'presume': 1, 'infection': 1, 'nt': 1, 'standard': 1, '50': 1, '?': 1, 'granted': 1, 'years': 1, 'influenza': 1, 'reach': 1, 'curious': 1, 'anyone': 1, 'knows': 1, 'minimum': 1, 'regulators': 1, 'consider': 1, 'acceptable': 1}, {'new': 1, 'york': 1, 'mainz': 1, 'germany': 1, 'march': 1, '15': 1, '2022': 1, 'äî': 1, 'pfizer': 1, 'inc': 1, 'nyse': 1, 'pfe': 1, 'biontech': 1, 'se': 1, 'nasdaq': 1, 'bntx': 1, 'today': 1, 'announced': 1, 'companies': 1, 'submitted': 1, 'application': 1, 'us': 1, 'food': 1, 'drug': 1, 'administration': 1, 'fda': 1, 'emergency': 1, 'use': 1, 'authorization': 1, 'eua': 1, 'additional': 1, 'booster': 1, 'dose': 1, 'adults': 1, '65': 1, 'years': 1, 'age': 1, 'older': 1, 'received': 1, 'initial': 1, 'authorized': 1, 'approved': 1, 'covid19': 1, 'vaccines': 1, 'submission': 1, 'based': 1, 'two': 1, 'realworld': 1, 'data': 1, 'sets': 1, 'israel': 1, 'analyzed': 1, 'time': 1, 'omicron': 1, 'variant': 1, 'widely': 1, 'circulating': 1, 'showed': 1, 'evidence': 1, 'mrna': 1, 'increases': 1, 'immunogenicity': 1, 'lowers': 1, 'rates': 1, 'confirmed': 1, 'infections': 1, 'severe': 1, 'illness': 1, 'analysis': 1, 'israeli': 1, 'ministry': 1, 'health': 1, 'records': 1, 'conducted': 1, '11': 1, 'million': 1, '60': 1, 'known': 1, 'history': 1, 'sarscov2': 1, 'infection': 1, 'eligible': 1, 'fourth': 1, '2': 1, 'times': 1, 'lower': 1, '4': 1, 'among': 1, 'individuals': 1, 'pfizerbiontech': 1, 'vaccine': 1, 'administered': 1, 'least': 1, 'four': 1, 'months': 1, 'third': 1, 'compared': 1, 'one': 1, 'also': 1, 'included': 1, 'results': 1, 'ongoing': 1, 'openlabel': 1, 'nonrandomized': 1, 'clinical': 1, 'trial': 1, 'healthcare': 1, 'workers': 1, '18': 1, 'single': 1, 'study': 1, 'center': 1, 'vaccinated': 1, 'three': 1, 'doses': 1, '154': 1, '700': 1, 'participants': 1, 'following': 1, 'neutralizing': 1, 'antibody': 1, 'titers': 1, 'increased': 1, 'approximately': 1, '7fold': 1, '8fold': 1, 'weeks': 1, 'five': 1, 'additionally': 1, '10fold': 1, 'increase': 1, 'b11529': 1, 'respectively': 1, 'revealed': 1, 'safety': 1, 'concerns': 1, 'emerging': 1, 'including': 1, 'kaiser': 1, 'permanente': 1, 'southern': 1, 'california': 1, 'suggests': 1, 'effectiveness': 1, 'symptomatic': 1, '12345': 1, 'disease15': 1, 'caused': 1, 'wanes': 1, '3': 1, '6': 1, 'receipt': 1, 'thus': 1, 'may': 1, 'needed': 1, 'ensure': 1, 'remain': 1, 'adequately': 1, 'protected': 1, 'early': 1, 'studies': 1, 'indicate': 1, 'could': 1, 'restore': 1, 'peak': 1, 'postthird': 1, 'titer': 1, 'levels6': 1, 'improve': 1, 'protection': 1, 'disease': 1, 'israel7': 1, 'similar': 1, 'profile': 1, 'previous': 1, 'doses6': 1, 'filing': 1, 'reviewed': 1}, {'really': 1, 'interesting': 1, 'paper': 1, 'authors': 1, 'major': 1, 'roles': 1, 'advisory': 1, 'committees': 1, 'public': 1, 'health': 1, 'important': 1, 'comprehensive': 1, 'dataset': 1, 'absolutely': 1, 'used': 1, 'inform': 1, 'policy': 1, 'uk': 1, 'abroad': 1, 'main': 1, 'take': 1, 'home': 1, 'risk': 1, 'following': 1, 'covid19': 1, 'vaccination': 1, 'largely': 1, 'restricted': 1, 'younger': 1, 'males': 1, 'aged': 1, 'less': 1, '40': 1, 'years': 1, 'risks': 1, 'myocarditis': 1, 'infection': 1, 'similar': 1, 'however': 1, 'notable': 1, 'exception': 1, 'receiving': 1, 'second': 1, 'dose': 1, 'mrna1273': 1, 'vaccine': 1, 'higher': 1, 'additional': 1, '101': 1, 'events': 1, 'estimated': 1, 'compared': 1, '7': 1, 'positive': 1, 'sarscov2': 1, 'test': 1, 'ie': 1, 'full': 1, 'strength': 1, 'moderna': 1, '1340': 1, 'gives': 1, 'spike': 1, 'markedly': 1, 'covid': 1, 'nt': 1, 'enough': 1, 'cases': 1, 'properly': 1, 'assess': 1, 'children': 1, '1317': 1, 'state': 1, 'needs': 1, 'pursued': 1, 'pooling': 1, 'international': 1, 'datasets': 1, 'expect': 1, 'already': 1, 'pursuing': 1, 'data': 1, 'thanks': 1, 'posting': 1, 'stated': 1, 'elsewhere': 1, 'one': 1, 'piece': 1, 'puzzle': 1, 'obviously': 1, 'number': 1, 'benefits': 1, 'feed': 1, 'recommendations': 1, 'made': 1, 'else': 1, 'equal': 1, 'could': 1, 'certainly': 1, 'affect': 1, 'vs': 1, 'options': 1, 'watching': 1, 'interest': 1, 'op': 1}, {'thank': 1, 'sorry': 1, 'could': 1, 'done': 1, 'enough': 1, 'coffee': 1, 'morning': 1, 'internal': 1, 'bias': 1, 'american': 1, 'unvaccinated': 1, 'would': 1, 'free': 1, 'behavior': 1, 'probably': 1, 'different': 1, 'sweden': 1}, {'pre': 1, 'boost': 1, 'neutralization': 1, 'titres': 1, '6': 1, 'months': 1, 'post': 1, 'primary': 1, 's': 1, 'unusual': 1, 'adenoviral': 1, 'vaccines': 1, 'nt': 1, 'wane': 1, 'fast': 1, 'pfizer': 1, 'vaccine': 1}, {'saw': 1, 'cited': 1, 'post': 1, 'saying': 1, 'around': 1, '800': 1, 'people': 1}, {'itäôs': 1, 'plausible': 1, 'seems': 1, 'like': 1, 'best': 1, 'explanation': 1, 'still': 1, 'somewhat': 1, 'shocking': 1, 'result': 1, 'apply': 1, 'behavioral': 1, 'adjustment': 1, 'thatäôs': 1, 'large': 1, 'enough': 1, 'offset': 1, '75': 1, '%': 1, 'even': 1, 'assuming': 1, 'true': 1, 'zero': 1, 'applying': 1, 'previous': 1, 'intervals': 1, 'would': 1, 'make': 1, 'high': 1, 'efficacy': 1, 'higher': 1, 'weäôve': 1, 'seen': 1, 'studies': 1, 'involving': 1, 'omicron': 1, 'authoräôs': 1, 'theory': 1, 'rapid': 1, 'spread': 1, 'happen': 1, 'vaccinated': 1, 'ago': 1, 'might': 1, 'explain': 1, 'though': 1, 'wouldnäôt': 1, 'constant': 1, 'across': 1, 'timescales': 1}, {'given': 1, 'data': 1, '6mo2year': 1, 'appears': 1, 'adequate': 1, 'review': 1, '?': 1, 'pfizer': 1, 'asking': 1, 'hence': 1, 'fda': 1, 'nt': 1, 'proactively': 1, 'maybe': 1, 'subset': 1, 'statistically': 1, 'valid': 1, 'd': 1, 'need': 1}, {'know': 1, 'j': 1, '&': 1, 'vaccine': 1, 'came': 1, 'doctors': 1, 'pointing': 1, 'effective': 1, 'preventing': 1, 'serious': 1, 'disease': 1, 'people': 1, 'taking': 1, 'mean': 1, 'point': 1, 'going': 1, 'get': 1, 'sick': 1, 'anyway': 1, 'significantly': 1, 'less': 1, 'likely': 1, 'though': 1, 'taken': 1, 'die': 1, 'covid': 1, 'nt': 1, 'forget': 1, 'also': 1, 'flu': 1, 'sense': 1, 'yes': 1, 'covid19': 1, 'similar': 1}, {'fighting': 1, 'risk': 1, 'myocarditis': 1, 'yes': 1, 'overall': 1, 'though': 1, 'many': 1, 'potential': 1, 'likely': 1, 'negative': 1, 'outcomes': 1, 'either': 1, 'group': 1, 'weighted': 1, 'potentially': 1, 'worse': 1}, {'iäôm': 1, 'sure': 1, 'sub': 1, 'everybody': 1, 'knows': 1, 'actual': 1, 'infection': 1, 'causes': 1, 'worse': 1, 'imprinting': 1, 'got': 1, 'references': 1, 'read': 1, '?': 1}, {'omicron': 1, 'sarscov2': 1, 'variant': 1, 'predominated': 1, 'us': 1, 'kidcove': 1, 'study': 1, 'younger': 1, 'age': 1, 'groups': 1, 'secondary': 1, 'endpoint': 1, 'vaccine': 1, 'efficacy': 1, 'confirms': 1, 'statistically': 1, 'significant': 1, 'lower': 1, 'covid19': 1, 'infection': 1, 'expected': 1, 'wave': 1, 'consistent': 1, 'adult': 1, 'observational': 1, 'data': 1, 'using': 1, 'phase': 1, '3': 1, 'cove': 1, 'definition': 1, 'children': 1, '6': 1, 'months': 1, '2': 1, 'years': 1, '437': 1, '%': 1, '375': 1, 'group': 1, 'case': 1, 'defined': 1, 'bound': 1, '95': 1, 'confidence': 1, 'interval': 1, 'greater': 1, '0': 1, 'majority': 1, 'cases': 1, 'mild': 1, 'severe': 1, 'disease': 1, 'observed': 1, 'either': 1, 'absence': 1, 'hospitalization': 1, 'death': 1, 'precludes': 1, 'assessment': 1, 'endpoints': 1, '&': 1, 'x200b': 1, 'best': 1, 'scenario': 1, 'since': 1, 'know': 1, 'wane': 1}, {'seem': 1, 'recall': 1, 'sources': 1, 'advising': 1, 'young': 1, 'males': 1, 'strenous': 1, 'exercise': 1, 'period': 1, 'either': 1, 'mrna': 1, 'vaccine': 1, 'covid19': 1, 'infection': 1, 'chance': 1, 'develop': 1, 'heart': 1, 'inflammation': 1, 'one': 1, 'given': 1, 'rare': 1, 'nt': 1, 'sample': 1, 'size': 1, 'used': 1, 'study': 1, 'seems': 1, '1628': 1, 'participants': 1, 'different': 1, 'stages': 1, 'bit': 1, 'small': 1, 'determine': 1, 'woulds': 1, 'exacerbate': 1, 'condition': 1, '?': 1}, {'advice': 1, 'given': 1, 'germany': 1, 'days': 1, 'week': 1, 'depending': 1, 'feel': 1, 'come': 1, 'back': 1, 'quickly': 1, 'exercise': 1, 'normally': 1, 'within': 1, 'two': 1, 'paper': 1, 'says': 1, '50mins': 1, 'time': 1, 'start': 1, 'kicking': 1}, {'findings': 1, 'like': 1, 'nt': 1, 'immediately': 1, 'grouped': 1, 'good': 1, 'bad': 1, 'um': 1, 'headline': 1, 'says': 1, 'without': 1, 'increase': 1, 'side': 1, 'effects': 1, 'unfortunately': 1, 'right': 1, 'much': 1, 'reluctance': 1, 'consider': 1, 'anything': 1, 'valid': 1, 'potentially': 1, 'pretty': 1, 'dangerous': 1, 'case': 1}, {'one': 1, 'largest': 1, 'complaints': 1, 'many': 1, 'covid': 1, 'studies': 1, 'iäôve': 1, 'seen': 1, 'coming': 1, 'media': 1, 'pull': 1, 'headlines': 1, 'based': 1, 'extremely': 1, 'poor': 1, 'spread': 1, 'misinformation': 1, 'quickly': 1, 'feels': 1, 'like': 1, 'canäôt': 1, 'figure': 1, 'true': 1, 'nowadays': 1, 'without': 1, 'reading': 1, 'study': 1, 'fully': 1, 'come': 1, 'resort': 1, 'maddening': 1, 'dense': 1, 'quantitative': 1, 'analysis': 1, 'please': 1}, {'antigenic': 1, 'change': 1, 'vaccine': 1, 'evasion': 1, 'assume': 1, 'layperson': 1, 'find': 1, 'hard': 1, 'time': 1, 'understand': 1, 'stuff': 1, 'simple': 1, 'manner': 1}, {'get': 1, 'ball': 1, 'rolling': 1, 'review': 1, 'process': 1, 'data': 1, '?': 1, 'itäôs': 1, 'submission': 1, '3rd': 1, 'dose': 1, 'comes': 1, 'opposed': 1, 'waiting': 1, 'reviewing': 1, 'would': 1, 'take': 1, 'longer': 1}, {'summary': 1, 'ndv': 1, 'underperforming': 1, 'vaccine': 1, 'title': 1, 'misguiding': 1, 'readers': 1, 'interpret': 1, 'inactivated': 1, 'far': 1, 'better': 1, 'comirnaty': 1, 'fact': 1, 'totally': 1, 'opposite': 1, 'ratio': 1, 'makes': 1, 'sense': 1, 'selling': 1, 'advantage': 1, 'based': 1, 'importance': 1, 'protein': 1, 'targeting': 1, 'way': 1, 'higher': 1, 'antibody': 1, 'levels': 1, 'terms': 1, 'neutralizing': 1, 'non': 1, 'ones': 1, 'data': 1, 'provided': 1, 'outperformed': 1, 'mrna': 1, 'log': 1, 'scales': 1, 'used': 1, 'figure': 1, 'general': 1, 'performs': 1, 'around': 1, '10': 1, 'fold': 1, 'binding': 1, 'activity': 1, 'nearly': 1, 'tests': 1, 'also': 1, 'coronavac': 1, 'control': 1, 'compare': 1, 'difference': 1, 'performance': 1, 'platform': 1}, {'account': 1, 'possibility': 1, 'vaccinated': 1, 'people': 1, 'test': 1, 'unvaccinated': 1, 'vice': 1, 'versa': 1, '?': 1}, {'vaers': 1, 'fine': 1, 'consider': 1, 'data': 1, 'source': 1, 'itäôs': 1, 'large': 1, 'pool': 1, 'largely': 1, 'self': 1, 'reported': 1, 'illness': 1, 'injuries': 1, 'intentionally': 1, 'inclusive': 1, 'ensure': 1, 'identify': 1, 'trends': 1, 'early': 1, 'actually': 1, 'found': 1, 'issue': 1, 'begin': 1, 'filter': 1, 'lot': 1, 'bs': 1, 'without': 1, 'much': 1, 'difficulty': 1}, {'would': 1, 'want': 1, 'also': 1, 'check': 1, 'vaccinated': 1, 'group': 1, 'places': 1, 'nt': 1, 'europe': 1, 'acknowledgement': 1, 'convalescent': 1, 'immunity': 1, 'whatsoever': 1, 'necessarily': 1, 'reason': 1, 'assume': 1, 'proportion': 1, 'previously': 1, 'infected': 1, 'even': 1, 'greater': 1, 'unvaccinated': 1}, {'mean': 1, 'boy': 1, 'likely': 1, 'adhd': 1, 'prescribed': 1, 'medication': 1, 'treat': 1, '?': 1, 'amphetamine': 1, 'well': 1, 'documented': 1, 'side': 1, 'effects': 1, 'iäôm': 1, 'sure': 1, 'see': 1, 'would': 1, 'impact': 1, 'medical': 1, 'exemptions': 1, 'taking': 1}, {'intentional': 1, 'selection': 1, 'pressure': 1, 'vaccines': 1, 'would': 1, 'create': 1, 'infectious': 1, 'less': 1, 'severe': 1, 'variant': 1, 'lucky': 1, '?': 1, 'donäôt': 1, 'think': 1, 'paper': 1, 'says': 1, 'anything': 1, 'possible': 1, 'benefits': 1, 'creating': 1, 'sever': 1, 'variants': 1, 'imagine': 1, 'itäôs': 1, 'still': 1, 'general': 1}, {'know': 1, 'thatäôs': 1, 'said': 1, 'wasnäôt': 1, 'fault': 1, 'misleading': 1, 'title': 1, 'publishing': 1}, {'essentially': 1, 'yes': 1, 'manifestation': 1, 'oas': 1}, {'abstract': 1, 'importance': 1, 'limited': 1, 'evidence': 1, 'effectiveness': 1, 'bnt162b2': 1, 'vaccine': 1, 'children': 1, 'particularly': 1, '511': 1, 'years': 1, 'omicron': 1, 'variant': 1, 's': 1, 'emergence': 1, 'objective': 1, 'estimate': 1, 'covid': 1, 'cases': 1, 'hospitalizations': 1, 'among': 1, '1217': 1, 'december': 1, '2021': 1, 'january': 1, '2022': 1, 'design': 1, 'analyses': 1, 'cohorts': 1, 'constructed': 1, 'linked': 1, 'statewide': 1, 'immunization': 1, 'laboratory': 1, 'testing': 1, 'hospitalization': 1, 'databases': 1, 'settingparticipants': 1, 'new': 1, 'york': 1, 'state': 1, '517': 1, 'main': 1, 'outcomesmeasures': 1, 'laboratoryconfirmed': 1, 'covid19': 1, 'comparisons': 1, 'made': 1, 'using': 1, 'incidence': 1, 'rate': 1, 'ratio': 1, 'irr': 1, 'comparing': 1, 'outcomes': 1, 'vaccination': 1, 'status': 1, 'estimated': 1, '1': 1, '1irr': 1, 'results': 1, '13': 1, '30': 1, '852384': 1, 'fullyvaccinated': 1, '365502': 1, 'declined': 1, '66': 1, '%': 1, '95': 1, 'ci': 1, '64': 1, '67': 1, '51': 1, '48': 1, '54': 1, '68': 1, '63': 1, '72': 1, '12': 1, '6': 1, '16': 1, '2430': 1, 'week': 1, '11': 1, '3': 1, '23': 1, 'age': 1, '62': 1, '71': 1, 'changed': 1, '85': 1, '73': 1, '53': 1, '87': 1, '100': 1, '189': 1, '75': 1, 'newly': 1, '2': 1, 'within': 1, 'two': 1, 'weeks': 1, 'full': 1, '76': 1, '81': 1, '2834': 1, 'days': 1, '56': 1, '43': 1, '65': 1, '8': 1, 'conclusions': 1, 'relevance': 1, 'era': 1, 'rapidly': 1, 'however': 1, 'protective': 1, 'severe': 1, 'disease': 1, 'recommended': 1, 'highlight': 1, 'potential': 1, 'need': 1, 'study': 1, 'alternative': 1, 'dosing': 1, 'continued': 1, 'layered': 1, 'protections': 1, 'including': 1, 'mask': 1, 'wearing': 1, 'prevent': 1, 'infection': 1, 'transmission': 1}, {'window': 1, 'benefits': 1, '?': 1, 'within': 1, 'hour': 1, 'week': 1}, {'bc': 1, 'canada': 1, 'spaced': 1, '2': 1, 'months': 1, 'due': 1, 'vaccine': 1, 'availability': 1, 'protecting': 1, 'omicron': 1, 'far': 1, 'see': 1}, {'two': 1, 'doses': 1, 'seems': 1, 'enough': 1, 'real': 1, 'need': 1, 'third': 1}, {'one': 1, 'possible': 1, 'factor': 1, 'unvaccinated': 1, 'cohort': 1, 'wouldäôve': 1, 'surely': 1, 'likely': 1, 'recent': 1, 'prior': 1, 'infection': 1, 'vaccinated': 1, 'due': 1, 'protective': 1, 'effect': 1, 'vaccination': 1, 'previous': 1, 'months': 1, 'individuals': 1, 'study': 1, 'matched': 1, 'based': 1, 'documented': 1, 'status': 1, 'course': 1, 'infections': 1, 'end': 1, 'confirmed': 1, 'donäôt': 1, 'think': 1, 'fully': 1, 'controlled': 1, 'uk': 1, 'example': 1, 'weekly': 1, 'random': 1, 'pcr': 1, 'sampling': 1, 'done': 1, 'ons': 1, 'suggests': 1, 'around': 1, '50': 1, '%': 1, 'missed': 1, 'june': 1, '2021': 1, 'jan': 1, '2022': 1, 'assume': 1, 'positivity': 1, 'lasts': 1, '14': 1, 'days': 1, 'average': 1, 'us': 1, 'cdc': 1, 'previously': 1, 'estimated': 1, '75': 1, 'feb': 1, '2020': 1, 'september': 1}, {'anybody': 1, 'looked': 1, 'basic': 1, 'mechanical': 1, 'parameters': 1, 'exercise': 1, 'activity': 1, 'post': 1, 'vaccinations': 1, '?': 1, 'know': 1, 'singapore': 1, 'recommends': 1, 'men': 1, '30': 1, 'donäôt': 1, 'engage': 1, 'vigorous': 1, 'two': 1, 'weeks': 1, 'mrna': 1, 'shot': 1, 'canäôt': 1, 'find': 1, 'hard': 1, 'data': 1, 'hypothetically': 1, 'explains': 1, '95': 1, '%': 1, 'myocarditis': 1, 'cases': 1, 'sounds': 1, 'like': 1, 'easy': 1, 'solution': 1}, {'symptom': 1, 'myocarditis': 1, '?': 1}, {'s': 1, 'reasonable': 1, 'assume': 1, 'might': 1, 'confounding': 1, 'factors': 1, 'sure': 1, 'completely': 1, 'explain': 1, 'away': 1, 'negative': 1, '?': 1, 'nt': 1, 'remain': 1, 'open': 1, 'possibility': 1}, {'iäôm': 1, 'great': 1, 'math': 1, 'department': 1, 'could': 1, 'somebody': 1, 'calculate': 1, 'rough': 1, 'vaccine': 1, 'efficacy': 1, 'fully': 1, 'vaccinated': 1, 'boosted': 1, 'numbers': 1, '?': 1, 'enough': 1, 'info': 1, 'iäôd': 1, 'much': 1, 'obliged': 1, 'thanks': 1}, {'delta': 1, 'adjusted': 1, 'vaccine': 1, 'nt': 1, 'commercialised': 1, 'existing': 1, 'mrna': 1, 'vaccines': 1, 'satisfactory': 1, 'boosters': 1, 'providing': 1, 'immunity': 1, 'symptomatic': 1, 'illness': 1, 'large': 1, 'majority': 1, 'cases': 1}, {'despite': 1, 'reports': 1, 'postvaccination': 1, 'misc': 1, 'vaccination': 1, 'clearly': 1, 'lowers': 1, 'overall': 1, 'burden': 1, 'probably': 1, 'preventing': 1, 'infection': 1, 'studies': 1, 'also': 1, 'suggest': 1, 'low': 1, 'likelihood': 1, 'triggering': 1, 'development': 1, 'play': 1, 'role': 1, 'pathogenesis': 1, 'likely': 1, 'extremely': 1, 'rare': 1, 'event': 1, 'may': 1, 'involve': 1, 'underlying': 1, 'genetic': 1, 'predisposition': 1, 'contingent': 1, 'extraneous': 1, 'factors': 1, 'like': 1, 'recent': 1, 'sarscov2': 1, 'community': 1, 'exposure': 1, 'findings': 1, '2': 1, 'cases': 1, 'within': 1, '1': 1, 'week': 1, 'dose': 1, 'bnt162b2': 1, 'raise': 1, 'possibility': 1, 'alter': 1, 'symptom': 1, 'profile': 1}, {'assumes': 1, 'people': 1, 'young': 1, 'healthy': 1, 'headline': 1, 'excludes': 1, 'lot': 1, 'gili': 1, 'regevyochay': 1, 'physician': 1, 'infectiousdiseases': 1, 'researcher': 1, 'sheba': 1, 'medical': 1, 'center': 1, 'ramat': 1, 'gan': 1, 'coauthored': 1, 'study': 1, 'äúpeople': 1, 'donäôt': 1, 'risk': 1, 'factors': 1, 'probably': 1, 'benefit': 1, 'much': 1, 'fourth': 1, 'doseäù': 1, 'faced': 1, 'omicron': 1, 'says': 1, 'still': 1, 'others': 1, 'say': 1, 'dose': 1, 'could': 1, 'beneficial': 1, 'higher': 1, 'severe': 1, 'illness': 1, 'several': 1, 'countries': 1, 'including': 1, 'israel': 1, 'chile': 1, 'sweden': 1, 'offering': 1, 'doses': 1, 'older': 1, 'adults': 1, 'groups': 1}, {'problem': 1, 'covid': 1, 'evolving': 1, 'linear': 1, 'fashion': 1, 'delta': 1, 'descendant': 1, 'alpha': 1, 'omicron': 1, 'nt': 1, 'confident': 1, 'next': 1, 'dominant': 1, 'variant': 1, 'necessarily': 1, 'contrast': 1, 'update': 1, 'flu': 1, 'vaccines': 1, 'roll': 1, 'ahead': 1, 'time': 1, 'evolution': 1, 'predict': 1, 'current': 1, 'usually': 1}, {'analysis': 1, 'shows': 1, 'unvaccinated': 1, 'patients': 1, 'covid19': 1, 'infection': 1, 'nearly': 1, 'five': 1, 'times': 1, 'likely': 1, 'develop': 1, 'gbs': 1, 'covidvaccinated': 1, 'rate': 1, '28': 1, 'per': 1, 'million': 1, '130': 1, 'covidpositive': 1}, {'wouldnäôt': 1, 'omicron': 1, 'boost': 1, 'required': 1, '416': 1, 'weeks': 1, 'post': 1, 'priming': 1, 'trigger': 1, 'bcells': 1, 'undergoing': 1, 'affinity': 1, 'maturation': 1, 'transform': 1, 'plasma': 1, 'subsequently': 1, 'generate': 1, 'specific': 1, 'antibodies': 1, '?': 1}, {'nt': 1, 'actually': 1, 'see': 1, 'information': 1, 'phase': 1, 'possibly': 1, 'look': 1, 'neutralising': 1, 'antibodies': 1, 'rather': 1, 'effectiveness': 1, 'children': 1, 's': 1, 'trial': 1, 'iirc': 1}, {'thanks': 1, 'lot': 1, 'haha': 1, 'iäôm': 1, 'bit': 1, 'confused': 1, 'though': 1, 'read': 1, 'fourth': 1, 'dose': 1, 'mrna': 1, 'vaccines': 1, 'likely': 1, 'recommended': 1, 'doses': 1, 'probably': 1, 'tailored': 1, 'dominant': 1, 'variant': 1, 'changes': 1, 'time': 1, 'like': 1, 'flu': 1, 'suppose': 1, 'doesnäôt': 1, 'contradict': 1, 'article': 1, 'somewhat': 1, '?': 1}, {'abstract': 1, 'concerns': 1, 'sarscov2': 1, 'omicron': 1, 'variant': 1, 'evades': 1, 'immune': 1, 'responses': 1, 'due': 1, 'unusually': 1, 'high': 1, 'numbers': 1, 'mutations': 1, 'spike': 1, 'protein': 1, 'report': 1, 'superspreading': 1, 'event': 1, 'infections': 1, 'amongst': 1, 'triplevaccinated': 1, 'healthcare': 1, 'workers': 1, 'infecting': 1, '21': 1, '33': 1, 'attending': 1, 'private': 1, 'gathering': 1, 'faroe': 1, 'islands': 1, '_____': 1, 'additional': 1, 'clarification': 1, 'pdf': 1, 'selfgoverning': 1, 'group': 1, 'located': 1, 'iceland': 1, 'norway': 1, 'relatively': 1, 'successful': 1, 'containing': 1, 'covid19': 1, 'pandemic': 1, '78': 1, 'on': 1, 'december': 1, '30': 1, '2020': 1, 'first': 1, 'faroese': 1, 'received': 1, 'bnt162b2': 1, 'vaccine': 1, 'comirnaty': 1, 'biontech': 1, 'mainz': 1, 'germany': 1, 'used': 1, 'since': 1, 'proportion': 1, 'population': 1, 'vaccinated': 1, '8': 1, '746': 1, '%': 1, 'two': 1, 'times': 1, '136': 1, 'three': 1, '9': 1, 'march': 1, 'september': 1, '2021': 1, 'registered': 1, '1001': 1, 'cases': 1, '1867': 1, 'per': 1, '100000': 1, 'deaths': 1, '373': 1, 'however': 1, 'loosening': 1, 'restrictions': 1, 'introduction': 1, 'contagious': 1, 'delta': 1, 'large': 1, 'outbreak': 1, 'plagued': 1, '3300': 1, '11': 1, 'last': 1, 'half': 1, 'months': 1, 'this': 1, 'paper': 1, 'reports': 1, 'infected': 1, 'social': 1, 'early': 1, 'even': 1, 'though': 1, 'participants': 1, 'recent': 1, 'negative': 1, 'test': 1}, {'clear': 1, 'say': 1, '85': 1, '%': 1, 'effective': 1, 'hospitalization': 1, 'comparison': 1, '?': 1, 's': 1, 'regular': 1, 'rate': 1, 'unvaxxed': 1, 'person': 1}, {'vocs': 1, 'theorised': 1, 'emerge': 1, 'chronic': 1, 'infections': 1, 'immunosuppressed': 1, 'patients': 1, 'since': 1, 'emerged': 1, 'without': 1, 'clear': 1, 'predecessors': 1, 'm': 1, 'sure': 1, 'much': 1, 'vaccination': 1, 'rates': 1, 'really': 1, 'impact': 1, 'emergence': 1}, {'yes': 1, 'think': 1, 'theyäôre': 1, 'agenda': 1, 'wouldnäôt': 1, 'first': 1, 'wonäôt': 1, 'last': 1}, {'think': 1, 'due': 1, 'multiple': 1, 'reasons': 1, 'usa': 1, 'seems': 1, 'already': 1, 'enough': 1, 'approved': 1, 'vaccine': 1, 'may': 1, 'need': 1, 'another': 1, 'good': 1, '2': 1, 'fully': 1, 'pfizer': 1, 'moderna': 1, 'adults': 1, 'younger': 1, 'age': 1, 'groups': 1, 'eua': 1, 'etc': 1, '1': 1, 'j': 1, '&': 1, 'coming': 1, 'way': 1, 'novavax': 1, 'soon': 1, 'get': 1, 'medicago': 1, 'far': 1, 'future': 1, 'safe': 1, 'effective': 1, 'covaxin': 1, 'data': 1, 's': 1, 'less': 1, 'full': 1, 'promising': 1, 'aspects': 1, 'documents': 1, 'like': 1, 'one': 1, 'interim': 1, 'recommendations': 1, 'use': 1, 'bharat': 1, 'biotech': 1, 'bbv152': 1, 'covaxinæ': 1, 'covid19': 1, 'https': 1, 'wwwwhointpublicationsiitemwho2019ncovvaccinessagerecommendationbbv152covaxin': 1, 'annexes': 1, 'wwwwhointpublicationsiitemwho2019ncovvaccinessagerecommendationbbv152covaxinannexes': 1, 'points': 1, 'safety': 1, 'aged': 1, '18äì59': 1, 'years': 1, 'limitation': 1, 'study': 1, 'design': 1, 'impact': 1, 'serious': 1, 'efficacy': 1, 'older': 1, 'â60': 1, 'moderately': 1, 'confident': 1, 'doses': 1, 'efficacious': 1, 'preventing': 1, 'pcrconfirmed': 1, 'â65': 1, 'general': 1, '60': 1, 'comorbidity': 1, 'moderate': 1, 'ci': 1, 'values': 1, 'seem': 1, 'wide': 1, 'limits': 1, 'also': 1, 'miss': 1, 'fda': 1, 'important': 1, 'well': 1, 'tested': 1, 'latinos': 1, 'inuits': 1, 'existing': 1, 'certifications': 1, 'manufacturing': 1, 'pass': 1, 'thru': 1, 'process': 1}, {'wait': 1, 'ci': 1, '43': 1, 'nt': 1, 'efficacy': 1, '0': 1, '?': 1, 'really': 1, 'means': 1, 'lot': 1, 's': 1, 'very': 1, 'big': 1, 'interval': 1}, {'get': 1, 'opinion': 1, 'study': 1, '?': 1}, {'means': 1, 'variant': 1, 'indeed': 1, 'worse': 1, 'delta': 1, '?': 1}, {'papers': 1, 'keep': 1, 'talking': 1, 'viral': 1, 'load': 1, 'ignore': 1, 'fact': 1, 'majority': 1, 'dead': 1, 'noninfectious': 1, 'virus': 1, 'thatäôs': 1, 'studies': 1, 'review': 1, 'paper': 1, 'whole': 1, 'point': 1, 'summarize': 1, 'people': 1, 'done': 1, 'itäôs': 1, 'lot': 1, 'labor': 1, 'intensive': 1, 'try': 1, 'culture': 1, 'better': 1, 'data': 1, 'none': 1, 'isnäôt': 1, 'perfect': 1, 'useful': 1, 'warning': 1, 'sign': 1, 'delta': 1, 'infectious': 1, 'vaccinated': 1, 'previous': 1, 'strains': 1}, {'also': 1, 'thought': 1, 'vaers': 1, 'reports': 1, 'worth': 1, 'paying': 1, 'attention': 1, 'thus': 1, 'view': 1, 'change': 1, 'recently': 1, '?': 1}, {'study': 1, 'conducted': 1, 'januaryaugust': 1, '2021': 1, 'weäôre': 1, 'talking': 1, 'alpha': 1, 'strain': 1, 'breakthrough': 1, 'infections': 1, 'likely': 1, 'higher': 1, 'delta': 1, 'omicron': 1}, {'interesting': 1, 'study': 1, '36000': 1, 'genomic': 1, 'sequences': 1, 'patients': 1, 'analysis': 1, '90': 1, '%': 1, 'total': 1, 'rest': 1, 'could': 1, 'nt': 1, 'get': 1, 'sequenced': 1, 'time': 1, 'assumed': 1, 'omicron': 1, 'sgene': 1, 'target': 1, 'failure': 1, 'houston': 1, 'methodist': 1, 'sequencing': 1, '100': 1, 'covid': 1, 'said': 1, 'point': 1, 'chances': 1, 'sgtf': 1, 'slimtonone': 1, 'imagine': 1, 'full': 1, 'really': 1, 'required': 1, 'yield': 1, 'good': 1, 'data': 1}, {'m': 1, 'seeing': 1, 'attempted': 1, 'differentiation': 1, 'severity': 1, 'vaccinatedpreviously': 1, 'infected': 1, 'unvaccinatedpreviously': 1, 'uninfected': 1, 's': 1, 'biggest': 1, 'tell': 1, 'pandemic': 1, 'endemic': 1, 'waning': 1, 'many': 1, 'infections': 1, 'still': 1, 'happening': 1, 'fewer': 1, 'ever': 1, 'needing': 1, 'hospital': 1, 'difference': 1, 'vaccinatedpre': 1, 'unvaccinatednever': 1, 'previously': 1, 'basically': 1, 'like': 1, 'catching': 1, 'novel': 1, 'virus': 1, 'concerning': 1}, {'western': 1, 'world': 1, 'south': 1, 'africa': 1, 'spend': 1, 'countless': 1, 'hours': 1, 'threads': 1, 'debating': 1, 'technical': 1, 'details': 1, 'studies': 1, 'matters': 1, 'us': 1, 'pov': 1, 'much': 1, 'larger': 1, 'country': 1, 'far': 1, 'older': 1, 'unhealthy': 1, 'population': 1, 'mean': 1, 'next': 1, 'nothing': 1, 'never': 1, 'going': 1, 'indicative': 1, 'experience': 1, 'variant': 1, 'reckless': 1, 'naive': 1, 'way': 1, 'scientific': 1, 'community': 1, 'media': 1, 'latched': 1, 'idea': 1, 'edit': 1, 'mentioned': 1, '65': 1, 'pop': 1, '55mm': 1, '80': 1, '%': 1, 'total': 1, 'covid': 1, 'deaths': 1, 'sa': 1, '35mmä': 1, 'get': 1, 'picture': 1, '?': 1}, {'ve': 1, 'asked': 1, 'many': 1, 'people': 1, '18': 1, 'died': 1, 'covid': 1, 'last': 1, 'year': 1, '12': 1, '?': 1, 'ca': 1, 'nt': 1, 'find': 1, 'good': 1, 'statistics': 1}, {'noteworthy': 1, 'appears': 1, 'little': 1, 'protection': 1, 'variant': 1, 'last': 1, 'vaxxed': 1, '6': 1, 'month': 1, 'ago': 1, 'big': 1, 'boost': 1, 'booster': 1, 'even': 1, 'recently': 1, 'perhaps': 1, 'slight': 1, 'edge': 1, 'moderna': 1}, {'think': 1, 'paper': 1, '2x': 1, 'az': 1, 'plus': 1, 'one': 1, 'mrna': 1, 'provides': 1, 'excelent': 1, 'results': 1, 'titers': 1}, {'someone': 1, 'could': 1, 'eli5': 1, 'boosting': 1, 'vaccine': 1, 'would': 1, 'elicit': 1, 'broader': 1, 'responsecrossreactivity': 1, 'knowing': 1, 'original': 1, 'antigen': 1, 'presented': 1, 'immune': 1, 'system': 1, '?': 1, 'expect': 1, 'dramatic': 1, 'albeit': 1, 'temporary': 1, 'increase': 1, 'titers': 1, 'help': 1, 'induce': 1, 'response': 1}, {'sample': 1, 'sizes': 1, 'adequate': 1, '?': 1, 'seem': 1, 'little': 1, 'small': 1, 'm': 1, 'layman': 1, 'nt': 1, 'know': 1, 'least': 1, 'could': 1, 'easily': 1, 'find': 1, 'volunteers': 1, 'imagine': 1}, {'s': 1, 'autopsy': 1, 'paper': 1, 'written': 1, 'mds': 1, 'typical': 1, 'type': 1, 'publication': 1}, {'omicron': 1, 'displaces': 1, 'delta': 1, 'completely': 1, 'risk': 1, 'infection': 1, 'removed': 1, 'possibility': 1, 'boosting': 1, 'wuhan': 1, 'variant': 1, 'spike': 1, 'breakthrough': 1, 'counter': 1, 'productive': 1, 'd': 1, 'already': 1, 'producing': 1, 'specific': 1, 'antibodies': 1, '?': 1, 'seems': 1, 'unlikely': 1, 'time': 1, 'adaptive': 1, 'immune': 1, 'system': 1, 'sees': 1, 'similar': 1, 'antigen': 1, 'passed': 1, 'since': 1, 'last': 1, 'saw': 1, 'causes': 1, 'broaden': 1, 'repertoire': 1, 'memory': 1, 'b': 1, 'cells': 1, 'produce': 1, 'cover': 1, 'wider': 1, 'range': 1, 'close': 1, 'variants': 1, 'example': 1, 're': 1, 'finding': 1, 'people': 1, 'got': 1, 'booster': 1, 'effective': 1, 'nt': 1, 'get': 1, 'even': 1, 'though': 1, 'based': 1, 'strain': 1, 'initial': 1, 'vaccination': 1, 'presented': 1, 'make': 1, 'narrow': 1, 'focus': 1, 'fear': 1, 'makes': 1, 'possible': 1, 'future': 1, 'variations': 1}, {'wa': 1, 'nt': 1, 'suggested': 1, 'interval': 1, 'doses': 1, '?': 1}, {'s': 1, 'definitely': 1, 'bad': 1, 'way': 1, 'best': 1, 'nt': 1, 'link': 1, 'remember': 1, 'seeing': 1, 'one': 1, 'paper': 1, 'analysing': 1, 'vaers': 1, 'reports': 1, 'finding': 1, 'questionable': 1, 'large': 1, 'majority': 1, 'real': 1, 'likely': 1, 'cases': 1, 'reported': 1, 'generally': 1, 'assume': 1, 'completely': 1, 'reliable': 1, 'right': 1, 'ballpark': 1, 'unfortunately': 1, 'many': 1, 'people': 1, 'think': 1, 'along': 1, 'lines': 1, 'faults': 1, 'ignored': 1, 'faulty': 1, 'thinking': 1, 'correlation': 1, 'implies': 1, 'causation': 1}, {'abstract': 1, 'severe': 1, 'acute': 1, 'respiratory': 1, 'syndrome': 1, 'coronavirus': 1, '2': 1, 'sarscov2': 1, 'antibodies': 1, 'decay': 1, 'persist': 1, '6': 1, 'months': 1, 'postvaccination': 1, 'lower': 1, 'levels': 1, 'neutralizing': 1, 'titers': 1, 'delta': 1, 'wildtype': 1, 'virus': 1, '227': 1, 'vaccinated': 1, 'healthcare': 1, 'workers': 1, 'tested': 1, 'experienced': 1, 'outpatient': 1, 'symptomatic': 1, 'breakthrough': 1, 'infections': 1, 'despite': 1, '59227': 1, 'exhibiting': 1, 'serologic': 1, 'evidence': 1, 'infection': 1, 'defined': 1, 'presence': 1, 'nucleocapsid': 1, 'protein': 1}, {'per': 1, 'press': 1, 'release': 1, '100': 1, '%': 1, 'efficacy': 1, '75': 1, 'severe': 1, 'disease': 1}, {'nt': 1, 'advice': 1, 'move': 1, 'one': 1, 's': 1, 'arm': 1, 'frequently': 1, 'injected': 1, 'vaccine': 1, 'influenza': 1, 'covid19': 1, '?': 1, 'seems': 1, 'tested': 1, 'exercises': 1, 'least': 1, 'moved': 1, 'quite': 1, 'bit': 1}, {'2x': 1, 'az': 1, '1y': 1, 'bnt': 1, 'probably': 1, 'nt': 1, 'apply': 1, 'combination': 1, 'discussed': 1, 'papers': 1, 'anyways': 1}, {'?': 1, 'flair': 1, 'makes': 1, 'clear': 1, 's': 1, 'preprint': 1, 'preprints': 1, 'posted': 1, 'routinely': 1, 'many': 1, 'report': 1, 'high': 1, 'quality': 1, 'research': 1, 'although': 1, 'one': 1, 'unfortunately': 1, 'nt': 1, 'conversely': 1, 'peer': 1, 'review': 1, 'guarantee': 1}, {'s': 1, 'also': 1, 'suggestions': 1, 'infected': 1, 'healthcare': 1, 'setting': 1, 'prone': 1, 'long': 1, 'covid': 1}, {'didnäôt': 1, 'realize': 1, 'risk': 1, 'covid': 1, 'saying': 1, 'could': 1, 'get': 1, 'vaccine': 1, '?': 1}, {'beta': 1, 'delta': 1, 'variants': 1, '2021': 1, 'nature': 1, 'defeated': 1, 'eventually': 1, 'variant': 1, 'much': 1, 'quicker': 1, 'pfizer': 1, 'biontech': 1, 'scientists': 1, 'nt': 1, 'think': 1, 'new': 1, 'research': 1, 'omicron': 1, 'would': 1, 'time': 1, 'next': 1, 'mutation': 1, 'occurs': 1}, {'wow': 1, 'authors': 1, 'nt': 1, 'even': 1, 'take': 1, 'break': 1, 'consider': 1, 'non': 1, 'breakthrough': 1, 'infections': 1, 'story': 1, 'seem': 1, 'inferring': 1, 'transmissibility': 1, 'vaccinated': 1, 'based': 1, 'completely': 1, 'ignored': 1, 'people': 1, 'never': 1, 'test': 1, 'positive': 1, 'ie': 1, 'majority': 1, 'according': 1, 'vaccine': 1, 'efficacy': 1, 'trials': 1, 'paper': 1, 'absolute': 1, 'antivax': 1, 'garbage': 1, 'great': 1, 'lie': 1, 'considering': 1, 'vaccinations': 1, 'population': 1, 'reached': 1, 'maximum': 1, 'saturation': 1}, {'cohort': 1, '3': 1, 'n205': 1, 'vaccinenaøve': 1, 'participants': 1, 'receive': 1, 'three': 1, 'doses': 1, 'omicronbased': 1, 'vaccine': 1, 'going': 1, 'find': 1, 'people': 1, '2022': 1, 'willing': 1, 'partake': 1, 'scientific': 1, 'research': 1, '?': 1}, {'vaccinated': 1, 'mean': 1, 'selection': 1, 'pressure': 1, 'differ': 1, 'regular': 1, 'vaccination': 1, '?': 1}, {'vaccinated': 1, 'almost': 1, 'half': 1, 'rate': 1, 'controls': 1, '?': 1, 'could': 1, 'see': 1, 'something': 1, 'like': 1, 'lower': 1, 'prevalence': 1, 'infectious': 1, 'diseases': 1, 'implicated': 1, 'gbs': 1, 'compared': 1, '2019': 1, 'nt': 1, '48': 1, 'also': 1, 'really': 1, 'high': 1, 'baseline': 1, 'thought': 1, 'much': 1, 'rarer': 1}, {'inhibition': 1, 'numbers': 1, 'look': 1, 'phenomenal': 1, 'much': 1, 'better': 1, 'adult': 1, '2': 1, 'series': 1, 'https': 1, 'wwwmedrxivorgcontent1011012021122321267374v1fullpdfhtml': 1, 'especially': 1, 'omicron': 1, 'something': 1, 'others': 1, 'results': 1, 'maybe': 1}, {'worse': 1, 'case': 1, '105': 1, 'myocarditis': 1, 'cases': 1, 'based': 1, 'million': 1, 'jabs': 1, 'even': 1, 'bad': 1, 'incidence': 1, 'fungal': 1, 'infections': 1, 'viruses': 1, 'parasites': 1, 's': 1, 'minor': 1}, {'point': 1, 'think': 1, 'enough': 1, 'empirical': 1, 'information': 1, 'treat': 1, 'future': 1, 'variants': 1, 'like': 1, 'flu': 1, '?': 1, 'eg': 1, 'development': 1, 'vaccines': 1, 'well': 1, 'advance': 1, 'season': 1}, {'assuming': 1, 'prevented': 1, 'deathhospitalizations': 1, 'm': 1, 'pretty': 1, 'sure': 1, 'case': 1, 'ca': 1, 'nt': 1, 'even': 1, 'show': 1, '01': 1, '%': 1, 'protection': 1, 'additionally': 1, 'risk': 1, 'infection': 1, 'much': 1, 'lower': 1, 'simply': 1, 'virus': 1, 'lull': 1, 'know': 1, 'likely': 1, 'wane': 1, 'lot': 1, '6': 1, 'months': 1, 're': 1, 'probably': 1, 'talking': 1, '20': 1, 'average': 1, 'minimum': 1, 'get': 1, 'booster': 1, 'summer': 1, 'takes': 1, '200k': 1, 'shots': 1, 'children': 1, 'prevent': 1, '300': 1, 'coldlike': 1, 'infections': 1, 'seems': 1, 'unlikely': 1, 'approval': 1}, {'thanks': 1, 'summary': 1, 'much': 1, 'appreciated': 1}, {'results': 1, 'participants': 1, 'detectable': 1, 'sarscov2äìspecific': 1, 'antibodies': 1, 'milk': 1, 'baseline': 1, 'n': 1, '9': 1, 'iga': 1, '3': 1, 'igg': 1, 'previous': 1, 'positive': 1, 'polymerase': 1, 'chain': 1, 'reaction': 1, 'test': 1, '7': 1, 'excluded': 1, 'analyses': 1, 'thus': 1, 'total': 1, '1650': 1, 'human': 1, 'samples': 1, '124': 1, 'lactating': 1, 'mothers': 1, 'included': 1, 'final': 1, 'analysis': 1, 'figure': 1, 'shows': 1, 'percentage': 1, 'study': 1, 'period': 1, 'almost': 1, 'received': 1, 'mrnabased': 1, 'vaccine': 1, 'showed': 1, '25': 1, '26': 1, '96': 1, '%': 1, '37': 1, '38': 1, '97': 1, 'bnt162b2': 1, 'mrna1273': 1, 'vaccines': 1, 'respectively': 1, 'vectorbased': 1, 'remarkably': 1, 'lower': 1, '13': 1, '33': 1, '39': 1, '10': 1, '21': 1, '48': 1, 'azd1222': 1, 'ad26cov2s': 1, 'depicted': 1, 'b': 1, 'doses': 1, 'however': 1, 'day': 1, '23': 1, '32': 1, 'first': 1, 'dose': 1, '94': 1, 'vaccination': 1, '1': 1, '6': 1, '28': 1, 'discussion': 1, 'demonstrated': 1, 'present': 1, 'frequently': 1, 'compared': 1, 'additionally': 1, 'receiving': 1, '2': 1, 'independent': 1, 'type': 1, 'earlier': 1, 'either': 1, 'mrna': 1, 'explained': 1, 'timing': 1, 'second': 1, 'limitation': 1, 'measure': 1, 'neutralizing': 1, 'capacity': 1, 'abundant': 1, 'antibody': 1, 'plays': 1, 'key': 1, 'role': 1, 'line': 1, 'defense': 1, 'invading': 1, 'viruses5': 1, 'although': 1, 'knowledge': 1, 'studies': 1, 'shown': 1, 'indisputable': 1, 'evidence': 1, 'humanmilk': 1, 'directly': 1, 'protects': 1, 'respiratory': 1, 'tract': 1, 'infections': 1, 'likely': 1, 'critical': 1, 'based': 1, 'data': 1, 'suggest': 1, 'optimal': 1, 'choice': 1, 'women': 1, 'want': 1, 'transfer': 1, 'infants': 1}, {'fair': 1, 'worse': 1, 'likely': 1, 'test': 1, 'positive': 1, 'realtive': 1, 'unvaccinated': 1, 'outcomes': 1}, {'abstract': 1, 'background': 1, 'duration': 1, 'effectiveness': 1, 'immunity': 1, 'infection': 1, 'vaccination': 1, 'severe': 1, 'acute': 1, 'respiratory': 1, 'syndrome': 1, 'coronavirus': 1, '2': 1, 'sarscov2': 1, 'relevant': 1, 'pandemic': 1, 'policy': 1, 'interventions': 1, 'including': 1, 'timing': 1, 'vaccine': 1, 'boosters': 1, 'methods': 1, 'investigated': 1, 'prospective': 1, 'cohort': 1, 'asymptomatic': 1, 'health': 1, 'care': 1, 'workers': 1, 'united': 1, 'kingdom': 1, 'underwent': 1, 'routine': 1, 'polymerasechainreaction': 1, 'pcr': 1, 'testing': 1, 'â10': 1, 'months': 1, 'first': 1, 'dose': 1, 'infectionacquired': 1, 'assessed': 1, 'comparing': 1, 'time': 1, 'pcrconfirmed': 1, 'vaccinated': 1, 'persons': 1, 'unvaccinated': 1, 'stratified': 1, 'according': 1, 'previous': 1, 'status': 1, 'used': 1, 'cox': 1, 'regression': 1, 'model': 1, 'adjustment': 1, 'type': 1, 'dosing': 1, 'interval': 1, 'demographic': 1, 'characteristics': 1, 'workplace': 1, 'exposure': 1, 'results': 1, '35768': 1, 'participants': 1, '27': 1, '%': 1, '9488': 1, 'coverage': 1, 'high': 1, '97': 1, 'received': 1, 'two': 1, 'doses': 1, '78': 1, 'bnt162b2': 1, 'pfizeräìbiontech': 1, 'long': 1, '9': 1, 'short': 1, '8': 1, 'chadox1': 1, 'ncov19': 1, 'astrazeneca': 1, 'december': 1, '7': 1, '2020': 1, 'september': 1, '21': 1, '2021': 1, 'total': 1, '2747': 1, 'primary': 1, 'infections': 1, '210': 1, 'reinfections': 1, 'observed': 1, 'among': 1, 'previously': 1, 'uninfected': 1, 'longinterval': 1, 'adjusted': 1, 'decreased': 1, '85': 1, '95': 1, 'confidence': 1, 'ci': 1, '72': 1, '92': 1, '14': 1, '73': 1, 'days': 1, 'second': 1, '51': 1, '22': 1, '69': 1, 'median': 1, '201': 1, 'interquartile': 1, 'range': 1, '197': 1, '205': 1, 'differ': 1, 'significantly': 1, 'shortinterval': 1, 'recipients': 1, '58': 1, '23': 1, '77': 1, 'äî': 1, 'considerably': 1, 'lower': 1, 'waned': 1, '1': 1, 'year': 1, 'remained': 1, 'consistently': 1, 'higher': 1, '90': 1, 'subsequently': 1, 'even': 1, 'infected': 1, '18': 1, 'conclusions': 1, 'associated': 1, 'shortterm': 1, 'protection': 1, '6': 1, 'boosted': 1}, {'thank': 1, 'know': 1, 'applied': 1, 'full': 1, 'approval': 1, 'ide': 1, 'typical': 1, 'timeline': 1, '?': 1}, {'controls': 1, 'pandemic': 1, 'completely': 1, 'eliminate': 1, 'covid19': 1, 'vaccines': 1, 'and': 1, 'virus': 1, 'factor': 1, 'cohort': 1, 'includes': 1, 'patients': 1, 'aged': 1, '099': 1, 'least': 1, 'one': 1, 'office': 1, 'visit': 1, 'encounter': 1, 'january': 1, '1': 1, '2019': 1, 'june': 1, '30': 1, 'inclusion': 1, 'date': 1, 'earliest': 1, 'patient': 1, 'dates': 1, 'documentation': 1, 'excluding': 1, 'condition': 1, 'guillainbarr': 1, 'prior': 1, 'removed': 1, 'seems': 1, 'likely': 1, 'lower': 1, 'rate': 1, 'vaccinated': 1, 'due': 1, 'npis': 1, 'masking': 1, 'distancing': 1, 'etc': 1, 'reducing': 1, 'exposure': 1, 'viruses': 1, 'might': 1, 'cause': 1, 'gbs': 1, 'despite': 1, 'association': 1, 'people': 1, 'mentally': 1, 'viral': 1, 'infections': 1, 'far': 1, 'common': 1}, {'excecise': 1, 'suppose': 1, 'increase': 1, 'antibody': 1, 'two': 1, 'weeks': 1, '90': 1, 'min': 1, 'lol': 1, '?': 1, 'really': 1, 'shouldnt': 1, 'study': 1, 'everyday': 1, 'excercise': 1}, {'020': 1, '%': 1, 'effectiveness': 1, '2': 1, 'doses': 1, '?': 1, 'back': 1, 'beginning': 1, 'pandemic': 1}, {'say': 1, 'hospitalized': 1, '?': 1}, {'science': 1, 'struggle': 1, 'wasnäôt': 1}, {'huh': 1, '?': 1, 'study': 1, 'says': 1, 'overall': 1, '30day': 1, 'incidence': 1, 'myocarditis': 1, 'following': 1, 'covid19': 1, 'diagnosis': 1, 'nearly': 1, '17': 1, 'times': 1, 'higher': 1, 'among': 1, 'patients': 1, 'receiving': 1, 'vaccine': 1, 'see': 1, 'nothing': 1, 'hospitalization': 1}, {'could': 1, 'possibly': 1, 'explained': 1, '?': 1, 'also': 1, 'mean': 1, 'chances': 1, 'higher': 1, 'infected': 1, 'eg': 1, 'get': 1, 'fourth': 1, 'fifth': 1, 'dose': 1}, {'guess': 1, 's': 1, 'short': 1, 'interval': 1, 'https': 1, 'wwwresearchsquarecomarticlers1226339v1': 1, 'paper': 1, 'got': 1, 'improvement': 1, 'neut': 1, 'post': 1, '2nd': 1, 'dose': 1, 'infected': 1, '3rd': 1, 'good': 1}, {'much': 1, 'anosmia': 1, 'defining': 1, 'feature': 1, 'mild': 1, 'cases': 1}, {'remember': 1, 'sarscov2': 1, 'migrates': 1, 'body': 1, 'affected': 1, 'organs': 1, 'one': 1, 'time': 1, 'another': 1, 'among': 1, 'various': 1, 'cases': 1, 'covid': 1, 'reason': 1, 'vaccines': 1, 'effective': 1, 'high': 1, 'serum': 1, 'antibody': 1, 'levels': 1, 'help': 1, 'prevent': 1, 'kind': 1, 'wide': 1, 'dissemination': 1, 'general': 1, 'really': 1, 'good': 1, 'preventing': 1, 'highly': 1, 'contagious': 1, 'respiratory': 1, 'viruses': 1, 'require': 1, 'lymphatic': 1, 'system': 1, 'cause': 1, 'disease': 1, 'like': 1, 'measles': 1, 'varicella': 1, 'route': 1, 'infection': 1, 'virus': 1, 'disseminates': 1, 'rash': 1, 'transmission': 1, 'diseases': 1, 'dont': 1, 'progression': 1, 'rsv': 1, 'rhinovirus': 1, 'parainfluenza': 1, 'metapneumonia': 1, 'durable': 1, 'immunity': 1, 'otherwise': 1, 'keep': 1, 'getting': 1, 'infected': 1, 'repeatedly': 1, 'follows': 1, 'similar': 1, 'paradigm': 1, 'prior': 1, 'vaccination': 1, 'not': 1, 'long': 1, 'term': 1, 'seems': 1, 'adequately': 1, 'thus': 1, 'severe': 1}, {'results': 1, 'measurably': 1, 'better': 1, 'multivalent': 1, 'vaccine': 1, 'wtbeta': 1, '211': 1, '50': 1, '%': 1, 'higher': 1, 'neutralization': 1, 'delta': 1, 'gamma': 1, 'wt': 1, 'alone': 1, 'nt': 1, 'huge': 1, 'number': 1, 'effect': 1, 'get': 1, 'doubling': 1, 'dose': 1, 's': 1, 'also': 1, 'worth': 1, 'noting': 1, 'farther': 1, 'beta': 1, 'wildtype': 1, 'phase': 1, '1': 1, 'trials': 1, 'supposed': 1, 'repeated': 1, 'wtbetadelta': 1, '213': 1, 'seen': 1, 'indeed': 1, 'named': 1, 'q2': 1, 'report': 1, 'since': 1, 'removed': 1, 'knowledge': 1, 'never': 1, 'published': 1, 'even': 1, 'medical': 1, 'preprint': 1}, {'far': 1, 'voc': 1, 'specific': 1, 'boosters': 1, 'proven': 1, 'effective': 1, 'another': 1, 'shot': 1, 'original': 1, 'based': 1, 'wildtype': 1, 'generating': 1, 'immune': 1, 'response': 1, 'moderna': 1, 'posted': 1, 'results': 1, 'seek': 1, '3rd': 1, 'quarter': 1, 'earning': 1, 'report': 1, 'pdf': 1, 'interested': 1, 're': 1, 'considering': 1, 'maturation': 1, 'time': 1, 'additional': 1, 'exposure': 1, 'vaccines': 1, '____': 1, 'superior': 1, 'immunity': 1, 'allows': 1, 'neutralization': 1, 'sarscov2': 1, 'variants': 1, 'concern': 1, 'develops': 1, 'covid19': 1, 'convalescents': 1, 'naøve': 1, 'individuals': 1, 'three': 1, 'vaccinations': 1, 'https': 1, 'wwwresearchsquarecomarticlers1226339v1': 1, 'structural': 1, 'basis': 1, 'omicron': 1, 'affinitymatured': 1, 'public': 1, 'antibodies': 1, 'wwwbiorxivorgcontent10110120220103474825v1': 1, 'latter': 1, '_____': 1, 'resolved': 1, 'structure': 1, 'caba17': 1, 'fab': 1, 'complex': 1, 'spike': 1, 'overall': 1, 'resolution': 1, '26': 1, 'ö': 1, 'cryoelectron': 1, 'microscopy': 1, 'defined': 1, 'breadth': 1, 'thus': 1, 'neutralizing': 1, 'without': 1, 'modified': 1, 'mature': 1, 'crossneutralize': 1, 'exceptionally': 1, 'antigenically': 1, 'diverged': 1}, {'incorrect': 1, 'significantly': 1, 'second': 1, 'barely': 1, 'third': 1, 'doses': 1, 'moderna': 1, 'myocarditis': 1, 'incidence': 1, 'rate': 1, 'infection': 1, '73': 1, 'per': 1, 'million': 1, 'dose': 1, 'measured': 1, '104': 1, 'believe': 1, 'thereäôs': 1, 'also': 1, 'language': 1, 'study': 1, 'suggesting': 1, 'severity': 1, 'worse': 1, 'covid': 1, 'patients': 1, 'need': 1, 'reread': 1, 'section': 1, 'carefully': 1, 'top': 1, 'statistically': 1, 'significant': 1, 'potential': 1, 'side': 1, 'effect': 1, 'rna': 1, 'vaccines': 1, 'thus': 1, 'far': 1, 'severe': 1, 'whole': 1, '2dose': 1, 'would': 1, 'better': 1, 'young': 1, 'males': 1, 'take': 1, 'risk': 1, 'although': 1, 'available': 1, 'may': 1, 'worth': 1, 'considering': 1, 'vaxs': 1, 'edit': 1, 'needed': 1, 'check': 1, 'number': 1, 'older': 1, '7': 1, 'younger': 1, 'numbers': 1, 'points': 1, 'starting': 1, 'paragraph': 1, '2': 1, 'still': 1, 'stand': 1, 'except': 1, 'fact': 1, 'definitely': 1, 'reconsider': 1, 'using': 1, 'options': 1, 'pfizer': 1, 'az': 1}, {'sorry': 1, 'explanation': 1, 'itäôs': 1, 'statistical': 1, 'noise': 1, 'hold': 1, 'look': 1, 'right': 1, 'edge': 1, 'graph': 1, 'even': 1, 'upper': 1, 'range': 1, 'confidence': 1, 'interval': 1, 'intersecting': 1, 'yaxis': 1, '0': 1, 'additionally': 1, 'actually': 1, 'went': 1, 'zero': 1, 'instead': 1, 'past': 1, 'negative': 1, 'would': 1, 'expect': 1, 'curve': 1, 'asymptotically': 1, 'approach': 1, 'rate': 1, 'descent': 1, 'much': 1, 'steadier': 1, 'straighter': 1}, {'also': 1, 'nt': 1, 'seem': 1, 'take': 1, 'account': 1, 'reduced': 1, 'severity': 1, '&': 1, 'duration': 1, 'vaccinated': 1, 'individuals': 1, 'leading': 1, 'window': 1, 'infecting': 1, 'others': 1}, {'makes': 1, 'lot': 1, 'sense': 1, 'thanks': 1, 'thoughtful': 1, 'response': 1}, {'s': 1, 'comparison': 1, 'sputnik': 1, 'vaccine': 1, 'antibodies': 1, 'concentration': 1, 'pfizers': 1, 'modernas': 1, '?': 1}, {'äúconsidering': 1, 'small': 1, 'effect': 1, 'size': 1, 'association': 1, 'good': 1, 'prognosis': 1, 'patients': 1, 'ssnhl': 1, 'potential': 1, 'influence': 1, 'condition': 1, 'public': 1, 'health': 1, 'appears': 1, 'relatively': 1, 'minoräù': 1, 'from': 1, 'source': 1, 'article': 1}, {'boosters': 1, 'less': 1, 'bad': 1, 'doubly': 1, 'vaccinated': 1}, {'news': 1, '3rd': 1, 'shots': 1, 'ages': 1, '511': 1, '?': 1, 'wonder': 1, 'll': 1, 'help': 1, 'bring': 1, 'back': 1, 'protection': 1}, {'many': 1, 'studies': 1, 'ignore': 1, 'impact': 1, 'hybrid': 1, 'immunity': 1, '?': 1}, {'rather': 1, 'opposite': 1, 'making': 1, 'pronouncement': 1, 'sentence': 1, 'literally': 1, 'translates': 1, 'nt': 1, 'enough': 1, 'evidence': 1, 'make': 1, 'yet': 1}, {'wait': 1, 'two': 1, 'weeks': 1, 'booster': 1, 'find': 1, 'increased': 1, 'risk': 1, 'symptomatic': 1, 'cases': 1, '?': 1, 'boosters': 1, 'useful': 1, 'metric': 1}, {'beyond': 1, 'lower': 1, 'rates': 1, 'pneumonia': 1, 'ct': 1, 'clinical': 1, 'course': 1, 'patients': 1, 'paralleled': 1, 'chest': 1, 'findings': 1, 'vaccinated': 1, 'much': 1, 'less': 1, 'likely': 1, 'require': 1, 'supplemental': 1, 'oxygen': 1, 'odds': 1, 'ratios': 1, '24': 1, 'p005': 1, 'rate': 1, 'intensive': 1, 'care': 1, 'unit': 1, 'admission': 1, 'ratio': 1, '08': 1, 'p02': 1, 'unvaccinated': 1, '008': 1, 'nt': 1, 'impressive': 1, '?': 1}, {'pick': 1, 'battles': 1, 'canäôt': 1, 'control': 1, 'virus': 1, 'itäôs': 1, 'becoming': 1, 'transmissible': 1, 'point': 1, 'catching': 1, 'hard': 1, 'long': 1, 'covid': 1, 'huge': 1, 'issue': 1, 'something': 1, 'iäôm': 1, 'concerned': 1, '?': 1, 'force': 1, 'world': 1, 'stay': 1, 'indoors': 1, 'anymore': 1, 'mask': 1, 'mandates': 1, 'dropped': 1, 'people': 1, 'starting': 1, 'live': 1, 'like': 1, '2019': 1, 'preventing': 1, 'infection': 1, 'seems': 1, 'impossible': 1, 'average': 1, 'person': 1, 'age': 1, 'omicron': 1}, {'kinda': 1, 'agree': 1, 'one': 1, 'caveat': 1, 'looked': 1, 'time': 1, 'period': 1, 'dominant': 1, 'alphadelta': 1, 'omicron': 1, 'far': 1, 'prevalent': 1, 'variant': 1, 'seemingly': 1, 'much': 1, 'less': 1, 'virulent': 1, 'hopefully': 1, 'likelyhood': 1, 'long': 1, 'covid': 1, 'infection': 1, 'turn': 1, 'significantly': 1, 'groups': 1, 'also': 1, 'nt': 1, 'could': 1, 'include': 1, 'anyone': 1, 'received': 1, '3': 1, 'shots': 1, 'perhaps': 1, 'provides': 1, 'greater': 1, 'protection': 1, 'primary': 1, 'course': 1, '2': 1, 'win': 1, 'month': 1}, {'links': 1, 'studies': 1, 'sinovac': 1, 'omicron': 1, '?': 1, 've': 1, 'tough': 1, 'time': 1, 'finding': 1, 'anything': 1, 'm': 1, 'triple': 1, 'vaxxed': 1, 'really': 1, 'freaked': 1, 'getting': 1, 'virus': 1}, {'source': 1, '?': 1, 'tcell': 1, 'based': 1, 'data': 1, 'long': 1, 'booster': 1, 'seems': 1, 'work': 1}, {'answer': 1, 'd': 1, 'need': 1, 'know': 1, 'severity': 1, 'vaccineassociated': 1, 'myocarditis': 1, 'rate': 1, 'covid': 1, 'reinfection': 1, 'rates': 1, 'sequelae': 1, 'following': 1, 'trying': 1, 'put': 1, 'whole': 1, 'picture': 1, 'together': 1, 'public': 1, 'health': 1, 'recommendations': 1}, {'3': 1, 'days': 1, 'ago': 1, 'sub': 1, 'study': 1, 'published': 1, 'saying': 1, 'omicron': 1, 'infections': 1, 'fact': 1, 'much': 1, 'mild': 1, 'delta': 1, 'linked': 1, 'looking': 1, 'viral': 1, 'replication': 1, 'rates': 1, 'says': 1, 'nothing': 1, 'disease': 1, 'severity': 1, 're': 1, 'referring': 1, 'south': 1, 'african': 1, 'showed': 1, '29': 1, '%': 1, 'lower': 1, 'hospitalisation': 1, 'rate': 1, 'ancestral': 1, 'strain': 1, 'nt': 1, 'fully': 1, 'controlled': 1, 'immunity': 1, 'prior': 1, 'infection': 1, 'specify': 1, 'documented': 1, 'vast': 1, 'majority': 1, 'covid': 1, 'cases': 1, 'go': 1, 'unreported': 1, 'surveillance': 1, 'africa': 1, 'great': 1, 'however': 1, 'hospitalization': 1, 'would': 1, 'suggest': 1, 'ommicron': 1, 'necessarily': 1, 'evidence': 1, 'variant': 1, 'less': 1, 'virulent': 1, 'occuring': 1, 'current': 1, 'wave': 1, 'also': 1, 'attributed': 1, 'higher': 1, 'levels': 1, 'population': 1, 'edit': 1, 'reading': 1, 'actually': 1, 'outright': 1, 'states': 1, 'äúthis': 1, 'lesser': 1, 'could': 1, 'confounded': 1, 'high': 1, 'seroprevalence': 1, 'sars': 1, 'cov2': 1, 'antibodies': 1, 'general': 1, 'especially': 1, 'following': 1, 'extensive': 1, 'infectionsäù': 1}, {'every': 1, 'cold': 1, 'exists': 1, 'today': 1, 'variant': 1, 'virus': 1, 'existed': 1, 'year': 1, 'two': 1, 'forth': 1}, {'moderna': 1, 'mainly': 1}, {'boys': 1, 'preexisting': 1, 'heart': 1, 'anomalies': 1, 'myocardial': 1, 'scarring': 1, 'boy': 1, 'cardiomegaly': 1, 'b': 1, 'also': 1, 'history': 1, 'amphetamine': 1, 'use': 1}, {'think': 1, 'equally': 1, 'plausible': 1, 'explanation': 1, 'occurring': 1, 'omicron': 1, 'spike': 1, 'divergent': 1, 'able': 1, 'engage': 1, 'existing': 1, 'b': 1, 'cells': 1, 'particularly': 1, 'well': 1, 'merely': 1, 'acts': 1, 'like': 1, 'first': 1, 'dose': 1, 'prime': 1, 'second': 1, 'booster': 1, 'may': 1, 'work': 1, 'much': 1, 'better': 1, 'note': 1, 'mouse': 1, 'study': 1, 'vaccine': 1, 'omicronspecific': 1, 'one': 1, 'wildtype': 1, 'trained': 1, 'would': 1, 'consistent': 1}, {'effective': 1, 'treatment': 1, 'options': 1, 'available': 1, 'locally': 1, 'eg': 1, 'paxlovid': 1, 'sotrovimab': 1, 'forego': 1, 'vaccinebooster': 1, 'instead': 1, 'plan': 1, 'seek': 1, 'early': 1, 'upon': 1, 'symptomatic': 1, 'infection': 1, '?': 1, 'especially': 1, 'knowing': 1, 'may': 1, 'one': 1, 'many': 1, 'infected': 1, 'turn': 1, 'asymptomatic': 1, 'update': 1, 'donäôt': 1, 'get': 1, 'downvoted': 1, 'people': 1, 'taking': 1, 'issue': 1, 'last': 1, 'statement': 1, 'systematic': 1, 'review': 1, 'concluded': 1, '35': 1, '%': 1, 'cases': 1, 'https': 1, 'wwwpnasorgcontent11834e2109229118': 1, 'also': 1, 'think': 1, 'itäôs': 1, 'controversial': 1, 'say': 1, 'first': 1, 'couple': 1, 'vaccine': 1, 'doses': 1, 'contemplating': 1, 'booster': 1, 'likely': 1, 'even': 1, 'case': 1, 'omicron': 1, 'declared': 1, 'milder': 1, 'conjecture': 1, 'ratio': 1, 'higher': 1, 'weäôll': 1, 'still': 1, 'see': 1, 'data': 1, 'bears': 1, 'piece': 1}, {'curve': 1, 'probably': 1, 'informed': 1, 'observations': 1, 'point': 1, 'chance': 1, 'might': 1, 'given': 1, 'unintuitive': 1, 'results': 1}, {'bharat': 1, 'biotech': 1, 'got': 1, 'approval': 1, 'indian': 1, 'regulators': 1, 'phase': 1, '3': 1, 'trial': 1, 'last': 1, 'month': 1}, {'curious': 1, 'imagine': 1, 'something': 1, 'antibody': 1, 'affinity': 1, 'maturation': 1}, {'seem': 1, 'two': 1, 'points': 1, 'along': 1, 'previous': 1, 'data': 1, 'showing': 1, 'superiority': 1, 'third': 1, 'dose': 1, 'second': 1, 'dose4': 1, 'results': 1, 'suggest': 1, 'maximal': 1, 'immunogenicity': 1, 'mrna': 1, 'vaccines': 1, 'achieved': 1, 'three': 1, 'doses': 1, 'antibody': 1, 'levels': 1, 'restored': 1, 'fourth': 1, 'boosting': 1, 'increase': 1, 'nt': 1, 'surprising': 1, 'imagine': 1, 'future': 1, 'studies': 1, 'observing': 1, 'similar': 1, '5th': 1, '6th': 1, 'nth': 1, 'booster': 1, 'furthermore': 1, 'observed': 1, 'low': 1, 'vaccine': 1, 'efficacy': 1, 'infections': 1, 'health': 1, 'care': 1, 'workers': 1, 'well': 1, 'relatively': 1, 'high': 1, 'viral': 1, 'loads': 1, 'suggesting': 1, 'infected': 1, 'infectious': 1, 'thus': 1, 'vaccination': 1, 'healthy': 1, 'young': 1, 'may': 1, 'marginal': 1, 'benefits': 1, 'important': 1, 'point': 1, 'despite': 1, 'antibodies': 1, 'existing': 1, 'efficacious': 1, 'reducing': 1, 'adds': 1, 'evidence': 1, 'omicronrelated': 1, 'strains': 1, 'better': 1, 'able': 1, 'evade': 1, 'immune': 1, 'detection': 1, 'due': 1, 'least': 1, 'part': 1, 'current': 1, '2022': 1, 'diverged': 1, '2019': 1, 'strain': 1, 'used': 1, 'make': 1}, {'also': 1, 'preprint': 1, 'think': 1, 'given': 1, 'title': 1, 'abstract': 1, 'misleading': 1, 'going': 1, 'yes': 1, 'lot': 1, 'people': 1, 'interpret': 1, 'omicron': 1, 'specific': 1, 'boosters': 1, 'wo': 1, 'nt': 1, 'induce': 1, 'strong': 1, 'responses': 1, 'voc': 1, 'study': 1, 'looks': 1, 'mice': 1, 'unexposed': 1, 'covid': 1, 'rather': 1, 'vaccinated': 1, 'wt': 1, 'response': 1, 'someone': 1, 'already': 1, 'previously': 1, 'exposed': 1, 'wtdelta': 1, 'booster': 1}, {'sweden': 1, 'much': 1, 'restrictions': 1, 'none': 1, 's': 1, 'study': 1, 'done': 1, 'exclude': 1, 'correlation': 1, 'possible': 1}, {'vaccines': 1, 'really': 1, 'donäôt': 1, 'prevent': 1, 'transmission': 1, 'well': 1}, {'anyone': 1, 'know': 1, 'timeline': 1, 'goes': 1, 'human': 1, 'trials': 1, '?': 1}, {'interesting': 1, 'memory': 1, 'serves': 1, 'correctly': 1, 'pfizer': 1, '70': 1, '%': 1, 'effective': 1, 'omicron': 1, 'used': 1, 'booster': 1, 'perhaps': 1, 'better': 1, 'option': 1, 'know': 1, 'antibodies': 1, 'continue': 1, 'rise': 1, 'beyond': 1, 'timeframe': 1, 'mrna': 1, 'vaccines': 1, 'begin': 1, 'fall': 1}, {'doesnäôt': 1, 'covaxin': 1, 'safe': 1, '&': 1, 'effective': 1, 'pediatric': 1, 'data': 1, 'usapproved': 1, 'vaccines': 1, 'yet': 1, '?': 1}, {'study': 1, 'covered': 1, 'first': 1, '6': 1, 'months': 1, 'vaccination': 1, 'dose': 1, 'yes': 1, 'accounted': 1, 'future': 1, 'monitoring': 1, 'probably': 1, 'wise': 1}, {'s': 1, 'acute': 1, 'response': 1, 'important': 1, 'fearstress': 1, 'works': 1, 'probably': 1, 'nt': 1, 'much': 1, 'actual': 1, 'exercise': 1, 'convincing': 1, 'body': 1, 'attacked': 1, 'lion': 1}, {'thought': 1, 'tcell': 1, 'immunity': 1, 'always': 1, 'long': 1, 'lasting': 1, 'whether': 1, 'resulted': 1, 'vaccination': 1, 'infection': 1, 'havenäôt': 1, 'seen': 1, 'papers': 1, 'published': 1, 'noted': 1, 'temporary': 1}, {'think': 1, 'youäôre': 1, 'reading': 1, 'bit': 1, 'much': 1, 'lines': 1, 'really': 1, 'paper': 1, 'opinionated': 1, '?': 1, 'reads': 1, 'like': 1, 'theyäôre': 1, 'simply': 1, 'reporting': 1, 'results': 1, 'havenäôt': 1, 'read': 1, 'whole': 1, 'thing': 1, 'thoroughly': 1, 'though': 1, 'missing': 1, 'something': 1}, {'paper': 1, 'ever': 1, 'claim': 1, 'shot': 1, 'helps': 1, 'improve': 1, 'mental': 1, 'health': 1, '?': 1}, {'one': 1, 'gave': 1, 'correct': 1, 'explanation': 1, 'itäôs': 1, 'graph': 1, 'cubic': 1, 'spline': 1, 'fitted': 1, 'observed': 1, 'values': 1, 'look': 1, 'table': 1, 'instead': 1, '9': 1, 'months': 1, 'estimated': 1, '23': 1, '%': 1, 'effectiveness': 1, 'infection': 1, 'wide': 1, 'confidence': 1, 'interval': 1, 'zero': 1, 'line': 1, 'actually': 1, 'data': 1, 'proper': 1, 'informed': 1, 'model': 1, 'simple': 1, 'smoothing': 1}, {'whatäôs': 1, 'next': 1, 'big': 1, 'treatment': 1, 'potentially': 1, 'horizon': 1, '?': 1}, {'read': 1, 'somewhere': 1, 'else': 1, 'significantly': 1, 'younger': 1, 'population': 1, 'overall': 1, 'basically': 1, 'common': 1, 'observation': 1, 'make': 1, 'virus': 1, 'ca': 1, 'nt': 1, 'translate': 1, 'west': 1, 'difference': 1, 'age': 1}, {'think': 1, 'mixed': 1, 'p02': 1, 'massive': 1, 'risk': 1, 'reduction': 1}, {'doesnäôt': 1, 'table': 1, 'shows': 1, 'drop': 1, '23': 1, '%': 1, 'graph': 1, 'smoothing': 1, 'line': 1, 'actually': 1, 'data': 1}, {'data': 1, 'provide': 1, 'evidence': 1, 'fourth': 1, 'dose': 1, 'mrna': 1, 'vaccine': 1, 'immunogenic': 1, 'safe': 1, 'somewhat': 1, 'efficacious': 1, 'primarily': 1, 'symptomatic': 1, 'disease': 1, 'comparison': 1, 'initial': 1, 'response': 1, 'peak': 1, 'third': 1, 'show': 1, 'substantial': 1, 'differences': 1, 'humoral': 1, 'levels': 1, 'omicronspecific': 1, 'neutralizing': 1, 'antibodies': 1, 'along': 1, 'previous': 1, 'showing': 1, 'superiority': 1, 'second': 1, 'dose4': 1, 'results': 1, 'suggest': 1, 'maximal': 1, 'immunogenicity': 1, 'vaccines': 1, 'achieved': 1, 'three': 1, 'doses': 1, 'antibody': 1, 'restored': 1, 'furthermore': 1, 'observed': 1, 'low': 1, 'efficacy': 1, 'infections': 1, 'health': 1, 'care': 1, 'workers': 1, 'well': 1, 'relatively': 1, 'high': 1, 'viral': 1, 'loads': 1, 'suggesting': 1, 'infected': 1, 'infectious': 1, 'thus': 1, 'vaccination': 1, 'healthy': 1, 'young': 1, 'may': 1, 'marginal': 1, 'benefits': 1, 'older': 1, 'vulnerable': 1, 'populations': 1, 'assessed': 1}, {'needs': 1, 'better': 1, 'education': 1, 'awareness': 1, 'longterm': 1, 'risks': 1, 'infection': 1, 'varios': 1, 'pathogens': 1, 'people': 1, 'incorrectly': 1, 'assess': 1, 'risk': 1, 'vaccineinduced': 1, 'injury': 1, 'greater': 1, 'aware': 1, 'viruses': 1, 'cause': 1, 'autoimmune': 1, 'diseases': 1, 'future': 1, 'researchers': 1, 'focused': 1, 'relationship': 1, 'viral': 1, 'infections': 1, 'various': 1, 'comorbidities': 1}, {'possible': 1, 'selective': 1, 'pressure': 1, 'towards': 1, 'milder': 1, 'forms': 1, 'iäôve': 1, 'seen': 1, 'argued': 1, 'time': 1, 'die': 1, 'covid': 1, 'virus': 1, 'gone': 1, 'moved': 1, 'live': 1, 'irrelevant': 1, 'inflammation': 1, 'left': 1, 'behind': 1, 'entirely': 1, 'separate': 1, 'second': 1, 'phase': 1, 'suggesting': 1, 'opinions': 1, '?': 1, 'valid': 1, 'argument': 1}, {'beta': 1, 'major': 1, 'vaccine': 1, 'evader': 1, 'well': 1}, {'recommending': 1, 'nonmrna': 1, 'vaccines': 1, 'young': 1, 'male': 1, 'cohort': 1, '?': 1}, {'find': 1, 'odd': 1, 'neutralization': 1, 'titers': 1, 'moderna': 1, 'lower': 1, 'pfizer': 1, 'yet': 1, 'efficacy': 1, 'consistently': 1, 'higher': 1, 'almost': 1, 'every': 1, 'study': 1}, {'doesnäôt': 1, 'jnj': 1, 'study': 1, 'contradict': 1, 'consensus': 1, '?': 1, 'got': 1, 'mrna': 1, 'booster': 1, 'cdc': 1, 'told': 1, 'itäôs': 1, 'superior': 1, 'looking': 1, 'thatäôs': 1, 'clearly': 1, 'case': 1}, {'nt': 1, 'south': 1, 'africa': 1, 'seeing': 1, 'uptick': 1, 'deaths': 1, 'yet': 1, '?': 1}, {'weäôre': 1, 'also': 1, 'dealing': 1, 'contagious': 1, 'variants': 1, 'time': 1, 'passes': 1, 'delta': 1, 'omicron': 1}, {'clear': 1, 'imprinting': 1, 'issue': 1, 'study': 1, 'date': 1, 'give': 1, 'sufficient': 1, 'time': 1, 'antibody': 1, 'maturation': 1, 'occur': 1, 'boost': 1, 'trigger': 1, 'plasma': 1, 'bcell': 1, 'conversion': 1, 'generation': 1, 'immune': 1, 'system': 1, 'problems': 1, 'tracking': 1, 'escape': 1, 'existing': 1, 'hcovs': 1, 'https': 1, 'journalsplosorgplospathogensarticle': 1, '?': 1, 'id101371journalppat1009453': 1, 'would': 1, 'astounded': 1, 'sarscov2': 1, 'different': 1}, {'moderate': 1, 'intensity': 1, 'activity': 1, 'jogging': 1, '10': 1, 'minute': 1, 'mile': 1, 'average': 1, 'american': 1, 'overweight': 1, 'obese': 1, 'americans': 1, 'probably': 1, 'could': 1, 'jog': 1, 'without': 1, 'take': 1, 'walking': 1, 'breaks': 1, 'certainly': 1, 'would': 1, 'nt': 1, '6mph': 1, 'pace': 1, 'middle': 1, 'aged': 1, 'person': 1}, {'old': 1, 'law': 1, 'needs': 1, 'rethought': 1, 'protect': 1, '6months': 1, '2': 1, 'years': 1, 'arenäôt': 1, '?': 1}, {'nab': 1, 'data': 1, 'interesting': 1, 'pfizer': 1, 's': 1, 'vaccine': 1, 'initially': 1, 'edges': 1, 'j': 1, '&': 1, 'bindingneutralizing': 1, 'titers': 1, 'start': 1, 'falling': 1, 'almost': 1, 'immediately': 1, 'consistent': 1, 'earlier': 1, 'literature': 1, 'demonstrating': 1, 'thing': 1, 'differential': 1, 'kinetics': 1, 'immune': 1, 'responses': 1, 'elicited': 1, 'covid19': 1, 'vaccines': 1, 'nejm': 1, 'https': 1, 'wwwnejmorgdoifull101056nejmc2115596': 1, 'very': 1, 'potent': 1, 'early': 1, 'humoral': 1, 'immunity': 1, 'significant': 1, 'issues': 1, 'staying': 1, 'power': 1, 'nt': 1, 'mind': 1, 'getting': 1, 'boosts': 1, 'routinely': 1, 'counteract': 1, 'm': 1, 'sure': 1, 'sustainable': 1, 'public': 1, 'policy': 1, 'perspective': 1, 'still': 1, 'imagine': 1, 'difference': 1, 'efficacy': 1, 'omicron': 1, 'certainly': 1, 'related': 1, 'cell': 1, 'function': 1, 'mrnas': 1, 'induce': 1, 'remarkable': 1, 'antibody': 1, 'response': 1, 'useful': 1, 'broad': 1, 'majority': 1, 'antibodies': 1, 'ca': 1, 'bind': 1, 'rbd': 1, 'adenoviral': 1, 'platforms': 1, 'like': 1, 'trade': 1, 'comparably': 1, 'low': 1, 'stronger': 1, 'cells': 1, 'tend': 1, 'robust': 1, 'largescale': 1, 'changes': 1, 'sequence': 1}, {'speed': 1, 'omicron': 1, '50': 1, '%': 1, 'us': 1, 'infected': 1, 'end': 1, 'january': 1, 'probably': 1, 'means': 1, 'limited': 1, 'effectiveness': 1, '&': 1, 'x200b': 1, 'mutations': 1, 'thats': 1, 'happening': 1, 'incomprehensible': 1, 'total': 1, 'guess': 1, 'attempting': 1, 'vaccinate': 1, 'ba2': 1, 'whatever': 1, 'seems': 1, 'like': 1, 'next': 1, 'explode': 1, 'march': 1, 'northeast': 1, 'would': 1, 'better': 1, 'could': 1, 'go': 1, 'knows': 1, 'variant': 1, 'south': 1, 'june': 1, '2022': 1, 'ba22': 1, 'even': 1, 'newer': 1, 'one': 1, 'winter': 1, '?': 1}, {'reading': 1, 'testicular': 1, 'inoculation': 1, 'correctly': 1, '?': 1, 'stabbed': 1, 'needle': 1, 'testicle': 1, 'injected': 1, 'sarscov2': 1, 'straight': 1, 'testicles': 1, 'hamsters': 1, 'exactly': 1, 'injecting': 1, 'virus': 1, 'normally': 1, 'spreads': 1, 'respiratory': 1, 'aerosols': 1, 'supposed': 1, 'demonstrate': 1, 'viruses': 1, 'thing': 1, 'done': 1}, {'started': 1, 'suspicious': 1, 'variant': 1, 'doses': 1, 'first': 1, 'heard': 1, 'deltaspecific': 1, 'booster': 1, 'nt': 1, 'better': 1, 'third': 1, 'shot': 1, 'original': 1, '?': 1, 'time': 1, 'everyone': 1, 'framed': 1, 'wow': 1, 'og': 1, 'good': 1, 'effective': 1, 'delta': 1, 'still': 1, 'weird': 1, 'one': 1}, {'m': 1, 'confused': 1, 'comment': 1, 'nt': 1, 'asymptomatic': 1, 'covid': 1, 'covid19like': 1, 'illness': 1, '?': 1, 'positive': 1, 'test': 1, 'typically': 1, 'result': 1, 'diagnosis': 1}, {'considering': 1, 'amount': 1, 'vaccine': 1, 'hesitancy': 1, 'antivaxxers': 1, 'possible': 1, 'risk': 1, 'vaers': 1, 'reports': 1, 'even': 1, 'coincidental': 1, 'accurate': 1, 'greater': 1, 'prior': 1, 'pandemic': 1, 'symptoms': 1, 'ignored': 1, 'many': 1, 'psychosomatic': 1, 'variables': 1, 'well': 1}, {'d': 1, 'really': 1, 'like': 1, 'looking': 1, 'population': 1, 'survey': 1, 'state': 1, 'publishes': 1, 'reinfectionbreakthrough': 1, 'infection': 1, 'etc': 1, 'also': 1, 'published': 1, 'vaccination': 1, 'rate': 1, 'convalescent': 1, 'patients': 1, 'could': 1, 'start': 1, 'see': 1, 'consistent': 1, 'analysis': 1, 'currently': 1, 'breakthrough': 1, 'seems': 1, 'common': 1, 'reinfection': 1, 'based': 1, 'mn': 1, 'doh': 1, 'data': 1}, {'reported': 1, 'cases': 1}, {'entirely': 1, 'false': 1, 'threedose': 1, 'vaccination': 1, 'defeated': 1, 'delta': 1, 'every': 1, 'country': 1, 'tried': 1, 'nothing': 1, 'else': 1, 'except': 1, 'letting': 1, 'everyone': 1, 'catch': 1, 'waiting': 1, 'reinfections': 1, 'start': 1, 'succeeded': 1, 'also': 1, 'know': 1, 'multivalent': 1, 'wtbetadelta': 1, 'vaccines': 1, 'used': 1, 'small': 1, 'trials': 1, 'significantly': 1, 'effective': 1, 'though': 1, 've': 1, 'done': 1, 'research': 1, 'certainly': 1, 'lot': 1, 'omicron': 1, 'wtomicron': 1, 'deltaomicronb1640': 1, 'deltaomicronsarsmers': 1, 'spike': 1, 'would': 1, 'nearcertainty': 1, 'better': 1, 'existing': 1, 'variant': 1, 'much': 1, 'future': 1, 'idea': 1, 'science': 1, 'solve': 1, 'nt': 1, 'really': 1, 'hold': 1, 'water': 1, 'betadelta': 1, 'spikes': 1, 'engineered': 1, 'polymutant': 1, 'sarsmers': 1, 'available': 1, 'vaccine': 1, 'use': 1, 'nearly': 1, 'year': 1, 'fear': 1, 'stopped': 1, 'us': 1, 'even': 1, 'trying': 1, 'shown': 1, 'broad': 1, 'dramatically': 1}, {'waste': 1, 'water': 1, 'detection': 1, 'increased': 1, 'starkly': 1, 'many': 1, 'places': 1, 'us': 1, 'large': 1, 'spikes': 1, 'abroad': 1, 'd': 1, 'say': 1, 'sooner': 1, 'better': 1, 'data': 1, 'supports': 1, 'efficacy': 1, 'safety': 1}, {'youäôve': 1, 'already': 1, 'covid': 1, 'getting': 1, 'vaccinated': 1, 'results': 1, 'robust': 1, 'protectionäî': 1, 'better': 1, 'infection': 1, 'alone': 1, 'vaccination': 1, 'makes': 1, 'sense': 1, 'wonder': 1, 'reverse': 1, 'folks': 1, 'first': 1, 'subsequently': 1, 'breakthrough': 1, 'assume': 1, 'compares': 1}, {'reducing': 1, 'hospitalizationdeath': 1, 'avoiding': 1, 'infection': 1, 'different': 1, 'success': 1, 'criteria': 1}, {'would': 1, 'agree': 1, 'mean': 1, 'failure': 1, '?': 1, 'real': 1, 'truth': 1, 'covid': 1, 'different': 1, 'enough': 1, 'must': 1, 'consider': 1, 'short': 1, 'period': 1, 'time': 1, 'created': 1, 'vaccines': 1, 'rushed': 1, 'get': 1, 'something': 1, 'public': 1, 'help': 1, 'slow': 1, 'deaths': 1, 'try': 1, 'imagine': 1, 'might': 1, 'took': 1, 'standard': 1, 'procedures': 1, 'developing': 1, 'vaccine': 1, 'long': 1, 'take': 1, 'create': 1}, {'wouldnäôt': 1, 'safe': 1, 'say': 1, 'lot': 1, 'people': 1, 'heightened': 1, 'stress': 1, 'fear': 1, 'anxiety': 1, 'etc': 1, 'reassured': 1, 'taking': 1, 'shot': 1, 'protection': 1, '?': 1, 'placebo': 1, 'effect': 1, 'äúthe': 1, 'helps': 1, 'improve': 1, 'mental': 1, 'healthäù': 1}, {'clear': 1, 'study': 1, 'estimate': 1, 'probability': 1, 'infected': 1, 'either': 1, 'omicron': 1, 'delta': 1, 'vaccination': 1, 'status': 1, 'examines': 1, 'test': 1, 'positivity': 1, 'rate': 1, 'given': 1, 'chosen': 1, 'get': 1, 'pcr': 1, 'percentage': 1, 'time': 1, 'tests': 1, 'give': 1, 'positive': 1, 'result': 1, 'variant': 1, 'people': 1, 'choose': 1, 'likely': 1, 'biased': 1, 'sample': 1, 'symptoms': 1, 'compared': 1, 'broader': 1, 'population': 1, 'actual': 1, 'random': 1, 'person': 1, 'different': 1, 'course': 1, 'authors': 1, 'make': 1, 'claim': 1, 'clarifying': 1, 'could': 1, 'misread': 1, 'way': 1}, {'s': 1, 'pretty': 1, 'much': 1, 'authors': 1, 'wrote': 1, '&': 1, 'x200b': 1, 'omicron': 1, 'similarity': 1, 'ors': 1, '3': 1, 'doses': 1, 'using': 1, 'unvaccinated': 1, 'referent': 1, 'group': 1, '2dose': 1, 'consistent': 1, 'attenuation': 1, '2': 1, 'vs': 1, 'time': 1, 'since': 1, 'second': 1, 'dose': 1, 'which': 1, 'reflected': 1, 'significant': 1, 'association': 1, '6': 1, 'months': 1, 'products': 1}, {'great': 1, 'response': 1}, {'yeah': 1, 'low': 1, 'effort': 1, 'contribution': 1, 'isnäôt': 1, 'even': 1, 'based': 1, 'paperäôs': 1, 'results': 1, 'countless': 1, 'papers': 1, 'shown': 1, 'äúvaccines': 1, 'workäù': 1, 'one': 1, '21': 1, 'people': 1, 'working': 1, 'age': 1, 'hospitalized': 1, 'hardly': 1, 'evidence': 1, 'vaccines': 1, 'reducing': 1, 'severity': 1, 'hospitalization': 1, 'rate': 1, 'single': 1, 'digits': 1, 'begin': 1, 'perhaps': 1, 'well': 1, '1': 1, '%': 1, 'omicron': 1, 'group': 1, 'unvaccinated': 1}, {'paper': 1, 'state': 1, 'whether': 1, 'vaccinated': 1, 'hamsters': 1, 'got': 1, 'sarscov2': 1, 'injected': 1, 'testes': 1, '?': 1}, {'niaid': 1, 'study': 1, 'showed': 1, 'starting': 1, 'j': 1, '&': 1, 'boosting': 1, 'mrna': 1, 'big': 1, 'bump': 1, 'antibodies': 1, 'erred': 1, 'already': 1, 'waning': 1, 'significantly': 1, 'week': 1, '2': 1, '4': 1, 'way': 1, 'around': 1, 'still': 1, 'increasing': 1}, {'antigenic': 1, 'sin': 1}, {'even': 1, 'delta': 1, '20': 1, 'weeks': 1, 'less': 1, '50': 1, '%': 1, 'effective': 1, 'against': 1, 'infection': 1, 'still': 1, 'provided': 1, '95': 1, 'protection': 1, 'hospitalization': 1, 'immunocompetent': 1, 'population': 1}, {'anyone': 1, 'access': 1, 'full': 1, 'paper': 1, '?': 1, 'ratio': 1, 'pre': 1, 'post': 1, 'vaccination': 1, 'antibody': 1, 'titer': 1, 'could': 1, 'also': 1, 'higher': 1, 'levels': 1, 'antibodies': 1, 'much': 1, 'lower': 1, 'prevaccination': 1, 'individuals': 1}, {'ba2': 1, 'information': 1, 'best': 1, 'vague': 1, 'anyone': 1, 'published': 1, 'results': 1, '?': 1, 'interested': 1, 'new': 1, 'mutation': 1, 'impact': 1, 'us': 1}, {'part': 1, 'stuck': 1, 'absence': 1, 'severe': 1, 'disease': 1, 'hospitalization': 1, 'death': 1, 'study': 1, 'precludes': 1, 'assessment': 1, 'vaccine': 1, 'efficacy': 1, 'endpoints': 1, 'think': 1, 's': 1, 'good': 1, 'thing': 1, 'serves': 1, 'reminder': 1, 'low': 1, 'risk': 1, 'omicron': 1, 'young': 1, 'children': 1, 'note': 1, 'edited': 1, 'clarity': 1}, {'seems': 1, 'protection': 1, 'severe': 1, 'disease': 1, 'stable': 1, 'tcells': 1, 'previous': 1, 'infection': 1, 'important': 1, 'https': 1, 'wwwbiorxivorgcontent10110120211212472315v1': 1}, {'yes': 1, 'even': 1, 'discussion': 1, 'developing': 1, 'vaccines': 1, 'back': 1, '2020': 1, 'set': 1, 'antivaxxers': 1, 'already': 1, 'gaining': 1, 'traction': 1, 'years': 1, 'prior': 1, 'covid': 1, 'wakefield': 1, 'days': 1, '1998': 1, 'pointing': 1, 'hypocrisy': 1, 'concern': 1, 'thereäôs': 1, 'far': 1, 'less': 1, '350000': 1, 'chemicals': 1, 'environment': 1, 'several': 1, 'thousand': 1, 'msds': 1, 'known': 1, 'carcinogens': 1, 'neurotoxins': 1, 'endocrine': 1, 'disrupters': 1, 'vocäôs': 1, 'one': 1, 'way': 1, 'get': 1, 'risk': 1, 'benefitharmrisk': 1, 'analysis': 1, 'broached': 1, 'another': 1, 'topic': 1, 'shortterm': 1, 'macro': 1, 'economic': 1, 'societal': 1, 'costs': 1, 'humans': 1, 'tend': 1, 'focused': 1, 'immediate': 1, 'concerns': 1, 'underestimate': 1, 'longterm': 1, 'risks': 1, 'consciously': 1, 'choose': 1, 'äúkick': 1, 'roadäù': 1, 'enough': 1, 'education': 1, 'unknown': 1, 'pathogens': 1, 'drugstreatments': 1, 'potential': 1, 'benefit': 1, 'outweighs': 1, 'part': 1, 'donäôt': 1, 'know': 1, 'additional': 1, 'yettobe': 1, 'discovered': 1, 'sequelae': 1, 'macroeconomic': 1, 'every': 1, 'variable': 1}, {'yes': 1, 'valid': 1, 'usually': 1, 'pressure': 1, 'become': 1, 'milder': 1, 'driven': 1, 'fact': 1, 'symptomatic': 1, 'people': 1, 'likely': 1, 'home': 1, 'bed': 1, 'actively': 1, 'riding': 1, 'subway': 1, 'whatever': 1, 'reducing': 1, 'symptoms': 1, 'virus': 1, 'access': 1, 'hosts': 1}, {'layman': 1, 'terms': 1, 'clue': 1, 'virology': 1, 'covid': 1, 'endemic': 1, 'stage': 1, '?': 1, 'like': 1, 'time': 1, 'next': 1, 'year': 1, 'would': 1, 'bear': 1, 'resemblance': 1, 'say': 1, 'common': 1, 'cold': 1, 'still': 1, 'long': 1, 'way': 1, 'go': 1, 'finally': 1, 'reaches': 1}, {'summary': 1, 'leaves': 1, 'lot': 1, 'important': 1, 'dataassumptions': 1, 'really': 1, 'main': 1, 'finding': 1, 'breadth': 1, 'immune': 1, 'response': 1, 'n501y': 1, 'better': 1, 'mrna': 1, 'vaccinated': 1, 'individuals': 1, 'convalescents': 1, 'rest': 1, 'points': 1, 'would': 1, 'perhaps': 1, 'explain': 1, 'difference': 1, 'overall': 1, 'titer': 1, 'decreasing': 1, 'time': 1, 'majority': 1, 'abstract': 1}, {'also': 1, 'novavax': 1, 'spike': 1, 'protein': 1, 'slightly': 1, 'different': 1, 'pfizerbiontech': 1, 'moderna': 1, 'vaccine': 1, 'nvxcov2373': 1, 'ps': 1, 'developed': 1, 'ad26cov2s': 1, 'nrvv': 1, 'janssen': 1, 'pharmaceuticals': 1, 'vaccines': 1, 'deploy': 1, 'glycoprotein': 1, 'mutated': 1, 'furin': 1, 'cleavage': 1, 'site': 1, 'k986pv987p': 1, 'proline': 1, 'substitutions': 1, 'https': 1, 'wwwfrontiersinorgarticles103389fimmu2021701501full': 1}, {'seems': 1, 'like': 1, 'one': 1, 'possibility': 1, 'would': 1, 'variant': 1, 'specific': 1, 'boosting': 1, 'needs': 1, '2': 1, 'doses': 1, 'anyone': 1, 'else': 1, 'come': 1, 'away': 1, 'open': 1, 'question': 1, '?': 1}, {'thatäôs': 1, 'saw': 1, 'reported': 1, 'fda': 1, 'encouraged': 1, 'pfizer': 1, 'submit': 1, 'data': 1, 'approval': 1, 'could': 1, 'review': 1, 'looks': 1, 'like': 1, 'needed': 1}, {'sorry': 1, 'couldnäôt': 1, 'find': 1, 'title': 1, 'article': 1, '?': 1}, {'graph': 1, 'drop': 1, 'zero': 1, '8': 1, 'months': 1, '?': 1, 'seems': 1, 'odd': 1}, {'idea': 1, 'mild': 1, 'forms': 1, 'viruses': 1, 'selected': 1, 'time': 1, 'isnäôt': 1, 'really': 1, 'fact': 1, 'much': 1, 'true': 1, 'offers': 1, 'little': 1, 'predictive': 1, 'power': 1, 'itäôs': 1, 'long': 1, 'timescales': 1, 'commonly': 1, 'stated': 1, 'often': 1, 'evolutionary': 1, 'tradeoff': 1, 'virulence': 1, 'transmissibility': 1, 'intrahost': 1, 'virus': 1, 'replication': 1, 'necessary': 1, 'facilitate': 1, 'interhost': 1, 'transmission': 1, 'may': 1, 'also': 1, 'lead': 1, 'disease': 1, 'impossible': 1, 'natural': 1, 'selection': 1, 'optimize': 1, 'traits': 1, 'simultaneously': 1, 'case': 1, 'myxv': 1, 'thought': 1, 'äòintermediateäô': 1, 'grades': 1, 'selectively': 1, 'advantageous': 1, 'higher': 1, 'mean': 1, 'rabbit': 1, 'host': 1, 'dies': 1, 'whereas': 1, 'lower': 1, 'increase': 1, 'rates': 1, 'similar': 1, 'model': 1, 'proposed': 1, 'explain': 1, 'evolution': 1, 'hiv': 1, 'virulence40': 1, 'however': 1, 'many': 1, 'doubts': 1, 'raised': 1, 'general': 1, 'applicability': 1, 'model35414243': 1, 'fitness': 1, 'affected': 1, 'transmissibility394144': 1, 'contrary': 1, 'results': 1, 'observed': 1, 'experimental': 1, 'studies45': 1, 'relatively': 1, 'known': 1, 'tradeoffs': 1, 'nature': 1, 'example': 1, 'second': 1, 'released': 1, 'biocontrol': 1, 'european': 1, 'rabbits': 1, 'australia': 1, 'äî': 1, 'haemorrhagic': 1, 'rhdv': 1, 'evidence': 1, 'increased': 1, 'probably': 1, 'occurs': 1, 'blow': 1, 'flies': 1, 'feed': 1, 'animal': 1, 'carcasses': 1, 'making': 1, 'death': 1, 'favourable46': 1, 'similarly': 1, 'studies': 1, 'plant': 1, 'rna': 1, 'shown': 1, 'high': 1, 'necessarily': 1, 'impede': 1, 'adaptation47': 1, 'malaria': 1, 'provide': 1, 'plasmodium': 1, 'parasites': 1, 'competitive': 1, 'advantage': 1, 'within': 1, 'hosts48': 1, 'https': 1, 'wwwnaturecomarticless4157601800555': 1, 'plenty': 1, 'since': 1, 'beginning': 1, 'pandemic': 1, 'people': 1, 'predicting': 1, 'sarscov2': 1, 'would': 1, 'mutate': 1, 'become': 1, 'milder': 1, 'mentioned': 1, 'sars': 1, 'mers': 1, 'epidemiologist': 1, 'know': 1, 'neither': 1, 'passed': 1, 'asymptomatically': 1, 'r0': 1, 'presented': 1, 'fever': 1, 'point': 1, 'covid': 1, 'started': 1, 'could': 1, 'spread': 1, 'strain': 1, 'ix': 1, 'requires': 1, 'transmit': 1, 'better': 1, 'without': 1, 'symptoms': 1, 'space': 1, 'landscape': 1, 'smaller': 1, 'became': 1, 'virulent': 1, 'essentially': 1, 'disappearing': 1, 'distinct': 1, 'antagonistic': 1, 'organism': 1, 'certain': 1, 'bird': 1, 'populations': 1, 'look': 1, 'things': 1, 'like': 1, 'ccr5': 1, 'see': 1, 'species': 1, 'reacted': 1, 'existential': 1, 'threats': 1, 'dude': 1, 'adaptation': 1, 'either': 1, 'plague': 1, 'consensus': 1, 'smallpox': 1, 'read': 1, 'paper': 1, 'argued': 1, 'likely': 1, 'provided': 1, 'selective': 1, 'pressure': 1, 'way': 1, 'demonstrates': 1, 'changed': 1, 'pathogen': 1, 'takes': 1, 'literally': 1, 'generations': 1, 'trait': 1, 'get': 1, 'fixed': 1}, {'conclusions': 1, 'crosssectional': 1, 'analysis': 1, 'baseline': 1, 'data': 1, 'collected': 1, 'patients': 1, 'enrolled': 1, 'phase': 1, '3': 1, 'randomized': 1, 'trial': 1, 'early': 1, 'outpatient': 1, 'treatment': 1, 'sarscov2': 1, 'infection': 1, 'vaccinated': 1, 'individuals': 1, 'lower': 1, 'viral': 1, 'load': 1, 'prevalence': 1, 'systemic': 1, 'symptoms': 1, 'effect': 1, 'longer': 1, 'present': 1, 'persons': 1, '6': 1, 'months': 1, 'prior': 1, 'primary': 1, 'goal': 1, 'äúfully': 1, 'vaccinatedäù': 1, 'prevent': 1, 'serious': 1, 'disease': 1, 'may': 1, 'still': 1, 'occur': 1, 'future': 1, 'research': 1, 'look': 1, 'beyond': 1, 'understand': 1, 'whether': 1, 'term': 1, 'transmission': 1, 'define': 1, 'within': 1, 'previous': 1, 'vaccine': 1, 'boosterinduced': 1, 'reduction': 1, 'important': 1, 'component': 1, 'achieving': 1, 'reduced': 1, 'coronavirus': 1, 'spread': 1}, {'thing': 1, 'found': 1, 'betaspecific': 1, 'booster': 1, 'recall': 1, 'seems': 1, 'fairly': 1, 'clear': 1, 'imprinting': 1, 'problem': 1, 'guess': 1, 'nobody': 1, 'wants': 1, 'admit': 1, 'way': 1, 'know': 1, 'sure': 1, 'would': 1, 'find': 1, 'sample': 1, 'group': 1, 'unvaccinated': 1, 'previously': 1, 'infected': 1, 'willing': 1, 'participate': 1, 'vaccine': 1, 'trial': 1, 'probably': 1, 'pretty': 1, 'small': 1}, {'youäôre': 1, 'linking': 1, 'study': 1, 'mostly': 1, 'delta': 1, 'cases': 1, 'months': 1, 'ago': 1, 'omicron': 1, 'thereäôs': 1, 'qualitative': 1, 'difference': 1, 'viral': 1, 'load': 1, 'weäôd': 1, 'see': 1, 'result': 1, 'household': 1, 'secondary': 1, 'attack': 1, 'rates': 1, 'whatever': 1, 'factor': 1, 'may': 1, 'real': 1, 'world': 1, 'evidence': 1, 'itäôs': 1, '10': 1, 'fold': 1}, {'would': 1, 'question': 1, 'underlying': 1, 'data': 1, 'uk': 1, 'example': 1, 'myocarditis': 1, 'adverse': 1, 'events': 1, 'reported': 1, 'voluntary': 1, 'basis': 1, 'go': 1, 'unreported': 1, 'case': 1, 'c19': 1, 'patients': 1, 'likely': 1, 'hospital': 1, 'setting': 1, 'monitored': 1, 'whole': 1, 'report': 1, 'could': 1, 'simply': 1, 'interpreted': 1, 'diagnosed': 1, 'others': 1}, {'s': 1, 'curious': 1, 'post': 1, 'downvoted': 1, 'noone': 1, 'said': 1, 'disagreed': 1, 'really': 1, 'nothing': 1, 'controversial': 1, 'idea': 1, 'secondary': 1, 'adaptive': 1, 'immune': 1, 'response': 1, 'stronger': 1, 'persistent': 1, 'primary': 1, 'basic': 1, 'immunology': 1, 'covid': 1, 'infection': 1, 'vaccine': 1, 'dose': 1, 'gives': 1, 'similar': 1, 'infections': 1, 'two': 1, 'doses': 1, 'demonstrated': 1, 'number': 1, 'studies': 1, 'basis': 1, 'guidance': 1, 'countries': 1, 'single': 1, 'required': 1, 'previously': 1, 'infected': 1, 'reviewed': 1, 'https': 1, 'wwwnaturecomarticlesd41586021016094': 1, 'nb': 1, 'prior': 1, '3rd': 1, 'recommendations': 1, 'vaccinated': 1, 'perhaps': 1, 'one': 1, 'downvoters': 1, 'would': 1, 'care': 1, 'give': 1, 'thoughts': 1, '?': 1}, {'mean': 1, 'link': 1, 'covid': 1, 'vaccines': 1, 'could': 1, 'inferred': 1, '?': 1, 'associations': 1, 'noncovid': 1, 'ones': 1, 'certainly': 1, 'exist': 1, 'eg': 1, 'influenza': 1}, {'thought': 1, 'beginning': 1, 'lowest': 1, 'acceptable': 1, 'efficacy': 1, 'going': 1, '50': 1, '%': 1, '?': 1, 'misremembering': 1}, {'early': 1, 'pfizer': 1, 'data': 1, 'israel': 1, 'states': 1, 'boosteräôs': 1, 'peak': 1, 'efficiency': 1, 'neighborhood': 1, '10': 1, 'weeks': 1, 'got': 1, 'moderna': 1, 'booster': 1, 'august': 1, 'full': 1, 'size': 1, 'half': 1, 'theyäôre': 1, 'giving': 1, 'tested': 1, 'positive': 1, 'first': 1, 'week': 1, 'january': 1, 'anecdotal': 1, 'case': 1, 'mild': 1, 'primarily': 1, 'sore': 1, 'throat': 1, 'congestion': 1, 'fatigue': 1, 'low': 1, 'grade': 1, 'feverchills': 1}, {'iäôm': 1, 'sure': 1, 'understand': 1, 'point': 1, 'using': 1, '99': 1, '%': 1, 'protection': 1, 'reinfection': 1, 'previous': 1, 'strains': 1, 'instead': 1, '85': 1, 'makes': 1, 'omicron': 1, 'look': 1, 'way': 1, 'worse': 1}, {'s': 1, 'definitely': 1, 'possibility': 1, 'inability': 1, 'get': 1, 'consistent': 1, 'results': 1, 'across': 1, 'regions': 1, 'make': 1, 'impossible': 1, 'measure': 1, 'may': 1, 'first': 1, 'time': 1, 'seen': 1, 'boosters': 1, '2dose': 1, 'data': 1, 'place': 1, 'ontario': 1, 'long': 1, 'dosing': 1, 'interval': 1, '100': 1, '%': 1, 'measured': 1, 'omicron': 1, 'one': 1, 'point': 1}, {'thereäôs': 1, 'early': 1, 'data': 1, 'study': 1, 'avv': 1, 'gene': 1, 'therapy': 1, 'showed': 1, 'elevated': 1, 'troponin': 1, 'levels': 1, 'mild': 1, 'transient': 1, 'myocarditis': 1, 'postip': 1, 'dose': 1, 'younger': 1, 'adult': 1, 'male': 1, 'subject': 1, 'physically': 1, 'active': 1, 'need': 1, 'dig': 1, 'deeper': 1, 'relationship': 1, 'immune': 1, 'activationstress': 1, 'testosterone': 1, 'physical': 1, 'activity': 1, 'level': 1, 'age': 1, 'troponinmyocarditis': 1, 'whether': 1, 'sequelae': 1, 'occur': 1}, {'edit': 1, 'edited': 1, 'response': 1, 'reading': 1, 'study': 1, 'well': 1, 'authors': 1, 'previous': 1, 'one': 1, 'pair': 1, 'studies': 1, 'used': 1, '16': 1, 'peptides': 1, '23mer': 1, '10': 1, 'tcell': 1, 'epitope': 1, 'optimized': 1, 'contain': 1, 'known': 1, 'bcell': 1, 'epitopes': 1, 'selected': 1, 'based': 1, 'computationally': 1, 'predicted': 1, 'filtered': 1, 'various': 1, 'criteria': 1, 'including': 1, 'hla': 1, 'binding': 1, 'immunogenicity': 1, 'location': 1, 'n': 1, 'protein': 1, 'opposed': 1, 'proteins': 1, 'like': 1, 'orf': 1, 's': 1, 'etc': 1, '6': 1, 'around': 1, 'three': 1, 'linear': 1, 'located': 1, 'functional': 1, 'conserved': 1, 'surface': 1, 'regions': 1, 'spike': 1, 'although': 1, 'broad': 1, 'coverage': 1, 'hlai': 1, 'alleles': 1, 'hlaii': 1, 'generally': 1, 'poor': 1, 'immunology': 1, 'review': 1, 'peptide': 1, 'ability': 1, 'bind': 1, 'range': 1, 'widelyexpressed': 1, 'major': 1, 'limiting': 1, 'factor': 1, 'viability': 1, 'good': 1, 'suggest': 1, 'vaccine': 1, 'designed': 1, 'stimulate': 1, 'cd4': 1, 'tcells': 1, 'would': 1, 'require': 1, 'use': 1, 'nonspatially': 1, 'overlapping': 1, 'sequences': 1, 'strong': 1, 'humoral': 1, 'detected': 1, 'elicited': 1, 'responses': 1, 'per': 1, 'second': 1, 'mice': 1, 'seem': 1, 'gain': 1, 'protection': 1, 'infection': 1, 'disease': 1, 'viral': 1, 'challenge': 1, 'way': 1, 'background': 1, 'general': 1, 'discovering': 1, 'elicit': 1, 'relatively': 1, 'developed': 1, 'note': 1, 'first': 1, 'attempts': 1, 'discover': 1, 'protective': 1, 'failed': 1, 'practice': 1, 'nt': 1, 'much': 1, 'practical': 1, 'application': 1, 'using': 1, 'either': 1, 'since': 1, 'probably': 1, 'need': 1, 'scaffolded': 1, 'something': 1, 'anyways': 1, 'naturally': 1, 'occurring': 1, 'current': 1, 'development': 1, 'efforts': 1, 'vaccines': 1, 'focused': 1, 'cancer': 1, 'surprise': 1, 'primary': 1, 'focus': 1}, {'log': 1, 'scales': 1, 'used': 1, 'figure': 1, 'comirnaty': 1, 'general': 1, 'performs': 1, 'around': 1, '10': 1, 'fold': 1, 'better': 1, 'terms': 1, 'binding': 1, 'neutralizing': 1, 'activity': 1, 'nearly': 1, 'tests': 1, 'agree': 1, 'looks': 1, 'worse': 1, 're': 1, 'overestimating': 1, 'difference': 1, 'antibody': 1, 'titers': 1, 'selected': 1, '3': 1, 'µg': 1, 'dose': 1, 'trials': 1, 's': 1, 'one': 1, 'looking': 1, 'comparison': 1, 'using': 1, 'wt': 1, 'shows': 1, 'little': 1, 'delta': 1, 'approximately': 1, '4fold': 1, '1021': 1, 'vs': 1, '1015': 1, 'beta': 1, 'similar': 1, 'ratio': 1, 'nonneutralizing': 1, 'antibodies': 1, 'rbdbased': 1, 'vaccine': 1, 'interest': 1, 'even': 1, 'nt': 1, 'say': 1, 'anything': 1, 'good': 1, 'particular': 1}, {'cutting': 1, 'risk': 1, 'hospitalization': 1, 'half': 1, 'still': 1, 'seems': 1, 'pretty': 1, 'good': 1, 'given': 1, 'rare': 1, 'serious': 1, 'side': 1, 'effects': 1}, {'studies': 1, 'comparing': 1, 'nvx': 1, 'omicron': 1, 'enough': 1, 'time': 1, 'set': 1, 'proper': 1, 'study': 1, 'compare': 1, '?': 1}, {'please': 1, 'correct': 1, 'reading': 1, 'wrong': 1, 'indicate': 1, 'vaccine': 1, 'preventing': 1, 'hospitalization': 1, 'kids': 1, '511': 1, 'decreased': 1, '100': 1, '%': 1, '48': 1, '?': 1}, {'seems': 1, 'authors': 1, 'arguing': 1}, {'spell': 1, 'saying': 1, 'immunity': 1, 'less': 1, 'specific': 1, 'word': 1, 'protection': 1, '?': 1, 'm': 1, 'sure': 1, 's': 1, 'always': 1, 'case': 1}, {'anyone': 1, 'know': 1, 'would': 1, 'two': 1, 'doses': 1, 'vaccine': 1, 'breakthrough': 1, 'infection': 1, 'long': 1, 'ago': 1, '12': 1, 'months': 1, 'offer': 1, 'significant': 1, 'protection': 1, '?': 1, 'especially': 1, 'considering': 1, 'itäôs': 1, 'since': 1, 'covid': 1}, {'great': 1, 'comment': 1, 'trade': 1, 'giving': 1, 'enough': 1, 'time': 1, 'enable': 1, 'least': 1, 'part': 1, 'dormancy': 1, 'maintaining': 1, 'neutralizing': 1, 'antibody': 1, 'levels': 1, 'circulation': 1, 'differentiation': 1, 'b': 1, 'cells': 1, 'recognize': 1, 'unseen': 1, 'mutations': 1, 'absolutely': 1, 'fascinating': 1, 'one': 1, 'could': 1, 'wonder': 1, 'got': 1, 'evolutionary': 1, 'conserved': 1}, {'s': 1, 'proposed': 1, 'mechanism': 1, 'action': 1, 'vaccination': 1, 'reducing': 1, 'symptoms': 1, 'existing': 1, 'long': 1, 'covid': 1, '?': 1}, {'person': 1, 'aimingwinesnailz': 1, 'said': 1, 'incorrect': 1, 'moderna': 1, 'developed': 1, 'tested': 1, 'voc': 1, 'specific': 1, 'boosters': 1, 'based': 1, 'delta': 1, '&': 1, 'beta': 1, 'neither': 1, 'elicited': 1, 'robust': 1, 'response': 1, 'another': 1, 'shot': 1, 'original': 1, 'vaccine': 1, 'wildtype': 1, 'also': 1, 'two': 1, 'omicron': 1, 'first': 1, 'discovered': 1, 'late': 1, 'last': 1, 'year': 1, 'worked': 1, 'well': 1, 'much': 1, 'mutated': 1, 'previous': 1, 'vocs': 1, 'decent': 1, 'chance': 1, 'updated': 1, 'vaccines': 1, 'pfizer': 1, 'developingtesting': 1, 'good': 1, 'option': 1, 'time': 1, 'potentially': 1, 'next': 1, 'mutation': 1, 'stems': 1, 'notwithstanding': 1, 'lack': 1, 'variant': 1, 'betadelta': 1, 'nothing': 1, 'w': 1, 'development': 1, 'nt': 1, 'prove': 1, 'significantly': 1, 'effective': 1, 'manufactureddistributed': 1, 'point': 1, 's': 1, 'info': 1, 'found': 1, '3rd': 1, 'quarter': 1, 'earning': 1, 'report': 1, 'pdf': 1}, {'read': 1, 'last': 1, 'paragraph': 1, 'page': 1, '5': 1, 'please': 1}, {'weirdly': 1, 'people': 1, '3': 1, 'vaccine': 1, 'doses': 1, 'infection': 1, 'full': 1, 'seriesbooster': 1, 'lower': 1, 'risk': 1, '2': 1, 'ie': 1, 'effect': 1, 'reversed': 1, 'guess': 1, 'would': 1, 'strange': 1, 'confounding': 1, 'factor': 1, 'https': 1, 'wwwmedrxivorgcontentmedrxivearly202202132022021022270744f4largejpg': 1}, {'personal': 1, 'level': 1, 'nt': 1, 'seem': 1, 'evidence': 1, 'unless': 1, 've': 1, 'missed': 1, 'something': 1, 'big': 1, 'case': 1, 'd': 1, 'appreciate': 1, 'links': 1, 'risk': 1, 'omicron': 1, 'variants': 1, 'spectacularly': 1, 'low': 1, 'indeed': 1, 'less': 1, 'flu': 1, 'normal': 1, 'winter': 1, 'last': 1, 'time': 1, 'checked': 1, 'figures': 1, 're': 1, 'possibly': 1, 'seen': 1, 'enough': 1, 'data': 1, 'recent': 1, 'second': 1, 'dose': 1, 'efficacy': 1, 'somewhat': 1, 'higher': 1, 'contracting': 1, 'passing': 1, 'around': 1, 'increased': 1, 'transmissibility': 1, 'still': 1, 'particularly': 1, 'concerned': 1, 'health': 1, 'outcomes': 1, 'perspective': 1, 'obviously': 1, 'wider': 1, 'societal': 1, 'issues': 1, 'secondary': 1, 'negative': 1, 'effects': 1, 'things': 1, 'like': 1, 'isolation': 1, 'narrow': 1, 's': 1, 'pretty': 1, 'much': 1, 'wash': 1}, {'perhaps': 1, 'unvaccinated': 1, 'cohort': 1, 'likely': 1, 'higher': 1, 'neutralizing': 1, 'antibody': 1, 'levels': 1, 'recent': 1, 'infection': 1, 'point': 1, 'time': 1, 'vaccinated': 1, 'since': 1, 'latter': 1, 'less': 1, 'infected': 1, 'months': 1, '?': 1, 'basically': 1, 'group': 1, 'slowly': 1, 'building': 1, 'immunity': 1, 'infections': 1, 'one': 1, 'dwindling': 1, 'hitting': 1, 'low': 1, 'certain': 1, 'level': 1, 'synchronicity': 1, 'live': 1, 'canada': 1, 'late': 1, 'december': 1, 'government': 1, 'showing': 1, 'data': 1, 'risks': 1, 'based': 1, 'positive': 1, 'pcr': 1, 'testing': 1, '07x': 1, '2': 1, 'doses': 1, 'omicron': 1, 'course': 1, 'could': 1, 'due': 1, 'get': 1, 'tested': 1, 'although': 1, 'used': 1, '35x': 1, 'early': 1, 'numbers': 1, 'previous': 1, '28': 1, 'days': 1, 'got': 1, 'wondering': 1, 'much': 1, 'delta': 1, 'prior': 1}, {'people': 1, 'notice': 1, 'vast': 1, 'bulk': 1, 'vaccinated': 1, 'mild': 1, 'side': 1, 'effects': 1, 'beaten': 1, 'thing': 1, 'vaccination': 1, 'accepted': 1, 'less': 1, 'think': 1, 'optimistic': 1, 'conspiratorial': 1, 'magical': 1, 'thinking': 1, 'moves': 1, 'goalposts': 1, 'time': 1, 'beyond': 1, 'reason': 1, 'could': 1, 'say': 1, 'äúwait': 1, 'years': 1, 'vaxxed': 1, 'see': 1, 'effectsäù': 1, 'likewise': 1, 'theyäôll': 1, 'interpret': 1, 'deaths': 1, 'unvaxxed': 1, 'deliberate': 1, 'even': 1, 'targeting': 1, 'hcp': 1}, {'says': 1, 're': 1, 'teens': 1, 'theory': 1, 'adult': 1, 'pfizer': 1, 'dose': 1, 'believe': 1, 'start': 1, 'lowering': 1, 'size': 1, '12s': 1}, {'exactly': 1, 'critical': 1, 'question': 1, 'unvaccinated': 1, 'previously': 1, 'infected': 1, 'settled': 1, 'definitely': 1, 'get': 1, 'vaccine': 1, 'crux': 1, 'additional': 1, 'benefit': 1, 'either': 1, 'boosting': 1, 'vaccination': 1, 'people': 1, 'offers': 1, 'regards': 1, 'severe': 1, 'diseasemyocarditis': 1, 'available': 1, 'evidence': 1, 'would': 1, 'say': 1, 'worth': 1, 'context': 1, 'potential': 1, 'side': 1, 'effects': 1, 'key': 1, 'demographic': 1, 'young': 1, 'teenager': 1, '30': 1, 'yo': 1, 'man': 1, 'depends': 1, 'study': 1, 'seem': 1, '110000': 1, 'risk': 1, 'myocarditis': 1, 'much': 1, 'higher': 1, 'women': 1, 'older': 1, 'younger': 1, 'men': 1}, {'thanks': 1, 'helpful': 1}, {'hmm': 1, 've': 1, 'loop': 1, 'studies': 1, 'mortality': 1, 'got': 1, 'ta': 1, 'admit': 1, 'figures': 1, '2': 1, 'dose': 1, '59': 1, '%': 1, 'less': 1, 'might': 1, 'expected': 1, 'albeit': 1, 's': 1, 'fing': 1, 'massive': 1, 'cis': 1, '482': 1, 'may': 1, 'play': 1, 'role': 1, 'still': 1, 'great': 1, '3': 1, 'working': 1, 'wonderfully': 1, 'though': 1}, {'correct': 1, 'iäôm': 1, 'wrong': 1, 'wonäôt': 1, 'basically': 1, 'everyone': 1, 'get': 1, 'covid': 1, 'young': 1, 'men': 1, 'children': 1, 'vaccine': 1, 'myocarditis': 1, 'chance': 1, 'plus': 1}, {'true': 1, 'omicron': 1, 'variant': 1, 'nt': 1, 'attack': 1, 'lungs': 1, 'like': 1, 'original': 1, 'covid19': 1, 'thus': 1, 'fewer': 1, 'hospitalizations': 1, '?': 1}, {'literally': 1, 'billion': 1, 'dollar': 1, 'question': 1, 'nobody': 1, 'seems': 1, 'know': 1, 'answer': 1}, {'opäôs': 1, 'fault': 1, 'title': 1, 'misleading': 1, 'theyäôre': 1, 'talking': 1, 'booster': 1, 'original': 1, 'vaccination': 1}, {'china': 1, 'russia': 1, 'happily': 1, 'violate': 1, 'patent': 1, 'problem': 1, 'fundamental': 1, 'reagents': 1, 'needed': 1, 'even': 1, 'make': 1, 'pills': 1, 'short': 1, 'supply': 1, 'actually': 1, 's': 1, 'products': 1, 'literally': 1, 'sodium': 1, 'shortfall': 1, 'insane': 1, 'https': 1, 'wwwscienceorgcontentblogpostmakingpaxlovid': 1, 'diboc': 1, 'pretty': 1, 'much': 1, 'commodity': 1, 'look': 1, 'closely': 1, 'chain': 1, 'find': 1, 'many': 1, 'original': 1, 'suppliers': 1, 'might': 1, 'thought': 1, 'fact': 1, 'problems': 1, 'scale': 1, 'right': 1, 'making': 1, 'needs': 1, 'among': 1, 'things': 1, 'another': 1, 'reagent': 1, 'called': 1, 'tbutoxide': 1, 'well': 1, 've': 1, 'used': 1, 'stuff': 1, 'every': 1, 'often': 1, 'since': 1, '1980s': 1, 'never': 1, 'gave': 1, 'moment': 1, 'comes': 1, 'need': 1, 'tbutanol': 1, 'metal': 1, 'turns': 1, 'bottleneck': 1, 'quite': 1, 'enough': 1, 'go': 1, 'around': 1, 'produced': 1, 'bruteforce': 1, 'energyintensive': 1, 'electrolysis': 1, 'process': 1, 'goes': 1, 'back': 1, '1924': 1, 'electricity': 1, 'interfered': 1, 'plants': 1}, {'itäôd': 1, 'interested': 1, 'see': 1, 'clinical': 1, 'outcomes': 1, 'matched': 1, 'cohorts': 1, 'vaccine': 1, 'types': 1, '1': 1, 'month': 1, 'vs': 1, '36': 1, 'months': 1, 'intervals': 1, 'first': 1, 'series': 1}, {'vaccine': 1, 'efficacy': 1, 'sarscov2': 1, 'infection': 1, '30': 1, '%': 1, '95': 1, 'confidence': 1, 'interval': 1, 'ci': 1, 'àí9': 1, '55': 1, 'bnt162b2': 1, '11': 1, 'àí43': 1, '44': 1, 'mrna1273': 1, 'figure': 1, '1c': 1, 'infected': 1, 'health': 1, 'care': 1, 'workers': 1, 'reported': 1, 'negligible': 1, 'symptoms': 1, 'control': 1, 'group': 1, 'intervention': 1, 'groups': 1, 'however': 1, 'participants': 1, 'potentially': 1, 'infectious': 1, 'relatively': 1, 'high': 1, 'viral': 1, 'loads': 1, 'nucleocapsid': 1, 'gene': 1, 'cycle': 1, 'threshold': 1, 'â25': 1, 'table': 1, 's6': 1, 'estimated': 1, 'higher': 1, 'prevention': 1, 'symptomatic': 1, 'disease': 1, '43': 1, '31': 1, 'fig': 1, 's4': 1, 'additional': 1, 'protection': 1, 'bad': 1, '4th': 1, 'dose': 1, 'diminishing': 1, 'returns': 1, 'expected': 1, 'feel': 1, 'like': 1, 'using': 1, 'terms': 1, 'marginal': 1, 'benefit': 1, 'bit': 1, 'uncharitable': 1}, {'thought': 1, 'marginally': 1, 'increased': 1, 'protection': 1, 'delta': 1, 'decreasing': 1, 'alpha': 1, 'wild': 1, 'type': 1, 'etcä': 1, 'deemed': 1, 'unnecessary': 1, 'perhaps': 1, 'detrimental': 1, 'net': 1}, {'thing': 1, 'greater': 1, 'risk': 1, 'taking': 1, 'argument': 1, 'getting': 1, 'vaccinated': 1, 'majority': 1, 'unvaccinated': 1, 'living': 1, 'way': 1, 'entire': 1, 'time': 1}, {'agree': 1, 'mean': 1, 'one': 1, 'main': 1, 'authors': 1, 'dr': 1, 'ferguson': 1, 'aka': 1, 'doom': 1, 'circles': 1, 'recently': 1, 'predicted': 1, 'like': 1, '5000': 1, 'deaths': 1, 'per': 1, 'day': 1, 'uk': 1, 'measures': 1, 'put': 1, 'place': 1, 'find': 1, 'number': 1, 'quite': 1, 'absurd': 1, 'honest': 1, 'even': 1, 'peak': 1, 'delta': 1, 'etc': 1, 'nt': 1, 'numbers': 1}, {'moderna': 1, 'tried': 1, 'back': 1, 'last': 1, 'fall': 1, 'believe': 1, 'half': 1, 'wildtype': 1, 'beta': 1, 'specific': 1, 'booster': 1, 'results': 1, 'perhaps': 1, 'first': 1, 'exposure': 1, 'someone': 1, 'd': 1, 'effective': 1, 'ca': 1, 'nt': 1, 'go': 1}, {'tcell': 1, 'response': 1, 'various': 1, 'vaccines': 1, 'different': 1, 'personal': 1, 'observation': 1, 'little': 1, 'scratching': 1, 'throat': 1, 'people': 1, '2': 1, '3': 1, 'doses': 1, 'sinovac': 1, 'comparing': 1, 'biontech': 1, '&': 1, 'x200b': 1, 'known': 1, 'generates': 1, 'less': 1, 'antibodies': 1, 'significantly': 1, 'better': 1, 'cell': 1, 'structural': 1, 'protein': 1}, {'interested': 1, 'seemingly': 1, 'better': 1, 'vaccine': 1, 'neutralization': 1, 'ba2': 1, 'ba1': 1, 'would': 1, 'possibly': 1, 'seeing': 1, 'currently': 1, 'replacing': 1, 'implications': 1}, {'guess': 1, 'theyäôd': 1, 'likely': 1, 'tested': 1, 'due': 1, 'vaccineortest': 1, 'mandates': 1, 'lot': 1, 'workplaces': 1, 'donäôt': 1, 'buy': 1, 'behavioural': 1, 'difference': 1, 'vaccination': 1, 'natural': 1, 'immunity': 1, 'reduce': 1, 'symptoms': 1, 'thus': 1, 'likeliness': 1, 'suspecting': 1, 'covid': 1, 'portion': 1, 'albeit': 1, 'possibly': 1, 'high': 1, 'unvaccinated': 1, 'effect': 1}, {'abstract': 1, 'several': 1, 'variants': 1, 'sarscov2': 1, 'emerged': 1, 'mutations': 1, 'angiotensinconverting': 1, 'enzyme': 1, 'ace2': 1, 'receptor': 1, 'binding': 1, 'domain': 1, 'rbd': 1, 'associated': 1, 'increased': 1, 'transmission': 1, 'severity': 1, 'study': 1, 'developed': 1, 'antibody': 1, 'quantification': 1, 'functional': 1, 'neutralization': 1, 'assays': 1, 'analyses': 1, 'covid19': 1, 'convalescent': 1, 'diagnostic': 1, 'cohorts': 1, 'strongly': 1, 'support': 1, 'use': 1, 'levels': 1, 'excellent': 1, 'surrogate': 1, 'biochemical': 1, 'activities': 1, 'data': 1, 'revealed': 1, 'samples': 1, 'mrna': 1, 'vaccinated': 1, 'individuals': 1, 'median': 1, '17': 1, 'times': 1, 'higher': 1, 'similar': 1, 'degree': 1, 'rbdace2': 1, 'natural': 1, 'infections': 1, 'showed': 1, 'n501y': 1, 'fivefold': 1, 'original': 1, 'variant': 1, 'antisera': 1, 'naturally': 1, 'infected': 1, 'subjects': 1, 'substantially': 1, 'reduced': 1, 'ability': 1, 'blood': 1, 'highly': 1, 'effective': 1, 'neutralizing': 1, 'thus': 1, 'our': 1, 'indicates': 1, 'vaccination': 1, 'may': 1, 'generate': 1, 'antibodies': 1, 'immunity': 1, 'suggests': 1, 'potential': 1, 'need': 1, 'maintain': 1, 'high': 1, 'control': 1, 'infectious': 1}, {'study': 1, 'measures': 1, 'igg': 1, 'titers': 1, 'nt': 1, 'think': 1, 've': 1, 'seen': 1, 'neutralizing': 1, 'iga': 1, 'omicron': 1, 'rapidly': 1, 'reproduces': 1, 'nose': 1, 'throat': 1, 'maybe': 1, 's': 1, 'case': 1, 'antibodies': 1, 'capable': 1, 'preventing': 1, 'breakthrough': 1, 'infection': 1, 'seeing': 1, 'vaccines': 1, 'responses': 1, 'pretty': 1, 'weak': 1, '?': 1}, {'read': 1, '?': 1, 'iäôve': 1, 'googling': 1, 'past': 1, '15': 1, 'minutes': 1, 'canäôt': 1, 'find': 1, 'mention': 1, 'eua': 1, 'withdrawn': 1, 'uultra003': 1, 'fauciäôs': 1, 'reasoning': 1, 'matter': 1, 'itäôs': 1, 'worth': 1, 'copy': 1, 'link': 1, 'iäôll': 1, 'capture': 1, 'relevant': 1, 'section': 1, '&': 1, 'x200b': 1, 'get': 1, 'approved': 1, 'united': 1, 'states': 1, 'fauci': 1, 'mistakenly': 1, 'said': 1, 'äúmorning': 1, 'americaäù': 1, 'covaxinäôs': 1, 'manufacturer': 1, 'bharat': 1, 'applied': 1, 'fda': 1, 'approval': 1, 'office': 1, 'followed': 1, 'later': 1, 'day': 1, 'statement': 1, 'äúbharat': 1, 'biotech': 1, 'company': 1, 'developed': 1, 'covaxin': 1, 'emergency': 1, 'use': 1, 'authorization': 1, 'vaccine': 1, 'currently': 1, 'evaluating': 1, 'data': 1, 'decision': 1, 'madeäù': 1, 'äúthe': 1, 'looks': 1, 'order': 1, 'give': 1, 'good': 1, 'scientific': 1, 'rationale': 1, 'approve': 1, 'äù': 1, 'also': 1, 'interview': 1, 'äúthere': 1, 'interventions': 1, 'reasons': 1, 'theyäôve': 1, 'either': 1, 'submitted': 1, 'strong': 1, 'enough': 1, 'warrant': 1, 'approvaläù': 1, 'asked': 1, 'application': 1, 'spokesperson': 1, 'ocugen': 1, 'stated': 1, 'phase': 1, '3': 1, 'clinical': 1, 'trial': 1, '934': 1, 'effective': 1, 'preventing': 1, 'severe': 1, 'covid': 1, 'cases': 1, '778': 1, 'percent': 1, 'overall': 1, 'disease': 1, 'noted': 1, 'children': 1, 'got': 1, 'similar': 1, 'results': 1, 'äúocugen': 1, 'pediatric': 1, 'based': 1, 'nov': 1, '5': 1, '2021': 1, 'parents': 1, 'healthcare': 1, 'providers': 1, 'us': 1, 'safe': 1, 'option': 1, 'effort': 1, 'end': 1, 'coronavirus': 1, 'pandemic': 1, 'newsnation': 1, 'think': 1, 'needed': 1, 'another': 1, 'instead': 1, 'people': 1, 'vaccinated': 1, 'vaccines': 1, 'äúitäôs': 1, 'alternative': 1, 'appearance': 1, 'äúwe': 1, 'donäôt': 1, 'need': 1}, {'moderna': 1, 'higher': 1, 'effective': 1, 'dose': 1, 'active': 1, 'ingredient': 1, '100ug': 1, 'vs': 1, '30ug': 1, 'pfizer': 1, 'booster': 1, 'doses': 1, '50ug': 1, 'respectively': 1}, {'nt': 1, 'poorly': 1, 'understood': 1, 'phenomenon': 1, 'called': 1, 'viral': 1, 'interference': 1, '?': 1, 'thought': 1, 'fairly': 1, 'uncommondifficult': 1, 'get': 1, 'competing': 1, 'infections': 1, 'time': 1, 'infection': 1, 'ramps': 1, 'bodies': 1, 'immune': 1, 'system': 1, 'broadgeneral': 1, 'fashion': 1, 'short': 1, 'period': 1, 'study': 1, 'explicitly': 1, 'states': 1, 'everyone': 1, 'booster': 1, 'arm': 1, 'less': 1, 'three': 1, 'months': 1, 'ago': 1, 'would': 1, 'deliberate': 1, 'coronavirus': 1, 'anything': 1, 'really': 1, 'matter': 1, 'also': 1, 'illicit': 1, 'neutralizing': 1, 'immunity': 1, 'least': 1, 'brief': 1, 'something': 1, 've': 1, 'curious': 1, 'since': 1, 'go': 1, 'especially': 1, 'quickly': 1, 'vaccines': 1, 'appeared': 1, 'wane': 1, 'group': 1, 'persons': 1, 'given': 1, 'vaccine': 1, 'another': 1, 'infected': 1, 'minor': 1, 'cold': 1, 'virus': 1, 'interval': 1, 'meaningfully': 1, 'different': 1, 'outcomes': 1, 'resisting': 1, 'covid19': 1, 'variants': 1, 'intervals': 1, 'plainly': 1, 'unethical': 1, 'likely': 1, 'lethal': 1, 'number': 1, 'succumb': 1, 'mild': 1, 'wondering': 1, 'mattered': 1, 'dosed': 1, 'people': 1, 'observed': 1, 'results': 1, 'sort': 1, 'd': 1, 'capture': 1, 'stuck': 1, 'induced': 1, 'general': 1, 'response': 1}, {'sweden': 1, 'part': 1, 'official': 1, 'guidelines': 1, 'unvaccinated': 1, 'extra': 1, 'careful': 1, 'avoid': 1, 'crowded': 1, 'places': 1, 'https': 1, 'wwwkrisinformationseenhazardsandrisksdisastersandincidents2020officialinformationonthenewcoronaviruscurrentrulesandrecommendations': 1}, {'understand': 1, 'opposition': 1, 'peddling': 1, 'arguments': 1, 'related': 1, 'duration': 1, 'exposure': 1, 'spike': 1, 'protein': 1, 'really': 1, 'seen': 1, 'argument': 1, 's': 1, 'government': 1, 'conspiracy': 1, 'thing': 1, 'anything': 1}, {'one': 1, 'admitted': 1, 'hospital': 1, 'vaccines': 1, 'work': 1}, {'negative': 1, '91150': 1, 'looks': 1, 'similar': 1, 's': 1, 'happening': 1, 'england': 1, 'infected': 1, 'per': 1, '100k': 1, 'among': 1, 'vaccinated': 1, 'unvaccinated': 1, 'age': 1, 'groups': 1, 'omicron': 1, 'related': 1, 'like': 1, 'long': 1}, {'nt': 1, 'understand': 1, 'thought': 1, 'spike': 1, 'protein': 1, 'significantly': 1, 'different': 1, '?': 1}, {'assigned': 1, 'control': 1, 'participants': 1, 'started': 1, 'sedentary': 1, 'period': 1, 'within': 1, '30': 1, 'min': 1, 'vaccination': 1, 'consisted': 1, 'sitting': 1, 'watching': 1, 'videos': 1, '90': 1, 'adults': 1, 'randomized': 1, 'exercise': 1, 'performed': 1, 'cycle': 1, 'ergometer': 1, '60äì70': 1, '%': 1, 'estimated': 1, 'maximal': 1, 'heart': 1, 'rate': 1, 'hr': 1, 'max': 1, 'looks': 1, 'like': 1, 'studying': 1, 'effects': 1, 'immediately': 1, 'immunization': 1, 'would': 1, 'interesting': 1, 'see': 1, 'outside': 1, 'time': 1, 'window': 1, 'think': 1, 'beyond': 1, 'scope': 1, 'paper': 1}, {'super': 1, 'interesting': 1, 'stuff': 1, 'though': 1, 'think': 1, 'mice': 1, 'nt': 1, 'exposed': 1, 'wt': 1, 'one': 1, 'thing': 1, 'sure': 1, 'expect': 1, 'delta': 1, 'well': 1, 'would': 1, 'loved': 1, 'tried': 1, 'instead': 1, 'making': 1, 'hybrid': 1, 'try': 1, 'new': 1, 'spike': 1, 'add': 1, 'bivalent': 1, 'alongside': 1, 'omicron': 1, 'edit': 1, 'still': 1, 'plasma': 1, 'experiments': 1, 'attempting': 1, 'identify': 1, 'serum': 1, 'escape': 1, 'mutations': 1, 'yet': 1, '?': 1}, {'abstract': 1, 'vaccines': 1, 'thought': 1, 'best': 1, 'available': 1, 'solution': 1, 'controlling': 1, 'ongoing': 1, 'sarscov2': 1, 'pandemic': 1, 'however': 1, 'emergence': 1, 'vaccineresistant': 1, 'strains': 1, 'may': 1, 'come': 1, 'rapidly': 1, 'current': 1, 'vaccine': 1, 'developments': 1, 'alleviate': 1, 'health': 1, 'economic': 1, 'social': 1, 'consequences': 1, 'quantify': 1, 'characterize': 1, 'risk': 1, 'scenario': 1, 'created': 1, 'sirderived': 1, 'model': 1, 'initial': 1, 'stochastic': 1, 'dynamics': 1, 'strain': 1, 'study': 1, 'probability': 1, 'establishment': 1, 'using': 1, 'parameters': 1, 'realistically': 1, 'resembling': 1, 'transmission': 1, 'wavelike': 1, 'pattern': 1, 'consider': 1, 'impact': 1, 'rate': 1, 'vaccination': 1, 'strength': 1, 'nonpharmaceutical': 1, 'intervention': 1, 'measures': 1, 'resistant': 1, 'expected': 1, 'found': 1, 'fast': 1, 'decreases': 1, 'counterintuitively': 1, 'when': 1, 'relaxation': 1, 'interventions': 1, 'happened': 1, 'time': 1, 'individuals': 1, 'population': 1, 'already': 1, 'vaccinated': 1, 'greatly': 1, 'increased': 1, 'consequently': 1, 'show': 1, 'period': 1, 'reduction': 1, 'close': 1, 'end': 1, 'campaign': 1, 'substantially': 1, 'reduce': 1, 'results': 1, 'suggest': 1, 'policymakers': 1, 'maintaining': 1, 'transmissionreducing': 1, 'behaviours': 1, 'throughout': 1, 'entire': 1, 'emphasis': 1, 'added': 1}, {'yes': 1, 's': 1, 'exactly': 1, 'comparison': 1, 'would': 1, 'like': 1, 'know': 1, 'risk': 1, 'get': 1, 'covid': 1, 'vaccination': 1, 'someone': 1, 'study': 1, '?': 1}, {'hereäôs': 1, 'one': 1, 'many': 1, 'https': 1, 'wwwnaturecomarticless4156902100662w': 1, 'myocarditis': 1, 'never': 1, 'huge': 1, 'issue': 1, 'ever': 1, 'itäôs': 1, 'really': 1, 'people': 1, 'understand': 1, 'statistics': 1, 'read': 1, 'headlines': 1}, {'edit': 1, 'reflection': 1, 'think': 1, 'better': 1, 'understanding': 1, 'poster': 1, 'trying': 1, 'convey': 1, 'm': 1, 'modifying': 1, 'response': 1, 'result': 1, 'ularge_pp_smol_brain': 1, 'although': 1, 'initially': 1, 'understand': 1, 'getting': 1, 'worked': 1, 'basically': 1, 'complaint': 1, 'seems': 1, 'journalism': 1, 'standards': 1, 'article': 1, 'reported': 1, 'paper': 1, 'necessarily': 1, 'preprint': 1, 'fairly': 1, 'insignificant': 1, 'speculative': 1, 'comment': 1, 'discussion': 1, 'section': 1, 'original': 1, 'placed': 1, 'first': 1, 'paragraph': 1, 'reporting': 1, 'thereby': 1, 'amplifying': 1, 'people': 1, 'read': 1, 'agree': 1, 'point': 1, 'journalist': 1, 'editor': 1, 'responsible': 1, 'chosen': 1, 'amplify': 1, 'matter': 1, 's': 1, 'main': 1, 'focus': 1, 'confused': 1, 'thought': 1, 'commenting': 1, 'really': 1, 'focuses': 1, 'omicron': 1, 'infection': 1, 'various': 1, 'populations': 1, 'apologize': 1, 'assuming': 1, 'nt': 1}, {'actually': 1, 'expect': 1, 'next': 1, 'variant': 1, 'descendant': 1, 'omicron': 1, '?': 1, 'delta': 1, 'alpha': 1, 'seems': 1, 'odd': 1, 'dominant': 1, 'keeps': 1, 'failing': 1, 'produce': 1, 'successful': 1, 'major': 1, 'mutation': 1, 'going': 1, 'priors': 1, 'good': 1, 'position': 1, 'bet': 1, 'favor': 1, 'based': 1, 'variants': 1}, {'including': 1, 'incidental': 1, 'findings': 1, 'covid': 1, 'unrelated': 1, 'visits': 1, '?': 1, 'omicron': 1, 'huge': 1, 'proportion': 1, 'patients': 1, 'coming': 1, 'reason': 1}, {'study': 1, 'clearly': 1, 'blinded': 1, 'placebo': 1, 'real': 1, 'claim': 1, 'vaccine': 1, 'improves': 1, 'gad7': 1, 'phq9': 1, 'see': 1, 'purpose': 1, 'paper': 1, 'counter': 1, 'concerns': 1, 'could': 1, 'worsen': 1, 'gad': 1, 'mdd': 1, 'symptomatology': 1, 'though': 1, 'believe': 1, 'major': 1, 'trials': 1, 'collected': 1, 'well': 1, 'addressed': 1, 'properly': 1, 'since': 1, 'adds': 1, 'picture': 1, 'article': 1, 'title': 1, 'dumb': 1}, {'would': 1, 'liked': 1, 'see': 1, 'use': 1, 'pms20': 1, 'rockefeller': 1, 'group': 1}, {'wow': 1, 'pretty': 1, 'compelling': 1, 'evidence': 1, 'vaccines': 1, 'held': 1, 'well': 1, 'meant': 1, 'preventing': 1, 'symptomatic': 1, 'covid': 1, 'even': 1, 'face': 1, 'delta': 1}, {'gbs': 1, 'occur': 1, 'vaccines': 1, 'meningitis': 1, 'vaccine': 1, 'well': 1, 'known': 1, 'though': 1, 'extremely': 1, 'rare': 1}, {'studies': 1, 'chronic': 1, 'infections': 1, 'vaccinated': 1, 'immunocompromised': 1, 'people': 1, '?': 1, 'case': 1, 'seen': 1, 'predate': 1, 'vaccines': 1}, {'mean': 1, 'unvaccinated': 1, '?': 1, 'vaccinated': 1, 'less': 1, 'likely': 1, 'would': 1, 'make': 1, 'results': 1, 'better': 1, 'longer': 1, 'keep': 1, 'watching': 1}, {'itäôs': 1, 'probably': 1, 'difficult': 1, 'many': 1, 'variables': 1, 'consider': 1, 'vaccines': 1, 'order': 1, 'matters': 1, 'hence': 1, 'studies': 1, 'posted': 1, 'usually': 1, 'stick': 1, 'vaccination': 1, 'schedules': 1, 'single': 1, 'variety': 1, 'even': 1, 'structure': 1, 'immune': 1, 'response': 1, 'changes': 1, 'ordering': 1, 'basic': 1, 'example': 1, 'mrna': 1, 'natural': 1, 'infection': 1, 'followed': 1, 'full': 1, 'looks': 1, 'different': 1, 'generated': 1, 'breakthrough': 1, 'case': 1, 'latter': 1, 'fascinating': 1, 'expands': 1, 'still': 1, 'mostly': 1, 'dependent': 1, 'antispike': 1, 'antibodies': 1, 'also': 1, 'breadth': 1, 'enlarged': 1, 'get': 1, 'stuff': 1, 'like': 1, 'tcells': 1, 'system': 1, 'seems': 1, 'treat': 1, 'almost': 1, 'another': 1, 'powerful': 1, 'vaccine': 1, 'basically': 1, 'answer': 1, 'question': 1, 'comparing': 1, 'covid': 1, 'naive': 1, 'vaccinees': 1, 'recovered': 1, 'nonvacinees': 1, 'far': 1, 'easier': 1, 'deal': 1, 'empirical': 1, 'scientific': 1, 'study': 1, 'pov': 1}, {'see': 1, 'graph': 1, 'page': 1, '12': 1, 'pdf': 1, 'compares': 1, 'test': 1, 'positivity': 1, 'rate': 1, 'omicron': 1, '&': 1, 'delta': 1, 'vaccination': 1, 'status': 1, 'per': 1, 'among': 1, 'unvaccinated': 1, 'people': 1, 'higher': 1, 'take': 1, 'look': 1, 'image': 1, 'disagree': 1, 'please': 1, 'reply': 1}, {'odds': 1, 'ratio': 1, 'thing': 1, 'tells': 1, 'much': 1, 'intervention': 1, 'better': 1, 'control': 1, 'outcomes': 1, '1': 1, 'null': 1, 'hypothesis': 1, '92': 1, '%': 1, 'time': 1, 'people': 1, 'group': 1, 'nt': 1, 'go': 1, 'icu': 1, 'compared': 1, 'p': 1, 'factor': 1, 'way': 1, 'show': 1, 'something': 1, 'statistically': 1, 'significant': 1, 'value': 1, 'likely': 1, 'result': 1, 'true': 1, 'difference': 1, 'small': 1, 'probably': 1, 'correct': 1, 'one': 1, 'correlation': 1, 'data': 1, 'smaller': 1, 'mean': 1, 'anything': 1, 's': 1, 'less': 1, 'happen': 1, 'fairly': 1, 'simplified': 1, 'though': 1}, {'previous': 1, 'studies': 1, 'note': 1, 'develop': 1, 'treatment': 1, 'wait': 1, 'hour': 1, 'goes': 1, 'away': 1, 'sure': 1, 'would': 1, 'like': 1, 'see': 1}, {'sounds': 1, 'promising': 1, 'm': 1, 'curious': 1, 'decrease': 1, 'hospitalization': 1, 'severity': 1, 'stands': 1, 'accounting': 1, 'age': 1, 'individuals': 1, 'study': 1, 'omicron': 1, 'patients': 1, 'significantly': 1, 'younger': 1}, {'https': 1, 'wwwmedrxivorgcontent1011012021102521265304v1fullpdfhtml': 1, 'wwwmedrxivorgcontent1011012021101721265101v2fullpdfhtml': 1, 'wwwmedrxivorgcontent1011012021122821268436v1fullpdfhtml': 1, 'last': 1, 'omicron': 1, 'around': 1, '65': 1, '%': 1, 'protection': 1, 'hospitalization': 1, 'boosting': 1, 'brings': 1, '85': 1}, {'mean': 1, 'immediately': 1, 'vaccine': 1, 'chance': 1, 'work': 1, '?': 1, 'risk': 1, 'would': 1, 'similar': 1, 'without': 1, 'taking': 1, 'protected': 1, 'reduced': 1, 'antibodies': 1, 'start': 1, 'neutralizing': 1, 'virus': 1, 'make': 1, 'hard': 1, 'replicate': 1, 'likely': 1, 'closer': 1, 'none': 1, 'anyway': 1, 'myocarditis': 1, 'rare': 1, 'well': 1, 'covid': 1, 'edit': 1, 'idea': 1, 'statements': 1, 'polarizing': 1, 'looks': 1, 'like': 1, 'post': 1, 'brigaded': 1}, {'would': 1, 'reduced': 1, 'severity': 1, 'anything': 1, 'transmissibility': 1, '?': 1}, {'remember': 1, 'sarscov2': 1, 'migrates': 1, 'body': 1, 'affected': 1, 'organs': 1, 'one': 1, 'time': 1, 'another': 1, 'among': 1, 'various': 1, 'cases': 1, 'covid': 1, 's': 1, 'inefficient': 1, 'vaccinate': 1, 'half': 1, 'inject': 1, '1000': 1, 'hamsters': 1, 'via': 1, 'normal': 1, 'route': 1, 'screen': 1, 'ones': 1, 'got': 1, 'migration': 1, 'testes': 1, 'could': 1, 'assess': 1, 'effect': 1, 'placebo': 1, 'vs': 1, 'vaccination': 1, 'potentially': 1, 'individuals': 1, 'assessment': 1, 'provide': 1, 'enough': 1, 'data': 1, 'points': 1, 'defensible': 1, 'conclusion': 1, 'example': 1, 'hear': 1, 'positive': 1, 'finding': 1, 'cancer': 1, 'test': 1, 'animals': 1, 'exposed': 1, 'chemical': 1, 'needing': 1, 'often': 1, 'injected': 1, 'directly': 1, 'researcher': 1, 'knows': 1, 'look': 1, 'damage': 1, 'kidneys': 1, 'popular': 1, 'purpose': 1, 'ingestion': 1, 'eating': 1, 'similarly': 1, 'always': 1, 'useful': 1, 'research': 1, 'particularly': 1, 'true': 1, 'causative': 1, 'agent': 1, 'expresses': 1, 'infrequently': 1}, {'see': 1, 'figures': 1, 'brackets': 1, '?': 1, 's': 1, '95': 1, '%': 1, 'confidence': 1, 'interval': 1, 'authors': 1, 'conclude': 1, 'yet': 1, 'nt': 1, 'genuine': 1, 'increase': 1, 'risk': 1, 'pfizer': 1, 'az': 1, 'moderna': 1, 'result': 1, 'though': 1, 'clear': 1, 'stats': 1, 'really': 1, 'important': 1, 'part': 1, 'analysing': 1, 'sort': 1, 'data': 1}, {'note': 1, 'convalescents': 1, 'study': 1, 'covid': 1, 'infection': 1, 'well': 1, 'least': 1, 'two': 1, 'doses': 1, 'vaccine': 1, 'either': 1, '2': 1, 'followed': 1, 'booster': 1, '6': 1, 'months': 1, 'later': 1, 'single': 1, 'dose': 1, 'everyone': 1, 'headline': 1, 'covers': 1, '3': 1, 'exposures': 1, 'fact': 1, 'vaccination': 1, 'produces': 1, 'higher': 1, 'titers': 1, 'really': 1, 'surprising': 1, 'even': 1, 'developed': 1, 'vaccinations': 1, 'third': 1, 'breakthrough': 1, 'twicevaccinated': 1, 'naive': 1, 'individuals': 1, '68': 1, 'gave': 1, 'written': 1, 'informed': 1, 'consent': 1, 'analyses': 1, 'covid19': 1, '2568': 1, 'convalescent': 1, 'continuously': 1, 'followedup': 1, 'received': 1, 'bnt162b2': 1, 'mrnavaccine': 1, 'comirnatyñ': 1, 'biontechpfizer': 1, 'immunization': 1, 'due': 1, 'change': 1, 'national': 1, 'guidelines': 1, 'march': 1, '2021': 1, 'remaining': 1, '4368': 1, 'first': 1, 'wave': 1, 'vaccinated': 1, 'mid': 1, 'assuming': 1, 'prior': 1, 'substitutes': 1, 'one': 1}, {'yes': 1, 'twiv': 1, 'analysis': 1, 'exactly': 1}, {'m': 1, 'immunologist': 1, 'ca': 1, 'nt': 1, 'say': 1, 'people': 1, 'research': 1, 'much': 1, 'want': 1, 'go': 1, 'school': 1, 'learn': 1, 'virology': 1, 'immunology': 1, 'whateverology': 1, 's': 1, 'like': 1, 'would': 1, 'walk': 1, 'lawyer': 1, 'office': 1, 'start': 1, 'telling': 1, 'strats': 1, 'win': 1, 'cases': 1, '?': 1, 'surgery': 1, 'room': 1, 'critiquing': 1, 'surgical': 1, 'technique': 1, 'saying': 1, 'blindly': 1, 'listen': 1, 'fauci': 1, 'whoever': 1, 'need': 1, 'stop': 1, 'acting': 1, 'know': 1, 'exactly': 1, 're': 1, 'talking': 1, 'means': 1, 'questions': 1, 'internet': 1, 'strangers': 1, 'answering': 1}, {'keywords': 1, 'posts': 1, 'get': 1, 'frequently': 1, 'brigaded': 1, 'masks': 1, 'myocarditis': 1, 'two': 1}, {'imagine': 1, 'due': 1, 'least': 1, 'part': 1, 'current': 1, '2022': 1, 'strains': 1, 'diverged': 1, '2019': 1, 'strain': 1, 'used': 1, 'make': 1, 'vaccines': 1, 's': 1, 'probably': 1, 'reproduce': 1, 'fast': 1, 'upper': 1, 'respiratory': 1, 'tract': 1, 'result': 1, 'symptoms': 1, 'immune': 1, 'system': 1, 'chance': 1, 'kick': 1, 'higher': 1, 'gear': 1, 'incubation': 1, 'period': 1, 'shorter': 1, 'time': 1, 'needed': 1, 'reactivate': 1, 'memory': 1, 'b': 1, 'cells': 1, 're': 1, 'relying': 1, 'circulating': 1, 'antibody': 1, 'levels': 1, 'reduce': 1, 'peak': 1, 'viral': 1, 'loads': 1, 'load': 1, 'typically': 1, 'occurs': 1, 'day': 1, 'appearing': 1, 'could': 1, '2': 1, 'days': 1, 'postexposure': 1}, {'gave': 1, 'total': 1, 'number': 1, 'suspected': 1, 'myocarditis': 1, 'cases': 1, 'subgroup': 1, 'nt': 1, 'see': 1, 'ie': 1, 'immunized': 1, 'persons': 1, 'per': 1, 'age': 1, 'range': 1, 'sex': 1, 'sure': 1, 'one': 1, 'extrapolate': 1, 'data': 1, 'elsewhere': 1, 'including': 1, 'analysis': 1, 'would': 1, 'help': 1, 'comfortable': 1, 'interpretation': 1, 'll': 1, 'much': 1, 'changed': 1, 'get': 1, 'past': 1, 'peer': 1, 'review': 1, 'anyone': 1, 'else': 1, 'noted': 1, 'authors': 1, 'estimating': 1, 'rate': 1, 'around': 1, '21000000': 1, 'vaccinated': 1, 'group': 1, 'small': 1, 'oppose': 1, 'covid': 1, 's': 1, 'mortality': 1, '2100': 1, 'complication': 1, 'calculate': 1, 'state': 1, 'public': 1, 'us': 1, '21000': 1, '2040': 1, 'year': 1, 'old': 1}, {'actually': 1, 'abbott': 1, 'reported': 1, 'much': 1, 'higher': 1, 'independent': 1, 'tests': 1, 'came': 1, '65': 1, '%': 1, 'taking': 1, 'two': 1, 'antigen': 1, 'contact': 1, 'surely': 1, 'better': 1, 'pcr': 1, 'done': 1, 'days': 1, 'beforehand': 1, 'unless': 1, 's': 1, 'rapid': 1, 'practical': 1}, {'includes': 1, 'pcr': 1, 'testing': 1, 'large': 1, 'amount': 1, 'omicron': 1, 'done': 1, 'va': 1, 'rapidantigen': 1, 'tests': 1}, {'vaccines': 1, 'help': 1, 'prevent': 1, 'humans': 1, 'potentially': 1, '?': 1}, {'ha': 1, 'yeah': 1, 'suck': 1, 'math': 1, 'iäôm': 1, 'going': 1, 'ask': 1, 'sub': 1, 'whatever': 1, 'itäôs': 1, '0': 1, 'basically': 1, 'saying': 1, '67': 1, '%': 1, 'higher': 1, 'x': 1, 'canäôt': 1, 'wrap': 1, 'mind': 1, 'around': 1, 'calculation': 1, 'iäôll': 1, 'report': 1, 'back': 1}, {'booster': 1, 'provide': 1, 'greater': 1, 'protection': 1, 'severe': 1, 'illness': 1, '?': 1, 'infection': 1, 'seems': 1, 'short': 1, 'lived': 1}, {'recall': 1, 'seeing': 1, 'speculation': 1, '2': 1, 'doses': 1, 'vaccine': 1, 'iirc': 1, 'pfizer': 1, 'testing': 1}, {'important': 1, 'definition': 1, 'constitutes': 1, 'interaction': 1, 'health': 1, 'system': 1, 'c19': 1, 'positive': 1, 'data': 1, 's': 1, 'hospitals': 1, 'ca': 1, 'nt': 1, 'generalize': 1, 'population': 1, 'level': 1}, {'studies': 1, 'show': 1, 'reduced': 1, 'transmission': 1, 'vaccinated': 1, 'individual': 1, 'infected': 1, 'delta': 1, 'variant': 1, 's': 1, 'example': 1, 'published': 1, 'less': 1, '2': 1, 'weeks': 1, 'ago': 1, 'https': 1, 'wwwnejmorgdoifull101056nejmoa2116597': 1, 'risk': 1, 'half': 1, 'index': 1, 'case': 1, 'bnt162b2': 1, 'aka': 1, 'comirnaty': 1, 'pfizer': 1, 'vaccine': 1, 'lower': 1, 'reduction': 1, 'alpha': 1, 'still': 1, 'significant': 1, 'course': 1, 'caveat': 1, 'like': 1, 'aspects': 1, 'effectiveness': 1, 'decreased': 1, 'time': 1}, {'canäôt': 1, 'find': 1, 'hard': 1, 'data': 1, 'hypothetically': 1, 'explains': 1, '95': 1, '%': 1, 'myocarditis': 1, 'cases': 1, 'sounds': 1, 'like': 1, 'easy': 1, 'solution': 1, 'mean': 1, 'thatäôs': 1, 'totally': 1, 'speculative': 1, 'hypothetical': 1, 'numbers': 1, 'singapore': 1, 'suggest': 1, 'experiencing': 1, '?': 1}, {'directly': 1, 'clickbaity': 1, 'title': 1, 'suggests': 1, 'also': 1, 'kind': 1, 'äúwe': 1, 'studied': 1, 'common': 1, 'sense': 1, 'reached': 1, 'obvious': 1, 'outcome': 1, 'äù': 1, 'sure': 1, 'actual': 1, 'relevance': 1, 'virus': 1}, {'undated': 1, 'omicron': 1, 'specific': 1, 'vaccine': 1, 'turned': 1, 'offer': 1, 'near': 1, 'zero': 1, 'protection': 1, 'delta': 1, 'according': 1, 'early': 1, 'studies': 1, 'ca': 1, 'nt': 1, 'really': 1, 'make': 1, 'bet': 1, 'right': 1, 'next': 1, 'major': 1, 'surge': 1, 'variant': 1, 'based': 1, 'fine': 1, 'turns': 1, 'unrelated': 1, 'vaccines': 1, 'may': 1, 'well': 1, 'fare': 1, 'worse': 1, 'original': 1, 'formula': 1, 'given': 1, 'descendant': 1, 'alpha': 1, 'would': 1, 'say': 1, 'odds': 1, 'great': 1, 'dominant': 1}, {'unknowns': 1, 'think': 1, 's': 1, 'quite': 1, 'clear': 1, 'mandates': 1, 'wrong': 1}, {'äúan': 1, 'epidemic': 1, 'uncertainty': 1, 'rumors': 1, 'conspiracy': 1, 'theories': 1, 'vaccine': 1, 'hesitancyäù': 1, 'https': 1, 'wwwnaturecomarticless4159102201728z': 1, 'abstract': 1, 'covid19': 1, 'äòinfodemicäô': 1, 'continues': 1, 'undermine': 1, 'trust': 1, 'vaccination': 1, 'efforts': 1, 'aiming': 1, 'bring': 1, 'end': 1, 'pandemic': 1, 'however': 1, 'challenge': 1, 'hesitancy': 1, 'problem': 1, 'information': 1, 'ecosystem': 1, 'often': 1, 'little': 1, 'vaccines': 1, 'perspective': 1, 'argue': 1, 'epidemiological': 1, 'social': 1, 'crises': 1, 'brought': 1, 'magnified': 1, 'widely': 1, 'held': 1, 'anxieties': 1, 'issues': 1, 'unique': 1, 'circumstances': 1, 'global': 1, 'exacerbated': 1, 'skepticism': 1, 'toward': 1, 'key': 1, 'overcoming': 1, 'especially': 1, 'context': 1, 'widespread': 1, 'public': 1, 'sentiment': 1, 'volatile': 1, 'finally': 1, 'draw': 1, 'implications': 1, 'argument': 1, 'strategies': 1, 'build': 1, 'confidence': 1}, {'noted': 1, 'commenters': 1, 'myocarditis': 1, 'mild': 1, 'transient': 1, 'resolved': 1, 'without': 1, 'intervention': 1, 'occur': 1, 'infections': 1, 'vaccinations': 1, 'stress': 1, 'active': 1, 'younger': 1, 'men': 1, '?': 1, 'part': 1, 'typical': 1, 'immune': 1, 'response': 1, 'never': 1, 'looking': 1, 'prior': 1, 'current': 1, 'times': 1, 'could': 1, 'one': 1, 'causes': 1, 'fatigue': 1, 'many': 1, 'postinfection': 1, 'andor': 1, 'postvaccination': 1}, {'reading': 1, 'figure': 1, '2': 1, 'correctly': 1, '?': 1, 'seems': 1, 'say': 1, 'occurrence': 1, 'myocarditis': 1, 'higher': 1, 'prior': 1, 'vaccine': 1, 'green': 1, 'bar': 1, '2019': 1, 'rates': 1, 'larger': 1, 'blue': 1, 'post': 1, 'vaccination': 1, '1517': 1, 'age': 1, 'group': 1}, {'exactly': 1, 'thought': 1, 'well': 1, 'patients': 1, 'infected': 1, 'omikron': 1, 'still': 1, 'less': 1, 'likely': 1, 'become': 1, 'hospitalized': 1, 'compared': 1, 'delta': 1, 'age': 1, 'group': 1, '?': 1}, {'promising': 1, 'vaccine': 1, 'already': 1, 'use': 1, 'infrastructure': 1, 'place': 1, 'several': 1, 'countries': 1, 'influenza': 1, 'butanta': 1, 'institute': 1, 'brazil': 1, 'produce': 1, '20': 1, 'million': 1, 'vaccines': 1, 'monthly': 1, 'without': 1, 'production': 1, 'expansion': 1, 'actually': 1, 'stock': 1, '40': 1, 'recall': 1, 'another': 1, 'advantage': 1, 'price': 1, 'cost': 1, '1': 1, '2': 1, 'dollar': 1, 'normal': 1, 'storage': 1}, {'improving': 1, 'indoor': 1, 'air': 1, 'quality': 1, 'developing': 1, 'prophylactic': 1, 'treatments': 1, 'including': 1, 'nasal': 1, 'sprays': 1, 'enhancement': 1, 'iga': 1, 'immunity': 1, 'fir': 1, 'respiratory': 1, 'pathogens': 1, 'barriers': 1, 'prevent': 1, 'viral': 1, 'adhesion': 1, 'highest': 1, 'priority': 1, 'research': 1, 'currently': 1, 'account': 1, 'collectively': 1, 'cause': 1, 'high': 1, 'amount': 1, 'illness': 1, 'ranging': 1, 'mild': 1, 'fatal': 1, 'potentially': 1, 'preventable': 1, 'least': 1, 'able': 1, 'mitigate': 1, 'risk': 1, 'cost': 1, 'healthcare': 1, 'systems': 1, 'economies': 1, 'globally': 1, 'billions': 1, 'lost': 1, 'productivity': 1, 'days': 1, 'workschool': 1, 'costs': 1, 'etc': 1}, {'summary': 1, 'emerging': 1, 'sarscov2': 1, 'variants': 1, 'concern': 1, 'voc': 1, 'threaten': 1, 'effectiveness': 1, 'current': 1, 'covid19': 1, 'vaccines': 1, 'administered': 1, 'intramuscularly': 1, 'designed': 1, 'target': 1, 'spike': 1, 'protein': 1, 'pressing': 1, 'need': 1, 'develop': 1, 'nextgeneration': 1, 'vaccine': 1, 'strategies': 1, 'broader': 1, 'longlasting': 1, 'protection': 1, 'using': 1, 'adenoviral': 1, 'vectors': 1, 'ad': 1, 'human': 1, 'chimpanzee': 1, 'origin': 1, 'evaluated': 1, 'advectored': 1, 'trivalent': 1, 'expressing': 1, 'spike1': 1, 'nucleocapsid': 1, 'rdrp': 1, 'antigens': 1, 'murine': 1, 'models': 1, 'show': 1, 'singledose': 1, 'intranasal': 1, 'immunization': 1, 'particularly': 1, 'superior': 1, 'intramuscular': 1, 'induction': 1, 'tripartite': 1, 'protective': 1, 'immunity': 1, 'consisting': 1, 'local': 1, 'systemic': 1, 'antibody': 1, 'responses': 1, 'mucosal': 1, 'tissueresident': 1, 'memory': 1, 'cells': 1, 'trained': 1, 'innate': 1, 'provides': 1, 'ancestral': 1, 'two': 1, 'b117': 1, 'b1351': 1, 'our': 1, 'findings': 1, 'indicate': 1, 'respiratory': 1, 'delivery': 1, 'multivalent': 1, 'represents': 1, 'effective': 1, 'strategy': 1, 'induce': 1, 'allaround': 1, 'future': 1}, {'according': 1, 'article': 1, 'cited': 1, 'ssnhl': 1, 'also': 1, 'observed': 1, 'vaccination': 1, 'oxfordastrazeneca': 1, 'well': 1, 'older': 1, 'vaccines': 1, 'influenza': 1, 'tetanus': 1, 'diphtheria': 1, 'meningococcal': 1, 'polysaccharide': 1, 'rabies': 1, 'mechanism': 1, 'known': 1, 'may': 1, 'immune': 1, 'autoimmunerelated': 1, 'sudden': 1, 'sensorineural': 1, 'hearing': 1, 'loss': 1, 'covid19': 1, 'https': 1, 'wwwsciencedirectcomsciencearticlepiis1201971221008158': 1}, {'ci': 1, 'surrounds': 1, '0': 1, 's': 1, 'likely': 1, 'statistical': 1, 'noise': 1, 'bringing': 1, 'also': 1, 'seems': 1, 'largely': 1, 'chadox1': 1, 'dragging': 1, 'data': 1, 'set': 1, 'vaccine': 1, 'effectiveness': 1, 'bnt162b2': 1, '92': 1, '%': 1, '95': 1, '93': 1, 'p': 1, '0001': 1, '15äì30': 1, 'days': 1, '47': 1, '39': 1, '55': 1, '121äì180': 1, '23': 1, 'àí2': 1, '41': 1, 'p007': 1, 'day': 1, '211': 1, 'onwards': 1, 'waning': 1, 'slightly': 1, 'slower': 1, 'mrna1273': 1, '96': 1, '94': 1, '97': 1, '59': 1, '18': 1, '79': 1, 'p0012': 1, '181': 1, 'heterologous': 1, 'ncov19': 1, 'plus': 1, 'mrna': 1, 'schedules': 1, '89': 1, '66': 1, '80': 1, '121': 1, 'contrast': 1, 'homologous': 1, '68': 1, '52': 1, 'detectable': 1, 'àí19': 1, 'äì98': 1, '28': 1, 'p049': 1}, {'means': 1, 'elderly': 1, 'really': 1, 'need': 1, 'drop': 1, 'hesitancy': 1, 'get': 1, 'vaccine': 1, 'big': 1, 'problem': 1, 'among': 1, 'esp': 1, '80': 1, 'age': 1, 'range': 1, 'chart': 1, 'proportion': 1, 'vaccinated': 1, 'vs': 1, 'opposite': 1, 'countries': 1}, {'uk': 1, 'papers': 1, 'continue': 1, 'study': 1, '2x': 1, 'az': 1, 'w': 1, 'bnt': 1, 'm1273': 1, 'boosters': 1}, {'absence': 1, 'evidence': 1}, {'actually': 1, 'know': 1, 'viral': 1, 'load': 1, 'show': 1, 'infectious': 1, '?': 1, 's': 1, 'rna': 1, 'fragments': 1, 'would': 1, 'necessarily': 1, 'correlate': 1, 'infectivity': 1, 'every': 1, 'study': 1, 'seen': 1, 'tried': 1, 'culture': 1, 'reported': 1, 'significantly': 1, 'lower': 1, 'vaccinated': 1, 'though': 1, 'range': 1, 'vary': 1}, {'seeing': 1, 'vaccines': 1, 'j': 1, '&': 1, 'excepted': 1, 'originally': 1, 'designed': 1, 'given': 1, 'prime': 1, 'boost': 1, 'regimen': 1, 'people': 1, 'vaccinated': 1, 'exposed': 1, 'spike': 1, 'protein': 1, 'twice': 1, '3x': 1, 'boosted': 1, 'would': 1, 'expected': 1, 'stronger': 1, 'persistent': 1, 'response': 1, 'second': 1, 'exposure': 1, 'single': 1, 'infection': 1, 'vaccine': 1, 'encountered': 1, 'sarscov2': 1, 'antigens': 1, 'giving': 1, 'act': 1, 'bit': 1, 'like': 1, 'heterologous': 1, 'priming': 1, 'interesting': 1, 'see': 1, 'infected': 1, 'better': 1, 'immunity': 1, 'caught': 1, 'probably': 1, 'enough': 1, 'cases': 1, 'able': 1, 'appropriate': 1, 'comparative': 1, 'studies': 1, 'twiv': 1, 'clinical': 1, 'update': 1, 'recently': 1, 'dr': 1, 'daniel': 1, 'griffin': 1, 'commented': 1, 'patients': 1, 'four': 1, 'times': 1}, {'thought': 1, 'could': 1, 'covid': 1, 'pass': 1, 'force': 1, 'vaccinated': 1, 'would': 1, 'social': 1, 'occasions': 1, 'get': 1, 'infected': 1, '?': 1}, {'exactly': 1, 'point': 1, 'going': 1, 'make': 1, 'luckily': 1, 'improved': 1, 'diet': 1, 'also': 1, 'help': 1, 'vaccine': 1, 'efficacy': 1, 'improve': 1, 'weight': 1, 'cholesterol': 1, 'high': 1, 'blood': 1, 'pressure': 1, 'vaccination': 1, 'https': 1, 'wwwncbinlmnihgovpmcarticlespmc8487656': 1}, {'really': 1, 'state': 1, 'three': 1, 'exposures': 1, 'like': 1, 'flu': 1, 'lineages': 1, 'time': 1, '10': 1, 'years': 1, 'old': 1, 'yearly': 1, 'sequence': 1, 'matched': 1, 'boost': 1, 'turbocharges': 1, 'little': 1}, {'yes': 1, 'according': 1, 'study': 1, 'twice': 1, 'likely': 1, 'get': 1, 'vaccine': 1, 'first': 1, 'second': 1, 'dose': 1, 'biontech': 1, '31215': 1, 'per': 1, 'million': 1, 'compared': 1, 'covid': 1, '7': 1, 'only': 1, 'cared': 1, 'myocarditis': 1, 'risk': 1, 'would': 1, 'make': 1, 'sense': 1, 'vaccinated': 1, 'young': 1, 'male': 1}, {'one': 1, 'statutory': 1, 'requirements': 1, 'granting': 1, 'eua': 1, 'adequate': 1, 'approved': 1, 'available': 1, 'alternative': 1, 'product': 1, 'diagnosing': 1, 'preventing': 1, 'treating': 1, 'disease': 1, 'condition': 1, 'https': 1, 'wwwlawcornelleduuscodetext21360bbb3': 1, 'two': 1, 'fdaapproved': 1, 'vaccines': 1, 'covid': 1, 'adults': 1, 'bar': 1, 'new': 1, 's': 1, 'getting': 1, 'higher': 1, 'spaces': 1, 'pfizer': 1, '&': 1, 'moderna': 1, 'small': 1, 'shrinking': 1}, {'conclusions': 1, 'messenger': 1, 'rna': 1, 'mrna': 1, 'boosterswerehighly': 1, 'effective': 1, 'symptomaticdelta': 1, 'infection': 1, 'but': 1, 'wereless': 1, 'againstsymptomatic': 1, 'omicron': 1, 'ä': 1, 'discussion': 1, 'bnt162b2': 1, 'booster': 1, 'vaccinationwas': 1, 'associated': 1, 'an861': 1, '%': 1, 'reductionin': 1, 'incidenceofsymptomaticdeltavariant': 1, 'infectionand': 1, 'a494': 1, 'incidenceofsymptomaticomicron': 1, 'themrna1273booster': 1, 'reduction': 1, 'incidence': 1, 'symptomatic': 1, 'infectionwiththeomicron': 1, 'variantwas': 1, 'similarat': 1, '473': 1}, {'nt': 1, 'feel': 1, 'right': 1, 'even': 1, 'omicron': 1, 'replicates': 1, 'vaccine': 1, 'targeted': 1, 'work': 1, 'effectively': 1, 'one': 1, 'basically': 1, 'target': 1, 'quickly': 1, 'overwhelms': 1, 'initially': 1, 'would': 1, 'expect': 1, 'virus': 1, 'deadly': 1, 'since': 1, 'viral': 1, 'load': 1, 'higher': 1, '?': 1, 'unvaccinated': 1, 'people': 1, 'significantly': 1, 'less': 1, 'however': 1, 'still': 1, 'many': 1}, {'would': 1, 'nt': 1, 'imply': 1, 'locking': 1, 'vaccinated': 1, 'least': 1, 'closing': 1, 'bars': 1, 'etc': 1, 'huge': 1, 'impact': 1, 'new': 1, 'case': 1, 'rate': 1, '?': 1}, {'infection': 1, 'naøve': 1, 'population': 1, '?': 1, 'would': 1, 'said': 1, 'south': 1, 'island': 1, 'new': 1, 'zealand': 1, 'omicron': 1, 'couple': 1, 'days': 1, 'weeks': 1, 's': 1, 'already': 1, 'country': 1, 'also': 1, 'hard': 1, 'find': 1, 'vaccine': 1, 'uninfected': 1}, {'health': 1, 'authorities': 1, 'almost': 1, 'experts': 1, 'wanted': 1, 'touch': 1, 'study': 1, '10': 1, 'foot': 1, 'pole': 1, 'eh': 1, '?': 1, '27': 1, 'studies': 1, 'cited': 1, 'five': 1, 'months': 1, 'since': 1, 'published': 1, 'highprofile': 1, 'journals': 1, 'nejm': 1, 'lancet': 1, 'jama': 1, 'etc': 1, 's': 1, 'compelling': 1, 'example': 1, 'avoidance': 1, 'https': 1, 'wwwnejmorgdoifull101056nejmoa2114114': 1, 'article_citing_articles': 1}, {'ah': 1, 'perfect': 1, 'thank': 1}, {'longer': 1, 'usa': 1, 'recommended': 1, 'time': 1, '?': 1, 'schedules': 1, 'recommending': 1, '23': 1, 'months': 1, 'first': 1, 'second': 1, 'doses': 1}, {'vaccines': 1, 'development': 1, 'target': 1, 'stable': 1, 'part': 1, 'virus': 1, 'rather': 1, 'spike': 1, 'protein': 1, '?': 1}, {'thankyou': 1, 'broadening': 1, 'vs': 1, 'narrowing': 1, 'analogy': 1, 'would': 1, 'nt': 1, 'say': 1, 'feared': 1, 'way': 1, 'much': 1, 'curious': 1, 'interactions': 1, 'aging': 1, 'vaccine': 1, 'relatively': 1, 'mutated': 1, 'variant': 1, 'imagine': 1, 'gets': 1, 'complicated': 1, 'oas': 1, 'really': 1, 'exist': 1, 'always': 1, 'case': 1, 'though': 1, '?': 1, 'assumed': 1, 'boosters': 1, 'effective': 1, 'brute': 1, 'forced': 1, 'sterilization': 1, 'sheer': 1, 'magnitude': 1, 'numbers': 1, 'even': 1, 'stronger': 1, 'immune': 1, 'response': 1, 'antibodies': 1, 'generated': 1, 'individual': 1, 'level': 1, 'remained': 1, 'less': 1}, {'quick': 1, 'correction': 1, 'lower': 1, 'bound': 1, '95': 1, '%': 1, 'ci': 1, 'mrna1273': 1, 'omicron': 1, '699': 1, 'positive': 1, 'wondering': 1, 'estimate': 1, 'could': 1, 'outside': 1, 'range': 1, 'looks': 1, 'like': 1, 'typo': 1}, {'s': 1, 'defined': 1, 'even': 1, 'study': 1, 'peer': 1, 'reviewed': 1, 'published': 1, 'journal': 1, 'blog': 1, 'nothing': 1, 'confirmed': 1, 'evaluated': 1, 'total': 1, 'garbage': 1}, {'downvoted': 1, '?': 1, 've': 1, 'wondering': 1, 'thing': 1}, {'press': 1, 'release': 1, 'text': 1, 'sans': 1, 'footer': 1, 'us': 1, 'food': 1, 'drug': 1, 'administration': 1, 'notified': 1, 'pfizer': 1, 'new': 1, 'data': 1, 'recently': 1, 'emerged': 1, 'regarding': 1, 'emergency': 1, 'use': 1, 'authorization': 1, 'request': 1, 'pfizerbiontech': 1, 'covid19': 1, 'vaccine': 1, 'children': 1, '6': 1, 'months': 1, '4': 1, 'years': 1, 'age': 1, 'part': 1, 'rolling': 1, 'submission': 1, 'company': 1, 'agency': 1, 'additional': 1, 'findings': 1, 'ongoing': 1, 'clinical': 1, 'trial': 1, 'based': 1, 'agencyäôs': 1, 'preliminary': 1, 'assessment': 1, 'allow': 1, 'time': 1, 'evaluate': 1, 'believe': 1, 'information': 1, 'evaluation': 1, 'third': 1, 'dose': 1, 'considered': 1, 'decisionmaking': 1, 'potential': 1, 'therefore': 1, 'fda': 1, 'postponing': 1, 'vaccines': 1, 'related': 1, 'biological': 1, 'products': 1, 'advisory': 1, 'committee': 1, 'meeting': 1, 'originally': 1, 'scheduled': 1, 'feb': 1, '15': 1, 'give': 1, 'consider': 1, 'allowing': 1, 'transparent': 1, 'public': 1, 'discussion': 1, 'usual': 1, 'scientific': 1, 'regulatory': 1, 'processes': 1, 'provide': 1, 'update': 1, 'timing': 1, 'receive': 1, 'group': 1, 'companyäôs': 1, 'opportunity': 1, 'complete': 1, 'updated': 1, 'since': 1, 'early': 1, 'days': 1, 'pandemic': 1, 'always': 1, 'followed': 1, 'science': 1, 'everchanging': 1, 'situation': 1, 'given': 1, 'recent': 1, 'omicron': 1, 'surge': 1, 'notable': 1, 'increase': 1, 'hospitalizations': 1, 'youngest': 1, 'highest': 1, 'levels': 1, 'far': 1, 'felt': 1, 'responsibility': 1, 'health': 1, 'act': 1, 'urgency': 1, 'available': 1, 'options': 1, 'including': 1, 'requesting': 1, 'initial': 1, 'two': 1, 'doses': 1, 'study': 1, 'goal': 1, 'understand': 1, 'would': 1, 'sufficient': 1, 'protection': 1, 'move': 1, 'forward': 1, 'authorizing': 1, 'approach': 1, 'conduct': 1, 'review': 1, 'thatäôs': 1, 'responsive': 1, 'urgent': 1, 'needs': 1, 'created': 1, 'adhering': 1, 'rigorous': 1, 'standards': 1, 'safety': 1, 'effectiveness': 1, 'able': 1, 'begin': 1, 'evaluating': 1, 'useful': 1, 'ensure': 1, 'support': 1, 'meantime': 1, 'best': 1, 'way': 1, 'protect': 1, 'school': 1, 'daycare': 1, 'practice': 1, 'social': 1, 'distancing': 1, 'masking': 1, 'accordance': 1, 'recommendations': 1, 'family': 1, 'members': 1, 'caregivers': 1, 'get': 1, 'vaccinated': 1, 'booster': 1, 'eligible': 1}, {'https': 1, 'wwwmedrxivorgcontent1011012022020222270302v1': 1, 'detectable': 1, 'omicronneutralizing': 1, 'activity': 1, 'nearly': 1, 'absent': 1, 'two': 1, 'vaccinations': 1, 'elicited': 1, '89': 1, '%': 1, 'individuals': 1, 'booster': 1, 'immunization': 1, 'neutralizing': 1, 'titers': 1, 'wu01': 1, 'delta': 1, 'omicron': 1, 'variants': 1, 'showed': 1, 'similar': 1, 'postboost': 1, 'declines': 1, '81': 1, 'maintained': 1, 'levels': 1, 'fall': 1, 'sheer': 1, 'ability': 1, 'neutralize': 1, 'distant': 1, 'voc': 1, 'retained': 1, 'probably': 1, 'recalled': 1}, {'getting': 1, 'huge': 1, 'boost': 1, 'antibodies': 1, 'would': 1, 'amplify': 1, 'also': 1, 'ones': 1, 'still': 1, 'work': 1, 's': 1, 'paper': 1, 'reporting': 1, 'nt': 1, 'contradict': 1, 'said': 1, 'do': 1, 'believe': 1, 'amplifying': 1, 'antibody': 1, 'levels': 1, 'means': 1, 'whatever': 1, 'already': 1, 'neutralize': 1, 'omicron': 1, 'present': 1, 'greater': 1, 'numbers': 1, 'among': 1, 'others': 1, 'breadth': 1, 'coverage': 1, 'variants': 1, 'exist': 1, 'yet': 1, 'chance': 1, 'better': 1, 'particular': 1, 'variant': 1, 'different': 1, 'original': 1, 'see': 1, 'comment': 1, 'post': 1, 'https': 1, 'wwwredditcomrcovid19commentss635r8mrnabased_covid19_vaccine_boosters_induceht1t2f7': 1, '?': 1, 'context1': 1}, {'previous': 1, 'papers': 1, 'similar': 1, 'positive': 1, 'spin': 1, 'narrative': 1, 'general': 1, 'tenor': 1, 'tension': 1, 'findings': 1, 'independent': 1, 'studies': 1, 'post': 1, '?': 1, 'interested': 1, 'j': 1, '&': 1, 'efficacy': 1, 'severe': 1, 'disease': 1, 'without': 1, 'booster': 1, 'long': 1, 'covid': 1}, {'honest': 1, 'think': 1, 'vastly': 1, 'overestimating': 1, 'much': 1, 'thought': 1, 'people': 1, 'give': 1, 'topic': 1, 'show': 1, 'rest': 1, 'population': 1, 'adopts': 1, 'group': 1, 'consensus': 1, 'tribe': 1, 'runs': 1}, {'memory': 1, 'b': 1, 'cells': 1, 'rescue': 1}, {'current': 1, 'increases': 1, 'europe': 1, 'china': 1, 'nt': 1, 'think': 1, 'rule': 1, 'spike': 1, 'starting': 1, 'april': 1, 'may': 1}, {'appears': 1, 'improvement': 1, 'fomite': 1, 'transmission': 1, 'side': 1, 'things': 1, 'per': 1, 'japanese': 1, 'study': 1, 'https': 1, 'wwwbiorxivorgcontent10110120220118476607v1': 1, 'aspect': 1, 'watching': 1, 'since': 1, 'beginning': 1, 'thing': 1, 'evolves': 1, 'substantively': 1, 'improve': 1, 'form': 1, 'bets': 1, 'cdc': 1, 'backgrounder': 1, 'formite': 1, 'wwwcdcgovcoronavirus2019ncovmorescienceandresearchsurfacetransmissionhtml': 1, 'm': 1, 'thinking': 1, 'though': 1, 'something': 1, 'else': 1, 'play': 1, 'survival': 1, 'times': 1, 'various': 1, 'surfaces': 1}, {'simply': 1, 'lot': 1, 'antibodies': 1, 'general': 1, '?': 1}, {'wouldnäôt': 1, 'control': 1, 'number': 1, 'viral': 1, 'infections': 1, 'group': 1, '?': 1, 'basically': 1, 'comparing': 1, 'less': 1, 'also': 1, 'comparable': 1, 'groups': 1, 'would': 1, 'vaxcovid': 1, 'positive': 1, 'vaccine': 1, 'really': 1, 'isolating': 1, 'either': 1, 'covid': 1, 'infection': 1, 'vax': 1, 'status': 1, 'relationship': 1, 'gbs': 1, 'design': 1}, {'well': 1, 'make': 1, 'blanket': 1, 'approach': 1, 'cdc': 1, 'took': 1, 'recommending': 1, 'either': 1, 'mrna': 1, 'vaccine': 1, 'j': 1, '&': 1, 'ages': 1, 'groups': 1, '28': 1, 'year': 1, 'old': 1, 'male': 1, 'probably': 1, 'less': 1, '1': 1, 'million': 1, 'chance': 1, 'developing': 1, 'blood': 1, 'clot': 1, 'even': 1, 'lower': 1, 'dying': 1, 'though': 1, 'myocarditis': 1, 'cases': 1, 'typically': 1, 'resolve': 1, 'still': 1, 'shows': 1, 'moderna': 1, 'likely': 1, 'high': 1, 'higher': 1, 'risk': 1, 'demographic': 1, 'note': 1, 'nt': 1, 'think': 1, 'restricted': 1, 'group': 1, 'point': 1, 'show': 1, 'sense': 1, 'especially': 1, 'since': 1, 'context': 1, 'omicron': 1, 'main': 1, 'advantage': 1, 'vaccines': 1, 'efficacy': 1, 'infection': 1, 'seem': 1, 'much': 1, 'factor': 1, 'anymore': 1, 'protection': 1, 'severe': 1, 'disease': 1, 'equalizer': 1, 'always': 1, 'held': 1, 'comparatively': 1}, {'like': 1, 'really': 1, 'frustrating': 1, 'piece': 1, 'information': 1, 'going': 1, 'around': 1, 'getting': 1, 'spun': 1, 'certain': 1, 'way': 1, 'says': 1, 'monkeys': 1, 'omicronspecific': 1, 'doses': 1, 'offered': 1, 'additional': 1, 'protection': 1, 'og': 1, 'mrna': 1, 'vaccines': 1, 'in': 1, 'immunenaive': 1, 'test': 1, 'subjects': 1, 'reported': 1, 'said': 1, 'omicron': 1, 'dose': 1, 'nt': 1, 'offer': 1, 'already': 1, 'knew': 1, 'experimental': 1, 'realworld': 1, 'data': 1, '1': 1, '2': 1, 'shots': 1, 'highest': 1, 'level': 1, 'well': 1, '3rd': 1, 'upped': 1, 'efficacy': 1, 'covid': 1, 'important': 1, 'overall': 1, 'vaccine': 1, 'production': 1, 'implementation': 1, 'big': 1, 'part': 1, 'purpose': 1, 'developing': 1, 'assessing': 1, 'whether': 1, 'booster': 1, '4th': 1, 'whatever': 1, 'shot': 1, 'offers': 1, 'beyond': 1, 'etc': 1, 'formula': 1, 'people': 1, 'vaccinated': 1, 'article': 1, 'does': 1, 'contain': 1, 'yet': 1, 'portrayed': 1, 'though': 1, 's': 1, 'clear': 1, 'evidence': 1, 'development': 1, 'wo': 1, 'successful': 1}, {'cells': 1, 'store': 1, 'memory': 1, 'invading': 1, 'pathogen': 1, 'immune': 1, 'systems': 1, 'response': 1, 'nt': 1, 'activate': 1, 'ai': 1, 'trickin': 1, 'shyt': 1}, {'think': 1, 'anybody': 1, 'idea': 1, 'hospitalized': 1, 'covid': 1, 'patient': 1, 'less': 1, 'chance': 1, 'developing': 1, 'myocarditis': 1, 'somebody': 1, 'getting': 1, 'vaccinated': 1, 'm': 1, 'sure': 1, 'lol': 1}, {'wow': 1, 'didnäôt': 1, 'realize': 1, 'far': 1, 'along': 1, 'seems': 1, 'pretty': 1, 'promising': 1, 'would': 1, 'love': 1, 'see': 1, 'direct': 1, 'comparison': 1, 'novavax': 1, 'like': 1, 'might': 1, 'push': 1, 'right': 1, 'way': 1, 'really': 1}, {'given': 1, 'sample': 1, 'size': 1, 'spread': 1, 'authors': 1, 'really': 1, 'reaching': 1, 'draw': 1, 'conclusion': 1, 'different': 1, 'response': 1, 'breakthrough': 1, 'infections': 1, '2': 1, '3': 1, 'vaccine': 1, 'doses': 1, 'personally': 1, 'would': 1, 'call': 1, 'indistinguishable': 1, 'warranting': 1, 'study': 1}, {'511': 1, 'already': 1}, {'infection': 1, 'relevant': 1, 'end': 1, 'points': 1, 'like': 1, 'long': 1, 'covid': 1, 'hospitalization': 1, 'death': 1, '2': 1, 'shots': 1, 'still': 1, 'show': 1, 'protection': 1}, {'?': 1, 'norwegen': 1, 'case': 1, 'one': 1, 'infecting': 1, '80': 1, 'party': 1}, {'agree': 1, 'however': 1, 'd': 1, 'like': 1, 'perspective': 1, 'following': 1, 'problem': 1, 'right': 1, 'canada': 1, 'covid': 1, 'prevalent': 1, 'hospitals': 1, 'dedicate': 1, 'lot': 1, 'resources': 1, 'isolating': 1, 'infected': 1, 'hospitalized': 1, 'people': 1, 'whose': 1, 'issues': 1, 'nothing': 1, 'even': 1, 'clear': 1, 'provincial': 1, 'governments': 1, 'know': 1, 'many': 1, 'opposed': 1, 'data': 1, 'never': 1, 'made': 1, 'public': 1, 'least': 1, 'quebec': 1, 'ontario': 1, 'long': 1, 'treated': 1, 'dangerous': 1, 'disease': 1, 'healthcare': 1, 'get': 1, 'overwhelmed': 1, 'every': 1, 'winter': 1, 'omicron': 1, 'extremely': 1, 'dominant': 1, 'recent': 1, 'delta': 1, 'prevalence': 1, 'vast': 1, 'majority': 1, 'population': 1, 'vaccinated': 1, 'significant': 1, 'percentage': 1, 'immunity': 1, 'infections': 1, 'unclear': 1, 'nt': 1, 'seem': 1, 'started': 1, 'treating': 1, 'normally': 1, 'would': 1, 'think': 1, 'take': 1, 'time': 1, 'hospital': 1, 'protocols': 1, 'change': 1, 'large': 1, 'segments': 1, 'still': 1, 'highly': 1, 'scared': 1, 'catching': 1, 'make': 1, 'decision': 1, 'hope': 1, 'changes': 1, 'next': 1, 'autumn': 1}, {'get': 1, 'covid': 1, 'test': 1, 'positive': 1, '?': 1, 'oh': 1, 's': 1, 'hospitalized': 1, 'tiny': 1, 'fraction': 1, 'percent': 1, 'age': 1, 'range': 1}, {'abstract': 1, '____': 1, 'objective': 1, 'assess': 1, 'shortterm': 1, 'change': 1, 'depressive': 1, 'anxiety': 1, 'symptoms': 1, 'relation': 1, 'covid19': 1, 'vaccination': 1, 'among': 1, 'swedish': 1, 'adults': 1, 'design': 1, 'prospective': 1, 'cohort': 1, 'study': 1, 'monthly': 1, 'data': 1, 'collections': 1, 'selfreported': 1, 'december': 1, '2020': 1, 'october': 1, '2021': 1, 'july': 1, 'setting': 1, 'omtanke2020': 1, 'sweden': 1, 'participants': 1, '7925': 1, 'complete': 1, 'status': 1, 'intervention': 1, 'exposure': 1, 'receiving': 1, 'first': 1, 'second': 1, 'dose': 1, 'vaccine': 1, 'main': 1, 'outcomes': 1, 'measure': 1, 'binary': 1, 'measures': 1, 'depression': 1, 'phq9': 1, 'cutoff': 1, 'â': 1, '10': 1, 'gad7': 1, 'one': 1, 'month': 1, 'applicable': 1, 'individuals': 1, 'vaccinated': 1, 'chose': 1, 'report': 1, 'unvaccinated': 1, 'selected': 1, 'three': 1, '2month': 1, 'intervals': 1, 'inbetween': 1, 'based': 1, 'availability': 1, 'results': 1, '5079': 1, '641': 1, '%': 1, 'received': 1, 'two': 1, 'doses': 1, '1977': 1, '249': 1, '305': 1, '39': 1, '564': 1, '71': 1, 'lower': 1, 'prevalence': 1, 'compared': 1, 'especially': 1, 'arr082': 1, '95': 1, 'ci': 1, '076088': 1, 'arr081': 1, '073089': 1, 'arr079': 1, '073085': 1, 'arr073': 1, '066081': 1, 'similar': 1, 'observed': 1, 'arr076': 1, '068084': 1, '072094': 1, 'comparing': 1, 'independent': 1, 'age': 1, 'sex': 1, 'recruitment': 1, 'type': 1, 'body': 1, 'mass': 1, 'index': 1, 'smoking': 1, 'relationship': 1, 'history': 1, 'psychiatric': 1, 'disorder': 1, 'number': 1, 'comorbidities': 1, 'infection': 1, 'seasonality': 1, 'conclusions': 1, 'positive': 1, 'current': 1, 'pandemic': 1}, {'takes': 1, 'longer': 1, 'get': 1, 'lungs': 1}, {'disappointingly': 1, 'low': 1, '?': 1, 'risk': 1, 'already': 1, 'relatively': 1, 'small': 1, 'marginally': 1, 'improved': 1, 'unvaccinated': 1, 'makes': 1, 'question': 1, 's': 1, 'even': 1, 'worth': 1, 'billions': 1, 'spent': 1, 'lockdowns': 1, 'forced': 1}, {'lockdown': 1, 'measures': 1, 'resulted': 1, 'practically': 1, 'benefit': 1, 'fact': 1, 'arguably': 1, 'detrimental': 1, 'overall': 1, 'research': 1, 'subreddit': 1, 'would': 1, 'mind': 1, 'citing': 1, '?': 1, 'quick': 1, 'search': 1, 'finds': 1, 'sources': 1, 'entirely': 1, 'contrary': 1, 'https': 1, 'journalsplosorgplosonearticle': 1, 'id101371journalpone0236619': 1, 'wwwsciencedirectcomsciencearticlepiis0048969720339528': 1}, {'could': 1, 'mention': 1, 'results': 1, 'vaccine': 1, 'effectiveness': 1, 'much': 1, 'negative': 1, '91150': 1, 'days': 1, 'vaccination': 1, 'moderna': 1, 'pfizer': 1, '765': 1, 'extreme': 1, 'result': 1}, {'iäôm': 1, 'aware': 1, 'two': 1, 'studies': 1, 'omicron': 1, 'sub': 1, 'threads': 1, 'redditcomrcovid19coronavirus_disease_2019_covid19_vaccine_boosting': 1, 'https': 1, 'wwwredditcomrcovid19commentssslf1a': 1, 'redditcomrcovid19protection_against_the_omicron_variant_from': 1, 'wwwredditcomrcovid19commentssophs7': 1, 'redditcomrcovid19protection_afforded_by_prior_infection_against': 1, 'wwwredditcomrcovid19commentsrxni1d': 1, 'studydataset': 1, 'second': 1, 'believe': 1}, {'people': 1, 'seriously': 1, 'uneducated': 1, 'fools': 1, 'ca': 1, 'nt': 1, 'sway': 1}, {'would': 1, 'love': 1, 'know': 1, 'info': 1, '5yo': 1, 'getting': 1, 'second': 1, 'shot': 1, 'later': 1, 'today': 1}, {'anyone': 1, 'happen': 1, 'link': 1, 'study': 1, 'information': 1, 'protective': 1, '?': 1}, {'could': 1, 'lead': 1, 'body': 1, 'becoming': 1, 'likely': 1, 'produce': 1, 'universal': 1, 'äúcommon': 1, 'denominatoräù': 1, 'antibodies': 1, '?': 1, 'exposure': 1, 'naive': 1, 'people': 1, 'maybe': 1, 'given': 1, 'numbers': 1, 'either': 1, 'infected': 1, 'vaccinated': 1, 'seems': 1, 'like': 1, 'already': 1, 'locked': 1, 'imprinted': 1, 'response': 1, 'form': 1, 'first': 1}, {'1': 1, 'especially': 1, 'interesting': 1, 'vaccines': 1, 'offer': 1, 'lifetime': 1, 'sterilizing': 1, 'immunity': 1, 'others': 1, 'donäôt': 1, '?': 1, 'even': 1, 'without': 1, 'get': 1, 'measles': 1, 'coronaviruses': 1, 'return': 1, 'periodically': 1, 'simply': 1, 'replicate': 1, 'fast': 1, 'foothold': 1, 'cellular': 1, 'respond': 1, 'iäôll': 1, 'use': 1, 'example': 1, 'slow': 1, 'one': 1, 'sinuses': 1, 'enter': 1, 'system': 1, 'first': 1}, {'6': 1, 'weeks': 1, 'illness': 1, 'onset': 1, 'lower': 1, 'prevalence': 1, 'among': 1, 'vaccinated': 1, 'participants': 1, '606': 1, '%': 1, 'compared': 1, 'unvaccinated': 1, 'vs': 1, '791': 1, 'arr': 1, '070': 1, '95': 1, 'ci': 1, '0580': 1, 'also': 1, 'remember': 1, 's': 1, 'conditional': 1, 'infection': 1, 'breakthrough': 1, 'health': 1, 'care': 1, 'workers': 1, 'severe': 1, 'slice': 1, 'infections': 1, 'asymptomatic': 1, 'mildly': 1, 'symptomatic': 1, 'individuals': 1, 'probably': 1, 'nt': 1, 'included': 1, 'study': 1}, {'oof': 1, '1': 1, 'especially': 1, '2': 1, 'serious': 1, 'question': 1, 'nt': 1, 'small': 1, 'sample': 1, 'size': 1, '?': 1, '41': 1, 'samples': 1, '33': 1, 'convalesced': 1, 'patients': 1, '28': 1, 'vaccinated': 1}, {'wouldnäôt': 1, 'control': 1, 'number': 1, 'viral': 1, 'infections': 1, 'group': 1, '?': 1, 'study': 1, 'looking': 1, 'relative': 1, 'rates': 1, 'gbs': 1, 'vaccinated': 1, 'vs': 1, 'infected': 1, 'unvaccinated': 1, 'infection': 1}, {'yeah': 1, 'gets': 1, 'rolled': 1, 'itäôs': 1, 'either': 1, 'going': 1, 'leave': 1, 'people': 1, 'vulnerable': 1, 'worst': 1, 'time': 1, 'holidaywinter': 1, 'season': 1, 'necessitate': 1, 'fifth': 1, 'dose': 1, 'think': 1, 'weäôre': 1, 'really': 1, 'start': 1, 'seeing': 1, 'big': 1, 'amount': 1, 'diminishing': 1, 'returns': 1, 'terms': 1, 'participation': 1, 'round': 1, 'shots': 1, 'need': 1, 'careful': 1}, {'think': 1, 'anybody': 1, 'idea': 1, 'hospitalized': 1, 'covid': 1, 'patient': 1, 'less': 1, 'chance': 1, 'developing': 1, 'myocarditis': 1, 'somebody': 1, 'getting': 1, 'vaccinated': 1, 'would': 1, 'interesting': 1, 'check': 1, 'risks': 1, 'involved': 1, 'vaccination': 1, 'person': 1, 'already': 1, 'immunized': 1, '3rd': 1, 'dose': 1, 'present': 1, 'better': 1, 'protection': 1, '?': 1, 'vaccines': 1, 'improve': 1, 'defense': 1, 'prior': 1, 'infection': 1, 'kind': 1, 'posed': 1}, {'x': 1, '100': 1, 'would': 1, 'extremely': 1, 'common': 1, 'let': 1, 's': 1, 'hope': 1, 'significantly': 1, 'better': 1}, {'study': 1, 'showed': 1, 'impact': 1, 'vaccination': 1, 'community': 1, 'transmission': 1, 'circulating': 1, 'variants': 1, 'sarscov2': 1, 'appeared': 1, 'significantly': 1, 'different': 1, 'among': 1, 'unvaccinated': 1, 'people': 1, 'm': 1, 'rather': 1, 'surprised': 1, 'interpretation': 1, 'quoted': 1, 'paper': 1, 'https': 1, 'wwwthelancetcomjournalslaninfarticlepiis14733099': 1, '21': 1, '006484fulltext': 1, 'text': 1, 'reduces': 1, 'risk': 1, 'delta': 1, 'variant': 1, 'infection': 1, 'accelerates': 1, 'viral': 1, 'clearance': 1, 'nonetheless': 1, 'fully': 1, 'vaccinated': 1, 'individuals': 1, 'breakthrough': 1, 'infections': 1, 'peak': 1, 'load': 1, 'similar': 1, 'cases': 1, 'efficiently': 1, 'transmit': 1, 'household': 1, 'settings': 1, 'including': 1, 'contacts': 1, 'hostäìvirus': 1, 'interactions': 1, 'early': 1, 'may': 1, 'shape': 1, 'entire': 1, 'trajectory': 1, 'quite': 1, 'clearly': 1, 'say': 1, 'asserting': 1, 'even': 1, 'examine': 1, 'perspective': 1, 'break': 1, 'earlier': 1, 'would': 1, 'expect': 1, 'reduce': 1, 'overall': 1}, {'moderna': 1, 'nt': 1, 'pfizer': 1, '?': 1, 'thanks': 1}, {'make': 1, 'phase': 1, '1': 1, '2': 1, 'trial': 1, 'soon': 1, '3': 1, 'eua': 1, '?': 1, 'omnicrap': 1, 'long': 1, 'term': 1, 'effects': 1, 'would': 1, 'really': 1, 'like': 1, 'get': 1, 'rid': 1}, {'wonder': 1, 's': 1, 'mechanism': 1, 'long': 1, 'haul': 1, 'symptoms': 1, 'induced': 1, 'vaccination': 1, 'individuals': 1, 'case': 1, 'haulers': 1, 'recover': 1, 'get': 1, 'back': 1, 'worsened': 1, 'post': 1, 'needs': 1, 'research': 1, 'underlying': 1, 'cause': 1, 'term': 1, 'effects': 1}, {'links': 1, 'similar': 1, 'comparative': 1, 'studies': 1, 'ways': 1, 'harm': 1, 'us': 1, '?': 1}, {'really': 1, 'would': 1, 'loved': 1, 'seen': 1, 'questions': 1, 'knowing': 1, 'someone': 1, 'died': 1, 'covid': 1, 'impacted': 1, 'vaccine': 1, 'hesitancy': 1}, {'iäôm': 1, 'going': 1, 'memory': 1, 'forgive': 1, 'wrong': 1, 'didnäôt': 1, 'pfizer': 1, '85': 1, '%': 1, '10': 1, 'months': 1, 'post': 1, 'vaccination': 1, '?': 1}, {'mean': 1, 'vaccine': 1, 'effectiveness': 1, 'drop': 1, 'below': 1, '0': 1, '%': 1, '?': 1}, {'also': 1, 'know': 1, 'though': 1, 'less': 1, 'confidence': 1, 'time': 1, 'memory': 1, 'b': 1, 'cells': 1, 'become': 1, 'dormant': 1, 'challenge': 1, 'immune': 1, 'system': 1, 'similar': 1, 'antigen': 1, 'happens': 1, 'leads': 1, 'recruiting': 1, 'naive': 1, 'process': 1, 'would': 1, 'exposure': 1, 'virus': 1, '?': 1, 'instance': 1, 'someone': 1, 'infectionacquired': 1, 'andor': 1, 'boosted': 1, 'immunity': 1, 'exposed': 1, 'considered': 1}, {'saying': 1, '?': 1, 'maybe': 1, 'misinterpreting': 1, 'nt': 1, 'know': 1, 'abstract': 1, 'support': 1, 'selection': 1, 'pressure': 1, 'vaccines': 1, 'directly': 1, 'creating': 1, 'environment': 1, 'omicron': 1, 'escape': 1, 'vaccineinduced': 1, 'immunity': 1, 'right': 1}, {'also': 1, 'need': 1, 'paxlovid': 1, 'patent': 1, 'free': 1, 'mass': 1, 'produced': 1}, {'would': 1, 'look': 1, 'previous': 1, 'infection': 1, 'since': 1, 'ab': 1, 'levels': 1, 'usually': 1, 'drop': 1, 'months': 1, '?': 1}, {'think': 1, 'need': 1, 'thinking': 1, 'terms': 1, 'long': 1, 'immunity': 1, 'lasts': 1, 'itäôs': 1, 'strong': 1, 'month': 1, 'two': 1, 'thatäôs': 1, 'going': 1, 'us': 1, 'lot': 1, 'good': 1}, {'although': 1, 'encouraging': 1, 'think': 1, 'wait': 1, 'data': 1, 'independent': 1, 'researchers': 1, 'assay': 1, 'sanofi': 1, 'used': 1, 'could': 1, 'biased': 1}, {'says': 1, 'exercise': 1, 'increase': 1, 'side': 1, 'effects': 1, 'covid19': 1, 'vaccination': 1, 'referring': 1, '?': 1, 'general': 1, 'soreness': 1, 'getting': 1, 'vaccine': 1, 'something': 1, 'else': 1}, {'vaccination': 1, 'protected': 1, 'testicular': 1, 'damage': 1, 'sarscov2': 1, 'challenge': 1, 'hamsters': 1, 'immunized': 1, 'two': 1, 'doses': 1, 'intramuscular': 1, 'inactivated': 1, 'whole': 1, 'virion': 1, 'vaccine': 1, '14': 1, 'days': 1, 'apart': 1, 'intranasally': 1, 'challenged': 1, '103': 1, 'pfu': 1, 'hk13': 1, 'second': 1, 'testes': 1, 'examined': 1, '4': 1, '28dpi': 1, 'figure': 1, '10a': 1, 'serum': 1, 'neutralizing': 1, 'antibodies': 1, 'detected': 1, 'vaccinated': 1, 'animals': 1, '4dpi': 1, 'gmt': 1, '1604382': 1, '1202309': 1, 'respectively': 1, 'testicles': 1, 'showed': 1, 'histopathological': 1, 'changes': 1, 'nine': 1, '10b': 1, 'one': 1, 'group': 1, 'n7': 1, '3': 1, 'first': 1, 'indicating': 1, 'effectively': 1, 'protects': 1, 'mild': 1, 'cases': 1, 'may': 1, 'spared': 1, 'detectable': 1, 'observed': 1, '10pfu': 1, '102': 1, 's1': 1, 'edit': 1, 'added': 1}, {'bharat': 1, 'biotech': 1, 'currently': 1, 'working': 1, 'stage': 1, 'iii': 1, 'trials': 1, 'nasal': 1, 'covid19': 1, 'vaccine': 1, 'used': 1, 'booster': 1, 'shot': 1}, {'doesnäôt': 1, 'matter': 1, 'randomize': 1, 'correctly': 1, 'effect': 1, 'previous': 1, 'infections': 1, 'similar': 1, 'cohorts': 1}, {'previous': 1, 'study': 1, 'smith': 1, 'et': 1, 'al': 1, 'genome': 1, 'medicine': 1, '2021': 1, '13101': 1, 'landscape': 1, 'selection': 1, 'vaccine': 1, 'epitopes': 1, 'sarscov2': 1, 'https': 1, 'doiorg101186s13073021009101': 1, 'abstract': 1, 'background': 1, 'early': 1, 'pandemic': 1, 'designed': 1, 'peptide': 1, 'containing': 1, 'epitope': 1, 'regions': 1, 'optimized': 1, 'concurrent': 1, 'b': 1, 'cell': 1, 'cd4': 1, 'cd8': 1, 'stimulation': 1, 'rationale': 1, 'design': 1, 'drive': 1, 'humoral': 1, 'cellular': 1, 'immunity': 1, 'high': 1, 'specificity': 1, 'avoiding': 1, 'undesired': 1, 'effects': 1, 'antibodydependent': 1, 'enhancement': 1, 'ade': 1, 'methods': 1, 'explored': 1, 'set': 1, 'computationally': 1, 'predicted': 1, 'hlai': 1, 'hlaii': 1, 'ligands': 1, 'examining': 1, 'protein': 1, 'source': 1, 'humanmurine': 1, 'coverage': 1, 'population': 1, 'beyond': 1, 'mhc': 1, 'affinity': 1, 'candidates': 1, 'refined': 1, 'immunogenicity': 1, 'sequence': 1, 'conservation': 1, 'abundance': 1, 'frequency': 1, 'hla': 1, 'alleles': 1, 'chosen': 1, 'linear': 1, 'mapping': 1, 'studies': 1, 'convalescent': 1, 'patient': 1, 'serum': 1, 'followed': 1, 'filtering': 1, 'surface': 1, 'accessibility': 1, 'spatial': 1, 'localization': 1, 'near': 1, 'functional': 1, 'domains': 1, 'spike': 1, 'glycoprotein': 1, 'avoidance': 1, 'glycosylation': 1, 'sites': 1, 'major': 1, 'histocompatibility': 1, 'complex': 1, 'human': 1, 'leucocyte': 1, 'antigen': 1}, {'betacoronaviruses': 1, 'less': 1, 'likely': 1, 'diverge': 1, 'subtypes': 1, 'influenza': 1, '?': 1}, {'iäôm': 1, 'sure': 1, 'understand': 1, 'trying': 1, 'say': 1, 'simpler': 1, 'language': 1, 'sounds': 1, 'like': 1, 'boosters': 1, 'blunted': 1, 'immune': 1, 'response': 1, 'high': 1, 'function': 1, '?': 1, 'certain': 1}, {'https': 1, 'coronavirushealthnygovcovid19breakthroughdata': 1, 'scientific': 1, 'compared': 1, 'houston': 1, 'study': 1, 'graphs': 1, 'showing': 1, 'consider': 1, 'vaccine': 1, 'efficacy': 1, 'infections': 1, 'hospitalization': 1, 'mobile': 1, 'friendly': 1, 'data': 1, '2': 1, 'week': 1, 'lag': 1, 'fully': 1, 'omicron': 1, 'cases': 1, 'yet': 1}, {'3rd': 1, 'shot': 1, 'booster': 1, 'produced': 1, 'robust': 1, 'immune': 1, 'response': 1, '2nd': 1, 'terms': 1, 'neutralizing': 1, 'antibodies': 1, 'also': 1, 'ability': 1, 'neutralize': 1, 'omicron': 1, 'much': 1, 'mutated': 1, 'variants': 1, 'concern': 1, 'fourth': 1, 'however': 1, 'seemed': 1, 'restore': 1, 'antibody': 1, 'levels': 1, 'greater': 1, 'found': 1, 'shift': 1, 'focus': 1, 'system': 1, 'parts': 1, 'virus': 1, 'spike': 1, 'helpful': 1, 'conclusion': 1, 'repeated': 1, 'boosting': 1, 'keep': 1, 'immunity': 1, 'long': 1, 'term': 1, 'option': 1, 'looked': 1, 'group': 1, 'healthcare': 1, 'workers': 1, 'received': 1, 'shots': 1, 'inactivated': 1, 'cov2': 1, 'vaccines': 1, 'mrna': 1, 'type': 1, 'pfizermoderna': 1, 'unlike': 1, 'kind': 1, 'produces': 1, 's': 1, 'unclear': 1, 'point': 1, 'away': 1, 'seems': 1, 'study': 1, 'w': 1, 'include': 1}, {'unlikely': 1, 'happen': 1, 'furthermore': 1, 'immersed': 1, 'brain': 1, 'cells': 1, 'vaccine': 1, '96hrs': 1, 'odd': 1, 'happens': 1, 'immerse': 1, 'tap': 1, 'water': 1, '?': 1, 'anything': 1, 'started': 1, 'spike': 1, 'protein': 1, 'compare': 1, 'time': 1, 'read': 1, 'last': 1, 'night': 1, 'baffled': 1}, {'going': 1, 'find': 1, '205': 1, 'people': 1, 'vaccinate': 1, 'already': 1, 'willing': 1, 'participate': 1, 'clinical': 1, 'trial': 1, '?': 1}, {'nt': 1, 'omicron': 1, 'started': 1, 'running': 1, 'course': 1, '?': 1, 'need': 1, 'prepared': 1, 'future': 1, 'variants': 1, 'wave': 1, 'seems': 1, 'mostly': 1, 'usa': 1}, {'hospitalizations': 1, 'falling': 1, 'south': 1, 'africa': 1, 'hopefully': 1, 'thing': 1, 'happens': 1, 'us': 1}, {'stop': 1, 'showing': 1, 'incidence': 1, 'rate': 1, '2': 1, 'doses': 1, '?': 1}, {'oslo': 1, 'study': 1, 'none': 1, 'subjects': 1, 'boosters': 1, 'double': 1, 'vaccinated': 1, '54': 1, '66': 1, 'infected': 1, '81': 1, '%': 1, 'faroe': 1, 'boostered': 1, '21': 1, '33': 1, '64': 1, 'average': 1, 'age': 1, '35': 1, '45': 1}, {'still': 1, 'think': 1, 'need': 1, 'look': 1, 'spacing': 1, '1st': 1, '2nd': 1, 'doses': 1, 'apart': 1, 'much': 1, 'currently': 1, 'shot': 1, 'especially': 1, 'recommended': 1, 'schedule': 1, 'may': 1, 'actually': 1, 'great': 1, 'deal': 1, 'compared': 1, 'booster': 1, 'months': 1, 'later': 1}, {'say': 1, 'third': 1, 'dose': 1, 'mean': 1, 'booster': 1, 'regular': 1, '?': 1}, {'inclusion': 1, 'criteria': 1, 'covid19': 1, 'diagnosis': 1, 'people': 1, 'test': 1, 'positive': 1, 'covid': 1, 'think': 1, 'word': 1, 'patient': 1, 'confusing': 1, 'lot': 1, 'paper': 1, 'said': 1, 'nothing': 1, 'hospitalizations': 1}, {'also': 1, 'talk': 1, 'preexisting': 1, 'hypertrophy': 1, 'one': 1, 'boys': 1, 'nt': 1, 'specifically': 1, 'rule': 1, 'ho': 1, 'cm': 1, 'despite': 1, 'running': 1, 'testing': 1, 'genetic': 1, 'markers': 1, 'arrhythmias': 1, 'moreover': 1, 'pair': 1, 'potentially': 1, 'questionable': 1, 'case': 1, 'reports': 1, 'dont': 1, 'see': 1, 'smoking': 1, 'gun': 1}, {'also': 1, 'relevant': 1, 'myocarditis': 1, 'negative': 1, 'health': 1, 'outcome': 1, 'covid19': 1, 's': 1, 'pretty': 1, 'easy': 1, 'call': 1, 'compare': 1, 'low': 1, 'risk': 1, 'comparing': 1, 'outcomes': 1, 'important': 1, 'well': 1}, {'ca': 1, 'nt': 1, 'know': 1, 'things': 1, 'like': 1, 'actual': 1, 'people': 1, 'time': 1, 'study': 1, 'two': 1, 'hurry': 1, 'studies': 1, 'nearly': 1, 'way': 1, 'really': 1, 'even': 1, 'need': 1, 'reviewed': 1, 'scientific': 1, 'peers': 1, 'organizers': 1, 'take': 1}, {'thanks': 1, 'nt': 1, 'understood': 1, 'beginning': 1}, {'yeah': 1, 'actually': 1, 'saw': 1, 'happen': 1, 'ontario': 1, 'last': 1, 'month': 1, 'populationadjusted': 1, 'infection': 1, 'rates': 1, 'fully': 1, 'vaccinated': 1, 'individuals': 1, 'surpassed': 1, 'unvaccinated': 1, 'compelling': 1, 'theory': 1, 'heard': 1, 'case': 1, 'could': 1, 'attend': 1, 'highcongregate': 1, 'settings': 1, 'like': 1, 'movie': 1, 'theatres': 1, 'bars': 1, 'sports': 1, 'games': 1, 'omicron': 1, 'ripped': 1, 'meant': 1, 'even': 1, 'controlling': 1, 'population': 1, 'still': 1, 'vaxxed': 1, 'getting': 1, 'infected': 1}, {'hong': 1, 'kong': 1, 'highest': 1, 'cfr': 1, 'world': 1, 'iäôm': 1, 'sure': 1, 'means': 1, 'vaccine': 1}, {'way': 1, 'could': 1, 'see': 1, 'happening': 1, 'feel': 1, 'confident': 1, 'willing': 1, 'risk': 1, 'exposure': 1, 'feeling': 1, 'confidence': 1, 'live': 1, 'places': 1, 'fewer': 1, 'restrictions': 1, 'higher': 1, 'vax': 1, 'rates': 1, 'increasing': 1, 'possible': 1, 'exposures': 1, '?': 1}, {'someone': 1, 'help': 1, 'understand': 1, 'whatäôs': 1, 'going': 1, 'clearly': 1, 'seeing': 1, 'vaccine': 1, 'effectiveness': 1, 'decreasing': 1, 'timeä': 1, 'itäôs': 1, 'almost': 1, 'every': 1, 'study': 1, 'iäôve': 1, 'read': 1, '2': 1, 'doses': 1, 'pfizer': 1, 'moderna': 1, 'dropped': 1, 'around': 1, '65': 1, '70': 1, '%': 1, '10': 1, '25': 1, 'weeks': 1, 'second': 1, 'dose': 1, 'omicron': 1, 'low': 1, '0': 1, 'percent': 1, 'astrazenecaä': 1, 'current': 1, 'boosters': 1, 'arenäôt': 1, 'even': 1, 'specific': 1, 'theyäôre': 1, 'exact': 1, 'formula': 1, 'original': 1, 'developed': 1, 'wild': 1, 'covidä': 1, 'expecting': 1, 'booster': 1, 'diminish': 1, 'wellä': 1, '?': 1, 'point': 1, '2doses': 1, 'basically': 1, 'irrelevant': 1, 'delta': 1, '20': 1, 'less': 1, '50': 1, 'effective': 1, 'begs': 1, 'question': 1, 'month': 1, 'trials': 1, 'still': 1, 'high': 1}, {'matched': 1, 'based': 1, 'age': 1, 'location': 1, 'comorbidities': 1, 'individual': 1, '11': 1, 'statistics': 1, 'sweden': 1, 'national': 1, 'agency': 1, 'one': 1, 'randomly': 1, 'sampled': 1, 'total': 1, 'population': 1, 'birth': 1, 'year': 1, 'sex': 1, 'municipality': 1, 'attempted': 1, 'adjust': 1, 'using': 1, 'cox': 1, 'proportional': 1, 'hazards': 1, 'model': 1, 'analysis': 1}, {'one': 1, '?': 1, 'az': 1, 'close': 1, 'useless': 1, 'omicron': 1, 'protection': 1, 'even': 1, 'hospitalisation': 1, 'severe': 1, 'symptoms': 1, 'drops': 1, 'cliff': 1, 'quickly': 1, 'also': 1, 'expressly': 1, 'recommended': 1, 'many': 1, 'places': 1, 'people': 1, '30': 1, 'j': 1, '&': 1, 'pulled': 1, 's': 1, 'basically': 1, 'novovax': 1, 'nt': 1, 'know': 1}, {'extend': 1, 'definition': 1, 'äúfocusing': 1, 'protecting': 1, 'hospitalization': 1, 'even': 1, 'immunocompromised': 1, 'long': 1, 'covidäù': 1, 'wonäôt': 1, 'care': 1, 'infections': 1, 'either': 1, 'would': 1, 'board': 1}, {'n2': 1, 'major': 1, 'finding': 1, '?': 1, 'cäômon': 1}, {'exactly': 1, 'comparing': 1, '?': 1, 'm': 1, 'mistaken': 1, 'vaccine': 1, 'myocarditis': 1, 'risk': 1, 'hospitalised': 1, 'covid19': 1, 'patient': 1}, {'discussion': 1, 'actual': 1, 'report': 1, '&': 1, 'x200b': 1, 'growth': 1, 'rates': 1, 'estimated': 1, 'omicron': 1, 'translate': 1, 'doubling': 1, 'times': 1, '25': 1, 'days': 1, 'even': 1, 'allowing': 1, 'potentially': 1, 'slowing': 1, '11': 1, 'th': 1, 'december': 1, 'estimates': 1, 'consistent': 1, 'faster': 1, 'reported': 1, 'south': 1, 'africa': 1, '13': 1, 'assuming': 1, 'exponentially': 1, 'distributed': 1, 'generation': 1, 'time': 1, '52': 1, 'r1': 1, 'currently': 1, 'delta': 1, 'reproduction': 1, 'number': 1, 'r': 1, '3': 1, 'sgtf': 1, 'genotype': 1, 'analyses': 1, 'period': 1, '8th': 1, '10th': 1, 'shorter': 1, 'assumed': 1, 'give': 1, 'lower': 1, 'distribution': 1, 'age': 1, 'region': 1, 'ethnicity': 1, 'differs': 1, 'markedly': 1, 'indicating': 1, 'transmission': 1, 'yet': 1, 'uniformly': 1, 'across': 1, 'population': 1, 'however': 1, 'note': 1, 'given': 1, 'immune': 1, 'evasion': 1, 'infection': 1, 'coming': 1, 'weeks': 1, 'may': 1, 'continue': 1, 'differ': 1, 'london': 1, 'substantially': 1, 'ahead': 1, 'english': 1, 'regions': 1, 'frequency': 1, 'find': 1, 'strong': 1, 'evidence': 1, 'natural': 1, 'risk': 1, 'reinfection': 1, '541': 1, '95': 1, '%': 1, 'ci': 1, '487600': 1, 'fold': 1, 'higher': 1, 'vaccineinduced': 1, 'protection': 1, 'largely': 1, 'agree': 1, 'ukhsaäôs': 1, 'tncc': 1, 'study': 1, 'predictions': 1, 'predicting': 1, 'neutralising': 1, 'antibody': 1, 'titres': 1, '414': 1, 'suggesting': 1, 'limited': 1, 'remaining': 1, 'symptomatic': 1, 'afforded': 1, 'two': 1, 'doses': 1, 'az': 1, 'low': 1, 'pfizer': 1, 'moderate': 1, 'high': 1, '5580': 1, 'people': 1, 'boosted': 1, 'mrna': 1, 'vaccine': 1, 'estimate': 1, 'hazard': 1, 'ratio': 1, 'relative': 1, 'also': 1, 'supports': 1, 'previous': 1, 'analysis': 1, '15': 1, 'prior': 1, 'siren': 1, 'cohort': 1, 'uk': 1, 'healthcare': 1, 'workers': 1, 'sarscov2': 1, 'gave': 1, '85': 1, '6': 1, 'months': 1, '16': 1, '015': 1, 'compared': 1, 'would': 1, 'suggest': 1, 'risen': 1, '081': 1, '073100': 1, 'ie': 1, '19': 1, '027': 1, 'hospitalisation': 1, 'attendance': 1, 'symptom': 1, 'status': 1, 'different': 1, 'severity': 1, 'though': 1, 'data': 1, 'hospitalisations': 1, 'still': 1, 'several': 1, 'limitations': 1, 'case': 1, 'numbers': 1, 'increasing': 1, 'quickly': 1, 'limits': 1, 'ability': 1, 'examine': 1, 'interactions': 1, 'variables': 1, 'considered': 1, 'differed': 1, 'conducted': 1, 'likely': 1, 'due': 1, 'groups': 1, 'initially': 1, 'seeded': 1, 'increases': 1, 'risks': 1, 'confounding': 1, 'imperfect': 1, 'proxy': 1, '60': 1, 'specificity': 1, 'date': 1, 'range': 1, 'analysed': 1, 'close': 1, '100': 1, 'intensified': 1, 'contact': 1, 'tracing': 1, 'around': 1, 'known': 1, 'cases': 1, 'increased': 1, 'ascertainment': 1, 'introducing': 1, 'additional': 1, 'biases': 1, 'reinforces': 1, 'emerging': 1, 'increasingly': 1, 'clear': 1, 'picture': 1, 'poses': 1, 'immediate': 1, 'substantial': 1, 'threat': 1, 'public': 1, 'health': 1, 'england': 1, 'widely': 1}, {'may': 1, 'simply': 1, 'confounding': 1, 'factor': 1, 'study': 1, 'design': 1, 'one': 1, 'remember': 1, 'groups': 1, 'random': 1, 'blinded': 1, 'example': 1, 'pure': 1, 'speculation': 1, 'could': 1, 'personnel': 1, 'working': 1, 'close': 1, 'contact': 1, 'covid': 1, 'patients': 1, 'likely': 1, 'want': 1, 'second': 1, 'booster': 1, 'shot': 1, 'overrepresented': 1, '2': 1, 'shots': 1, 'group': 1, 'time': 1, 'might': 1, 'markedly': 1, 'increased': 1, 'risk': 1, 'catching': 1, 'omicron': 1, 'scenario': 1, 'theoretically': 1, 'even': 1, 'raise': 1, 'immunity': 1, 'due': 1, 'confounders': 1, 'look': 1, 'would': 1, 'make': 1, 'get': 1, 'infected': 1, 'another': 1, 'similar': 1, 'imaginable': 1, 'persons': 1, 'children': 1, 'willing': 1, 'extra': 1, 'thinking': 1, 'protect': 1, 'families': 1, 'catch': 1, 'm': 1, 'saying': 1, 'true': 1, 's': 1, 'hypothesis': 1, 'lowers': 1, 'important': 1, 'correlations': 1, 'seen': 1, 'unblinded': 1, 'nonrandom': 1, 'studies': 1, 'often': 1, 'causations': 1}, {'unfortunately': 1, 'theyäôre': 1, 'probably': 1, 'going': 1, 'crossed': 1, 'long': 1, 'time': 1, 'think': 1, 'general': 1, 'consensus': 1, 'well': 1, 'year': 1, 'talking': 1, 'december': 1, 'perhaps': 1, 'significantly': 1, 'longer': 1, 'thatäôs': 1, 'assuming': 1, 'work': 1, 'hoped': 1, 'unless': 1, 'someone': 1, 'comes': 1, 'along': 1, 'äúwarp': 1, 'speedsäù': 1, 'weäôve': 1, 'seen': 1, 'indication': 1, 'occurring': 1, 'juncture': 1}, {'type': 1, 'basic': 1, 'statistical': 1, 'analysis': 1, 'missing': 1, 'many': 1, 'published': 1, 'studies': 1, 'worries': 1, 'peer': 1, 'review': 1, 'nt': 1, 'catching': 1, 'foundational': 1, 'aspects': 1, 'probability': 1}, {'results': 1, 'really': 1, 'strange': 1, 'adeno': 1, 'vaccines': 1, 'higher': 1, 'neutralization': 1, 'titres': 1, 'vs': 1, 'mrna': 1, 'studies': 1, 'find': 1, 'hard': 1, 'believe': 1, 'single': 1, 'jj': 1, 'dose': 1, 'lead': 1, 'pfizer': 1, 'vaccine': 1, '56': 1, 'year': 1, 'olds': 1, 'said': 1, 'sanofi': 1, 'little': 1, 'bit': 1, 'careful': 1, '2020': 1, 'maybe': 1, 'one': 1, 'major': 1, '2021': 1, 'would': 1, 'pitty': 1}, {'seems': 1, 'like': 1, 'title': 1, 'little': 1, 'misleading': 1, 'mixed': 1, 'cocktail': 1, 'work': 1, 'great': 1, 'specific': 1, 'omicron': 1, 'delta': 1, 'rbd': 1, 'vaccine': 1, 'protocols': 1, 'nt': 1, 'much': 1, 'also': 1, 'preprint': 1, 'think': 1, 'given': 1, 'abstract': 1, 'going': 1}, {'without': 1, 'even': 1, 'looking': 1, 'study': 1, 'pretty': 1, 'sure': 1, 'sampling': 1, 'vaccinated': 1, 'cohorts': 1, 'going': 1, 'within': 1, '2': 1, 'months': 1, 'second': 1, 'dose': 1, 'boost': 1, 'antibodies': 1, 'start': 1, 'wane': 1, 'almost': 1, 'always': 1, 'case': 1, 'studies': 1, 'favor': 1, 'vaccination': 1, 'compared': 1, 'natural': 1, 'immunity': 1, 'point': 1, 'mixture': 1, '3': 1, '6': 1, '12': 1, 'boosters': 1, 'accurately': 1, 'represent': 1, 'population': 1, 'tells': 1, 'us': 1, 'nothing': 1, 'new': 1, 'really': 1, 's': 1, 'different': 1, 'two': 1, 'following': 1, 'someone': 1, 'recovering': 1, 'covid': 1}, {'omicron': 1, 'delta': 1, 'numbers': 1, 'concerning': 1, 'last': 1, 'two': 1, 'dominant': 1, 'strains': 1, 'wonder': 1, 'wait': 1, 'next': 1, 'study': 1, 'guess': 1}, {'controlling': 1, 'vaccine': 1, 'status': 1, 'age': 1, 'sex': 1, 'ethnicity': 1, 'asymptomatic': 1, 'region': 1, 'specimen': 1, 'date': 1, 'omicron': 1, 'associated': 1, '540': 1, '95': 1, '%': 1, 'ci': 1, '438663': 1, 'fold': 1, 'higher': 1, 'risk': 1, 'reinfection': 1, 'compared': 1, 'delta': 1, 'put': 1, 'context': 1, 'preomicron': 1, 'era': 1, 'uk': 1, 'äúsirenäù': 1, 'study': 1, 'covid': 1, 'infection': 1, 'healthcare': 1, 'workers': 1, 'estimated': 1, 'prior': 1, 'afforded': 1, '85': 1, 'protection': 1, 'second': 1, '6': 1, 'months': 1, 'current': 1, 'suggests': 1, 'fallen': 1, '19': 1, '027': 1, 'finds': 1, 'evidence': 1, 'lower': 1, 'severity': 1, 'judged': 1, 'either': 1, 'proportion': 1, 'people': 1, 'testing': 1, 'positive': 1, 'report': 1, 'symptoms': 1, 'cases': 1, 'seeking': 1, 'hospital': 1, 'care': 1, 'researchers': 1, 'found': 1, 'significantly': 1, 'increased': 1, 'developing': 1, 'symptomatic': 1, 'case': 1, 'two': 1, 'weeks': 1, 'past': 1, 'dose': 1, 'booster': 1, 'astrazeneca': 1, 'pfizer': 1, 'vaccines': 1, 'depending': 1, 'estimates': 1, 'used': 1, 'effectiveness': 1, 'variant': 1, 'translates': 1, '0': 1, '20': 1, 'doses': 1, '55': 1, '80': 1}, {'0327': 1, 'relative': 1, 'risk': 1, 'versus': 1, '0337': 1, '0970': 1, '3': 1, '%': 1, 'efficacy': 1, 'math': 1, 'nt': 1, 'magic': 1, 'trick': 1, 'learn': 1, 'stuff': 1}, {'abstract': 1, 'sarscov2': 1, 'omicron': 1, 'variant': 1, 'concern': 1, 'comprises': 1, 'three': 1, 'sublineages': 1, 'designated': 1, 'ba1': 1, 'ba2': 1, 'ba3': 1, 'steadily': 1, 'replacing': 1, 'globally': 1, 'dominant': 1, 'show': 1, 'large': 1, 'number': 1, 'spike': 1, 'mutations': 1, 'severely': 1, 'dampen': 1, 'plasma': 1, 'neutralizing': 1, 'activity': 1, 'elicited': 1, 'infection': 1, 'seven': 1, 'clinical': 1, 'vaccines': 1, 'crossneutralization': 1, 'consistently': 1, 'potent': 1, 'independent': 1, 'vaccine': 1, 'platform': 1, 'doses': 1, 'although': 1, 'mrna': 1, 'induced': 1, 'greatest': 1, 'magnitude': 1, 'administration': 1, 'booster': 1, 'based': 1, 'wuhanhu1': 1, 'sequence': 1, 'markedly': 1, 'increased': 1, 'antibody': 1, 'titers': 1, 'breadth': 1, 'across': 1, 'evaluated': 1, 'data': 1, 'suggest': 1, 'evade': 1, 'polyclonal': 1, 'responses': 1, 'current': 1, 'boosting': 1, 'regimens': 1, 'may': 1, 'provide': 1, 'sufficient': 1, 'protection': 1, 'omicroninduced': 1, 'disease': 1}, {'study': 1, 'vaccinated': 1, 'balbc': 1, 'mice': 1, 'peptides': 1, 'derived': 1, 'sarscov2': 1, 'proteome': 1, 'designed': 1, 'either': 1, 'elicit': 1, 'tcell': 1, 'responses': 1, 'bcell': 1, 'linear': 1, 'epitopes': 1, 'm': 1, 'bit': 1, 'confused': 1, 'part': 1, 'design': 1, 'antigen': 1, 'b': 1, 'cells': 1, 'response': 1, '?': 1, 'would': 1, 'nt': 1, 'immune': 1, 'system': 1, 'automatically': 1, 'generate': 1}, {'worst': 1, 'part': 1, 'whole': 1, 'äúmyocarditis': 1, 'vaccineäù': 1, 'analysis': 1, 'even': 1, 'myocarditis': 1, 'post': 1, 'vaccination': 1, 'pretty': 1, 'small': 1, 'study': 1, 'notes': 1, 'possible': 1, 'statistic': 1, 'around': 1, 'developing': 1, 'vaccine': 1, '86': 1, '100000': 1, '00086': 1, '%': 1, 'keep': 1, 'mind': 1, 'previous': 1, 'studies': 1, 'note': 1, 'develop': 1, 'treatment': 1, 'wait': 1, 'hour': 1, 'goes': 1, 'away': 1, 'outcome': 1, 'äúmyocarditisäù': 1, 'folks': 1, 'never': 1, 'huge': 1, 'issue': 1, 'continuation': 1, 'know': 1, 'covid': 1, 'worse': 1, 'normal': 1, 'operations': 1, 'body': 1, 'side': 1, 'effects': 1, 'minimal': 1, 'frankly': 1, 'society': 1, 'didnäôt': 1, 'make': 1, 'pst': 1, 'high': 1, 'school': 1, 'statistics': 1}, {'agree': 1, 'statement': 1, 'sample': 1, 'size': 1, 'rather': 1, 'small': 1, 'hospitalization': 1, 'rates': 1, 'nt': 1, 'high': 1, 'covid19': 1, 'seem': 1, 'indications': 1, 'omicron': 1, 'strain': 1, 'less': 1, 'likely': 1, 'lead': 1}, {'vaccine': 1, 'boosters': 1, 'must': 1, 'timed': 1, 'expected': 1, 'coronavirus': 1, 'season': 1, 'idea': 1, 'maximum': 1, 'amount': 1, 'people': 1, 'antibodies': 1, 'blood': 1, 'stream': 1, 'time': 1, 'peak': 1, 'covid': 1, '19': 1}, {'tried': 1, 'make': 1, 'vaccine': 1, 'focusing': 1, 'variants': 1, 'nt': 1, 'much': 1, 'difference': 1, 'according': 1, 'study': 1, 's': 1, 'subreddit': 1}, {'s': 1, 'widely': 1, 'reported': 1, 'immunity': 1, 'conferred': 1, 'omicron': 1, 'infection': 1, 'backwards': 1, 'compatible': 1, 'apt': 1, 'term': 1, 'could': 1, 'come': 1, 'nt': 1, 'know': 1, 'robust': 1, 'findings': 1, 'also': 1, 'heard': 1, 'opposing': 1, 'viewpoints': 1, 'may': 1, 'well': 1, 'moot': 1, 'displaced': 1, 'delta': 1, 'anyway': 1}, {'data': 1, 'original': 1, 'vaccination': 1, '?': 1}, {'looks': 1, 'like': 1, 'itäôs': 1, 'animal': 1, 'models': 1, 'far': 1, '?': 1, 'concept': 1, 'sounds': 1, 'promising': 1}, {'seen': 1, 'much': 1, 'protection': 1, 'severe': 1, 'disease': 1, 'drops': 1, 'single': 1, 'dosejj': 1, 'vaccine': 1, '?': 1, 'recall': 1, 'seeing': 1, 'studies': 1, 'fall': 1, 'showed': 1, 'people': 1, 'vaccinated': 1, 'early': 1, 'spring': 1, '2021': 1, 'still': 1, 'strong': 1, 'hospitalization': 1, 'delta': 1, 'although': 1, 'exact': 1, 'title': 1, 'papers': 1, 'moment': 1, 'recently': 1, 'shown': 1, 'one': 1, 'dose': 1, 'j': 1, '&': 1, 'offered': 1, 'basically': 1, 'zero': 1, 'symptomatic': 1, 'omicron': 1, 'donäôt': 1, 'numbers': 1}, {'burn': 1, 'nonimmune': 1, 'people': 1, 'first': 1, 'becoming': 1, 'endemic': 1, 'take': 1, 'longer': 1, 'since': 1, 'previous': 1, 'infection': 1, 'andor': 1, 'vaccination': 1, 'completely': 1, 'protective': 1, 'circulating': 1, 'variants': 1, 'one': 1, 'knows': 1, 'many': 1, 'emerge': 1, 'either': 1}, {'nt': 1, 'omicron': 1, 'specific': 1, 'vaccines': 1, 'fairing': 1, 'fairly': 1, 'equally': 1, 'original': 1, 'far': 1, '?': 1}, {'wish': 1, 'broken': 1, 'risk': 1, 'myocarditis': 1, 'covid19': 1, 'infected': 1, 'individuals': 1, 'age': 1, 'groups': 1, 'figure': 1, '2': 1}, {'going': 1, 'say': 1, 'fact': 1, 'delta': 1, 'positivity': 1, 'reduced': 1, '4550': 1, '%': 1, 'two': 1, 'doses': 1, 'seemed': 1, 'surprising': 1, 'since': 1, 'remember': 1, 'seeing': 1, 'figures': 1, 'boosters': 1, 'widely': 1, 'available': 1, '7075': 1, 'effectiveness': 1, 'makes': 1, 'sense': 1, 'particular': 1, 'study': 1, 'biased': 1, 'towards': 1, 'people': 1, 'symptomsaccess': 1, 'testing': 1}, {'ve': 1, 'seen': 1, 'timelag': 1, 'effects': 1, 'hospitalization': 1, '&': 1, 'death': 1, 'statistics': 1, 'many': 1, 'different': 1, 'cases': 1, 'wo': 1, 'nt': 1, 'comfortable': 1, 'characterization': 1, 'sa': 1, 's': 1, 'data': 1, 'weeks': 1, 'testing': 1, 'peak': 1, 'even': 1, 'scales': 1}, {'find': 1, 'quote': 1, 'paper': 1}, {'addition': 1, 'usual': 1, 'efficacy': 1, 'data': 1, 'report': 1, 'contains': 1, '17': 1, 'pages': 1, 'vaccination': 1, 'pregnancy': 1, 's': 1, 'good': 1, 'charts': 1, 'tables': 1, 'birthweight': 1, 'stillbirths': 1}, {'data': 1, 'studies': 1, 'progress': 1, 'booster': 1, 'otherwise': 1, 'mixed': 1, 'vax': 1, 'flavors': 1, '?': 1, 'looked': 1, 'really': 1, 'promising': 1, 'attractive': 1, 'many': 1, 'people': 1, 'year': 1, 'ago': 1, 's': 1, 'shame': 1, 'taken': 1, 'long': 1}, {'protection': 1, 'infection': 1, 'dropping': 1, 'zero': 1, 'around': 1, 'point': 1, 'undetected': 1, 'unvaccinated': 1, 'group': 1, 'setting': 1, 'true': 1, 'graphed': 1, 'apparent': 1, 'baseline': 1, 'slightly': 1, 'likely': 1, 'seen': 1, 'estimates': 1, 'centers': 1, 'specific': 1, 'waves': 1, 'timing': 1, 'studies': 1, 'like': 1, 'design': 1, 'looking': 1, 'sars2': 1, 'outcomes': 1, 'control': 1, 'healthcare': 1, 'seeking': 1, 'behavior': 1, 'test': 1, 'negative': 1, 'would': 1, 'nt': 1, 'see': 1}, {'conclusion': 1, 'repeated': 1, 'boosting': 1, 'keep': 1, 'immunity': 1, 'long': 1, 'term': 1, 'option': 1, 'going': 1, 'research': 1, 'different': 1, 'variant': 1, 'vaccine': 1, 'whether': 1, 'll': 1, 'restore': 1, 'usefulness': 1, '?': 1, 'understand': 1, '4': 1, 'shots': 1, 'exact': 1, 'thing': 1, 'probably': 1, 'useful': 1}, {'know': 1, 'partial2dose': 1, 'vaccination': 1, 'particularly': 1, 'separated': 1, 'month': 1, 'cdc': 1, 'insisted': 1, 'recently': 1, 'prevent': 1, 'omicron': 1, 'infection': 1, 'smaller': 1, 'dose': 1, 'would': 1, 'also': 1, 'strong': 1, 'impact': 1, 'hitting': 1, 'specific': 1, 'extremely': 1, 'high': 1, 'cutoff': 1, 'needed': 1, 'originaltargeted': 1, 'antibodies': 1, 'reasonably': 1, 'short': 1, 'news': 1, 'antigenpresenting': 1, 'cells': 1, 'still': 1, 'teach': 1, 'b': 1, 'fight': 1, 'covid': 1, 'begin': 1, 'affinity': 1, 'maturation': 1, 'scale': 1, 'futurevariant': 1, 'protection': 1, 'guess': 1, 'boost': 1, 'given': 1, 'primeboost': 1, 'prime': 1, 'often': 1, 'small': 1, 'nt': 1, 'trigger': 1, 'enough': 1, 'response': 1, 'across': 1, 'many': 1, 'diseases': 1, 'one': 1, 'might': 1, 'question': 1, 'usefulness': 1, 'second': 1, 'since': 1, 'theoretically': 1, 'contribute': 1, 'much': 1}, {'s': 1, 'important': 1, 'note': 1, 'however': 1, 'booster': 1, 'thing': 1, 'original': 1, 'vaccine': 1, 'composition': 1, 'dosage': 1, 'second': 1, 'identical': 1, 'first': 1, 'true': 1, 'pfizer': 1, 'well': 1, 'moderna': 1, 'half': 1}, {'article': 1, 'assumes': 1, 'public': 1, 'reaction': 1, 'vaccination': 1, 'played': 1, 'individual': 1, 'interactions': 1, 'facebook': 1, 'incoming': 1, 'information': 1, 'real': 1, 'world': 1, 'think': 1, 'year': 1, 'covid': 1, 'comparable': 1, 'flu': 1, 'perhaps': 1, 'vulnerable': 1, 'groups': 1, 'restrictions': 1, 'people': 1, 'notice': 1, 'vast': 1, 'bulk': 1, 'vaccinated': 1, 'mild': 1, 'side': 1, 'effects': 1, 'beaten': 1, 'thing': 1, 'accepted': 1, 'less': 1, 'still': 1, 'lockdowns': 1, 'vaccinations': 1, 'every': 1, 'four': 1, 'months': 1, 'required': 1, 'government': 1, 'edict': 1, 'hard': 1, 'sell': 1, 'lots': 1, 'stories': 1, 'say': 1, 'forced': 1, 'accept': 1, 'harmed': 1, 'question': 1, 'far': 1, 'news': 1, 'filters': 1, 'slowly': 1, 'opinions': 1, 'driven': 1, 'dynamics': 1, 'short': 1, 'term': 1, 'important': 1, 'understand': 1, 'damaging': 1, 'nt': 1, 'answered': 1, 'well': 1, 'model': 1, 'impact': 1}, {'also': 1, 'extremely': 1, 'interested': 1, 'whether': 1, 'would': 1, 'probably': 1, 'repeated': 1, 'mrna': 1, 'boosting': 1, 'well': 1, 'deliver': 1, 'spike': 1, 'whole': 1, 'inactivated': 1, 'virus': 1, 'obviously': 1, '4th': 1, '5th': 1, '6th': 1, 'boostings': 1, 'arenäôt': 1, 'going': 1, 'bring': 1, 'antibodies': 1, 'beyond': 1, '3rd': 1, 'dose': 1, 'got': 1, 'active': 1, 'harm': 1, 'immunity': 1, '?': 1}, {'shorter': 1, 'length': 1, 'hospitalization': 1, '?': 1}]\n",
            "  (0, 0)\t1.0\n",
            "  (0, 1)\t1.0\n",
            "  (0, 2)\t1.0\n",
            "  (0, 3)\t1.0\n",
            "  (0, 4)\t1.0\n",
            "  (0, 5)\t1.0\n",
            "  (0, 6)\t1.0\n",
            "  (0, 7)\t1.0\n",
            "  (0, 8)\t1.0\n",
            "  (0, 9)\t1.0\n",
            "  (0, 10)\t1.0\n",
            "  (0, 11)\t1.0\n",
            "  (0, 12)\t1.0\n",
            "  (0, 13)\t1.0\n",
            "  (0, 14)\t1.0\n",
            "  (1, 7)\t1.0\n",
            "  (1, 15)\t1.0\n",
            "  (1, 16)\t1.0\n",
            "  (1, 17)\t1.0\n",
            "  (1, 18)\t1.0\n",
            "  (2, 19)\t1.0\n",
            "  (2, 7)\t1.0\n",
            "  (2, 20)\t1.0\n",
            "  (2, 21)\t1.0\n",
            "  (2, 22)\t1.0\n",
            "  :\t:\n",
            "  (598, 404)\t1.0\n",
            "  (598, 22)\t1.0\n",
            "  (598, 1372)\t1.0\n",
            "  (598, 307)\t1.0\n",
            "  (598, 15)\t1.0\n",
            "  (598, 1652)\t1.0\n",
            "  (598, 2095)\t1.0\n",
            "  (598, 1956)\t1.0\n",
            "  (598, 819)\t1.0\n",
            "  (598, 1984)\t1.0\n",
            "  (598, 403)\t1.0\n",
            "  (598, 1925)\t1.0\n",
            "  (598, 126)\t1.0\n",
            "  (598, 1508)\t1.0\n",
            "  (598, 205)\t1.0\n",
            "  (598, 206)\t1.0\n",
            "  (598, 377)\t1.0\n",
            "  (598, 215)\t1.0\n",
            "  (598, 555)\t1.0\n",
            "  (598, 270)\t1.0\n",
            "  (598, 18)\t1.0\n",
            "  (599, 2136)\t1.0\n",
            "  (599, 1334)\t1.0\n",
            "  (599, 318)\t1.0\n",
            "  (599, 18)\t1.0\n",
            "[{'op': 1, 'making': 1, 'vaccine': 1, 'likely': 1, 'waste': 1, 'money': 1, 'figures': 1, 'tell': 1, 'us': 1, 'way': 1, 'outperformed': 1, 'comirnaty': 1, 'data': 1, 'line': 1, 'current': 1, 'conclusion': 1, 'mrna': 1, 'vaccines': 1, 'better': 1, 'inactivated': 1, 'terms': 1, 'depth': 1, 'breadth': 1, 'antibodies': 1, 'raised': 1, 'another': 1, 'critical': 1, 'issue': 1, 'omicron': 1, 'platforms': 1, 'already': 1, 'shown': 1, 'using': 1, 'acestral': 1, 'strain': 1, 'raises': 1, 'minimal': 1, 'neutralizing': 1, 'effect': 1, 'variant': 1, 'even': 1, 'giving': 1, 'booster': 1, 'nt': 1, 'expect': 1, 'would': 1, 'make': 1, 'difference': 1}, {'note': 1, 'fully': 1, 'vaccinated': 1, 'group': 1, 'includes': 1, 'booster': 1, 'shots': 1, 'without': 1, 'breaking': 1, 'also': 1, 'always': 1, 'stayed': 1, 'quite': 1, 'high': 1, 'data': 1, 'probably': 1, 'vaccines': 1, 'big': 1, 'behavioral': 1, 'differences': 1, 'vaxxed': 1, 'unvaxxed': 1}, {'thats': 1, 'clear': 1, 'imo': 1, 'mainly': 1, 'cause': 1, 'mechanisms': 1, 'lc': 1}, {'also': 1, 'like': 1, 'norway': 1, 'cluster': 1, 'experienced': 1, 'symptoms': 1, 'although': 1, 'healthcare': 1, 'workers': 1, 'monitoring': 1, '1': 1, 'day': 1, 'would': 1, 'sharper': 1, 'point': 1, 'possible': 1, 'falsepositive': 1, 'true': 1, 'positive': 1, 'disease': 1}, {'assuming': 1, 'true': 1, 'mrna': 1, 'vaccines': 1, 'higher': 1, 'risk': 1, 'causing': 1, 'myocarditis': 1, 'males': 1, 'younger': 1, '40': 1, 'seems': 1, 'get': 1, 'natural': 1, 'infection': 1, 'much': 1, 'severe': 1, 'either': 1, 'case': 1, 'rare': 1, 'less': 1, 'kinds': 1, 'cardiac': 1, 'injury': 1, 'covid19': 1, '1928': 1, '%': 1, 'range': 1, 'https': 1, 'wwwncbinlmnihgovpmcarticlespmc7988375': 1, 'sec13title': 1, 'also': 1, 'lot': 1, 'negative': 1, 'sideeffects': 1, 'longterm': 1, 'risks': 1}, {'possibility': 1, 'vaccinated': 1, 'people': 1, 'around': 1, 'patients': 1, 'like': 1, 'providing': 1, 'selective': 1, 'pressure': 1, 'moreso': 1, 'ie': 1, 'many': 1, 'variants': 1, 'arise': 1, 'patient': 1, 'vaccine': 1, 'resistant': 1, 'ones': 1, 'would': 1, 'able': 1, 'transmit': 1, 'onwards': 1, 'm': 1, 'sure': 1, 'could': 1, 'though': 1, 'apply': 1, 'capable': 1, 'breakthrough': 1, 'infections': 1, 'fairly': 1, 'effective': 1, 'treatments': 1, 'approved': 1, 'hopefully': 1, 'chronic': 1, 'cured': 1, '?': 1}, {'finally': 1, 'dragged': 1, 'kicking': 1, 'screaming': 1, 'line': 1, 'hope': 1, 'claims': 1, 'made': 1, 'able': 1, 'make': 1, 'omicronspecific': 1, 'one': 1, 'pretty': 1, 'much': 1, 'immediately': 1, 'nt': 1, 'bluster': 1}, {'exactly': 1, 'looks': 1, 'like': 1, 'talking': 1, 'symptomatic': 1, 'infection': 1, '67': 1, '%': 1, 'chance': 1, 'wo': 1, 'nt': 1, 'even': 1, 'know': 1, 've': 1, 'got': 1}, {'donäôt': 1, 'think': 1, 'sufficient': 1, 'information': 1, 'come': 1, 'conclusion': 1, 'delta': 1, 'small': 1, 'confidence': 1, 'intervals': 1, 'ba2': 1, 'huge': 1}, {'endemic': 1, 'means': 1, 'continuously': 1, 'present': 1, 'given': 1, 'population': 1, 'area': 1, 'without': 1, 'new': 1, 'introduction': 1, 'nothing': 1, 'severity': 1}, {'1991': 1, 'cases': 1, '192': 1, 'million': 1, 'persons': 1, '359': 1, 'doses': 1}, {'helps': 1, 'strengthem': 1, 'body': 1, 'nt': 1, 'mean': 1, 'covid': 1, 'lol': 1}, {'better': 1, 'worse': 1, 'mrna': 1, 'vaccines': 1, '?': 1}, {'stating': 1, 'obvious': 1, 'point': 1, 'syphilis': 1, 'changed': 1, 'smallpox': 1, 'called': 1, 'small': 1, 'relation': 1, 'great': 1, 'pox': 1, 'laying': 1, 'waste': 1, 'continent': 1, 'different': 1, 'course': 1, 'disease': 1, 'vs': 1, 'recent': 1, 'untreated': 1, 'cases': 1, 'mers': 1, 'sars': 1, 'covid19': 1, 'family': 1, 'least': 1, 'two': 1, 'three': 1, 'seasonal': 1, 'nuisance': 1, 'cold': 1, 'like': 1, 'versions': 1, 'makes': 1, 'similar': 1, 'somehow': 1, 'mid': 1, 'worst': 1, 'case': 1, 'pandemic': 1, 'nightmare': 1, 'essentially': 1, 'disappearing': 1, 'virtually': 1, 'overnight': 1, '?': 1, 'nt': 1, 'able': 1, 'crossover': 1, 'first': 1, 'covid': 1, 'ongoing': 1, 'epi': 1, 'perspective': 1, 'front': 1, 'end': 1, 'somebody': 1, 'take': 1, 'genomic': 1, 'understanding': 1, 'look': 1, 'comparatively': 1}, {'good': 1, 'point': 1, 'current': 1, 'study': 1, 'derive': 1, '19': 1, '%': 1, '54': 1, 'fold': 1, 'number': 1, 'vice': 1, 'versa': 1, '?': 1}, {'4th': 1, 'dose': 1, 'actually': 1, 'seemed': 1, 'result': 1, 'antibody': 1, 'levels': 1, 'lower': 1, '3rd': 1, 'per': 1, 'abstract': 1, 'äúthe': 1, 'peak': 1, 'rbdnabs': 1, 'level': 1, 'induced': 1, 'inferior': 1, 'doseäù': 1}, {'study': 1, 'nt': 1, 'meant': 1, 'detect': 1, 'efficacy': 1, 'positive': 1, 'signal': 1, 'cherry': 1, 'top': 1, 'know': 1, 'many': 1, 'data': 1, 'sources': 1, 'vaccines': 1, 'durable': 1, 'way': 1, 'prevent': 1, 'disease': 1, 'particularly': 1, 'effective': 1, 'preventing': 1, 'infection': 1, 'long': 1, 'term': 1}, {'page': 1, '12': 1, 'effect': 1, 'vaccine': 1, 'booster': 1, 'occurrence': 1, 'covid19': 1, 'multivariable': 1, 'analyses': 1, 'boosting': 1, 'designed': 1, 'earlier': 1, 'variant': 1, 'associated': 1, 'withsignificantly': 1, 'reduced': 1, 'risk': 1, 'infection': 1, 'omicron': 1, 'cox': 1, 'proportional': 1, 'hazards': 1, 'regression': 1, 'among': 1, 'people': 1, 'previously': 1, 'vaccinated': 1, 'table': 1, '3': 1, 'infected': 1, '6': 1, 'months': 1, 'past': 1, 'prior': 1, 'vaccination': 1, '4': 1, 'number': 1, 'doses': 1, 'analyzed': 1, 'analysis': 1, 'individuals': 1, 'natural': 1, 'immunity': 1, 'advantage': 1, 'one': 1, 'dose': 1, 'received': 1, 'two': 1, 'significantly': 1, 'higher': 1, 'getting': 1, 'single': 1, '5': 1, 'supporting': 1, 'findings': 1, 'unadjusted': 1, 'comparison': 1, 'visually': 1, 'depicted': 1, 'figure': 1, 'look': 1, 'see': 1, '1': 1, '2': 1, 'increased': 1, 's': 1, 'd': 1, 'like': 1, 'others': 1, 'find': 1}, {'abstract': 1, 'genome': 1, 'sequencing': 1, 'proved': 1, 'excellent': 1, 'tool': 1, 'monitor': 1, 'molecular': 1, 'epidemiology': 1, 'disease': 1, 'caused': 1, 'sarscov2': 1, 'ie': 1, 'coronavirus': 1, 'covid19': 1, 'reports': 1, 'infected': 1, 'vaccinated': 1, 'individuals': 1, 'aroused': 1, 'great': 1, 'interest': 1, 'primarily': 1, 'circulating': 1, 'variants': 1, 'concern': 1, 'vocs': 1, 'investigate': 1, 'cases': 1, 'salvador': 1, 'bahia': 1, 'brazil': 1, 'performed': 1, 'genomic': 1, 'monitoring': 1, 'estimate': 1, 'magnitude': 1, 'different': 1, 'nasopharyngeal': 1, 'swabs': 1, 'symptomatic': 1, 'asymptomatic': 1, 'fully': 1, 'n29': 1, 'varying': 1, 'age': 1, 'rtqpcr': 1, 'ct': 1, 'values': 1, 'â30': 1, 'subjected': 1, 'viral': 1, 'using': 1, 'nanopore': 1, 'technology': 1, 'analysis': 1, 'revealed': 1, 'omicron': 1, 'variant': 1, 'found': 1, '99': 1, '%': 1, 'one': 1, 'case': 1, 'due': 1, 'delta': 1, 'patients': 1, 'favorable': 1, 'clinical': 1, 'prognosis': 1, 'however': 1, 'within': 1, 'community': 1, 'become': 1, 'carriers': 1, 'aggravating': 1, 'factor': 1, 'dissemination': 1, 'neutralized': 1, 'vaccines': 1}, {'wonder': 1, 'heterologous': 1, 'vaccination': 1, 'rather': 1, 'property': 1, 'particular': 1, 'vaccines': 1, 'would': 1, 'curious': 1, 'see': 1, 'combinations': 1, 'well': 1}, {'interesting': 1, 'see': 1, 'high': 1, 'levels': 1, 'neutralization': 1, 'omicron': 1, 'adult': 1, 'boost': 1, 'study': 1, 'wonder': 1, 's': 1, 'due': 1, 'different': 1, 'immunogenicity': 1, 'vlps': 1, 'compared': 1, 'spike': 1, 'proteins': 1, 'alone': 1}, {'unless': 1, 'data': 1, 'age': 1, 'adjusted': 1, 'wont': 1, 'work': 1, 'starting': 1, 'point': 1}, {'similar': 1, 'study': 1, 'using': 1, 'uk': 1, 'participants': 1, 'first': 1, 'second': 1, 'shots': 1, '8': 1, 'weeks': 1, 'apart': 1, '?': 1}, {'8month': 1, 'mark': 1, 'sweden': 1, 'adult': 1, 'vaccination': 1, 'rate': 1, '80': 1, '%': 1, 'look': 1, 'odd': 1, 'suppose': 1, 'could': 1, 'confounding': 1, 'bias': 1, 'like': 1, 'maybe': 1, 'vaccinated': 1, 'individuals': 1, 'expose': 1, 'pathogen': 1, 'consider': 1, 'pandemic': 1, 'part': 1, 'lot': 1, 'covid19': 1, 'restrictions': 1, 'also': 1, 'apply': 1, 'factor': 1, 'well': 1}, {'m': 1, 'still': 1, 'unsure': 1, 'whether': 1, 'omicron': 1, 'overall': 1, 'better': 1, 'worse': 1, 'delta': 1, 'considering': 1, 'fact': 1, 'much': 1, 'contagious': 1, 'hope': 1, 'right': 1}, {'ok': 1, 'case': 1, 'would': 1, 'worth': 1, 'avoid': 1, 'infection': 1, 'hold': 1, 'bit': 1, 'longer': 1, 'quite': 1, 'hard': 1, '10r': 1, 'yeah': 1}, {'pfizer': 1, 'seems': 1, 'notified': 1, 'fda': 1}, {'fda': 1, 'ever': 1, 'approve': 1, 'vaccine': 1, 'trial': 1, 'run': 1, 'outside': 1, 'us': 1, 'modern': 1, 'day': 1, '?': 1}, {'mean': 1, 'kids': 1, 'age': 1, '511': 1, 'recently': 1, 'got': 1, 'two': 1, 'jabs': 1, '?': 1}, {'willing': 1, 'get': 1, 'vaccinated': 1, 'part': 1, 'study': 1}, {'iäôm': 1, 'sure': 1, 'possible': 1, 'get': 1, 'general': 1, 'population': 1, 'understand': 1, 'estimate': 1, 'risk': 1, 'host': 1, 'cognitive': 1, 'biases': 1, 'work': 1, 'understanding': 1, 'wonäôt': 1, 'rehearse': 1, 'newspapers': 1, 'written': 1, '6th': 1, 'grade': 1, 'level': 1, 'lower': 1, 'reason': 1, 'stood': 1, '1': 1, 'diverse': 1, 'especially': 1, 'negative': 1, 'narratives': 1, 'compelling': 1, 'undecideds': 1, '2': 1, 'smaller': 1, 'pages': 1, 'underestimated': 1, 'provaccination': 1, 'groups': 1, '3': 1, 'networks': 1, 'localwithglobal': 1, 'involved': 1, 'successful': 1, 'antivaccination': 1, '4': 1, 'mentioned': 1, 'explicitly': 1, 'guess': 1, 'part': 1, 'happens': 1, 'result': 1, 'facebooks': 1, 'äúhigh': 1, 'engagementäù': 1, 'algorithms': 1, 'push': 1, 'controversial': 1, 'content': 1, 'gets': 1, 'clicks': 1, 'think': 1, 'coming': 1, 'stories': 1, 'people': 1, 'without': 1, 'statistically': 1, 'important': 1, 'anecdotes': 1, 'eg': 1, 'polio': 1, 'science': 1, 'heroes': 1, 'fear': 1, 'anger': 1, 'generating': 1, 'always': 1, 'going': 1, 'engagement': 1, 'news': 1, 'editors': 1, 'äúif': 1, 'bleeds': 1, 'leadsäù': 1, 'seen': 1, 'lot': 1, 'psych': 1, 'research': 1, 'well': 1, 'respond': 1, '?': 1, 'would': 1, 'personally': 1, 'like': 1, 'see': 1, 'legislation': 1, 'pushing': 1, 'high': 1, 'gather': 1, 'uk': 1, 'working': 1, 'towards': 1}, {'https': 1, 'wwwnaturecomarticlesd41587021000253': 1}, {'one': 1, 'interesting': 1, 'tidbit': 1, 'level': 1, 'protection': 1, 'following': 1, 'previous': 1, 'infection': 1, '532': 1, '%': 1, 'omicron': 1, '887': 1, 'delta': 1, 'greater': 1, 'two': 1, 'doses': 1, 'vaccine': 1, 'reach': 1, 'levels': 1, 'attained': 1, 'never': 1, 'natural': 1, 'received': 1, 'third': 1, 'dose': 1, 'boosters': 1, 'boosted': 1, 'infected': 1, 'nonvaccinated': 1, '2': 1, 'guess': 1, 's': 1, 'surprising': 1}, {'abstract': 1, 'background': 1, 'male': 1, 'patients': 1, 'ages': 1, '12äì17': 1, 'years': 1, 'elevated': 1, 'risk': 1, 'mrna': 1, 'vaccinationassociated': 1, 'myopericarditis': 1, 'riskbenefit': 1, 'analysis': 1, 'first': 1, 'second': 1, 'doses': 1, 'vaccination': 1, 'adolescent': 1, 'boys': 1, 'health': 1, 'status': 1, 'history': 1, 'sarscov2': 1, 'infection': 1, 'performed': 1, 'methods': 1, 'using': 1, 'vaccine': 1, 'adverse': 1, 'event': 1, 'reporting': 1, 'system': 1, 'vaers': 1, 'identified': 1, 'bnt162b2': 1, 'pfizerbiontech': 1, 'occurrence': 1, 'according': 1, 'cdc': 1, 'criteria': 1, 'main': 1, 'outcomes': 1, 'follows': 1, '1': 1, 'postvaccination': 1, 'crude': 1, 'incidence': 1, 'adolescents': 1, 'aged': 1, '12äì15': 1, '16äì17': 1, '2': 1, 'two': 1, 'analyses': 1, 'age': 1, 'sex': 1, 'comorbidity': 1, 'variant': 1, 'results': 1, 'cases': 1, 'n': 1, '253': 1, 'included': 1, '129': 1, 'dose': 1, '124': 1, '869': 1, '%': 1, 'hospitalized': 1, 'per': 1, 'million': 1, '1622': 1, '930': 1, 'respectively': 1, 'weighing': 1, 'covid19': 1, 'hospitalization': 1, 'delta': 1, 'suggests': 1, 'among': 1, '12äì17yearolds': 1, 'twodose': 1, 'uniformly': 1, 'favourable': 1, 'nonimmune': 1, 'girls': 1, 'prior': 1, 'comorbidities': 1, 'even': 1, 'one': 1, 'carried': 1, 'benefit': 1, 'international': 1, 'estimates': 1, 'setting': 1, 'omicron': 1, 'may': 1, 'protective': 1, 'children': 1, 'appear': 1, 'confer': 1, 'additional': 1, 'population': 1, 'level': 1, 'conclusions': 1, 'findings': 1, 'strongly': 1, 'support': 1, 'individualized': 1, 'paediatric': 1, 'strategies': 1, 'weigh': 1, 'protection': 1, 'severe': 1, 'disease': 1, 'vs': 1, 'risks': 1, 'vaccineassociated': 1, 'research': 1, 'needed': 1, 'nature': 1, 'implications': 1, 'effect': 1, 'well': 1, 'immunization': 1, 'reduce': 1, 'harms': 1, 'overall': 1, 'lowrisk': 1, 'cohort': 1}, {'question': 1, '1': 1, 'start': 1, 'reading': 1, 'yewdell': 1, 's': 1, 'review': 1, 'article': 1, 'https': 1, 'journalsplosorgplospathogensarticle': 1, '?': 1, 'id101371journalppat1009509': 1, 'excellent': 1, 'idea': 1, 'case': 1}, {'introduced': 1, 'vaccines': 1, 'created': 1, 'confusion': 1, 'normally': 1, '2nd': 1, '3rd': 1, 'dose': 1, 'would': 1, 'called': 1, 'booster': 1, 'doses': 1, 'using': 1, '1st': 1, 'much': 1, 'less': 1, 'ambiguous': 1, 'understand': 1, 'mean': 1, 'difference': 1, 'moderna': 1, 's': 1, 'quite': 1, 'high': 1, 'reduced': 1, 'half': 1, 'safety': 1, 'still': 1, 'gave': 1, 'option': 1, 'get': 1, 'full': 1, 'immunocompromised': 1, 'people': 1, 'could': 1, 'benefit': 1, 'stronger': 1, 'reaction': 1, 'since': 1, 'cancer': 1, 'patients': 1, 'eligible': 1, 'nt': 1, 'look': 1, 'like': 1, 'talk': 1, 'specifically': 1, 'think': 1, 'distinction': 1, 'irrelevant': 1, 'case': 1, 'point': 1, 'consensus': 1, 'start': 1, 'likely': 1, 'longer': 1, 'taken': 1, 'account': 1, 'current': 1, 'research': 1}, {'anyone': 1, 'else': 1, 'thinks': 1, 'tcells': 1, 'far': 1, 'ignored': 1, '?': 1}, {'anything': 1, 'delta': 1, '6970': 1, 'ba1': 1, 'vs': 1, 'ba2': 1, 'deletion': 1, 'note': 1, 'also': 1, 'occured': 1, 'alpha': 1, 'variant': 1}, {'s': 1, 'simple': 1, 'technically': 1, 'variants': 1, 'sublineages': 1, 'initial': 1, 'variant': 1, 'nt': 1, 'vaccines': 1, 'based': 1, 'effective': 1, '?': 1, 'ba2': 1, 'already': 1, 'similar': 1, 'amount': 1, 'mutations': 1, 'compared': 1, 'original': 1, 'omicron': 1, 'alpha': 1, 'delta': 1, 'unable': 1, 'get': 1, 'immunity': 1, 'might': 1, 'also': 1, 'able': 1, 'protect': 1, 'author': 1, 'said': 1, 'pace': 1, 'fast': 1, 'getting': 1, 'new': 1, 'due': 1, 'spreading': 1, 'much': 1, 'faster': 1, 'definitely': 1, 'unclear': 1, 'going': 1, 'immune': 1, 'evading': 1, 'coming': 1, 'soon': 1, 'public': 1, 'place': 1, 'near': 1, 'mean': 1, 'try': 1, 'course': 1}, {'animal': 1, 'models': 1, 'far': 1, 'remember': 1, 'sage': 1, 'advice': 1, 'clinical': 1, 'trial': 1, 'veterans': 1, 'mice': 1, 'lie': 1, 'apes': 1, 'exaggerate': 1}, {'far': 1, 'understood': 1, 'technical': 1, 'article': 1, 'results': 1, 'regard': 1, 'pfizer': 1, 'astrazeneca': 1, 'tests': 1, 'means': 1, 'result': 1, 'applied': 1, 'vaccine': 1, 'variants': 1, 'since': 1, 'based': 1, 'working': 1, 'principles': 1, '?': 1, 'missed': 1, 'entirely': 1, 'point': 1}, {'us': 1, 'doctors': 1, 'already': 1, 'able': 1, 'prescribe': 1, 'additional': 1, 'boosters': 1, 'offlabel': 1, 'since': 1, 'pfizer': 1, 'vaccine': 1, 'officially': 1, 'approved': 1, 'least': 1, 'older': 1, 'age': 1, 'groups': 1, '?': 1}, {'wonder': 1, 'might': 1, 'utility': 1, 'pursuing': 1, 'anyways': 1, 'assumption': 1, 'next': 1, 'problematic': 1, 'variant': 1, 'descendent': 1, 'omicron': 1, 'lineage': 1, '?': 1, 'words': 1, 'may': 1, 'little': 1, 'gain': 1, 'directly': 1, 'since': 1, 'shots': 1, 'update': 1, 'vaccine': 1, 'code': 1, 'dominant': 1, 'protective': 1, 'immuneevasive': 1, 'descendants': 1, 'shot': 1, 's': 1, 'still': 1, 'based': 1, 'wildtype': 1, 'strain': 1, 'two': 1, 'years': 1, 'ago': 1}, {'math': 1, 'gave': 1, '000001': 1, '%': 1}, {'interesting': 1, 'useful': 1, 'study': 1, 'course': 1, 'perhaps': 1, 'full': 1, 'story': 1, 'humans': 1}, {'rapid': 1, 'tests': 1, 'exact': 1, 'problem': 1, 'vaccines': 1, 'variants': 1, 'use': 1, 'rate': 1, 'false': 1, 'negatives': 1, 'low': 1, 'enough': 1, 'appears': 1, 'case': 1, 'current': 1, 'omicron': 1, 'variant': 1, 'hopium': 1, 'doomed': 1, 'get': 1, 'longcovid': 1, 'unless': 1, 'develop': 1, 'better': 1, 'vaccine': 1, '90': 1, '%': 1, 'infection': 1}, {'well': 1, 'considering': 1, 'omicron': 1, 'higher': 1, 'affinity': 1, 'ace2': 1, 'delta': 1, 'endothelial': 1, 'dysfunction': 1, 'one': 1, 'prevalent': 1, 'problems': 1, 'long': 1, 'covid': 1}, {'need': 1, 'read': 1, 'science': 1, 'short': 1, 'synthesis': 1, 'paxlovid': 1, 's': 1, 'precursor': 1, 'reagents': 1, 'badly': 1, 'needed': 1, 'reaction': 1, 'step': 1, 'documented': 1, 'mass': 1, 'production': 1, 'difficult': 1, 're': 1, 'working': 1}, {'know': 1, 'still': 1, 'would': 1, 'nice': 1, 'include': 1, 'regimes': 1, 'used': 1, 'omicron': 1, 'version': 1, 'dose': 1, '2': 1, '1': 1, 'least': 1, 'demonstrate': 1, 'efforts': 1, 'actually': 1, 'matter': 1, 'comes': 1, 'protection': 1, 'delta': 1, 'macaques': 1, 'unvaccinated': 1, 'undervaccinated': 1, 'people': 1, 'clear': 1, 'information': 1, 'different': 1, 'versions': 1, 'really': 1, 'vaccination': 1, 'opposed': 1, 'disease': 1}, {'already': 1, 'taken': 1, 'account': 1, 'compared': 1, 'unvaccinated': 1, 'person': 1, 'read': 1, 'efficacy': 1, 'effectiveness': 1, 'protection': 1, 'mean': 1, 'https': 1, 'wwwwhointnewsroomfeaturestoriesdetailvaccineefficacyeffectivenessandprotection': 1, 'study': 1, 'discussed': 1, 'oldredditcomrcovid19commentsrrz28zvaccine_effectiveness_against_hospital_admission': 1, 'estimated': 1, 'vaccine': 1, 'ad26cov2s': 1, 'booster': 1, '69': 1, '092': 1, 'hcw': 1, 'individuals': 1, 'enrolled': 1, 'managed': 1, 'care': 1, 'organization': 1, 'using': 1, 'test': 1, 'negative': 1, 'design': 1, 'covid19': 1, 'admission': 1, 'omicron': 1, 'period': 1, '15': 1, 'november': 1, '20': 1, 'december': 1, '2021': 1, 'adjusting': 1, 'confounders': 1, 'observed': 1, 'hospitalisation': 1, 'increased': 1, 'time': 1, 'since': 1, 'dose': 1, '63': 1, '%': 1, '95': 1, 'ci': 1, '3181': 1, '84': 1, '6792': 1, '85': 1, '5495': 1, '013': 1, 'days': 1, '1427': 1, '12': 1, 'months': 1, 'postboost': 1}, {'seems': 1, 've': 1, 'never': 1, 'heard': 1, 'case': 1, 'studies': 1}, {'short': 1, 'answer': 1}, {'s': 1, 'kind': 1, 'depressing': 1, 'bad': 1, 'people': 1, 'reading': 1, 'm': 1, 'including': 1, 'means': 1, 'excluded': 1}, {'h1n1': 1, 'nt': 1, 'linear': 1, 'evolution': 1, 'novel': 1, 'virus': 1, 'new': 1, 'antigen': 1, 'caused': 1, '2009': 1, 'pandemic': 1}, {'idea': 1, 'long': 1, 'postimmunization': 1, '?': 1, 'immediately': 1, 'point': 1, 'make': 1, 'difference': 1}, {'studies': 1, 'like': 1, 'typically': 1, 'take': 1, 'account': 1, 'vaccinated': 1, 'people': 1, 'previously': 1, 'covid': 1, '?': 1, 'relevant': 1, 'possible': 1, 'meaningfully': 1}, {'usually': 1, 'moderna': 1, 'places': 1, 'half': 1, 'dose': 1, 'think': 1, 'using': 1, 'stronger': 1, 'begin': 1, 'based': 1, 'actual': 1, 'data': 1, 'around': 1, 'efficacy': 1, 'side': 1, 'effects': 1, 'least': 1, 's': 1, 'canada': 1, 'https': 1, 'wwwcanadacaenhealthcanadanews202111healthcanadaauthorizestheuseofthemodernaspikevaxcovid19vaccineasaboostershothtml': 1, 'nt': 1, 'know': 1, 'study': 1, 'looked': 1, 'even': 1, 'vaccine': 1}, {'discussion': 1, 'cite': 1, 'recent': 1, 'study': 1, 'shows': 1, 'trend': 1, 'toward': 1, 'less': 1, 'nab': 1, 'generation': 1, 'additional': 1, 'booster': 1, 'w': 1, 'mrna': 1, '1273': 1, 'seems': 1, 'line': 1, 'results': 1, 'https': 1, 'wwwmedrxivorgcontent1011012022021522270948v1fulltext': 1, 'neutralization': 1, 'titers': 1, '4th': 1, 'dose': 1, 'slightly': 1, 'higher': 1, '3rd': 1, 's': 1, 'towards': 1, 're': 1, 'substantially': 1, 'increased': 1, 'unlike': 1, 'compared': 1, '2nd': 1, 'vaccines': 1, 'worrying': 1, 'simply': 1, 'suggest': 1, 'need': 1, '3': 1, 'doses': 1, 'achieve': 1, 'peak': 1, 'humoral': 1, 'immunity': 1, 'subsequent': 1, 'bring': 1, 'back': 1, 'improve': 1, 'risk': 1, 'shifting': 1, 'response': 1, 'away': 1, 'spike': 1, 'antigen': 1}, {'missing': 1, 'theyäôre': 1, 'coming': 1, 'waning': 1, 'vaccine': 1, 'effectiveness': 1, '?': 1, 'canäôt': 1, 'seem': 1, 'find': 1, 'interval': 1, 'saying': 1, 'example': 1, '3': 1, 'doses': 1, 'moderna': 1, 'wanes': 1, '75': 1, '%': 1, '65': 1, 'anybody': 1, 'shine': 1, 'light': 1, 'thanks': 1}, {'mixed': 1, 'cocktail': 1, 'seems': 1, 'work': 1, 'great': 1, 'specific': 1, 'omicron': 1, 'delta': 1, 'rbd': 1, 'vaccine': 1, 'protocols': 1, 'nt': 1, 'much': 1, 'howcome': 1, 'abstract': 1, 'adds': 1, 'bivalent': 1, 'rbdlnp': 1, 'hand': 1, 'generated': 1, 'antibody': 1, 'broadly': 1, 'neutralizing': 1, 'activity': 1, 'wildtype': 1, 'virus': 1, 'variants': 1, 'surprisingly': 1, 'similar': 1, 'crossprotection': 1, 'also': 1, 'shown': 1, 'deltaspecifc': 1, 'saying': 1, 'deltaspecific': 1, 'ones': 1, 'results': 1, 'nonomicron': 1, '?': 1, 're': 1, 'contradict': 1, 'clarify': 1}, {'according': 1, 'posted': 1, 'sub': 1, 'recently': 1, 'states': 1, '70': 1, '%': 1, 'hospitalization': 1, 'https': 1, 'wwwnejmorgdoifull101056nejmc2119270': 1}, {'abstract': 1, 'severe': 1, 'acute': 1, 'respiratory': 1, 'syndrome': 1, 'coronavirus': 1, '2': 1, 'sarscov2': 1, 'omicron': 1, 'variant': 1, 'sparked': 1, 'concern': 1, 'due': 1, 'fast': 1, 'spread': 1, 'unprecedented': 1, 'number': 1, 'mutations': 1, 'spike': 1, 'protein': 1, 'enables': 1, 'partially': 1, 'evade': 1, 'spikebased': 1, 'covid19': 1, 'vaccineinduced': 1, 'humoral': 1, 'immunity': 1, 'anticipation': 1, 'potential': 1, 'need': 1, 'vaccine': 1, 'generated': 1, 'ad26': 1, 'vector': 1, 'encoding': 1, 'ba1': 1, 'ad26cov2s529': 1, 'encodes': 1, 'prefusion': 1, 'stabilized': 1, 'similar': 1, 'current': 1, 'ad26cov2s': 1, 'wuhanhu1': 1, 'verified': 1, 'expression': 1, 'comparable': 1, 'immunogenicity': 1, 'evaluated': 1, 'naøve': 1, 'mice': 1, 'preimmunized': 1, 'hamsters': 1, 'elicited': 1, 'robust': 1, 'neutralizing': 1, 'antibodies': 1, 'delta': 1, 'b16172': 1, 'opposite': 1, 'observed': 1, 'preimmune': 1, 'vaccination': 1, 'resulted': 1, 'increases': 1, 'antibody': 1, 'titers': 1, 'increased': 1, 'data': 1, 'imply': 1, 'expand': 1, 'boost': 1, 'spikeprimed': 1, 'immune': 1, 'response': 1, 'protect': 1, 'distant': 1, 'variants': 1}, {'covid19äìassociated': 1, 'educ': 1, 'visits': 1, 'abstract': 1}, {'forget': 1, 'read': 1, 'might': 1, 'something': 1, 'npr': 1, 'often': 1, 'listening': 1, 'key': 1, 'vaccines': 1, 'prevent': 1, 'catching': 1, 'virus': 1, 'reduce': 1, 'chances': 1, 'seriousdeadly': 1, 'symptoms': 1, 'go': 1, 'hospital': 1, 'found': 1, 'https': 1, 'healthwusfusfedunprhealth20220221asboostershotprotectionswaneheresthelatestresearchona4thvaccinedose': 1}, {'public': 1, 'health': 1, 'recommendations': 1, 'practice': 1, 'mandates': 1, 'countries': 1, 'given': 1, 'without': 1, 'based': 1, 'data': 1, 'list': 1, 'that': 1, 'm': 1, 'strongly': 1}, {'nt': 1, 'make': 1, 'determination': 1, 'quote': 1, 'find': 1, 'evidence': 1, 'risk': 1, 'hospitalisation': 1, 'attendance': 1, 'symptom': 1, 'status': 1, 'omicron': 1, 'saying': 1, 'exactly': 1, 'said': 1, 'stating': 1, 'no': 1, 'simply': 1, 'statement': 1, 'exacy': 1, 'not': 1, 're': 1, 'inferring': 1, 'pronouncement': 1, 'difference': 1, 'severity': 1, 'claimed': 1}, {'disappointing': 1, 'seems': 1, 'single': 1, 'dose': 1, 'omicrontargeted': 1, 'vaccines': 1, 'recall': 1, 'seeing': 1, 'speculation': 1, '2': 1, 'doses': 1, 'vaccine': 1, 'ideal': 1, 'consider': 1, 'effort': 1, 'produce': 1, 'roll': 1, 'especially': 1, 'considering': 1, 'booster': 1, 'uptake': 1, 'low': 1, 'still': 1, 's': 1, 'least': 1, 'hope': 1}, {'sure': 1, 'nt': 1, 'mean': 1, 'decline': 1, 'booster': 1, 'pfizer': 1, '10': 1, 'weeks': 1, '?': 1, 'talking': 1, 'second': 1, 'dose': 1, 'half': 1, 'size': 1, 'think': 1, 'peopel': 1, 'getting': 1, '3rd': 1, 'shot': 1, 'already': 1, 'august': 1, 'reading': 1, '12': 1, 'anti': 1, 'body': 1, 'levels': 1, 'spike': 1}, {'s': 1, 'really': 1, 'shocking': 1, 'different': 1, 'estimates': 1, 'across': 1, 'regions': 1, 'depending': 1, 'demographics': 1, 'vaccinated': 1, 'vs': 1, 'unvaccinated': 1, 'sharp': 1, 'drop': 1, 'casenegative': 1, 'measured': 1, 'efficacy': 1, 'delta': 1, 'us': 1, 'exact': 1, 'opposite': 1, 'uk': 1, 'hsa': 1, 'confounding': 1, 'factors': 1, 'seem': 1, 'make': 1, 'studies': 1, 'longer': 1, 'useful': 1, 're': 1}, {'1': 1, 'humans': 1, 'nt': 1, 'tend': 1, 'hold': 1, 'onto': 1, 'antibodies': 1, 'general': 1, 'individual': 1, 'last': 1, 'long': 1, 's': 1, 'metabolically': 1, 'expensive': 1, 'keep': 1, 'making': 1, 'things': 1, 'regularly': 1, 'exposed': 1}, {'accept': 1, 'breakthrough': 1, 'infections': 1, 'going': 1, 'happen': 1, 'memory': 1, 'b': 1, 'cells': 1, 'time': 1, 'stop': 1, 'infection': 1, 'becoming': 1, 'severe': 1, 'covid': 1, 'repeats': 1, 'every': 1, 'year': 1, 'divides': 1, 'much': 1, 'test': 1, 'detect': 1, 'accumulative': 1, 'damage': 1, 'edit': 1, 'getting': 1, 'downvoted': 1, '?': 1, 'often': 1, 'virusäôs': 1, 'plentiful': 1, 'progeny': 1, 'punish': 1, 'good': 1, 'deed': 1, 'cell': 1, 'produced': 1, 'lysing': 1, 'äî': 1, 'punching': 1, 'holes': 1, 'outer': 1, 'membrane': 1, 'busting': 1, 'destroying': 1, 'process': 1, 'enveloped': 1, 'viruses': 1, 'escape': 1, 'alternative': 1, 'called': 1, 'budding': 1, 'whereby': 1, 'wrap': 1, 'piece': 1, 'infected': 1, 'diffuse': 1, 'celläôs': 1, 'without': 1, 'structurally': 1, 'damaging': 1, 'even': 1, 'birthed': 1, 'myriad': 1, 'baby': 1, 'left': 1, 'fatally': 1, 'weakened': 1, 'https': 1, 'stanmedstanfordedu2020issue2howcoronavirusdestroyscellstreatmentshtml': 1, 'already': 1, 'significantly': 1, 'lowered': 1, 'life': 1, 'expectancy': 1, 'guarantee': 1, 'yearly': 1, 'bout': 1, 'lower': 1, 'maybe': 1}, {'healthcare': 1, 'workers': 1, 'doubt': 1, 'one': 1, 'person': 1, 'infecting': 1, '20': 1}, {'plenty': 1, 'studies': 1, 'subject': 1, 'exercise': 1, 'done': 1, 'injection': 1, 'usually': 1, 'armweight': 1, 'exercises': 1, 'portable': 1, 'easy': 1, 'anywhere': 1}, {'nt': 1, 'israel': 1, 'concluding': 1, 'dose': 1, '4': 1, 'holding': 1, '?': 1}, {'serious': 1, 'issues': 1, 'term': 1, 'viral': 1, 'load': 1, 'assay': 1, 'nt': 1, 'culturebased': 1, 'plaque': 1, 'focus': 1, 'tcid50': 1, 'take': 1, 'issue': 1, 'use': 1, 'seen': 1, 'recent': 1, 'swiss': 1, 'study': 1, 'ct': 1, 'value': 1, 'well': 1, 'correlated': 1, 'actual': 1, 'infectious': 1, 'virus': 1, 'infections': 1, 'vaccinated': 1, 'people': 1, 'produce': 1, 'markedly': 1, 'reduced': 1, 'number': 1, 'ffu': 1, 'respect': 1, 'unvaccinated': 1, 'even': 1, 'pcr': 1, 'values': 1, 'similar': 1, 'two': 1, 'years': 1, 'want': 1, 'actually': 1, 'see': 1, 'culture': 1, 'data': 1}, {'kids': 1, 'vaccinated': 1, 'subsequently': 1, 'infected': 1, 'covid': 1, '?': 1}, {'rate': 1, 'itäôs': 1, 'spreading': 1, 'epidemiological': 1, 'modelling': 1, 'iäôve': 1, 'seen': 1, 'least': 1, 'country': 1, 'specific': 1, 'level': 1, 'indicated': 1, 'probably': 1, 'wouldnäôt': 1, 'take': 1, 'long': 1, 'infact': 1, 'vast': 1, 'majority': 1, 'individuals': 1}, {'resultsäì': 1, 'microscopic': 1, 'examination': 1, 'revealed': 1, 'features': 1, 'resembling': 1, 'catecholamineinduced': 1, 'injury': 1, 'typical': 1, 'myocarditis': 1, 'pathology': 1, 'sounds': 1, 'like': 1, 'major': 1, 'finding': 1, 'supports': 1, 'vaccine': 1, 'coronavirus': 1, 'contributing': 1, 'factor': 1, 'thoughts': 1, '?': 1}, {'mention': 1, 'asymptomatic': 1, 'infection': 1, 'purpose': 1, 'policy': 1, 'mitigation': 1, 'seems': 1, 'point': 1, 're': 1, 'making': 1, 'ca': 1, 'nt': 1, 'tell': 1, 'someone': 1, 'going': 1, 'infectious': 1, 'based': 1, 'vaccination': 1, 'status': 1, 'even': 1, 'symptomology': 1, 'thus': 1, 'argument': 1, 'npi': 1, 'beyond': 1}, {'another': 1, 'illustration': 1, 'different': 1, 'omicron': 1, 'wt': 1, 'based': 1, 'know': 1, 'iäôm': 1, 'shocked': 1, 'omicrononly': 1, 'spike': 1, 'doesnäôt': 1, 'great': 1, 'antibodies': 1, 'key': 1, 'thing': 1, 'watch': 1, 'next': 1, 'days': 1, 'response': 1, 'like': 1, 'nonnaive': 1, 'individuals': 1, 'iäôll': 1, 'watching': 1, 'space': 1}, {'150': 1, 'double': 1, 'vaccine': 1, 'low': 1, 'stopping': 1, 'virus': 1, '?': 1}, {'omicron': 1, 'long': 1, 'covid': 1, '?': 1}, {'iäôm': 1, 'confused': 1, 'paper': 1, 'says': 1, 'myocarditis': 1, 'likely': 1, 'covid': 1, 'mrna': 1, 'vaccine': 1, 'adenovirus': 1, 'even': 1, 'suggests': 1, 'increase': 1, '12': 1, 'cases': 1, 'per': 1, 'million': 1, 'doses': 1, 'opposed': 1, 'unvaccinated': 1, 'individuals': 1, 'anyone': 1, 'get': 1, 'idea': 1, 'vaccines': 1, 'bad': 1, '?': 1}, {'would': 1, 'combination': 1, 'vaccinations': 1, 'viral': 1, 'exposures': 1, 'play': 1, '?': 1}, {'would': 1, 'imagine': 1, 'reasoning': 1, 'goes': 1, 'get': 1, 'vaccine': 1, 'point': 1, 'still': 1, 'catch': 1, 'virus': 1, 'people': 1, 'change': 1, 'minds': 1, 's': 1, 'one': 1, 'year': 1, 'since': 1, 'approval': 1, 'nt': 1, 'caused': 1, 'mass': 1, 'death': 1, 'anything': 1, 'see': 1, 'little': 1, 'risk': 1, 'reward': 1}, {'wonder': 1, 'durable': 1, 'previous': 1, 'study': 1, 'qatar': 1, 'efficacy': 1, 'infection': 1, 'went': 1, '0': 1, 'eventually': 1, 'https': 1, 'wwwnejmorgdoifull101056nejmoa2114114': 1, 'could': 1, 'never': 1, 'find': 1, 'explanation': 1, 'maybe': 1, '3': 1, 'week': 1, 'interval': 1, 'us': 1, 'repeated': 1, '512': 1, 'discussion': 1, 'really': 1, 'one': 1, 'studies': 1, 'made': 1, 'realize': 1, 're': 1, 'want': 1, 'understand': 1, 'immunity': 1, 'ie': 1, 's': 1, 'actually': 1, 'impossible': 1, 'without': 1, 'expertise': 1, 'health': 1, 'authorities': 1, 'almost': 1, 'experts': 1, 'wanted': 1, 'touch': 1, '10': 1, 'foot': 1, 'pole': 1}, {'booster': 1, 'dose': 1, 'third': 1, 'normal': 1}, {'hospital': 1, 'yet': 1, 'get': 1, 'trying': 1, 'correct': 1, 'someone': 1, 'else': 1, 'study': 1, 's': 1, 'content': 1}, {'think': 1, 'authors': 1, 'article': 1, 'making': 1, 'similar': 1, 'mistake': 1, 'many': 1, 'political': 1, 'pundits': 1, 'sides': 1, 'tend': 1, 'make': 1, 'reduce': 1, 'complex': 1, 'issue': 1, 'two': 1, 'like': 1, 'politics': 1, 'actually': 1, 'possible': 1, 'views': 1, 'case': 1, 'vaccinations': 1, 'well': 1}, {'abstract': 1, 'highly': 1, 'mutated': 1, 'sarscov2': 1, 'omicron': 1, 'b11529': 1, 'variant': 1, 'shown': 1, 'evade': 1, 'substantial': 1, 'fraction': 1, 'neutralizing': 1, 'antibody': 1, 'responses': 1, 'elicited': 1, 'current': 1, 'vaccines': 1, 'encode': 1, 'wa12020': 1, 'spike': 1, 'immunogen': 1, 'resulting': 1, 'increased': 1, 'breakthrough': 1, 'infections': 1, 'reduced': 1, 'vaccine': 1, 'efficacy': 1, 'cellular': 1, 'immune': 1, 'particularly': 1, 'cd8': 1, 'cell': 1, 'likely': 1, 'critical': 1, 'protection': 1, 'severe': 1, 'disease': 1, 'show': 1, 'immunity': 1, 'induced': 1, 'crossreactive': 1, 'individuals': 1, 'received': 1, 'ad26cov2s': 1, 'bnt162b2': 1, 'demonstrated': 1, 'durable': 1, 'cd4': 1, 'showed': 1, 'extensive': 1, 'crossreactivity': 1, 'delta': 1, 'variants': 1, 'including': 1, 'central': 1, 'effector': 1, 'memory': 1, 'subpopulations': 1, 'median': 1, 'omicronspecific': 1, '8284': 1, '%': 1, 'wa12020specific': 1, 'data': 1, 'suggest': 1, 'may': 1, 'provide': 1, 'considerable': 1, 'despite': 1, 'reduction': 1}, {'flu': 1, 'vaccines': 1, 'year': 1, 'nt': 1, 'average': 1, 'necessary': 1, 'prevent': 1, 'severe': 1, 'illness': 1, 'long': 1, 'somewhat': 1, 'recent': 1, 'past': 1, 'couple': 1, 'decades': 1, '?': 1, 'history': 1, 'exposure': 1, 'vaccination': 1, 'risk': 1, 'group': 1}, {'think': 1, 'argument': 1, 'vaccine': 1, 'regards': 1, 'myocarditis': 1, 'lies': 1, 'within': 1, '40': 1, 'male': 1, 'age': 1, 'sex': 1, 'category': 1, 'large': 1, 'study': 1, 'posted': 1, 'subreddit': 1, 'showed': 1, 'males': 1, 'actually': 1, 'higher': 1, 'risk': 1, 'getting': 1, 'covid': 1, 'said': 1, 'vaccines': 1, 'worse': 1, 'others': 1, 's': 1, 'get': 1, 'vs': 1, 'vaccinated': 1}, {'data': 1, 'suggests': 1, 'vaccines': 1, 'overwhelmingly': 1, 'effective': 1, 'preventing': 1, 'hospitalization': 1, 'among': 1, 'children': 1, 'adults': 1, 'probably': 1, 'vaccinated': 1, 'hospitalized': 1, 'breakthrough': 1, 'covid19': 1, 'find': 1, 'statistically': 1, 'meaningful': 1, 'number': 1, 'specifically': 1, 'myocarditis': 1, 'one': 1, 'rarer': 1, 'symptoms': 1}, {'paper': 1, 'interesting': 1, 'studied': 1, 'compared': 1, 'asserted': 1, 'evidence': 1, 'vaccine': 1, 'developed': 1, 'inducing': 1, 'antibodies': 1, 'specific': 1, 'domain': 1, 'assay': 1, 'showing': 1, 'higher': 1, 'greater': 1, 'specificity': 1, 'however': 1, 'doesnäôt': 1, 'seem': 1, 'discuss': 1, 'utility': 1, 'broader': 1, 'range': 1, 'antibody': 1, 'binding': 1, 'targets': 1, 'comes': 1, 'infection': 1, 'fact': 1, 'lab': 1, 'study': 1, 'makes': 1, 'strong': 1, 'claim': 1, 'expected': 1, 'real': 1, 'world': 1, 'outcomes': 1, 'would': 1, 'interested': 1, 'others': 1, 'think': 1, 'methodology': 1}, {'one': 1, 'use': 1, 'antivirals': 1, 'age': 1, 'group': 1, 'risk': 1, 'profile': 1, 'low': 1}, {'think': 1, 'siren': 1, 'study': 1, 'ongoing': 1, 'thereäôs': 1, 'studies': 1, 'looked': 1, 'boosters': 1, 'linked': 1, 'one': 1, 'comment': 1}, {'abstract': 1, '____': 1, 'background': 1, 'protection': 1, 'offered': 1, 'five': 1, 'different': 1, 'forms': 1, 'immunity': 1, 'combining': 1, 'natural': 1, 'vaccine': 1, 'investigated': 1, 'sarscov2': 1, 'omicron': 1, 'symptomatic': 1, 'ba1': 1, 'infection': 1, 'ba2': 1, 'hospitalization': 1, 'death': 1, 'qatar': 1, 'december': 1, '23': 1, '2021': 1, 'february': 1, '21': 1, '2022': 1, 'methods': 1, 'six': 1, 'national': 1, 'matched': 1, 'testnegative': 1, 'casecontrol': 1, 'studies': 1, 'conducted': 1, 'estimate': 1, 'effectiveness': 1, 'bnt162b2': 1, 'pfizerbiontech': 1, 'mrna1273': 1, 'moderna': 1, 'due': 1, 'prior': 1, 'preomicron': 1, 'variants': 1, 'hybrid': 1, 'vaccination': 1, 'results': 1, '461': 1, '%': 1, '95': 1, 'ci': 1, '395519': 1, 'twodose': 1, 'negligible': 1, '11': 1, '7146': 1, 'nearly': 1, 'individuals': 1, 'received': 1, 'second': 1, 'dose': 1, 'several': 1, 'months': 1, 'earlier': 1, 'threedose': 1, '522': 1, '481559': 1, '551': 1, '509589': 1, '773': 1, '724814': 1, 'meanwhile': 1, 'showed': 1, 'strong': 1, '70': 1, 'severe': 1, 'critical': 1, 'fatal': 1, 'covid19': 1, 'similar': 1, 'levels': 1, 'patterns': 1, 'observed': 1, 'conclusions': 1, 'discernable': 1, 'differences': 1, 'effects': 1, 'versus': 1, 'resulting': 1, 'recent': 1, 'booster': 1, 'confers': 1, 'strongest': 1, 'either': 1, 'subvariant': 1, 'enhances': 1}, {'call': 1, 'disease': 1, 'induced': 1, 'instead': 1, 'natural': 1, 'immunity': 1, '?': 1, 'indications': 1, 'asymptomatic': 1, 'infection': 1, 'not': 1, 'induce': 1, 'full': 1, 'immune': 1, 'response': 1, 'probably': 1, 'strong': 1, 'enough': 1}, {'many': 1, 'words': 1, 'sift': 1, 'someone': 1, 'tell': 1, 'effectiveness': 1, '3rd': 1, 'shot': 1, 'pfizer': 1, 'long': 1, 'lasts': 1, '?': 1, 'specifically': 1, 'omicron': 1}, {'one': 1, 'possible': 1, 'explanation': 1, 'changes': 1, 'behavior': 1, 'greater': 1, 'risk': 1, 'taking': 1, 'vaccination': 1, 'another': 1, 'might': 1, 'simply': 1, 'small': 1, 'sample': 1, 'size': 1, 'multiple': 1, 'adjustment': 1, 'statistical': 1, 'analysis': 1, 'negative': 1, 'effectiveness': 1, 'estimated': 1, 'based': 1, 'total': 1, '112': 1, 'events': 1, 'fully': 1, 'adjusted': 1, 'included': 1, '14': 1, 'variables': 1, 'may': 1, 'look': 1, 'like': 1, 's': 1, 'much': 1, 'estimating': 1, 'effects': 1, 'esimate': 1, 'reliable': 1, 'explanations': 1, 'true': 1}, {'laymans': 1, 'terms': 1, 'vaccine': 1, 'administered': 1, 'via': 1, 'nose': 1, 'spray': 1, 'appears': 1, 'preferred': 1, 'strategy': 1, 'moving': 1, 'forward': 1, '?': 1}, {'area': 1, 'ongoing': 1, 'research': 1, 'broad': 1, 'outline': 1, 'seems': 1, 'understood': 1, 'though': 1, 'course': 1, 's': 1, 'always': 1, 'chance': 1, 'll': 1, 'learn': 1, 'something': 1, 'new': 1, 'shifts': 1, 'things': 1, 'significantly': 1, 'know': 1, 'germinal': 1, 'centers': 1, 'b': 1, 'cells': 1, 'trained': 1, 'iterate': 1, 'towards': 1, 'both': 1, 'produce': 1, 'best': 1, 'antibodies': 1, 'antigens': 1, 'observed': 1, 'and': 1, 'mutated': 1, 'random': 1, 'variation': 1, 'former': 1, 'sent': 1, 'lymph': 1, 'nodes': 1, 'become': 1, 'plasma': 1, 'make': 1, 'lots': 1, 'latter': 1, 'fed': 1, 'back': 1, 'training': 1, 'try': 1, 'find': 1, 'better': 1, 'also': 1, 'subset': 1, 'turned': 1, 'memory': 1, 'hang': 1, 'around': 1, 'future': 1, 'therefore': 1, 'produced': 1, 'bunch': 1, 'variations': 1, 'believed': 1, 'intended': 1, 'head': 1, 'start': 1, 'variants': 1, 'less': 1, 'confidence': 1, 'time': 1, 'dormant': 1, 'challenge': 1, 'immune': 1, 'system': 1, 'similar': 1, 'antigen': 1, 'happens': 1, 'leads': 1, 'recruiting': 1, 'naive': 1, 'process': 1, 'may': 1, 'creating': 1, 'd': 1, 'challenged': 1, 'previous': 1, 'still': 1, 'active': 1, 'think': 1, 'm': 1, 'getting': 1, 'vaguer': 1, 'parts': 1, 'current': 1, 'understanding': 1, 'one': 1, 'way': 1, 'another': 1, 'cause': 1, 'center': 1, 'activity': 1, 'means': 1, 'branched': 1, 'antibody': 1, 'giving': 1, 'sufficient': 1, 'amount': 1, '4': 1, 'months': 1, '?': 1, '6': 1, '8': 1, 'even': 1, 'comes': 1, 'shortly': 1, 'greater': 1, 'breadth': 1}, {'reading': 1, 'authors': 1, 'pair': 1, 'studies': 1, 'think': 1, 'yes': 1, 'benefit': 1, 'peptide': 1, 'vaccines': 1, 'developing': 1, 'modality': 1, 'theoretically': 1, 'expand': 1, 'tools': 1, 'fight': 1, 'disease': 1, 'biotech': 1, 'focus': 1, 'right': 1, 'seems': 1, 'stimulating': 1, 'tcells': 1, 'treat': 1, 'vaccinate': 1, 'cancer': 1, 'could': 1, 'applications': 1, 'well': 1, 'also': 1, 'antigens': 1, 'preferentially': 1, 'stimulate': 1, 'one': 1, 'type': 1, 'lymphocyte': 1, 'another': 1, 'help': 1, 'elucidate': 1, 'poorly': 1, 'understood': 1, 'areas': 1, 'immunology': 1, 'example': 1, 'believe': 1, 'questions': 1, 'explored': 1, 'whether': 1, 'tcell': 1, 'immunity': 1, 'sufficient': 1, 'prevent': 1, 'infection': 1, 'coronavirus': 1}, {'also': 1, 'obtain': 1, 'hybrid': 1, 'immunity': 1, 'via': 1, 'breakthrough': 1, 'infection': 1, 'unlikely': 1, 'anything': 1, 'resembling': 1, 'representative': 1, 'rather': 1, 'definition': 1, 'group': 1, 'going': 1, 'far': 1, 'larger': 1, 'proportion': 1, 'generated': 1, 'weak': 1, 'immune': 1, 'responses': 1, 'vaccines': 1, 'first': 1, 'place': 1, 'indeed': 1, 'would': 1, 'nt': 1, 'surprised': 1, 'see': 1, 'naive': 1, 'calculations': 1, 'taking': 1, 'account': 1, 'giving': 1, 'negative': 1, 'protection': 1}, {'ruled': 1, 'selective': 1, 'pressure': 1, 'vaccinated': 1, 'people': 1, '?': 1, 'blame': 1, 'social': 1, 'distancing': 1, 'enough': 1}, {'see': 1, 'wave': 1, 'pr': 1, 'claiming': 1, 'well': 1, 'actually': 1, 'nt': 1, 'supposed': 1, 'protect': 1, 'ways': 1, 've': 1, 'claimed': 1, 'primary': 1, 'purpose': 1, 'vaccines': 1, 'something': 1, 'smell': 1, 'right': 1, 'especially': 1, 'people': 1, 'estimating': 1, 'thresholds': 1, 'herd': 1, 'immunity': 1, 'beforehand': 1, 'citing': 1, 'reason': 1, 'low': 1, 'risk': 1, 'groups': 1, 'like': 1, 'kids': 1, 'young': 1, 'adults': 1, 'vaccinated': 1, 'obviously': 1, 'banking': 1, 'sterilising': 1, 'least': 1, 'partial': 1, 'longer': 1, 'lasting': 1, 'months': 1}, {'s': 1, 'press': 1, 'release': 1, 'vaccine': 1, 'manufacturer': 1, 'allow': 1, 'per': 1, 'sidebar': 1, 're': 1, 'fine': 1}, {'publicly': 1, 'ask': 1, 'pfizer': 1, 'submit': 1, 'first': 1, 'place': 1, 'failed': 1, 'trial': 1, '?': 1, 'caused': 1, 'lot': 1, 'unnecessary': 1, 'controversy': 1, 'erode': 1, 'public': 1, 'trust': 1, 'nt': 1, 'fda': 1, 'instead': 1, 'focused': 1, 'expediting': 1, 'eua': 1, 'covaxin': 1, 'given': 1, 'one': 1, 'already': 1, 'completed': 1, 'successful': 1, 'phase': 1, '2': 1, '3': 1, 'pediatric': 1, 'use': 1, 'ocugen': 1, 'filed': 1, 'three': 1, 'months': 1, 'ago': 1, 'now': 1, 'taken': 1, 'action': 1}, {'21': 1, 'working': 1, 'age': 1, 'people': 1, 'hospitalized': 1, 'omicron': 1, 'hardly': 1, 'evidence': 1, 'disagree': 1, 'vaccines': 1, 'work': 1, 'quite': 1, 'low': 1, 'effort': 1, 'contribution': 1, 'really': 1, 'isnäôt': 1, 'based': 1, 'paper': 1, 'fact': 1, 'paperäôs': 1, 'authors': 1, 'draw': 1, 'conclusion': 1, 'lack': 1, 'hospitalization': 1, 'due': 1, 'vaccination': 1}, {'papers': 1, 'keep': 1, 'talking': 1, 'viral': 1, 'load': 1, 'ignore': 1, 'fact': 1, 'majority': 1, 'dead': 1, 'noninfectious': 1, 'virus': 1, 'every': 1, 'paper': 1, 'actually': 1, 'cultured': 1, 'reported': 1, 'amount': 1, 'infectious': 1, 'lower': 1, 'vaccinated': 1, 'individuals': 1, 'https': 1, 'wwwredditcomrcovid19commentsp9j8rdvirological_characteristics_of_sarscov2_vaccine': 1, 'people': 1, 'need': 1, '10': 1, 'times': 1, 'culture': 1, 'live': 1, 'unvaccinated': 1, 'edit': 1, 'typo': 1}, {'pretty': 1, 'clear': 1, 'moving': 1, 'muscle': 1, 'injected': 1, 'good': 1, 'thing': 1}, {'layman': 1, 'asking': 1, 've': 1, 'reached': 1, 'point': 1, 'oas': 1, 'basically': 1, 'mean': 1, 'ca': 1, 'nt': 1, 'beat': 1, 'covid': 1, 'vaccines': 1, 'anymore': 1, '?': 1}, {'current': 1, 'advice': 1, 'light': 1, 'exercise': 1, 'covid': 1, 'influenza': 1, 'vaccination': 1, 'rather': 1, 'take': 1, 'easy': 1, 'joggers': 1, 'gym': 1, 'bunnies': 1, 'swimmers': 1, 'told': 1, 'lay': 1, 'next': 1, 'couple': 1, 'days': 1, 'coincidentally': 1, 'later': 1, 'day': 1, 'many': 1, 'already': 1, 'feeling': 1, 'effects': 1, 'immune': 1, 'system': 1, 'kicking': 1, 'paper': 1, 'understand': 1, 'right': 1, 'first': 1, 'bout': 1, 'within': 1, '50': 1, 'mins': 1}, {'doescan': 1, 'happen': 1, 'vaccinations': 1, 'well': 1, '?': 1, 'know': 1, 'complication': 1, 'viral': 1, 'infections': 1, 'would': 1, 'guess': 1, 'like': 1, 'myocarditis': 1, 'vaccine': 1, 'increases': 1, 'risk': 1, 'exposure': 1, 'infection': 1, 'vaccination': 1}, {'analysis': 1, 'done': 1, 'vaccines': 1, 'opposed': 1, 'jnj': 1, '?': 1, 'small': 1, 'minority': 1, 'people': 1, 'took': 1, 'signals': 1, 'heavily': 1, 'diluted': 1, 'mrna': 1}, {'datapresentation': 1, 'suggests': 1, 'myocarditis': 1, 'risk': 1, 'goes': 1, 'vaccine': 1, 'compared': 1, 'historical': 1, 'rates': 1, 'comparing': 1, '30': 1, 'day': 1, 'myoc': 1, 'vaccines': 1, 'infection': 1, '1': 1, 'year': 1, 'right': 1, 'comparison': 1, 'unvax': 1, 'chance': 1, 'covid': 1, 'extra': 1, 'us': 1, '20': 1, '%': 1, 'gotgetting': 1, 'general': 1, 'population': 1, 'means': 1, 'least': 1, 'get': 1, 'even': 1, '7': 1, 'would': 1, 'higher': 1, 'total': 1, 'vaccination': 1, 'still': 1, 'shot': 1, 'per': 1, 'getting': 1, '2': 1, 'shotsyear': 1, 'compare': 1, '14': 1, 'yet': 1, 'lead': 1, 'much': 1, 'long': 1, 'term': 1, 'negatives': 1, 'addition': 1, 'initial': 1, 'discomfortdeath': 1, 'shit': 1, 'happen': 1, 'weighted': 1, 'severity': 1, 'result': 1, 'vaccinated': 1, 'vs': 1, 'unvaxed': 1, 'excluding': 1, 'accidents': 1, 'may': 1, 'reason': 1, 'avoid': 1, 'booster': 1, 'shots': 1, 'going': 1, 'forward': 1, 'study': 1, 'nt': 1, 'give': 1, 'info': 1}, {'point': 1, 's': 1, 'obvious': 1, 'need': 1, 'change': 1, 'strategy': 1, '2019': 1, 'sequence': 1, 'good': 1, 'enough': 1}, {'pcr': 1, 'samples': 1, 'heart': 1, 'nt': 1, 'see': 1, 'testing': 1, 'would': 1, 'rule': 1, 'prior': 1, 'history': 1, 'covid': 1, 'infection': 1, '?': 1, 'look': 1, 'cdc': 1, 'website': 1, 'blood': 1, 'differentiate': 1, 'person': 1, 'one': 1, 'vaccinated': 1}, {'may': 1, 'matter': 1, 'lineage': 1, 'comes': 1, 'saying': 1, 'life': 1, 'finds': 1, 'way': 1, 'holds': 1, 'true': 1, 'itäôs': 1, 'fruitless': 1, 'battle': 1, 'trying': 1, 'stave': 1, 'non': 1, 'serious': 1, 'infections': 1, 'immune': 1, 'evasive': 1, 'necessarily': 1, 'follow': 1, 'lineages': 1, 'relationship': 1, 'somewhere': 1, 'line': 1, 'another': 1, 'omicron': 1, 'lineaged': 1, 'variant': 1, 'becomes': 1, 'previous': 1, 'variants': 1, 'vaccines': 1, 'nature': 1, 'different': 1, 'enough': 1, 'evolved': 1, 'parallel': 1, 'closer': 1, 'ancestral': 1, 'strain': 1, 'yet': 1, 'delta': 1, 'based': 1, 'effective': 1}, {'please': 1, 'excuse': 1, 'lazy': 1, 'trying': 1, 'find': 1, 'study': 1, 'comparable': 1, 'groups': 1, '?': 1, 'would': 1, 'imagine': 1, 'bc': 1, 'seems': 1, 'like': 1, 'thatäôs': 1, 'fair': 1, 'comparison': 1, 'vaccination': 1, 'rates': 1, 'much': 1, 'higher': 1, 'older': 1, 'health': 1, 'conditions': 1}, {'confidence': 1, 'interval': 1, 'wide': 1, 'enough': 1, 'drive': 1, 'truck': 1, 'add': 1, 'test': 1, 'negative': 1, 'study': 1, 'high': 1, 'degree': 1, 'seroprevalence': 1, 'control': 1, 'arm': 1, 'rate': 1, 'vaccination': 1, 'vulnerable': 1, 'think': 1, 'careful': 1, 'interpreting': 1, 'results': 1}, {'donäôt': 1, 'solid': 1, 'data': 1, 'yet': 1, 'patients': 1, 'require': 1, 'mechanical': 1, 'ventilation': 1, 'lower': 1, 'rates': 1, 'omicron': 1, 'might': 1, 'point': 1, 'towards': 1, 'theory': 1, 'think': 1, 'weäôll': 1, 'wait': 1, 'look': 1, 'harder': 1, 'complete': 1, 'answer': 1}, {'source': 1, '050': 1, 'cost': 1, 'figure': 1, '?': 1}, {'sure': 1, 'year': 1, 'boot': 1, 'https': 1, 'siteskriegerjhueduiaefiles202201aliteraturereviewandmetaanalysisoftheeffectsoflockdownsoncovid19mortalitypdf': 1, 's': 1, 'important': 1, 'note': 1, 'studies': 1, 'listed': 1, 'published': 1, 'may': 1, '1': 1, 'month': 1, 'lockdown': 1, 'usa': 1, 'november': 1, '7': 1, 'months': 1, '2020': 1, 'jhu': 1, 'study': 1, 'linked': 1, 'nearly': 1, '2': 1, 'years': 1, 'data': 1, 'draw': 1}, {'stop': 1, 'confidently': 1, 'wrong': 1, 'things': 1, 'whatever': 1, 'om': 1, 'specificity': 1, 'exists': 1, 'extremely': 1, 'likely': 1, 'effective': 1, 'sublineages': 1, 'ba2': 1, 'also': 1, 'taking': 1, 'gamble': 1, 'educated': 1, 'one': 1, 'omicron': 1, 'source': 1, 'significant': 1, 'variants': 1, 'least': 1, 'next': 1, 'waves': 1, 'good': 1, 'logic': 1}, {'abstract': 1, 'multisystem': 1, 'inflammatory': 1, 'syndrome': 1, 'children': 1, 'misc': 1, 'hyperinflammatory': 1, 'state': 1, 'occurs': 1, 'severe': 1, 'acute': 1, 'respiratory': 1, 'coronavirus': 1, '2': 1, 'sarscov2': 1, 'infection': 1, 'present': 1, 'cases': 1, 'vaccination': 1, '1': 1, 'patient': 1, 'evidence': 1, 'recent': 1, 'findings': 1, 'suggest': 1, 'modulates': 1, 'pathogenesis': 1}, {'nt': 1, 'say': 1, 'great': 1, 'news': 1, 'said': 1, 'reduced': 1, 'immune': 1, 'escape': 1, 'obviously': 1, 'greater': 1, 'inherent': 1, 'transmissibility': 1, 'problem': 1, 'walk': 1, 'chew': 1, 'gum': 1, 'time': 1, 'recognizing': 1, 'good': 1, 'detract': 1, 'b': 1, 'bad': 1}, {'speculation': 1, 'spaced': 1, 'boosters': 1, 'lead': 1, 'antibodies': 1, 'much': 1, 'resistant': 1, 'mutation': 1}, {'yup': 1, 'vaccine': 1, 'vs': 1, 'covid': 1, 'false': 1, 'dichotomy': 1, 'since': 1, 'likely': 1, 'catch': 1, 'multiple': 1, 'breakthroughs': 1, 'reinfections': 1, 'next': 1, 'several': 1, 'years': 1}, {'males': 1, '40': 1, 'moderna': 1, 'and': 1, 'pfizer': 1, '2nd3rd': 1, 'dose': 1, 'causes': 1, 'significantly': 1, 'myocarditis': 1, 'vaccines': 1, 'good': 1, 'used': 1, 'right': 1, 'way': 1, 'people': 1, 'encouraging': 1, 'fully': 1, 'vaxxed': 1, 'young': 1, 'men': 1, 'potentially': 1, 'recent': 1, 'breakthroughs': 1, 'get': 1, 'boosted': 1, 'could': 1, 'possibly': 1, 'harm': 1, 'mandating': 1, 'even': 1, 'harder': 1, 'justify': 1, 'light': 1, 'new': 1, 'study': 1, 'edit': 1, 'misused': 1, 'word': 1, 'referring': 1, 'difference': 1, 'point': 1, 'estimates': 1, 'statistical': 1, 'significance': 1}, {'better': 1, 'education': 1, 'ä': 1, 'longterm': 1, 'risks': 1, 'people': 1, 'argued': 1, 'back': 1, 'started': 1, 'vaccinating': 1, 'children': 1, 'mayyyybe': 1, '3': 1, 'deaths': 1, 'somehow': 1, 'worse': 1, 'hundreds': 1, 'thousands': 1, 'for': 1, 'sure': 1, 'trolley': 1, 'problem': 1, 'preempts': 1, 'serious': 1, 'weighing': 1, 'risk': 1, 'matter': 1, 'public': 1, 'dialog': 1}, {'study': 1, 'tested': 1, 'neutralising': 1, 'antibodies': 1, 'blood': 1, 'quite': 1, 'specific': 1}, {'sub': 1, 'routinely': 1, 'brigaded': 1, 'people': 1, 'really': 1, 'want': 1, 'vaccines': 1, 'dangerous': 1, 'young': 1, 'males': 1}, {'this': 1, 'study': 1, 'looked': 1, 'inactivated': 1, 'sars279': 1, 'cov2': 1, 'vaccines': 1, 'discussion': 1, 'cite': 1, 'recent': 1, 'shows': 1, 'trend': 1, 'toward': 1, 'less': 1, 'nab': 1, 'generation': 1, 'additional': 1, 'booster': 1, 'w': 1, 'mrna': 1, '1273': 1, 'seems': 1, 'line': 1, 'results': 1, 'nt': 1, 'include': 1, 'anything': 1, 'spike': 1, 's': 1, 'unknown': 1, 'll': 1, 'also': 1, 'induce': 1, 'shift': 1, 'immune': 1, 'focus': 1, 'multiple': 1, 'boosts': 1, '____': 1, 'abstract': 1, 'mmwr': 1, 'reported': 1, 'effectiveness': 1, '3rd': 1, 'dose': 1, 'sarscov2': 1, 'vaccine': 1, 'waned': 1, 'quickly': 1, 'omicronpredominant': 1, 'period': 1, 'similarly': 1, 'substantial': 1, 'decline': 1, 'responses': 1, 'induced': 1, 'observed': 1, 'response': 1, 'fast': 1, 'waning': 1, 'great': 1, 'threat': 1, 'omicron': 1, 'variant': 1, 'concern': 1, 'voc': 1, 'frontline': 1, 'healthcare': 1, 'workers': 1, 'hcws': 1, '38': 1, 'previous': 1, 'cohort': 1, 'investigating': 1, 'first': 1, 'three': 1, 'doses': 1, 'participated': 1, 'current': 1, 'volunteered': 1, 'receive': 1, '4th': 1, 'homologous': 1, 'demonstrated': 1, 'safe': 1, 'capable': 1, 'recalling': 1, '6': 1, 'months': 1, 'however': 1, 'greater': 1, 'suppression': 1, 'induction': 1, 'overall': 1, 'neutralizing': 1, 'antibodies': 1, 'nabs': 1, 'targeting': 1, 'receptorbinding': 1, 'domain': 1, 'rbd': 1, 'found': 1, 'participants': 1, 'stronger': 1, 'result': 1, 'a': 1, 'stepwise': 1, 'elevation': 1, 'rbdnabs': 1, '1st': 1, 'vaccination': 1, 'achieved': 1, 'turning': 1, 'point': 1, 'peak': 1, 'level': 1, 'inferior': 1, 'accompanied': 1, 'reduced': 1, 'system': 1, 'shifted': 1, 'nucleocapsid': 1, 'protein': 1, 'np': 1, 'nterminal': 1, 'ntd': 1, 'although': 1, 'directed': 1, 'neutralization': 1, 'compensated': 1, 'loss': 1, 'ancestral': 1, 'virus': 1, 'due': 1, 'conformational': 1, 'change': 1, 'longitudinal': 1, 'clinical': 1, 'monitored': 1, 'every': 1, 'shaping': 1, 'relationship': 1, 'trajectory': 1, 'dynamics': 1, 'potency': 1, 'evolving': 1, 'data': 1, 'reveal': 1, 'could': 1, 'endlessly': 1, 'elevated': 1, 'heightened': 1, 'focusing': 1, 'one': 1, 'subunit': 1, 'together': 1, 'subunits': 1, 'would': 1, 'occur': 1, 'repeated': 1, 'thus': 1, 'updated': 1, 'diverse': 1, 'epitopes': 1, 'inducing': 1, 'vocs': 1, 'future': 1, 'direction': 1, 'boosters': 1}, {'interested': 1, 'part': 1, 'common': 1, 'symptoms': 1, 'muscle': 1, 'joint': 1, 'pain': 1, 'fatigue': 1, 'fever': 1, 'least': 1, 'loss': 1, 'taste': 1, 'smell': 1, 'one': 1, 'admitted': 1, 'hospital': 1, 'assume': 1, 'exposure': 1, 'sarscov2': 1, 'evening': 1, 'gathering': 1, 'incubation': 1, 'period': 1, 'short': 1, 'ranging': 1, '2': 1, '6': 1, 'days': 1, 'mean': 1, '324': 1, '95': 1, '%': 1, 'ci': 1, '287': 1, '360': 1, 'time': 1, 'resolution': 1, 'varied': 1, 'end': 1, 'followup': 1, 'five': 1, 'individuals': 1, 'still': 1, 'reported': 1, 'rest': 1, 'lasting': 1, '1': 1, '9': 1, 'median': 1, 'age': 1, '45': 1}, {'take': 1, 'account': 1, 'vaccinated': 1, 'still': 1, 'get': 1, 'covid': 1, 'another': 1, 'chance': 1, 'gbs': 1, '?': 1}, {'iäôd': 1, 'really': 1, 'like': 1, 'know': 1}, {'well': 1, 'particular': 1, 'vaccine': 1, 'nt': 1, 'introduce': 1, 'spikes': 1, 'instructs': 1, 'body': 1, 'produce': 1, 'unless': 1, 'm': 1, 'misunderstanding': 1, 're': 1, 'saying': 1, 'right': 1, 'mrna': 1, 'end': 1, 'result': 1, 'essentially': 1, 'wind': 1, 'protein': 1, 'system': 1, 'issue': 1, 'mere': 1, 'presence': 1, 'lungs': 1, 'form': 1, 'deadunable': 1, 'reproduce': 1, 'spike': 1, 'multiplying': 1, 'actual': 1, 'covid': 1, '?': 1, 'much': 1, 'problem': 1, 'open': 1, 'debate': 1, 'understand': 1, 'actually': 1, 'attach': 1, 'cells': 1, 'stay': 1, 'tcell': 1, 'comes': 1, 'along': 1, 'takes': 1, 'care': 1, 'would': 1, 'assume': 1, 'inhaled': 1, 'allow': 1, 'address': 1, 'quickly': 1, 'provide': 1, 'needed': 1, 'local': 1, 'immunity': 1, 'one': 1, 'sites': 1, 'really': 1, 'causes': 1, 'yeah': 1, 'main': 1, 'place': 1, 'seems': 1, 'possible': 1, 'could': 1, 'get': 1, 'least': 1, 'clear': 1, 'theorizing': 1, 'want': 1, 'hear': 1, 'formal': 1, 'reasoning': 1, 'not': 1, 'rationale': 1, 'making': 1, 'intramuscular': 1, 'injection': 1, 'first': 1}, {'admittedly': 1, 'limited': 1, 'understanding': 1, 's': 1, 'used': 1, 'surveillance': 1, 'meaning': 1, 'expect': 1, 'say': 1, '3000': 1, 'cases': 1, 'myocarditis': 1, 'males': 1, 'certain': 1, 'age': 1, 'group': 1, 'every': 1, 'year': 1, 'due': 1, 'xyz': 1, 'things': 1, 'know': 1, 'cause': 1, 'aka': 1, 'background': 1, 'rate': 1, 'vaers': 1, 'pops': 1, 're': 1, 'suddenly': 1, 'seeing': 1, '4000': 1, 'specific': 1, 'becomes': 1, 'significant': 1, 'number': 1, 'reported': 1, 'statistically': 1, 'higher': 1, 'expected': 1}, {'yet': 1, 'see': 1, 'study': 1, 'shows': 1, 'long': 1, 'lasting': 1, 'protection': 1, 'lab': 1, 'animals': 1, 'tcell': 1, 'vaccines': 1, 'taking': 1, 'granted': 1, 'non': 1, 'tissue': 1, 'resident': 1, 'tcells': 1, 'protect': 1, 'severe': 1, 'disease': 1, 'dangerous': 1, 'seen': 1, 'much': 1, 'drops': 1, 'single': 1, 'dosejj': 1, 'vaccine': 1, 'produces': 1, 'good': 1, 'response': 1}, {'abstract': 1, 'importance': 1, 'identification': 1, 'adverse': 1, 'events': 1, 'vaccination': 1, 'increases': 1, 'awareness': 1, 'vaccineassociated': 1, 'complications': 1, 'leading': 1, 'early': 1, 'diagnosis': 1, 'treatment': 1, 'evidence': 1, 'remains': 1, 'scarce': 1, 'association': 1, 'bnt162b2': 1, 'messenger': 1, 'rna': 1, 'mrna': 1, 'covid19': 1, 'vaccine': 1, 'pfizerbiontech': 1, 'sudden': 1, 'sensorineural': 1, 'hearing': 1, 'loss': 1, 'ssnhl': 1, 'objective': 1, 'assess': 1, 'design': 1, 'setting': 1, 'participants': 1, 'retrospective': 1, 'populationbased': 1, 'cohort': 1, 'study': 1, 'performed': 1, 'december': 1, '20': 1, '2020': 1, 'may': 1, '31': 1, '2021': 1, 'using': 1, 'data': 1, 'largest': 1, 'health': 1, 'care': 1, 'organization': 1, 'israel': 1, 'patients': 1, '16': 1, 'years': 1, 'older': 1, 'received': 1, 'first': 1, 'dose': 1, 'april': 1, '30': 1, 'second': 1, 'january': 1, '10': 1, 'included': 1, 'exposures': 1, 'receipt': 1, 'doses': 1, 'main': 1, 'outcomes': 1, 'measures': 1, 'outcome': 1, 'based': 1, 'international': 1, 'classification': 1, 'diseases': 1, 'ninth': 1, 'revision': 1, 'icd9': 1, 'codes': 1, 'conjunction': 1, 'concurrent': 1, 'prednisone': 1, 'dispensing': 1, 'observed': 1, 'cases': 1, 'occurring': 1, 'within': 1, '21': 1, 'days': 1, 'compared': 1, 'expected': 1, 'experience': 1, 'population': 1, '2018': 1, '2019': 1, 'standardized': 1, 'incidence': 1, 'ratios': 1, 'sirs': 1, 'attributable': 1, 'risks': 1, 'computed': 1, 'results': 1, 'overall': 1, '2äø602äø557': 1, 'mean': 1, 'sd': 1, 'age': 1, '468': 1, '196': 1, '515': 1, '%': 1, 'female': 1, '91': 1, 'reported': 1, '2äø441äø719': 1, '938': 1, '79': 1, 'sexweighted': 1, '135': 1, '95': 1, 'ci': 1, '109165': 1, '123': 1, '098153': 1, 'estimated': 1, 'pronounced': 1, 'aged': 1, '44': 1, 'sir': 1, '192': 1, '098343': 1, '65': 1, '168': 1, '115237': 1, 'highest': 1, 'male': 1, '245': 1, '136407': 1, 'generally': 1, 'small': 1, 'similar': 1, 'used': 1, 'reference': 1, 'estimate': 1, 'number': 1, 'conclusions': 1, 'relevance': 1, 'suggests': 1, 'might': 1, 'associated': 1, 'increased': 1, 'risk': 1, 'however': 1, 'effect': 1, 'size': 1, 'studies': 1, 'warranted': 1, 'establish': 1, 'possible': 1}, {'iäôm': 1, 'always': 1, 'confused': 1, 'theory': 1, 'would': 1, 'myocarditis': 1, 'risk': 1, 'specific': 1, 'younger': 1, 'males': 1, 'case': 1, '?': 1}, {'comparing': 1, 'rates': 1, 'myocarditis': 1, 'vaccine': 1, 'vs': 1, 'covid': 1, 'stupidest': 1, 'thing': 1, 'iäôve': 1, 'ever': 1, 'seen': 1, 'many': 1, 'ways': 1, 'harm': 1, 'one': 1, 'lesser': 1, 'similar': 1, 'argument': 1, 'would': 1, 'äúthe': 1, 'dangerous': 1, 'youäôre': 1, 'likely': 1, 'get': 1, 'hurt': 1, 'via': 1, 'needle': 1, 'contract': 1, 'covidäù': 1, 'like': 1, 'shit': 1, 'sherlock': 1}, {'probably': 1, 'pretty': 1, 'good': 1, 'since': 1, 'eua': 1, 'really': 1, 'available': 1, 'alternatives': 1, 'full': 1, 'bla': 1, 'pfizer': 1, 'moderna': 1, 'approved': 1, 's': 1, 'harder': 1, 'argument': 1, 'make': 1}, {'case': 1, 'lower': 1, 'odds': 1, 'ratio': 1, 'better': 1, '1': 1, 'would': 1, 'mean': 1, 'vaccine': 1, 'absolutely': 1, 'zero': 1, 'effect': 1, 'impact': 1}, {'among': 1, '100': 1, 'patients': 1, 'solid': 1, 'cancer': 1, 'two': 1, 'vaccine': 1, 'doses': 1, 'nabt': 1, 'omicron': 1, 'detectable': 1, '37': 1, '%': 1, 'appendix': 1, 'p': 1, '4': 1, 'whereas': 1, 'delta': 1, '56': 1, 'mcnemar': 1, 'test': 1, 'p00002': 1, 'wt': 1, 'sarscov2': 1, '97': 1, '00001': 1, '2': 1, '115': 1, 'third': 1, 'dose': 1, '104': 1, '90': 1, '112': 1, 'p0013': 1, '114': 1, '99': 1, 'p00044': 1, '79': 1, 'blood': 1, '15': 1, '19': 1, 'detetable': 1, '31': 1, '39': 1, 'nabs': 1, '89': 1, '84': 1, 'received': 1, '47': 1, 'patientspatients': 1, '60': 1, '71': 1, 'p00009': 1, '72': 1, '86': 1, 'considering': 1, '64': 1, 'undetectable': 1, '29': 1, '45': 1, 'developed': 1, 'indicating': 1, 'effective': 1, 'boosting': 1, 'many': 1, 'correlated': 1, 'respectively': 1, 'consistently': 1, 'lower': 1}, {'nothing': 1, 'new': 1, 'really': 1, 'published': 1, 'efficacy': 1, 'data': 1, 'delta': 1, 'omicron': 1, 'far': 1}, {'right': 1, 'decision': 1, 'get': 1, 'point': 1, 'first': 1, 'place': 1, '?': 1, 'already': 1, 'knew': 1, 'nt': 1, 'data': 1, 'showing': 1, 's': 1, 'effective': 1, '34': 1, 'year': 1, 'olds': 1, 'needed': 1, 'shot': 1, '3': 1, 'asked': 1, 'submit': 1, 'anyway': 1}, {'study': 1, 'finds': 1, 'evidence': 1, 'omicron': 1, 'lower': 1, 'severity': 1, 'delta': 1, '3': 1, 'days': 1, 'ago': 1, 'sub': 1, 'published': 1, 'saying': 1, 'infections': 1, 'fact': 1, 'much': 1, 'mild': 1, 'https': 1, 'wwwredditcomrcovid19commentsrgylbkhkumed_finds_omicron_sarscov2_can_infect_faster': 1, 'says': 1, 'opposite': 1, 'nt': 1, 'know': 1, 'wait': 1, 'see': 1, 'guess': 1, 'however': 1, 'hospitalization': 1, 'rates': 1, 'africa': 1, 'would': 1, 'suggest': 1, 'ommicron': 1}, {'report': 1, 'lots': 1, 'claims': 1, 'reporting': 1, 'nt': 1, 'strongly': 1, 'related': 1, 'adverse': 1, 'effects': 1, 'vaccines': 1, 'comparison': 1, 'national': 1, 'mortality': 1, 'data': 1, 'suggests': 1, 'certain': 1, 'causes': 1, 'death': 1, 'accidents': 1, 'suicides': 1, 'cancer': 1, 'less': 1, 'likely': 1, 'reported': 1, 'vaers': 1, 'underreporting': 1, 'general': 1, 'expected': 1}, {'find': 1, 'evidence': 1, 'risk': 1, 'hospitalisation': 1, 'attendance': 1, 'symptom': 1, 'status': 1, 'omicron': 1, 'different': 1, 'severity': 1, 'delta': 1, 'though': 1, 'data': 1, 'hospitalisations': 1, 'still': 1, 'limited': 1, 'nt': 1, 'hospitalization': 1, 'rates': 1, 'large': 1, 'part': 1, 'measured': 1, '?': 1, 'seems': 1, 'premature': 1, 'make': 1, 'pronouncement': 1}, {'know': 1, 'pfizeräôs': 1, 'numbers': 1, '6': 1, 'month': 1, '2': 1, 'years': 1, 'met': 1, 'whatever': 1, 'endpoint': 1, '25': 1, 'didnäôt': 1, '?': 1}, {'anyone': 1, 'manage': 1, 'interpret': 1, 'vaccinated': 1, 'group': 1, 'efficacy': 1, 'boosters': 1, 'compared': 1, '?': 1, 'people': 1, 'study': 1, 'similar': 1, 'time': 1, '2nd': 1, 'dose': 1, 'hugely': 1, 'negative': 1}, {'nt': 1, 'reported': 1, '100': 1, '%': 1, 'efficacy': 1, 'severe': 1, 'disease': 1, '75': 1, 'someone': 1, 'getting': 1, 'moderate': 1}, {'abstract': 1, '____': 1, 'importance': 1, 'although': 1, 'covid19': 1, 'vaccines': 1, 'protect': 1, 'infection': 1, 'severe': 1, 'disease': 1, 'role': 1, 'vaccination': 1, 'preventing': 1, 'prolonged': 1, 'symptoms': 1, 'subsequent': 1, 'unclear': 1, 'objective': 1, 'determine': 1, 'differences': 1, 'stratified': 1, 'prior': 1, 'reported': 1, 'healthcare': 1, 'personnel': 1, 'hcp': 1, '6': 1, 'weeks': 1, 'onset': 1, 'whether': 1, 'timing': 1, 'return': 1, 'work': 1, 'design': 1, 'nested': 1, 'cohort': 1, 'study': 1, 'within': 1, 'multicenter': 1, 'vaccine': 1, 'effectiveness': 1, 'december': 1, '2020': 1, 'august': 1, '2021': 1, 'followed': 1, 'illness': 1, 'setting': 1, 'health': 1, 'systems': 1, '12': 1, 'us': 1, 'states': 1, 'participants': 1, 'participating': 1, 'eligible': 1, 'inclusion': 1, 'confirmed': 1, 'either': 1, 'verified': 1, 'mrna': 1, 'symptom': 1, 'â14': 1, 'days': 1, 'two': 1, 'doses': 1, 'among': 1, '681': 1, '419': 1, '61': 1, '%': 1, 'completed': 1, 'followup': 1, 'survey': 1, 'approximately': 1, 'exposures': 1, 'compared': 1, 'main': 1, 'outcomes': 1, 'measures': 1, 'presence': 1, 'results': 1, '298': 1, '71': 1, 'one': 1, 'covidlike': 1, 'lower': 1, 'prevalence': 1, 'vaccinated': 1, '606': 1, 'unvaccinated': 1, 'vs': 1, '791': 1, 'arr': 1, '070': 1, '95': 1, 'ci': 1, '058084': 1, 'returned': 1, 'median': 1, '20': 1, '1030': 1, 'sooner': 1, 'ahr': 1, '137': 1, '104179': 1, 'conclusions': 1, 'history': 1, 'associated': 1, 'decreased': 1, 'risk': 1, 'earlier': 1, 'improved': 1, 'recovery': 1, 'addition': 1, 'symptomatic': 1}, {'saying': 1, 'vaccine': 1, 'causes': 1, 'brain': 1, 'cancer': 1, '?': 1, 'also': 1, 'op': 1, 'looks': 1, 'like': 1, 'bot': 1, 'post': 1, 'history': 1, 'vitro': 1, 'nt': 1, 'mean': 1, 'vivo': 1, 'account': 1, 'spread': 1, 'blood': 1, 'barrier': 1}, {'woah': 1, 'interesting': 1, 'flu': 1, 'vaccine': 1, 'reducing': 1, 'heart': 1, 'attacks': 1, 'able': 1, 'direct': 1, 'somewhere': 1, 'could': 1, 'read': 1, '?': 1, 'cool': 1}, {'iäôm': 1, 'ontario': 1, 'canada': 1, 'space': 1, 'shots': 1, 'due': 1, 'availability': 1, '2': 1, 'today': 1, 'weäôre': 1, '918': 1, '%': 1, 'https': 1, 'covid19sciencetablecaontariodashboard': 1, 'reduction': 1, 'icu': 1, 'occupancy': 1, 'per': 1, 'million': 1, 'compared': 1, 'unvaccinated': 1}, {'yeah': 1, 'completely': 1, 'redo': 1, 'phase': 1, '2': 1, 'trial': 1, 'original': 1, 'design': 1, 'nt': 1, 'immunogenic': 1, 'enough': 1, 'doubt': 1, 'd': 1, 'major': 1, 'player': 1, 'nailed': 1, 'first': 1, 'time': 1}, {'s': 1, '24': 1, 'hospitalized': 1, 'omicron': 1, 'patients': 1, 'evidence': 1, 'means': 1, 'ca': 1, 'nt': 1, 'make': 1, 'statement': 1, 'doesnt': 1, 'mean': 1, 'suggests': 1, 'severe': 1, 'probably': 1, 'left': 1, 'article': 1, 'add': 1, 'anything': 1, 'analysis': 1}, {'1': 1, 'study': 1, 'cite': 1, 'demonstrating': 1, 'integration': 1, 'viral': 1, 'genome': 1, 'cells': 1, 'widely': 1, 'panned': 1, 'artifact': 1, 'published': 1, 'pnas': 1, 'bypassing': 1, 'peer': 1, 'review': 1, '2': 1, 'basically': 1, 'forced': 1, 'reverse': 1, 'transcription': 1, 'happen': 1, 'reported': 1, 'happened': 1, 'article': 1, 'misinformation': 1, 'edit': 1, 'friend': 1, 'mine': 1, 'already': 1, 'nice': 1, 'takedown': 1, 'blog': 1, 'canäôt': 1, 'post': 1, 'auto': 1, 'mod': 1, 'follow': 1, 'edward': 1, 'nirenbergäôs': 1, 'deplatformdisease': 1, 'youäôll': 1, 'find': 1}, {'booster': 1, 'uptake': 1, 'really': 1, 'high': 1, 'vulnerable': 1, 'populations': 1, 'much': 1, 'better': 1, 'preventing': 1, 'hospitalizations': 1, 'would': 1, 'amazing': 1, 'province': 1, 'quebec': 1, '33': 1, '%': 1, 'new': 1, 'covidrelated': 1, 'last': 1, '28': 1, 'days': 1, 'people': 1, 'received': 1, '3': 1, 'doses': 1, 'maybe': 1, 'population': 1, 'severe': 1, 'immune': 1, 'problems': 1, 'prevent': 1, 'vaccines': 1, 'protecting': 1, 'efficiently': 1}, {'sorry': 1, 'bother': 1, 'nt': 1, 'much': 1, 'knowledge': 1, 'experiment': 1, 'still': 1, 'questions': 1, 'said': 1, 'study': 1, 'indeed': 1, 'correct': 1, 'would': 1, 'need': 1, 'experiments': 1, 'people': 1, 'actually': 1, 'prove': 1, 'saying': 1, '?': 1, 'also': 1, 'worst': 1, 'case': 1, 'scenario': 1, 'true': 1, 'pardon': 1, 'english': 1, 'first': 1, 'time': 1, '6': 1, 'months': 1, 'm': 1, 'conversation': 1, 'anyone': 1, 'internet': 1}, {'old': 1, 'data': 1, 'comparing': 1, 'age': 1, 'groups': 1, 'mrna': 1, 'specific': 1, 'group': 1, 'good': 1, 'design': 1, 'want': 1, 'see': 1, 'accurate': 1, 'picture': 1, 'look': 1, 'towards': 1, 'denmark': 1, 'norway': 1, 'excellent': 1, 'tracking': 1, 'one': 1, 'example': 1, 'https': 1, 'wwwfhinonyheter2021myokardittetterkoronavaksinasjoninorge': 1}, {'m': 1, 'surprised': 1, 'reading': 1, 'anything': 1, 'happened': 1, 'sars': 1, '?': 1, 'change': 1, 'efficient': 1, 'killing': 1, 'machine': 1, 'essentially': 1, 'disappearing': 1, 'extant': 1, 'threat': 1, 'mers': 1, 'able': 1, 'make': 1, 'transition': 1, 'something': 1, 'like': 1, 'covid': 1, 'heck': 1, 'syphilis': 1, 'turn': 1, 'sexually': 1, 'transmitted': 1, 'slow': 1, 'motion': 1, 'killer': 1, 'days': 1, 'ca': 1, 'nt': 1, 'find': 1, 'journal': 1, 'articles': 1, 'currently': 1, 'controlled': 1, 'antibiotics': 1, 'fear': 1, 'hiv': 1, 'sars1': 1, 'killed': 1, 'aggressive': 1, 'public': 1, 'health': 1, 'containment': 1, 'measures': 1, 'zoonotic': 1, 'virus': 1, 'camels': 1, 'spread': 1, 'well': 1, 'humans': 1, 'tends': 1, 'put': 1, 'icu': 1, 's': 1, 'category': 1, 'avian': 1, 'influenza': 1}, {'usa': 1, 'pfizer': 1, 'vaccine': 1, 'one': 1, 'approved': 1, 'use': 1, 'eua': 1, 'adolescents': 1, 'children': 1, 'age': 1, '5': 1, 'non': 1, 'mrna': 1, 'j': 1, '&': 1, 'production': 1, 'discontinued': 1, '18': 1, 'see': 1, 'relevant': 1, 'study': 1, 'using': 1, 'vaers': 1, 'reports': 1, 'reporting': 1, 'system': 1, 'used': 1, 'us': 1, 'cdc': 1}, {'nt': 1, 'human': 1, 'trials': 1}, {'counterintuitive': 1, 'result': 1, 'analysis': 1, 'highest': 1, 'risk': 1, 'resistant': 1, 'strain': 1, 'establishment': 1, 'occurs': 1, 'large': 1, 'fraction': 1, 'population': 1, 'already': 1, 'vaccinated': 1, 'transmission': 1, 'controlled': 1, 've': 1, 'seen': 1, 'lockdown': 1, 'measures': 1, 'resulted': 1, 'practically': 1, 'benefit': 1, 'fact': 1, 'arguably': 1, 'detrimental': 1, 'overall': 1, 'research': 1, 'subreddit': 1, 'implication': 1, 'hypothesis': 1, 'vaccinate': 1, 'atrisk': 1, 'pandemic': 1, 'intentionally': 1, 'avoid': 1, 'producing': 1, 'new': 1, 'strains': 1, 'disease': 1, 'becomes': 1, 'endemic': 1, 'correct': 1, 'selection': 1, 'pressure': 1, 'action': 1}, {'unvaccinated': 1, 'cohort': 1, 'wouldäôve': 1, 'surely': 1, 'likely': 1, 'recent': 1, 'prior': 1, 'infection': 1, 'vaccinated': 1, 'due': 1, 'protective': 1, 'effect': 1, 'vaccination': 1, 'previous': 1, 'months': 1, 'know': 1, 'thought': 1, 'maybe': 1, 'example': 1, 'spike': 1, 'provided': 1, 'natural': 1, 'immunity': 1, 'bit': 1, 'would': 1, 'expect': 1, 'graph': 1, 'positive': 1, 'correlating': 1, 'noninfections': 1, 'vs': 1, '?': 1, 'corrected': 1, 'slope': 1, 'line': 1, 'seems': 1, 'pretty': 1, 'steady': 1}, {'mention': 1, 'gsk': 1, 'pandemic': 1, 'adjuvant': 1, 'anybody': 1, 'know': 1, 'used': 1, 'sanofigsk': 1, 'protein': 1, 'subunit': 1, 'vaccine': 1, 'press': 1, 'release': 1, 'made': 1, 'yesterday': 1, '?': 1}, {'completely': 1, 'unfounded': 1, 'hypothesis': 1, 'delta': 1, 'mutation': 1, 'nt': 1, 'actually': 1, 'affect': 1, 'protein': 1, 's': 1, 'morphologic': 1, 'shape': 1, 'much': 1, 'seems': 1, 'increased': 1, 'infectionsness': 1, 'mostly': 1, 'based': 1, 'furin': 1, 'cleavage': 1, 'expulsion': 1, 'infected': 1, 'cell': 1, 'https': 1, 'wwwnaturecomarticlesd41586021022752': 1, 'omicron': 1, 'seem': 1, 'different': 1, 'especially': 1, 'sproteinwise': 1, 'new': 1, 'customtailored': 1, 'vaccine': 1, 'antibody': 1, 'mrna': 1, 'sequence': 1, 'would': 1, 'promising': 1}, {'nice': 1, 'study': 1, 'major': 1, 'limitation': 1, 'control': 1, 'possible': 1, 'confounding': 1, 'factors': 1, 'vaccine': 1, 'hesitancy': 1, 'hong': 1, 'kong': 1, 'highest': 1, 'among': 1, 'elderly': 1, 'individuals': 1, 'underlying': 1, 'health': 1, 'conditions': 1, '36': 1, 'scenario': 1, 'socalled': 1, 'äòhealthy': 1, 'vaccinee': 1, 'biasäô': 1, 'recipients': 1, 'healthier': 1, 'unvaccinated': 1, 'peers': 1, 'may': 1, 'inflate': 1, 'estimates': 1, '35': 1, 'although': 1, 'accounted': 1, 'age': 1, 'current': 1, 'lack': 1, 'individuallevel': 1, 'data': 1, 'controls': 1, 'mean': 1, 'formally': 1, 'assessed': 1, 'currently': 1, 'available': 1}, {'expect': 1, 'booster': 1, 'diminish': 1, 'time': 1, 'particularly': 1, 'symptomatic': 1, 'diseaseinfection': 1, 'would': 1, 'using': 1, 'omicron': 1, 'specific': 1, 'well': 1, 'though': 1, 'might': 1, 'take': 1, 'longer': 1, 'original': 1, 'formula': 1, 'provides': 1, 'better': 1, 'elicits': 1, 'antibodies': 1, 'even': 1, 'peak': 1, 'amount': 1, 'two': 1, 'doses': 1, 'increasing': 1, 'evidence': 1, 'elicited': 1, 'äúbetteräù': 1, 'higher': 1, 'quality': 1, 'breadth': 1, 'avidity': 1, 'helps': 1, 'b': 1, 'cells': 1, 'continue': 1, 'making': 1, 'address': 1, 'new': 1, 'variants': 1, 'like': 1, 'waned': 1, 'expected': 1, 'immune': 1, 'system': 1, 'jump': 1, 'gear': 1, 'clear': 1, 'infection': 1, 'quickly': 1, 'efficiently': 1, 'far': 1, '10': 1, 'month': 1, 'pfizer': 1, 'trial': 1, 'data': 1, 'iäôm': 1, 'sure': 1, 'youäôre': 1, 'referring': 1}, {'finally': 1, 'actual': 1, 'qualitative': 1, 'analysis': 1, 'studies': 1, 'maddeningly': 1, 'binary': 1, 'ie': 1, 'occasional': 1, 'headaches': 1, 'month': 1, 'breakthrough': 1, 'infection': 1, 'congratulations': 1, 'long': 1, 'covid': 1, 'least': 1, 'according': 1, '&': 1, 'x200b': 1, 'symptoms': 1, 'less': 1, 'severe': 1, 'vaccinated': 1, 'compared': 1, 'unvaccinated': 1, 'participants': 1, '120': 1, 'days': 1, 'recruitment': 1, 'mean': 1, 'difference': 1, 'st': 1, 'score': 1, '18': 1, '95': 1, '%': 1, 'ci': 1, '25': 1, '10': 1, 'remission': 1, '166': 1, 'versus': 1, '75': 1, 'hr': 1, '197': 1, '123': 1, '315': 1, 'ä': 1, 'impact': 1, 'lives': 1, 'also': 1, '33': 1, '62': 1, '05': 1, 'fewer': 1, 'found': 1, 'unacceptable': 1, '389': 1, '464': 1, 'risk': 1, '144': 1, 'think': 1, 'many': 1, 'people': 1, 'really': 1, 'waiting': 1, 'baited': 1, 'breath': 1, 'risks': 1, 'individuals': 1, 'nt': 1, 'worried': 1, 'dying': 1, 'winding': 1, 'hospital': 1, 'anymore': 1, 'lot': 1, 'aspects': 1, 'normal': 1, 'life': 1, 'returning': 1, 'ought': 1, 'able': 1, 'say': 1, 'confidence': 1, 'plain': 1, 'terms': 1, 'actually': 1, 'vaxxed': 1, 'boosted': 1, 'would': 1, 'go': 1, 'way': 1, 'significant': 1, 'term': 1, 'impacts': 1, 'rare': 1, 'x': 1, '100': 1, 'even': 1, 'good': 1, 'health': 1}, {'saying': 1, 'life': 1, 'finds': 1, 'way': 1, 'holds': 1, 'true': 1, '99999999': 1, '%': 1, 'species': 1, 'ever': 1, 'emerged': 1, 'went': 1, 'extinct': 1, 'fleeting': 1, 'miracle': 1, 'viruses': 1, 'protolife': 1, 'simple': 1, 'code': 1, 'written': 1, 'language': 1, 'bodies': 1, 'understand': 1, 'stomp': 1, 'masks': 1, 'distance': 1, 'handwashing': 1, 'vaccines': 1, 'make': 1, 'chose': 1, 'like': 1, 'australia': 1, 'new': 1, 'zealand': 1, 'even': 1, 'kept': 1, 'reinfecting': 1}, {'good': 1, 'keep': 1, 'mind': 1, 'booster': 1, 'recent': 1, '2': 1, 'doses': 1, 'matters': 1, 'israel': 1, 'going': 1, '4th': 1, 'dose': 1, '60': 1, 'healthcare': 1, 'workers': 1, 'indicating': 1, 'seeing': 1, 'great': 1, 'efficacy': 1, '3rd': 1, 'feels': 1, 'similar': 1, 'fighting': 1, 'influenza': 1, 'last': 1, 'season': 1, 's': 1, 'vaccine': 1}, {'danish': 1, 'study': 1, 'well': 1, 'see': 1, 'table': 1, '2': 1, 'preprint': 1, 'https': 1, 'wwwmedrxivorgcontent1011012021122721268278v1fulltext': 1, 'gist': 1, 'äúfully': 1, 'vaccinatedäù': 1, 'people': 1, 'likely': 1, 'unvaccinated': 1, 'become': 1, 'infected': 1, '104x': 1, 'omicron': 1, 'boosted': 1, 'half': 1, 'fully': 1, 'vaccinated': 1, '054x': 1, 'recent': 1, 'ontario': 1, 'came': 1, 'similar': 1, 'conclusions': 1, 'essentially': 1, 'ineffective': 1, 'preventing': 1, 'infection': 1, 'slightly': 1, 'pessimistic': 1, 'booster': 1, 'group': 1, 'suggesting': 1, 'effectiveness': 1, '37': 1, '%': 1, 'find': 1, 'wwwmedrxivorgcontent1011012021123021268565v1': 1, 'serious': 1, 'illness': 1}, {'yeah': 1, 'strange': 1, 'oneäand': 1, 'frankly': 1, 'care': 1, 'donäôt': 1, 'work': 1, 'independently': 1, 'designed': 1, 'antigen': 1, '?': 1, 'guess': 1, 'thereäôs': 1, 'always': 1, 'something': 1, 'learn': 1, 'almost': 1, 'feels': 1, 'like': 1, 'seeing': 1, 'trick': 1, 'immune': 1, 'system': 1, 'try': 1, 'hard': 1, 'enough': 1}, {'hand': 1, 'may': 1, 'good': 1, 'first': 1, 'course': 1, 'yet': 1, 'vaccinated': 1, 'previously': 1, 'exposed': 1}, {'pretty': 1, 'sure': 1, 'target': 1, 'requirement': 1, 'measured': 1, 'prevention': 1, 'moderate': 1, 'severe': 1, 'disease': 1, 'least': 1, 'symptomatic': 1, 'infection': 1}, {'selfselection': 1, 'bias': 1, 'people': 1, 'experience': 1, 'suffers': 1, 'influenza': 1, 'epidemics': 1, 'likely': 1, 'get': 1, 'vaccine': 1, 'rarely': 1, 'ever': 1, 'sick': 1, 'flu': 1}, {'anyone': 1, 'know': 1, 'happened': 1, 'deltaspecific': 1, 'booster': 1, 'research': 1, '?': 1, 'thought': 1, 'pfizer': 1, 'going': 1, 'release': 1, 'early': 1, 'data': 1, 'dec': 1, '2021': 1}, {'true': 1, 'sweden': 1, '?': 1, 'understanding': 1, 'never': 1, 'really': 1, 'vaccine': 1, 'passport': 1, 'system': 1}, {'thanks': 1, 'much': 1, 'thatäôs': 1, 'great': 1, 'explanation': 1, 'makes': 1, 'sense': 1}, {'thanks': 1, 'missed': 1, 'yes': 1, 'anyone': 1, 'typical': 1, 'covid': 1, 'symptoms': 1, 'would': 1, 'classified': 1, 'covidlike': 1, 'illness': 1, 'positive': 1, 'test': 1, 'confirms': 1, 'covid19': 1}, {'completely': 1, 'agree': 1}, {'read': 1, 'study': 1, 'properly': 1, 'vaccinated': 1, 'group': 1, 'negative': 1, 'cv': 1, 'antibodies': 1, 'andor': 1, 'known': 1, 'confirmed': 1, 'case': 1, 'cv19': 1}, {'sure': 1, 'long': 1, '?': 1, 'social': 1, 'distancing': 1, 'masks': 1, 'ca': 1, 'nt': 1, 'go': 1, 'years': 1, 'end': 1, 'soon': 1, 'healthcare': 1, 'systems': 1, 'risk': 1, 'overwhelmed': 1, 'anymore': 1}, {'say': 1, 'hospitalized': 1, '?': 1, 'notes': 1, 'said': 1, 'data': 1, 'pulled': 1, 'hospitals': 1, 'clinics': 1}, {'feel': 1, 'like': 1, 'study': 1, 'set': 1, 'poorlyä': 1, 'summary': 1, 'leaves': 1, 'lot': 1, 'important': 1, 'dataassumptions': 1, '1': 1, 'figure': 1, 'https': 1, 'mediaspringernaturecomfullspringerstaticimageart': 1, '%': 1, '3a101038': 1, '2fs41598022066292mediaobjects41598_2022_6629_fig1_htmlpng': 1, '?': 1, 'aswebp': 1, 'clearly': 1, 'shows': 1, 'time': 1, 'sampling': 1, 'grossly': 1, 'disproportionate': 1, 'vaccinated': 1, 'samples': 1, 'taken': 1, 'anywhere': 1, '1050': 1, 'days': 1, 'post': 1, '2nd': 1, 'dose': 1, 'convalescent': 1, 'averaged': 1, '210': 1, 'symptom': 1, 'onsetä': 1, '2': 1, 'gross': 1, 'age': 1, 'difference': 1, 'knowing': 1, 'younger': 1, 'people': 1, 'produce': 1, 'stronger': 1, 'immune': 1, 'response': 1, 'äúthere': 1, 'differences': 1, 'immunized': 1, 'groups': 1, 'group': 1, 'median': 1, '355': 1, 'years': 1, 'different': 1, '590äù': 1, '3': 1, 'antibody': 1, 'levels': 1, 'within': 1, 'months': 1, '6': 1, 'second': 1, 'sharply': 1, 'loweräù': 1, '4': 1, 'äúin': 1, 'contrast': 1, 'sera': 1, 'exhibit': 1, 'correlative': 1, 'followup': 1, '207': 1, 'disease': 1, 'onsetäù': 1}, {'maybe': 1, 'study': 1, 'alone': 1, 'arenäôt': 1, 'close': 1, 'consensus': 1, 'omicron': 1, 'largely': 1, 'evades': 1, 'antibodies': 1, 'prior': 1, 'infectionvaccination': 1, 'neutralized': 1, 'broader': 1, 'b': 1, 'cell': 1, 'response': 1, '?': 1, 'vaccines': 1, 'protect': 1, 'well': 1, 'infection': 1, 'severity': 1, 'one': 1, 'unknown': 1, 'severe': 1, 'zero': 1, 'covid19': 1, 'immunity': 1}, {'looks': 1, 'like': 1, 'studies': 1, 'underway': 1, 'research': 1, 'progress': 1, 'four': 1, 'additional': 1, 'identified': 1, 'still': 1, 'ä': 1, 'nihr': 1, 'funded': 1, 'study': 1, 'prietoalhambra': 1, 'et': 1, 'al': 1, 'examine': 1, 'effect': 1, 'different': 1, 'covid19': 1, 'vaccines': 1, 'long': 1, 'covid': 1, 'uk': 1, '23': 1, 'massey': 1, 'project': 1, 'recovery': 1, 'vaccination': 1, 'measure': 1, 'changes': 1, 'participantsäô': 1, 'moderate': 1, 'severe': 1, 'pasc': 1, 'symptoms': 1, '6': 1, '12': 1, '15': 1, 'weeks': 1, 'us': 1, '24': 1, 'premkumar': 1, 'evalongcovid': 1, 'nct05107271': 1, 'haul': 1, 'related': 1, 'adults': 1, 'chronic': 1, 'liver': 1, 'disease': 1, 'india': 1, '25': 1, 'randomised': 1, 'controlled': 1, 'trial': 1, 'årea': 1, 'de': 1, 'ensayos': 1, 'clnicos': 1, 'euctr202100333128': 1, 'es': 1, 'randomise': 1, 'persisting': 1, '3': 1, 'acute': 1, 'phase': 1, 'spain': 1, 'either': 1, 'pfizer': 1, 'vaccine': 1, 'placebo': 1, 'change': 1, 'frequency': 1, 'intensity': 1, '26': 1}, {'relevant': 1, 'end': 1, 'points': 1, 'like': 1, 'long': 1, 'covid': 1, 'hospitalization': 1, 'death': 1, '2': 1, 'shots': 1, 'still': 1, 'show': 1, 'protection': 1, 'given': 1, 'youäôve': 1, 'said': 1, 'twice': 1, 'thread': 1, 'iäôd': 1, 'see': 1, 'citation': 1, 'regards': 1, 'linked': 1, 'paper': 1, 'https': 1, 'wwwresearchsquarecomarticlers1062160v1': 1, 'would': 1, 'say': 1, 'figure': 1, '4': 1, 'shows': 1, 'isnäôt': 1, 'really': 1, 'much': 1, 'biggest': 1, 'numbers': 1, 'seen': 1, 'studies': 1, 'arenäôt': 1, 'even': 1, '50': 1, '%': 1, 'found': 1, 'significant': 1, 'effect': 1, 'itäôs': 1, 'promising': 1, 'front': 1, 'happy': 1, 'proven': 1, 'wrong': 1, 'agree': 1, 'two': 1, 'doses': 1, 'seems': 1, 'strong': 1, 'thatäôs': 1, 'good': 1, 'thing': 1}, {'itäôa': 1, 'patent': 1, 'free': 1, 'license': 1, 'however': 1, 'producing': 1, 'drug': 1, 'takes': 1, 'long': 1, 'think': 1, 'pfizer': 1, 'said': 1, '8': 1, 'months': 1, '1': 1, 'batch': 1}, {'doesnäôt': 1, 'matter': 1, 'randomize': 1, 'correctly': 1, 'effect': 1, 'previous': 1, 'infections': 1, 'similar': 1, 'cohorts': 1, 'okay': 1, 'well': 1, 'theyäôre': 1, 'randomizing': 1, 'cohort': 1, '1': 1, 'n': 1, '615': 1, 'received': 1, 'two': 1, 'doses': 1, 'current': 1, 'pfizerbiontech': 1, 'covid19': 1, 'vaccine': 1, '90180': 1, 'days': 1, 'prior': 1, 'enrollment': 1, 'study': 1, 'participants': 1, 'receive': 1, 'one': 1, 'omicronbased': 1, '2': 1, '600': 1, 'three': 1, 'dose': 1, '3': 1, 'n205': 1, 'vaccinenaøve': 1, 'pleeeease': 1, 'read': 1, 'things': 1, 'comment': 1, 'especially': 1, 'science': 1, 'sub': 1, 'since': 1, 'said': 1, 'äúboth': 1, 'cohortsäù': 1, 'itäôs': 1, 'clear': 1, 'didnäôt': 1, 'contents': 1, 'isnäôt': 1, 'randomized': 1}, {'great': 1, 'cdc': 1, 'need': 1, 'wake': 1, 'use': 1, 'guidance': 1, 'europe': 1, 'jnj': 1, 'get': 1, 'third': 1, 'dose': 1}, {'anyone': 1, 'know': 1, 'novavax': 1, 'trials': 1, '5': 1, 'year': 1, 'olds': 1, '?': 1, 'big': 1, 'gap': 1, 'us': 1, 'right': 1}, {'ca': 1, 'nt': 1, 'download': 1, 'study': 1, 'reason': 1, 'understand': 1, 'question': 1, 'looking': 1, 'covid': 1, 'patients': 1, 'comparing': 1, 'risk': 1, 'covidinduced': 1, 'gbs': 1, 'vaccinated': 1, 'vs': 1, 'unvaccinated': 1, '?': 1, 'overview': 1, 'seem': 1, 'like': 1, 'actually': 1, 'vaccine': 1, 'otherwise': 1, 'would': 1, 'select': 1, 'group': 1, 'got': 1}, {'alright': 1, 's': 1, 'protection': 1, 'severe': 1, 'critical': 1, 'cases': 1, '2': 1, 'doses': 1, 'omicron': 1, 'compared': 1, '3': 1, '?': 1}, {'study': 1, 'low': 1, 'number': 1, 'samples': 1, 'n8': 1, 'mistaken': 1, 'statistical': 1, 'value': 1, '?': 1}]\n",
            "  (0, 729)\t1.0\n",
            "  (0, 4)\t1.0\n",
            "  (0, 1)\t1.0\n",
            "  (0, 964)\t1.0\n",
            "  (0, 1141)\t1.0\n",
            "  (0, 1198)\t1.0\n",
            "  (0, 1273)\t1.0\n",
            "  (0, 189)\t1.0\n",
            "  (0, 1691)\t1.0\n",
            "  (0, 204)\t1.0\n",
            "  (0, 214)\t1.0\n",
            "  (0, 591)\t1.0\n",
            "  (0, 412)\t1.0\n",
            "  (0, 100)\t1.0\n",
            "  (0, 245)\t1.0\n",
            "  (0, 147)\t1.0\n",
            "  (0, 307)\t1.0\n",
            "  (0, 556)\t1.0\n",
            "  (0, 1918)\t1.0\n",
            "  (0, 126)\t1.0\n",
            "  (0, 496)\t1.0\n",
            "  (0, 1876)\t1.0\n",
            "  (0, 1697)\t1.0\n",
            "  (0, 43)\t1.0\n",
            "  (0, 990)\t1.0\n",
            "  :\t:\n",
            "  (197, 240)\t1.0\n",
            "  (197, 554)\t1.0\n",
            "  (197, 4)\t1.0\n",
            "  (197, 1584)\t1.0\n",
            "  (197, 260)\t1.0\n",
            "  (197, 421)\t1.0\n",
            "  (197, 377)\t1.0\n",
            "  (198, 2)\t1.0\n",
            "  (198, 316)\t1.0\n",
            "  (198, 47)\t1.0\n",
            "  (198, 1876)\t1.0\n",
            "  (198, 68)\t1.0\n",
            "  (198, 28)\t1.0\n",
            "  (198, 99)\t1.0\n",
            "  (198, 43)\t1.0\n",
            "  (198, 511)\t1.0\n",
            "  (198, 49)\t1.0\n",
            "  (198, 18)\t1.0\n",
            "  (199, 157)\t1.0\n",
            "  (199, 1498)\t1.0\n",
            "  (199, 1149)\t1.0\n",
            "  (199, 1865)\t1.0\n",
            "  (199, 1456)\t1.0\n",
            "  (199, 665)\t1.0\n",
            "  (199, 18)\t1.0\n",
            "[{'gaithersburg': 1, 'md': 1, 'feb': 1, '10': 1, '2022': 1, 'prnewswire': 1, 'novavax': 1, 'inc': 1, 'nasdaq': 1, 'nvax': 1, 'biotechnology': 1, 'company': 1, 'dedicated': 1, 'developing': 1, 'commercializing': 1, 'nextgeneration': 1, 'vaccines': 1, 'serious': 1, 'infectious': 1, 'diseases': 1, 'today': 1, 'announced': 1, 'nvxcov2373': 1, 'recombinant': 1, 'nanoparticle': 1, 'proteinbased': 1, 'covid19': 1, 'vaccine': 1, 'achieved': 1, 'primary': 1, 'effectiveness': 1, 'endpoint': 1, 'pediatric': 1, 'expansion': 1, 'prevent19': 1, 'pivotal': 1, 'phase': 1, '3': 1, 'trial': 1, 'demonstrated': 1, '80': 1, '%': 1, 'efficacy': 1, 'overall': 1, 'time': 1, 'delta': 1, 'variant': 1, 'predominant': 1, 'circulating': 1, 'strain': 1, 'us': 1, 'study': 1, 'enrolled': 1, '2247': 1, 'adolescents': 1, 'aged': 1, '12': 1, '17years': 1, 'across': 1, '73': 1, 'sites': 1, 'evaluate': 1, 'safety': 1, 'immunogenicity': 1, 'emphasis': 1, 'ensuring': 1, 'well': 1, 'balanced': 1, 'racial': 1, 'ethnic': 1, 'representation': 1, 'among': 1, 'participants': 1, 'encouraged': 1, 'results': 1, 'adolescent': 1, 'population': 1, 'given': 1, 'ongoing': 1, 'need': 1, 'alternative': 1, 'options': 1, 'said': 1, 'filip': 1, 'dubovsky': 1, 'chief': 1, 'medical': 1, 'officer': 1, 'believe': 1, 'offers': 1, 'differentiated': 1, 'technology': 1, 'option': 1, 'younger': 1, 'established': 1, 'already': 1, 'used': 1, 'positive': 1, 'responses': 1, 'variants': 1, 'conducted': 1, 'adults': 1, '18': 1, 'years': 1, 'older': 1, 'published': 1, 'new': 1, 'england': 1, 'journal': 1, 'medicine': 1, 'nejm': 1, 'approximately': 1, '30000': 1, 'mexico': 1, '904': 1, 'reassuring': 1, 'tolerability': 1, 'profile': 1, 'severe': 1, 'adverse': 1, 'events': 1, 'low': 1, 'number': 1, 'placebo': 1, 'groups': 1, 'common': 1, 'reactions': 1, 'observed': 1, 'clinical': 1, 'studies': 1, 'frequency': 1, 'category': 1, 'â110': 1, 'headache': 1, 'nausea': 1, 'vomiting': 1, 'myalgia': 1, 'arthralgia': 1, 'injection': 1, 'site': 1, 'tendernesspain': 1, 'fatigue': 1, 'malaise': 1, 'continue': 1, 'collect': 1, 'analyze': 1, 'realworld': 1, 'data': 1, 'including': 1, 'monitoring': 1, 'evaluation': 1, 'distributed': 1, 'yet': 1, 'authorized': 1, 'expects': 1, 'submit': 1, 'regulatory': 1, 'filings': 1, 'indication': 1, 'global': 1, 'authorities': 1, 'first': 1, 'quarter': 1, 'also': 1, 'initiate': 1, 'additional': 1, 'globally': 1, 'evaluating': 1, 'age': 1, 'second': 1, 'date': 1, 'received': 1, 'authorization': 1, 'multiple': 1, 'conditional': 1, 'marketing': 1, 'european': 1, 'commission': 1, 'medicines': 1, 'healthcare': 1, 'products': 1, 'agency': 1, 'emergency': 1, 'use': 1, 'listing': 1, 'eul': 1, 'world': 1, 'health': 1, 'organization': 1, 'opportunity': 1, '170': 1, 'countries': 1, 'potential': 1, 'reach': 1, 'six': 1, 'billion': 1, 'lives': 1, 'currently': 1, 'review': 1, 'agencies': 1, 'worldwide': 1, 'food': 1, 'drug': 1, 'administration': 1, 'fda': 1, 'consistent': 1, 'adult': 1, 'placebocontrolled': 1, 'observerblinded': 1, 'randomized': 1, '21': 1, 'receive': 1, 'active': 1, 'underwent': 1, 'blinded': 1, 'crossover': 1, 'alternate': 1, 'material': 1, 'required': 1, 'collected': 1, 'ensure': 1, 'period': 1, 'observation': 1, 'protective': 1, '795': 1, '95': 1, 'ci': 1, '468': 1, '921': 1, 'cases': 1, 'group': 1, 'mild': 1, 'defined': 1, 'protocol': 1, 'endpoints': 1, 'accrued': 1, 'may': 1, '24': 1, 'september': 1, '27': 1, '2021': 1, 'äì': 1, 'showing': 1, 'high': 1, 'transmission': 1, 'severity': 1, 'disease': 1, 'sequence': 1, 'available': 1, '11': 1, '20': 1, 'confirmed': 1, '100': 1, 'determined': 1, 'caused': 1, '820': 1, '324': 1, '952': 1, 'response': 1, 'showed': 1, 'post': 1, 'hoc': 1, 'analyses': 1, 'robust': 1, 'immune': 1, 'igg': 1, 'spike': 1, 'proteins': 1, 'several': 1, 'alpha': 1, 'beta': 1, 'gamma': 1, 'mu': 1, 'omicron': 1, '23fold': 1, 'higher': 1, 'seroconversion': 1, 'following': 1, '2dose': 1, 'series': 1, 'vaccinations': 1, 'functional': 1, 'hace2': 1, 'receptor': 1, 'inhibition': 1, '244fold': 1, 'evaluated': 1, 'reactogenicity': 1, 'preliminary': 1, 'generally': 1, 'welltolerated': 1, 'considered': 1, 'related': 1, 'local': 1, 'systemic': 1, 'lower': 1, 'similar': 1, 'dose': 1, 'increase': 1, '15': 1, 'old': 1, 'compared': 1, 'signal': 1, 'portion': 1, 'neutralizing': 1, 'antibody': 1, 'noninferior': 1, 'youngadult': 1, '26': 1, 'using': 1, 'wildtype': 1, 'sarscov2': 1, '15fold': 1, 'young': 1, 'meeting': 1, 'fdaspecified': 1, 'criteria': 1}, {'much': 1, 'moderna': 1, 'booster': 1, 'helping': 1, 'also': 1, 'long': 1, 'effective': 1, '?': 1}, {'thanks': 1, 'sharing': 1, 'several': 1, 'studies': 1, 'preprints': 1, 'actually': 1, 'see': 1, 'small': 1, 'improvement': 1, 'b1': 1, 'customized': 1, 'vaccines': 1, 'however': 1, 'effect': 1, 'size': 1, 'nt': 1, 'tremendous': 1, 'results': 1, 'really': 1, 'beg': 1, 'question': 1, 'rather': 1, 'answer': 1, 'virus': 1, 'rapidly': 1, 'evolving': 1, 'know': 1, 'fact': 1, 'original': 1, 'preformed': 1, 'less': 1, 'effectively': 1, 'omicron': 1, 'humans': 1, 'proof': 1, 'enough': 1, 'need': 1, 'preemptively': 1, 'update': 1, 'vaccine': 1, 'anticipation': 1, 'next': 1, 'wave': 1}, {'abstract': 1, 'multiple': 1, 'covid19': 1, 'vaccines': 1, 'representing': 1, 'diverse': 1, 'vaccine': 1, 'platforms': 1, 'successfully': 1, 'protect': 1, 'symptomatic': 1, 'cases': 1, 'deaths': 1, 'headtohead': 1, 'comparisons': 1, 'cell': 1, 'b': 1, 'antibody': 1, 'responses': 1, 'humans': 1, 'likely': 1, 'informative': 1, 'understanding': 1, 'protective': 1, 'immunity': 1, 'particular': 1, 'interest': 1, 'immune': 1, 'memory': 1, 'sarscov2spikespecific': 1, 'moderna': 1, 'mrna1273': 1, 'pfizerbiontech': 1, 'bnt162b2': 1, 'janssen': 1, 'ad26cov2s': 1, 'novavax': 1, 'nvxcov2373': 1, 'examined': 1, 'longitudinally': 1, '6': 1, 'months': 1, '100': 1, '%': 1, 'individuals': 1, 'made': 1, 'cd4': 1, 'cells': 1, 'ctfh': 1, 'cd4ctl': 1, 'highly': 1, 'represented': 1, 'mrna': 1, 'vaccination': 1, 'induced': 1, 'comparable': 1, 'cd8': 1, 'frequencies': 1, 'though': 1, 'detectable': 1, '6067': 1, 'subjects': 1, 'strongest': 1, 'immunogen': 1, 'measurement': 1, 'relatively': 1, 'stable': 1, 'differentiating': 1, 'feature': 1, 'immunization': 1, 'high': 1, 'frequency': 1, 'cxcr3': 1, 'vaccinees': 1, 'substantial': 1, 'declines': 1, 'neutralizing': 1, 'antibodies': 1, 'comparatively': 1, 'results': 1, 'detailed': 1, 'immunological': 1, 'evaluations': 1, 'may': 1, 'also': 1, 'relevant': 1, 'design': 1, 'insights': 1, 'pathogens': 1}, {'mrna': 1, 'vaccines': 1, 'big': 1, 'point': 1, 'concern': 1, 'introduction': 1, 'proteins': 1, 'spikes': 1, 'body': 1, 'see': 1, 'potentially': 1, 'harmful': 1, 'well': 1, 'particular': 1, 'vaccine': 1, 'nt': 1, 'introduce': 1, 'instructs': 1, 'produce': 1, 'unless': 1, 'm': 1, 'misunderstanding': 1, 're': 1, 'saying': 1, 'inhaled': 1, 'isnäôt': 1, 'good': 1, 'chance': 1, 'least': 1, 'adenoviruses': 1, 'going': 1, 'wind': 1, 'lungs': 1, '?': 1, 'issue': 1, 'mere': 1, 'presence': 1, 'form': 1, 'deadunable': 1, 'reproduce': 1, 'spike': 1, 'multiplying': 1, 'actual': 1, 'covid': 1, 'would': 1, 'assume': 1, 'allow': 1, 'address': 1, 'quickly': 1, 'provide': 1, 'much': 1, 'needed': 1, 'local': 1, 'immunity': 1, 'one': 1, 'sites': 1, 'really': 1, 'causes': 1, 'get': 1, 'mucosal': 1, 'level': 1, 'airway': 1, 'entry': 1, 'points': 1}, {'spike': 1, 'getäôs': 1, 'lower': 1, 'itäôs': 1, 'going': 1, '0': 1, 'us': 1, 'inactive': 1, 'vaccines': 1, 'antibody': 1, 'test': 1, 'n': 1, 'protein': 1, 'return': 1, '00': 1, 'auml': 1, 'incase': 1, 'prior': 1, 'infection': 1}, {'150': 1, 'days': 1, 'look': 1, 'positive': 1, '?': 1}, {'totally': 1, 'possible': 1, 'also': 1, 'true': 1, 'exercising': 1, 'might': 1, 'increase': 1, 'antibody': 1, 'response': 1, 'myocarditis': 1, 'risk': 1, 'findings': 1, 'like': 1, 'nt': 1, 'immediately': 1, 'grouped': 1, 'good': 1, 'bad': 1, 'walking': 1, '90': 1, 'minutes': 1, 'qualifies': 1, 'exercise': 1, 'm': 1, 'reading': 1, 'probably': 1, 'wo': 1, 'result': 1, 're': 1, 'saying': 1, 'need': 1, 'intense': 1, 'workout': 1}, {'1': 1, 'better': 1, 'antibody': 1, 'match': 1, 'shouldcould': 1, 'lead': 1, 'initially': 1, 'higher': 1, 'durable': 1, 'protection': 1, 'infection': 1, 'also': 1, 'wonder': 1, 'thereäôs': 1, 'hypothesizing': 1, 'priming': 1, 'immune': 1, 'system': 1, 'original': 1, 'wuhan': 1, 'spike': 1, 'subsequently': 1, 'showing': 1, 'nearworstcasescenario': 1, 'mutated': 1, 'omicron': 1, 'might': 1, 'make': 1, 'really': 1, 'go': 1, 'äúhyperdriveäù': 1, 'far': 1, 'quantity': 1, 'breadth': 1, 'avidity': 1, 'response': 1, 'perhaps': 1, 'leave': 1, 'well': 1, 'equipped': 1, 'least': 1, 'address': 1, 'future': 1, 'branches': 1, 'either': 1, 'end': 1, 'spectrum': 1, 'variants': 1, 'arise': 1, 'always': 1, 'going': 1, 'waning': 1, 'good': 1, 'b': 1, 'cells': 1, 'highly': 1, 'trained': 1, 'handle': 1, 'whatever': 1, 'variant': 1, 'see': 1, 'could': 1, 'put': 1, 'us': 1, 'place': 1, '2': 1, 'understanding': 1, 'based': 1, 'fda': 1, 'guidance': 1, 'last': 1, 'year': 1, 'äútrialsäù': 1, 'specific': 1, 'vaccines': 1, 'akin': 1, 'yearly': 1, 'flu': 1, 'shot': 1, 'trials': 1, 'focusing': 1, 'largely': 1, 'safety': 1, 'demonstrating': 1, 'vitro': 1, 'theyäôve': 1, 'saying': 1, 'along': 1, 'deployment': 1, 'somewhere': 1, 'around': 1, 'march': 1, 'optimistic': 1, 'side': 1, 'say': 1, 'theyäôre': 1, 'already': 1, 'manufacturing': 1, 'doses': 1, 'risk': 1, 'assume': 1, 'pfizeräôs': 1, 'still': 1, 'much': 1, 'table': 1, 'itäôs': 1, 'shown': 1, 'safe': 1, 'stimulate': 1, 'sufficient': 1, 'ball': 1, 'obviously': 1, 'ultimately': 1, 'cdc': 1, 'äôs': 1, 'court': 1, 'take': 1, 'announcement': 1, 'mean': 1, 'track': 1}, {'open': 1, 'letter': 1, 'group': 1, 'public': 1, 'health': 1, 'experts': 1, 'clinicians': 1, 'scientists': 1, 'sarscov2': 1, 'infected': 1, '278': 1, 'million': 1, 'people': 1, 'globally': 1, 'least': 1, '54': 1, 'deaths': 1, 'recorded': 1, 'world': 1, 'organisation': 1, '26': 1, 'december': 1, '2021': 1, 'omicron': 1, 'b11529': 1, 'variant': 1, 'concern': 1, 'spreading': 1, 'rapidly': 1, 'countries': 1, 'view': 1, 'infection': 1, 'net': 1, 'harm': 1, 'pursue': 1, 'strategies': 1, 'ranging': 1, 'suppression': 1, 'elimination': 1, 'seek': 1, 'sustain': 1, 'low': 1, 'rates': 1, 'combination': 1, 'vaccination': 1, 'measures': 1, 'financial': 1, 'support': 1, 'vaccinesplus': 1, 'implemented': 1, 'mitigation': 1, 'aim': 1, 'prevent': 1, 'systems': 1, 'overwhelmed': 1, 'building': 1, 'population': 1, 'immunity': 1, 'rely': 1, 'vaccinesonly': 1, 'approach': 1, 'seem': 1, 'willing': 1, 'tolerate': 1, 'high': 1, 'levels': 1, 'provided': 1, 'healthcare': 1, 'cope': 1, 'transmissibility': 1, 'degree': 1, 'immune': 1, 'escape': 1, 'delta': 1, 'variants': 1, 'means': 1, 'sustained': 1, 'protective': 1, 'unlikely': 1, 'achieved': 1, 'current': 1, 'vaccines': 1, 'based': 1, 'original': 1, 'strain': 1, 'compared': 1, 'much': 1, 'likely': 1, 'infect': 1, 'vaccinated': 1, 'exposed': 1, 'previous': 1, 'suggesting': 1, 'significant': 1, 'widespread': 1, 'transmission': 1, 'brings': 1, 'unpredictability': 1, 'pandemic': 1, 'response': 1, 'risks': 1, 'rapid': 1, 'adaptation': 1, 'outcomes': 1, 'include': 1, 'increased': 1, 'seen': 1, 'œ': 1, 'antibody': 1, 'greater': 1, 'pathogenicity': 1, 'drawbacks': 1, 'strategy': 1, 'tolerated': 1, 'rises': 1, 'covidspecific': 1, 'allcause': 1, 'mortality': 1, 'worker': 1, 'shortages': 1, 'repeated': 1, 'lockdowns': 1, 'control': 1, 'surges': 1, 'case': 1, 'numbers': 1, 'suppressed': 1, 'early': 1, 'saw': 1, 'reduced': 1, 'less': 1, 'economic': 1, 'damage': 1, 'greatly': 1, 'reduces': 1, 'serious': 1, 'illness': 1, 'death': 1, 'long': 1, 'covid': 1, 'remains': 1, 'disruption': 1, 'education': 1, 'result': 1, 'staff': 1, 'student': 1, 'sickness': 1, 'andor': 1, 'due': 1, 'failure': 1, 'virus': 1, 'lasting': 1, 'impact': 1, 'wellbeing': 1, 'prospects': 1, 'next': 1, 'generation': 1, 'also': 1, 'create': 1, 'negative': 1, 'feedback': 1, 'loop': 1, 'whereby': 1, 'important': 1, 'test': 1, 'trace': 1, 'isolate': 1, 'become': 1, 'making': 1, 'effective': 1, 'fuelling': 1, 'reasons': 1, 'adopted': 1, 'slow': 1, 'emergence': 1, 'new': 1, 'ensure': 1, 'exist': 1, 'background': 1, 'controlled': 1, 'allowing': 1, 'everyone': 1, 'including': 1, 'clinically': 1, 'vulnerable': 1, 'go': 1, 'lives': 1, 'freely': 1, 'welcome': 1, 'organisationäôs': 1, 'recent': 1, 'guidance': 1, 'community': 1, 'mask': 1, 'use': 1, 'believe': 1, 'done': 1, 'suppress': 1, 'without': 1, 'adversely': 1, 'impacting': 1, 'social': 1, 'activity': 1, 'accordingly': 1, 'call': 1, 'upon': 1, 'national': 1, 'governments': 1, 'unequivocally': 1, 'declare': 1, 'airborne': 1, 'pathogen': 1, 'stress': 1, 'implications': 1, 'preventing': 1, 'clear': 1, 'message': 1, 'help': 1, 'remove': 1, 'confusion': 1, 'used': 1, 'justify': 1, 'outdated': 1, 'policies': 1, 'promote': 1, 'highquality': 1, 'face': 1, 'masks': 1, 'indoor': 1, 'gatherings': 1, 'hightransmission': 1, 'settings': 1, 'benefits': 1, 'masking': 1, 'well': 1, 'established': 1, 'respirators': 1, 'eg': 1, 'n95': 1, 'p2ffp2': 1, 'kf94': 1, 'preferred': 1, 'mix': 1, 'workers': 1, 'times': 1, 'advise': 1, 'ventilation': 1, 'filtration': 1, 'air': 1, 'time': 1, 'beyond': 1, 'opening': 1, 'windows': 1, 'paradigm': 1, 'shift': 1, 'buildings': 1, 'optimally': 1, 'designed': 1, 'built': 1, 'adapted': 1, 'utilised': 1, 'maximise': 1, 'clean': 1, 'occupantsäîstrategies': 1, 'shown': 1, 'reduce': 1, 'set': 1, 'criteria': 1, 'imposing': 1, 'relaxing': 1, 'covid19': 1, 'spread': 1, 'find': 1, 'continue': 1, 'essential': 1, 'intercept': 1, 'give': 1, 'available': 1, 'best': 1, 'chance': 1, 'creating': 1, 'positive': 1, 'selfreinforcing': 1, 'cycle': 1, 'disease': 1, 'sufficient': 1, 'practical': 1, 'isolation': 1, 'everywhere': 1, 'particularly': 1, 'middleincome': 1, 'deprived': 1, 'parts': 1, 'highincome': 1, 'urgent': 1, 'achieve': 1, 'global': 1, 'vaccine': 1, 'equity': 1, 'sharing': 1, 'suspension': 1, 'patents': 1, 'removal': 1, 'barriers': 1, 'technology': 1, 'transfer': 1, 'establish': 1, 'regional': 1, 'production': 1, 'centres': 1, 'plentiful': 1, 'local': 1, 'supply': 1, 'rollout': 1, 'coordinated': 1, 'efforts': 1, 'tackle': 1, 'misinformation': 1, 'access': 1, 'timely': 1, 'accurate': 1, 'data': 1, 'effectiveness': 1, 'protection': 1, 'affordable': 1, 'achievable': 1, 'policy': 1, 'advocated': 1, 'director': 1, 'general': 1, 'tedros': 1, 'adhanom': 1, 'ghebreyesus': 1, 'statement': 1, '14': 1, 'äúi': 1, 'need': 1, 'alone': 1, 'get': 1, 'country': 1, 'crisis': 1, 'must': 1, 'work': 1, 'today': 1, 'itäôs': 1, 'instead': 1, 'distancing': 1, 'hand': 1, 'hygiene': 1, 'consistently': 1, 'welläù': 1}, {'oh': 1, 's': 1, 'good': 1, 'one': 1, 'expert': 1, 'think': 1, 'flu': 1, 'vaccine': 1, 'selection': 1, 'mostly': 1, 'depends': 1, 'multiple': 1, 'cocirculating': 1, 'variants': 1, 'dominant': 1, 'given': 1, 'year': 1, 'evidence': 1, 'sarscov2': 1, 'could': 1, 'end': 1, 'resulting': 1, 'regionalization': 1, 'speciation': 1, 'https': 1, 'wwwpnasorgdoi101073pnas2104241118': 1, 'still': 1, 'happening': 1, 'right': 1, 'strain': 1, 'time': 1, 'long': 1, 'd': 1, 'say': 1, 'already': 1, 'enough': 1, 'empirical': 1, 'information': 1, 'prediction': 1, 'ca': 1, 'nt': 1, 'predict': 1, 'new': 1, 'mutations': 1, 'emerge': 1, 'future': 1, 'far': 1, 'perfect': 1, 'subtypes': 1, 'm': 1, 'sure': 1, 'hazard': 1, 'guess': 1, 'would': 1, 'possible': 1, 'real': 1, 'crazy': 1, 'explosion': 1, 'sequencing': 1, 'efforts': 1}, {'67': 1, '%': 1, 'effectiveness': 1, 'low': 1, '?': 1, 'mean': 1, 'yeah': 1, 'itäôs': 1, '95': 1, 'pretty': 1, 'good': 1, 'book': 1, 'month': 1, 'two': 1, 'ago': 1, 'nobody': 1, 'sure': 1, 'would': 1, 'provide': 1, 'anything': 1}, {'ba2': 1, 'expected': 1, 'less': 1, 'immune': 1, 'escape': 1, 'ba1': 1, 's': 1, 'great': 1, 'news': 1, 'considering': 1, 'coming': 1, 'behind': 1, 'also': 1, 'indication': 1, 'transmission': 1, 'advantage': 1, 'much': 1, 'inherent': 1, 'transmissibility': 1}, {'pcr': 1, 'done': 1, 'days': 1, 'event': 1, 'shitty': 1, 'way': 1, 'detect': 1, 'infectivity': 1, 'day': 1, 'party': 1, 'take': 1, 'home': 1, 'antigen': 1, 'thanks': 1, 'correction': 1, 'tests': 1, 'hour': 1, 'catch': 1, 'people': 1, 'infectious': 1, 'window': 1, 'would': 1, 'likely': 1, 'michael': 1, 'mina': 1, 'stuff': 1, 'one': 1, 'person': 1, 'infecting': 1, '21': 1, '?': 1, 'hopefully': 1, 'sequencing': 1, 'determine': 1, 'something': 1, 'transmission': 1, 'dynamics': 1, 'studies': 1, 'regarding': 1, 'much': 1, 'others': 1, 'greater': 1, 'expulsion': 1, 'viral': 1, 'spittle': 1, 'behavioral': 1, 'edit': 1, 'aaannnnd': 1, 'post': 1, 'locked': 1, 'gj': 1, 'mods': 1, 'response': 1, 'question': 1, 'test': 1, 'sensitivity': 1, 'low': 1, 'relative': 1, 'however': 1, 'nt': 1, 'care': 1, 'absurdly': 1, 'high': 1, 'cycle': 1, 'threshold': 1, 'machines': 1, 'correlate': 1, 'infectiousness': 1, 'producing': 1, 'enough': 1, 'droplets': 1, 'infect': 1, 'presumably': 1, 'good': 1, 'consider': 1, 've': 1, 'found': 1, 'sarscov2': 1, 'variants': 1, 'dispersion': 1, 'parameter': 1, 'k': 1, 'meaning': 1, 's': 1, 'smaller': 1, 'proportion': 1, 'population': 1, 'majority': 1, 'spreading': 1, 'likelihood': 1, 'spreaders': 1, 'drive': 1, 'r': 1, 'testing': 1, 'everyone': 1, 'get': 1, 'together': 1, 'discussed': 1, 'since': 1, 'mid2020': 1}, {'ca': 1, 'nt': 1, 'calculate': 1, 'vaccine': 1, 'efficacy': 1, 'data': 1}, {'s': 1, 'great': 1, 'news': 1, 'nt': 1, 'think': 1, 'greater': 1, 'inherent': 1, 'transmissibility': 1}, {'showed': 1, 'higher': 1, 'neutralization': 1, 'capacity': 1, '140': 1, 'sarscov2': 1, 'vocs': 1, 'compared': 1, 'infectionnaive': 1, 'individuals': 1, 'even': 1, 'afte': 1, 'nt': 1, 'followed': 1, 'literature': 1, 'extremely': 1, 'closely': 1, 've': 1, 'seen': 1, '3': 1, 'prior': 1, 'papers': 1, 'evaluated': 1, 'relative': 1, 'effectiveness': 1, 'infection': 1, 'recovery': 1, 'vaccine': 1, 'consistent': 1, 'findings': 1, 'one': 1, '2': 1, 'based': 1, 'israel': 1, 'data': 1, 'another': 1, 'recent': 1, 'paper': 1, 'us': 1, 'delta': 1, 'surge': 1, 'period': 1, 'variation': 1, 'statistical': 1, 'significance': 1, 'none': 1, 'vaccination': 1, 'alone': 1, 'provide': 1, 'better': 1, 'protection': 1, 'recovered': 1, 'ca': 1, 'locate': 1, 's': 1, 'https': 1, 'wwwcdcgovmmwrvolumes71wrmm7104e1htm': 1, '?': 1, 's_cidmm7104e1_w': 1}, {'äúon': 1, 'december': 1, '17': 1, '2021': 1, 'pfizer': 1, 'biontech': 1, 'announced': 1, 'companies': 1, 'would': 1, 'test': 1, 'third': 1, '3': 1, 'µg': 1, 'dose': 1, 'given': 1, 'least': 1, 'two': 1, 'months': 1, 'second': 1, 'children': 1, 'age': 1, '5': 1, '10': 1, 'formulation': 1, '12': 1, 'years': 1, 'ageäù': 1}, {'currently': 1, 'africa': 1, 'cases': 1, 'sky': 1, 'rocketing': 1, 'meanwhile': 1, 'deaths': 1, 'flat': 1, 'make': 1, 'data': 1}, {'poorly': 1, 'written': 1, 'preprint': 1, 'reporting': 1, 'results': 1, 'obtained': 1, 'completely': 1, 'artificial': 1, 'conditions': 1, 'nothing': 1, 'interesting': 1, 'learn': 1}, {'hopefully': 1, 'll': 1, 'help': 1, 'severe': 1, 'disease': 1}, {'need': 1, 'nasal': 1, 'vaccine': 1, 'elicits': 1, 'better': 1, 'mucosal': 1, 'immunity': 1, 's': 1, 'omicron': 1, 'causing': 1, 'many': 1, 'breakthroughs': 1, 'nt': 1, 'think': 1, 'enough': 1, 'focus': 1, 'getting': 1, 'least': 1, '1': 1, 'testedapproved': 1, 'spite': 1, 'positive': 1, 'preprints': 1, 'potential': 1, 'efficacy': 1}, {'yeah': 1, 'iäôm': 1, 'thinking': 1, 'bc': 1, 'omicron': 1, 'although': 1, '1215': 1, 'looks': 1, 'better': 1, 'lower': 1, 'dose': 1, 'issues': 1, '?': 1, 'wonder': 1, 'compares': 1, 'modernaäôs': 1, 'trial': 1, '511': 1, 'also': 1, 'age': 1, 'lowest': 1, 'risk': 1, 'around': 1, 'perhaps': 1, 'itäôs': 1, 'something': 1, 'specific': 1, 'immune': 1, 'system': 1}, {'study': 1, 'https': 1, 'wwwsciencedirectcomsciencearticlepiis0092867422000769': 1, 'preomicron': 1, 'mongolian': 1, 'data': 1, 'several': 1, 'vaccines': 1, 'including': 1, 'sputnik': 1, 'appears': 1, 'perform': 1, 'sinopharm': 1, 'az': 1, 'well': 1, 'mrna': 1, 'recent': 1, 'hungarian': 1, 'preprint': 1, 'wwwmedrxivorgcontent1011012022021822271179v1': 1, 'shows': 1, 'similar': 1, 'results': 1}, {'thatäôs': 1, 'shame': 1, 'guess': 1, 'wild': 1, 'type': 1, 'still': 1, 'way': 1, 'go': 1, 'matter': 1, 'much': 1, 'variants': 1, 'diverge': 1, 'wt': 1, 'one': 1, 'variant': 1, 'others': 1, 'guaranteed': 1, 'relatively': 1, 'close': 1, 'connection': 1}, {'argentina': 1, 'overall': 1, 'data': 1, 'suggest': 1, 'maturation': 1, 'antibody': 1, 'response': 1, 'observed': 1, 'time': 1, 'standard': 1, 'sputnik': 1, 'v': 1, 'vaccination': 1, 'unable': 1, 'overcome': 1, 'ability': 1, 'omicron': 1, 'escape': 1, 'humoral': 1, 'induced': 1, 'vaccine': 1, 'emphasising': 1, 'need': 1, 'administer': 1, 'booster': 1, 'dose': 1, 'urgently': 1, 'combining': 1, 'platforms': 1, 'would': 1, 'option': 1, 'increase': 1, 'neutralising': 1, 'levels': 1, 'variant': 1}, {'couple': 1, 'questions': 1, 'science': 1, 'antibodies': 1, 'anyone': 1, 'qualified': 1, '1': 1, 'reason': 1, 'humans': 1, 'nt': 1, 'tend': 1, 'hold': 1, 'onto': 1, 'coronavirus': 1, '?': 1, 've': 1, 'read': 1, '2020': 1, 'preprints': 1, 'spike': 1, 'somewhat': 1, 'cross': 1, 'reactive': 1, 'endogenous': 1, 'human': 1, 'proteins': 1, 'covid': 1, 'infection': 1, 'prevaccine': 1, 'possible': 1, 'waning': 1, 'humoral': 1, 'immunity': 1, 'design': 1, 'avoid': 1, 'leaving': 1, 'cellular': 1, 'protect': 1, 'long': 1, 'term': 1, 'serious': 1, 'illnessdeath': 1, '2': 1, 'omicron': 1, 'displaces': 1, 'delta': 1, 'completely': 1, 'risk': 1, 'removed': 1, 'possibility': 1, 'boosting': 1, 'wuhan': 1, 'variant': 1, 'breakthrough': 1, 'counter': 1, 'productive': 1, 'd': 1, 'already': 1, 'producing': 1, 'specific': 1, 'm': 1, 'relative': 1, 'layman': 1, 'please': 1, 'forgive': 1, 'breaks': 1, 'rules': 1, 'highlights': 1, 'naivety': 1}, {'thought': 1, 'real': 1, 'goal': 1, 'much': 1, 'omicron': 1, 'inevitable': 1, 'variants': 1, 'dependent': 1, 'thus': 1, 'abstracted': 1, 'earlier': 1, 'strain': 1, 'something': 1, 'ready': 1, 'case': 1, 'thatäôs': 1, 'needed': 1, 'quickly': 1, 'deployed': 1, 'test': 1, 'would': 1, 'comes': 1, 'next': 1}, {'little': 1, 'data': 1, 'many': 1, 'combinations': 1, 'hybrid': 1, 'immunity': 1, 's': 1, 'guess': 1}, {'ca': 1, 'nt': 1, 'randomize': 1, 'across': 1, 'different': 1, 'cohorts': 1, 'looking': 1, 'people': 1, 'vaccination': 1, 'histories': 1, '?': 1}, {'immune': 1, 'system': 1, 'lack': 1, 'better': 1, 'term': 1, 'wear': 1, 'constant': 1, 'boosting': 1, 'like': 1, '?': 1, 'read': 1, 'immunologist': 1, 'twitter': 1, 'evidence': 1, 'viruses': 1, 'donäôt': 1, 'literature': 1, 'link': 1}, {'study': 1, 'states': 1, 'eligible': 1, 'medical': 1, 'encounters': 1, 'defined': 1, 'among': 1, 'adults': 1, 'aged': 1, 'â18': 1, 'years': 1, 'covid19äìlike': 1, 'illness': 1, 'diagnosis': 1, 'nt': 1, 'think': 1, 'asymptomatic': 1, 'patients': 1, 'included': 1}, {'still': 1, 'supports': 1, 'mandated': 1, 'double': 1, 'vaccinations': 1, 'healthy': 1, 'young': 1, 'males': 1, 'already': 1, 'covid19': 1, '?': 1, 'scientific': 1, 'rationale': 1, '1316': 1, 'years': 1, 'age': 1, 'group': 1, 'covid': 1, 'causing': 1, 'myocarditis': 1, 'risk': 1, 'vaccine': 1, 'getting': 1, 'infected': 1, 'https': 1, 'wwwncbinlmnihgovpmcarticlespmc7988375': 1}, {'older': 1, '2020': 1, 'article': 1, 'see': 1, 'posted': 1, 'yet': 1, 'abstract': 1, 'distrust': 1, 'scientific': 1, 'expertise1234567891011121314': 1, 'dangerous': 1, 'opposition': 1, 'vaccination': 1, 'future': 1, 'vaccine': 1, 'sarscov2': 1, 'causal': 1, 'agent': 1, 'covid19': 1, 'example': 1, 'could': 1, 'amplify': 1, 'outbreaks234': 1, 'happened': 1, 'measles': 1, '201956': 1, 'homemade': 1, 'remedies78': 1, 'falsehoods': 1, 'shared': 1, 'widely': 1, 'internet': 1, 'well': 1, 'dismissals': 1, 'expert': 1, 'advice91011': 1, 'lack': 1, 'understanding': 1, 'evolves': 1, 'system': 1, 'level1314': 1, 'provide': 1, 'map': 1, 'contention': 1, 'surrounding': 1, 'vaccines': 1, 'emerged': 1, 'global': 1, 'pool': 1, 'around': 1, 'three': 1, 'billion': 1, 'facebook': 1, 'users': 1, 'core': 1, 'reveals': 1, 'multisided': 1, 'landscape': 1, 'unprecedented': 1, 'intricacy': 1, 'involves': 1, 'nearly': 1, '100': 1, 'million': 1, 'individuals': 1, 'partitioned': 1, 'highly': 1, 'dynamic': 1, 'interconnected': 1, 'clusters': 1, 'across': 1, 'cities': 1, 'countries': 1, 'continents': 1, 'languages': 1, 'although': 1, 'smaller': 1, 'overall': 1, 'size': 1, 'antivaccination': 1, 'manage': 1, 'become': 1, 'entangled': 1, 'undecided': 1, 'main': 1, 'online': 1, 'network': 1, 'whereas': 1, 'provaccination': 1, 'peripheral': 1, 'our': 1, 'theoretical': 1, 'framework': 1, 'reproduces': 1, 'recent': 1, 'explosive': 1, 'growth': 1, 'views': 1, 'predicts': 1, 'dominate': 1, 'decade': 1, 'insights': 1, 'provided': 1, 'inform': 1, 'new': 1, 'policies': 1, 'approaches': 1, 'interrupt': 1, 'shift': 1, 'negative': 1, 'results': 1, 'challenge': 1, 'conventional': 1, 'thinking': 1, 'issues': 1, 'health': 1, 'shed': 1, 'light': 1, 'climate': 1, 'change11': 1, 'highlight': 1, 'key': 1, 'role': 1, 'cluster': 1, 'dynamics': 1, 'multispecies': 1, 'ecologies15': 1}, {'postvaccination': 1, 'symptoms': 1, 'fatigue': 1, 'joint': 1, 'pain': 1, 'taste': 1, 'olfactory': 1, 'abnormalities': 1, 'relieved': 1, 'worsened': 1, 'unchanged': 1, '7': 1, '167': 1, '%': 1, '9': 1, '214': 1, '26': 1, '619': 1, 'patients': 1, 'respectively': 1, 'ratios': 1, 'pre': 1, 'antibody': 1, 'titers': 1, '53': 1, '40': 1, '174': 1, 'relief': 1, 'groups': 1, 'group': 1, 'significantly': 1, 'highest': 1, 'titer': 1, 'ratio': 1, 'p': 1, '002': 1, 'higher': 1, 'increased': 1, 'rate': 1, 'nonworsened': 1, 'suggests': 1, 'excessive': 1, 'immune': 1, 'response': 1, 'vaccination': 1, 'associated': 1, 'worsening': 1, 'sequelae': 1, 'although': 1, 'long': 1, 'covid': 1, 'vaccinated': 1, 'additional': 1, 'concerns': 1, 'addressed': 1, 'emphasis': 1, 'added': 1, 'first': 1, 'doesnäôt': 1, 'seem': 1, 'scientific': 1, 'make': 1, 'claim': 1, 'like': 1, 'äúx': 1, 'doneäù': 1, 'even': 1, 'ethical': 1, 'calculations': 1, 'science': 1, 'papers': 1, 'correct': 1, '?': 1, 'health': 1, 'benefit': 1, 'reducing': 1, 'infencfion': 1, 'worth': 1, 'cost': 1, 'peopleäôs': 1, 'quantified': 1, 'determined': 1, 'unfortunately': 1, 'iäôm': 1, 'lazy': 1, 'didnäôt': 1, 'go': 1, 'beyond': 1, 'abstract': 1, 'reasoning': 1, 'seems': 1, 'skipped': 1, 'clumsily': 1, 'attempting': 1, 'say': 1, 'something': 1, 'äúitäôs': 1, 'intention': 1, 'argue': 1, 'favor': 1, 'change': 1, 'rates': 1, 'targets': 1, 'side': 1, 'effects': 1, 'prepare': 1, 'mitigateäù': 1}, {'s': 1, 'good': 1, 'question': 1, 'booster': 1, 'performance': 1, 'going': 1, 'much': 1, 'salient': 1, 'part': 1, 'wonder': 1, 'nt': 1, 'recruit': 1, 'bigger': 1, 'cohort': 1, '600': 1, 'seems': 1, 'bit': 1, 'low': 1, 'pick': 1, 'potential': 1, 'variation': 1, 'depending': 1, 'immune': 1, 'response': 1, 'first': 1, 'course': 1}, {'let': 1, 'get': 1, 'rightyoung': 1, 'males': 1, 'higher': 1, 'risk': 1, 'mycoarditis': 1, 'vaccination': 1, 'covid': 1, 'infection': 1, '?': 1}, {'abstract': 1, 'intramuscular': 1, 'vaccines': 1, 'greatly': 1, 'reduced': 1, 'hospitalization': 1, 'death': 1, 'due': 1, 'severe': 1, 'covid19': 1, 'however': 1, 'countries': 1, 'experiencing': 1, 'resurgence': 1, 'infection': 1, 'driven': 1, 'predominantly': 1, 'delta': 1, 'omicron': 1, 'variants': 1, 'sarscov2': 1, 'response': 1, 'booster': 1, 'dosing': 1, 'implemented': 1, 'many': 1, 'address': 1, 'waning': 1, 'immunity': 1, 'protection': 1, 'boosting': 1, 'fails': 1, 'elicit': 1, 'mucosal': 1, 'therefore': 1, 'solve': 1, 'problem': 1, 'persistent': 1, 'viral': 1, 'carriage': 1, 'transmission': 1, 'even': 1, 'patients': 1, 'protected': 1, 'disease': 1, 'study': 1, 'two': 1, 'doses': 1, 'stabilized': 1, 'prefusion': 1, 'spike': 1, 's2p': 1, 'based': 1, 'vaccine': 1, 'adjuvanted': 1, 'alumcpg1018': 1, 'mvccov1901': 1, 'used': 1, 'primary': 1, 'vaccination': 1, 'series': 1, 'followed': 1, 'intranasal': 1, 'nanoemulsion': 1, 'ne01': 1, 'hamster': 1, 'model': 1, 'demonstrate': 1, 'immunogenicity': 1, 'challenge': 1, 'report': 1, 'regimen': 1, 'resulted': 1, 'induction': 1, 'robust': 1, 'weight': 1, 'loss': 1, 'lung': 1, 'pathology': 1, 'following': 1, 'also': 1, 'led': 1, 'increased': 1, 'clearance': 1, 'upper': 1, 'lower': 1, 'respiratory': 1, 'tracts': 1, 'our': 1, 'findings': 1, 'showed': 1, 'ne01adjuvanted': 1, 'promotes': 1, 'protective': 1, 'suggesting': 1, 'immunization': 1, 'protocol': 1, 'may': 1, 'offer': 1, 'solution': 1, 'addressing': 1, 'significant': 1, 'unmet': 1, 'medical': 1, 'need': 1, 'future': 1, 'pandemics': 1}, {'s': 1, 'entirely': 1, 'possible': 1, 'true': 1, 'variants': 1, 'omicron': 1, 'less': 1, 'likely': 1, 'cause': 1, 'anosmia': 1, 'think': 1, 'data': 1, 'nt': 1, 'convincing': 1, 'previously': 1, 'anyway': 1}, {'time': 1, 'frame': 1, 'infectionneutralizing': 1, 'antibody': 1, 'response': 1, 'last': 1, '?': 1}, {'find': 1, '3': 1, 'shots': 1, 'nt': 1, 'work': 1, '34': 1, 'year': 1, 'olds': 1, 'wo': 1, 'resubmit': 1, '2': 1, '6mo2': 1, 'years': 1, '?': 1}, {'studies': 1, 'teaching': 1, 'us': 1, 'rules': 1, 'engagement': 1, 'immune': 1, 'system': 1, 'boost': 1, 'variant': 1, 'vaccine': 1, 'äù': 1, 'says': 1, 'montefiori': 1, 'suggest': 1, 'single': 1, 'variantmatched': 1, 'probably': 1, 'isnäôt': 1, 'solution': 1, 'still': 1, 'fingers': 1, 'crossed': 1, 'walter': 1, 'reed': 1, 'shot': 1}, {'ever': 1, 'likely': 1, 'really': 1, 'happen': 1, 'though': 1, '?': 1, 'injections': 1, 'intramuscular': 1, 'shouldnäôt': 1, 'migrate': 1, 'much': 1, 'let': 1, 'alone': 1, 'get': 1, 'brain': 1}, {'note': 1, 'interest': 1, 'data': 1, 'england': 1, 'vaccine': 1, 'injections': 1, 'aspiration': 1, 'technique': 1, 'nt': 1, 'mandated': 1, 'concerns': 1, 'https': 1, 'pubmedncbinlmnihgov34406358': 1, 'badly': 1, 'placed': 1, 'result': 1, 'adverse': 1, 'reactions': 1, 'like': 1, 'myocarditis': 1}, {'study': 1, 'mentioning': 1, 'secondary': 1, 'attack': 1, 'rate': 1, 'meaning': 1, 'people': 1, 'getting': 1, 'infected': 1, 'unvaccinated': 1, 'also': 1, 'explains': 1, 'high': 1, 'sar': 1, 'vaccinated': 1, 'omicron': 1, 'immune': 1, 'escape': 1, 'nt': 1, 'see': 1, 'mention': 1, 'index': 1, 'cases': 1, 'less': 1, 'like': 1, 'transmit': 1, 'others': 1, 'unless': 1, 'missed': 1, 'similar': 1, 'household': 1, 'uk': 1, 'https': 1, 'wwwthelancetcomjournalslaninfarticlepiis14733099': 1, '21': 1, '006484fulltext': 1, 'found': 1, 'among': 1, 'contacts': 1, 'exposed': 1, 'fully': 1, '25': 1, '%': 1, '95': 1, 'ci': 1, '15äì35': 1, 'vs': 1, '23': 1, '15äì31': 1}, {'go': 1, 'https': 1, 'wwwmedrxivorgcontent1011012021093021264363v1': 1}, {'tell': 1, 'efficacy': 1, 'means': 1, 'terms': 1, 'probability': 1, 'll': 1, 'average': 1, '11': 1, '%': 1, 'eg': 1, 'take': 1, 'multiplicative': 1, 'model': 1, '43': 1, '1': 1, '57': 1, '143': 1, 'geometric': 1, 'mean': 1, 'around': 1, '10': 1}, {'would': 1, 'nt': 1, 'put': 1, 'context': 1, 'agesex': 1, 'actually': 1, 'think': 1, 'rather': 1, 'entire': 1, 'population': 1, '?': 1, 'also': 1, 'thought': 1, 'vaers': 1, 'reports': 1, 'worth': 1, 'paying': 1, 'attention': 1, 'thus': 1, 'view': 1, 'change': 1, 'recently': 1}, {'effectiveness': 1, 'dropped': 1, '12': 1, '%': 1, '34': 1, 'days': 1, '511': 1, '?': 1, 'wowä': 1}, {'abstract': 1, 'vaccination': 1, 'effective': 1, 'public': 1, 'health': 1, 'measure': 1, 'yet': 1, 'vaccine': 1, 'efficacy': 1, 'varies': 1, 'across': 1, 'different': 1, 'populations': 1, 'adjuvants': 1, 'improve': 1, 'often': 1, 'increase': 1, 'reactogenicity': 1, 'unconventional': 1, 'behavioral': 1, 'äúadjuvantäù': 1, 'physical': 1, 'exercise': 1, 'time': 1, 'separate': 1, 'experiments': 1, 'examined': 1, 'effect': 1, '90minute': 1, 'light': 1, 'moderateintensity': 1, 'cycle': 1, 'ergometer': 1, 'outdoor': 1, 'walkjog': 1, 'aerobic': 1, 'performed': 1, 'immunization': 1, 'serum': 1, 'antibody': 1, 'response': 1, 'three': 1, 'vaccines': 1, '2009': 1, 'pandemic': 1, 'influenza': 1, 'h1n1': 1, 'seasonal': 1, 'covid19': 1, 'took': 1, 'place': 1, 'first': 1, 'dose': 1, 'pfizerbiontech': 1, 'mouse': 1, 'model': 1, 'used': 1, 'examine': 1, 'role': 1, 'ifnœ': 1, 'potential': 1, 'mechanism': 1, 'treating': 1, 'mice': 1, 'antiifnœ': 1, 'results': 1, 'show': 1, '90': 1, 'min': 1, 'consistently': 1, 'increased': 1, 'four': 1, 'weeks': 1, 'postimmunization': 1, 'may': 1, 'partially': 1, 'contribute': 1, 'exerciserelated': 1, 'benefit': 1, 'side': 1, 'effects': 1, 'findings': 1, 'suggest': 1, 'adults': 1, 'regularly': 1, 'performing': 1, 'single': 1, 'session': 1}, {'fully': 1, 'approved': 1, 'alternative': 1, 'using': 1, 'mrna': 1, 'technology': 1, 'think': 1, 'good': 1, 'argument': 1, 'vaccine': 1, 'eua': 1, 'd': 1, 'people': 1, 'history': 1, 'myocarditis': 1, 'traditional': 1, 'actually': 1, 'would': 1, 'convince': 1, 'fence': 1}, {'this': 1, 'peerreviewed': 1, 'version': 1, 'previously': 1, 'discussed': 1, 'preprint': 1, 'https': 1, 'wwwredditcomrcovid19commentsqhfvfbsafety_monitoring_of_mrna_vaccines_administered': 1}, {'vaccinated': 1, 'catch': 1, 'covid': 1, '?': 1}, {'unless': 1, 'thereäôs': 1, 'another': 1, 'super': 1, 'contagious': 1, 'variant': 1, 'coming': 1, 'like': 1, 'last': 1, 'summeräôs': 1, 'delta': 1, 'peak': 1}, {'say': 1, 'latest': 1, 'booster': 1, 'date': 1, '2': 1, 'december': 1, '2021': 1, 'several': 1, 'people': 1, 'might': 1, 'entirely': 1, 'clear': 1, 'earliest': 1, 'october': 1, 'least': 1, 'one': 1, 'person': 1, 'weeks': 1, 'post': 1}, {'take': 1, 'home': 1, 'antibody': 1, 'tests': 1, 'hour': 1, 'catch': 1, 'people': 1, 'infectious': 1, 'window': 1, 'would': 1, 'likely': 1, '?': 1, 'meaning': 1, 'say': 1, 'antigen': 1, 'aka': 1, 'rapid': 1, 'sensitivity': 1, 'varies': 1, 'abbot': 1, 'binaxnow': 1, 'reported': 1, '65': 1, '%': 1}, {'longer': 1, 'copypaste': 1, 'discussion': 1, 'äúwe': 1, 'suspect': 1, 'acute': 1, 'cardiac': 1, 'changes': 1, 'seen': 1, 'two': 1, 'boys': 1, 'result': 1, 'epinephrinemediated': 1, 'effects': 1, 'cardiomyocytes': 1, 'occurrences': 1, 'generally': 1, 'favorable': 1, 'prognosis': 1, 'however': 1, 'patients': 1, 'may': 1, 'die': 1, 'underlying': 1, 'noncardiac': 1, 'cause': 1, 'myocardial': 1, 'findings': 1, 'eg': 1, 'subarachnoid': 1, 'hemorrhage': 1, 'histologically': 1, 'diffuse': 1, 'hypereosinophilic': 1, 'myocytes': 1, 'contraction': 1, 'bands': 1, 'coagulative': 1, 'myocytolysis': 1, 'patchy': 1, 'random': 1, 'pattern': 1, 'neutrophilicmononuclear': 1, 'cell': 1, 'infiltrate': 1, 'survival': 1, 'global': 1, 'ischemia': 1, 'develop37': 1, 'postvaccine': 1, 'reaction': 1, 'represent': 1, 'overly': 1, 'exuberant': 1, 'immune': 1, 'response': 1, 'injury': 1, 'mediated': 1, 'similar': 1, 'mechanisms': 1, 'described': 1, 'sarscov2': 1, 'multisystem': 1, 'inflammatory': 1, 'syndrome': 1, 'misc': 1, 'cytokine': 1, 'storms38': 1, 'rare': 1, 'systemic': 1, 'illness': 1, 'presenting': 1, 'persistent': 1, 'fever': 1, 'extreme': 1, 'inflammation': 1, 'following': 1, 'exposure': 1, 'sars': 1, 'cov2': 1, 'affected': 1, 'children': 1, 'abdominal': 1, 'pain': 1, 'diarrhea': 1, 'vomiting': 1, 'muscle': 1, 'painmalaise': 1, 'hypotension': 1, 'reported': 1, 'symptoms': 1, 'include': 1, 'rashes': 1, 'enlarged': 1, 'lymph': 1, 'nodes': 1, 'swellingäù': 1}, {'unvaccinated': 1, '?': 1, 'm': 1, 'assuming': 1}, {'soon': 1, 'get': 1, 'results': 1, 'start': 1, 'wide': 1, 'scale': 1, 'production': 1, '?': 1, 'risk': 1, 'begin': 1, 'trial': 1, 'press': 1, 'reports': 1, 'pfizer': 1, 'making': 1, '50': 1, '100': 1, 'million': 1, 'doses': 1, 'say': 1, 'says': 1, 'nt': 1, 'work': 1, 'discard': 1}, {'three': 1, 'dose': 1, 'titers': 1, 'gsk': 1, 'series': 1, 'something': 1}, {'2': 1, 'booster': 1, 'äúancientäù': 1, 'memory': 1, 'bcells': 1, 'probably': 1, 'induced': 1, 'common': 1, 'cold': 1, 'coronaviruses': 1, 'mostly': 1, 'activated': 1, 'https': 1, 'wwwmedrxivorgcontent1011012021123021268554v1': 1, 'b': 1, 'cells': 1, 'derived': 1, 'ancient': 1, 'preexisting': 1, 'recognize': 1, 'fulllength': 1, 'wildtype': 1, 'spike': 1, 'highest': 1, 'avidity': 1, 'boosting': 1, 'also': 1, 'bind': 1, 'omicron': 1, 'variant': 1, 'protein': 1}, {'short': 1, 'answer': 1, 'probably': 1, 'going': 1, 'long': 1, 'time': 1, 'come': 1, 'good': 1, 'news': 1, 'this': 1, 'study': 1, 'suggests': 1, 'emergence': 1, 'new': 1, 'variants': 1, 'less': 1, 'dramatic': 1, 'passes': 1, '&': 1, 'x200b': 1, 'beginning': 1, 'pandemic': 1, 'lot': 1, 'academic': 1, 'discussion': 1, 'whether': 1, 'sarscov2': 1, 'already': 1, 'fully': 1, 'well': 1, 'adapted': 1, 'human': 1, 'hosts': 1, 'recognized': 1, 'example': 1, 'https': 1, 'wwwbiorxivorgcontent10110120200501073262v1full': 1, 'sure': 1, 'never': 1, 'published': 1, 'read': 1, 'cautiously': 1, 'suppose': 1, 'wwwnaturecomarticless41467020198182': 1, 'happened': 1, 'another': 1, 'betacoronavirus': 1, 'coronavirus': 1, 'hku1': 1, 'identified': 1, 'circulating': 1, 'consequently': 1, 'likely': 1, 'past': 1, 'period': 1, 'rapid': 1, 'host': 1, 'adaptation': 1, 'following': 1, 'zoonosis': 1, 'considered': 1, 'unlikely': 1, 'many': 1, 'start': 1, 'considering': 1, 'high': 1, 'pathogenicity': 1, 'consensus': 1, 'shifted': 1, 'established': 1, 'mutational': 1, 'repertoire': 1, 'virus': 1, 'allowing': 1, 'increased': 1, 'fitness': 1, 'within': 1, 'pretty': 1, 'big': 1, 'translating': 1, 'sustained': 1, 'ongoing': 1, 'wwwpnasorgdoi101073pnas2104241118': 1, 'next': 1, 'question': 1, 'basically': 1, 'combinations': 1, 'mutations': 1, 'behave': 1, 'much': 1, 'differently': 1, 'sum': 1, 'individual': 1, 'effects': 1, 'mutation': 1, 'epistasis': 1, 'true': 1, 'singlemutation': 1, 'vast': 1, 'room': 1, 'evolve': 1, 'practically': 1, 'unmeasurable': 1, 'limited': 1, 'cases': 1, 'discussed': 1, 'wwwsciencedirectcomsciencearticlepiis002228362100276x': 1, 'shown': 1, 'robust': 1, 'widespread': 1, 'would': 1, 'concerning': 1, 'demonstrates': 1, 'computationally': 1, 'take': 1, 'grain': 1, 'salt': 1, 'receptor': 1, 'binding': 1, 'domain': 1, 'boring': 1, 'authors': 1, 'state': 1, 'indicating': 1, 'single': 1, 'approximation': 1, 'total': 1, 'evolutionary': 1, 'flexibility': 1, 'interactions': 1, 'spike': 1, 'protein': 1, 'words': 1, 'plenty': 1, 'emerging': 1, 'unfortunately': 1, 'possibly': 1, 'years': 1, 'characteristics': 1, 'similar': 1, 've': 1, 'seen': 1, 'caveat': 1, 'may': 1, 'happen': 1, 'parts': 1, 'proteins': 1, 'different': 1, 'farther': 1, 'apart': 1, 'viral': 1, 'genome': 1, 'studied': 1, 'regions': 1, 'nterminal': 1, 'wwwnaturecomarticless42003021028589': 1, 'provide': 1, 'greater': 1}, {'studies': 1, 'done': 1, 'animals': 1, 'yet': 1, 'humans': 1, 'real': 1, 'world': 1, 'effectiveness': 1, 'nt': 1, 'see': 1, 'omnicron': 1, 'specific': 1, 'booster': 1, 'couldnt': 1, 'effective': 1, 'current': 1, 'boosters': 1, 'unless': 1, 'omicron': 1, 's': 1, 'ability': 1, 'evade': 1, 'antibodies': 1, 'nothing': 1, 'simply': 1, 'looking': 1, 'different': 1, 'variants': 1}, {'exactly': 1, 'thinking': 1, 'would': 1, 'make': 1, 'sense': 1, 'little': 1, 'delta': 1, 'example': 1, 'forked': 1, 'wuhan': 1, 'even': 1, 'thing': 1, '50': 1, 'changes': 1, 'spike': 1, 'honestly': 1, 'dumb': 1, 'luck': 1, 'anything': 1, 'common': 1, 's': 1, 'many': 1, 'different': 1, 'variables': 1, 'two': 1, 'feel': 1, 'like': 1, 'future': 1, 'holds': 1, 'quadrivalent': 1, 'type': 1, 'vaccines': 1, 'flu': 1, '&': 1, 'x200b': 1, 'study': 1, 'learn': 1, 'us': 1, 'army': 1, 'vaccine': 1, 'seems': 1, 'may': 1, 'one': 1, 'ahead': 1, 'game': 1, 'built': 1, 'deal': 1, 'panning': 1}, {'us': 1, 'distributor': 1, 'covaxin': 1, 'pulled': 1, 'eua': 1, 'application': 1, 'applied': 1, 'full': 1, 'approval': 1, 'nt': 1, 'know': 1, 'decided': 1, 'seems': 1, 'like': 1, 'slower': 1, 'path': 1, 'may': 1, 'also': 1, 'reluctance': 1, 'approve': 1, 'vaccine': 1, 'pediatric': 1, 'population': 1, 'used': 1, 'adults': 1, 'anyway': 1, 'm': 1, 'sure': 1, 's': 1, 'scientific': 1, 'rationale': 1, 'could': 1}, {'abstract': 1, 'background': 1, 'data': 1, 'conflict': 1, 'whether': 1, 'vaccination': 1, 'decreases': 1, 'severe': 1, 'acute': 1, 'respiratory': 1, 'syndrome': 1, 'coronavirus2': 1, 'sarscov2': 1, 'viral': 1, 'load': 1, 'objective': 1, 'analysis': 1, 'compare': 1, 'baseline': 1, 'symptoms': 1, 'vaccinated': 1, 'unvaccinated': 1, 'adults': 1, 'enrolled': 1, 'randomized': 1, 'trial': 1, 'outpatient': 1, 'covid19': 1, 'treatment': 1, 'methods': 1, 'first': 1, '433': 1, 'sequential': 1, 'participants': 1, 'enrolling': 1, 'covidout': 1, 'analyzed': 1, 'aged': 1, '3085': 1, 'body': 1, 'mass': 1, 'index': 1, 'bmi': 1, '25kgm': 1, '2': 1, 'eligible': 1, 'within': 1, '3': 1, 'days': 1, 'positive': 1, 'test': 1, '7': 1, 'log': 1, '10': 1, 'pcr': 1, 'loads': 1, 'normalized': 1, 'human': 1, 'rnase': 1, 'p': 1, 'status': 1, 'time': 1, 'results': 1, '274': 1, 'known': 1, 'contributed': 1, 'optional': 1, 'nasal': 1, 'swabs': 1, 'measurement': 1, 'median': 1, 'age': 1, '46': 1, 'years': 1, '312': 1, 'kgm': 1, 'iqr': 1, '364': 1, 'overall': 1, '159': 1, '58': 1, '%': 1, 'women': 1, '217': 1, '80': 1, 'white': 1, 'mean': 1, 'relative': 1, 'log10': 1, '6': 1, 'months': 1, 'date': 1, 'enrollment': 1, '011': 1, '95': 1, 'ci': 1, '048': 1, '071': 1, 'significantly': 1, 'lower': 1, 'group': 1, '001': 1, 'prior': 1, 'differ': 1, 'respect': 1, '099': 1, '041': 1, '240': 1, '085': 1, 'fewer': 1, 'moderatesevere': 1, 'subjective': 1, 'fever': 1, 'chills': 1, 'myalgias': 1, 'nausea': 1, 'diarrhea': 1, '005': 1, 'conclusions': 1, 'suggest': 1, 'infection': 1, 'associated': 1, 'likelihood': 1, 'systemic': 1}, {'figures': 1, 'provide': 1, 'tell': 1, 'us': 1, 'far': 1, 'worse': 1, 'mrna': 1, 'vaccine': 1, 'antigen': 1, 'deviated': 1, 'ancestral': 1, 'strain': 1, 'note': 1, 'using': 1, 'log': 1, 'scale': 1, 'represent': 1, 'tick': 1, 'represents': 1, 'ten': 1, 'fold': 1, 'difference': 1, 'ratio': 1, 'nt': 1, 'matter': 1, 'neutralizing': 1, 'virus': 1}, {'beta': 1, 'blockers': 1, 'cheap': 1, 'readily': 1, 'available': 1, 'class': 1, 'drugs': 1, 'side': 1, 'effects': 1, 'short': 1, 'term': 1, 'low': 1, 'doses': 1, 'may': 1, 'effective': 1, 'myocarditis': 1, 'week': 1, 'two': 1, 'could': 1, 'prescribed': 1, 'preventative': 1, 'https': 1, 'journalsphysiologyorgdoifull101152ajpheart002582005': 1}, {'common': 1, 'nomenclature': 1, 'seen': 1, 'used': 1, 'professionals': 1, 'infectioninduced': 1, 'immunity': 1, 'certain': 1, 'aesthetic': 1, 'calling': 1, 'natural': 1, 'difficult': 1, 'overcome': 1, 'even': 1, 'correct': 1}, {'iäôd': 1, 'guess': 1, 'controls': 1, 'mix': 1, 'vaccinated': 1, 'unvaccinated': 1, 'makes': 1, 'sense': 1, 'prevalence': 1, 'patients': 1, 'page': 1, 'doesnäôt': 1, 'seem': 1, 'indicate': 1}, {'going': 1, 'look': 1, 'previous': 1, 'infection': 1, 'kind': 1, 'study': 1, '?': 1, 'one': 1, 'cohort': 1, 'got': 1, 'infections': 1, 'previously': 1, 'itäôs': 1, 'affect': 1, 'results': 1, 'dramatically': 1, 'also': 1, 'sample': 1, 'size': 1, 'already': 1, 'quite': 1, 'low': 1, 'iäôm': 1, 'sure': 1, 'lot': 1, 'people': 1, 'eliminated': 1, 'due': 1, 'omicron': 1, 'trial': 1, 'think': 1, 'needs': 1, 'bigger': 1, 'infectionnaive': 1}, {'long': 1, 'randomization': 1, 'nt': 1, 'unlucky': 1}, {'sweden': 1, 'introduced': 1, 'vaccine': 1, 'passes': 1, 'december': 1, 'explanation': 1, 'unlikely': 1, 's': 1, 'possible': 1, 'people': 1, 'changed': 1, 'behavior': 1, 'vaccination': 1, 'independently': 1, 'formal': 1, 'rules': 1}, {'couple': 1, 'questions': 1, '1': 1, 'release': 1, 'says': 1, 'trying': 1, 'achieve': 1, 'durable': 1, 'protection': 1, 'infection': 1, '?': 1, '2': 1, 'soon': 1, 'get': 1, 'results': 1, 'start': 1, 'wide': 1, 'scale': 1, 'production': 1}, {'appear': 1, 'assessed': 1, 'effectiveness': 1, 'prior': 1, 'ba1': 1, 'infection': 1, 'vs': 1, 'hospitalization': 1, 'death': 1, 'ba2': 1, 'disagree': 1, 'please': 1, 'point': 1, 'page': 1, 'within': 1, 'pdf': 1}, {'least': 1, 'updating': 1, 'mrna': 1, 'match': 1, 'newer': 1, 'strains': 1, '?': 1, 'circulating': 1, 'variants': 1, '2': 1, 'years': 1, 'diverged': 1, 'sequence': 1, 'used': 1, 'vaccine': 1, 'expect': 1, 'existing': 1, 'vaccines': 1, 'become': 1, 'anything': 1, 'lessandless': 1, 'effective': 1, 'time': 1, 'goes': 1}, {'m': 1, 'sure': 1, 'perhaps': 1, 'traditional': 1, 'vaccine': 1, 'portion': 1, 'clarify': 1, 'mrna': 1, 'tech': 1, 'nt': 1, 'want': 1, 'get': 1, 'anecdotes': 1, 'pro': 1, 'purpose': 1, 'stating': 1, 'moreso': 1, 's': 1, 'unlikely': 1, 'surprise': 1, 'adverse': 1, 'reactions': 1, 'inactivated': 1, 'virus': 1, 'type': 1, 'one': 1, 'like': 1, 'might': 1, 'convince': 1, 'parents': 1, 'vaccinate': 1, 'kids': 1}, {'would': 1, 'imply': 1, 'vaccine': 1, 'work': 1, 'therapeutic': 1, 'long': 1, 'covid': 1, 'symptoms': 1, 'emergence': 1, '?': 1}, {'consensus': 1, 're': 1, 'referring': 1, 'established': 1, 'preomicron': 1, 'study': 1, 'speaks': 1, 'specifically': 1, 'omicron': 1, 'know': 1, 'vaccines': 1, 'challenged': 1, 's': 1, 'surprising': 1, 'see': 1, 'efficacy': 1, 'vary': 1, 'according': 1, 'variant': 1, 'question': 1, 'yes': 1, 'pfizer': 1, 'moderna': 1, '2': 1, 'shots': 1, 'superior': 1, 'jnj': 1, '1': 1, 'shot': 1, 'notable': 1, 'margin': 1, 'still': 1, 'relatively': 1, 'narrow': 1, 'j': 1, '&': 1, 'certainly': 1, 'expected': 1, '3': 1, 'either': 1, 'mrnas': 1, 'would': 1, 'variants': 1, 'prior': 1, '21': 1, 'compares': 1, '11': 1, 'impressive': 1, 'commonly': 1, 'believed': 1, 've': 1, 'always': 1, '2shot': 1, 'interesting': 1, 'contemplate': 1, 'today': 1, 'comparing': 1, 'likeforlike': 1, 'vs': 1, 'especially': 1, 'given': 1, 'south': 1, 'africa': 1, 'also': 1, 'particular': 1, 'relevance': 1, 'two': 1, 'reasons': 1, 'originated': 1, '42': 1, '%': 1, 'african': 1, 'vaccinations': 1, 'november': 1, '2021': 1}, {'abstract': 1, 'ndvhxps': 1, 'recombinant': 1, 'newcastle': 1, 'disease': 1, 'virus': 1, 'basedvaccine': 1, 'severe': 1, 'acute': 1, 'respiratory': 1, 'syndrome': 1, 'coronavirus': 1, '2': 1, 'sarscov2': 1, 'expresses': 1, 'optimized': 1, 'hexapro': 1, 'spike': 1, 'protein': 1, 'surface': 1, 'vaccine': 1, 'produced': 1, 'embryonated': 1, 'chicken': 1, 'eggs': 1, 'using': 1, 'process': 1, 'employed': 1, 'production': 1, 'influenza': 1, 'vaccines': 1, 'performed': 1, 'secondary': 1, 'analysis': 1, 'antibody': 1, 'responses': 1, 'vaccination': 1, 'inactivated': 1, 'phase': 1, 'clinical': 1, 'study': 1, 'thailand': 1, 'neutralizing': 1, 'binding': 1, 'activity': 1, 'postvaccination': 1, 'serum': 1, 'samples': 1, 'compared': 1, 'matched': 1, 'mrna': 1, 'bnt162b2': 1, 'pfizer': 1, 'vaccinees': 1, 'sera': 1, 'comparable': 1, 'individuals': 1, 'vaccinated': 1, 'interstingly': 1, 'vaccinee': 1, 'lower': 1, 'obtained': 1, 'let': 1, 'us': 1, 'calculate': 1, 'ratios': 1, 'titers': 1, 'similar': 1, 'convalescent': 1, 'suggesting': 1, 'high': 1, 'proportion': 1, 'antibodies': 1, 'low': 1, 'nonneutralizing': 1, 'showed': 1, 'contrast': 1, 'induces': 1, 'strong': 1, 'receptor': 1, 'domain': 1, 'rbd': 1, 'nterminal': 1, 's2': 1, 'focused': 1, 'response': 1, 'little': 1, 'reactivity': 1, 'explains': 1, 'since': 1, 'epitopes': 1, 'located': 1, 'conclusion': 1, 'absolute': 1}, {'regarding': 1, 'third': 1, 'dose': 1, 'booster': 1, 'itäôs': 1, 'already': 1, 'trials': 1, 'äúon': 1, 'december': 1, '17': 1, '2021': 1, 'pfizer': 1, 'biontech': 1, 'announced': 1, 'companies': 1, 'would': 1, 'test': 1, '3': 1, 'µg': 1, 'given': 1, 'least': 1, 'two': 1, 'months': 1, 'second': 1, 'children': 1, 'age': 1, '5': 1, '10': 1, 'formulation': 1, '12': 1, 'years': 1, 'ageäù': 1}, {'omicron': 1, 'well': 1, 'https': 1, 'wwwmedrxivorgcontent1011012021122721268278v1': 1, 'we': 1, 'found': 1, 'increased': 1, 'transmission': 1, 'unvaccinated': 1, 'individuals': 1, 'reduced': 1, 'boostervaccinated': 1, 'compared': 1, 'fully': 1, 'vaccinated': 1, 'comparing': 1, 'households': 1, 'infected': 1, 'delta': 1, 'voc': 1, '117': 1, '95': 1, '%': 1, 'ci': 1, '099138': 1, 'times': 1, 'higher': 1, 'sar': 1, '261': 1, '234290': 1, '366': 1, '265505': 1, 'demonstrating': 1, 'strong': 1, 'evidence': 1, 'immune': 1, 'evasiveness': 1}, {'iäôm': 1, 'concerned': 1, 'catching': 1, 'people': 1, 'going': 1, 'er': 1, 'uc': 1, 'mild': 1, 'symptoms': 1, 'perhaps': 1, 'hope': 1, 'getting': 1, 'test': 1, 'failed': 1, 'able': 1, 'find': 1, 'schedule': 1, 'one': 1, 'elsewhere': 1, 'data': 1, 'time': 1, 'period': 1, 'tests': 1, 'exceedingly': 1, 'hard': 1, 'high': 1, 'demand': 1}, {'abstract': 1, 'brief': 1, 'communication': 1, 'showing': 1, 'original': 1, 'research': 1, 'results': 1, 'early': 1, 'estimates': 1, 'danish': 1, 'nationwide': 1, 'databases': 1, 'vaccine': 1, 'effectiveness': 1, 'novel': 1, 'sarscov2': 1, 'omicron': 1, 'variant': 1, 'b11529': 1, 'five': 1, 'months': 1, 'primary': 1, 'vaccination': 1, 'series': 1, 'bnt162b2': 1, 'mrna1273': 1, '19': 1, 'vaccines': 1, 'study': 1, 'provides': 1, 'evidence': 1, 'protection': 1, 'infection': 1, 'completion': 1, 'particular': 1, 'found': 1, '552': 1, '%': 1, '95': 1, 'confidence': 1, 'interval': 1, 'ci': 1, '235': 1, '737': 1, '367': 1, '699': 1, '764': 1, 'respectively': 1, 'first': 1, 'month': 1, 'however': 1, 'significantly': 1, 'lower': 1, 'delta': 1, 'declines': 1, 'rapidly': 1, 'reestablished': 1, 'upon': 1, 'revaccination': 1, '546': 1, '304': 1, '704': 1}, {'else': 1, 'would': 1, 'make': 1, 'sure': 1, 'preventative': 1, 'really': 1, 'worked': 1, '?': 1}, {'nt': 1, 'understand': 1, 'people': 1, 'think': 1, 'vaccine': 1, 'worse': 1, 'get': 1, 'covid': 1, 's': 1, 'spike': 1, 'protein': 1, 'binds': 1, 'ace2': 1, 'sites': 1, 'actually': 1, 'getting': 1, 'whole': 1, 'fucking': 1, 'virus': 1, 'would': 1, 'make': 1, 'sense': 1, 'danger': 1, 'might': 1, 'pose': 1, 'multiplied': 1, 'one': 1, 'gets': 1, '?': 1, 'really': 1, 'antivax': 1, 'movement': 1, 're': 1, 'going': 1, 'eventually': 1, 'inevitable': 1, 'gon': 1, 'na': 1, 'either': 1, 'way': 1, 'vaxxed': 1, 'build': 1, 'immune': 1, 'system': 1, 'makes': 1, 'absolutely': 1, '0': 1}, {'havenäôt': 1, 'heard': 1, 'novavax': 1, 'vaccine': 1, 'long': 1, 'time': 1, 'someone': 1, 'mind': 1, 'filling': 1, 'happened': 1, '?': 1}, {'people': 1, 'thinking': 1, 'overall': 1, 'risk': 1, 'terms': 1, 'likelihood': 1, 'young': 1, 'person': 1, 'get': 1, 'covid': 1, 'myocarditis': 1, 'result': 1, 'versus': 1, 'getting': 1, 'vaccine': 1, '?': 1, 'iäôm': 1, 'sorry': 1, 'expressing': 1, 'precisely': 1, 'enough': 1, 'donäôt': 1, 'know': 1, 'anything': 1, 'stats': 1, 'etc': 1, 'trying': 1, 'understand': 1}, {'wouldnäôt': 1, 'really': 1, 'prior': 1, 'covid19': 1, 'infection': 1, 'occurred': 1, 'vaccination': 1, 'started': 1, 'even': 1, 'first': 1, 'dose': 1, 'offers': 1, 'quite': 1, 'bit': 1, 'protection': 1, 'less': 1, '2': 1, 'weeks': 1, 'shot': 1, 'guess': 1, 'could': 1, 'argue': 1, '12': 1, 'days': 1, 'thatäôs': 1, 'splitting': 1, 'hairs': 1, 'https': 1, 'wwwnejmorgdoi101056nejmoa2034577': 1, 'äúbetween': 1, 'second': 1, '39': 1, 'cases': 1, 'bnt162b2': 1, 'group': 1, '82': 1, 'placebo': 1, 'observed': 1, 'resulting': 1, 'vaccine': 1, 'efficacy': 1, '52': 1, '%': 1, '95': 1, 'ci': 1, '295': 1, '684': 1, 'interval': 1, 'indicating': 1, 'early': 1, 'starting': 1, 'soon': 1, 'doseäú': 1}, {'could': 1, 'reading': 1, 'wrong': 1, 'think': 1, 'study': 1, 'says': 1, 'mrna': 1, 'vaccine': 1, 'plus': 1, 'j': 1, '&': 1, 'booster': 1, 'effective': 1, 'words': 1, 'exposure': 1, '2': 1, 'different': 1, 'vaccines': 1, 'better': 1, 'exposing': 1, 'body': 1, 'one': 1, 'always': 1, 'suspected': 1, 'little': 1, 'evidence': 1, 'support': 1, 'companies': 1, 'nt': 1, 'want': 1, 'say': 1, 'use': 1, 'guys': 1, 'product': 1, 'instead': 1, 'using': 1, 'twice': 1, 'studies': 1, 'mix': 1, 'less': 1, 'looking': 1, 'front': 1, 'side': 1, 'headshot': 1, 'suspect': 1, 'helps': 1, 'spot': 1}, {'odds': 1, 'ratio': 1, '08': 1, 'means': 1, '100': 1, 'unvaccinated': 1, 'needs': 1, 'icu': 1, '8': 1, 'vaccinated': 1}, {'m': 1, 'talking': 1, 'hindsight': 1, 'yes': 1, 'may': 1, 'find': 1, 'omicron': 1, 'damage': 1, 'know': 1, 'moment': 1, 'right': 1, 'seems': 1, 'like': 1, 'fortunate': 1, 'able': 1, 'overtake': 1, 'delta': 1, 'data': 1, 'confirmed': 1, 'vaccinations': 1, 'made': 1, 'possible': 1}, {'abstract': 1, 'vaccinationbased': 1, 'exposure': 1, 'spike': 1, 'protein': 1, 'derived': 1, 'early': 1, 'sarscov2': 1, 'sequences': 1, 'key': 1, 'public': 1, 'health': 1, 'strategy': 1, 'covid19': 1, 'successive': 1, 'waves': 1, 'infections': 1, 'characterised': 1, 'evolution': 1, 'highly': 1, 'mutated': 1, 'variants': 1, 'transmissible': 1, 'partially': 1, 'evade': 1, 'adaptive': 1, 'immune': 1, 'response': 1, 'omicron': 1, 'fifth': 1, 'äúvariants': 1, 'concernäù': 1, 'voc': 1, 'step': 1, 'change': 1, 'transmission': 1, 'capability': 1, 'suggesting': 1, 'significant': 1, 'antigenic': 1, 'biological': 1, '45': 1, 'amino': 1, 'acid': 1, 'substitutions': 1, 'including': 1, '30': 1, 'changes': 1, 'relative': 1, 'one': 1, 'earliest': 1, 'wuhanhu1': 1, '15': 1, 'occur': 1, 'receptor': 1, 'binding': 1, 'domain': 1, 'area': 1, 'strongly': 1, 'associated': 1, 'humoral': 1, 'evasion': 1, 'study': 1, 'demonstrate': 1, 'markedly': 1, 'decreased': 1, 'neutralisation': 1, 'serology': 1, 'assays': 1, 'realworld': 1, 'vaccine': 1, 'effectiveness': 1, 'recipients': 1, 'two': 1, 'doses': 1, 'efficacy': 1, 'recovered': 1, 'third': 1, 'mrna': 1, 'booster': 1, 'dose': 1, 'also': 1, 'show': 1, 'immunity': 1, 'natural': 1, 'infection': 1, 'without': 1, 'vaccination': 1, 'protective': 1, 'inferior': 1, 'three': 1, 'finally': 1, 'fundamental': 1, 'entry': 1, 'process': 1, 'vitro': 1, 'towards': 1, 'tmprss2independent': 1, 'fusion': 1, 'representing': 1, 'major': 1, 'shift': 1, 'replication': 1, 'properties': 1, 'overall': 1, 'findings': 1, 'underlie': 1, 'rapid': 1, 'global': 1, 'may': 1, 'alter': 1, 'clinical': 1, 'severity': 1, 'disease': 1, 'variant': 1}, {'wish': 1, 'could': 1, 'find': 1, 'studies': 1, 'regarding': 1, 'age': 1, '1316': 1, 'population': 1, 'us': 1, '6': 1, 'months': 1, 'since': 1, 'last': 1, 'dose': 1, 'approved': 1, 'booster': 1, 'shots': 1, 'young': 1, 'immune': 1, 'system': 1, 'appears': 1, 'good': 1, '2': 1, 'vaccine': 1, 'series': 1, 'likely': 1, 'protective': 1, 'even': 1, 'would': 1, 'nice': 1, 'see': 1, 'data': 1}, {'papers': 1, 'measure': 1, 'neutralizing': 1, 'antibodies': 1, 'estimate': 1, 'vaccine': 1, 'efficacy': 1, 'correct': 1, 'thinking': 1, 'prevent': 1, 'symptomatic': 1, 'infection': 1, 'nonneutralizing': 1, 'still': 1, 'help': 1, 'reduce': 1, 'disease': 1, 'severity': 1, '?': 1}, {'many': 1, 'documented': 1, 'cases': 1, 'myocarditis': 1, 'resulted': 1, 'mortality': 1, 'severe': 1, 'injury': 1, 'sequelae': 1, '?': 1, 'obviously': 1, 'concern': 1, 'severity': 1, 'longterm': 1, 'also': 1, 'part': 1, 'equation': 1, 'still': 1, 'able': 1, 'determine': 1, 'baseline': 1, 'mild': 1, 'transient': 1, 'among': 1, 'various': 1, 'demographics': 1, 'whether': 1, 'mostly': 1, 'occurs': 1, 'mrna': 1, 'vaccines': 1, 'infections': 1, 'well': 1, 'result': 1, 'patients': 1, 'risks': 1, 'weakening': 1, 'cardiac': 1, 'tissue': 1, 'reducing': 1, 'output': 1, 'time': 1, 'risk': 1, 'future': 1, 'class': 1, 'drugs': 1, 'avv': 1, 'gene': 1, 'therapies': 1}, {'yes': 1, 'logistics': 1, 'hard': 1, 'though': 1, 'great': 1, 'lakes': 1, 'way': 1, 'mason': 1, 'dixon': 1, 'towards': 1, 'maine': 1, 'gets': 1, 'spring': 1, 'fall': 1, 'wave': 1, 'south': 1, 'summer': 1, 'winter': 1, 'd': 1, 'give': 1, 'people': 1, 'boosters': 1, 'twice': 1, 'season': 1, 'much': 1, 'boosting': 1, 're': 1, 'already': 1, 'going': 1, 'cause': 1, 'massive': 1, 'imprinting': 1, 'issues': 1, 'may': 1, 'take': 1, 'years': 1, 'sort': 1, 'immune': 1, 'system': 1}, {'risk': 1, 'vaccinated': 1, 'people': 1, 'get': 1, 'covid': 1, 'versus': 1, 'unvaccinated': 1, '?': 1, 'seems': 1, 'like': 1, 'everybody': 1, 'included': 1, 'going': 1, 'havenäôt': 1, 'already': 1, 'sounds': 1, 'would': 1, 'relevant': 1, 'data': 1}, {'results': 1, 'among': 1, '422äø034': 1, 'vaccinated': 1, 'individuals': 1, 'mean': 1, 'sd': 1, 'age': 1, '547': 1, '174': 1, 'years': 1, '236äø437': 1, '560': 1, '%': 1, 'women': 1, '1äø645äø397': 1, 'matched': 1, 'unvaccinated': 1, '545': 1, '175': 1, '922äø937': 1, '561': 1, '76': 1, '95': 1, 'ci': 1, '75': 1, '77': 1, 'covid19': 1, 'infections': 1, '81': 1, '78': 1, '82': 1, 'covid19äìrelated': 1, 'hospitalizations': 1, 'stable': 1, 'least': 1, '180': 1, 'days': 1, 'vaccination': 1, 'calendar': 1, 'time': 1, 'states': 1, 'high': 1, 'delta': 1, 'variant': 1, 'incidence': 1, 'june': 1, 'august': 1, '2021': 1, '74': 1, '71': 1, '86': 1, 'higher': 1, 'younger': 1, '65': 1, '79': 1, 'lower': 1, 'immunocompromised': 1, 'patients': 1, '64': 1, '59': 1, '68': 1, 'estimates': 1, 'corrected': 1, 'underrecording': 1, 'uncorrected': 1, 'served': 1, 'bound': 1, '66': 1, '67': 1, 'recorded': 1, 'infection': 1, '72': 1, '69': 1, 'hospitalization': 1, 'conclusions': 1, 'relevance': 1, 'cohort': 1, 'study': 1, 'us': 1, 'clinical': 1, 'practice': 1, 'showed': 1, 'ad26cov2s': 1, '6': 1, 'months': 1, 'well': 1, 'emerged': 1, 'became': 1, 'dominant': 1}, {'s': 1, 'as03': 1, 'adjuvant': 1, 'believe': 1, 'used': 1, 'sanofi': 1, 'sk': 1, 'bioscience': 1, 'protein': 1, 'based': 1, 'vaccines': 1}, {'new': 1, 'uk': 1, 'siren': 1, 'study': 1, 'findings': 1, 'https': 1, 'wwwmedrxivorgcontent1011012021112921267006v1': 1, '?': 1, 'perhaps': 1, 'basing': 1, '85': 1, '%': 1, 'delta': 1, 'since': 1, 'original': 1, 'predelta': 1, 'iäôve': 1, 'skimmed': 1, 'preprint': 1, 'doesnäôt': 1, 'look': 1, 'like': 1, 'writeup': 1, 'detailed': 1, 'published': 1, 'lancet': 1, 'nt': 1, 'discuss': 1, 'confirmed': 1, 'probable': 1, 'possible': 1, 'infections': 1, 'edit': 1, 'sorry': 1, 'incorrect': 1, 'checked': 1, 'actual': 1, 'full': 1, 'pdf': 1, 'cite': 1, 'still': 1, 'interested': 1, 'think': 1, 'though': 1, 'appear': 1, 'knowledgable': 1, 'topic': 1}, {'study': 1, 'seems': 1, 'conjectural': 1, 'elements': 1, 'many': 1, 'studies': 1, 'ie': 1, 'assuming': 1, 'omicron': 1, 'based': 1, 'proxy': 1, 'designator': 1, 'tables': 1, 'also': 1, 'hard': 1, 'read': 1, 'would': 1, 'love': 1, 'see': 1, 'better': 1, 'data': 1, 'presentation': 1}, {'among': 1, 'things': 1, 'think': 1, 'might': 1, 'reminder': 1, 'single': 1, 'study': 1, 'nt': 1, 'necessarily': 1, 'conclusive': 1, 'plus': 1, 'hospitalizations': 1, 'part': 1, 'picture': 1, 'take': 1, 'months': 1, 'find': 1, 'omicron': 1, 'infection': 1, 'opens': 1, 'us': 1, 'possibility': 1, 'long': 1, 'covid': 1, 'numbers': 1, 're': 1, 'going': 1, 'see': 1, 'even': 1, '5': 1, '%': 1, 'get': 1, 'symptoms': 1, 's': 1, 'huge': 1, 'problem': 1}, {'paper': 1, 'states': 1, 'booster': 1, 'group': 1, 's': 1, 'efficacy': 1, 'relative': 1, '2x': 1, 'vaccinated': 1}, {'asking': 1, 'question': 1, 'spent': 1, 'time': 1, 'proteinatlas': 1, 'dot': 1, 'org': 1, 'sure': 1, 'whether': 1, 'link': 1, 'certainly': 1, 'seems': 1, 'older': 1, 'strains': 1, 'prefer': 1, 'organs': 1, 'high': 1, 'tmprss2': 1, 'like': 1, 'lungs': 1, 'kidneys': 1, 'gi': 1, 'tract': 1, 'early': 1, '2020': 1, 'scary': 1, 'much': 1, 'learned': 1, 'nonrespiratory': 1, 'effects': 1, 'heart': 1, 'attack': 1, 'blood': 1, 'clots': 1, 'stroke': 1, 'etc': 1, 'hopefully': 1, 'wo': 1, 'nt': 1, 'uncover': 1, 'nasty': 1, 'surprises': 1}, {'time': 1, 'period': 1, 'covered': 1, 'right': 1, 'vaccination': 1, 'would': 1, 'concerns': 1}, {'abstract': 1, 'background': 1, 'role': 1, 'sarscov2': 1, 'pathogenesis': 1, 'testicular': 1, 'damage': 1, 'uncertain': 1, 'methods': 1, 'investigated': 1, 'virological': 1, 'pathological': 1, 'immunological': 1, 'changes': 1, 'testes': 1, 'hamsters': 1, 'challenged': 1, 'wildtype': 1, 'variants': 1, 'intranasal': 1, 'direct': 1, 'inoculation': 1, 'using': 1, 'influenza': 1, 'virus': 1, 'h1n1': 1, 'pdm09': 1, 'control': 1, 'results': 1, 'besides': 1, 'selflimiting': 1, 'respiratory': 1, 'tract': 1, 'infection': 1, 'challenge': 1, 'caused': 1, 'acute': 1, 'decrease': 1, 'sperm': 1, 'count': 1, 'serum': 1, 'testosterone': 1, 'inhibin': 1, 'b': 1, '4': 1, '7': 1, 'days': 1, 'postinfection': 1, 'dpi': 1, 'subsequently': 1, 'reduced': 1, 'size': 1, 'weight': 1, 'sex': 1, 'hormone': 1, 'level': 1, '42': 1, '120': 1, 'histopathological': 1, 'varying': 1, 'degree': 1, 'inflammation': 1, 'haemorrhage': 1, 'necrosis': 1, 'degeneration': 1, 'seminiferous': 1, 'tubules': 1, 'disruption': 1, 'orderly': 1, 'spermatogenesis': 1, 'seen': 1, 'increasing': 1, 'inoculum': 1, 'sertoli': 1, 'leydig': 1, 'cells': 1, 'found': 1, 'though': 1, 'viral': 1, 'loads': 1, 'nucleocapid': 1, 'n': 1, 'protein': 1, 'expression': 1, 'markedly': 1, 'lower': 1, 'lung': 1, 'tissues': 1, 'intratesticular': 1, 'injection': 1, 'showed': 1, 'expressing': 1, 'interstitial': 1, 'epididymal': 1, 'epithelial': 1, 'apoptosis': 1, 'immune': 1, 'complex': 1, 'deposition': 1, 'depletion': 1, 'spermatogenic': 1, 'cell': 1, 'spermatozoa': 1, 'persisted': 1, 'omicron': 1, 'delta': 1, 'could': 1, 'also': 1, 'induce': 1, 'similar': 1, 'damages': 1, 'prevented': 1, 'vaccination': 1, 'conclusions': 1, 'cause': 1, 'subsequent': 1, 'chronic': 1, 'asymmetric': 1, 'atrophy': 1, 'associated': 1, 'hormonal': 1, 'despite': 1, 'pneumonia': 1, 'awareness': 1, 'possible': 1, 'hypogonadism': 1, 'subfertility': 1, 'important': 1, 'managing': 1, 'convalescent': 1, 'covid19': 1, 'males': 1}, {'large': 1, 'negative': 1, '91150': 1, 'days': 1, 'shocking': 1, 'authors': 1, 'suggest': 1, 'behavioral': 1, 'differences': 1, 'definitely': 1, 'plausible': 1, 'äî': 1, 'intervals': 1, 'positive': 1, '?': 1, 'iäôm': 1, 'trouble': 1, 'back': 1, 'napkin': 1, 'math': 1, 'makes': 1, 'sense': 1, 'since': 1, 'seems': 1, 'like': 1, 'explaining': 1, 'result': 1, 'behaviorally': 1, 'would': 1, 'also': 1, 'involve': 1, 'previous': 1, 'high': 1, 'adjusted': 1, 'go': 1, 'way': 1, 'make': 1, 'much': 1, 'higher': 1, 'weäôve': 1, 'seen': 1, 'studies': 1}, {'individuals': 1, 'natural': 1, 'immunity': 1, 'advantage': 1, 'one': 1, 'dose': 1, 'vaccine': 1, 'those': 1, 'received': 1, 'two': 1, 'doses': 1, 'significantly': 1, 'higher': 1, 'risk': 1, 'getting': 1, 'covid19': 1, 'single': 1, 'interesting': 1, 'see': 1, 'finding': 1, 'replicated': 1, 'studies': 1}, {'tracks': 1, 'iäôve': 1, 'baffled': 1, 'suggestion': 1, 'many': 1, 'get': 1, 'vaccinated': 1, 'booster': 1, 'two': 1, 'weeks': 1, 'recovering': 1, 'covid': 1, 'flies': 1, 'logic': 1, 'knowledge': 1, 'basic': 1, 'immunology': 1, 'thought': 1, '90': 1, 'days': 1, '6': 1, 'months': 1, 'sounds': 1, 'right': 1}, {'actually': 1, '001': 1, '%': 1, 're': 1, '1617': 1, 'year': 1, 'old': 1, 'boy': 1, 'big': 1, 'proportion': 1, '10x': 1, 'higher': 1, 'total': 1, 'risk': 1, 'population': 1, 'nevertheless': 1, 'even': 1, 'group': 1, 'myocarditis': 1, 'due': 1, 'covid': 1}, {'still': 1, 'remain': 1, 'frustrated': 1, 'studies': 1, 'nothing': 1, 'assess': 1, 'much': 1, 'cryptic': 1, 'spread': 1, 'unvaccinated': 1, 'group': 1, 're': 1, '2': 1, 'years': 1, 'pandemic': 1, 'becoming': 1, 'harder': 1, 'believe': 1, 's': 1, 'many': 1, 'completely': 1, 'unexposed': 1, 'people': 1, 'also': 1, 'need': 1, 'assessment': 1, 'hardtoinfect': 1, 'left': 1, 'whose': 1, 'biology': 1, 'immune': 1, 'system': 1, 'nt': 1, 'permissive': 1, 'viral': 1, 'replication': 1, 'waning': 1, 'may': 1, 'represent': 1, 'accumulation': 1, 'immunity': 1, 'time': 1}, {'glaring': 1, 'issue': 1, 'entirely': 1, 'misleading': 1, 'last': 1, 'sentence': 1, 'abstract': 1, 'also': 1, 'show': 1, 'bnt162b2': 1, 'mrna': 1, 'reverse': 1, 'transcribed': 1, 'intracellularly': 1, 'dna': 1, 'fast': 1, '6': 1, 'h': 1, 'upon': 1, 'exposure': 1, 'given': 1, 'blatantly': 1, 'think': 1, 'deliberate': 1, 'one': 1, 'several': 1, 'reasons': 1, 'reads': 1, 'like': 1, 'propaganda': 1, 'rather': 1, 'reputable': 1, 'journal': 1, 'article': 1, 'unless': 1, 'invest': 1, 'time': 1, 'knowledge': 1, 'understand': 1, 'rest': 1, 'misunderstand': 1, 'mean': 1, 'observed': 1, 'integration': 1, 'genome': 1, 'ie': 1, 'becomes': 1, 'part': 1, 'permanent': 1, 'however': 1, 'means': 1, 'whatsoever': 1, 'actually': 1, 'vaccine': 1, 'amplicons': 1, 'a': 1, 'piece': 1, 'resulting': 1, 'transcription': 1, 'observe': 1, 'explain': 1, 'near': 1, 'end': 1, 'study': 1, 'shows': 1, 'liver': 1, 'cell': 1, 'line': 1, 'huh7': 1, 'may': 1, 'give': 1, 'rise': 1, 'concern': 1, 'bnt162b2derived': 1, 'integrated': 1, 'host': 1, 'affect': 1, 'integrity': 1, 'genomic': 1, 'potentially': 1, 'mediate': 1, 'genotoxic': 1, 'side': 1, 'effects': 1, 'at': 1, 'stage': 1, 'know': 1, 'studies': 1, 'needed': 1, 'demonstrate': 1, 'effect': 1, 'including': 1, 'whole': 1, 'sequencing': 1, 'cells': 1, 'exposed': 1, 'well': 1, 'tissues': 1, 'human': 1, 'subjects': 1, 'received': 1, 'vaccination': 1, 'emphasis': 1, 'added': 1, 'notquiteenglish': 1, 'grammar': 1, 'even': 1, 'turns': 1, 'level': 1, 'would': 1, 'necessarily': 1, 'portion': 1, 'result': 1, 'meaningful': 1, 'harmful': 1, 'gene': 1, 'expression': 1, 'worth': 1, 'noting': 1, 'authors': 1, 'caveat': 1, 'probably': 1, 'happen': 1, 'ordinary': 1, 'in': 1, 'vivo': 1, 'the': 1, 'model': 1, 'used': 1, 'carcinoma': 1, 'active': 1, 'replication': 1, 'differs': 1, 'nondividing': 1, 'somatic': 1, 'shown': 1, 'display': 1, 'significant': 1, 'sic': 1, 'different': 1, 'protein': 1, 'upregulated': 1, 'proteins': 1, 'involved': 1, 'rna': 1, 'metabolism': 1, '56': 1}, {'s': 1, 'intended': 1, 'help': 1, 'distribute': 1, 'injected': 1, 'material': 1, 'throughout': 1, 'muscle': 1, 'reduce': 1, 'soreness': 1, 'injection': 1, 'site': 1, 'moving': 1, 'arm': 1, 'improve': 1, 'immune': 1, 'response': 1}, {'https': 1, 'wwwredditcomrcovid19commentsse1s2eefficacy_and_safety_of_a_plantbased_viruslike': 1, '?': 1, 'utm_mediumandroid_app': 1, '&': 1, 'utm_sourceshare': 1}, {'thanks': 1, 'pulling': 1, 's': 1, 'waiting': 1, 'vaxxed': 1, 'boosted': 1, 'doubts': 1, 'keeping': 1, 'hospital': 1, 'morgue': 1, 'concern': 1, 'long': 1, 'covid': 1, 'page': 1, '4': 1, 'analysis': 1, 'covers': 1, 'vaccination': 1, 'infection': 1, 'heading': 1, 'pulls': 1, '8': 1, 'studies': 1, 'fully': 1, 'vaccinated': 1, 'participants': 1, 'half': 1, 'likely': 1, 'symptoms': 1, 'lasting': 1, 'â28': 1, 'days': 1, 'unvaccinated': 1, 'odds': 1, 'ratio': 1, '051': 1, '95': 1, '%': 1, 'ci': 1, '032': 1, '082': 1, 'p0005': 1, 'whereas': 1, 'partially': 1, '104': 1, '086': 1, '125': 1, 'p069': 1, 'good': 1, 'news': 1, 'still': 1, 'reading': 1, 'see': 1, 'else': 1, 'found': 1}, {'abstract': 1, 'genetic': 1, 'variants': 1, 'sarscov2': 1, 'continue': 1, 'dramatically': 1, 'alter': 1, 'landscape': 1, 'covid19': 1, 'pandemic': 1, 'recently': 1, 'described': 1, 'variant': 1, 'concern': 1, 'designated': 1, 'omicron': 1, 'b11529': 1, 'rapidly': 1, 'spread': 1, 'worldwide': 1, 'responsible': 1, 'majority': 1, 'cases': 1, 'many': 1, 'countries': 1, 'recognized': 1, 'knowledge': 1, 'gaps': 1, 'exist': 1, 'epidemiology': 1, 'clinical': 1, 'severity': 1, 'disease': 1, 'course': 1, 'comprehensive': 1, 'genome': 1, 'sequencing': 1, 'study': 1, 'houston': 1, 'methodist': 1, 'healthcare': 1, 'system': 1, 'identified': 1, '862': 1, 'symptomatic': 1, 'patients': 1, 'infections': 1, 'caused': 1, 'late': 1, 'november': 1, '2021': 1, 'december': 1, '18': 1, 'increased': 1, 'three': 1, 'weeks': 1, 'cause': 1, '90': 1, '%': 1, 'new': 1, 'compared': 1, 'infected': 1, 'either': 1, 'alpha': 1, 'delta': 1, 'significantly': 1, 'younger': 1, 'vaccine': 1, 'breakthrough': 1, 'rates': 1, 'less': 1, 'likely': 1, 'hospitalized': 1, 'required': 1, 'intense': 1, 'respiratory': 1, 'support': 1, 'shorter': 1, 'length': 1, 'hospital': 1, 'stay': 1, 'consistent': 1, 'decreased': 1, 'although': 1, 'number': 1, 'studied': 1, 'relatively': 1, 'small': 1, 'aggregate': 1, 'data': 1, 'document': 1, 'unusually': 1, 'rapid': 1, 'occurrence': 1, 'metropolitan': 1, 'provide': 1, 'information': 1, 'character': 1}, {'yes': 1, 'embarrassing': 1, 'typo': 1, 'perhaps': 1, 'even': 1, '95': 1, '%': 1, 'ci': 1, 'äî': 1, 'almost': 1, '150': 1, 'wide': 1, 'minus': 1, 'sign': 1, 'included': 1, 'results': 1, 'section': 1, 'vastness': 1, 'acknowledged': 1, 'discussion': 1, 'although': 1, 'phrasing': 1, 'äúestimated': 1, 'less': 1, 'precision': 1, 'äù': 1, 'arguably': 1, 'tad': 1, 'understated': 1, 'methods': 1, 'unvaccinated': 1, 'group': 1, 'followed': 1, 'nov': 1, '20': 1, 'part': 1, 'vaccinated': 1, 'later': 1, 'date': 1, 'sizable': 1, 'fraction': 1, 'seems': 1, 'like': 1, 'could': 1, 'produce': 1, 'large': 1, 'negative': 1, 'bias': 1, 'estimate': 1, 'given': 1, 'ongoing': 1, 'explosive': 1, 'exponential': 1, 'growth': 1, 'infection': 1, 'rates': 1, '?': 1, 'poor': 1, 'statistics': 1, 'statistical': 1, 'analysis': 1, 'plausible': 1, 'contender': 1, 'äòexplainingäô': 1, 'estimates': 1}, {'getting': 1, 'covid': 1, 'makes': 1, 'sound': 1, 'like': 1, 'digital': 1, '01': 1, 'kind': 1, 'situation': 1, 'nt': 1, 'vaccines': 1, 'work': 1, 'seems': 1, 'many': 1, 'people': 1, 'infected': 1, 'symptomatic': 1, 'consider': 1, 'breakout': 1, 'symptoms': 1, 'due': 1, 'decreased': 1, 'neutralizing': 1, 'antibody': 1, 'protection': 1, 'catching': 1, 'spite': 1, 'vaccine': 1, 'even': 1, 'though': 1, 'tcell': 1, 'response': 1, 'still': 1, 'likely': 1, 'strong': 1, 's': 1, 'sometimes': 1, 'think': 1, 'flu': 1, 'shot': 1, 'gives': 1, 'mild': 1, 'immune': 1, 'system': 1}, {'longer': 1, 'reliant': 1, 'tmprss2': 1, 'mean': 1, 'expect': 1, 'target': 1, 'different': 1, 'parts': 1, 'body': 1, '?': 1}, {'study': 1, 'using': 1, 'front': 1, 'line': 1, 'hcws': 1, 'subject': 1, 'matter': 1, 'really': 1, 'questionable': 1, 'individuals': 1, 'contact': 1, 'actual': 1, 'pathogen': 1, 'routine': 1, 'basis': 1, 'strongly': 1, 'colors': 1, 'assumptions': 1, 'made': 1}, {'also': 1, 'nt': 1, 'know': 1, 'how': 1, 'omicron': 1, 'major': 1, 'vaccine': 1, 'evader': 1, 'happened': 1, 's': 1, 'realistic': 1, 'possibility': 1, 'occurred': 1, 'via': 1, 'gradual': 1, 'evolution': 1, 'resistant': 1, 'human': 1, 'population': 1, 'different': 1, 'transmissible': 1, 'many': 1, 'changes': 1, 'model': 1, 'evolutionary': 1, 'failures': 1}, {'back': 1, 'heard': 1, 'big': 1, 'factor': 1, 'delays': 1, 'getting': 1, 'manufacturing': 1, 'set': 1, 's': 1, 'case': 1, 'new': 1, 'vaccine': 1, 'nt': 1, 'issues': 1, 'could': 1, 'use': 1, 've': 1, 'll': 1, 'see': 1}, {'s': 1, 'moderna': 1, 'problem': 1, 'though': 1, 'even': 1, 'pfizer': 1, 'see': 1, 'weaker': 1, 'clear': 1, 'signal': 1, 'infection': 1, '202': 1, '113': 1, '361': 1, 'dose': 1, '1': 1, '166': 1, '114': 1, '341': 1, '2': 1, '244': 1, '478': 1, '3': 1, '760': 1, '192': 1, '3015': 1, 'bombshell': 1, 'lack': 1, 'better': 1, 'words': 1, 'really': 1, 'wish': 1, 'someone': 1, 'could': 1, 'show': 1, 'college': 1, 'administrators': 1, 'mandating': 1, '3d': 1, 'students': 1, '6': 1, 'months': 1, 'regard': 1, 'recent': 1, 'breakthrough': 1, 'infections': 1, 'edit': 1, 'know': 1, 'cis': 1, 'overlap': 1, 'fact': 1, 'point': 1, 'estimate': 1, 'clearly': 1, 'outside': 1, 'ci': 1, 'already': 1, 'concerning': 1, 'm': 1, 'merely': 1, 'advocating': 1, 'caution': 1, 'healthy': 1, 'young': 1, 'males': 1, 'covid': 1, 'miniscule': 1, 'threat': 1}, {'isnäôt': 1, 'exercising': 1, 'going': 1, 'help': 1, 'general': 1, 'covid': 1, 'though': 1, '?': 1}, {'18': 1, 'kids': 1, 'used': 1, 'develop': 1, 'dosing': 1, 'size': 1, 'age': 1, 'group': 1}, {'zoe': 1, 'covid': 1, 'study': 1, 'shown': 1, 'symptoms': 1, 'much': 1, 'common': 1, 'classic': 1, 'three': 1, 'website': 1, 'keeps': 1, 'date': 1, 'list': 1}, {'interesting': 1, 'whatäôs': 1, 'tech': 1, '?': 1, 'original': 1, 'covid': 1, 'vaccine': 1, 'traditional': 1, 'inactivated': 1, 'virus': 1, 'approach': 1, 'right': 1}, {'provide': 1, 'anecdotes': 1, 'personally': 1, 'identifying': 1, 'information': 1, 'discussions': 1, 'abstract': 1, 'regard': 1, 'read': 1, 'rules': 1, 'strict': 1}, {'100': 1, '%': 1, 'nt': 1, 'taken': 1, 'face': 1, 'value': 1, 'week': 1, 'got': 1, 'figure': 1, '5': 1, 'kids': 1, '511': 1, 'fully': 1, 'vaccinated': 1, 'plus': 1, 'vaccine': 1, '66': 1, 'efficacy': 1, 'vs': 1, 'injection': 1, 'led': 1, '200': 1, '10000': 1, 'unvaccinated': 1, 'reporting': 1, 'covidpositive': 1, '18': 1, 'hospitalised': 1, 'ignoring': 1, 'lag': 1, 'testing': 1, 'positive': 1, 'roughly': 1, '2': 1, '1000': 1, 'c': 1, 'would': 1, 'expect': 1, '0': 1, 'even': 1, 'nothing': 1, 'reduce': 1, 'severity': 1, 'literally': 1, 'mathematically': 1, 'resulting': 1, 'hospitalisation': 1, 'reality': 1, 'draw': 1, 'meaningful': 1, 'conclusion': 1, 'next': 1, 'already': 1, 'fallen': 1, '73': 1, 'super': 1, 'wide': 1, 'confidence': 1, 'intervals': 1, 'rose': 1, '82': 1, 'third': 1}, {'think': 1, 'basing': 1, 'macaques': 1, 'study': 1, 'mice': 1, 'nabs': 1, 'much': 1, 'better': 1, 's': 1, 'lung': 1, 'nasal': 1, 'tests': 1, 'nt': 1, 'show': 1, 'major': 1, 'differences': 1, 'looking': 1, 'human': 1, 'infection': 1, 'studies': 1, 'need': 1, 'wait': 1, 'clinical': 1, 'first': 1, 'omicron': 1, 'infections': 1, 'seem': 1, 'induce': 1, 'strong': 1, 'protection': 1, '2': 1, 'dose': 1, 'breakthroughs': 1, '3': 1, 'doses': 1, 'https': 1, 'wwwmedrxivorgcontent1011012022020922270692v1fullpdfhtml': 1}, {'doesnäòt': 1, '?': 1, 'conclusion': 1, 'seem': 1, 'exactly': 1, 'indicate': 1, 'äûcontributing': 1, 'rapid': 1, 'riseäú': 1, 'sounds': 1, 'lot': 1, 'like': 1, 'äûhas': 1, 'higher': 1, 'chance': 1, 'infection': 1, 'among': 1, 'vaccinatedäú': 1}, {'new': 1, 'york': 1, '&': 1, 'mainz': 1, 'germany': 1, 'business': 1, 'wire': 1, 'pfizer': 1, 'inc': 1, 'nyse': 1, 'pfe': 1, 'biontech': 1, 'se': 1, 'nasdaq': 1, 'bntx': 1, 'today': 1, 'announced': 1, 'initiation': 1, 'clinical': 1, 'study': 1, 'evaluate': 1, 'safety': 1, 'tolerability': 1, 'immunogenicity': 1, 'omicronbased': 1, 'vaccine': 1, 'candidate': 1, 'healthy': 1, 'adults': 1, '18': 1, '55': 1, 'years': 1, 'age': 1, 'three': 1, 'cohorts': 1, 'examining': 1, 'different': 1, 'regimens': 1, 'current': 1, 'pfizerbiontech': 1, 'covid19': 1, 'draw': 1, 'upon': 1, 'participants': 1, 'companiesäô': 1, 'phase': 1, '3': 1, 'booster': 1, 'part': 1, 'ongoing': 1, 'efforts': 1, 'address': 1, 'omicron': 1, 'determine': 1, 'potential': 1, 'need': 1, 'variantbased': 1, 'vaccines': 1, 'äúwhile': 1, 'research': 1, 'realworld': 1, 'data': 1, 'show': 1, 'boosters': 1, 'continue': 1, 'provide': 1, 'high': 1, 'level': 1, 'protection': 1, 'severe': 1, 'disease': 1, 'hospitalization': 1, 'recognize': 1, 'prepared': 1, 'event': 1, 'wanes': 1, 'time': 1, 'potentially': 1, 'help': 1, 'variants': 1, 'future': 1, 'äù': 1, 'said': 1, 'kathrin': 1, 'u': 1, 'jansen': 1, 'phd': 1, 'senior': 1, 'vice': 1, 'president': 1, 'head': 1, 'development': 1, 'äústaying': 1, 'vigilant': 1, 'virus': 1, 'requires': 1, 'us': 1, 'identify': 1, 'approaches': 1, 'people': 1, 'maintain': 1, 'believe': 1, 'developing': 1, 'investigating': 1, 'like': 1, 'one': 1, 'essential': 1, 'towards': 1, 'goaläù': 1, 'äúvaccines': 1, 'offer': 1, 'strong': 1, 'caused': 1, 'yet': 1, 'emerging': 1, 'indicate': 1, 'vaccineinduced': 1, 'infection': 1, 'mild': 1, 'moderate': 1, 'rapidly': 1, 'observed': 1, 'prior': 1, 'strains': 1, 'prof': 1, 'ugur': 1, 'sahin': 1, 'ceo': 1, 'cofounder': 1, 'äúthis': 1, 'sciencebased': 1, 'approach': 1, 'develop': 1, 'achieves': 1, 'similar': 1, 'earlier': 1, 'longer': 1, 'duration': 1, 'protectionäù': 1, '1420': 1, 'across': 1, 'cohort': 1, '1': 1, 'n': 1, '615': 1, 'received': 1, 'two': 1, 'doses': 1, '90180': 1, 'days': 1, 'enrollment': 1, 'receive': 1, '2': 1, '600': 1, 'dose': 1, 'n205': 1, 'vaccinenaøve': 1, 'find': 1, 'vaccinated': 1, 'particularly': 1, 'companies': 1, 'previously': 1, 'expect': 1, 'produce': 1, 'four': 1, 'billion': 1, '2022': 1, 'capacity': 1, 'expected': 1, 'change': 1, 'adapted': 1, 'required': 1}, {'thatäôs': 1, 'start': 1, 'means': 1, 'close': 1, 'nothing': 1, 'without': 1, 'knowing': 1, 'percentage': 1, 'population': 1, 'vaccinated': 1, 'boosted': 1}, {'could': 1, 'boosting': 1, 'vaccine': 1, 'would': 1, 'elicit': 1, 'broader': 1, 'responsecrossreactivity': 1, 'knowing': 1, 'original': 1, 'antigen': 1, 'presented': 1, 'immune': 1, 'system': 1, '?': 1, 'nt': 1, 'know': 1, 'yet': 1, 'mrnas': 1, 'pushing': 1, 'boundaries': 1, 'department': 1}, {'yup': 1, 'evidence': 1, 'probably': 1, 'testing': 1, 'much': 1, 'rtpcr': 1, 'tested': 1, 'respiratory': 1, 'diseases': 1, 'd': 1, 'shocked': 1, 'many': 1, 'people': 1, 'get': 1, 'sort': 1, 'cold': 1, 'seasons': 1}, {'full': 1, 'pdf': 1, 'give': 1, 'lot': 1, 'different': 1, 'theories': 1, 'donäôt': 1, 'sound': 1, 'particularly': 1, 'sure': 1, 'given': 1, 'boys': 1, 'died': 1, 'sleep': 1, 'without': 1, 'anyone': 1, 'trying': 1, 'cpr': 1, 'cardiac': 1, 'tissue': 1, 'uniquely': 1, 'preserved': 1, 'even': 1, 'gave': 1, 'options': 1, 'thatäôs': 1, 'probably': 1, 'much': 1, 'post': 1, 'longer': 1, 'version': 1, 'abstract': 1, 'äúthe': 1, 'myocardial': 1, 'injury': 1, 'seen': 1, 'postvaccine': 1, 'hearts': 1, 'similar': 1, 'histologic': 1, 'appearance': 1, 'catecholaminemediated': 1, 'stress': 1, 'cardiomyopathy': 1, 'severe': 1, 'sarscov2': 1, 'infection': 1, 'including': 1, 'äúmyocarditisäù': 1, 'associated': 1, 'cytokine': 1, 'release': 1, 'syndromeäù': 1}, {'omicron': 1, 'replaced': 1, 'delta': 1, 'fast': 1, 'nt': 1, 'think': 1, 're': 1, 'looking': 1, 'waning': 1}, {'third': 1, 'exposure': 1, 'original': 1, 'spike': 1, 'protein': 1, 'encoded': 1, 'vaccines': 1, 'grants': 1, 'immunity': 1, 'current': 1, 'variants': 1, 'different': 1, 'flu': 1, 'nt': 1, 'work': 1, 'right': 1, '?': 1, 'whole': 1, 'reason': 1, 'spin': 1, 'new': 1, 'year': 1, 's': 1, 'much': 1, 'crossimmunity': 1, 'function': 1, 'slower': 1, 'rate': 1, 'mutations': 1, 'coronaviruses': 1, 'versus': 1, 'viruses': 1, 'dynamic': 1, 'eg': 1, 'regardless': 1, 'mutation': 1, 'need': 1, 'remain': 1, 'fairly': 1, 'static': 1, 'key': 1, 'region': 1, 'order': 1, 'functional': 1, 'would': 1, 'give': 1, 'higher': 1, 'hopes': 1, 'ideas': 1, 'pancoronavirus': 1, 'vaccine': 1}, {'really': 1, 'helpful': 1, 'thank': 1}, {'seen': 1, 'think': 1, 'passed': 1, 'peer': 1, 'review': 1, 'nt': 1, 'surprise': 1, 'since': 1, 's': 1, 'extensive': 1, 'well': 1, 'done': 1, 'title': 1, 'gives': 1, 'enough': 1, 'justice': 1, 'even': 1, '4th': 1, 'exposure': 1, 'spike': 1, 'via': 1, 'convalescents': 1, 'boosters': 1, 'shows': 1, 'nice': 1, 'improvement': 1, 'looking': 1, 'extended': 1, 'figure': 1, '6': 1, 'limited': 1, 'pure': 1, 'peak': 1, 'antibody': 1, 'volume': 1, 'getting': 1, 'activity': 1, 'iqrs': 1, 'ranges': 1, 'much': 1, 'superior': 1, 'x3': 1, 'exposures': 1, 'either': 1, 'vaccination': 1, 'convalescent': 1, 'x2': 1, 'edit': 1, 'particularly': 1, 'delta': 1, 'gamma': 1, 'omicron': 1, 'responses': 1, 'bad': 1, 'something': 1, 'iga': 1, 'cells': 1, 'x4': 1}, {'true': 1, 'adeno': 1, 'numbers': 1, 'bit': 1, 'weirdconfusing': 1}, {'could': 1, 'related': 1, 'vaccinated': 1, 'people': 1, 'allowed': 1, 'attend': 1, 'events': 1, 'nightclubs': 1, 'combination': 1, 'vaccines': 1, 'efficiency': 1, 'omicron': 1}, {'updated': 1, 'vaccines': 1, 'better': 1, 'trials': 1, 'original': 1, 'shot': 1, 'https': 1, 'wwwnaturecomarticlesd4158602200003y': 1, 'happened': 1, 'delta': 1, 'effective': 1, 'nt': 1, 'matter': 1, 'least': 1, 'want': 1, 'avoid': 1, 'infection': 1}, {'holds': 1, 'true': 1, 's': 1, 'likely': 1, 'vaccines': 1, 'saved': 1, 'many': 1, 'lives': 1, 'giving': 1, 'omicron': 1, 'advantage': 1, 'delta': 1, 'significantly': 1, 'less': 1, 'cause': 1, 'death': 1, 'recovery': 1, 'infection': 1, 'seem': 1, 'prevent': 1, 'reinfection': 1, 'least': 1, 'near': 1, 'term': 1, 'm': 1, 'sure': 1, 'could': 1, 'conclude': 1, 'much': 1, 'certainty': 1, 'currently': 1, 'killing': 1, 'americans': 1, 'per': 1, 'capita': 1, 'peak': 1, 'deadly': 1, 'places': 1, 'like': 1, 'united': 1, 'states': 1, 'respective': 1, 'peaks': 1, 'even': 1, 'nt': 1, 'case': 1}, {'s': 1, 'going': 1, 'see': 1, 'light': 1, 'day': 1, 'fauci': 1, 'already': 1, 'eluded': 1, 'keeping': 1, 'rainy': 1}, {'nt': 1, 'think': 1, 's': 1, 'obvious': 1, '4': 1, 'shots': 1, 'many': 1, '65': 1, '%': 1, 'efficacy': 1, 'symptomatic': 1, 'disease': 1, 'good': 1, 'enough': 1, '?': 1}, {'s': 1, 'control': 1, 'group': 1, 'though': 1, 'prevalence': 1, 'one': 1, 'symptoms': 1, 'like': 1, 'headache': 1, 'fatigue': 1, 'cough': 1, 'sore': 1, 'throat': 1, 'uninfected': 1, 'people': 1, '?': 1, 'zero': 1, 'nt': 1, 'reasonable': 1, 'baseline': 1, 'example': 1, 'vaccine': 1, 'trials': 1, 'third': 1, 'reported': 1, 'least': 1, 'systemic': 1, 'adverse': 1, 'effect': 1, 'similar': 1, 'list': 1, 'receiving': 1, 'placebo': 1, 'https': 1, 'jamanetworkcomjournalsjamanetworkopenfullarticle2788172': 1}, {'one': 1, 'interesting': 1, 'background': 1, 'pathogen': 1, 'mandated': 1, 'immunity': 1, 'confound': 1, 'results': 1, 'hong': 1, 'kong': 1, 'maintained': 1, 'extremely': 1, 'low': 1, 'circulation': 1, 'sarscov2': 1, 'major': 1, 'community': 1, 'epidemic': 1, 'omicron': 1, 'ba2': 1, 'starting': 1, 'january': 1, '2022': 1, 'mrna': 1, 'bnt162b2': 1, 'biontechfosun': 1, 'pharma': 1, 'inactivated': 1, 'coronavac': 1, 'sinovac': 1, 'vaccines': 1, 'widely': 1, 'available': 1, 'however': 1, 'coverage': 1, 'remained': 1, 'older': 1, 'adults': 1, 'vaccine': 1, 'effectiveness': 1, 'predominantly': 1, 'infectionnaive': 1, 'population': 1, 'unknown': 1, 'methods': 1, 'used': 1, 'individuallevel': 1, 'case': 1, 'data': 1, 'mildmoderate': 1, 'severefatal': 1, 'fatal': 1, 'hospitalized': 1, 'covid19': 1, 'december': 1, '31': 1, '2021': 1, 'march': 1, '8': 1, 'along': 1, 'census': 1, 'information': 1, 'negative': 1, 'binomial': 1, 'model': 1, 'adjusting': 1, 'age': 1, 'calendar': 1, 'day': 1, 'estimate': 1, 'two': 1, 'three': 1, 'dose': 1, 'schedules': 1, 'relative': 1, 'number': 1, 'doses': 1, 'type': 1, 'findings': 1, 'total': 1, '127': 1, 'million': 1, 'administered': 1, '73': 1, 'analyzed': 1, 'confirmed': 1, 'cases': 1, 'n5474': 1, 'n5294': 1, 'n4093': 1, 'either': 1, 'protected': 1, 'against': 1, 'severe': 1, 'disease': 1, 'death': 1, 'higher': 1, 'among': 1, 'â60': 1, 'years': 1, '882': 1, '%': 1, '95': 1, 'confidence': 1, 'interval': 1, 'ci': 1, '844': 1, '911': 1, 'compared': 1, '741': 1, '678': 1, '792': 1, 'offered': 1, 'high': 1, 'levels': 1, 'protection': 1, 'outcomes': 1, '981': 1, '971': 1, '988': 1, 'interpretation': 1, 'third': 1, 'provide': 1, 'substantial': 1, 'additional': 1, 'prioritized': 1, 'particularly': 1, 'received': 1, 'primary': 1, 'longer': 1, 'followup': 1, 'needed': 1, 'assess': 1, 'persistence': 1, 'different': 1, 'platforms': 1}, {'result': 1, 'nt': 1, 'super': 1, 'surprising': 1, 'considering': 1, 'moderna': 1, 's': 1, 'beta': 1, '&': 1, 'delta': 1, 'specific': 1, 'boosters': 1, 'also': 1, 'perform': 1, 'better': 1, '3rd': 1, 'shot': 1, 'original': 1, 'vaccine': 1, 'based': 1, 'wildtype': 1, 'incorrect': 1, 'slide': 1, '29': 1, 'https': 1, 's29q4cdncom745959723filesdoc_financials2021q2moderna2q2021earningspresentation': 1, '080521': 1, 'pdf': 1, 'betaonly': 1, 'nearly': 1, 'twice': 1, 'well': 1, 'titer': 1, 'measurements': 1, 'gamma': 1, 'd614g': 1, 'exact': 1, 'opposite': 1, 'study': 1, 'found': 1, 'omicron': 1, 'significantly': 1, 'worse': 1, 'multivalent': 1, 'vaccines': 1, 'even': 1, 'across': 1, 'board': 1, 'unfortunately': 1, 'using': 1, 'would': 1, 'extremely': 1, 'good': 1, 'could': 1, 'stop': 1, 'repeating': 1, 'upvoting': 1, 'statement': 1, 'every': 1, 'thread': 1}, {'idk': 1, 'efficacy': 1, 'm': 1, 'sure': 1, 's': 1, 'enough': 1, 'data': 1, 'curious': 1, 'total': 1, 'hospitalizations': 1, 'study': 1, '1313': 1, 'breakthroughs': 1, '675': 1, 'boosted': 1, '140': 1}, {'imprinting': 1, 'possibility': 1, '?': 1, 'study': 1, 'looked': 1, 'people': 1, 'previously': 1, 'infected': 1, 'preomicron': 1, 'variants': 1, 'effects': 1, 'boosting': 1, 'one': 1, 'two': 1, 'doses': 1, 'omicron': 1, 'wave': 1, 'perhaps': 1, 'single': 1, 'dose': 1, 'boosted': 1, 'immune': 1, 'system': 1, 'create': 1, 'wide': 1, 'variety': 1, 'antibodies': 1, 'including': 1, 'work': 1, 'second': 1, 'resulted': 1, 'boost': 1, 'less': 1, 'breadth': 1, 'focus': 1, 'focused': 1, 'original': 1, 'antigen': 1}, {'50': 1, '%': 1, 'rumored': 1, '?': 1, 'lowest': 1, 'acceptable': 1, 'adult': 1, 'c19': 1, 'vaccines': 1, 'think': 1}, {'good': 1, 'point': 1, 're': 1, 'comparing': 1, 'unvaxxed': 1, 'population': 1, 'likely': 1, 'well': 1, 'half': 1, 'natural': 1, 'immunity': 1, 's': 1, 'massive': 1, 'confounding': 1, 'factor': 1}, {'think': 1, 'one': 1, 'important': 1, 'condition': 1, 'determine': 1, 'mandate': 1, 'policy': 1, 'based': 1, 'available': 1, 'statistics': 1, 'entire': 1, '1316': 1, 'group': 1, 'nt': 1, 'identifiable': 1, 'subset': 1, 'data': 1, 'suggests': 1, 'different': 1, 'example': 1, 'overall': 1, 'beneficial': 1, 'harmful': 1, '1314': 1, 'apply': 1, 'probably': 1, 'obvious': 1, 'm': 1, 'driving': 1, 'point': 1, 'step': 1, 'case': 1, '70': 1, '%': 1, 'kids': 1, 'overweight': 1, 'net': 1, 'remaining': 1, '30': 1, 'final': 1, 'healthy': 1, 'furthermore': 1, 'greatly': 1, 'reduced': 1, 'odds': 1, 'getting': 1, 'infected': 1, 'due': 1, 'following': 1, 'strict': 1, 'regimen': 1, 'npis': 1, 'yet': 1, 'd': 1, 'clump': 1, 'together': 1, 'big': 1, 'demographic': 1, 'forcing': 1, 'take': 1, 'vaccine': 1, 'comes': 1, 'mathematical': 1, 'expectation': 1, 'harm': 1, 'specific': 1}, {'selection': 1, 'bias': 1, 'likely': 1, 'considered': 1, 'high': 1, 'risk': 1, 'group': 1, 'choose': 1, 'early': 1, 'vaccination': 1}, {'study': 1, 'nt': 1, 'say': 1, 'contrary': 1, 'states': 1, 'triple': 1, 'vaccinated': 1, 'people': 1, 'got': 1, 'infected': 1, 'omicron': 1, 'corona': 1, 'variant': 1, 'seems': 1, 'evade': 1, 'immune': 1, 'response': 1, 'abstract': 1, 'reasons': 1, 'admitted': 1, 'hospital': 1, 'yet': 1, 'could': 1, 'many': 1, 'age': 1, 'health': 1, 'preexisting': 1, 'conditions': 1, 'vaccination': 1, 'etc': 1, 'numerous': 1, 'studies': 1, 'documented': 1, 'lesser': 1, 'vaccine': 1, 'efficacy': 1, 'nonetheless': 1, 'like': 1, 'reasonable': 1, 'assertion': 1, 'really': 1, 'know': 1, 'extend': 1, 'vaccines': 1, 'work': 1, 'long': 1, 'across': 1, 'covid19': 1, 'strains': 1}, {'compared': 1, 'delta': 1, 'two': 1, 'weeks': 1, 'cutoff': 1, 'start': 1, 'counting': 1, 'subjects': 1, 'received': 1, '2': 1, '3': 1, 'doses': 1, 'get': 1, 'infected': 1, 'less': 1, 'last': 1, 'dose': 1, 's': 1, 'counted': 1, 'numbers': 1, 'gotten': 1, '1': 1}, {'fact': 1, 'infection': 1, 'vaccination': 1, 'produces': 1, 'higher': 1, 'titers': 1, 'really': 1, 'surprising': 1, 'even': 1, 'two': 1, 'doses': 1, 'vaccine': 1, 'matter': 1, 'titer': 1, 'could': 1, 'also': 1, 'diversity': 1, 'among': 1, 'antibodies': 1, 'formed': 1, 'following': 1, 'help': 1, 'neutralize': 1, 'variants': 1, '?': 1}, {'result': 1, 'nt': 1, 'super': 1, 'surprising': 1, 'considering': 1, 'moderna': 1, 's': 1, 'beta': 1, '&': 1, 'delta': 1, 'specific': 1, 'boosters': 1, 'also': 1, 'perform': 1, 'better': 1, '3rd': 1, 'shot': 1, 'original': 1, 'vaccine': 1, 'based': 1, 'wildtype': 1, 'shared': 1, 'results': 1, 'earnings': 1, 'call': 1, 'pdf': 1, 'last': 1, 'fall': 1, 'seems': 1, 'like': 1, 'must': 1, 'oas': 1, 'antigenic': 1, 'sin': 1, 'going': 1, 'even': 1, 'prevents': 1, 'robust': 1, 'response': 1, 'omicron': 1, 'much': 1, 'mutated': 1, 'vocs': 1, 'difficult': 1, 'part': 1, 'think': 1, 'confirmed': 1, 'humans': 1, 'convincing': 1, 'layman': 1, 'updated': 1, 'offer': 1, 'benefit': 1, 'needed': 1, 'inability': 1, 'understand': 1, 'counterintuitive': 1, 'leads': 1, 'unfair': 1, 'skeptism': 1, 'vaccines': 1, 'silver': 1, 'lining': 1, 'pov': 1, 'vast': 1, 'majority': 1, 'people': 1, 'first': 1, 'exposure': 1, 'covid19': 1, 'virus': 1, 'one': 1, 'less': 1, 'instance': 1, 'pathogenic': 1, 'likely': 1, 'cause': 1, 'death': 1, 'pathogen': 1, 'come': 1, 'around': 1, 'would': 1, 'get': 1, 'immune': 1, 'system': 1, 'protect': 1, 'virulent': 1, 'variants': 1, 'due': 1, '_____': 1, 'maybe': 1, 'helpful': 1, 'term': 1, 'äúoriginal': 1, 'sinäù': 1, 'used': 1, '1960s': 1, 'describe': 1, 'oneäôs': 1, 'influenza': 1, 'shapes': 1, 'outcome': 1, 'subsequent': 1, 'exposures': 1, 'antigenically': 1, 'related': 1, 'strains': 1, '____': 1, 'another': 1, 'preprint': 1, 'w': 1, 'hamsters': 1, 'day': 1, 'ago': 1, 'suggest': 1, 'effective': 1, 'replicating': 1, 'rna': 1, 'platform': 1, 'enables': 1, 'rapid': 1, 'sarscov2': 1, 'variant': 1, 'elicits': 1, 'enhanced': 1, 'protection': 1, 'naøve': 1, 'compared': 1, 'ancestral': 1, 'https': 1, 'oldredditcomrcovid19commentssjpvxqreplicating_rna_platform_enables_rapid_response': 1}, {'huge': 1, 'number': 1, 'doses': 1, 'administered': 1, 'iäôm': 1, 'sure': 1, 'chance': 1, 'people': 1, 'heart': 1, 'attack': 1, 'something': 1, 'right': 1, 'vaccination': 1, 'brought': 1, 'derek': 1, 'lowe': 1, 'vaccines': 1, 'got': 1, 'eua': 1, 'title': 1, 'post': 1, 'like': 1, 'get': 1, 'ready': 1, 'false': 1, 'sideeffects': 1, 'edit': 1, 'nailed': 1, 'https': 1, 'wwwredditcomrcovid19commentsk6rs2rget_ready_for_false_side_effects': 1, 'second': 1, 'comment': 1, 'key': 1, 'point': 1}, {'yes': 1, 's': 1, 'exactly': 1, 'comparison': 1, 'wait': 1, '?': 1, 'risk': 1, 'äúvaccine': 1, 'myocarditis': 1, 'hospitalised': 1, 'covid19': 1, 'patient': 1, 'riskäù': 1, 'iäôm': 1, 'pretty': 1, 'sure': 1, 'user': 1, 'says': 1, 'theyäôre': 1, 'talking': 1, 'vaccineinduced': 1, 'donäôt': 1, 'think': 1, 'study': 1, 'itäôs': 1, 'relative': 1, 'odds': 1, 'covid': 1, 'vaccinated': 1, 'versus': 1, 'unvaccinated': 1, 'patients': 1}, {'absolutely': 1, 'vaccines': 1, 'make': 1, 'many': 1, 'cases': 1, 'much': 1, 'milder': 1, 'also': 1, 'treatments': 1}, {'re': 1, 'talking': 1, 'relevant': 1, 'study': 1, 'describe': 1, 'took': 1, 'blood': 1, 'serum': 1, 'samples': 1, 'people': 1, 'tested': 1, 'neutralization': 1, 'assay': 1, 'used': 1, 'pseudoviruses': 1, 'onto': 1, 'attached': 1, 'spike': 1, 'proteins': 1, 'different': 1, 'variants': 1, 'sarscov2': 1, 'specifically': 1, 'well': 1, 'antibodies': 1, 'sample': 1, 'neutralized': 1, 'likely': 1, 'viral': 1, 'interference': 1, 'talk': 1, 'comes': 1, 'factors': 1, 'example': 1, 'another': 1, 'virus': 1, 'detected': 1, 'interferon': 1, 'released': 1, 'areas': 1, 'goes': 1, 'uninfected': 1, 'cells': 1, 'instructs': 1, 'enter': 1, 'antiviral': 1, 'state': 1, 'lot': 1, 'time': 1, 'exposed': 1, 'next': 1, 'less': 1, 'chance': 1, 'infecting': 1, 'ways': 1, 'immune': 1, 'system': 1, 'could': 1, 'cause': 1, 'effect': 1, 's': 1, 'one': 1, 'also': 1, 'even': 1, 'if': 1, 'caused': 1, 'neutralizing': 1, 'seems': 1, 'unlikely': 1, 'induced': 1, 'neutralize': 1, 'significantly': 1, 'compared': 1, 'groups': 1, 'patients': 1, 'see': 1, 'statistically': 1, 'significant': 1, 'differences': 1, 'unless': 1, 'systematic': 1, 'reason': 1, 'say': 1, 'boosted': 1, 'infected': 1, 'recently': 1, 'unboosted': 1, 'infection': 1, 'effects': 1, 'would': 1, 'random': 1, 'among': 1, 'affect': 1, 'results': 1}, {'well': 1, 'would': 1, 'nt': 1, 'want': 1, 'guess': 1, 'motivation': 1, 'much': 1, 'week': 1, '2': 1, 'https': 1, 'assetspublishingservicegovukgovernmentuploadssystemuploadsattachment_datafile1047814vaccinesurveillancereportweek22022pdf': 1, 'showing': 1, 'apparent': 1, 'efficacy': 1, 'like': 1, '100': 1, '%': 1, 'cohorts': 1, 'except': 1, '18': 1, 'recently': 1, 'dosed': 1, '?': 1, '80': 1, 'phenomenon': 1, 'source': 1, 'considerable': 1, 'political': 1, 'wrangling': 1, 'ons': 1, 'ukhsa': 1, 'producers': 1, 'report': 1, 'soooo': 1, 'maybe': 1, 'feel': 1, '3': 1, 'dose': 1, 'data': 1, 'quite': 1, 'embarrassing': 1, 'looking': 1, 'questionable': 1, 's': 1, 'making': 1, 'boosters': 1, 'look': 1, 'worse': 1, 'd': 1, 'expect': 1, 'even': 1, 'boosting': 1, 'anyone': 1, '30': 1, 'cohort': 1, 'idk': 1, 'people': 1, 'substack': 1, 'field': 1, 'day': 1, 'regardless': 1}, {'think': 1, 'weäôre': 1, 'going': 1, 'find': 1, 'immunity': 1, 'breadth': 1, 'gained': 1, '69': 1, 'months': 1, 'somatic': 1, 'hypermutation': 1, 'mature': 1, 'memory': 1, 'b': 1, 'cells': 1, 'polymorphism': 1, 'cell': 1, 'receptors': 1, 'greater': 1, 'affinity': 1, 'variants': 1, 'play': 1, 'larger': 1, 'role': 1, 'short': 1, 'run': 1, 'neutralizing': 1, 'antibodies': 1, 'really': 1, 'primers': 1}, {'infection': 1, 'pfizer': 1, 'vaccines': 1, 'efficacy': 1, 'hospitalization': 1, 'higher': 1, 'around': 1, '90': 1, '%': 1}, {'toms': 1, 'people': 1, 'whoäôve': 1, 'never': 1, 'vaccinated': 1, 'infected': 1, 'key': 1, 'point': 1, 'theyäôre': 1, 'ruling': 1, 'stand': 1, 'outside': 1, 'hospital': 1, 'youäôll': 1, 'find': 1, 'recovered': 1, 'patients': 1, 'probably': 1, 'rethinking': 1, 'prior': 1, 'decision': 1, 'get': 1}, {'die': 1, 'things': 1, 'like': 1, 'hiv': 1, 'tuberculosis': 1, 'yes': 1, 'us': 1, 'keeps': 1, 'millions': 1, 'people': 1, 'alive': 1, 'horribly': 1, 'unhealthy': 1, 'would': 1, 'dead': 1, 'modern': 1, 'medicine': 1, 'south': 1, 'africa': 1, 'part': 1, 'infrastructure': 1, 'western': 1, 'nearly': 1, 'accustomed': 1, 'unthinkable': 1, 'west': 1, 'doesnäôt': 1, 'make': 1, 'covid': 1, 'experience': 1, 'worse': 1, 'westäôs': 1, 'though': 1, 'terms': 1, 'severe': 1, 'disease': 1, 'given': 1, 'median': 1, 'age': 1, '28': 1, 'vs': 1, '38': 1, 'additionally': 1, '60': 1, 'entire': 1, 'population': 1, '6': 1, '%': 1, '65': 1, '18': 1, 'much': 1, '?': 1, 'sample': 1, 'size': 1, 'meaningless': 1, 'youäôre': 1, 'comparing': 1, 'weäôre': 1, 'obviously': 1, 'quite': 1, 'different': 1, 'numbers': 1, '16x': 1, 'getting': 1, 'stuck': 1, 'minutia': 1, 'studies': 1, 'thus': 1, 'pointless': 1}, {'interesting': 1, 'study': 1, '36000': 1, 'genomic': 1, 'sequences': 1, 'patients': 1, 'analysis': 1, '90': 1, '%': 1, 'total': 1, 'rest': 1, 'could': 1, 'nt': 1, 'get': 1, 'sequenced': 1, 'time': 1, 'assumed': 1, 'omicron': 1, 'sgene': 1, 'target': 1, 'failure': 1, 'best': 1, 'knowledge': 1, 'studies': 1, 'diseaseseverity': 1, 'far': 1, 'rely': 1, 'variant': 1, 'proportion': 1, 'estimates': 1, 'alone': 1}, {'yes': 1, 'heart': 1, 'inflammation': 1, 'myocarditis': 1, 'pericarditis': 1, 'known': 1, 'issue': 1, 'viral': 1, 'diseases': 1, 'including': 1, 'covid': 1, 'tends': 1, 'severe': 1, 'high': 1, 'rate': 1, 'permanent': 1, 'damage': 1, 'fact': 1, 'number': 1, 'one': 1, 'intervention': 1, 'reducing': 1, 'attacks': 1, 'flu': 1, 'vaccine': 1, 'influenza': 1, 'also': 1, 'trigger': 1, 'issues': 1, 'vaccineassociated': 1, 'rare': 1, 'age': 1, 'groups': 1, 'risks': 1, 'disease': 1, 'far': 1, 'exceed': 1, 'treatable': 1, 'sideeffects': 1}, {'relatively': 1, 'accepted': 1, 'shots': 1, 'safe': 1, 'keep': 1, 'getting': 1, 'every': 1, '46': 1, 'months': 1, 'persons': 1, 'desire': 1, '?': 1, 'think': 1, 'eventually': 1, 'may': 1, 'stop': 1, 'recommending': 1, 'official': 1, 'doses': 1, 'everyone': 1, 'say': 1, 'want': 1, 'continue': 1, 'make': 1, 'sure': 1, 'itäôs': 1, 'previous': 1, 'one': 1}, {'wondering': 1, 'quite': 1, 'dumbfounded': 1, 'omitted': 1, 'despite': 1, 'substantial': 1, 'portion': 1, 'population': 1, 'still': 1, 'anyone': 1, 'know': 1, 'find': 1, 'many': 1, 'total': 1, 'people': 1, 'age': 1, 'decade': 1, '2': 1, 'doses': 1, 'period': 1, '?': 1, 'could': 1, 'least': 1, 'derive': 1, 'incidence': 1, 'rates': 1, 'using': 1, 'data': 1, 'tables': 1, '1012': 1}, {'conclusion': 1, 'antibody': 1, 'levels': 1, 'predictive': 1, 'clinical': 1, 'course': 1, 'covid19': 1, 'vaccinated': 1, 'patients': 1, 'delta': 1, 'omicron': 1, 'variant': 1, 'infections': 1, 'data': 1, 'highlight': 1, 'need': 1, 'concentrated': 1, 'efforts': 1, 'monitor': 1, 'sarscov2': 1, 'infection': 1, 'risk': 1, 'low': 1, 'read': 1, 'suggesting': 1, 'environments': 1, 'early': 1, 'testing': 1, 'antibodies': 1, 'useful': 1, 'determining': 1, 'interventions': 1, 'like': 1, 'antivirals': 1, 'example': 1, 'would': 1, 'valuable': 1, 'nt': 1, 'surprising': 1, 'tied': 1, 'progression': 1, 'disease': 1, 'wonder': 1, 'suggests': 1, 'maintaining': 1, 'high': 1, 'titers': 1, 'may': 1, 'important': 1, 'reducing': 1, 'severe': 1, 'outcomes': 1, 'establishing': 1, 'robust': 1, 'tcell': 1, 'response': 1, 'impact': 1, 'vaccine': 1, 'strategy': 1, 'consequence': 1, '?': 1}, {'one': 1, 'word': 1, 'preprint': 1, 'masks': 1}, {'n29': 1, 'unsurprisingly': 1, 'variant': 1, 'known': 1, 'evade': 1, 'antibodies': 1, 'prevalent': 1}, {'studies': 1, 'using': 1, 'astrazeneca': 1, 'booster': 1, 'johnson': 1, '?': 1, 'got': 1, '7': 1, 'months': 1, 'ago': 1, 'right': 1, 's': 1, 'available': 1, 'live': 1}, {'mean': 1, 'effect': 1, 'nth': 1, 'booster': 1, 'following': 1, 'three': 1, 'months': 1, 'percent': 1, 'resistant': 1, '?': 1, 'seems': 1, 'like': 1, 's': 1, 'beneficial': 1, 'beyond': 1, 'remaining': 1, 'could': 1, 'explain': 1, 'several': 1, 'countries': 1, 'procured': 1, '4': 1, 'doses': 1, 'per': 1, 'citizen': 1, 'year': 1, 'years': 1, 'advance': 1, 'assuming': 1, 'known': 1, 'informally': 1, 'among': 1, 'manufacturer': 1, 'leadership': 1}, {'nature': 1, 'page': 1, 'nt': 1, 'loading': 1, 'right': 1, 'paper': 1, 'original': 1, 'sin': 1, '?': 1, 'data': 1, 'omicron': 1, 'jab': 1, 'would': 1, 'perform': 1, 'first': 1, 'dose': 1, 'edit': 1, 's': 1, 'loaded': 1, 'third': 1, 'produce': 1, 'elevated': 1, 'immune': 1, 'response': 1, 'seen': 1, 'mice': 1, 'received': 1, 'one': 1, 'vaccine': 1, 'based': 1, 'ancestral': 1, 'strain': 1, 'two': 1, 'doses': 1, 'omicronspecific': 1}, {'s': 1, 'interesting': 1, 'wt': 1, 'vaccine': 1, 'offers': 1, 'protection': 1, 'types': 1, 'variants': 1, 'specific': 1, 'omicron': 1, 'variant': 1, 'reads': 1, 'like': 1, 'movie': 1, 'techno': 1, 'babble': 1, 'original': 1, 'strain': 1, 'needs': 1, 'found': 1, 'develop': 1, 'cure': 1, 'practically': 1, 'suggest': 1, 'unvaccinated': 1, 'individuals': 1, 'get': 1, 'infected': 1, 'first': 1, 'still': 1, 'risk': 1, 'another': 1, 'infection': 1, 'delta': 1, '?': 1}, {'viral': 1, 'persistence': 1}, {'5': 1, 'theyäôre': 1, 'looking': 1, 'antibody': 1, 'produced': 1, 'vaccines': 1, 'antibodies': 1, 'natural': 1, 'infection': 1, 'broad': 1, 'n': 1, 'protein': 1, 'would': 1, 'give': 1, 'completely': 1, 'different': 1, 'picture': 1, '6': 1, 'supported': 1, 'epidemiological': 1, 'data': 1}, {'imprinting': 1, 'issues': 1, 'please': 1, '?': 1}, {'nt': 1, 'link': 1, 'right': 1, 'memory': 1, 'trials': 1, 'show': 1, 'significant': 1, 'advantage': 1, 'original': 1, 'vaccine': 1}, {'countries': 1, 'vaccines': 1, 'widely': 1, 'available': 1}, {'probably': 1, 'degree': 1, 'really': 1, 'depends': 1, 'tropism': 1, 'cells': 1}, {'words': 1, 'leads': 1, 'antibodies': 1, 'much': 1, 'mutated': 1, '?': 1}, {'one': 1, 'risks': 1, 'need': 1, 'acknowledged': 1, 'fears': 1, 'worst': 1, 'case': 1, 'scenarios': 1, 'accepted': 1, 'valid': 1, 'communication': 1, 'towards': 1, 'people': 1, 'failed': 1, 'miserably': 1, 'pandemic': 1, 'you': 1, 'must': 1, 'take': 1, 'vaccine': 1, 'messaging': 1, 'huge': 1, 'relentless': 1, 'campaigning': 1, 'actually': 1, 'creates': 1, 'opposite': 1, 'effect': 1}, {'article': 1, 'nt': 1, 'seem': 1, 'mention': 1, 'ages': 1, 'given': 1, 'adult': 1, 'dose': 1, 'lower': 1, 'would': 1, 'justification': 1, 'adjustment': 1, 'maybe': 1, 'conditions': 1, '?': 1}, {'also': 1, 'makes': 1, 'clinical': 1, 'trials': 1, 'fixed': 1, 'spelling': 1, 'really': 1, 'challenging': 1, 'imo': 1}, {'suggestion': 1, 'clarification': 1, 'statement': 1, 'general': 1, 'since': 1, 'authors': 1, 'used': 1, 'vague': 1, 'language': 1, 'describe': 1, 'causationrisk': 1, 'factors': 1, 'looked': 1, 'mayo': 1, 'clinic': 1, 'reference': 1, 'vaccine': 1, 'listed': 1, 'risk': 1, 'factor': 1, 'j': 1, '&': 1, 'covid19': 1, 'list': 1, 'infection': 1, 'influenza': 1, 'virus': 1, 'webpage': 1, 'https': 1, 'wwwmayoclinicorgdiseasesconditionsguillainbarresyndromesymptomscausessyc20362793': 1}, {'layperson': 1, 's': 1, 'trying': 1, 'wrap': 1, 'head': 1, 'around': 1, 'correct': 1, 'interpretation': 1, 'one': 1, 'hypothesis': 1, 'could': 1, 'draw': 1, 'given': 1, 'conditions': 1, 'two': 1, 'hearts': 1, 'prior': 1, 'vaccination': 1, 'possible': 1, 'sarscov2': 1, 'infection': 1, 'immune': 1, 'response': 1, 'would': 1, 'cause': 1, 'similar': 1, 'reaction': 1, 'fatality': 1, 'vaccine': 1, 'case': 1, 'words': 1, 'nt': 1, 'vaccinated': 1, 'infected': 1, 'may': 1, 'died': 1, 'mechanism': 1, 'anyway': 1, 'getting': 1, 'right': 1, 'missing': 1, 'point': 1, '?': 1}, {'statement': 1, 'accounting': 1, 'much': 1, 'longer': 1, 'lag': 1, 'initial': 1, 'infection': 1, 'death': 1, '?': 1}, {'would': 1, 'love': 1, 'see': 1, 'chart': 1, 'comparing': 1, 'numbers': 1, 'prevalence': 1, 'population': 1, 'vaccines': 1, 'also': 1, 'covid': 1, 'unvaccinated': 1, 'huge': 1, 'number': 1, 'doses': 1, 'administered': 1, 'iäôm': 1, 'sure': 1, 'chance': 1, 'people': 1, 'heart': 1, 'attack': 1, 'something': 1, 'right': 1, 'vaccination': 1}, {'researchers': 1, 'examine': 1, 'differences': 1, 'immunity': 1, 'based': 1, 'time': 1, 'since': 1, 'last': 1, 'dose': 1, 'independent': 1, 'whether': 1, '2nd': 1, '3rd': 1, 'shot': 1, '?': 1}, {'qualified': 1, 'share': 1, 'understanding': 1, 'm': 1, 'reading': 1, 'though': 1, 'janeway': 1, 's': 1, 'immunobiology': 1, 'lifespan': 1, 'shortlived': 1, 'plasma': 1, 'cells': 1, 'https': 1, 'ashpublicationsorgbloodarticle11618344527964thelifespanofshortlivedplasmacellsis': 1, 'antibodies': 1, 'produced': 1, 'primary': 1, 'secondary': 1, 'response': 1, 'differentiated': 1, 'subset': 1, 'migrate': 1, 'bone': 1, 'marrow': 1, 'stromal': 1, 'keep': 1, 'long': 1, 'lived': 1, 'alive': 1, 'nt': 1, 'selected': 1, 'migration': 1, 'end': 1, 'dying': 1, 'cycled': 1, 'capase3': 1, '9': 1, 'fully': 1, 'understand': 1, 'also': 1, 'endoplasmic': 1, 'reticulum': 1, 'stress': 1, 'signals': 1, 'capase12': 1, 'correct': 1, 'basically': 1, 'means': 1, 'cellular': 1, 'machinery': 1, 'cell': 1, 'gets': 1, 'worn': 1, 'triggers': 1, 'programed': 1, 'death': 1, 'high': 1, 'volume': 1, 'temporary': 1, 'low': 1, 'level': 1, 'maintained': 1, 'migrated': 1, 'years': 1, 'prolonged': 1, 'levels': 1, 'lead': 1, 'hyperviscosity': 1, 'syndrome': 1, 'blood': 1, 'becomes': 1, 'viscous': 1, 'makes': 1, 'number': 1, 'organ': 1, 'processess': 1, 'harder': 1, '&': 1, 'x200b': 1, 'upon': 1, 'reexposure': 1, 'memory': 1, 'b': 1, 'differentiate': 1, 'produce': 1, 'effector': 1, 'results': 1, 'producing': 1}, {'severity': 1, 'infection': 1, 'determines': 1, 'long': 1, 'tcell': 1, 'immunity': 1, 'lasts': 1, 'always': 1, 'find': 1, 'disconcerting': 1, 'level': 1, 'suggested': 1, 'provide': 1, 'protection': 1, 'vaccines': 1, 'boosters': 1, 'accurate': 1, 'form': 1, 'determining': 1, 'waning': 1, 'without': 1, 'costly': 1, 'bab': 1, 'titer': 1, 'count': 1, 'tests': 1, 'terms': 1, 'seem': 1, 'get': 1, 'misunderstood': 1, 'goes': 1, 'press': 1, 'wearing': 1, 'fitted': 1, 'mask': 1, 'goggles': 1}, {'last': 1, 'data': 1, 'study': 1, '2': 1, 'weeks': 1, 'post': 1, 'vaccination': 1, '3': 1, 'particular': 1, 'useful': 1, 'answer': 1, 'question': 1, 's': 1, 'clear': 1, 're': 1, 'continuing': 1, 'follow': 1, 'cohort': 1, 'publish': 1, 'update': 1, 'point': 1, 'unfortunately': 1, 'basically': 1, 'way': 1, 'accelerate': 1, 'research': 1, 'long': 1, 'immune': 1, 'response': 1}, {'91150': 1, 'looks': 1, 'strongly': 1, 'negative': 1, '150': 1, 'would': 1, 'positive': 1, 'zero': 1, 'study': 1, 'good': 1, 'result': 1}, {'s': 1, 'pretty': 1, 'big': 1, 'phase': 1, '1': 1, 'standards': 1, 'would': 1, 'nice': 1, 'cohort': 1, '2': 1, 'bigger': 1, 'think': 1, 'study': 1, 'look': 1, 'antibody': 1, 'generation': 1, 'protection': 1, 'actual': 1, 'infection': 1, 'nt': 1, 'need': 1, 'nearly': 1, 'large': 1, '3': 1, 'trials': 1}]\n",
            "  (0, 1734)\t1.0\n",
            "  (0, 302)\t1.0\n",
            "  (0, 1612)\t1.0\n",
            "  (0, 1065)\t1.0\n",
            "  (0, 2107)\t1.0\n",
            "  (0, 178)\t1.0\n",
            "  (0, 997)\t1.0\n",
            "  (0, 245)\t1.0\n",
            "  (0, 407)\t1.0\n",
            "  (0, 979)\t1.0\n",
            "  (0, 1856)\t1.0\n",
            "  (0, 1060)\t1.0\n",
            "  (0, 101)\t1.0\n",
            "  (0, 4)\t1.0\n",
            "  (0, 1013)\t1.0\n",
            "  (0, 96)\t1.0\n",
            "  (0, 417)\t1.0\n",
            "  (0, 482)\t1.0\n",
            "  (0, 1581)\t1.0\n",
            "  (0, 959)\t1.0\n",
            "  (0, 49)\t1.0\n",
            "  (0, 960)\t1.0\n",
            "  (0, 342)\t1.0\n",
            "  (0, 654)\t1.0\n",
            "  (0, 248)\t1.0\n",
            "  :\t:\n",
            "  (198, 32)\t1.0\n",
            "  (199, 2)\t1.0\n",
            "  (199, 909)\t1.0\n",
            "  (199, 378)\t1.0\n",
            "  (199, 959)\t1.0\n",
            "  (199, 19)\t1.0\n",
            "  (199, 2119)\t1.0\n",
            "  (199, 260)\t1.0\n",
            "  (199, 406)\t1.0\n",
            "  (199, 923)\t1.0\n",
            "  (199, 28)\t1.0\n",
            "  (199, 360)\t1.0\n",
            "  (199, 157)\t1.0\n",
            "  (199, 191)\t1.0\n",
            "  (199, 84)\t1.0\n",
            "  (199, 611)\t1.0\n",
            "  (199, 316)\t1.0\n",
            "  (199, 25)\t1.0\n",
            "  (199, 27)\t1.0\n",
            "  (199, 41)\t1.0\n",
            "  (199, 609)\t1.0\n",
            "  (199, 666)\t1.0\n",
            "  (199, 514)\t1.0\n",
            "  (199, 49)\t1.0\n",
            "  (199, 967)\t1.0\n",
            "Dev accuracy for best dev model: 0.745, 95% CIs: [0.685 0.805]\n",
            "\n",
            "Test accuracy for best dev model: 0.750, 95% CIs: [0.685 0.805]\n",
            "\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.7/dist-packages/sklearn/utils/deprecation.py:87: FutureWarning: Function plot_confusion_matrix is deprecated; Function `plot_confusion_matrix` is deprecated in 1.0 and will be removed in 1.2. Use one of the class methods: ConfusionMatrixDisplay.from_predictions or ConfusionMatrixDisplay.from_estimator.\n",
            "  warnings.warn(msg, category=FutureWarning)\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 720x720 with 2 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {
            "needs_background": "light"
          }
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Agreement\t0.223\t&\n",
            "Agreement\t0.186\t?\n",
            "Agreement\t0.184\t%\n",
            "Agreement\t0.183\tleast\n",
            "Agreement\t0.175\tinfections\n",
            "Agreement\t0.172\tget\n",
            "Agreement\t0.159\tsimilar\n",
            "Agreement\t0.158\tshowed\n",
            "Agreement\t0.157\thttps\n",
            "Agreement\t0.157\tsymptoms\n",
            "\n",
            "Disagreement\t0.354\tnt\n",
            "Disagreement\t0.340\t?\n",
            "Disagreement\t0.292\tactually\n",
            "Disagreement\t0.249\tgoing\n",
            "Disagreement\t0.225\tsay\n",
            "Disagreement\t0.218\tsure\n",
            "Disagreement\t0.218\tgraph\n",
            "Disagreement\t0.195\tsimply\n",
            "Disagreement\t0.189\tcertain\n",
            "Disagreement\t0.180\tspikes\n",
            "\n",
            "Neutral\t0.400\tabstract\n",
            "Neutral\t0.257\tcovid19\n",
            "Neutral\t0.186\tvaccine\n",
            "Neutral\t0.180\tpandemic\n",
            "Neutral\t0.174\tsarscov2\n",
            "Neutral\t0.160\tage\n",
            "Neutral\t0.159\tb\n",
            "Neutral\t0.156\tmaturation\n",
            "Neutral\t0.149\tantibodies\n",
            "Neutral\t0.140\troll\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# trainX, trainY=load_data(trainingFile)\n",
        "print(\"On Train:\",Counter(trainY))\n",
        "\n",
        "sm = SMOTE(random_state=20)\n",
        "X_train_res, y_train_res = sm.fit_resample(trainX_array, trainY_array)\n",
        "\n",
        "# print(\"On Train:\",Counter(y_train_res))"
      ],
      "metadata": {
        "id": "oc3RjR9sqrXe"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        ""
      ],
      "metadata": {
        "id": "MhdGpgiZtOCe"
      },
      "execution_count": null,
      "outputs": []
    }
  ],
  "metadata": {
    "colab": {
      "collapsed_sections": [],
      "name": "LogReg.ipynb",
      "provenance": [],
      "toc_visible": true,
      "include_colab_link": true
    },
    "kernelspec": {
      "display_name": "Python 3 (ipykernel)",
      "language": "python",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.8.8"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}